AU725547B2 - Multi-functional chimeric hematopoietic receptor agonists - Google Patents

Description

WO 98/17810 PCT/US97/20037 MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS The present application claims priority under Title United States Code, §119 of United States Provisional application Serial No. 60/029,629, filed October 1996.

Field of the Invention The present invention relates to multi-functional chimeric hematopoietic receptor agonists. These multifunctional chimeric hematopoietic receptor agonists retain one or more activities of individual components of the chimera molecule and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with individual hematopoietic growth factors and/or have improved physical properties which may include increased solubility, stability and refold efficiency.

Background of the Invention Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF

(M-

CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively, while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL- 3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.

WO 98/17810 PCTIUS97/20037

I

U.S. 4,877,729 and U.S. 4,959,455 disclose a gibbon IL-3 cDNA and a deduced human IL-3 DNA sequence and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser' Pro 8 replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.

U.S. 4,810,643 discloses a DNA sequence encoding human G-CSF.

WO 91/02754 discloses a fusion protein comprised of GM-CSF and IL-3 which has increased biological activity compared to GM-CSF or IL-3 alone. Also disclosed are nonglycosylated IL-3 and GM-CSF analog proteins as components of the multi-functional chimeric hematopoietic receptor agonist.

WO 92/04455 discloses fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-

CSF.

WO 95/21197 and WO 95/21254 disclose fusion proteins capable of broad multi-functional hematopoietic properties.

GB 2,285,446 relates to the c-mpl ligand (thrombopoietin) and various forms of thrombopoietin which are shown to influence the replication, differentiation and maturation of megakaryocytes and megakaryocytes progenitors which may be used for the treatment of thrombocytopenia.

EP 675,201 Al relates to the c-mpl ligand (Megakaryocyte growth and development factor (MGDF), allelic variations of c-mpl ligand and c-mpl ligand attached to water soluble polymers such as polyethylene glycol.

WO 98/17810 PCT/US97/20037 3 WO 95/21920 provides the murine and human c-mpl ligand and polypeptide fragments thereof. The proteins are useful for in vivo and ex vivo therapy for stimulating platelet production.

U.S. Patent No. 4,703,008 by Lin, F-K. discloses the a cDNA sequence encoding erythropoietin, methods of production and uses for erythropoietin.

WO 91/05867 discloses analogs of human erythropoietin having a greater number of sites for carbohydrate attachment than human erythropoietin, such as EPO (Asn69), EPO (Asn 25 Ser 2 7 EPO (Thr2 and EPO (Pro 124 Thr 125 WO 94 /24160 discloses erythropoietin muteins which have enhanced activity, specifically amino acid substitutions at positions 20, 49, 73, 140, 143, 146, 147 and 154.

WO 94/28391 discloses the native flt3 ligand protein sequence and a cDNA sequence encoding the flt3 ligand, methods of expressing flt3 ligand in a host cell transfected with the cDNA and methods of treating patients with a hematopoietic disorder using flt3 ligand.

US Patent No. 5,554,512 is directed to human flt3 ligand as an isolated protein, DNA encoding the flt3 ligand, host cells transfected with cDNAs encoding flt3 ligand and methods for treating patients with flt3 ligand.

WO 94/26891 provides mammalianflt3 ligands, including an isolate that has an insertion of 29 amino acids, and fragments there of.

Rearrancement of Protein Sequences In evolution, rearrangements of DNA sequences serve an important role in generating a diversity of protein WO 98/17810 PCT/US97/20037 structure and function. Gene duplication and exon shuffling provide an important mechanism to rapidly generate diversity and thereby provide organisms with a competitive advantage, especially since the basal mutation rate is low (Doolittle, Protein Science 1:191- 200, 1992).

The development of recombinant DNA methods has made it possible to study the effects of sequence transposition on protein folding, structure and function. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al., Proc. Natl. Acad.

Sci. U.S.A. 76:3218-3222, 1979; Teather Erfle, J.

Bacteriol. 172: 3837-3841, 1990; Schimming et al., Eur.

J. Biochem. 204: 13-19, 1992; Yamiuchi and Minamikawa, FEBS Lett. 260:127-130, 1991; MacGregor et al., FEBS Lett. 378:263-266). The first in vitro application of this type of rearrangement to proteins was described by Goldenberg and Creighton Mol. Biol. 165:407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this point the new sequence is joined, either directly or through an additional portion of sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new Cterminus of the chain.

This approach has been applied to proteins which range in size from 58 to 462 amino acids (Goldenberg Creighton, J. Mol. Biol. 165:407-413, 1983; Li Coffino, Mol. Cell. Biol. 13:2377-2383, 1993). The proteins examined have represented a broad range of WO 98/17810 PCT/US97/20037 structural classes, including proteins that contain predominantly a-helix (interleukin-4; Kreitman et al., Cytokine 7:311-318, 1995), b-sheet (interleukin-l; Horlick et al., Protein Eng. 5:427-431, 1992), or mixtures of the two (yeast phosphoribosyl anthranilate isomerase; Luger et al., Science 243:206-210, 1989).

Broad categories of protein function are represented in these sequence reorganization studies: Enzymes T4 lysozyme dihydrofolate reductase ribonuclease T1 Bacillus b-glucanse aspartate transcarbamoylase phosphoribosyl anthranilate isomerase pepsin/pepsinogen Zhang et al., Biochemistry 32:12311-12318, 1993; Zhang et al., Nature Struct. Biol. 1:434-438 (1995) Buchwalder et al., Biochemistry 31:1621-1630, 1994; Protasova et al., Prot. Eng. 7:1373-1377, 1995) Mullins et al., J. Am. Chem. Soc.

116:5529-5533, 1994; Garrett et al., Protein Science 5:204-211, 1996) Hahn et al., Proc. Natl. Acad. Sci.

U.S.A. 91:10417-10421, 1994) Yang Schachman, Proc. Natl. Acad.

Sci. U.S.A. 90:11980-11984, 1993) Luger et al., Science 243:206-210 (1989; Luger et al., Prot. Eng.

3:249-258, 1990) Lin et al., Protein Science 4:159- 166, 1995) WO 98/17810 glyceraldehyde-3 phosphate dehydrogenase ornithine decarboxylase yeast phosphoglycerate dehydrogenase PCTIUS97/20037 Vignais et al., Protein Science 4: 994-100 0, 1995) Li Coftino, Mo1. Cell. Biol.

13:2377-2383, 1993) Ritco-Vonsovici et al., Biochemistry 34 :16543 -165 51, 1995) Enzyme inhibitor basic pancreatic trypsin inhibitor Goldenberg Creighton, LT. Mol.

Biol. 165:407-413, 1983) Cytokines interleukin-lb Horlick et al. Protein Eng. 5:427- 431, 1992) Kreitman et al., Cytokine 7:311- 318, 1995) interleukin-4 Tyrosine Kinase Recognition Domain a-spectrin SH3 domain Transmenibrane Protein Viguera, et al., J.

Mol. Biol. 247:670-681, 1995) omp A Koebnik Krdmer, J. Mol. Biol.

250:617-626, 1995) Chimeric Protein WO 98/17810 PCT/US97/20037 7 interleukin-4- Kreitman et al., Proc. Natl. Acad.

Pseudomonas Sci. U.S.A. 91:6889-6893, 1994).

exotoxin The results of these studies have been highly variable. In.many cases substantially lower activity, solubility or thermodynamic stability were observed (E.

coli dihydrofolate reductase, aspartate transcarbamoylase, phosphoribosyl anthranilate isomerase, glyceraldehyde-3-phosphate dehydrogenase, ornithine decarboxylase, omp A, yeast phosphoglycerate dehydrogenase). In other cases, the sequence rearranged protein appeared to have many nearly identical properties as its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, ribonuclease Tl, Bacillus b-glucanase, interleukin-lb, a-spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases, an unexpected improvement over some properties of the natural sequence was observed, the solubility and refolding rate for rearranged a-spectrin SH3 domain sequences, and the receptor affinity and anti-tumor activity of transposed interleukin-4-Pseudomonas exotoxin fusion molecule (Kreitman et al., Proc. Natl.

Acad. Sci. U.S.A. 91:6889-6893, 1994; Kreitman et al,, Cancer Res. 55:3357-3363, 1995).

The primary motivation for these types of studies has been to study the role of short-range and long-range interactions in protein folding and stability. Sequence rearrangements of this type convert a subset of interactions that are long-range in the original sequence into short-range interactions in the new sequence, and vice versa. The fact that many of these sequence rearrangements are able to attain a conformation with at least some activity is persuasive evidence that protein folding occurs by multiple folding pathways (Viguera, et al., J. Mol. Biol. 247:670-681, 1995). In the case of the SH3 domain of a-spectrin, choosing new termini at locations that corresponded to b-hairpin turns resulted in proteins with slightly less stability, but which were nevertheless able to fold.

The positions of the internal breakpoints used in the studies cited here are found exclusively on the surface of proteins, and are distributed throughout the linear sequence without any obvious bias towards the ends or the middle (the variation in the relative distance from the original N-terminus to the breakpoint is ca. 10 to 80% of the total sequence length). The linkers connecting the original N- and C-termini in these studies have ranged from 0 to 9 residues. In one case (Yang Schachman, Proc. Natl. Acad. Sci. U.S.A.

90:11980-11984, 1993), a portion of sequence has been deleted from the original C-terminal segment, and the connection made from the truncated C-terminus to the original N-terminus. Flexible hydrophilic residues such as Gly and Ser are frequently used in the linkers.

Viguera, et al.(J. Mol. Biol. 247:670-681, 1995) 20 compared joining the original N- and C- termini with 3or 4-residue linkers; the 3-residue linker was less thermodynamically stable. Protasova et al. (Protein Eng. 7:1373-1377, 1994) used 3- or 5-residue linkers in connecting the original N-termini of E. coli dihydrofolate reductase; only the 3-residue linker produced protein in good yield.

With reference to the use of the word(s) "comprise" or "comprises" or "comprising" in the description and/or in the following claims, we note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that we intend each of those words to be so interpreted in construing the description and/or the following claims.

WO 98/17810 PCT1US97/20037 Summary of the Invention A hematopoietic protein comprising; an amino acid sequence of the formula:

R

1

-L

1 R

R

1

-R

2 or R 2

-R

1 wherein R 1 and R 2 are independently selected from the group consisting of; A human EPO receptor agonist polypeptide, comprising a modified EPO amino acid sequence of the Formula: AlaProProArgLeulleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys GluAlaGluAsnI leThrThrGlyCysAlaoluHisCysgerbeuAsnGluAsnx leThr Val ProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValGlyGflQ1n~l ValGiuVa lTrpGlnGlyLeuAlaLeuLeuSercluAlaValLeuArgGlyG1n~laLeu 70 LeuValAsnSerSerclnProTrpGluProLeuGlnLeuHisVa lAspLysAlaValSer 100 Gl~ur~re~rhLue~g~ae~yl~ny~ullee 110 120 ProProAspAl aAlaSerAlaAlaProLeuArgThrl leThrAlaAspThrPheArgLys 130 140 Le~er~ly~rs~ee~g~yy~uy~uy~rl~ul 150 160 CysArgThrGlyAspArg SEQ ID NO:464 166 wherein optionally 1-6 amino acids from the N-terminus and 1-5 from the C-terminus can be deleted from said EPO receptor agonist polypeptide; WO 98/17810 PCT/US97/20037 wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and Ntermini at amino acids; 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27-28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 118-119 33-34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44-45 88-89 130-131 45-46 108-109 131-132 46-47 respectively; and (II) A human stem cell factor receptor agonist polypeptide, comprising a modified stem cell factor amino acid sequence of the Formula: WO 98/1 7810 PCT/US97/20037 G luGlyl leCysArgAsnArgValThrAsnAsnValLysAspValThrLysLeuValAla AsnLeuProLysAspTyrMetI leThrLeuLysTyrValProGlyMetAspValLeuPro 30 SerHi sCysTrp IleSerGluMetValValGlnLeuSerAspSerLeuThrAspLeuLeu AspLysPheSerAsnI 1eSerGluG~yLeuSerAsnTyrSerI leIleAspLysLeuVal AsnI leValAspAspLeuVa1GluCysValLysG1uAsnSerSerLysAspLeuLysLys 100 SerPheLysSerProGluProArgLeuPheThrProGluGluPhePheArgl lePheAsn 110 120 ArgSerl leAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVa1 130 140 SerSerThrLeuSerProGluLysAspSerArgValSerValThrLys ProPheMetLeu 150 160 ProProValAlaAla SEQ ID NO:465 165 wherein optionally 1-23 amino acids can be deleted from the C-terminus of said stem cell factor receptor agonist polypeptide; wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and Ntermini at amino acids; 23-24 24-25 2 5-26 2 6-27 27-28 39-40 40-41 64-65 65-66 66-67 9 6-97 97-98 9 8-99 99-100 100-101 WO 98/17810 WO 98/ 7810PCTIUS97/20037 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 respectively; and (III) A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence of the Formula: ThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArg GluLeuserAspTyrLeuLeuGlnAspTyrProVaThrVaAaSerAsnLeuGnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGl1rgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnolyLeuLeuGiuArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 90 100 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysproTrplleThr 110 120 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysclnProAspSerSerThrLeu 130 SEQ ID NO:466 wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt-3 receptor agonist polypeptide; WO 98/17810 PCT/US97/20037 /3 wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and Ntermini at amino acids; 28-29 29-30 30-31 31-32 32-33 34-35 36-37 37-38 38-39 39-40 40-41 41-42 42-43 64-65 65-66 66-67 86-87 87-88 88-89 89-90 90-91 91-92 92-93 93-94 94-95 95-96 96-97 97-98 98-99 99-100 100-101 101-102 102-103 respectively; and (IV) A polypeptide comprising; a modified human G- CSF amino acid sequence of the formula: 1 Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 100 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 110 Xaa Thr Leu Gin Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp WO 98/17810 PCT/US97/20037 120 Gin Gin 130 Leu Gin Pro Thr Met Glu Xaa Xaa Gly Met Ala Pro Ala 140 Phe Gin Gly Ala Met Pro Ala Ala Ser Ala Xaa Gin Xaa Xaa Ala 150 Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Leu Xaa Xaa 170 Xaa Ser Tyr Arg Val Leu Xaa Leu Ala Gin Pro SEQ ID NO:858 wherein Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position or Leu; Xaa at position or Thr; Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; 2 is Pro or Leu; 3 is Leu, Arg, Tyr or Ser; 13 is Phe, Ser, His, Thr or Pro; 16 is Lys, Pro, Ser, Thr or His; 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg; 18 is Leu, Thr, Pro, His, Ile or Cys; 22 is Arg, Tyr, Ser, Thr or Ala; 24 is Ile, Pro, Tyr or Leu; 27 is Asp, or Gly; 30 is Ala, Ile, Leu or Gly; 34 is Lys or Ser; 36 is Cys or Ser; 42 is Cys or Ser; 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, Glu, Arg, Phe, Arg, Ile or Ala; Leu or Thr; Leu, Phe, Arg or Ser; Leu, Ile, His, Pro or Tyr; Leu or His; Cys or Ser; Gln, Lys, Leu or Cys; Gln, Pro, Leu, Arg or Ser; Cys or Ser; 104 is Asp, 108 is Leu, 115 is Thr, Gly or Val; Ala, Val, Arg, Trp, Gin or Gly; His, Leu or Ala; WO 98/17810 PCT/US97/20037 Xaa at position 120 Xaa at position 123 Xaa at position 144 Xaa at position 146 Xaa at position 147 Xaa at position 156 Xaa at position 159 Xaa at position 162 Xaa at position 163 Xaa at position 169 Xaa at position 170 is Gin, Gly, Arg, Lys or His is Glu, Arg, Phe or Thr is Phe, His, Arg, Pro, Leu, Gin or Glu; is Arg or Gin; is Arg or Gin; is His, Gly or Ser; is Ser, Arg, Thr, Tyr, Val or Gly; is Glu, Leu, Gly or Trp; is Val, Gly, Arg or Ala; is Arg, Ser, Leu, Arg or Cys; is His, Arg or Ser; wherein optionally 1-11 amino acids from the N-terminus and 1-5 from the C-terminus can optionally be deleted from said modified human G-CSF amino acid sequence; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and Ntermini at amino acids; 38-39 39-40 40-41 41-42 42-43 43-44 45-46 48-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-59 59-60 62-63 63-64 64-65 65-66 66-67 67-68 68-69 69-70 70-71 71-72 91-92 92-93 93-94 94-95 95-96 96-97 97-98 123-124 124-125 125-126 126-127 128-129 128-129 129-130 130-131 131-132 132-133 133-134 134-135 135-136 136-137 137-138 138-139 139-140 WO 98/17810 WO 9817810PCTIUS97/20037 60-61 61-62 98-99 99-100 14 0-141 141-142 or 142-143 respectively; A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala 1 Pro Met Thr Gin Thr Thr Ser Leu 5 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Thr Ser Trp Vai Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Thr Thr Leu Ser Ala Ile Phe SEQ ID NO:859 Gly, Asp, Met, Gin, or Arg; wherein xaa at position 17 Xaa at position 18 is Asn, Xaa at position 19 is Met, Xaa at position 20 is Ile, Xaa at position 21 is Asp, Thr, Ser or Vai; Xaa at position 22 is Giu, Leu, Vai or Giy; is Ser, Lys, His, Phe, Cys, Phe, Leu, Ile, Gin, Lys, Ile, Arg, Giu, Arg, PheI Gly, Arg, Ala, Arg, Ala, Pro, Giy, or Gin; or Cys; or Ala; Giu, Gin, Asn, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, WO 98/17810 PCT/US97/20037 Xaa at position Leu, Ser, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Lys; Xaa at position Xaa at position Xaa at position Xaa at position Arg, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Val, Glu, Xaa at position Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Xaa at position Xaa at position Ala, Ile, Xaa at position Xaa at position Xaa at position Met; Xaa at position Lys, His, Xaa at position Xaa at position is Ile, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Val, Ala, Gly, Trp, Lys, Phe, Gly, His, Thr, Gly, Arg, Asn, His, Val, Gly, Phe, Arg, Leu, Leu, Thr, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gin, Ser, Leu, or 31 is 32 is 33 is 34 is Phe, 35 is 36 is 37 is 38 is 40 is 41 is 42 is Phe, 43 is Thr, 44 is Gin, 45 is Asn, 46 is Ala, SPro, Asp, Gly, Ala, Arg, Leu, SLeu, Val, Arg, Gin, Asn, Gly, Pro, Leu, Gin, Ala, Thr, or Gl Leu, Val, Gly, Ser, Lys, Glu, Ile or Met; Leu, Ala, Gly, Asn, Pro, Gin, Asp, Leu, or Val; Phe, Ser, Pro, Trp, or Ile; Asn, or Ala; Leu, Trp, or Arg; Asn, Cys, Arg, Leu, His, Met, Gly, Asp, Ser, Cys, Asn, Lys, Tyr, Ile, Met or Ala; Glu, Asn, Tyr, Leu, Phe, Asp, Gly or Ser; SAsp, Ser, Leu, Arg, Lys, Thr, Ala or Pro; Gin, Pro, Phe, Val, Met, Leu, Arg, Ser, Ala, Ile, Glu or His; SAsp, Phe, Ser, Thr, Cys, Glu, Tyr, Ile, Val or Gly; or Gin; Ala, or Glu; u; Gin, Thr, or Val; or Pro; Thr, Leu, Ala, Cys, Met, Trp, Thr, Lys, Asn, Gin, 47 is Ile, Gly, Val, Ser, Arg, 48 is Leu, Ser, Cys, Arg, Ile, Ala, Met, Val or Asn; 49 is Met, Arg, Ala, Gly, Pro, 50 is Glu, Leu, Thr, Asp, Tyr, Pro, or His; His, Phe, Glu, Val, 51 is 52 is 53 is His, Asn, SAsn, SLeu, Phe, Met or Gln; Arg, Met, Pro, His, Arg, Leu, Thr, Ala, Gly, Asn, Lys, Thr, Ser, Pro, His, Asn, or Asp; Ser, Ser, Gly, Gl31u, or His; or Thr; Lys, Ser, or 54 is Arg, Asp, Ala or Leu; 55 is Arg, Thr, 56 is Pro, Gly, Ile, Ser, Val, Thr, Gin, Asn, Val, Ser, Leu, or Gly; Cys, Ser, Gin, Glu, Arg, His, WO 98/17810 PCTIUS97/20037 Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 Xaa at position 58 Xaa at position 59 Xaa at position 60 Xaa at position 61 Xaa at position 62 Xaa at position 63 Xaa at position 64 Xaa at position 65 Xaa at position 66 Xaa at position 67 His; Xaa at position 68 Xaa at position 69 Leu; Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Xaa at position 74 Xaa at position 75 Gin, or Leu; Xaa at position 76 Asp; Xaa at position 77 Xaa at position 78 Xaa at position 79 Xaa at position 80 Xaa at position 81 Xaa at position 82 His, Thr, Se Xaa at position 83 Xaa at position 84 Xaa at position 85 Xaa at position 86 Xaa at position 87 Xaa at position 88 Xaa at position 89 Ser; Xaa at position 90 Xaa at position 91 Xaa at position 92 or Leu; Asn or Gly; Leu, Ser, Asp, Arg, Gin, Val, or Cys; Glu Ala, Phe, Asn, Arg, Ala, Val, Lys, Ser, Tyr, His, Leu, Pro, or Arg; Ser, Asn, His, Tyr, Asn, Thr, Ile, Ala, Pro, Glu, Val, Trp, Pro, Pro, Arg, Phe, Tyr, Pro, Arg, Lys, Ser, His, Val, Val, Asn, or Thr; Lys, Arg, or Ser; Pro, Thr, Asp, or Ile; Ser, His, Pro, or Val; or Lys; Leu, Phe, Asn, Glu, Gly, Asn, or Ser; or Ser;.

Ile, Pro, or is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or is Asn, Leu, Val, Trp, Pro, or Ala; is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Ser, Ala, Ile Glu, Glu, Glu, ,Met Lys, Met, Asp, ,Thr Gly, Ala, Leu, ,Pro, Asp, His, Ser, Arg, Asn, Arg, or Asp; Gly, Thr, or Arg; Gly, Ala; Pro, Trp, Arg, Ser, is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or is Ile, is Leu, is Lys, is Asn, is Leu, is Leu, r, Ala, is Pro, is Cys, is Leu, is Pro, is Leu, is Ala, is Thr, is Ala, is Ala, is Pro, Ser, Ala, Thr, Trp, Gin, Gin, Tyr, Ala, Glu, Asn, Cys, Ser, Lys, Asp, Pro, Pro, Phe, Arg, Ser, Asn, Val, Gly, Lys, Phe, Thr, Gly, Val, Arg, Trp, Arg, Cys, Ser, Ser, Arg, Thr, or Leu; Glu, Phe, Gly, or Arg; Met, Arg, Ile, Gly, or Asp; Gly, Thr, Leu, Glu, or Arg; Ala, Trp, Arg, Val, or Lys; Trp, Arg, Asp, Glu, Asn, Ile, Met or Val; Trp, Arg, or Met; Arg, Met, or Val; or Gin; Ala, or Lys; or Gly; Val, or Trp; Leu, Val, Glu, His, Asn, or Thr, Gly, Asp, Ile, or Met; Thr, Phe, Leu, Asp, or His; Ser, Lys, His, Ala, Gly, Ile WO 98/17810 PCT/US97/20037 1, Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala, or Pro; Xaa at position Lys, Ser, Xaa at position Xaa Xaa at position at position Glu, Gin, 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Ala, Trp, Phe, Ile, or Tyr; 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; 97 is Ile, Val, Lys, Ala, or Asn; 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; 99 is Ile, Leu, Arg, Asp, Val, Pro, Gin, Phe, or His; 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin, or 101 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ser, Ala, Gly, Ile, Leu, or Gin; Xaa at position Gly, Ser, Xaa at position Pro; Xaa at position Tyr, Glu, Xaa at position Xaa at position Xaa at position Gin, Lys, Xaa at position Leu, Lys, Xaa at position Xaa at position 102 is Gly, Leu, Glu, 103 is Asp, or Ser; 104 is Trp, Val, Cys, Ala, Phe, or Gly; 105 is Asn, Pro, Ala, Ile, Asp, or His; Lys, Ser, Tyr, or Pro; Tyr, Thr, Met, Pro, Leu, Phe, Ser, Trp, Gin, Tyr, 106 is Glu, 108 is Arg, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Xaa at position 110 is Lys, Ser, or Trp; Xaa at position Xaa at position Xaa at position Lys, Leu, Xaa at position Xaa at position Trp, or Me Xaa at position Arg, Trp, Xaa at position Xaa at position Xaa at position 11 11.

11 Il.

11 11 it; 1 is Leu, 2 is Thr, 3 is Phe, e, Val or 4 is Tyr, 5 is Leu, Thr, Ala, Ile, Val, Ser, Asn; Cys, Asn, Pro, Glu, Tyr, Leu, Ser, or Gly; Asn, Thr, Leu, Arg, Gin, His, Glu, Arg, Gin, Cys, His, Val, Asp, Tyr, His, Ser, Pro, or Met; Glu, His, Gly, Trp, Ser, or Phe; Tyr, Asp, Trp, Arg, or Leu; Arg, Ala, His, Thr, Xaa 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Ser, Asn, His, Ala, Tyr, Phe, Gin, or Ile; 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, or Cys; 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; at position Xaa at position Xaa at position Ile, Tyr, Xaa at position WO 98/17810 PCT/US97/20037 wherein from 1 to 14 amino acids can optionally be deleted from the N-terminus and/or from 1 to 15 amino acids can optionally be deleted from the C-terminus of said modified human IL-3 amino acid sequence; wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids; 26-27 49-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-31 53-54 87-88 31-32 54-55 88-89 32-33 64-65 89-90 33-34 65-66 90-91 34-35 66-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38-39 70-71 99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83 102-103 or 103-104 respectively; (VI) A polypeptide comprising; a modified human cmpl ligand amino acid sequence of the formula: SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer 1 5 10 WO 98/17810 PCTfUS97/20037 2.1 HisValLeuHisSerArgLeuSerGlncysProGluValHis ProLeuProThrPro 25 30 ValLeuLeuProAlaValAspPheSerLeuGlyG luTrpLysThrGlniMetGluGlu 40 45 50 ThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 65 70 AlaArgGlyGlnLeuGlyPromhrcysLeuSerSerLeuLeuGlyGlnLeuSerdly 85 90 GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrolnXaaXaXaa 100 105 110 XaaGlyArgThrThrAlaHisLysAspProAsnAlaI lePheLeuSerPheGinHis 115 120 125 130 LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVa1 135 140 145 150 Arg SEQ ID NO: 860 153 wherein; Xaa at position 112 is Pro, Phe, Trp, or Met; Xaa at position 113 is Leu, Ile, Trp, or Met; Xaa at position 114 is Leu, Ile, Trp, or Met; Xaa at position 115 is Tyr, or Asn; and deleted or Leu, deleted or Pro, deleted or Pro, Ala, Val, Ile, Phe, Ala, Val, Phe, Ala, Val, deleted or Gin, Gly, Ser, Thr, wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus-to the C-terminus and having new C- and Ntermini at amino acids; 26-27 62751-52 108-109 WO 98/17810 Wfl QR17R10PCTflJS97/2003l7 22 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55 111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-115 34-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80 118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-122 43-44 83-84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87 125-126 48-49 87-88 126-127 50-51 88-89 or 127-128 respectively; (VII) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa xaa Xaa- xaa xaa xaa xaa xaa 25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 40 *Xaa Xaa Xaa Xaa Xaa xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 55 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 WO 98/17810 PCT/US97/20037 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa 110 Gin 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Thr Leu Ser Xaa Xaa 100 Xaa 115 Leu 130 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Ala Ile Phe SEQ ID N0:859 Gly, Asp, Met, Gin, or Arg; wherein Xaa at position 17 Xaa at position 18 is Asn, Xaa at position 19 is Met, Xaa at position 20 is Ile, Xaa at position 21 is Asp, Thr, Ser or Val; Xaa at position 22 is Glu, Leu, Val or Gly; is Ser, Lys, His, Leu, II Phe, Ile, Ar Cys, Gin, G1 Phe, Lys, Ar e, g, u, g, Phe, Gly, Arg, Ala, Arg, Ala, Pro, Gly, or Gin; or Cys; or Ala; Glu, Gin, Asn, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Val, Ala, Gly, Trp, Lys, Phe, Xaa at position Leu, Ser, Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa at position at position at position at position at position at position at position Lys; at position at position at position at position Arg, Ala, at position at position at position at position at position at position at position is Ile, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Gly, His, Thr, Gly, Arg, Asn, His, Asp, Val, Leu, Val, Val, Gly, Phe, Arg, Leu, Leu, Thr, Gly, Arg, Gin, Gly, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ala, Gin, Ala, Ser, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Arg, Asn, Thr, Lys, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gin, Ser, Leu, or Pro, Leu, Pro, Leu, Leu, or Gin; Gly, Ala, or or Glu; Glu, Gin, Th Glu; r, Phe, Ile or Met; 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; 36 is Asp, 37 is Phe, 38 is Asn, 40 is Leu, 41 is Asn, 42 is Gly, Leu, or Val; Ser, Pro, Trp, or Ile; or Ala; Trp, or Arg; Cys, Arg, Leu, His, Met, Asp, Ser, Cys, Asn, Lys, or Pro; Thr, Leu, Val, Glu, Xaa at position Phe, Tyr, Ile, Met or Ala; 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, WO 98/17810 PCT/US97/20037 Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Xaa at position Thr, Gly or Ser; 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Gin, Ala or Pro; 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Asn, Arg, Ser, Ala, Ile, Glu or His; 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Ala, Tyr, Ile, Val or Gly; 47 is Ile, Gly, Val, Ser, Arg, Pro, or H 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Ala, Met, Val or Asn; 49 is Met, Arg, Ala, Gly, Pro, Asn, His, 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Val, His, Phe, Met or Gin; 51 is Asn, Arg, Met, Pro, Ser, Thr, or H 52 is Asn, His, Arg, Leu, Gly, Ser, or T 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Trp, Lys, Gin, is; Glu, Xaa Xaa Xaa Xaa or Asp; Ser, at position Ala, Ile, at position at position at position is; hr; Ser, Met; Xaa at position Lys, His, Xaa at position Xaa at position Thr, Ala, 54 is Arg, Asp, Ile, Ser, Val, Ala or Leu; 55 is Arg, Thr, Val, Ser, Leu, 56 is Pro, Gly, Cys, Ser, Gin, Thr, Gin, Asn, or Gly; Glu, Arg, His, Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa at position at position at position at position at position at position at position at position at position at position at position Tyr, 57 is 58 is 59 is 60 is 61 is 62 is 63 is 64 is 65 is 66 is 67 is Phe, Leu, Val or Lys; Asn or Gly; Leu, Ser, Asp, Arg, Gin, Val, or Cys; 3 g 3 Glu Tyr, His, Leu, Pro, or Arg; Ala, Phe, Asn, Arg, Ala, Val, Lys, Ser, Ser, Asn, His, Tyr, Asn, Thr, Ile, Ala, Pro, Glu, Val, Trp, Pro, Pro, Arg, Phe, Tyr, Pro, Arg, Lys, Ser, His, Val, Val, Asn, or Thr; Lys, Arg, or Ser; Pro, Thr, Asp, or Ser, His, Pro, or or Lys; Leu, Phe, or Ser; Asn, Glu, or Ser; Gly, Asn, Ile, Pr Ile; Val; 3, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Xaa at position 74 Xaa at position 75 Gin, or Leu; is Asn, Leu, Val, Trp, Pro, or Ala; is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Ser, Ala, Ile, Glu, Glu, Glu, Met, Lys, Met, Asp, Thr, Gly, Ala, Leu, Pro, Asp, His, Ser, Arg', Pro, Asn, Arg, Gly, Thr, Gly, Ala; Trp, Arg, or Asp; or Arg; Ser, WO 98/17810 PCT/US97/20037 Xaa at position 76 Asp; Xaa at position 77 Xaa at position 78 Xaa at position 79 Xaa at position 80 Xaa at position 81 Xaa at position 82 His, Thr, Se: Xaa at position 83 Xaa at position 84 Xaa at position 85 Xaa at position 86 Xaa at position 87 Xaa'at position 88 Xaa at position 89 Ser; Xaa at position 90 Xaa at position 91 Xaa at position 92 or Leu; Xaa at position 93 Xaa at position 94 Ala, or Pro; Xaa at position 95 Lys, Ser, Ali Xaa at position 96 Xaa at position 97 Xaa at position 98 Glu, Gin, Se: Xaa at position 99 Gly, Ser, Ph Xaa at position 10 Pro; Xaa at position 10 Tyr, Glu, As Xaa at position 10 Xaa at position 10 Xaa at position 10 Gin, Lys, Al Xaa at position 10 Leu, Lys, II Xaa at position 10 Xaa at position 10 Ala or Pro; is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or is is is is is is r is is is is is is5 i-s Ile, Leu, SLys, SAsn, i Leu, SLeu, Ala, SPro, SCys, Leu, Pro, Leu, SAla, Thr, SAla, i Ala, SPro, Ser, Ala, Thr, Trp, Gin, Gin, Tyr, Ala, Glu, Asn, Cys, Ser, Lys, Asp, Pro, Pro, Phe, Arg, Thr, or Ser, Glu, Ph Asn, Met, Ar Val, Gly, Th Gly, Ala, Tr Lys, Trp, Ar Phe, Ile, Met Thr, Trp, Ar Gly, Arg, Me Val, or Gin; Arg, Ala, or Trp, or Gly; Arg, Val, or Cys, Leu, Va Leu; e, Gly, g, Ile, Leu, p, Arg, g, Asp, or Val g, or Me t, or Va Lys; Trp; 1, Glu, or Arg; Gly, or Asp; Glu, or Arg; Val, or Lys; Glu, Asn, et; al; His, Asn, or Ser, Ser, Arg, Thr, Thr, Ser, Gly, Phe, Lys, Asp, Leu, His, Ile, Asp, Ala, or Met; or His; Gly, Ile is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; is Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, is a, is is i-s His, Trp, SPro, SIle, His, Gin, Phe, Lys, Val, Ile, Pro, Ile, Tyr, Lys, Arg, V or Tyr; Gly, I Ala, o al, Leu, Gly, Thr, Asn, le, or Thr; r Asn; Asn, Leu, Asp, Ala, Thr, Phe, Met, Val, Lys, Arg, Tyr or Pro; Ile, Leu, Arg, Asp, Val, Pro, Gin, e, or His; 0 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin, or 1 is Asp, Pro, Met, Lys, His, Thr, Val, n, Ser, Ala, Gly, Ile, Leu, or Gin; 2 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; 3 is Asp, or Ser; 4 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Le a, Phe, orGly; 5 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Ty e, Asp, or His; 6 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or

U,

r, Pro; 8 is Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, WO 98/17810 PCT/US97/20037 Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids can optionally be deleted from the N-terminus and/or from 1 to 15 amino acids can optionally be deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and (VIII) a factor selected from the group consisting of: a colony stimulating factor, .a cytokine, a lymphokine, an interleukin;.

and wherein L, is a linker capable of linking R, to R,; with the proviso that at least R or R 2 is selected from the polypeptide of formula or (III); and WO 98/17810 PCT/US97/20037 said hematopoietic protein can optionally be immediately preceded by (methionine 1 (alanine 1 or (methionine 2 alanine 1 The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide above are; 23-24, 24-25, 25-26, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 52-53, 53-54, 54-55, 55-56, 77-78, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 109-110, 110-111, 110-111, 111-112, 112- 113, 113-114, 114-115, 115-116, 116-117, 117-118, 118- 119, 119-120, 120-121, 121-122, 122-123, 123-124, 124- 125, 125-126, 126-127, 127-128, 128-129, 129-130, 130- 131, and 131-132.

The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide above are; 23-24, 24-25, 31-32, 32-33, 37-38, 38-39, 82-83, 83-84, 85-86, 86-87, 87-88, 125-126, 126-127 and 131-132.

The EPO receptor agonists of the present invention may contain amino acid substitutions, such as those disclosed in WO 94/24160 or one or more of the 24 83 126 glycosylation sites at Asn Asn and Asn are changed to other amino acids such as but not limited to Asp or Glu, deletions and/or insertions. It is also intended that the EPO receptor agonists of the present invention may also have amino acid deletions at either/or both the N- and C- termini of the original protein and or deletions from the new N- and/or Ctermini of the sequence rearranged proteins in the formulas shown above.

The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide WO 98/17810 PCT/US97/20037 (II) above are; 23-24, 24-25, 25-26, 33-34, 34-35, 36, 36-37, 38-39, 39-40, 40-41, 64-65, 65-66, 66-67, 67- 68, 68-69, 69-70, 70-71, 89-90, 90-91, 91-92, 9-93, 93- 94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, 103-104, 104-105 and 105-106 respectively.

The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (II) above are; 64-65, 65-66, 92-93 and 93-94 respectively.

The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (III) above are; 36-37, 37-38, 39-40, 41-42, 42-43, 64- 65-66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91- 92, 92-93, 93-94, 94-95, 95,-96, 96-97, 97-98, 98-99, 99-100 and 100-101 The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (III) above are; 39-40, 65-66, 89-90, 99-100 and 100- 101.

The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (IV) above are; 38-39, 39-40, 40-41, 41-42, 48-49, 53- 54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 60-61, 61- 62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96- 97, 125-126, 126-127, 127-128, 128-129, 129-130, 130- 131, 131-132, 132-133, 133-134, 134-135, 135-136, 136- 137, 137-138, 138-139, 139-140, 140-141 and 141-142.

The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (IV) above are; 38-39, 48-49, 96-97, 125-126, 132-133 and 141-142.

WO 98/17810 PCT/US97/20037 .79 The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide above are; 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66-67, 6 7 6 8 68-69, 69-70, 70-71, 84-85; 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 99-100, 100-101 and 101-102.

The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide above are; 34-35, 69-70 and 90-91.

The more preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (VI) above are; 80-81, 81-82, 82-83, 83-84, 84-85, 86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126 and 126-127.

The most preferred breakpoints at which new Cterminus and N-terminus can be made in the polypeptide (VI) above are; 81-82, 108-109, 115-116, 119-120, 122- 123 and 125-126.

The multi-functional receptor agonist of the present invention can also be represented by the following formulas:

(T

1

-X

2

(L

2 )d-(T 2 )e or

-Y

2 in which:

X

1 is a peptide comprising an amino acid sequence corresponding to the sequence of residues n+l through J of the original protein having amino acids residues WO 98/17810 PCT/US97/20037 numbered sequentially 1 through J with an amino terminus at residue 1; L is an optional linker;

X

2 is a peptide comprising an amino acid sequence of residues 1 through n of the original protein; y' is a peptide comprising an amino acid sequence corresponding to the sequence of residues n=l through K of the original protein having amino acids residues numbered sequentially 1 through K with an amino terminus at residue 1;

Y

2 is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

L

I and L 2 are optional peptide spacers: n is an integer ranging from 1 to J-l; b, c, and d are each independently 0 or 1; a and e are either 0 or i, provided that both a and e cannot both be 0; and T' and T 2 are proteins.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may contain amino acid substitutions, deletions and/or insertions in the individual protein components of the chimera molecule. It is also intended that the multi-functional chimeric hematopoietic receptor agonists of the present invention may also have amino acid deletions at either/or both the N- and C- termini of the original protein and or deletions from the new N- and/or Ctermini of the sequence rearranged proteins in the formulas shown above.

A preferred embodiment of the present invention the linker or (L 2 of the above formulas, joining the N-terminus to the C-terminus is a polypeptide selected from the group consisting of: Ser; WO 98/17810 WO 9817810PCT[US97I20037 Asn; Gly; Thr; GlySer; AlaAla; GlySerGly; GlyGlyGly; GlyAsnGly; GlyAlaGly; GlyThrGly; AiLaSerAla; AlaAlaAla; GlyGlyGlySer SEQ ID NO:778; GlyGlyGlySerGlyGlyGlySer SEQ ID NO:779; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO:780; SerGlyGIlySerGlyGlySer SEQ ID NO:781; GluPheGlyAsnMet SEQ ID NO:782; GluPheGlyGlyAsnMet SEQ ID NO:783; GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO:784; GlyGlySerAspMetAlaGly SEQ ID NO:785; SerGIlyGlyAsnGly SEQ ID NO:786; SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:787; SerGlyGlyAsnGlySerGlyGlyAsnGlyS erGlyGlyAsnGly SEQ ID NO:788; SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:789; SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:790; GlyGlyGlySerGlyGly SEQ ID NO:791; GlyGlyGlySerGlyGlyGly SEQ ID NO:792; GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:793; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:794; GlyGlyGlySerGlyGlyGlySerGlyoIlyGlySerGlyGlyGly SEQ ID NO:795; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyclyGlySerGly GlyGlySerGhy SEQ ID NO:796; WO 98/17810 PCT/US97/20037 32, ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly GlnProProLeu SEQ ID N0:797; ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO:798; and ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer SEQ ID N0:799.

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional chimeric hematopoietic receptor agonists, related microbial expression systems, and processes for making the multifunctional chimeric hematopoietic receptor agonists. The invention also relates to pharmaceutical compositions containing the multi-functional chimeric hematopoietic receptor agonists, and methods for using the multifunctional chimeric hematopoietic receptor agonists.

In addition to the use of the multi-functional chimeric hematopoietic receptor agonists of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients. Another intended use is for the production of dendritic cells both in vivo and ex vivo.

It is believed that the reduced affinity of fusion proteins is due, at least in part, to the inability of the individual moieties to achieve their native conformation when incorporated into a chimeric molecule or to steric hindrance between the active site of the individual moieties of the fusion protein. This invention overcomes these limitations providing novel multi-functional chimeric hematopoietic receptor agonists that have a binding affinity comparable to or greater than the individual components of the chimeric molecule.

WO 98/17810 PCTIUS97/20037 PAGE INTENTIONALLY LEFT BLANK WO 98/17810 PCT/US97/20037 34 Brief Description of the Figures Figure 1 schematically illustrates the sequence rearrangement of a protein. The N-terminus and the C-terminus of the native protein are joined through a linker, or joined directly. The protein is opened at a breakpoint creating a new N-terminus (new N) and a new C-terminus (new-C) resulting in a protein with a new linear amino acid sequence. A rearranged molecule may be synthesized de novo as linear molecule and not go through the steps of joining the original N-terminus and the C-terminus and opening of the protein at the breakpoint.

Figure 2 shows a schematic of Method I, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus 174) joined to the amino acid 11 1- 10 are deleted) through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

Figure 3 shows a schematic of Method II, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined without a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus 174) joined to the original N-terminus and a new C-terminus created at amino acid 96 of the original sequence.

WO 98/17810 PCT/US97/20037 Figure 4 shows a schematic of Method III, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus 174) joined to amino acid 1 through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

Figure 5 shows the bioactivity of the multifunctional receptor agonists comprising flt3 receptor agonists pMON32332, pMON32333, pMON32334 and pMON32335 compared to recombinant native flt3 (Genzyme) in the MUTZ-2 cell proliferation assay. MT mock transfection Figure 6 shows a DNA sequence encoding human mature EPO based on the sequence of Lin et al. (PNAS 82:7580- 7584, 1985).

Figure 7a and 7b shows a DNA sequence encoding native stem cell factor based on the sequence of Martin et al. (Cell 63:203-211, 1990).

Figure 8 shows a DNA sequence encoding soluble stem cell factor based on the sequence of Langley et al.

(Archives of Bichemistry and Biophysica 311:55-61, 1994).

Figure 9a and 9b shows the DNA sequence encoding the 209 amino acid mature form of flt3 ligand from Lyman et al. (Oncogene 11:1165-1172, 1995).

Figure 10 shows the DNA sequence encoding the 134 amino acid soluble form of flt3 ligand from Lyman et al.(Oncogene 11:1165-1172, 1995).

WO 98/17810 PCT/US97/20037 36 Detailed Description of the Invention The present invention encompasses multi-functional chimeric hematopoietic receptor agonists formed from covalently linked polypeptides, each of which may act through a different and specific cell receptor to initiate complementary biological activities.

Hematopoiesis requires a complex series of cellular events in which stem cells generate continuously into large populations of maturing cells in all major lineages. There are currently at least 20 known regulators with hematopoietic proliferative activity.

Most of these proliferative regulators can only stimulate one or another type of colony formation in vitro, the precise pattern of colony formation stimulated by each regulator is quite distinctive. No two regulators stimulate exactly the same pattern of colony formation, as evaluated by colony numbers or, more importantly, by the lineage and maturation pattern of the cells making up the developing colonies.

Proliferative responses can most readily be analyzed in simplified in vitro culture systems. Three quite different parameters can be distinguished: alteration in colony size, alteration in colony numbers and cell lineage. Two or more factors may act on the progenitor cell, inducing the formation of larger number of progeny thereby increasing the colony size. Two or more factors may allow increased number of progenitor cells to proliferate either because distinct subsets of progenitors cells exist that respond exclusively to one factor or because some progenitors require stimulation by two or more factors before being able to respond.

Activation of additional receptors on a cell by the use of two or more factors is likely to enhance the mitotic signal because of coalescence of initially differing signal pathways into a common final pathway reaching the nucleus (Metcalf, Nature 339:27, 1989). Other mechanisms could explain synergy. For example, if one signaling WO 98/17810 PCT/US97/20037 37 pathway is limited by an intermediate activation of an additional signaling pathway which is caused by a second factor, then this may result in a super additive response. In some cases, activation of one receptor type can induce an enhanced expression of other receptors (Metcalf, Blood 82:3515-3523, 1993). Two or more factors may result in a different pattern of cell lineages than from a single factor. The use of multi-functional chimeric hematopoietic receptor agonists may have a potential clinical advantage resulting from a proliferative response that is not possible by any single factor.

The receptors of hematopoietic and other growth factors can be grouped into two distinct families of related proteins: tyrosine kinase receptors, including those for epidermal growth factor, M-CSF (Sherr, Blood 75:1, 1990) and SCF (Yarden et al., EMBO J. 6:3341, 1987): and hematopoietic receptors, not containing a tyrosine kinase domain, but exhibiting obvious homology in their extracellular domain (Bazan, PNAS USA 87:6934-6938, 1990). Included in this latter group are erythropoietin (EPO) (D'Andrea et al., Cell 57:277, 1989), GM-CSF (Gearing et al., EMBO J. 8:3667, 1989), IL-3 (Kitamura et al., Cell 66:1165, 1991), G-CSF (Fukunaga et al., J. Bio. Chem. 265:14008-15, 1990), IL- 4 (Harada et al., PNAS USA 87:857, 1990), IL-5 (Takaki et al., EMBO J. 9:4367, 1990), IL-6 (Yamasaki et al., Science 241:825, 1988), IL-7 (Goodwin et al., Cell 60:941-51, 1990), LIF (Gearing et al., EMBO J. 10:2839, 1991) and IL-2 (Cosman et al., Mol-Immunol. 23: 935-94, 1986). Most of the latter group of receptors exists in a high-affinity form as heterodimers. After ligand binding, the specific a-chains become associated with at least one other receptor chain (b-chain, g-chain). Many of these factors share a common receptor subunit. The achains for GM-CSF, IL-3 and IL-5 share the same b-chain (Kitamura et al., Cell 66:1165, 1991), Takaki et al., EMBO J. 10:2833-8, 1991) and receptor complexes for IL- WO 98/17810 PCT/US97/20037 39 6, LIF and IL-11 share a common b-chain (gpl30) (Taga et al., Cell 58:573-81, 1989; Gearing et al., Science 255:1434-7, 1992). The receptor complexes of IL-2, IL- 4, IL-7, IL-9 and IL-15 share a common g-chain (Kondo et al., Science 262:1874, 1993; Russell et al., Science 266: 1042-1045, 1993; Noguchi et al., Science 262:1877, 1993; Giri et al., EMBO J. 13:2822-2830, 1994).

The use of a multiply acting hematopoietic factor may also have a potential advantage by reducing the demands placed on factor-producing cells and their induction systems. If there are limitations in the ability of a cell to produce a factor, then by lowering the required concentrations of each of the factors, and using them in combination may usefully reduce demands on the factor-producing cells. The use of a multiply acting hematopoietic factor may lower the amount of the factors that would be needed, probably reducing the likelihood of adverse side-effects.

Novel compounds of this invention are represented by a formula selected from the group consisting of:

R,-L,-R

2

R

2

-L

1

-R

1

R,-R

2 and R 2

-R

i Where R I and R 2 are as defined above.

R

2 is preferably a colony stimulating factor with a different but complementary activity than By complementary activity is meant activity which enhances or changes the response to another cell modulator. The R, polypeptide is joined either directly or through a linker segment to the R 2 polypeptide. The term "directly" defines multi-functional chimeric hematopoietic receptor agonists in which the polypeptides are joined without a peptide linker. Thus L represents a chemical bond or polypeptide segment to which both R, and R 2 are joined in frame, most commonly L is a linear peptide to which R1 and'R, are joined by amide bonds linking the carboxy terminus of R, to the amino terminus of L, and carboxy terminus of L, to the WO 98/17810 PCT/US97/20037 amino terminus of By "joined in frame" is meant that there is no translation termination or disruption between the reading frames of the DNA encoding R, and R,.

A non-exclusive list of other growth factors, i.e.

colony stimulating factors (CSFs), are cytokines, lymphokines, interleukins, hematopoietic growth factors which can be joined to (II) or (III) include GM- CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M- CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL- LIF, flt3/flk2 ligand, human growth hormone, B-cell growth factor, B-cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF) also known as steel factor or c-kit ligand. Additionally, this invention encompasses the use of modified R, or R 2 molecules or mutated or modified DNA sequences encoding these R i or R 2 molecules. The present invention also includes multi-functional chimeric hematopoietic receptor agonists in which R, or R 2 is an hIL-3 variant, c-mpl ligand variant, or G-CSF variant. A "hIL-3 variant" is defined as a hIL-3 molecule which has amino acid substitutions and/or portions of hIL-3 deleted as disclosed in WO 94/12638, WO 94/12639 and WO 95/00646, as well as other variants known in the art. A "c-mpl ligand variant" is defined an c-mpl ligand molecule which has amino acid substitutions and/or portions of cmpl ligand deleted, disclosed in United States Application Serial Number 08/383,035 as well as other variants known in the art. A "G-CSF variant" is defined an G-CSF molecule which has amino acid substitutions and/or portions of G-CSF deleted, as disclosed herein, as well as other variants known in the art. In addition to the list above, IL-3 variants taught in WO 94/12639 and WO 94/12638, G-CSF receptor agonists disclosed in WO 97/12977, c-mpl receptor agonists disclosed in WO 97/12978, IL-3 receptor agonists disclosed in WO 97/12979 can be R, or R, of the present invention. As WO 98/17810 PCT/US97/20037 used herein "IL-3 variants" refer to IL-3 variants taught in WO 94/12639 and WO 94/12638. As used herein "fusion proteins" refer to fusion protein taught in WO 95/21197, and WO 95/21254. As used herein "G-CSF receptor agonists" refer to G-CSF receptor agonists disclosed in WO 97/12978. As used herein "c-mpl receptor agonists" refer to c-mpl receptor agonists disclosed in WO 97/12978. As used herein "IL-3 receptor agonists" refer to IL-3 receptor agonists disclosed in WO 97/12979. As used herein "multi-functional receptor agonists" refer to multi-functional receptor agonists taught in WO 97/12985.

The linking group is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, have minimal hydrophobic characteristics which could interact with the functional protein domains and provide steric separation of R 1 and R 2 such that R, and R 2 could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional chimeric hematopoietic receptor agonists.

Preferred L linkers of the present invention include sequences selected from the group of formulas: WO 98/17810 PCT/US97/20037 (Gly 3 Ser)n (SEQ ID NO:861), (Gly 4 Ser)" (SEQ ID NO:862), (GlysSer)" (SEQ ID NO:863), (Gly"Ser)" (SEQ ID NO:864) or (AlaGlySer)" (SEQ ID N0:865).

One example of a highly-flexible linker is the glycine and serine-rich spacer region present within the pIII protein of the filamentous bacteriophages, e.g.

bacteriophages M13 or fd (Schaller et al., PNAS USA 72: 737-741, 1975). This region provides a long, flexible spacer region between two domains of the pIII surface protein. The spacer region consists of the amino acid sequence: GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGlu GlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO:800).

The present invention also includes linkers in which an endopeptidase recognition sequence is included.

Such a cleavage site may be valuable to separate the individual components of the multi-functional chimeric hematopoietic receptor agonist to determine if they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom protease, postproline cleavage enzyme, V8 protease, Thrombin and factor Xa.

Peptide linker segments from the hinge region of heavy chain immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship between the attached polypeptides. Especially useful are those hinge regions where the cysteines are replaced with serines. Preferred linkers of the present invention include sequences derived from murine IgG gamma 2b hinge region in which the cysteines have been changed to serines. These linkers may also include an endopeptidase cleavage site.

Examples of such linkers include the following sequences: WO 98/17810 PCT/US97/20037 IleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLys GluSerHisLysSerPro (SEQ ID NO:801) and IleGluGlyArgIleSerGluProSerGlyProIleSerThrIleAsnProSer ProProSerLysGluSerHisLysSerPro (SEQ ID NO:802).

The present invention is, however, not limited by the form, size or number of linker sequences employed and the only requirement of the linker is that functionally it does not interfere with the folding and function of the individual molecules of the multifunctional chimeric hematopoietic receptor agonist.

Determination of the Linker L.

The length of the amino acid sequence of the linker L 2 to be used in R, and/or R 2 can be selected empirically or with guidance from structural information, or by using a combination of the two approaches.

When no structural information is available, a Ssmall series of linkers can be prepared for testing using a design whose length is varied in order to span a range from 0 to 50 A and whose sequence is chosen in order to be consistent with surface exposure (hydrophilicity, Hopp Woods, Mol. Immunol. 20: 483- 489, 1983), Kyte Doolittle, J. Mol. Biol. 157:105-132; solvent exposed surface area, Lee Richards, J. Mol.

Biol. 55:379-400, 1971) and the ability to adopt the necessary conformation with out deranging the conformation of R 1 or R 2 (conformationally flexible; Karplus Schulz, Naturwissenschaften 72:212-213, 1985).

Assuming an average of translation of 2.0 to 3.8 A per residue, this would mean the length to test would be between 0 to 30 residues, with 0 to 15 residues being the preferred range. Exemplary of such an empirical series would be to construct linkers using a cassette sequence such as "Gly-Gly-Gly-Ser" repeated n times, WO 98/17810 PCT/US97/20037 413 where n is 1, 2, 3 or 4. Those skilled in the art will recognize that there are many such sequences that vary in length or composition that can serve as linkers with the primary consideration being that they be neither excessively long nor short Sandhu, Critical Rev.

Biotech. 12: 437-462, 1992); if they are too long, entropy effects will likely destabilize the threedimensional fold, and may also make folding kinetically impractical, and if they are too short, they will likely destabilize the molecule because of torsional or steric strain.

Those skilled in the analysis of protein structural information will recognize that using the distance between the chain ends, defined as the distance between the c-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that must be tested in an empirical selection of linkers. They will also recognize that it is sometimes the case that the positions of the ends of the polypeptide chain are ill-defined in structural models derived from x-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when true, this situation will therefore need to be taken into account in order to properly estimate the length of the linker required. From those residues whose positions are well defined are selected two residues that are close in sequence to the chain ends, and the distance between their c-alpha carbons is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8A per residue) are then selected. These linkers may be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues may be chosen to be flexible and hydrophilic as described above; or optionally the original sequence may be substituted for using a series WO 98/17810 PCT/US97/20037 of linkers, one example being the "Gly-Gly-Gly-Ser" cassette approach mentioned above; or optionally a combination of the original sequence and new sequence having the appropriate total length may be used.

Determination of the Amino and Carboxyl Termini of R_ ,gnd

R.

and Sequences of R 1 and R 2 capable of folding to biologically active states can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while using the linker sequence L 2 as described above. Amino and carboxyl termini are selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases the selection of the new termini will be such that the original position of the carboxyl terminus immediately preceded that of the amino terminus.

However, those skilled in the art will recognize that selections of termini anywhere within the region may function, and that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.

It is a central tenet of molecular biology that the primary amino acid sequence of a protein dictates folding to the three-dimensional structure necessary for expression of its biological function. Methods are known to those skilled in the art to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear magnetic resonance spectroscopy of protein solutions.

Examples of structural information that are relevant to the identification of breakpoint regions include the WO 98/17810 PCT/US97/20037 location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets, chain reversals and turns, and loops; Kabsch Sander, Biopolymers 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, Ann. Rev. Biochem. 53:537-572, 1984) and the static and dynamic distribution of conformations along the polypeptide chain (Alber Mathews, Methods Enzymol.

154: 511-533, 1987). In some cases additional information is known about solvent exposure of residues; one example is a site of post-translational attachment of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or is not feasible to obtain, methods are also available to analyze the primary amino acid sequence in order to make predictions of protein tertiary and secondary structure, solvent accessibility and the occurrence of turns and loops. Biochemical methods are also sometimes applicable for empirically determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure (Gentile Salvatore, Eur. J. Biochem. 218:603-621, 1993) Thus using either the experimentally derived structural information or predictive methods Srinivisan Rose Proteins: Struct., Funct. Genetics, 22: 81-99, 1995) the parental amino acid sequence is inspected to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel and antiparallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of WO 98/17810 PCT/US97/20037 4, solvent exposure are more likely to be part of the socalled hydrophobic core of the protein and should also be avoided for selection of amino and carboxyl termini.

In contrast, those regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, are the preferred sites for location of the extremes of the polypeptide chain. Continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as a breakpoint region.

Additional peptide sequences may also be added to facilitate purification or identification of multifunctional chimeric hematopoietic receptor agonist proteins poly-His). A highly antigenic peptide may also be added that would enable rapid assay and facile purification of the multi-functional chimeric hematopoietic receptor agonist protein by a specific monoclonal antibody.

"Mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refers to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid deletions, substitutions, or both, or is encoded by a nucleotide sequence intentionally made variant from a native sequence.. "Native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Hematopoietic growth factors can be characterized by their ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Many of the hematopoietic growth factors have demonstrated the ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial WO 98/17810 PCT/US97/20037 levels in studies performed initially in primates and subsequently in humans. Many or all of these biological activities of hematopoietic growth factors involve signal transduction and high affinity receptor binding.

Multi-functional chimeric hematopoietic receptor agonists of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional chimeric hematopoietic receptor agonists which have little or no agonist activity maybe useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins.

Biological activity of the multi-functional chimeric hematopoietic receptor agonist proteins of the present invention can be determined by DNA synthesis in factor-dependent cell lines or by counting the colony forming units in an in vitro bone marrow assay.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may have an improved therapeutic profile as compared to single acting hematopoietic agonists. For example, some multi-functional chimeric hematopoietic receptor agonists of the present invention may have a similar or more potent growth factor activity relative to other hematopoietic agonists without having a similar or corresponding increase in side-effects.

The present invention also includes the DNA sequences which code for the multi-functional chimeric hematopoietic receptor agonist proteins, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which WO 98/17810 PCT/US97/20037 differ from the DNAs encoding the multi-functional chimeric hematopoietic receptor agonists of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides.

Genetic engineering techniques now standard in the art (United States Patent 4,935,233 and Sambrook et al., "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al., Gene 34:315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites.

Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of the DNA sequences of the novel multifunctional hematopoietic agonists wherein at least one of the with the DNA sequence of the other colony stimulating factor may be accomplished by the use of intermediate vectors. Alternatively one gene can be WO 98/17810 PCT/US97/20037 cloned directly into a vector containing the other gene.

Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest.

Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has a colony stimulating factor joined by a linker region to a second colony stimulating factor.

Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these novel multi-functional chimeric hematopoietic receptor agonists. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the multifunctional chimeric hematopoietic receptor agonists include expression vectors comprising nucleotide sequences coding for the multi-functional chimeric hematopoietic receptor agonists joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional chimeric hematopoietic receptor agonist polypeptides.

The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding-sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

As another aspect of the present invention, there is provided a method for producing the novel multifunctional chimeric hematopoietic receptor agonists.

WO 98/17810 PCT/US97/20037 The method of the present invention involves culturing suitable cells or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional chimeric hematopoietic receptor agonist. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 (Yanish-Perron et al. Gene 33: 103-119, 1985) and MON105 (Obukowicz et al., Applied Environmental Microbiology 58: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional chimeric hematopoietic receptor agonist protein utilizing a chromosomal expression vector for E. coli based on the bacteriophage Mu (Weinberg et al., Gene 126: 25-33, 1993). Various strains of B. subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

When expressed in the E. coli cytoplasm, the gene encoding the multi-functional chimeric hematopoietic receptor agonists of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met -Ala or Met' at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of E. coli are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., J. Bac. 169:751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional chimeric hematopoietic receptor agonists of the present invention may include multi-functional chimeric hematopoietic receptor agonist polypeptides having Met', Ala or Met2-Ala at the N-terminus. These mutant multi-functional chimeric hematopoietic receptor agonists may also be expressed in E. coli by fusing a secretion signal peptide to the N-terminus. This signal WO 98/17810 PCT/US97/20037 peptide is cleaved from the polypeptide as part of the secretion process. Additional strategies for achieving high-level expression of genes in E. coli can be found in Savvas, C.M. (Microbiological Reviews 60;512-538, 1996).

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. 1987) Genetic Engineering, Principles and Methods, Vol. 9, J.

K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional chimeric hematopoietic receptor agonist. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, California) can be used.

The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al., Proc.

Natl. Acad. Sci. USA 84: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24 72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, Gething and Sambrook, Nature, 293:620- WO 98/17810 PCT/US97/20037 625, 1981), or alternatively, Kaufman et al, Mol. Cell.

Biol., 5(7):1750-1759, 1985) or Howley et al., U.S. Pat.

No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, Miller et al., Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. 1987) A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional chimeric hematopoietic receptor agonist polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, California) can be used. After construction of the vector carrying the gene encoding the multi-functional chimeric hematopoietic receptor agonist polypeptide, two micrograms of this DNA is co-transfected with one microgram of Baculovirus DNA (see Summers Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the multi-functional chimeric hematopoietic receptor agonist is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kansas). The multi-functional chimeric hematopoietic receptor agonist secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional chimeric hematopoietic WO 98/17810 PCT/US97/20037 S3 receptor agonist protein can be first concentrated using any of a number of commercial concentration units.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the treatment of diseases characterized by decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation.

It is often a side effect of various forms of cancer therapy, exposure to chemotherapeutic drugs, radiation and of infection or hemorrhage. Therapeutic treatment of leukopenia with these multi-functional chimeric hematopoietic receptor agonists of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.

The multi-functional chimeric hematopoietic receptor agonist of the present invention may be useful in the treatment or prevention of thrombocytopenia.

Currently the only therapy for thrombocytopenia is platelet transfusion which are costly and carry the significant risks of infection (HIV, HBV) and alloimunization. The multi-functional chimeric hematopoietic receptor agonist may alleviate or diminish the need for platelet transfusion. Severe WO 98/17810 PCT/US97/20037 thrombocytopenia may result from genetic defects such as Fanconi's Anemia, Wiscott-Aldrich, or May Hegglin syndromes. Acquired thrombocytopenia may result from auto- or allo-antibodies as in Immune Thrombocytopenia Purpura, Systemic Lupus Erythromatosis, hemolytic anemia, or fetal maternal incompatibility. In addition, splenomegaly, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, infection or prosthetic heart valves may result in thrombocytopenia.

Severe thrombocytopenia may also result from chemotherapy and/or radiation therapy or cancer.

Thrombocytopenia may also result from marrow invasion by carcinoma, lymphoma, leukemia or fibrosis.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the mobilization of hematopoietic progenitors and stem cells in peripheral blood. Peripheral blood derived progenitors have been shown to be effective in reconstituting patients in the setting of autologous marrow transplantation. Hematopoietic growth factors including G-CSF and GM-CSF have been shown to enhance the number of circulating progenitors and stem cells in the peripheral blood. This has simplified the procedure for peripheral stem cell collection and dramatically decreased the cost of the procedure by decreasing the number of pheresis required. The multi-functional chimeric hematopoietic receptor agonist may be useful in mobilization of stem cells and further enhance the efficacy of peripheral stem cell transplantation.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be useful in the ex vivo expansion of hematopoietic progenitors and stem cells. Colony stimulating factors (CSFs), such as hIL-3, have been administered alone, coadministered with other CSFs, or in combination with bone marrow transplants subsequent to high dose WO 98/17810 PCT/US97/20037 chemotherapy to treat the neutropenia and thrombocytopenia which are often the result of such treatment. However the period of severe neutropenia and thrombocytopenia may not be totally eliminated. The myeloid lineage, which is comprised of monocytes (macrophages), granulocytes (including neutrophils) and megakaryocytes, is critical in preventing infections and bleeding which can be life-threatening. Neutropenia and thrombocytopenia may also be the result of disease, genetic disorders, drugs, toxins, radiation and many therapeutic treatments such as conventional oncology therapy.

Bone marrow transplants have been used to treat this patient population. However, several problems are associated with the use of bone marrow to reconstitute a compromised hematopoietic system including: 1) the number of stem cells in bone marrow, spleen, or peripheral blood is limited, 2) Graft Versus Host Disease, 3) graft rejection and 4) possible contamination with tumor cells. Stem cells make up a very small percentage of the nucleated cells in the bone marrow, spleen and peripheral blood. It is clear that a dose response exists such that a greater number of stem cells will enhance hematopoietic recovery. Therefore, the in vitro expansion of stem cells should enhance hematopoietic recovery and patient survival. Bone marrow from an allogeneic donor has been used to provide bone marrow for transplant. However, Graft Versus Host Disease and graft rejection limit bone marrow transplantation even in recipients with HLA-matched sibling donors. An alternative to allogeneic bone marrow transplants is autologous bone marrow transplants. In autologous bone marrow transplants, some of the patient's own marrow is harvested prior to myeloablative therapy, e.g. high dose chemotherapy, and is transplanted back into the patient afterwards.

Autologous transplants eliminate the risk of Graft Versus Host Disease and graft rejection. However, WO 98/17810 PCT/US97/20037 autologous bone marrow transplants still present problems in terms of the limited number of stems cells in the marrow and possible contamination with tumor cells. The limited number of stem cells may be overcome by ex-vivo expansion of the stem cells. In addition, stem cells can be specifically isolated, based on the presence of specific surface antigens such as CD34+ in order to decrease tumor cell contamination of the marrow graft.

The following patents contain further details on separating stem cells, CD34+ cells, culturing the cells with hematopoietic factors, the use of the cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy.

5,061,620 relates to compositions comprising human hematopoietic stem cells provided by separating the stem cells from dedicated cells.

5,199,942 describes a method for autologous hematopoietic cell transplantation comprising: (1) obtaining hematopoietic progenitor cells from a patient; ex-vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand, c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein and combinations thereof; administering cellular preparation to a patient.

5,240,856 relates to a cell separator that includes an apparatus for automatically controlling the cell separation process.

WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a mixture of cells.

WO 98/17810 PCTIUS97/20037 WO 91/18972 describes methods for in vitro culturing of bone marrow, by incubating suspension of bone marrow cells, using a hollow fiber bioreactor.

WO 92/18615 relates to a process for maintaining and expanding bone marrow cells, in a culture medium containing specific mixtures of cytokines, for use in transplants.

WO 93/08268 describes a method for selectively expanding stem cells, comprising the steps of separating CD34+ stem cells from other cells and incubating the separated cells in a selective medium, such that the stem cells are selectively expanded.

WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood.

WO 93/18648 relates to a composition comprising human neutrophil precursor cells with a high content of myeloblasts and promyelocytes for treating genetic or acquired neutropenia.

WO 94/08039 describes a method of enrichment for human hematopoietic stem cells by selection for cells which express c-kit protein.

WO 94/11493 describes a stem cell population that are CD34+ and small in size, which are isolated using a counterflow elutriation method.

WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a nucleated heterogeneous cell population from a heterogeneous cell mixture.

WO 98/17810 PCT/US97/20037 WO 94/25848 describes a cell separation apparatus for collection and manipulation of target cells.

The long term culturing of highly enriched CD34+ precursors of hematopoietic progenitor cells from human bone marrow in cultures containing IL-la, IL-3, IL-6 or GM-CSF is discussed in Brandt et al J. Clin. Invest.

86:932-941, 1990).

One aspect of the present invention provides a method for selective ex-vivo expansion of stem cells. The term "stem cell" refers to the totipotent hematopoietic stem cells as well as early precursors and progenitor cells which can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the differentiation and proliferation of the cells. The present invention provides a method for selective exvivo expansion of stem cells, comprising the steps of: separating stem cells from other cells, (b) culturing said separated stem cells with a selective media which contains multi-functional chimeric hematopoietic receptor agonist protein(s) and (c) harvesting said stems cells. Stem cells, as well as committed progenitor cells destined to become neutrophils, erythrocytes, platelets, etc. may be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as CD34, that are present on the surface of these cells and/or by morphological characteristics. The phenotype for a highly enriched human stem cell fraction is reported as CD34+, Thy-l+ and lin-, but it is to be understood that the present invention is not limited to the expansion of this stem cell population. The CD34+ enriched human stem cell fraction can be separated by a number of reported methods, including affinity columns or beads, magnetic beads or flow cytometry using antibodies directed to surface antigens such as the WO 98/17810 PCT/US97/20037 CD34+. Further, physical separation methods such as counterflow elutriation may be used to enrich hematopoietic progenitors. The CD34+ progenitors are heterogeneous, and may be divided into several subpopulations characterized by the presence or absence of co-expression of different lineage associated cell surface associated molecules. The most immature progenitor cells do not express any known lineage associated markers, such as HLA-DR or CD38, but they may express CD90(thy-l). Other surface antigens such as CD33, CD38, CD41, CD71, HLA-DR or c-kit can also be used to selectively isolate hematopoietic progenitors. The separated cells can be incubated in selected medium in a culture flask, sterile bag or in hollow fibers. Various colony stimulating factors may be utilized in order to selectively expand cells. Representative factors that have been utilized for ex-vivo expansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF, IL-1, IL-6, IL-11, flt-3 ligand or combinations thereof. The proliferation of the stem cells can be monitored by enumerating the number of stem cells and other cells, by standard techniques hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent to incubation.

Several methods for ex-vivo expansion of stem cells have been reported utilizing a number of selection methods and expansion using various colony stimulating factors including c-kit ligand (Brandt et al., Blood 83:1507-1514 [1994], McKenna et al., Blood 86:3413-3420 [1995]), IL-3 (Brandt et al., Blood 83:1507-1514 [1994], Sato et al., Blood 82:3600-3609 [1993]), G-CSF (Sato et al., Blood 82:3600-3609 [1993]), GM-CSF (Sato et al., Blood 82:3600-3609 [1993]), IL-1 (Muench et al., Blood 81:3463-3473 [1993]), IL-6 (Sato et al., Blood 82:3600- 3609 [1993]), IL-11 (Lemoli et al., Exp. Hem. 21:1668- 1672 [1993], Sato et al., Blood 82:3600-3609 [1993]), flt-3 ligand (McKenna et al., Blood 86:3413 3420 [1995]) and/or combinations thereof (Brandt et al., Blood WO 98/17810 PCT/US97/20037 83:1507 1514 [1994], Haylock et al., Blood 80:1405-1412 [1992], Koller et al., Biotechnology 11:358-363 [1993], (Lemoli et al., Exp. Hem. 21:1668-1672 [1993]), McKenna et al., Blood 86:3413-3420 [1995], Muench et al., Blood 81:3463-3473 [1993], Patchen et al., Biotherapy 7:13-26 [1994], Sato et al., Blood 82:3600-3609 [1993], Smith et al., Exp. Hem. 21:870-877 [1993], Steen et al., Stem Cells 12:214-224 [1994], Tsujino et al., Exp. Hem.

21:1379-1386 [1993]). Among the individual colony stimulating factors, hIL-3 has been shown to be one of the most potent in expanding peripheral blood CD34+ cells (Sato et al., Blood 82:3600-3609 [1993], Kobayashi et al., Blood 73:1836-1841 [1989]). However, no single factor has been shown to be as effective as the combination of multiple factors. The present invention provides methods for ex vivo expansion that utilize multi-functional chimeric hematopoietic receptor agonists that are more effective than a single factor alone.

Another aspect of the invention provides methods of sustaining and/or expanding hematopoietic precursor cells which includes inoculating the cells into a culture vessel which contains a culture medium that has been conditioned by exposure to a stromal cell line such as HS-5 (WO 96/02662, Roecklein and Torok-Strob, Blood 85:997-1105, 1995) that has been supplemented with a multi-functional hematopoietic chimeric receptor agonist of the present invention.

It is also envisioned that uses of multi-functional hematopoietic chimeric receptor agonists of the present invention would include blood banking applications, where the EPO receptor agonists are given to a patent to increase the number of blood cells and blood products are removed from the patient, prior to some medical procedure. The blood products stored and transfused back into the patient after the medical procedure.

WO 98/17810 PCT/US97/20037 Additionally, it is envisioned that uses of multifunctional hematopoietic chimeric receptor agonists would include giving the multi-functional hematopoietic chimeric receptor agonists to a blood donor prior to blood donation to increase the number of blood cells, thereby allowing the donor to safely give more blood.

Another projected clinical use of growth factors has been in the in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the long life-span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the entire body, hematopoietic progenitor cells are good candidates for ex vivo gene transfection. In order to have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell one needs to stimulate cell division and DNA replication.

Hematopoietic stem cells cycle at a very low frequency which means that growth factors may be useful to promote gene transduction and thereby enhance the clinical prospects for gene therapy. Potential applications of gene therapy (review Crystal, Science 270:404-410 [1995]) include; 1) the treatment of many congenital metabolic disorders and immunodeficiencies (Kay and Woo, Trends Genet. 10:253-257 [1994]), 2) neurological disorders (Friedmann, Trends Genet. 10:210-214 [1994]), 3) cancer (Culver and Blaese, Trends Genet. 10:174-178 [1994]) and 4) infectious diseases (Gilboa and Smith, Trends Genet. 10:139-144 [1994]).

There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and nonviral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include; 1) replication deficient recombinant retrovirus (Boris- Lawrie and Temin, Curr. Opin. Genet. Dev. 3:102-109 [1993], Boris-Lawrie and Temin, Annal. New York Acad.

WO 98/17810 PCT/US97/20037 Sci. 716:59-71 [1994], Miller, Current Top. Microbiol.

Immunol. 158:1-24 [1992]) and replication-deficient recombinant adenovirus (Berkner, BioTechniques 6:616-629 [1988], Berkner, Current Top. Microbiol. Immunol.

158:39-66 [1992], Brody and Crystal, Annal. New York Acad. Sci. 716:90-103 [1994]). Non-viral based vectors include protein/DNA complexes (Cristiano et al., PNAS USA. 90:2122-2126 [1993], Curiel et al., PNAS USA 88:8850-8854 [1991], Curiel, Annal. New York Acad. Sci.

716:36-58 [1994]), electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., Annal. New York Acad. Sci. 716:23-35 [1994]).

The present invention provides an improvement to the existing methods of expanding hematopoietic cells, which new genetic material has been introduced, in that it provides methods utilizing multi-functional chimeric hematopoietic receptor agonist proteins that have improved biological activity, including an activity not seen by any single colony stimulation factor.

Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, analgesics such as aminopyrine and dipyrone, anticonvulsants such as phenytoin or carbamazepine, antithyroids such as propylthiouracil and methimazole and diuretics. The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections, burns and as a result of treatment for renal disease or renal failure, dialysis. The multi-functional chimeric hematopoietic receptor agonists of the present WO 98/17810 PCT/US97/20037 invention may be useful in treating such hematopoietic deficiencies.

The treatment of hematopoietic deficiency may include administration of a pharmaceutical composition containing the multi-functional chimeric hematopoietic receptor agonists to a patient. The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the multi-functional chimeric hematopoietic receptor agonist proteins of the present invention prior to injecting the cells into a patient.

Various immunodeficiencies, in T and/or B lymphocytes, or immune disorders, rheumatoid arthritis, may also be beneficially affected by treatment with the multi-functional chimeric hematopoietic receptor agonists of the present invention. Immunodeficiencies may be the result of viral infections, HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be employed, alone or in combination with other colony stimulating factors, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are the in vivo and ex vivo treatment of patients recovering from bone marrow transplants, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional chimeric hematopoietic receptor agonists of the present invention in a mixture with a WO 98/17810 PCT/US97/20037 pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

Another intended use of the multi-functional chimeric hematopoietic receptor agonists of the present invention is for the generation of larger numbers of dendritic cells, from precursors, to be used as adjuvants for immunization. Dendritic cells play a crucial role in the immune system. They are the professional antigen-presenting cells most efficient in the activation of resting T cells and are the major antigen-presenting cells for activation of naive T cells in vivo and, thus, for initiation of primary immune responses. They efficiently internalize, process and present soluble tumor-specific antigens Dendritic cells have the unique capacity to cluster naive T cells and to respond to Ag encounter by rapid upregulation of the expression of major histocompatability complex (MHC) and co-stimulatory molecules, the production of cytokines and migration towards lymphatic organs. Since dendritic cells are of central importance for sensitizing the host against a neoantigen for CD4dependent immune responses, they may also play a crucial role in the generation and regulation of tumor immunity.

Dendritic cells originate from a bone marrow CD34+ precursor common to granulocytes and macrophages, and the existence of a separate dendritic cell colonyforming unit (CFU-DC) that give rise to pure dendritic cell colonies has been established in humans. In addition, a post-CFU CD14+ intermediate has been WO 98/17810 PCT/US97/20037 described with the potential to differentiate along the dendritic cell or the macrophage pathway under distinct cytokine conditions. This bipotential precursor is present in the bone marrow, cord blood and peripheral blood. Dendritic cells can be isolated based on specific cell surface markers, such as CDla+, CD3-, CD4-, CD80+, and CD83+, to delineate the maturation of cultured dendritic cells.

Dendritic cells based strategies provide a method for enhancing immune response against tumors and infectious agents. AIDS is another disease for which dendritic cell based therapies can be used, since dendritic cells can play a major role in promoting HIV- 1 replication. An immunotherapy requires the generation of dendritic cells from cancer patients, their in vitro exposure to tumor Ag, derived from surgically removed tumor masses, and reinjection of these cells into the tumor patients. Relatively crude membrane preparations of tumor cells will suffice as sources of tumor antigen, avoiding the necessity for molecular identification of the tumor antigen. The tumor antigen may also be synthetic peptides, carbohydrates, or nucleic acid sequences. In addition, concomitant administration of cytokines such as the multi-functional chimeric hematopoietic receptor agonists of the present invention may further facilitate the induction of tumor immunity.

It is foreseen that the immunotherapy can be in an in vivo setting, wherein the multi-functional chimeric hematopoietic receptor agonists of the present invention is administered to a patient, having a tumor, alone or with other hematopoietic growth factors to increase the number of dendritic cells and endogenous tumor antigen is presented on the dendritic cells. It is also envisioned that in vivo immunotherapy can be with exogenous antigen. It is also envisioned that the immunotherapy treatment may include the mobilization of dendritic cell precursors or mature dendritic, by WO 98/17810 PCT/US97/20037 administering the multi-functional chimeric hematopoietic receptor agonists of the present invention alone or with other hematopoietic growth factors to the patient, removing the dendritic cell precursors or mature dendritic cells from the patient, exposing the dendritic cells to antigen and returning the dendritic cells to the patient. Furthermore, the dendritic cells that have been removed can be cultured ex vivo with the multi-functional chimeric hematopoietic receptor agonists of the present invention alone or with other hematopoietic growth factors to increase the number of dendritic cells prior to exposure to antigen. Dendritic cells based strategies also provide a method for reducing the immune response in auto-immune diseases.

Studies on dendritic cells have been greatly hampered by difficulties in preparing the cells in sufficient numbers and in a reasonably pure form. In an ex-vivo cell expansion setting, granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-a (TNF-a cooperate in the ex vivo generation of dendritic cells from hematopoietic progenitors (CD34+ cells) retrieved from bone marrow, cord blood, or peripheral blood and flk-2/flt-3 ligand and c-kit ligand (stem cell factor [SCF]) synergize to enhance the GM-CSF plus TNF-a induced generation of dendritic cells (Siena, S. et al. Experimental Hematology 23:1463-1471, 1995).

Also provide is a method of ex vivo expansion of dendritic cell precursors or mature dendritic cells using the multi-functional chimeric hematopoietic receptor agonists of the present invention to provide sufficient quantities of dendritic cells for immunotherapy.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering WO 98/17810 PCT/US97/20037 various factors which modify the action of drugs, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2 150 pg/kg of multifunctional chimeric hematopoietic receptor agonist protein per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multifunctional chimeric hematopoietic receptor agonist protein and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of multi-functional chimeric hematopoietic receptor agonist would be adjusted higher or lower than the range of 0.2 150 micrograms per kilogram of body weight. These include co-administration with other colony stimulating factors or IL-3 variants or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional chimeric hematopoietic receptor agonist protein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate colony stimulating factors (CSFs), cytokines, lymphokines, hematopoietic growth factors and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL- 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-16, LIF, flt3/flk2 ligand, B-cell growth factor, Bcell differentiation factor and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to WO 98/17810 PCT/US97/20037 compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, differential cell count and the like.

MATERIALS AND METHODS Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, MO). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN).

Transformation of E. coli strains E. coli strains, such as DH5aTM (Life Technologies, Gaithersburg, MD) and TG1 (Amersham Corp., Arlington Heights, IL) are used for transformation of ligation reactions and are the source of plasmid DNA for transfecting mammalian cells. E. coli strains, such as JM101 (Yanisch-Perron, et al., Gene, 33: 103-119, 1985) and MON105 (Obukowicz, et al., Appl. and Envir. Micr., 58: 1511-1523, 1992) can be used for expressing the multi-functional chimeric hematopoietic receptor agonist of the present invention in the cytoplasm or periplasmic space.

MON105 ATCC#55204: lambda-,IN(rrnD, rrE)l, rpoD+, rpoH358 phi80dlacZdeltaM15, delta(lacZYA-argF)U169, deoR, recAl, endAl, hsdR17(rk-,mk+), phoA, supE441amda-, thi-1, gyrA96, relAl TG1: delta(lac-pro), supE, thi-l, hsdD5/F'(traD36, proA+B+, laclq, WO 98/17810 PCT/US97/20037 JM101 ATCC#33876: delta (pro lac), supE, thi, F' (traD36, proA+B+, laclq, DH5aTM Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both E. coli strains TG1 and MON105 are rendered competent to take up DNA using a CaC1 2 method. Typically, 20 to 50 mL of cells are grown in LB medium Bacto-tryptone, 0.5% Bactoyeast extract, 150 mM NaCl) to a density of approximately 1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush Lomb Spectronic spectrophotometer (Rochester, NY). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCI 2 solution (50 mM CaC1 2 10 mM Tris-Cl, pH7.4) and are held at 40C for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCI 2 solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4 0 C for 30-60 minutes. The samples are shifted to 42 0 C for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37 0 C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37 0 C. Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37 0 C while shaking.

Methods for creation of genes with new N-terminus/Cterminus WO 98/17810 PCT/US97/20037 7<o Method I. Creation of genes with new N-terminus/Cterminus which contain a linker region (L 2 Genes with new N-terminus/C-terminus which contain a linker region (L 2 separating the original C-terminus and N-terminus can be made essentially following the method described in L. S. Mullins, et al Am. Chem.

Soc. 116, 5529-5533, 1994). Multiple steps of polymerase chain reaction (PCR) amplifications are used to rearrange the DNA sequence encoding the primary amino acid sequence of the protein. The steps are illustrated in Figure 2.

In the first step, the first primer set ("new start" and "linker start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein followed by the linker (L 2 that connects the C-terminal and N-terminal ends of the original protein. In the second step, the second primer set ("new stop" and "linker stop") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Stop") that encodes the same linker as used above, followed by the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include the appropriate restriction sites which allow cloning of the new gene into expression plasmids. Typical PCR conditions are one cycle melting for two minutes; 25 cycles 94 0 C denaturation for one minute, 50 0 C annealing for one minute and 720C extension for one minute; plus one cycle 72 0 C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and Ix PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM WO 98/17810 PCT/US97/20037 MgCl2. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT).

"Fragment Start" and "Fragment Stop", which have complementary sequence in the linker region and the coding sequence for the two amino acids on both sides of the linker, are joined together in a third PCR step to make the full-length gene encoding the new protein. The DNA fragments "Fragment Start" and "Fragment Stop" are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen).

These fragments are combined in equimolar quantities, heated at 70 0 C for ten minutes and slow cooled to allow annealing through their shared sequence in "linker start" and "linker stop". In the third PCR step, primers "new start" and "new stop" are added to the annealed fragments to create and amplify the full-length new N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95 0 C melting for two minutes; 25 cycles 94 0 C denaturation for one minute, 60 0 C annealing for one minute and 72 0 C extension for one minute; plus one cycle 72 0 C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and approximately 0.5 ug of DNA; and Ix PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgC1 2 PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Method II. Creation of genes with new N-terminus/Cterminus without a linker region.

New N-terminus/C-terminus genes without a linker joining the original N-terminus and C-terminus can be made using two steps of PCR amplification and a blunt end ligation. The steps are illustrated in Figure 3.

In the first step, the primer set ("new start" and "P-bl WO 98/17810 PCT/US97/20037 start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein. In the second step, the primer set ("new stop" and "P-bl stop") is used to create and amplify, from gene sequence, the DNA fragment ("Fragment Stop") that contains the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include appropriate restriction sites which allow cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95 0 C melting for two minutes; 25 cycles 94 0 C denaturation for one minute, 50 0 C annealing for seconds and 72 0 C extension for 45 seconds. Deep Vent polymerase (New England Biolabs) is used to reduce the occurrence of overhangs in conditions recommended by the manufacturer. The "P-bl start" and "P-bl stop" primers are phosphorylated at the 5' end to aid in the subsequent blunt end ligation of "Fragment Start" and "Fragment Stop" to each other. A 100 ul reaction contained 150 pmole of each primer and one ug of template DNA; and Ix Vent buffer (New England Biolabs), 300 uM dGTP, 300 uM dATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT). PCR reaction products are purified using a Wizard PCR Preps kit (Promega).

The primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typically "Fragment Start" is designed to create NcoI restriction site and "Fragment Stop" is designed to create a HindIII restriction site. Restriction digest reactions are purified using a Magic DNA Clean-up System kit (Promega). Fragments Start and Stop are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These WO 98/17810 PCT/US97/20037 73 fragments are combined with and annealed to the ends of the 3800 base pair NcoI/HindIII vector fragment of pMON3934 by heating at 500C for ten minutes and allowed to slow cool. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim). The result is a plasmid containing the full-length new N-terminus/Cterminus gene. A portion of the ligation reaction is used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Plasmid DNA is purified and sequence confirmed as below.

Method III. Creation of new N-terminus/C-terminus genes by tandem-duplication method New N-terminus/C-terminus genes can be made based on the method described in R. A. Horlick, et al Protein Eng. 5:427-431, 1992). Polymerase chain reaction (PCR) amplification of the new N-terminus/C-terminus genes is performed using a tandemly duplicated template DNA. The steps are illustrated in Figure 3.

The tandemly-duplicated template DNA is created by cloning and contains two copies of the gene separated by DNA sequence encoding a linker connecting the original C- and N-terminal ends of the two copies of the gene.

Specific primer sets are used to create and amplify a full-length new N terminus/C-terminus gene from the tandemly-duplicated template DNA. These primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 950C melting for two minutes; 25 cycles 94 0 C denaturation for one minute, 50 0 C annealing for one minute and 72 0

C

extension for one minute; plus one cycle 72 0 C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit (Perkin Elmer Corporation, Norwalk, CT). is used. A 100 ul reaction contains 100 pmole of each WO 98/17810 PCT/US97/20037 primer and one ug of template DNA; and Ix PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, units AmpliTaq DNA polymerase and 2 mM MgC1 2

PCR

reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT). PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Cloning of new N-terminus/C-terminus genes into multifunctional receptor aqonist expression vectors.

The new N-terminus/C-terminus gene is digested with restriction endonucleases to create ends that are compatible to insertion into an expression vector containing another colony stimulating factor gene. This expression vector is likewise digested with restriction endonucleases to form compatible ends. After purification, the gene and the vector DNAs are combined and ligated using T4 DNA ligase. A portion of the ligation reaction is used to transform E. coli. Plasmid DNA is purified and sequenced to confirm the correct insert. The correct clones are grown for protein expression.

DNA isolation and characterization Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. A few such methods are shown herein. Plasmid DNA is isolated using the Promega WizardT Miniprep kit (Madison, WI), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000 x plasmid DNA released with sequential NaOH/acid treatment, and WO 98/17810 PCT/US97/20037 cellular debris is removed by centrifugation (10000 x The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted with TE. After screening for the colonies with the plasmid of interest, the E. coli cells are inoculated into 50-100 mLs of LB plus appropriate antibiotic for overnight growth at 37 0

C

in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into mammalian, E. coli or other cells.

Sequence confirmation.

Purified plasmid DNA is resuspended in dH 2 O and quantitated by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxyT terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the manufacturers suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture.

Sequencing reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions.

Samples are purified to remove excess dye terminators with Centri-Sep m spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using an ABI Model 373A automated DNA sequencer. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI).

WO 98/17810 PCT/US97/20037 Expression of multi-functional receptor agonists in mammalian cells Mammalian Cell Transfection/Production of Conditioned Media The BHK-21 cell line can be obtained from the ATCC (Rockville, MD). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum (FBS). This formulation is designated BHK growth media.

Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (Calbiochem, San Diego, CA).

The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 (See Hippenmeyer et al., Bio/Technology, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., Poultry Sci., 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid is available from ATCC, pSV2-hph.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3 X 10 cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM"M (Gibco-BRL, Gaithersburg, MD) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE" per dish. The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours posttransfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the.dish by trypsin-EDTA, diluted 1:10 and transferred to 100 mm tissue culture dishes WO 98/17810 PCT/US97/20037 77 containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media.

After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of multi-functional receptor aronists in E.

coli E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37 0 C in M9 plus casamino acids medium with shaking in a air incubator Model G25 from New Brunswick Scientific (Edison, New Jersey). Growth is monitored at OD600 until it reaches a value of 1.0 at which time Nalidixic acid milligrams/mL) in 0.1 N NaOH is added to a final concentration of 50 pg/mL. The cultures are then shaken at 37 0 C for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al.

Molecular Cloning: A Laboratory Manual, 1982). The culture is centrifuged (5000 x g) to pellet the cells.

Inclusion Body preparation, Extraction, Refolding, Dialysis, DEAE Chromatography, and Characterization of the multi-functional chimeric hematopoietic receptor WO 98/17810 PCT/US97/20037 78 agonists which accumulate as inclusion bodies in E.

coli.

Isolation of Inclusion Bodies: The cell pellet from a 330 mL E. coli culture is resuspended in 15 mL of sonication buffer (10 mM 2amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0 1 mM ethylenediaminetetraacetic acid (EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disrupter (Model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, New York). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets: Following the final centrifugation step, the IB pellet is resuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes to allow for denaturation of the expressed protein.

The extraction solution is transferred to a beaker containing 70 mL of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred while exposed to air at 4 0 C for 18 to 48 hours to allow the proteins to refold. Refolding is monitored by analysis on a Vydac (Hesperia, Ca.) C18 reversed phase high pressure liquid chromatography (RP- HPLC) column (0.46x25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed to monitor the refold. This gradient is developed over 30 minutes at a flow rate of 1.5 mL WO 98/17810 PCT/US97/20037 ?9 per minute. Denatured proteins generally elute later in the gradient than the refolded proteins.

Purification: Following the refold, contaminating E. coli proteins are removed by acid precipitation. The pH of the refold solution is titrated to between pH 5.0 and pH 5.2 using 15% acetic acid (HOAc). This solution is stirred at 4 0 C for 2 hours and then centrifuged for minutes at 12,000 x g to pellet any insoluble protein.

The supernatant from the acid precipitation step is dialyzed using a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of 3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-fold excess) of mM Tris-HCl, pH 8.0 for a total of 18 hours. Dialysis lowers the sample conductivity and removes urea prior to DEAE chromatography. The sample is then centrifuged minutes at 12,000 x g) to pellet any insoluble protein following dialysis.

A Bio-Rad Bio-Scale DEAE2 column (7 x 52 mm) is used for ion exchange chromatography. The column is equilibrated in a buffer containing 10 mM Tris-HCl, pH 8.0, and a 0-to-500 mM sodium chloride (NaC1) gradient, in equilibration buffer, over 45 column volumes is used to elute the protein. A flow rate of 1.0 mL per minute is used throughout the run. Column fractions (2.0 mL per fraction) are collected across the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Ca.) C18 column (0.46 x 25 cm). A linear gradient of 40% to acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed. This gradient is developed over minutes at a flow rate of 1.5 mL per minute. Pooled fractions are then dialyzed against 2 changes of 4 liters (50-to-500-fold excess) of 10 mM ammonium acetate (NH4Ac), pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra/Por 3 membrane with a MWCO of WO 98/17810 PCT/US97/20037 3,500 daltons. Finally, the sample is sterile filtered using a 0.22pm syringe filter (pStar LB syringe filter, Costar, Cambridge, and stored at 4 0

C.

In some cases the folded proteins can be affinity purified using affinity reagents such as mAbs or receptor subunits attached to a suitable matrix.

Alternatively, (or in addition) purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC.

These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 'Guide to Protein Purification' edited by Murray Deutscher, Academic Press, San Diego, CA (1990).

Protein Characterization: The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

AML Proliferation Assay for Bioactive Human Interleukin- 3 The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, MD). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM-CSF supplemented medium (Lange, et al., Blood 70: 192, 1987; Valtieri, et al., J. Immunol.

138:4042, 1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, et al., J. Immunol. 139: 348, WO 98/17810 PCT/US97/20037 1987). A cell line variant was used, AML 193 1.3, which was adapted for long term growth in IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells are then replated at 1x10 cells/well in a 24 well plate in media containing 100 U/mL IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells are maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells are washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, NY) by centrifuging cell suspensions at 250 x g for minutes followed by decantation of the supernatant.

Pelleted cells are resuspended in HBSS and the procedure is repeated until six wash cycles are completed. Cells washed six times by this procedure are resuspended in tissue culture medium at a density ranging from 2 x to 5 x 10 viable cells/mL. This medium is prepared by supplementing Iscove's modified Dulbecco's Medium (IMDM, Hazelton, Lenexa, KS) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer- Mannheim, Indianapolis, IN) is added at 500 ug/mL; human transferrin (Boehringer-Mannheim, Indianapolis, IN) is added at 100 pg/mL; soybean lipid (Boehringer-Mannheim, Indianapolis, IN) is added at 50 pg/mL; and 2mercaptoethanol (Sigma, St. Louis, MO) is added at 5 x

M.

Serial dilutions of human interleukin-3 or multifunctional chimeric hematopoietic receptor agonist proteins are made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 pl of medium containing interleukin-3 or multi-functional chimeric hematopoietic receptor agonist proteins once serial dilutions are completed. Control wells contained WO 98/17810 PCT/US97/20037 tissue culture medium alone (negative control). AML 193 1.3 cell suspensions prepared as above are added to each well by pipetting 50 pl (2.5 x 10 cells) into each well. Tissue culture plates are incubated at 37 0 C with 5% CO 2 in humidified air for 3 days.. On day 3, 0.5 pCi 3 H-thymidine (2 Ci/mM, New England Nuclear, Boston, MA) is added in 50 pi of tissue culture medium. Cultures are incubated at 37 0 C with 5% CO 2 in humidified air for 18-24 hours. Cellular DNA is harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, MD) using a TOMTEC cell harvester (TOMTEC, Orange, CT) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats are allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, MO or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, MD) is added. Beta emissions of samples from individual tissue culture wells are counted in a LKB BetaPlate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, MD) and data is expressed as counts per minute of 3 H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or multi-functional chimeric hematopoietic receptor agonist protein preparation is quantitated by measuring cell proliferation 3 H-thymidine incorporation) induced by graded concentrations of interleukin-3 or multifunctional chimeric hematopoietic receptor agonist.

Typically, concentration ranges from 0.05 pM 10 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or multifunctional chimeric hematopoietic receptor agonist protein which provides 50% of maximal proliferation (EC 50 0.5 x (maximum average counts per minute of 3Hthymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested WO 98/17810 PCT/US97/20037 background proliferation measured by 'H-thymidine incorporation observed in triplicate cultures lacking interleukin-3). This EC 50 value is also equivalent to 1 unit of bioactivity. Every assay is performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Typically, the multi-functional chimeric hematopoietic receptor agonist proteins were tested in a concentration range of 2000 pM to 0.06 pM titrated in serial 2 fold dilutions.

Activity for each sample was determined by the concentration which gave 50% of the maximal response by fitting a four-parameter logistic model to the data. It was observed that the upper plateau (maximal response) for the sample and the standard with which it was compared did not differ. Therefore relative potency calculation for each sample was determined from estimations for the sample and the standard as indicated above. AML 193.1.3 cells proliferate in response to hIL-3, hGM-CSF and hG-CSF. Therefore the following additional assays were performed for some samples to demonstrate that the G-CSF receptor agonist portion of the multi-functional chimeric hematopoietic receptor agonist proteins was active. The proliferation assay was performed with the multi-functional chimeric hematopoietic receptor agonist plus and minus neutralizing monoclonal antibodies to the hIL-3 receptor agonist portion. In addition, a fusion molecule with the factor Xa cleavage site was cleaved then purified and the halves of the molecule were assayed for proliferative activity. These experiments showed that both components of the multi-functional chimeric hematopoietic receptor agonist proteins were active.

TF1 c-mpl liqand dependent proliferation assay The c-mpl ligand proliferative activity can be assayed using a subclone of the pluripotential human WO 98/17810 PCT/US97/20037 cell line TF1 (Kitamura et al., J. Cell Physiol 140:323- 334. [1989]). TF1 cells are maintained in h-IL3 (100 U/mL). To establish a sub-clone responsive to c-mpl ligand, cells are maintained in passage media containing 10% supernatant from BHK cells transfected with the gene expressing the 1-153 form of c-mpl ligand (pMON26448).

Most of the cells die, but a subset of cells survive.

After dilution cloning, a c-mpl ligand responsive clone is selected, and these cells are split into passage 6 media to a density of 0.3 x 10 cells/mL the day prior to assay set-up. Passage media for these cells is the following: RPMI 1640 (Gibco), 10% FBS (Harlan, Lot #91206), 10% c-mpl ligand supernatant from transfected BHK cells, 1 mM sodium pyruvate (Gibco), 2 mM glutamine (Gibco), and 100 ug/mL penicillin-streptomycin (Gibco).

The next day, cells are harvested and washed twice in RPMI or IMDM media with a final wash in the ATL, or assay media. ATL medium consists of the following: IMDM (Gibco), 500 ug/mL of bovine serum albumin, 100 ug/mL of human transferrin, 50 ug/mL soybean lipids, 4 x 10-8M beta-mercaptoethanol and 2 mL of A9909 (Sigma, antibiotic solution) per 1000 mL of ATL. Cells are diluted in assay media to a final density of 0.25 x cells/mL in a 96-well low evaporation plate (Costar) to a final volume of 50 ul. Transient supernatants (conditioned media) from transfected clones are added at a volume of 50 ul as duplicate samples at a final concentration of 50% and diluted three-fold to a final dilution of Triplicate samples of a dose curve of IL-3 variant pMON13288 starting at 1 ng/mL and diluted using three-fold dilutions to 0.0014ng/mL is included as a positive control. Plates are incubated at 5% CO 2 and 370 C. At day six of culture, the plate is pulsed with Ci of 3H/well (NEN) in a volume of 20 ul/well and allowed to incubate at 5% CO 2 and 370 C for four hours.

WO 98/17810 PCT/US97/20037 The plate is harvested and counted on a Betaplate counter.

MUTZ-2 Cell Proliferation Assay A cell line such as MUTZ-2, which is a human myeloid leukemia cell line (German Collection of Microorganisms and Cell Cultures, DSM ACC 271), can be used to determine the cell proliferative activity of flt3 receptor agonists. MUTZ-2 cultures are maintained with recombinant native flt3 ligand (20-100ng/mL) in the growth medium. Eighteen hours prior to assay set-up, MUTZ-2 cells are washed in IMDM medium (Gibco) three times and are resuspended in IMDM medium alone at a concentration of 0.5-0.7 x 10E6 cells/mL and incubated at 37 0 C and 5%CO 2 to starve the cells of flt3 ligand.

The day of the assay, standards and flt3 receptor agonists are diluted to two fold above desired final concentration in assay media in sterile tissue culture treated 96 well plates. Flt3 receptor agonists and standards are tested in triplicate. 50pl of assay media is loaded into all wells except row A. 75pl of the flt3 receptor agonists or standards are added to row A and 25pl taken from that row and serial dilutions (1:3) performed on the rest of the plate (rows B through G).

Row H remains as a media only control. The starved MUTZ-2 cells are washed two times in IMDM medium and resuspended in 50pl assay media. 50pl of cells are added to each well resulting in a'final concentration of 0.25 x 10E6cells/mL. Assay plates containing cells are incubated at 37 0 C and 5%CO 2 for 44hrs. Each well is then pulsed with lpCi/well of tritiated thymidine in a volume of 20pl for four hours. Plates are then harvested and counted.

Other in vitro cell based proliferation assays WO 98/17810 PCT/US97/20037 Other in vitro cell based assays, known to those skilled in the art, may also be useful to determine the activity of the multi-functional chimeric hematopoietic receptor agonists depending on the factors that comprise the molecule in a similar manner as described in the AML 193.1.3 cell proliferation assay. The following are examples of other useful assays.

TF1 proliferation assay: TF1 is a pluripotential human cell line (Kitamura et al., J. Cell Physiol 140:323-334.

[1989]) that responds to hIL-3.

32D proliferation assay: 32D is a murine IL-3 dependent cell line which does not respond to human IL-3 but does respond to human G-CSF which is not species restricted.

Baf/3 proliferation assay: Baf/3 is a murine IL-3 dependent cell line which does not respond to human IL-3 or human c-mpl ligand but does respond to human G-CSF which is not species restricted.

T1165 proliferation assay: T1165 cells are a IL-6 dependent murine cell line (Nordan et al., 1986) which respond to IL-6 and IL-11.

Human Plasma Clot meg-CSF Assay: Used to assay megakaryocyte colony formation activity (Mazur et al., 1981).

Transfected cell lines: Cell lines such as the murine Baf/3 cell line can be transfected with a colony stimulating factor receptor, such as the human G-CSF receptor or human cmpl receptor, which the cell line does not have. These transfected cell lines can be used to determine the activity of the ligand for which the receptor has been transfected into the cell line.

WO 98/17810 PCT/US97/20037 One such transfected Baf/3 cell line was made by cloning the cDNA encoding c-mpl from a library made from a c-mpl responsive cell line and cloned into the multiple cloning site of the plasmid pcDNA3 (Invitrogen, San Diego Baf/3 cells were transfected with the plasmid via electroporation. The cells were grown under G418 selection in the presence of mouse IL-3 in Wehi conditioned media. Clones were established through limited dilution.

In a similar manner the human G-CSF receptor can be transfected into the Baf/3 cell line and used to determine the bioactivity of the multi-functional chimeric hematopoietic receptor agonists.

Analysis of c-mpl liqand proliferative activity Methods 1. Bone marrow proliferation assay a. CD34+ Cell Purification: Bone marrow aspirates (15-20 mL) were obtained from normal allogeneic marrow donors after informed consent.

Cells were diluted 1:3 in phosphate buffered saline (PBS, Gibco-BRL), 30 mL were layered over 15 mL Histopaque-1077 (Sigma) and centrifuged for 30 minutes at 300 RCF. The mononuclear interface layer was collected and washed in PBS. CD34+ cells were enriched from the mononuclear cell preparation using an affinity column per manufacturers instructions (CellPro, Inc., Bothell WA). After enrichment, the purity of CD34+ cells was 70% on average as determined by using flow cytometric analysis using anti-CD34 monoclonal antibody conjugated to fluorescein and anti-CD38 conjugated to phycoerythrin (Becton Dickinson, San Jose CA).

Cells were resuspended at 40,000 *cells/mL in X-Vivo media (Bio-Whittaker, Walkersville, MD) and 1 mL was plated in 12-well tissue culture plates (Costar). The WO 98/17810 PCT/US97/20037 growth factor rhIL-3 was added at 100 ng/mL (pMON5873) was added to some wells. hIL3 variants were used at ng/mL to 100 ng/mL. Conditioned media from BHK cells transfected with plasmid encoding c-mpl ligand or multifunctional chimeric hematopoietic receptor agonists were tested by addition of 100 pl of supernatant added to 1 mL cultures (approximately a 10% dilution). Cells were incubated at 37 0 C for 8-14 days at 5% CO 2 in a 37 0

C

humidified incubator.

b. Cell Harvest and Analysis: At the end of the culture period a total cell count was obtained for each condition. For fluorescence analysis and ploidy determination cells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 pm PGE1, 11 mM glucose, 3% w/v BSA, in PBS, pH (Tomer et al., Blood 70: 1735- 1742, 1987) resuspended in 500 pl of MK buffer containing anti-CD41a FITC antibody (1:200, AMAC, Westbrook, ME) and washed in MK buffer. For DNA analysis cells were permeablized in MK buffer containing Tween 20 (Fisher, Fair Lawn NJ)for 20 min. on ice followed by fixation in 0.5% Tween-20 and 1% paraformaldehyde (Fisher Chemical) for 30 minutes followed by incubation in propidium iodide (Calbiochem La Jolla Ca) (50 pg/mL) with RNA-ase (400 U/mL) in v/v MK buffer (200mOsm) for 1-2 hours on ice. Cells were analyzed on a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, CA). Green fluorescence (CD41a-FITC) was collected along with linear and log signals for red fluorescence (PI) to determine DNA ploidy. All cells were collected to determine the percent of cells that were CD41+. Data analysis was performed using software by LYSIS (Becton Dickinson, San Jose, CA). Percent of cells expressing the CD41 antigen was obtained from flow cytometry analysis(Percent).

WO 98/17810 PCT/US97/20037 Absolute (Abs) number of CD41+ cells/mL was calculated by: (Abs)=(Cell Count)*(Percent)/100.

2. Megakaryocyte fibrin clot assay.

CD34+ enriched population were isolated as described above. Cells were suspended at 25,000 cells/mL with or without cytokine(s) in a media consisting of a base Iscoves IMDM media supplemented with 0.3% BSA, 0.4mg/mL apo-transferrin, 6.67pM FeCl 2 25pg/mL CaC1 2 25pg/mL Lasparagine, 500pg/mL e-amino-n-caproic acid and penicillin/streptomycin. Prior to plating into plates, thrombin was added (0.25 Units/mL) to initiate clot formation. Cells were incubated at 37 0 C for 13 days at 5% CO 2 in a 37 0 C humidified incubator.

At the end of the culture period plates were fixed with methanol:acetone air dried and stored at -200C until staining. A peroxidase immunocytochemistry staining procedure was used (Zymed, Histostain-SP. San Francisco, CA) using a cocktail of primary monoclonal antibodies consisting of anti-CD41a, CD42 and CD61.

Colonies were counted after staining and classified as negative, CFU-MK (small colonies, 1-2 foci and less that approx. 25 cells), BFU-MK (large, multi-foci colonies with 25 cells) or mixed colonies (mixture of both positive and negative cells.

Methylcellulose Assay This assay reflects the ability of colony stimulating factors to stimulate normal bone marrow cells to produce different types of hematopoietic colonies in vitro (Bradley et al., Aust. Exp Biol. Sci. 44:287-300, 1966), Pluznik et al., J. Cell Comp. Physio 66:319-324, 1965).

WO 98/17810 PCT/US97/20037 go Methods Approximately 30 mL of fresh, normal, healthy bone marrow aspirate are obtained from individuals following informed consent. Under sterile conditions samples are diluted 1:5 with a lX PBS (#14040.059 Life Technologies, Gaithersburg, MD.) solution in a 50 mL conical tube (#25339-50 Corning, Corning MD). Ficoll (Histopaque 1077 Sigma H-8889) is layered under the diluted sample and centrifuged, 300 x g for 30 min. The mononuclear cell band is removed and washed two times in 1X PBS and once with 1% BSA PBS (CellPro Co., Bothel, WA).

Mononuclear cells are counted and CD34+ cells are selected using the Ceprate LC (CD34) Kit (CellPro Co., Bothel, WA) column. This fractionation is performed since all stem and progenitor cells within the bone marrow display CD34 surface antigen.

Cultures are set up in triplicate with a final volume of mL in a 35 X 10 mm petri dish (Nunc#174926).

Culture medium is purchased from Terry Fox Labs. (HCC- 4230 medium (Terry Fox Labs, Vancouver, Canada) and erythropoietin (Amgen, Thousand Oaks, CA.) is added to the culture media. 3,000-10,000 CD34+ cells are added per dish. Recombinant IL-3, purified from mammalian cells or E. coli, and multi-functional chimeric hematopoietic.receptor agonist proteins, in conditioned media from transfected mammalian cells or purified from conditioned media from transfected mammalian cells or E. coli, are added to give final concentrations ranging from .001 nM to 10 nM.

Recombinant hIL-3, GM-CSF, c-mpl ligand and multifunctional chimeric hematopoietic receptor agonist are supplied in house. G-CSF (Neupogen) is from Amgen (Thousand Oaks Calf.). Cultures are resuspended using a 3cc syringe and 1.0 mL is dispensed per dish. Control (baseline response) cultures received no colony stimulating factors. Positive control cultures received conditioned media (PHA stimulated human cells: Terry Fox WO 98/17810 PCT/US97/20037 Lab. H2400). Cultures are incubated at 37 0 C, 5% CO 2 in humidified air.

Hematopoietic colonies which are defined as greater than cells are counted on the day of peak response (days 10-11) using a Nikon inverted phase microscope with a objective combination. Groups of cells containing fewer than 50 cells are referred to as clusters.

Alternatively colonies can be identified by spreading the colonies on a slide and stained or they can be picked, resuspended and spun onto cytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays Bone marrow cells are traditionally used for in vitro assays of hematopoietic colony stimulating factor (CSF) activity. However, human bone marrow is not always available, and there is considerable variability between donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer et al., PNAS USA 89:4109-113, 1992; Mayani et al., Blood 81:3252-3258, 1993). In contrast to bone marrow, cord blood is more readily available on a regular basis. There is also a potential to reduce assay variability by pooling cells obtained fresh from several donors, or to create a bank of cryopreserved cells for this purpose. By modifying the culture conditions, and/or analyzing for lineage specific markers, it is be possible to assay specifically for granulocyte macrophage colonies (CFU- GM), for megakaryocyte CSF activity, or for high proliferative potential colony forming cell (HPP-CFC) activity.

Methods Mononuclear cells (MNC) are isolated from cord blood within 24 hr. of collection, using a standard density WO 98/17810 PCT/US97/20037 gradient (1.077 g/mL Histopaque). Cord blood MNC have been further enriched for stem cells and progenitors by several procedures, including immunomagnetic selection for CD14-, CD34+ cells; panning for SBA-, CD34+ fraction using coated flasks from Applied Immune Science (Santa Clara, CA); and CD34+ selection using a CellPro (Bothell, WA) avidin column. Either freshly isolated or cryopreserved CD34+ cell enriched fractions are used for the assay. Duplicate cultures for each serial dilution of sample (concentration range from 1 pM to 1204 pM) are 4 prepared with 1x10 cells in iml of 0.9% methylcellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies, Vancouver, In some experiments, Methocult H4330 containing erythropoietin (EPO) was used instead of Methocult H4230, or Stem Cell Factor (SCF), 50 ng/mL (Biosource International, Camarillo, CA) was added. After culturing for 7-9 days, colonies containing >30 cells are counted.

In order to rule out subjective bias in scoring, assays are scored blind.

Additional details about recombinant DNA methods which may be used to create the variants, express them in bacteria, mammalian cells or insect cells, purification and refold of the desired proteins and assays for determining the bioactvity of the proteins may be found in co-filed Applications WO 95/00646, WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and US 08/383,035 which are hereby incorporated by reference in their entirety.

Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, 1989) and references. cited therein, incorporated herein by reference.

A"

'9 WO 98/17810 PCTIUS97/20037 TABLE 1

OLIGONUCLEOTIDES

c-mpJ.NcoI ACGTCCATGGCNTCNCCNCCNCCNCCTGCTTGTGCACTCCGAGTC SEQ ID NO:317 N=A,C,G or T Ecompi ATGCACGAATTCCCTGACGCAGAGGGTGGA SEQ ID NO:318 c-mplHindIII TGACAAGCTTACCTGACGCAGAGGGTGGACCCT SEQ ID NO:319 AATTCGGCAA SEQ ID NO:320 4L-3' CATGTTGCCG SEQ ID NO:321 AATTCGGCGGCAJA SEQ ID NO:322 5L-3' CATGTTGCCGCCG SEQ ID NO:323 8L-5' AATTCGGCGGCAACGGCGGCJA SEQ ID NO:324 8L-3' CATGTTGCCGCCGTTGCCGCCG SEQ ID NO:325 31-5' CGATCCATGGAGGTTCACCCTTTGCCT SEQ ID NO:326 31-3' GATCAAGCTTATGGGCACTGGCTCAGTCT SEQ ID NO:327 35-5' CGATACATGTTGCCTACACCTGTCCTG SEQ ID NO: 328 35-3' GATCAAGCTTAAGGGTGAJACCTCTGGGCA SEQ ID NO:329 3 9-5' CGATCCATGGTCCTGCTGCCTGCTGTG SEQ ID NO:330 39-3' GATCAAGCTTAAGGTGTAGGCmAGGGTG SEQ ID NO:331 43-5' CGATCCATGGCTGTGGACTTTAGCTTGGGA SEQ ID NO:332 43-3' GATCAAGCTTAAGGCAGCAGGACAGGTGT SEQ ID NO: 333 45-5' CGATCCATGGACTTTAGCTTGGGAGAA SEQ ID NO:334 45-3' GATCAAGCTTACACAGCAGGCAGCAGGAC SEQ ID NO:335 49-5' CGATCCATGGGAGAATGGAAAACCCAG SEQ ID NO:336 49-3' GATCAAGCTTACAAGCTAGTCCACAGC SEQ ID NO: 337 82-5 CGATCCATGGGACCCACTTGCCTCTCA SEQ ID NO:338 82-3' GATCAAGCTTACAGTTGTCCCCGTGCTGC SEQ ID NO:339 109-5' CAGTCCATGGGAACCCAGCTTCCTCCA SEQ ID NO:340 109-3' GATCAAGCTTAAAGGAGGCTCTGCAGGGC SEQ ID NO:341 116-5' CGATCCATGGGCAGGACCACAGCTCAC SEQ ID NO:342 116-3' GATCAAGCTTACTGTGGAGGAAGCTGGGTT SEQ ID NO: 343 120-5' CGATCCATGGCTCACAJ\GGATCCCAATGCC SEQ ID NO:344 120-3' GATCAAGCTTATGTGGTCCTGCCCTGTGG SEQ ID NO:345 123-5' CGATCCATGGATCCCAATGCCATCTTCCTG SEQ ID NO:346 123-3' GATCAAGCTTACTTGTGAGCTGTGGTCCT SEQ ID NO: 347 12 6-5' CGATCCATGGCCATCTTCCTGAGCTTCCAJA SEQ ID NO:348 126-3' GATCAAGCTTAATTGGGATCCTTGTGAGCTGT SEQ ID NO:349 SYNNOXAl.REQ AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC SEQ ID NO:350 WO 98/17810 WO 9817810PCTIUS97/20037 SYNNOXA2. REQ CCGGGGAGCC -TCCACCGCCC TCTACGTACT GTTGAGCCTG

CGCGTTCTCC

CGG SEQ ID Llsyn.f or GTTACCCTTG

CTAACTGCTC

AAGGTTTTCA GATAGAAGGT CAGTTTACGA NO: 351 AGCAAGCGCA GGAACAACAG GGTGGTGGCT TATAATGAT SEQ ID NO:352 Llsyn.rev CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG SEQ L3syn.for GTTACCCTTG AGCAAGCGCA CTGGCGGTGG CAGCGGCGGC SEQ ID NO:354 L3syn.rev CGATCATTAT AGAGCAGTTA GCCAGAGCCA CCACCCTGTT GATCGACCAT GGCTCTGGAC 34rev.seq CTCGATTACG TACAAAGGTG 7Ostart.seq GATCGACCAT GGCTAATGCA 69rev.seq CTCGATTACG TATTCTAAGT 91start.seq GATCGACCAT GGCTGCACCC 9Orev.sea CTCGATTACG TAGGCCGTGG ID NO:353

GGAACAACAG

GGTTCTAACT

GAACCGCCGC CGCTGCCACC GTTCCTGCGC TTGCTCAAGG SEQ ID NO:355 CCGAACAACC TC SEQ ID NO:356 CAGGTGGT SEQ ID NO:357 TCAGGTATTG AG SEQ ID NO:358 TCTTGACA SEQ ID NO:359 TCTCGACATC CA SEQ ID NO:360 CAGAGGGC SEQ ID NO:361

GGTGGTGGCT

GCTCTATAAT GAT 101start.seq GATCGACCAT GGCTGCAGGT GACTGGCAAG AA SEQ ID NO:362 CTCGATTACG TACTTGATGA TGATTGGA SEQ ID NO: 363 L-llstart.seq GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG SEQ ID NO:364 L-llStop.seq CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG SEQ ID NO:365 P-bls tart. seq GGGCTGCGCA AGGTGGCG SEQ ID NO:366 P-blstop seq 39start. seq 38stop .Seq 97start .seq 96stop.Seq 126start -seq 133start seq 132 stop seq 142start.seq 141stop. Seq GLYXA1 GLYXA2 1GGGS for ACACCATTGG GCCCTGCCAG C SEQ ID NO:367 GATCGACCAT GGCTTACAAG CTGTGCCACC CC SEQ ID NO:368 CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT SEQ ID NO:369 GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC SEQ ID NO:370 CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT SEQ ID NO:371 GATCGACCAT GGCTATGGCC CCTGCCCTGC AG SEQ ID NO:372 CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT SEQ ID NO:373 GATCGACCAT GGCTACCCAG GGTGCCATGC CG SEQ ID NO:374 CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA SEQ ID NO:375 GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG SEQ ID NO:376 CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC SEQ ID NO:377 GTAGAGGGCG GTGGAGGCTC C SEQ ID NO: 378 CCGGGGAGCC TCCACCGCCC TCTAC SEQ ID NO:379 TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG SEQ ID NO:380 CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA SEQ ID NO:381 CTGACCATGGCNACCCAGGACT1GCTCCTTCCAA SEQ ID NO:807 1GGGSrev

NCOFLT

1: WO 98/17810 PCT1US97I20037 HIND160 HIND165 FL23For FH3AFor

SCF.REV

39F0R 3 9REV 65F0R 89F0R 8 9REV

LIQA

339F0R2 339REV2 339-1OFOR3 339-15FOR2 339REV3 FLN3 FLN7 ACTGAAGCTTAGGGCTGACACTGCAGCTCCAG SEQ ID NO:808 ACTGAAGCTTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 809 GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO; 810 GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO: 811 TGTCCAAACTCATCAATGTATC SEQ ID NO: 812 CATGGCCATGGCCGACGAGGAGCTCTGCGGGGGCCTCT SEQ ID NO:813 GCTAGAAGCTTACTGCAGGTTGGAGGCCACGGTGAC SEQ ID NO: 814 CATGGCCATGGCCTCCAAGATGCAAGGCTTGCTGGAGC SEQ ID NO: 815 GCTAGAAGCTTACCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO: 816 CATGGCCATGGCCCCCCCCAGCTGTCPTCGCTTCGT SEQ ID NO:817 GCTAGAAGCTTAGGGCTGAAAGGCACATTTGGTGACA SEQ ID NO: 818 CCCTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 819 GCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 820

ACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGA.ACCCAGGACT

GCTCCTTCCAAC SEQ ID NO:821 GTGCCGTTGCCGCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 822 ATTACCTCCACTGCCGTTACCGCCTGACAGGGTTGAGGAGTCGGG CTG SEQ ID NO: 823

GCTCCCATTGCCACCACTGCCGTTACCTCCAGACAGGGTTGAGGA

GTCGGGCTG SEQ ID NO:824

GATGAGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGG

ACTGCTCCTTCCACC SEQ ID NO:825 GATGACGGATCCGTTACCTCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 826 GATGACGGATCCGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 827 GACTGCCATGGCCGACGAGGAGCTCTGCG SEQ ID NO: 828 GACTCAAGCTTACTGCAGGTTGGAGGCC SEQ ID NO:829 GACTCGGGATCCGGAGGTTCTGGCACCCAGGACTGCTCC SEQ ID NO: 830 GACTGGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACC SEQ ID NO:831 GACTTGGGATCCACTACCTCCAGACAGGGTTGAGGA GTC SEQ ID NO: 832 ACTGACGGATCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 833 ACTGACGGATCCACCTCCTGACCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 834

ACTGACGGATCCACCTCCTGACCCACCTCCTGACCCACCGCCCAG

GGTTGAGGAGTCGGGCTG SEQ ID NO: 835 ACGTAAAGCTTACAGGGTTGAGGAGTCG SEQ ID NO:836 GTCAGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAA C SEQ ID NO:837 GTCAGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 838 TCAGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAAC SEQ ID NO:839 TAGTCCATGGCCACCCAGGACTGCTCC SEQ ID NO:840 GCATTACGTAGGGCTGACACTGCAGCTCCAG SEQ ID NO: 841 F~LN11 C- term FLC3 FLC4 FLC1O N-term 134.rev WO 98/17810 139 -e F129f or FL2 9rev FL35rev FL63 for FL63 rev for FL99for FL99rev FLTAFLS1 FLTRlN

HGCFOR

HGCREV

FL29FOR PCTIUS97/20037 GCATTACGTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 842 GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO: 843; TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 844; GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA SEQ ID NO: 845; TCTGACAAOCTTACACGGTGACTGGT-CTTGAAGC SEQ ID NO: 846; GTCAGACCATGGCCGTCGCTGGGTCCAJAGATGCAAGGC SEQ ID NO: 847; TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 848; GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 849; TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 850; GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO: 851; CTCGACAAGCTTACTGGACGAAGCGAJAGACAGCTGGG SEQ ID NO:852; GATCACATGTCTACJLAATCAAGATCTGCCTGTG SEQ ID NO: 853 GATCGAATTCGTTGTCTTGGATGAAAGGGA SEQ ID NO:854 ACTTGAATTCATCATCCTGGGCCTGTTCGGGC SEQ ID NO:855 ACTCAAGCTTAGAAGCTCCCCAGCGCCTCC SEQ ID NO:856 GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO: 382 GTACCTGCCTCACGAGCAG SEQ ID NO: 383 GTCAGACCATGGCCGTCGCTGGGTCCAJAGATGCAAGGC SEQ ID NO: 384 GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 385 GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO :386 FL3 5FOR FL63 FOR

FOR

FL99FOR FL2 9REV TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 387 FL3 5REV TCTGACAAGCTTACACGGTGACTGGGTATCTTGAAGC SEQ ID NO: 388 FL63REV 89 REVSTOP TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 389 GTCAAGAAGCTTACGGCTGAAAGGCACATTTG SEQ ID NO: 390 TCTGACAAGCTTAA.AGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 391 CTCGACAAGCTTACTGGACGAJ\GCGAAGACAGCTGGG SEQ ID NO: 392 FL9 5REV FL9 9REV Flt36 Flt37

GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGT

GCOGGGGCCTCTGGCGGCTG SEQ ID NO:393

GTTGCCATGGCNAAYCTGCARGAYGARGARCTGTGYG

GOGGCCTCTGGCGGCTGGTC SEQ ID NO:394

GTTGCCATGGCNCTGCARGAYGARGARCTGTGYGGYG

GCCTCTGGCGGCTGGTCCTG SEQ ID NO:-395

GTTGCCATGGCNCARGAYGARGARCTGTGYGGYGGYC

Flt38 Flt39 WO 98/17810 WO 9817810PCTIUS97/20037 TCTGGCGGCTGGTCCTGGCA SEQ ID NO: 396 Fit 40 GTTGCCATGGCNGAYGARGARCTGTGYGGYGGYCTCT GGCGGCTGGTCCTGGCACAG SEQ ID NO:397 Flt4 1 GTTGCCATGGCNGARGARCTGTGYGGYGGYCTCTGGC GGCTGGTCCTGGCACAGCGC SEQ ID NO:398 Fl t42 GTTGCCATGGCNGARCTGTGYGGYGGYCTGTGGCGYC TOGTCCTGGCACAGCGCTGG SEQ ID NO:399 Fit 43 GTTGCCATGGCNCTGTGYGGYGGYCTGTGGCGYCTGG TCCTGGCACAGCGCTGGATG SEQ ID NO:400 40 COLI GTTGCCATGGCWGATGAAGAACTGTGTGGNGGNCTGTGGCGG SEQ ID NO:4O1 3 6REV TATGCAAGCTTAGGCCACGGTGACTGGGTA SEQ ID NO:402 37REV TATGCAAGCTTAGGAGGCCACGGTOACTGG SEQ ID NO:403 3 8REV TATGCAAGCTTAGTTGGAGGCCACGGTGAC SEQ ID NO:404 3 9REV TATGCAAGCTTACAGGTTGGAGGCCACGGT SEQ ID NO: 405 41REV TATGCAAGCTTAGTCCAGGTTGGAGGCCAC SEQ ID NO:406 42REV TATGCAAGCTTACTCGTCCAGGTTGGAGGC SEQ ID NO:407 43REV TATGCAAGCTTACTCCTCGTCCAGGTTGGA SEQ ID NO: 408 3 9N TERM- 2 GACTAGCCATGGCNGAYGARGARCTGTGYGGTGGCCTCTGGCGG SEQ ID NO:409 SNA BiCTERM GACTAGTACGTACTGCAGGTTGGAGGCCACGG SEQ ID NO:410 29SMBl GCAGGTTACGTATTGAAGCAGGTAGTCAGACAGCTC SEQ ID NO: 411 34SNAB1 GCAGGTTACGTACACGGTGACTGGGTAATCTTGAAG SEQ ID NO: 12 63 SNAB1 GCAGGTTACGTA.AGTCTTGAGCCGCTCCATCCAGC SEQ ID NO: 413 66SNAB1 GCAGGTTACGTAGCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO: 414 WO 98/17810 8 9N-TERMCSLI GTCAAGCCATGGCNCCRCCRAGCTGTCTRCGCT TCGTTCAGACCA.ACTC SEQ ID NO: 415 PCTIUS97/20037 89SNAB1 945 SMB.

98SUAB1 BAJA FOR BAM REV NAVREV L NAVREV S

NAVFOR

XBAFOR1 XBAREV1 GCAGGTTACGTACGGCTGAGGCACATTTGGTGACA.A SEQ ID NO: 416 GCAGGTTACGTAAGACAGCTGOGGGGGO SEQ ID NO: 417 GCAGGTTACGTACTGGACGAAGCGAAGACAGCTG SEQ ID NO: 418

TCAGTTGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTA

SEQ ID NO:426

TCAGTTGGATCCTCCGCCAGAACCACCGCCTGACCCACCTCCTGACCC

SEQ ID NO:427

GTCTGAGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCC

AGGACTGCTCCTTC SEQ ID NO:428

GTCTGAGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAAC

SEQ ID NO:429

GTCTGAGGCGCCGAGTGGACGCGGGCTCCACGGTGGCGGCAGGGT

TGAGGAGTCGGGCTG SEQ ID NO:430

GCTACGTCTAGATCTCCTGACCTCGACCCAGGACTGCTCCTTCCA-C

SEQ ID NO:447

GCTAGTTCTAGACCATCCTGGCTGACACGGTGAAACACCGTCTCTACG

GGCTGACACTGCAGCTCCAG SEQ ID NO:448

GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGCTCCTGCAGG

TTGGAGGCCACGG SEQ ID NO:449

GTCAGTACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGC

SEQ ID NO:450

GTCAGTTCCGGAGATTTCGGTTCTGCAGAGGGCTGCGCAAGG

TGGCGTA SEQ ID NO:451

GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTTCTA

ATCTGCAAGATGAAGAGCTG SEQ ID NO: 452

GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGAAAGGCACATTT

GGTGACAAAGTGTATC SEQ ID NO:453

GTCAGTACTAGTCCGCCATCTCCGGGTACACCATTAGGCCCTG

CCAGC SEQ ID NO:454

GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTAJAOGCC

TTTCAGCCCCCCCCCAG SEQ ID NO:455 GTCAGACCATGGCCACTCAGGACTCCTCTTTTC SEQ ID NO: 456 LNK1 FOR LNKlREV LNK2FOR LNK2 REV LNK7 FOR LNK7 REV LNK8REV ClFOR WO 98/17810 PCTIUS97/20037 C3FOR C3REV C5FOR C6REV CACTTTGTCACCAAATCTGCCTTTCAG SEQ ID NO.:457 CTGAAAGGCAGATTTGGTGACAAAGTG SEQ ID NO: 458 GCCCCCCCCCAGCTCTCTTCG SEQ ID NO:459 CGAAGAGAGCTGGGGGGGGGC SEQ ID NO:460 GTCAGTTACGTACAGGGTTGA.AGGAGTCGGGCTGAGACTGC SEQ ID NO: 461 GTCAGTCCATGGCTACTCAAGGTGCTATGC SEQ ID NO: 462 GTAGCATACGTAGGGCTGCAGGGCAGGGGCC SEQ ID NO:463 GPFOR1 GPREV2 WO 98/17810 PCT[US97/20037 to TABLE 2 GENE SEQUENCES pMON3 0304

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCIGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGA-ATCTCATAAATCTCCAAACATGT SEQ ID NO: 1 pM0N26458

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGGGAATTC SEQ ID NO: 2 pMON28548

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG

CTTCGTGACTCCCATrGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG

CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA

GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTG

GGGCAGCTTTCTGGACAGGTCCGTCTCCTCCI'TGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACA

GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT

GTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO:3 pMON2 8500

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT

CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG

CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA

GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG

CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC

AGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTC

CTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: pMON2 85 01

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAA.ACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCPCCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG

CTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG

CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA

GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTG

GGGCAGCTTTCtGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG

GGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGT

TTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: pMON28502 WO 98/17810 PTU9103 PCT[US97/20037

TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCC.TC

AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA

CCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGAC

ATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG-GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA

TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTT

CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA

AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG

SEQ ID NO:6 Syntanl 1 51 101 151 201 251 301 351 401 451 501 551 601 651 CATGGCTAAC TGCTCTATAA GACCACCTGC ACCTTTGCTG TCTATCCTGA TGGACCGAAA AAGGGCTGTC AAGAACTTAG GTAATCTCCA ACCATGTCTG

CCAATCATCA

GTTCTATCTG

CTAACTGCTC

CCTGCACCTT

CCTGATGGAC

CTGTCAAGAA

CTCCAACCAT

CATCATCAAG

ATCTGGTTAC

SEQ ID NO:

TCAAGGCAGG

GTTACCCTTG

TATAATGATC

TGCTGGACCC

CGAAACCTTC

CTTAGAAAAT

GTCTGCCCTC

GCAGGTGACT

CCTTGAGCAA

TGATCGATGA

GACCCGAACA

CCTTCGACTT

AAAATGCATC

CCCTCTGCCA

TGACTGGCAA

AGCAAGCGCA

GATGAAATTA

GAACAACCTC

GACTTCCAAA

GCATCAGGTA

TGCCACGGCC

GGCAAGAATT

GCGCAGGAAC

AATTATACAT

ACCTCA.ATGA

CCAAACCTGG

AGGTATTGAG

CGGCCGCACC

GAATTCCGGG

GGAACA-ACAG

TACATCACTT

AATGACGAAG

CCTGGAGAGC

TTGAGGCAAT

GCACCCTCTC

CCGGGAAAAA

AACAGTAC

CACTTAAAGA

CGAAGACGTC

AGAGCTTCGT

GCAATTCTTC.

CTCTCGACAT

AAAAACTGAC

GGTGGTGGCT

AAAGAGACCA

ACGTCTCTAT

TTCGTAAGCG

TCTTCGTAAT

GACATCCAAT

CTGACGTTCT

syntan3 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701

CATGGCTALAC

GACCACCTGC

TCTATCCTGA

AAGGGCTGTC

GTAATCTCCA

CCAATCATCA

GTTCTATCTG

CTGGCGGTGG

ATTATACATC

CCTCAATGAC

CAA.ACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TGCTCTATAA TGATCGATGA ACCTTTGCTG GACCCGAACA TGGACCGAAA CCTTCGACTT AAGAACTTAG AAAATGCATC ACCATGTCTG CCCTCTGCCA TCAAGGCAGG TGACTGGCAA GTTACCCTTG AGCAAGCGCA CAGCGGCGGC GGTTCTAACT ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT AAAACTGACG TTCTA'rCTGG AC SEQ ID NO:8 AATTATACAT CACTTAAAGA ACCTCAATGA CGAAGACGTC CCAAACCTGG AGAGCTTCGT AGGTATTGAG GCAATTCTTC CGGCCGCACC CTCTCGACAT GAATTCCGGG AAAAACTGAC GGAACALACAG GGTGGTGGCT GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG pMON311O4 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 ATGGCTCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCALAG TTACCCTTGA GCAAGCGCAG ATAATGATCG ATGAAATTAT GTACGTAGAG GGCGGTGGAG CTACTATCAA CCCGTCTCCT ATGGCTACCC AGGGTGCCAT GGCAGGAGGG GTCCTGGTTG CGTACCGCGT TCTACGCCAC TCTCAGAGCT TCCTGCTCAA CGATGGCGCA GCGCTCCAGG ACCCCGAGGA GCTGGTGCTG CCCCTGAGCT CCTGCCCCAG CCAACTCCAT AGCGGCCTTT AAGGGATATC CCCCGAGTTG GTCGCCGACT TTGCCACCAC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGG

ACATCACTTA

GCTCCCCGGG

CCGTCTAAAG

GCCGGCCTTC

CTAGCCATCT

CTTGCGCAGC

GTCTTTAGAG

AGAAGCTGTG

CTCGGACACT

CCAGGCCCTG

TCCTCTACCA

GGTCCCACCT

CATCTGGCAG

GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT AAAACTGACG TTCTATCTGG GTGGTGGCTC TAACTGCTCT AAGAGACCAC CTGCACCTTT TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTCTGGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCI'CCTG CAGGCCCTGG TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT WO 98/17810 951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 9 PCT/US97ZOO37 pMON3 1105 1 51 101 151.

201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAATG

TCTGCCCTCT

CAGGTGACTG

CTTGAGCAAG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

ATACGTAGAG

CTACTATCAA

ATGGCTACCC

GGCAGGAGG

CGTACCGCGT

TCTCAGAGCT

CGATGGCGCA

ACCCCGAGGA

CCCCTGAGCT

CCAACTCCAT

AAGGGATATC

GTCGCCGACT

GGCCCCTGCC

CATCAGGTAT

GCCACGGCCG

GCAAGAATTC

CGCAGGAACA

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGCGGTGGAG

CCCGTCTCCT

AGGGTGCCAT

GTCCTGGTTG

TCTACGCCAC

TCCTGCTCAA

GCGCTCCAGG

GCTGGTGCTG

CCTGCCCCAG

AGCGGCCTTT

CCCCGAGTTG

TTGCCACCAC

CTGCAGCCCT

TGAGGCAATT

CACCCTCTCG

CGGGAAAAAC

ACAGGGTGGT

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

GCTCCCCGGG

CCGTCTAAAG

GCCGGCCTTC

CTAGCCATCT

CTTGCGCAGC

GTCTTTAGAG

AGAAGCTGTG

CTCGGACACT

CCAGGCCCTG

TCCTCTACCA

GGTCCCACCT

CATCTGGCAG

CTTCGTAATC

ACATCCAATC

TGACGTTCTA

GGCTCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TGAACCGTCT

AATCTCATAA

GCCTCTGCTT

GCAGAGCTTC

CCTCTGGCGG

CAAGTGAGAA

TGCCACCTAC

CTCTGGGCAT

CAGCTGGCAG

GGGGCTCCTG

TGGACACACT

CAGATGGA.AG

TCCAACCATG

ATCATCAAGG

TCTGGTTACC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

GGTCCAATCT

ATCTCCAAAC

TCCAGCGCCG

CTGGAGGTGT

CTCTGGCGGC

AGATCCAGGG

AAGCTGTGCC

CCCCTGGGCT

GCTGCTTGAG

CAGGCCCTGG

GCAGCTGGAC

AACTGGGAAT

AATAA SEQ ID NO: pMON3 1106 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTGCAC

AGAATTCCGG

AGGAACAACA

ATACATCACT

CAATGACGAA

ACCTGGAGAG

ATTGAGGCAA

CTACGTAGAG

CTACTATCAA

ATGGCTACCC

GGCAGGAGGG

CGTACCGCGT

TCTCAGAGCT

CGATGGCGCA

ACCCCGAGGA

CCCCTGAGCT

CCAACTCCAT

AAGGGATATC

GTCGCCGACT

GGCCCCTGCC

CCTCTCGACA

GAAAAACTGA

GGGTGGTGGC

TAAAGAGACC

GACG'rCTCTA

CTTCGTAAGG

TTCTTCGTAA

GGCGGTGGAG

CCCGTCTCCT

AGGGTGCCAT

GTCCTGGTTG

TCTACGCCAC

TCCTGCTCAA

GCGCTCCAGG

GCTGGTGCTG

CCTGCCCCAG

AGCGGCCTTT

CCCCGAGTTG

TTGCCACCAC

CTGCAGCCCT

TCCAATCATC ATCAAGGCAG CGTTCTATCT GGTTACCCTT TCTAACTGCT CTATAATGAT ACCTGCACCT TTGCTfGGACC TCCTGATGGA CCGAAACCTT GCTGTCAAGA ACTTAGAAAA TCTCCAACCA TGTCTGCCCT GCTCCCCGGG TGAACCGTCT CCGTCTAAAG AATCTCATAA GCCGGCCTTC GCCTCTGCTT CTAGCCATCT GCAGAGCTTC CTTGCGCAGC CCTCrGGCGG GTCTTTAGAG CAAGTGAGAA AGAAGCTGTG TGCCACCTAC CTCGGACACT CTCTGGGCAT CCAGGCCCTG CAGCTGGCAG TCCTCTACCA GGGGCTCCTG GGTCCCACCT TGGACACACT CATCTGGCAG CAGATGGAAG AATAA SEQ ID NO:11

GTGACTGGCA

GAGCAAGCGC

CGATGAAATT

CGAACAACCT

CGACTTCCAA

TGCATCAGGT

CTGCCACGGC

GGTCCAATCT

ATCTCCAAAC

TCCAGCGCCG

CTGGAGGTGT

CTCTGGCGGC

AGATCCAGGG

AAGCTGTGCC

CCCCTGGGCT

GCTGCTTGAG

CAGGCCCTGG

GCAGCTGGAC

AAC'IGGGAAT

pMON3 1107 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTGCAG

GGTTACCCTT

CTATALATGAT

TTGCTGGACC

CCGAAACCTT

ACTTAGAAAA

TGTCTGCCCT

GTACGTAGAG

CTACTATCAA

ATGGCTACCC

GGCAGGAGGG

CGTACCGCGT

TCTCAGAGCT

CGATGGCGCA

ACCCCGAGGA

CCCCTGAGCT

CCAACTCCAT

AAGGGATATC

GTCGCCGACT

GGCCCCTGCC

GTGACTGGCA

GAGCAAGCGC

CGATGAAATT

CGAACAACCT

CGACTTCCAA

TGCATCAGGT

CTGCCACGGC

GGCGGTGGAG

CCCGTCTCCT

AGGGTGCCAT

GTCCTGGTTG

TCTACGCCAC

TCCTGCTCAA

GCGCTCCAGG

GCTGGTGCTG

CCTGCCCCAG

AGCGGCCTTT

CCCCGAGTTG

TTGCCACCAC

CTGCAGCCCT

AGAATTCCGG

AGGAACAACA

ATACATCACT

CAATGACGAA

ACCTGGAGAG

ATTGAGGCA.A

CGCACCCTCT

GCTCCCCGGG

CCGTCTAAAG

GCCGGCCTTC

CTAGCCATCT

CTTGCGCAGC

GTCTTTAGAG

AGAAGCTGTG

CTCGGACACT

CCAGGCCCTG

TCCTCTACCA

GGTCCCACCT

CATCTGGCAG

GAAAAACTGA CGTTCTATCT GGGTGGTGGC TCTAACTGCT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA CTTCGTAAGG GCTGTCAAGA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTC1'GGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT AATAA SEQ ID NO:12 WO 98/17810 WO 9817810PCT/US97/20037 pMON3 1108 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

AGCGGCGGCG

CTTAAAGAGA

CGGGTGAACC

AAAGAATCTC

CTTCGCCTCT

ATCTrGCAGAG

CAGCCCTCTG

AGAGCAAGTG

TGTGTGCCAC

CACTCTCTGG

CCTGCAGCTG

ACCAGGGGCT

ACCTTGGACA

GCAGCAGATG

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

GTTCTAACTG

CCACCTGCAC

GTCTGGTCCA

ATAAATCTCC

GCTTTCCAGC

CTTCCTGGAG

GCGGCTCTGG

AGAAAGATCC

CTACAAGCTG

GCATCCCCTG

GCAGGCTGCT

CCTGCAGGCC

CACTGCAGCT

GAAGAACTGG

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGG

CTCTATAATG

CTTTGTACGT

ATCTCTACTA

AAACATGGCT

GCCGGGCAGG

GTGTCGTACC

CGGCTCTCAG

AGGGCGATGG

TGCCACCCCG

GGCTCCCCTG

TGAGCCAACT

CTGGAAGGGA

GGACGTCGCC

GAATGGCCCC

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

GTGGTGGCTC

ATCGATGAAA

AGAGGGCGGT

TCAACCCGTC

ACCCAGGGTG

AGGGGTCCTG

GCGTTCTACG

AGCTTCCTGC

CGCAGCGCTC

AGGAGCTGGT

AGCTCCTGCC

CCATAGCGGC

TATCCCCCGA

GACTTTGCCA

TGCCCTGCAG

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

TGGCGGTGGC

TTATACATCA

GGAGGCTCCC

TCCTCCGTCT

CCATGCCGGC

GTTGCTAGCC

CCACCTTGCG

TCAAGTCTTT

CAGGAGAAGC

GCTGCTCGGA

CCAGCCAGGC

CTTTTCCTCT

GTTGGGTCCC

CCACCATCTG

CCCTAATAA

SEQ ID NO:13 pMON31109 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951 ATGGCTAATG CATCAGGTAT TCTGCCCTCT GCCACGGCCG CAGGTGACTG GCAAGAATTC CTTGAGCAAG CGCAGGAACA CGGCGGTTCT AACTGCTCTA AGAGACCACC TGCACCTTTG GTCTCTATCC TGATGGACCG CGTAAGGGCT GTCAAGAACT CGGGTGAACC GTCTGGTCCA AAAGAATCTC ATAAATCTCC CTTCGCCTCT GCTTTCCAGC ATCTGCAGAG CTTCCTGGAG CAGCCCTCTG GCGGCTCTGG AGAGCAAGTG AGAAAGATCC TGTGTGCCAC CTACAAGCTG CACTCTCTGG GCATCCCCTG CCTGCAGCTG GCAGGCTGCT ACCAGGGGCT CCTGCAGGCC ACCTTGGACA CACTGCAGCT GCAGCAGATG GAAGAACTGG SEQ ID NO:14

TGAGGCAATT

CACCCTCTCG

CGGGAAAAAC

ACAGGGTGGT

TAATGATCGA

CTGGACCCGA

AAACCTTCGA

TAGAATACGT

ATCTCTACTA

AAACATGGCT

GCCGGGCAGG

GTGTCGTACC

CGGCTCTCAG

AGGGCGATGG

TGCCACCCCG

GGCTCCCCTG

TGAGCCAACT

CTTCGTAATC

ACATCCAATC

T~GACGTTCTA

GGCTCTGGCG

TGAAATTATA

ACAACCTCAA

CTTCCAAACC

AGAGGGCGGT

TCAACCCGTC

ACCCAGGGTG

AGGGGTCCTG

GCGTTC'rACG

AGCTTCCTGC

CGCAGCGCTC

AGGAGCTGGT

AGCTCCTGCC

CCATAGCGGC

TCCA.ACCATG

ATCATCAAGG

TCTGGTTACC

GTGGCAGCGG

CATCACTTAA

TGACGAAGAC

TGGAGAGCTT

GGAGGCTCCC

TCCTCCGTCT

CCATGCCGGC

GTTGCTAGCC

CCACCTTGCG

TCAAGTCTTT

CAGGAGAAGC

GCTGCTCGGA

CCAGCCAGGC

CTTTTCCTCT

GTTGGGTCCC

CCACCATCTG

CCCTAATAA

CTGGAAGGGA TATCCCCCGA GGACGTCGCC GACTTTGCCA GAATGGCCCC TGCCCTGCAG pMON3 1110 .1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTGCAC

AGAATTCCGG

AGGAACAACA

TGCTCTATAA

ACCTTTGCTG

TGGACCGAAA

AAGAACTTAG

ACCATGTCTG

CGGGTGAACC

AAAGAATCTC

CTTCGCCTCT

ATCTGCAGAG

CAGCCCTCTG

AGAGCAAGTG

TGTGTGCCAC

CACTCTCTGG

CCTGCAGCTG

ACCAGGGGCT

ACCTTGGACA

GCAGCAGATG

CCTCTCGACA

GAAAAACT GA

GGGTGGTGGC

TGATCGATGA

GACCCGAACA

CCTTCGACTT

AAAATGCATC

CCCTCTGCCA

GTCTGGTCCA

ATAAATCTCC

GCTTTCCAGC

CTTCCTGGAG

GCGGCTCTGG

AGAAAGATCC

CTACAAGCTG

GCATCCCCTG

GCAGGCTGCT

CCTGCAGGCC

CACTGCAGCT

GAAGAACTGG

TCCAATCATC

CGTTCTATCT

TCTGGCGGTG

AATTATACAT

ACCTCAATGA

CCAAACCTGG

AGGTATTGAG

CGGCCTACGT

ATCTCTACTA

AAACATGGCT

GCCGGGCAGG

GTGTCGTACC

CGGCTCTCAG

AGGGCGATGG

TGCCACCCCG

GGCTCCCCTG

TGAGCCAACT

CTGGAAGGGA

GGACGTCGCC

GAATGGCCCC

ATCAAGGCAG

GGTTACCCTT

GCAGCGGCGG

CACTTAAAGA

CGAAGACGTC

AGAGCTTCGT

GCAATTCTTC

AGAGGGCGGT

TCAACCCGTC

ACCCAGGGTG

AGGGGTCCTG

GCGTTCTACG

AGCTTCCTGC

CGCAGCGCTC

AGGAGCTGGT

AGCTCCTGCC

CCATAGCGGC

TATCCCCCGA

GACTTTGCCA

TGCCCTGCAG

GTGACTGGCA

GAGCAAGCGC

CGGTTCTAAC

GACCACCTGC

TCTATCCTGA

AAGGGCTGTC

GTAATCTCCA

GGAGGCTCCC

TCCTCCGTCT

CCATGCCGGC

GTTGCTAGCC

CCACCTTGCG

TCAAGTCTTT

CAGGAGAAGC

GCTGCTCGGA

CCAGCCAGGC

CTTTTCCTCT

GTTGGGTCCC

CCACCATCTG

CCCTAATAA

SEQ ID pMON3 1111 1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT WO 98/17810 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951 PCT/UJS97/20037 GGTTACCCTT GAGCAAGCGC GCAGCGGCGG CGGTTCTAAC CACTTAAAGA GACCACCTGC CGAAGACGTC TCTATCCTGA AGAGCTTCGT AAGGGCTGTC GCAATTCTTC GTAATCTCCA CTCTCGACAT CCAATCATCA CGGGTGAACC GTCTGGTCCA AAAGAATCTC ATAAATCTCC CTTCGCCTCT GCTTTCCAGC ATCTGCAGAG CTTCCTGGAG CAGCCCTCTG GCGGCTCTGG AGAGCAAGTG AGAAAGATCC TGTGTbCCAC CTACA.AGCTG CACTCTCTGG GCATCCCCTG CCTGCAGCTG GCAGGCTGCT ACCAGGGGCT CCTGCAGGCC ACCTTGGACA CACTGCAGCT GCAGCAGATG GAAGAACTGG SEQ ID NO:16

AGGAACAACA

TGCTCTATAA

ACCTTTGCTG

TGGACCGAAA

AAGAACTTAG

ACCATGTCTG

TCAAGTACGT

ATCTCTACTA

AAACATGGCT

GCCGGGCAGG

GTGTCGTACC

CGGCTCTCAG

AGGGCGATGG

TGCCACCCCG

GGCTCCCCTG

TGAGCCAACT

CTGGAAGGGA

GGACGTCGCC

GAATGGCCCC

GGGTGGTGGC

TGATCGATGA

GACCCGAACA

CCTTCGACTT

AAAATGCATC

CCCTCTGCCA

AGAGGGCGGT

TCAACCCGTC

ACCCAGGGTG

AGGGGTCCTG

GCGTTCTACG

AGCTTCCTGC

CGCAGCGCTC

AGGAGCTGGT

AGCTCCTGCC

CCATAGCGGC

TATCCCCCGA

GACTTTGCCA

TGCCCTGCAG

TCTGGCGGTG

AATTATACAT

ACCTCAATGA

CCAAACCTGG

AGGTATTGAG

CGGCCGCACC

GGAGGCTCCC

TCCTCCGTCT

CCATGCCGGC

GTTGCTAGCC

CCACCTTGCG

TCAAGTCTTT

CAGGAGAAGC

GCTGCTCGGA

CCAGCCAGGC

CTTTTCCTCT

GTTGGGTCCC

CCACCATCTG

CCCTAATAA

pMON1 3182 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

ACAAGCTGTG

ATCCCCTGGG

AGGCTGCTTG

TGCAGGCCCT

CTGCAGCTGG

AGAACTGGGA

CCTTCGCCTC

CATCTGCAGA

GCAGCCCTCT

TAGAGCAAGT

CTGTGTGCCA

GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG CCACCCCGAG GAGCTGGTGC CTCCCCTGAG CTCCTGCCCC AGCCAACTCC ATAGCGGCCT GGAAGGGATA TCCCCCGAGT ACGTCGCCGA CTTTGCCACt ATGGCCCCTG CCCTGCAGCC TGCTTTCCAG CGCCGGGCAG GCTTCCTGGA GGTGTCGTAC GGCGGCTCTG GCGGCTCTCA GAGAAAGATC CAGGGCGATG CCTAATAA SEQ ID NO:17

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

CGGCGGCTCC

TGCTCGGACA

AGCCAGGCCC

TTTCCTCTAC

TGGGTCCCAC

ACCATCTGGC

CACCCAGGGT

GAGGGGTCCT

CGCGTTCTAC

GAGCTTCCTG

GCGCAGCGCT

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTT

CTCTCTGGGC

TGCAGCTGGC

CAGGGGCTCC

CTTGGACACA

AGCAGATGGA

GCCATGCCGG

GGTTGCTAGC

GCCACCTTGC

CTCAAGTCTT

CCAGGAGAAG

PMON13183 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

CTGTGCCACC

CTGGGCTCCC

GCTTGAGCCA

GCCCTGGAAG

GCTGGACGTC

TGGGAATGGC

GCCTCTGCTT

GCAGAGCTTC

CCTCTGGCGG

CAAGTGAGAA

TGCCACCTAA

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CCGAGGAGCT

CTGAGCTCCT

ACTCCATAGC

GGATATCCCC

GCCGACTTTG

CCCTGCCCTG

TCCAGCGCCG

CTGGAGGTGT

CTCTGGCGGC

AGATCCAGGG

TA.A SEQ ID

GATCGATGAA

ACCCGAACAA

CT'TCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGTGCTGCTC

GCCCCAGCCA

GGCCTT'ITCC

CGAGTTGGGT

CCACCACCAT

CAGCCCACCC

GGCAGGAGGG

CGTACCGCGT

TCTCAGAGCT

CGATGGCGCA

NO: 18 ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG pMON1 3184 1 .51 101 151 201

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC WO 98/17810 WO 9817810PCTIUS97/20037 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCPGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTP 451 GCCACCACCA TCTGGCAGCA GATGGAAGA-A CTGGGAATGG CCCCTGCCCP 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG 651 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG 701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC 751 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCPGGCA GGCTGCTTGA 851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 901 GAAGGGATAT CCTAATAA SEQ ID NO:19 pMON13 185 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

TTGGGTCCCA

CACCATCTGG

CCACCCAGGG

GGAGGGGTCC

CCGCGTTCTA

AGAGCTTCCT

GGCGCAGCGC

CGAGGAGCTG

TGAGCTCCTG

CTCCATAGCG

GATATCCTAA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAA.AGAA

CCTTGGACAC

CAGCAGATGG

TGCCATGCCG

TGGTTGCTAG

CGCCACCTTG

GCTCAAGTCT

TCCAGGAGAA

GTGCTGCTCG

CCCCAGCCAG

GCCTTTTCCT

TAA SEQ ID GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAA.ACAT GGCTCCCGAG ACTGCAGCTG GACGTCGCCG ACTTTGCCAC AAGAACTGGG AATGGCCCCT GCCCTGCAGC GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GCTGTGTGCC ACCTACAAGC TGTGCCACCC

GACACTCTCT

GCCCTGCAGC

CTACCAGGGG

NO:

GGGCATCCCC

TGGCAGGCTG

CTCCTGCAGG

TGGGCTCCCC

CTTGAGCCAA

CCCTGGAAGG

pMON13 186 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTA.ACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

TGGCCCCTGC

GCTTTCCAGC

CTTCCTGGAG

GCGGCTCTGG

AGAA-AGATCC

CTACAAGCTG

GCATCCCCTG

GCAGGCTGCT

CCTGCAGGCC

CACTGCAGCT

GAAGAACTGG

GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG CCTGCAGCCC ACCCAGGGTG GCCGGGCAGG AGGGGTCCTG GTGTCGTACC GCGTTCTACG CGGCTCTCAG AGCTTCCTGC AGGGCGATGG CGCAGCGCTC TGCCACCCCG AGGAGCTGGT GGCTCCCCTG AGCTCCTGCC TGAGCCAACT CCATAGCGGC CTGGAAGGGA TATCCCCCGA GGACGTCGCC GACTTTGCCA GATAATAA SEQ ID NO:21

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

CGGCGGCTCC

CCATGCCGGC

GTTGCTAGCC

CCACCTTGCG

TCAAGTCTTT

CAGGAGA-AGC

GCTGCTCGGA

CCAGCCAGGC

CTTTTCCTCT

GTTGGGTCCC

CCACCATCTG

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTA

CTTCGCCTCT

ATCTGCAGAG

CAGCCCTCTG

AGAGCAAGTG

TGTGTGCCAC

CACTCTCTGG

CCTGCAGCTG

ACCAGGGGCT

ACCTTGGACA

GCAGCAGATG

pMON13 187 1 51 101 151 201 251 301 351 401 451

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

CCTGCCCTGC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

AGCCCACCCA

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAA-AT

GGGTGCCATG

ATTATACATC

CCTCA.ATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

CCGGCCTTCG

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTATGGCC

CCTCTGCTTT

4

I.

WO 98/17810 501 551 601 651 701 751 801 851 901 951 PCTIUS97/20037

CCAGCGCCGG

TGGAGGTGTC

TCTrGGCGGCT

GATCCAGGGC

AGCTGTGCCA

CCCTGGGCTC

CTGCTTGAGC

AGGCCCTGGA

CAGCTGGACG

ACTGGGATAA

GCAGGAGGGG

GTACCGCGTT

CTCAGAGCTT

GATGGCGCAG

CCCCGAGGAG

CCCTGAGCTC

CAACTCCATA

AGGGATATCC

TCGCCGACTT

TAA SEQ ID

TCCTGGTTGC

CTACGCCACC

CCTGCTCAAG

CGCTCCAGGA

CTGGTGCTGC

CTGCCCCAGC

GCGGCCTTTT

CCCGAGTTGG

TGCCACCACC

NO: 22

TAGCCATCTG

TTGCGCAGCC

TCTTTAGAGC

GAAGCTGTGT

TCGGACACTC

CAGGCCCTGC

CCTCTACCAG

GTCCCACCTT

ATCTGGCAGC

CAGAGCTTCC

CTCTGGCGGC

AAGTGAGAAA

GCCACCTACA

TCTGGGCATC

AGCTGGCAGG

GGGCTCCTGC

GGACACACTG

AGATGGAAGA

pMON13 188 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CCCAGGGTGC

6GGGTCCTGG

CGTTCTACGC

GCTTCCTGCT

GCAGCGCTCC

GGAGCTGGTG

GCTCCTGCCC

CATAGCGGCC

ATCCCCCGAG

ACTTTGCCAC

GCCCTGCAGC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

CATGCCGGCC

TTGCTAGCCA

CACCTTGCGC

CAAGTCTTTA

AGGAGAAGCT

CTGCTCGGAC

CAGCCAGGCC

TTTTCCTCTA

TTGGGTCCCA

CACCATCTGG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

GTGGTTCTGG

TTCGCCTCTG

TCTGCAGAGC

AGCCCTCTGG

GAGCAAGTGA

GTGTGCCACC

ACTCTCTGOG

CTGCAGCTGG

CCAGGGGCTC

CCTTGGACAC

CAGCAGATGG

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

CGGCGGCTCC

CTTTCCAGCG

TTCCTGGAGG

CGGCTCTGGC

GAAAGATCCA

TACAAGCTGT

CATCCCCTGG

CAGGCTGCTT

CTGCAGGCCC

ACTGCAGCTG

AAGAACTGGG

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTA

CCGGGCAGGA

TGTCGTACCG

GGCTCTCAGA

GGGCGATGGC

GCCACCCCGA

GCTCCCCTGA

GAGCCAACTC

TGGAAGGGAT

GACGTCGCCG

AATGGCCCCT

CCTAATAA SEQ ID NO:23 pMON13 189 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

CTGCTCAAGT

GCTCCAGGAG

TGGTGCTGCT

TGCCCCAGCC

CGGCCTTTTC

CCGAGTTGGG

GCCACCACCA

GCAGCCCTAA

GCTCTATAAr GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA 5'CTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC TCTGGCGGCT CTTTAGAGCA AGTGAGAAAG

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

CAGCGCCGGG

GGAGGTGTCG

CTGGCGGCTC

ATCCAGGGCG

GCTGTGCCAC

CCTGGGCTCC

TGCTTGAGCC

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTACOCAG

CAGGAGGGGT

TACCGCGTTC

TCAGAGCTTC

ATGGCGCAGC

CCCGAGGAGC

CCTGAGCTCC

AACTCCATAG

GGGATATCCC

CGCCGACTTT

CCCCTGCCCT

pMON13190 1 51 101 151 201 251 301 351 401 451 501 551 601 651

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CTGCTTTCCA

AGCTTCCTGG

TGGCGGCTCT

TGAGAAAGAT

ACCTACAAGC

GGGCATCCCC

AAGCTGTGTG

CGGACACTCT

AGGCCCTGCA

CTCTACCAGG

TCCCACCTTG

TCTGGCAGCA

TAA SEQ ID

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GCGCCGGGCA

AGGTGTCGTA

GGCGGCTCTC

CCAGGGCGAT

TGTGCCACCC

TGGGCTCCCC

GGCTCCTGCA GGCCCTGGAA GACACACTGC AGCTGGACGT GATGGAAGAA CTGGGA.ATGG NO: 24

CCACCTACAA

CTGGGCATCC

GCTGGCAGGC

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

GTGGTTCTGG

GGAGGGGTCC

CCGCGTTCTA

AGAGCTTCCT

GGCGCAGCGC

CGAGGAGCTG

TGAGCTCCTG

ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGCGGCTCC AACATGGCTT TGGTTGCTAG CCATCTGCAG CGCCACCTTG CGCAGCCCTC GCTCAAGTCT TTAGAGCAAG TCCAGGAGAA GCTGTGTGCC GTGCTGCTCG GACACTCTCT CCCCAGCCAG GCCCTGCAGC WO 98/17810 PTU9/03 PCT[US97/20037 701 751 801 851 901

TGGCAGGCTG

CTCCTGCAGG

CACACTGCAG

TGGAAGAACT

CCGGCCTTCG

CTTGAGCCAA CTCCATAGCG CCCTGGA-AGG GATATCCCCC CTGGACGTCG CCGACTTTGC GGGAATGGCC CCTGCCCTGC CCTAATAA SEQ ID

GCCTTTTCCT

GAGTTGGGTC

CACCACCATC

AGCCCACCCA

CTACCAGGGG

CCACCTTGGA

TGGCAGCAGA

GGGTGCCATG

pMON13191 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCA.A

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

TTCCAGCGCC

CCTGGAGGTG

GCTCTGGCGG

AAGATCCAGG

CAAGCTGTGC

TCCCCTGGGC

GGCTGCTTGA

GCAGGCCCTG

TGCAGCTGGA

GAACTGGGAA

CTTCGCCTAA

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

GGGCAGGAGG

TCGTACCGCG

CTCTCAGAGC

GCGATGGCGC

CACCCCGAGG

TCCCCTGAGC

GCCAACTCCA

GAAGGGATAT

CGTCGCCGAC

TGGCCCCTGC

TAA SEQ ID

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGTCCTGGTT

TTCTACGCCA

TTCCTGCTCA

AGCGCTCCAG

AGCTGGTGCT

TCCTGCCCCA

TAGCGGCCTT

CCCCCGAGTT

TTTGCCACCA

CCTGCAGCCC

NO: 26

ATTAPACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

GCTAGCCATC

CCTTGCGCAG

AGTCTTTAGA

GAGAAGCTGT

GCTCGGACAC

GCCAGGCCCT

TTCCTCTACC

GGGTCCCACC

CCATCTGGCA

ACCCAGGGTG

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTTCTGCT

TGCAGAGCTT

CCCTCTGGCG

GCAAGTGAGA

GTGCCACCTA

TCTCTGGGCA

GCAGCTGGCA

AGGGGCTCCT

TTGGACACAC

GCAGATGGAA

CCATGCCGGC

pMON1 3192 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

ACAAGCTGTG

ATCCCCTGGG

AGGCTGCTTG

TGCAGGCCCT

CTGCAGCTGG

AGAACTGGGA

CCTTCGCCTC

CATCTGCAGA

GCAGCCCACA

TCAAGTCTTT

CAGGAGAAGC

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

CCACCCCGAG

CTCCCCTGAG

AGCCAACTCC

GGAAGGGATA

ACGTCGCCGA

ATGGCCCCTG

TGCTTTCCAG

GCTTCCTGGA

CCATTGGGCC

AGAGCAAGTG

TGTGTGCCAC

GATCGATGAA ATTATACATC ACCCGAACAA CCTCAATGAC CTTCGACTTC CAAACCTGGA AAATGCATCA GGTATTGAGG CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGT GTGGTTCTGG CGGCGGCTCC GAGCTGGTGC TGCTCGGACA CTCCTGCCCC AGCCAGGCCC ATAGCGGCCT TTTCCTCTAC TCCCCCGAGT TGGGTCCCAC CTTTGCCACC ACCATCTGGC CCCTGCAGCC CACCCAGGGT CGCCGGGCAG GAGGGGTCCT GGTGTCGTAC CGCGTTCTAC CTGCCAGCTC CCTGCCCCAG AGAAAGATCC AGGGCGATGG CTAATAA SEQ ID NO:27

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTT

CTCTCTGGGC

TGCAGCTGGC

CAGGGGCTCC

CTTGGACACA

AGCAGATGGA

GCCATGCCGG

GGTTGCTAGC

GCCACCTTGC

AGCTTCCTGC

CGCAGCGCTC

pMON13 193 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

CTGTGCCACC

CTGGGCTCCC

GCTTGAGCCA

GCCCTGGAAG

GCTGGACGTC

TGGGAATGGC

GCCTCTGCTT

GCAGAGCTTC

CCACACCATT

TCTTTAGAGC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CCGAGGAGCT

CTGAGCTCCT

ACTCCATAGC

GGATATCCCC

GCCGACTTTG

CCCTGCCCTG

TCCAGCGCCG

CTGGAGGTGT

GGGCCCTGCC

AAGTGAGAAA

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGTGCTGCTC

GCCCCAGCCA

GGCCTTTTCC

CGAGTTGGGT

CCACCACCAT

CAGCCCACCC

GGCAGGAGGG

CGTACCGCGT

AGCTCCCTGC

GATCCAGGGC

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

GGACACTCTC

GGCCCTGCAG

TCTACCAGGG

CCCACCTTGG

CTGGCAGCAG

AGGGTGCCAT

GTCCTGGTTG

TCTACGCCAC

CCCAGAGCTT

GATGGCGCAG

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTTACAAG

TGGGCATCCC

CTGGCAGGCT

GCTCCTGCAG

ACACACTGCA

ATGGAAGAAC

GCCGGCCTTC

CTAGCCATCT

CTTGCGCAGC

CCTGCTCAAG

CGCTCCAGGA

WO 98/17810 951 GAAGCTGTGT GCCACCTAAT AA SEQ ID NO:28 PCT/US97/20037 PMON25190 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CCGAGTTGGG

GCCACCACCA

GCAGCCCACC

GGGCAGGAGG

TCGTACCGCG

CAGCTCCCTG

AGATCCAGGG

AAGCTGTGCC

CCCCTGGGCT

GCTGCTTGAG

CAGGCCCTGG

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

TCCCACCTTG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

GTGGTTCTGG

GACACACTGC

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

CGGCGGCTCC

AGCTGGACGT

CTGGGAATGG

CGCCTCTGCT

TGCAGAGCTT

CCCACACCAT

GTCTTTAGAG

AGAAGCTGTG

CTCGGACACT

CCAGGCCCTG

TCCTCTACCA

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTC

CGCCGACTTT

CCCCTGCCCT

TTCCAGCGCC

CCTGGAGGTG

TGGGCCCTGC

CAAGTGAGAA

TGCCACCTAC

CTCTGGGCAT

CAGCTGGCAG

GGGGCTCCTG

TCTGGCAGCA GATGGAAGAA CAGGGTGCCA TGCCGGCCTT

GGTCCTGGTT

TTCTACGCCA

CCCCAGAGCT

CGATGGCGCA

ACCCCGAGGA

CCCCTGAGCT

CCAACTCCAT

AAGGGATATC

GCTAGCCATC

CCTTGCGCAG

TCCTGCTCAA

GCGCTCCAGG

GCTGGTGCTG

CCTGCCCCAG

AGCGGCCTTT

CTAATAA SEQ ID NO:29 pMON2 5191 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

TTGGGTCCCA

CACCATCTGG

CCACCCAGGG

GGAGGGGTCC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CCTTGGACAC

CAGCAGATGG

TGCCATGCCG

TIGGTTGCTAG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

ACTGCAGCTG

AAGAACTGGG

GCCTTCGCCT

CCATCTGCAG

CGCAGCCCAC

CTCAAGTCTT

CCAGGAGAAG

TGCTGCTCGG

CCCAGCCAGG

CCTTTTCCTC

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

GACGTCGCCG

AATGGCCCCT

CTGCTTTCCA

AGCTTCCTGG

ACCATTGGGC

TAGAGCAAGT

CTGTGTGCCA

ACACTCTCTG

CCCTGCAGCT

TACCAGGGGC

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTCCCGAG

ACTTTGCCAC

GCCCTGCAGC

GCGCCGGGCA

AGGTGTCGTA

CCTGCCAGCT

GAGAAAGATC

CCTACAAGCT

GGCATCCCCT

GGCAGGCTGC

TCCTGCAGGC

CCGCGTTCTA CGCCACCTTG CCCTGCCCCA GAGCTTCCTG

CAGGGCGATG

GTGCCACCCC

GGGCTCCCCT

TTGAGCCAAC

CCTGGAAGGG

GCGCAGCGCT

GAGGAGCTGG

GAGCTCCTGC

TCCATAGCGG

ATATCCTAAT AA SEQ ID pMON13 194 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

TGGCCCCTGC

GCTTTCCAGC

CTTCCTGGAG

CATTGGGCCC

GAGCAAGTGA

GTGTGCCACC

ACTCTCTGGG

CTGCAGCTGG

CCAGGGGCTC

CCTTGGACAC

CAGCAGATGG

GCTCTATAA'r GATCGATGAA ATTATACATC CCTTTGCTGG ACCCGAACAA CCTCAATGAC GGACCGAA.AC CTTCGACTTC CAAACCTGGA AGAACTTAGA AAATGCATCA GGTATTGAGG CCATGTCPGC CCTCTGCCAC GGCCGCACCC CAAGGCAGGT GACTGGCAAG AATTCCGGGA TTACCCTTGA GCAAGCGCAG GAACAACAGT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC GTGTCGTACC GCGTTCTACG CCACCTTGCG TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT GAAAGATCCA GGGCGATGGC GCAGCGCTCC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGGCTGCTT GAGCCAACTC* CATAGCGGCC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG ACTGCAGCTG GACGTCGCCG ACTTTGCCAC AAGAACTGGG ATAATAA SEQ ID NO: 31

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTA

CTTCGCCTCT

ATCTGCAGAG

CAGCCCACAC

CAAGTCTI'TA

AGGAGAAGCT

CTGCTCGGAC

CAGCCAGGCC

TTTTCCTCTA

TTGGGTCCCA

CACCATCTGG

pMONl 3195 WO 98/17810 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951 PCTIUS97/20037

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGC

CGTCTCCTCC

CCTGCCCTGC

CCAGCGCCGG

TGGAGGTGTC

GGCCCTGCCA

AGTGAGAAAG

CCACCTACAA

CTGGGCATCC

GCTGGCAGGC

GGCTCCTGCA

GACACACTGC

GATGGAAGAA

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGA.A

AGCCCACCCA

GCAGGAGGGG

GTACCGCGTT

GCTCCCTGCC

ATCCAGGGCG

GCTGTGCCAC

CCTGGGCTCC

TGCTTGAGCC

GGCCCTGGAA

AGCTGGACGT

CTGGGATAAT

GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAA GCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC 'rCTCATAAAT CTCCAAACAT GGCTATGGCC GGGTOCCATG CCGGCCTTCG CCTCTGCTTT TCCTGGTTGC TAGCCATCTG CAGAGCTTCC CTACGCCACC TTGCGCAGCC CACACCATTG CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCCGAGGAGC TGGTGCTGCT CGGACACTCT CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA AACTCCATAG CGGCCTTTTC CTCTACCAGG GGGATATCCC CCGAGTTCGGG TCCCACCTTG CGCCGACTTT GCCACCACCA TCTGGCAGCA AA SEQ ID NO:32 pMON13196 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CCCAGGGTGC

GGGGTCCTGG

CGTTCTACGC

TGCCCCAGAG

GGCGATGGCG

CCACCCCGAG

CTCCCCTGAG

AGCCAACTCC

GGAAGGGATA

ACGTCGCCGA

ATGGCCCCTG

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

CATGCCGGCC

TTGCTAGCCA

CACCTTGCGC

CTTCCTGCTC

CAGCGCTCCA

GAGCTGGTGC

CTCCTGCCCC

ATAGCGGCCT

TCCCCCGAGT

CTTTGCCACC

CCCTGCAGCC

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

GTGGTTCTGG

TTCGCCTCTG

TCTGCAGAGC

AGCCCACACC

AAGTCTTTAG

GGAGAAGCTG

TGCTCGGACA

AGCCAGGCCC

TTTCCTCTAC

TGGGTCCCAC

ACCATCTGGC

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

CGGCGGCTCC

CTTTCCAGCG

TTCCTGGAGG

ATTGGGCCCT

AGCAAGTGAG

TGTGCCACCT

CTCTCTGGGC

TGCAGCTGGC

CAGGGGCTCC

CTTGGACACA

AGCAGATGGA

ACTTAA.AGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTA

CCGGGCAGGA

TGTCGTACCG

GCCAGCTCCC

AAAGATCCAG

ACAAGCTGTG

ATCCCCTGGG

AGGCTGCTTG

TGCAGGCCCT

CTGCAGCTGG

AGAACTGGGA

CTAATAA SEQ ID NO:33 PMON13 197 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

CAGAGCTTCC

TGGCGCAGCG

CCGAGGAGCT

CTGAGCTCCT

ACTCCATAGC

GGATATCCCC

GCCGACTTTG

CCCTGCCCTG

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CGGCCTTCGC

AGCCATCTGC

TGCGCAGCCC

TGCTCAAGTC

CTCCAGGAGA

GGTGCTGCTC

GCCCCAGCCA

GGCCTTTTCC

CGAGTTGGGT

CCACCACCAT

GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTACCCAG CTCTGCTTTC CAGCGCCGGG CAGGAGGGGP AGAGCTTCCT GGAGGTGTCG TACCGCGTTC ACACCATTGG GCCCTGCCAG CTCCCTGCCC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA AGCTGTGTGC CACCTACAAG CTGTGCCACC GGACACTCTC TGGGCATCCC CTGGGCTCCC GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA TCTACCAGGG GCTCCTGCAG GCCCTGGAAG CCCACCTTGG ACACACTGCA GCTGGACGTC CTGGCAGCAG ATGGA.AGAAC TGGGAATGGC CAGCCCTAAT AA SEQ ID NO-34 pMON13198 1 ATGGCTAACT 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG WO 98/17810 WO 9817810PCTIUS97/20037 201 TAATCTCCAA CCATGTCTGC 251 301 351 401 451 501 551 601 651 701 751 801 851 901

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CTGCTTTCCA

AGCTTCCTGG

ACCATTGGGC

TAGAGCAAGT

CTGTGTGCCA

ACACTCTCTG

CCCTGCAGCT

TACCAGGGGC

CACCTTGGAC

GGCAGCAGAT

GGTGCCATGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GCGCCGGGCA

AGGTGTCGTA

CCTGCCAGCT

GAGAAAGATC

CCTACAAGCT

GGCATCCCCT

GGCAGGCTGC

TCCTGCAGGC

ACACTGCAGC

GGAAGAACTG

CGGCCTTCGC

Ito CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGT GTGGTTCTGG CGGCGGCTCC GGAGGGGTCC TGGTTGCTAG CCGCGTTCTA CGCCACCTTG CCCTGCCCCA GAGCTTCCTG CAGGGCGATG GCGCAGCGCT GTGCCACCCC GAGGAGCTGG GGGCTCCCCT GAGCTCCTGC TTGAGCCAAC TCCATAGCGG CCTGGAAGGG ATATCCCCCG TGGACGTCGC CGACTTTGCC GGAATGGCCC CTGCCCTGCA CTAATAA SEQ ID

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

AACATGGCTT

CCATCTGCAG

CGCAGCCCAC

CTCAAGTCTT

CCAGGAGAAG

TGCTGCTCGG

CCCAGCCAGG

CCTTTTCCTC

AGTTGGGTCC

ACCACCATCT

GCCCACCCAG

pMON13 199 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

'rTCCAGCGCC

CCTGGAGGTG

TGGGCCCTGC

CAAGTGAGAA

TGCCACCTAC

CTCTGGGCAT

CAGCTGGCAG

GGGGCTCCTG

TGGACACACT

CAGATGGAAG

CATGCCGGCC

GCTCTATAAT

CCTTTGCTGG

GGACCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

GGGCAGGAGG

TCGTACCGCG

CAGCTCCCTG

AGATCCAGGG

AAGCTGTGCC

CCCCTGGGCT

GCTGCTTGAG

CAGGCCCTGG

GCAGCTGGAC

AACTGGGAAT

TTCGCCTAAT

GCTCTAACAT

CCGCTGCTGG

GGACAATAAC

AGTCTCTGCA

CCATGTCTGC

CAAGGACGGT

AAACCTTGGA

TCCCCGGGTG

GTCTAAAGAA

CGGCCTTCGC

AGCCATCTGC

TGCGCAGCCC

CTTTAGAGCA

AAGCTGTGTG

CGGACACTCT

AGGCCCTGCA

CTCTACCAGG

TCCCACCTTG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGTCCTGGTT

TTCTACGCCA

CCCCAGAGCT

CGATGGCGCA

ACCCCGAGGA

CCCCTGAGCT

CCAACTC CAT

AAGGGATATC

GTCGCCGACT

GGCCCCTGCC

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

GCTAGCCATC

CCTTGCGCAG

TCCTGCTCAA

GCGCTCCAGG

GCTGGTGCTG

CCTGCCCCAG

AGCGGCCTTT

CCCCGAGTTG

TTGCCACCAC

CTGCAGCCCA

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GGCTTCTGCT

TGCAGAGCTT

CCCACACCAT

GTCTTTAGAG

AGAAGCTGTG

CTCGGACACT

CCAGGCCCTG

'PCCTCTACCA

GGTCCCACCT

CATCTGGCAG

CCCAGGGTGC

AA SEQ ID NO: 36 pMON3 1112 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

GCCACCGCTG

ATATCCTAAT

CGTGCTGTCA

AAATCTCCTG

CAATCCATAT

TTCTATCTGA

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

CTGCTCAAGT

GCTCCAGGAG

TGGTGCTGCT

TGCCCCAGCC

CGGCCTTTTC

CCGAGTTGGG

GCCACCACCA

GCAGCCCTAA

GATCGATGAA

ACTTCAACAA

CTTCGTCGTC

GAATGCATCA

CGCTAGCCAC

GACTGGAATG

GAACGCGCAG

AACCGTCTGG

TCTCATAAAT

CTCTGCTTTC

AGAGCTTCCT

TCTGGCGGCT

AGTGAGAAAG

CCACCTACAA

CTGGGCATCC

GC'rGGCAGGC

GGCTCCTGCA

GACACACTGC

ATCATCACCC ACCTGAAGCA CCTCAATGGT GAAGACCAAG CAAACCTCGA GGCATTCAAC GCAATTGAGA GCATTCTTAA GGCCGCACCC ACGCGACATC AATTCCGTCG TAAACTGACC GCTCAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC CTGGCGGCTC TCAGAGCTTC ATCCAGGGCG ATCGCGCAGC GCTGTGCCAC CCCGAGGAGC CCTGGGCTCC CCTGAGCTCC TGCTTGAGCC AACTCCATAG GGCCCTGGAA GGGATATCCC AGCTGGACGT CGCCGACTTT CTGGGAATGG CCCCTGCCCT pMON3 1113 1 51 101 151 201 251 301 351 401 451

ATGGCTAACT

GCCACCGCTG

ATATCCTGAT

CGTGCTGTCA

AAATCTCCTG

CAATCATCAT

TTCTATCTGA

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

TCTGGCAGCA GATGGAAGAA TAA SEQ ID 1'O:37 GCTCTAACAT GATCGATGAA CCGCTGCTGG ACTTCAACAA GGAAAATAAC CTTCGTCGTC AGTCTCTGCA GAATGCATCA CCATGTCTGC CCCTGGCCAC CCGTGACGGT GACTGGAATG AAACCTTGGA GAACGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC

ATCATCACCC

CCTCA.ATGGT

CAAACCTCGA

GCAATTGAGA

GGCCGCACCC

AATTCCGTCG

GCTCAACAGT

TCCAATCTCT

CTCCAAACAT

CAGCGCCGGG

ACCTGAAGCA

GAAGACCAAG

GGCATTCAAC

GCATTCTTAA

ACGCGACATC

TAAACTGACC

ACGTAGAGGG

ACTATCAACC

GGCTACCCAG

CAGGAGGGGT

C.

f.

WO 98/17810 501 551 601 6S1 701 751 801 851 901 951 PCT/US97/20037

CCTGGTTGCT

TACGCCACCT

CAGAGCTTCC

TGGCGCAGCG

CCGAGGAGCT

CTGAGCTCCT

ACTCCATAGC

GGATATCCCC

GCCGACTTTG

CCCTGCCCTG

PMON3 1114 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

GCCACCGCTG

ATATCCTGAT

CGTGCTGTCA

AAATCTCCTG

CAATCATCAT

TTCTATCTGA

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

CTGCTCAAGT

GCTCCAGGAG

TGGTGCTGCT

TGCCCCAGCC

CGGCCTTTTC

CCGAGTTGGG

GCCACCACCA

GCAGCCCTAA

AGCCATCTGC

TGCGCAGCCC

TGCTCAAGTC

CTCCAGGAGA

GGTGCTGCTC

GCCCCAGCCA

GGCCTTTTCC

CGAGTTGGGT

CCACCACCAT

CAGCCCTAAT

GCTCTAACAT

CCGCTGCTGG

GGAAAATAAC

AGTCTCTGCA

CCATGTCTGC

CCGTGACGGT

AAACCTTGGA

TCCCCGGGTG

GTCTAAAGAA

CGGCCTTCGC

AGCCATCTGC

TGCGCAGCCC

CTTTAGAGCA

AAGCTGTGTG

CGGACACTCT

AGGCCCTGCA

CTCTACCAGG

TCCCACCTTG

TCTGGCAGCA

TAA SEQ ID AGAGCTTCCT GGAGGTGTCG ACACCATTGG GCCCTGCCAG TTTAGAGCAA GTGAGAAAGA AGCTGTGTGC CACCTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AA SEQ ID NO:38

TACCGCGTTC

CTCCCTGCCC

TCCAGGGCGA

CTGTGCCACC

CTGGGCTCCC

GCTTGAGCCA

GCCCTGGAAG

GCTGGACGTC

TGGGAATGGC

GATCGATGAA ATCATCACCC ACCTGAAGCA ACTTCAACAA CCTCAATGGT GAAGACCAAG CTTCGTCGTC CAAACCTCGA GGCATTCAAC GAATGCATCA GCAATTGAGA GCATTCTTAA CCCTGGCCAC GGCCGCACCC ACGCGACATC GACTGGAATG AATTCCGTCG TAAACTGACC GAACGCGCAG GCTCAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTACCCAG CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC CCACCTACAA GCTGTGCCAC CCCGAGGAGC CTGGGCATCC CCTGGGCTCC CCTGAGCTCC GCTGGCAGGC 'rGCTTGAGCC AACTCCATAG GGCTCCTGCA GGCCCTGGAA GGGATATCCC GACACACTOC AGCTGGACGT CGCCGACTTT GATGGAAGAA CTGGGAATGG CCCCTGCCCT NO: 39 pMON3 1115 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

GCCACCGCTG

ATATCCTAAT

CGTGCTGTCA

AAATCTCCTG

CAATCCATAT

TTCTATCTGA

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

CAGAGCTTCC

TGGCGCAGCG

CCGAGGAGCT

CTGAGCTCCT

ACTCCATAGC

GGATATCCCC

GCCGACTTTG

CCCTGCCCTG

GCTCTAACAT

CCGCTGCTGG

GGACAATAAC

AG'rCTCTGCA

CCATGTCTGC

CAAGGACGGT

AAACCTTGGA

TCCCCGGGTG

GTCTAAAGAA

CGGCCTTCGC

AGCCATCTGC

TGCGCAGCCC

TGCTCAAGTC

CTCCAGGAGA

GGTGCTGCTC

GCCCCAGCCA

GGCCTTTTCC

CGAGTTGGGT

CCACCACCAT

CAGCCCTAAT

GATCGATGAA ATCATCACCC ACCTGAAGCA ACTTCAACAA CCTCAATGGT CTTCGTCGTC CAAACCTCGA GAATGCATCA GCAATTGAGA CGCTAGCCAC GGCCGCACCC GACTGGAATG ATTCCGTCG GAACGCGCAG GCTCAACAGT AACCGTCTGG TCCAATCTCT TCTCATAAAT CTCCAAACAT CTCTGCTTTC CAGCGCCGGG AGAGCTTCCT GGAGGTGTCG ACACCATTGG GCCCTGCCAG TTTAGAGCAA GTGAGAAAGA AGCTGTGTGC CACCTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AA SEQ ID

GAAGACCAAG

GGCATTCAAC

GCATTCTTAA

ACGCGACATC

TAAACTGACC

ACGTAGAGGG

ACTATCAACC

GGCTACCCAG

CAGGAGGGGT

TACCGCGTTC

CTCCCTGCCC

TCCAGGGCGA

CTGTGCCACC

CTGGGCTCCC

GCTTGAGCCA

GCCCTGGAAG

GCTGGACGTC

TGGGAATGGC

pMON28505

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAJAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGACTTAGAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCAGGTGACTGGCAAGAATTCCGGGAAAJAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATATCTCCAACATGGAGTTCACCCT

TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAOATGGAAACCCAGATGGAGGAGACCAAG

GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT

TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA

ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG

CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATG

GCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTrCCCATGTCCTTCACAGC AGACTGAGCCAGTGCCCA SEQ ID NO:41 WO 98/17810 PCT/US97/20037 pMON285OE

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCMA.CCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCT

GTCCTGCTGCCTrGCTGTGGACTTTAGCTTGGGAGAATGGA'AACCCAGATGGAGGAGACCAAGGCACAGGACATT

CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCACACGGGGACAACTGGGACCCACT'GCCTCTCATCC

CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTrGAAjCCCACTTCC'r

CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAA-AG

GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCT

CCGCCTGCTTGTGACCTCCGAGTCCTCAGTA.AACTGCTrCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAG TGCCCAGAGGTTCACCCT SEQ ID NO:42 pMON2 8507

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGACCTTCGACTTCCAAACCTGGAGAGCTTCGTAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCT

GCTGTGGACTTTAGCTTGGGAGAATG-GAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG

CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG

ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG

ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGT

GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT

CACCCTTTGCCTACACCT SEQ ID NO:43 pMON2 8508

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTT

AGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG

GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG

GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCAC

AAGGATCCCAATGCCATCTTCCTGAGCTTCCA.ACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA

GGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGrGACCTCCGAGTC

CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCT

ACACCTGTCCTGCTGCCT SEQ ID NO:44 pMON2 85 09

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTG

GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA

GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT

CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT

CCCAATGCCATCTTCCTGAGCTTCCA.ACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGT

AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT

GTCCTGCTGCCTGCTGTG SEQ ID pMON28510

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGAC'rTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGA-ATTCCGGGAAAAACTGACGTTC

TATCGGTTACCCTTGAGCAAGCGCAGGACACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGG

TCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAXACTCCAAACATGGGAGATGGAAAACC

CAGATGGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGG

GACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCT

GCAGGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTTCCTGA

WO 98/17810 PCTIUS97/20037

GCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCTGCGTCAGGGAATT

CGGCGGCAACATGGCGTC'rCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT GTCC'rTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACT TTAGTTG SEQ ID NO:46 pMON28511

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGA-AC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATcATPcATcAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC

CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC

CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCG

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTG SEQ ID NO:47 PMON2 8512

GCTAACTGCTCTATA-ATGATCGATGAA.ATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTrATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAA.ATCTCCAAACATGGGAACCCAGCTT

CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA

AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCC

GCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC

CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAA

ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA

CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG

GCCCTGCAGAGCCTCCTT SEQ ID NO:48 pMON2 8513

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACAGGGCAGGACCACA

GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT

GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC

CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT

TTGCCTACACCTGTCCTIGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG

GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACA.ACTGGGACCCACT

TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA

ACCCAGCTTCCTCCACAG SEQ ID NO:49 pMQN2 8514

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAA.AGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAALACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT

CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGT

AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT

GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT

CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC

CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT

CCACAGGGCAGGACCACA SEQ ID pMON28515

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGT'rC WO 98/1 7810 PCT/UJS97/20037

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGA.ATCTCATAAATCTCCAAACATGGATCCCAATGCC

ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC

GTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT

CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG

CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA

GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG

CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC

AGGACCACAGCTCACAAG SEQ ID NO:51 pMON2 8516

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCA.AGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTG

AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA

TTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCC

CATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG

GACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTT

CTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCT

GGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA

GCTCACAAGGATCCCAAT SEQ ID NO:52 pMON2 8519

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATrGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCALACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGc3CGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCT

TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG

GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT

TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA

ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGA PCCCAATGCCATCTTCCTGAGCTTCCAACACCTG

CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCG

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAA-ACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCA SEQ ID NO:53 pMON2852O

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCA.AGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCT

GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT

CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC

CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT

CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG

GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCG

CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC

CCAGAGGTTCACCCT SEQ ID NO:54 pMON28521

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAiATCTCATAAATCTCCAAACATGGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAjGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG

CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA.CCCAGCTTCCTCCACAGGGCAGG

ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG

ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC

CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC

CCTTTGCCTACACCT SEQ ID pMON28522 WO 98/17810 PCT/US97/20037

GCTAACTGCTCTATAATGATCGATGAALATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCA.ATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTC'rTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTT

AGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG

GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG

GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGC'rCAC

AAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA

GGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTC

AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA

CCTGTCCTGCTGCCT SEQ ID NO:56 pMON2 8523

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACG'rCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTrC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTG

GGArGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGG'rCCGT

CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT

CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA

CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC

CTGCTGCCTGCTGTG SEQ ID NO:57 PMON2 8524

G'CTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTrGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCA.ACCCGTCTCCTCCGTCTAAAGAATCCATAAATCTCCAAACATGGGAGAATGGAAA

ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA

CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGO

GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC

TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC

AGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGAC

TCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCT

GTGGACTTTAGCTTG SEQ ID NO: 58 pMON2 8525

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCtrGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTrGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC

CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC

CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCT

CCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTCACAGCAGACTG

AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGG

AAAACCCAGATGGAGGAGACCAAGGCACAGGACA'ETCTGGGAGCAGTGACCCTTCTGCTGGAGGAGTGAPGGCA

GCACGGGGACAACTG SEQ ID NO:59 PMON2 8526

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTMATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTT

CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCC'rGAGCTTCCAACACCTGCTCCGAGGA

AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCT

CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACACAGACTGAGCCAG

TGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACC

WO 98/17810 PCT1US97/20037 'lb

CAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGG

GGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC

CTGCAGAGCCTCCTT SEQ ID pMON28527

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGT'IC

TATCTGGTTACCCTTGAGCAAGCGCAGGACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACA

GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCA-ACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT

GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGA

GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG

CCTACACCTGTCCrGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCA-AGGCA

CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC

CAGCTTCCTCCACAG SEQ ID NO:6.

pMON2 8528

GCTACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGG.CAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT

CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA

CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC

CTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTG

GGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC

CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCA

CAGGGCAGGACCACA SEQ ID NO:62 pMON2 8529

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC

ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC

GTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTA.ACTGCTTCGT

GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT

GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG

CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG

ACCACAGCTCACAAG SEQ ID NO:63 pMON2 8530

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATICCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCA-ACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA-AGAATCTCATAAATCTCCAAACATGGCCATCTTCCTG

AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA

TTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT

GTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGAC

TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG

CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGA

CAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCT

CACAAGGATCCCAAT SEQ ID N'O:64 pMON28533

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAACCTGGAGAGCTTCGTAAGGG

CTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC

GGCCGCACCCTCTCGCATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT

TGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCA

WO 98/17810 PCTIUS97120037

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCT

ACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAG

GACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTC

TCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAG

CTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA

GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGATTCGGCGGCAACGGCGGCAAC

ATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC

AGCAGACTGAGCCAGTGCCCA SEQ ID NO: pMON28534

GCTACTGCTCTATAATGATCGATGAATTATACATCACTTAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCGTTCCGGGAACTGACGTTC

TATCTGdTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGMATCTCATAAATCTCCAACATGTTGCCTACACCT

GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCA-GGCACAGGACATT

CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC

CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT

CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG

GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCG

TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAA.ACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCT SEQ ID NO: 66 PMON2 8535

GCTAACTGCTCTATAATGATCGATGAA.ATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAJAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAA.ACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAACTGACGTTIC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAGAATCTCATATCTCCAACATGGTCCTGCTGCCT

GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG

CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAOG

ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG

ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCG

CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC

CCAGAGGTTCACCCTTTGCCTACACCT SEQ ID NO:.67 pMON28536

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCACCTGGAGAGCTTCGTA-AGG

GCTGTCAAGAACTTAGAATGCATCAGGTATTGAGGCAATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCA.AGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAALACATGGCTGTGGACTTT

AGCTTGGGAGAATGGAAA1ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG

GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG

GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGALCCCAGCTTCCTCCACAGGGCAGGACCACAGCTCAC

AAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA

GGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGAC

CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC

CCTTTGCCTACACCTGTCCTGCTGCCT SEQ ID NO:68 pMON28537

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGACCTTCGACTTCCAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAGCGTATGAGATCGAAATAGT

TACGTACTGGAGGAGAACGAGAAGCGGAGTCCGTACGC

GGCATTTCACACGCCTCTTALGACCTATTCACTGCTACT

GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGAGGGA

GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT

CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAJAGGAT

CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGA

GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG

CCTACACCTGTCCTGCTGCCTGCTGTG SEQ ID NO: 69 DMON28538 WO 98/17810 PCT/US97/20037 lie GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGAcCCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCT'rCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAA

ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA

CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG

GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC

TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC

AGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA

CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC

CTGCTGCCTGCTGTGGACTTTAGCTTG SEQ ID pMON28539 GCTAACTGCTCTATAATGATCGATGAAAT TATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGA-AC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCA-ATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC

CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC

CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGC

AACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTT

CACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC

TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAG

GGAGTGATGGCAGCACGGGGACAACTG SEQ ID NO:7.

PMON2 8540

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTT

CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA

AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATG

GCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGC

AGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGA

GAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTG

ATGGCAGCACGGGGACAAC'IGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTC

CTCCTTGGGGCCCTGCAGAGCCTCCTT SEQ ID NO:72 pMON28541

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACAGGGCAGGACCACA

GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGC'rCCGAGGAAAGGTGCGTTTCCTGATGCTT

GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCT

TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAG

GTTCACCCTTTGCCTACACCTGTCCTGCTGCCTCTGTGGACTTTAGCTGGGAGAATGGAAAACCCAGATGGAG

GAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG

GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGC

CTCCTTGGAACCCAGCTTCCTCCACAG SEQ ID NO:73 pMON2 8542

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTI

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT

CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC

ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGA

GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG

CCTAGACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAcACCGATGGAGGAGACCAAGGCA

CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC

WO 98/17810 PCT[US97/20037

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC

CAGCTTCCTCCACAGGGCAGGACCACA SEQ ID NO:74 pMON2 8543

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCA.ACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC

ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC

GTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGT

AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT

GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT

CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC

CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT

CCACAGGGCAGGACCACAGCTCACAAG SEQ ID pMON28544

GCTAACTGCTCTATAATGATCGATGAA.ATTATACATCACTTAAAGAGAOCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA-ACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCC TG

AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA

TTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT

CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG

CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA

GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG

CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC

AGGACCACAGCTCACAAGGATCCCAAT SEQ ID NO: 76 pMON28545

GCTAACTGCTCTATAATGATCGATGAAATITATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCA ATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCA-AGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC

ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC

GTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT

CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG

CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA

GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG

CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCT

CACAAG SEQ ID NO:77 pMON15981 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTA'rCTGG

CGGTGGAGGC

CGTCTCCTCC

CTGTGCCACC

CTGGGCTCCC

GCTTGAGCCA

GCCCTGGAAG

GCTGGACGTC

TGGGAATGGC

GCCTCTGCTT

GCAGAGCTTC

CCGGCGGCGG

CCCCAGAGCT

CGATGGCGCA

GCTCTATAAT GATCGATGA.A CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CCGAGGAGCT GGTGCTGCTC CTGAGCTCCT GCCCCAGCCA ACTCCATAGC GGCCTTTTCC GGATATCCCC CGAGTTGGGT GCCGACTTTG CCACCACCAT CCCTGCCCTG CAGCCCACCC TCCAGCGCCG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT CTCTGACATG GCTACACCAT TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TAGGCCCTGC CAGCTCCCTG CAAGTGAGGA AGATCCAGGG TGCCACCTAA TAA; SEQ ID NO:78 WO 98/17810 WO 9817810PCTIUS97/20037

IV

pMON15982 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTA.ACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

TTGGGTCCCA

CACCATCTGG

CCACCCAGGG

GGAGGGGTCC

CCGCGTTCTA

CACCATTAGG

TTAGAGCAAG

GCTGTGTGCC

GACACTCTCT

GCCCTGCAGC

CTACCAGGGG

pMON15965

GCTCTATAAT

CCTTTGCTGG

GGATCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CCTTGGACAC

CAGCAGATGG

TGCCATGCCG

TGGTTGCTAG

CGCCACCTTG

CCCTGCCAGC

TGAGGAAGAT

ACCTACAAGC

GGGCATCCCC

TGGCAGGCTG

CTCCTGCAGG

GCTCTATAAT

CCTTTGCTGG

GGATCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

GGGCAGGAGG

TCGTACCGCG

GGCTACACCA

AGTCTTTAGA

GAGAAGCTGT

GCTCGGACAC

GCCAGGCCCT

TTCCTCTACC

GGGTCCCACC

CCATCTGGCA

ACCCAGGGTG

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

T1CTCATAAAT

ACTGCAGCTG

AAGAACTGGG

GCCTTCGCCT

CCATCTGCAG

CGCAGCCCGG

TCCCTGCCCC

CCAGGGCGAT

TGTGCCACCC

TGGGCTCCCC

CTTGAGCCAA

CCCTGGAAGG

ATTATACATC

CCTCAATGAC

CAAACCTGGA

GGTATTGAGG

GGCCGCACCC

AATTCCGGGA

GAACAACAGT

TCCAATCTCT

CTCCAAACAT

GACGTCGCCG

AATGGCCCCT

CTGCTTTCCA

AGCTTCCTGG

CGGCGGCTCT

AGAGCTTCCT

GGCGCAGCGC

CGAGGAGCTG

TGAGCTCCTG

CTCCATAGCG

GATATCCTAA

ACTTAAAGAG

GAAGACGTCT

GAGCTTCGTA.

CAATTCTTCG

TCTCGACATC

AAAACTGACG

ACGTAGAGGG

ACTATCAACC

GTCTCCCGAG

ACTTTGCCAC

GCCCTGCAC

GCGCCGGGCA

AGGTGTCGTA

GACATGGCTA

GCTCAAGTCT

TCCAGGAGAA

GTGCTGCTCG

CCCCAGCCAG

GCCTTTTCCT

TAA; SEQ ID NO:79 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

TTCCAGCGCC

CCTGGAGGTG

GCTCTGACAT

TTCCTGCTCA

AGCGCTCCAG

AGCTGGTGCT

TCCTGCCCCA

TAGCGGCCTT

CCCCCGAGTT

TTTGCCACCA

CCTGCAGCCC

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGTCCTGGTT

TTCTACGCCA

TTAGGCCCTG

GCAAGTGAGG

GTGCCACCTA

TCTCTGGGCA

GCAGCTGGCA

AGGGGCTCCT

TTGGACACAC

GCAGATGGAA

CCATGCCGGC

ATTATACATC ACTTAA.AGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACPATCAACC CTCCAAACAT GTCTTCTGCT GCTAGCCATC TGCAGAGCTT CCTTGCGCAG CCCGGCGGCG CCAGCTCCCT GCCCCAGAGC AAGATCCAGG GCGATGGCGC CAAGCTGTGC CACCCCGAGG TCCCCTGGGC TCCCCTGAGC GGCTGCTTGA GCCAACTCCA GCAGGCCCTG GAAGGGATAT TGCAGCTGGA CGTCGCCGAC GAACTGGGAA TGGCCCCTGC CTTCGCCTAA TAA SEQ ID pMON1 5966 1 51 101 151 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

ATGGCTAACT

ACCACCTGCA

CTATCCTGAT

AGGGCTGTCA

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

CCTGCCCTGC

CCAGCGCCGG

TGGAGGTGTC

TCTGACATGG

CCTrGCTCAAG

CGCTCCAGGA

CTGGTGCTGC

CTGCCCCAGC

GCGGCCTTTT

CCCGAGTTGG

TGCCACCACC

GCTCTATAAT

CCTTTGCTGG

GGATCGAAAC

AGAACTTAGA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

AGCCCACCCA

GCAGGAGGGG

GTACCGCGTT

CTACACCATT

TCTTTAGAGC

GAAGCTGTGT

TCGGACACTC

CAGGCCCTGC

CCTCTACCAG

GTCCCACCTT

ATCTGGCAGC

GATCGATGAA

ACCCGAACAA

CTTCGACTTC

AAATGCATCA

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

GGGTGCCATG

TCCTGGTTGC

CTACGCCACC

AGGCCCTGCC

AAGTGAGGAA

GCCACCTACA

TCTGGGCATC

AGCTGGCAGG

GGGCTCCTGC

GGACACACTG

AGATGGAAGA

ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTATGGCC CCGGCCTTCG CCTCTGCTTT TAGCCATCTG CAGAGCTTCC TTGCGCAGCC CGGCGGCGGC AGCTCCCTGC CCCAGAGCTT GATCCAGGGC GATGGCGCAG AGCTGTGCCA CCCCGAGGAG CCCTGGGCTC CCCTGAGCTC CTGCTTGAGC CAACTCCATA AGGCCCTGGA AGGGATATCC CAGCTGGACG TCGCCGACTT ACTGGGATAA TAA SEQ ID NO: 81 pMON15967 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCTCAATGAC GAAGACGTCT CAAAkCCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG WO 98/17810 WO 9817810PCTIUS97/20037 201 251 301 351 401 451 501 551 601 651 701 751 801 851 901 951

TAATCTCCAA

CAATCATCAT

TTCTATCTGG

CGGTGGAGGC

CGTCTCCTCC

GGTGCCATGC

CCTGGTTGCT

TACGCCACCT

GGCCCTGCCA

AGTGAGGAAG

CCACCTACAA

CTGGGCATCC

GCTGGCAGGC

GGCTCCTGCA

GACACACTGC

GATGGAAGAA

CCATGTCTGC

CAAGGCAGGT

TTACCCTTGA

TCCCCGGGTG

GTCTAAAGAA

CGGCCTTCGC

AGCCATCTGC

TGCGCAGCCC

GCTCCCTGCC

ATCCAGGGCG

GCTGTGCCAC

CCTGGGCTCC

TGCTTGAGCC

GGCCCTGGAA

AGCTGGACGT

CTGGGAATGG

CCTCTGCCAC

GACTGGCAAG

GCAAGCGCAG

AACCGTCTGG

TCTCATAAAT

CTCTGCTTTC

AGAGCTTCCT

GGCGGCGGCT

CCAGAGCTTC

ATGGCGCAGC

CCCGAGGAGC

CCTGAGCTCC

AACTCCATAG

GGGATATCCC

CGCCGACTTT

CCCCTGCCCT

GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCA.ATCTCT ACTATCAACC CTCCAAACAT GTCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC CTGACATGGC TACACCATTA CTGCTCAAGT CTTTAGAGCA GCTCCAGGAG AAGCTGTGTG TGGTGCTGCT CGGACACTCT TGCCCCAGCC AGGCCCTGCA CGGCCTTTTC CTCTACCAGG CCGAGTTGGG TCCCACCTTG GCCACCACCA TCTGGCAGCA GCAGCCCTAA TAA SEQ ID NO:82 pMON15960 1 51 101 151 201 251 301 351 401 451 501 551 601 651' 701 751 801 851 901 1001 1051

ATGGCTACAC

CAAGTCTTTA

AGGAGAAGCT

CTGCTCGGAC

CAGCCAGGCC

TTTTCCTCTA

TTGGGTCCCA

CACCATCTGG

CCACCCAGGG

GGAGGGGTCC

CCGCGTTCTA

CACCATTGGG

TTAGAGCAAG

GCTGTGTGCC

GACACTCTCT

GCCCTGCAGC

CTACCAGGGG

CCACCTTGGA

TGGCAGCAGA

TCCTGGTTGC

CTACGCCACC

CATTGGGCCC

GAGCAAGTGA

GTGTGCCACC

ACTCTCTGGG

CTGCAGCTGG

CCAGGGGCTC

CCTTGGACAC

CAGCAGATGG

TGCCATGCCG

TGGTTGCTAG

CGCCACCTTG

CCCTGCCAGC

TGAGGAAGAT

AC CTACAAGC

GGGCATCCCC

TGGCAGGCTG

CTCCTGCAGG

CACACTGCAG

TGGAAGAACT

TAGCCATCTG

TTGCGCAGCC

TGCCAGCTCC

GGAAGATCCA

TACAAGCTGT

CATCCCCTGG

CAGGCTGCTT

CTGCAGGCCC

ACTGCAGCTG

AAGAACTGGG

GCCTTCGCCT

CCATCTGCAG

CGCAGCCCGG

TCCC'rGCCCC

CCAGGGCGAT

TGTGCCACCC

TGGGCTCCCC

CTTGAGCCAA

CCCTGGAAGG

CTGGACGTCG

GGGAATGGCC

CAGAGCTTCC

CTGCCCCAGA

GGGCGATGGC

GCCACCCCGA

GCTCCCCTGA

GAGCCAACTC

TGGAAGGGAT

GACGTCGCCG

AATGGCCCCT

CTGCTTTCCA

AGCTTCCTGG

CGGCGGCTCT

AGAGCTTCCT

GGCGCAGCGC

CGAGGAGCTG

TGAGCTCCTG

CTCCATAGCG

GATATCCCCC

CCGACTTTGC

CCTGCCCTGC

TGGAGGTGTC

GCTTCCTGCT

GCAGCGCTCC

GGAGCTGGTG

GCTCCTGCCC

CATAGCGGCC

ATCCCCCGAG

ACTTTGCCAC

GCCCTGCAGC

GCGCCGGGCA

AGGTGTCGTA

GACATGGCTA

GCTCAAGTCT

TCCAGGAGAA

GTGCTGCTCG

CCCCAGCCAG

GCCTTTTCCT

GAGTTGGGTC

CACCACCATC

AGCCCACCCA

GTACCGCGTT

CTGATAA SEQ I D NO:8 3 PMON3 2132

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCA-ACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGG SEQ ID NO:84 PM05N32133

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGcCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTG

AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG

SEQ ID pMON32134

TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC

TGCGTCAGG SEQ ID NO:86 Pmon13 18 1 1 CCATGGCTAA CTC-CTCTATA ATGATCGATG AAATTATACA TCACTTAAAG 51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT WO 98/17810 PCT/US97/20037 101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 201 CGTAATCTCC AACCATGTCT OCCCTCTGCC ACGGCCGCAC CCTCTCGACA 251 TCCAA'rCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA 401 CCCGTCTCCT CCGTCTAAAG AA'rCTCATAA ATCTCCAAAC ATGTAAGGTA 451 CCGCATGCAA GCTT SEQ ID NO:87 Pmon1318O.Seg 1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG 51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT 101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA 251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA 401 AGGTACCGCA TGCAAGCTT SEQ ID NO:88 pMON30237 .seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCC SEQ ID NO:89 pMON30238.seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTG SEQ ID pMON30239 .seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA-AGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGGAGACCTCCGAGCAGCTGGTGGCGCTGMA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTG SEQ ID NO:91 pMON32329.seq

GGAACTCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC

*TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCC SEQ ID NO:92 pMON32330.seq

GGTACCCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC

WO 98/178 10 1. PCTIUJS97/20037

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGG'rGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO:93 pMON32341.seq

GCCACTCAGGACTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCC SEQ ID NO:94 pMON32342.seq

GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTG SEQ ID pMON3232O seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC

CCAGGACTGCTCCTTCCAACACAGCCCCATC'rCCTCCGACTTCGCTGTCA

AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAG SEQ ID NO:96 pMON32321 .seq GCCGACGAGGAGCTCTGCGGGGGCCTCrGGCGGCTGTCCrGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA-AGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT

CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT

CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

SEQ ID NO:97 pMON32322.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT

CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC-TACCTGCTTC

AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 98 WO098/17810 A4PCT/US97/20037 pMON32323 .seq

GCCTCCAAGATGCA.AGGCTTGCTGGAGCGCGTGA.ACACGGAGATACACTT

TGTCACCAAATGTGCCTTTCAGCCCCCcCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA

ATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC'r

TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT

GCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGG SEQ ID NO:99 pMON3 2324. seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT

TGTCACCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA

ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC

GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT

CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC

GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

SEQ ID NO: 100 pMON32325.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT

TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

C'rGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACT

GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA.ATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAcCCGTGGCCTCCAA

CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC

AGCGCTGGATGGAGCCGCTCAAGACTGTCGCTGGG SEQ ID NO:101 pMON32326.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA'rCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC

CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCPGTCA

AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT

CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA

TGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA

TGTGCCTTTCAGCCC SEQ ID NO:102 pMON32327 .seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT

CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGT

CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCMACCTGCAG

GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG

GATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGG

AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC

SEQ ID NO:103 pMON32328 .seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

WO 98/17810 1425 PCTIUS97/20037

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCAT

CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC

AAGATTACCCAGTCACCGTGGCCTCCAACC'rGCAGGACGAGGAGCTCTGC

GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA

GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG

AGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 104 pMON32348.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAA-ATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAGTGGATCCGGAGGTTCTGGCAACCCAGGACTGCTCCT

TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

SEQ ID NO:105 pMON3235O .seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCPGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAAC

CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA

AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAG SEQ ID NO:106 F'LT3N. seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC

AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT

TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACT1CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCC SEQ ID NO:107 FLT3C. seq

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC

CGACTTCGCTG'PCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT

ACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC

CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT

CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC

ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC

GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT

GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC

TGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT SEQ ID NO:108 FLT7N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC

AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT

TGTCACCAA.ATGTGCC'rTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGA.AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGC-AGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC

WO 98/17810 PCT1US97/20037 SEQ ID NO:109 lFLT4C.seq

GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC

CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG

ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG

GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC

TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA

TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCcCCCAGCTGTCTTCGC

TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT

GGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGG

AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT

SEQ ID NO:l1O F'LT11N. seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC

AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGGTCCAAGATCCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT

TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC

AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAG

GAGGTGGATCC SEQ ID NO:111 FLT1OC seq

GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT

CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAkAATCCGTGAGCTGT

CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCC'rGGCACAGCGCTG

GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG

AGCGCGTGAACACGGAGATACACTrTTGTCACCAAATGTGCCTTTCAGcCC

CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCA

GGAGACCTCCGAGCAGCTGGTGGCGCTGAXGCCCTGGATCACTCGCCAGA

ACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG

TAAGCTT SEQ ID NO:112 pMON32365.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTGC

TGGAGCGCG'rGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCA-ACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 113 pMON32366.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAGACTGTCGCTGGTCCAJGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG

CCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACC

TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:114 pMON32367 .seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

WO098/17810 1424 PCTIUS97/20037

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGC-GGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACCCTCAACC

CTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTT

CCAACACAGCCCCATC'rCCTCCGACTTCGCTGTC?.AAATCCGTGAGCTGT

CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA.ACCTGCAG

SEQ ID NO:115 pMON32368 .seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA

CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCC

GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC

AACCTGCAG SEQ ID NO:116 pMON32369.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAkTGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCAC

CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA

AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGA'rTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO:117 pM0N32370.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGCCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTC

AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT

CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA2A GATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:118 pMON3O247 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAGAGACC

ACCTGCACCTTTGCTGGACCCGACAJACCTCATGACGAGACGTCTCTA

TCCTGATGGACCGAACCTTCGACTTCCACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAJATTCTTCGTAJA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCC-

TCATCATCAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAJACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCACATGGCCACCAGGAC

TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCG

TGAGCTGTCTGACTACCTGCTTCAAGA'rTACCCAGTCACCGTGGCCTCCA

ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAJAGG

CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA.TGTGCCT

TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC

TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO:119 pMON3O248.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGAGACC

WO 98/17810 AIPCTIUS97/20037

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACT1TAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC

TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG

TGAGCTGTCTGACTACCTGCT'rCAAGATTACCCAGTCACCGTGGCCTCCA

ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG

CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT

TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC

TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT

CAACCCTG SEQ ID 140:120 pM0N32332.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAA.ACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCrGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCcCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTcCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAA-ATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCA-ACCTGCAG SEQ ID 140:121 pM40132333 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAI\GACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACG'PPC

TATCTGGTTACCCTTGAGCAAGCGCAGGA.ACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJ4CCTG CAG SEQ ID 140:122 pM0N32334.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAA.ACCTTCGACTTCCAACCTGGAGAGCTTCGTAJAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJA

TCATCATCAAGGCAGGTGACTGGCAGATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAp.ATCTCCAAACATGGCCTCCAJAGATG WO098/17810 A PCTIUS97/20037

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA-ACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGC'rCCTTCCAAC

ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA-ACCTGCAGGACGA

GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG

AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO:123 pMON32335 .seq

GCTAACTGCTCTATAATGATCGATGA-AATTATACATCACTTA-AAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGA.ATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG

ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC

CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC

CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG

CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 124 pMON32336.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGA.ACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA.AGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG

GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC

AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGG SEQ ID NO:125 pMON32337.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGC'rGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC

AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT-

CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAOC'rCTGCGGGGGCCTCTGG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGCTCAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG

WO 98/17810 PCTUS97ZOO37 TCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 126 pMON32338 .seq GCTAACTGCTC1'ATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG3GAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCMAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCC'rCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 127 pMON32339.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAA.ATGTGCCTTTCAG

CCC SEQ ID NO: 12 8 pMON32364 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCA-ACCCGT

CTCCTCCGTCTAA.AGAATCTCATAAATCTCCAAACATGGCGACTCAGGAC

TGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG

TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA

ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG

CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT

TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC

TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO: 129 pMON32377.seq

GCTAACTGCTC.TATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAAC:CTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

WO 98/17810 144PCT/US97/20037

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACA-ACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGAC

TGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG

TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA

ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG

C'rTGCTGGAGCGCGTGAACACGGAGATACACTTTG3TCACCAA.ATGTGCCT

TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC

TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT

CAACCCTG SEQ ID NO: 130 pMON3 2392. seq

GCCACTCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTc4TCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC

AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACA'rCACTTAA

AGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC

ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT

CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTC

TTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGA

CATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACT

GACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 131 pMON3 2352. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAAcCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACC'rTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTG'rCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 132 pMON3 23 53. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGC'rGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC.CCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGALAGCCCTGGATCACTCGCCAGAACTTCTCCC

WO 98/17810 PCT/US97/20037

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGATCCGGTGGCAA'rGGGAGCGGCGGAAATGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAG SEQ ID NO:133 pMON32354 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTACCCTTTGCTGGACCCA-ACACCTCAATCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAAT'rCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC

ACAGCCCCATCTCCTCCGACTTCGCTGTCAAA-ATCCGTGAGCTGTCTGAC

TACCTGCTTCA.AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA

GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG

AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO:134 pMON32355.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

'TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGG'rAATGGCACCCAGG

ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC

CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC

CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCrCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 135 pMON32356 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAAT'rCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGALACAACAGTACGTAGAGGGCGC

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG

GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC

AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTrGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO:136 pMON32357.seq WO 98/17810 PCTIUS97/20037

GCTACTGCTCTATAATGATCATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGTTCCGGAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAA.ATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCtCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCGGATCACTCGCCAGACTTCTcC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC

AACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT

CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG

TCACCAAATGTGCCTTTCAGCCC SEQ ID NO:137 pMON32358 .seq

GCTACTGCTCTATATGATCGATGAAATTATACATCACTTAAGAGACC

ACCTAACCCTTTGCTGGACCCGAIACAACCTCAATTCTGAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCAT1GTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACACATACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCcCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO:138 pM0N32359 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA4

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAA-AGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAALATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCC SEQ ID NO:139 pMON3236O .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA~

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

WO098/17810 PCT1US97/20037

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AGTGGATCCGGAGGTTCTGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 140 pMDN32362.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT~AA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACATACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCPOGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCcCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT1GGCCTCCAACCTG CAG SEQ ID NO:141 pMON32393.seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTcTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCGGGT

GAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA.AGA

ATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAA

TTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAAC

CTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCC

AAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAG

GTATTGAGGCAATTCTTCGTA.ATCTCCAACCATGTCTGCCCTCTGCCACG

GCCGCACCCTCTCGACATCCA.ATCATCATCAAGGCAGGTGACTGGCAAGA

ATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGG

AACAACAG SEQ ID NO:142 pMON32371..seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAACAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGA'rACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

WO 98/1 78 10 ;5PCTfIUS97/20037

TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA

CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC

CAGTCACCGTGGCCrCCAACCTGCAG SEQ ID NO: 143 pMON32372 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA.A

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTG;AACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC

CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT

ACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 144 pMON32373 .seq

GCTAACTGCTCTATAATGATCGATGAA-ATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAA.ACCT1GCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCA-AGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAOAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCCTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCA.ACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

PTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 145 pMON32374.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCALACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAALATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA

ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG

ACTACCTGCTTCAAGATTACCCAGTCAcCGTGGCCTCCAACCTGCAG SEQ ID NO: 146 pMON3 23

GCTALACTGCTCTATALATGATCGATGAAATTATACATCACTTAA.AGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

WO098/17810 /1 PCTIUS97200O37

TCCTGATGGAJACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCA-AGCACTTAGAAXATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACArGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTrCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCA-AGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTcCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC

CTTCCA.ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACcCAGTCACCGTGGCCTCCAACCTG CAG SEQ ID NO;147 pMON32376. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGA-ATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCA-AGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG

TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG

CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAG SEQ ID NO:148 pMON32378 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGA.ACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCA.ACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCC

AACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT

GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA

CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA

TGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 14 9 pmON32379.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCALACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGT.TC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

WO 9/1780 PCTIUS97/20037

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCT

TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA

GGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT

GGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 150 pM0N32380.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGA-ATCTCATAAATCVCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGG

ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC

CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC

CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG

CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 151 pMON3 2381. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTG

GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC

CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC

TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 152 pMON32382 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCA.AGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG

GAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC

ACTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT

GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

WO098/17810 A!VPCT/UJS97/20037 GGG SEQ ID NO:153 pMO1432383.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCA-AGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG

GAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC

AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA

CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG

AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG

CGGCTCAAGACTGTCGCTGGG SEQ ID NO:154 pMON3 2384. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGM'SACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACA.ACAGTACGTAGAGGGC!GG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA

CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC

CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCALAGACTGTCGC

TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT

TTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 155 pMON32385. seq

GCTALACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACALACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAkACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC

CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT

ACCCAGTCACCGTGGCCTCCAACCTGCAGGATGAGGAGCTCTGCGGGGGC

CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT

CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC

ACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 156 pMON32386.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTALACCCTTTGCTGGACCCGAACAACCT2CAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

WO098/17810 A9PCTIUJS97/20037

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA-A

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGG'rGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGC'rTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO:157 pMON32387 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCA-ACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCC'rGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA

ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG

ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC

GAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT

GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC

GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 158 pMON32388.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCC SEQ ID NO:159 pMON32389 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACALACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCALAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

W098/7810PCTIUS97/20037 WO 9817810440

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG

TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG

CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG

GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT

CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCIC SEQ ID NO: 160 hflt3-28291ink10 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGA.ACAACCTCAATTCTGAAGACATGGATA

T CCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCT1GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGG

AGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 161 hflt3-28291ink15 seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATA-AATCTCCAAACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG

AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCA

TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT

CAA SEQ ID NO:162 hflt3-34351ink10 seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGA.ACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC

CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC

GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCA.AGATTACCCAGTCACCGTG SEQ ID NO: 163 WO 98/17810. PCTIUS97/20037 ,141 hflt3-34351inkl5 seq GCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAAkCCTCA-ATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAAGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC

CTGCAGGACGAGGAGCTC'rGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC

GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG

CACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG

TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC

GTG SEQ ID NO:164 hflt3-62631ink10 seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGA-ATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAG

GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC

CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC

TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO:165 hflt3-62631inkl5.seq

GCTAACTGCTCTATAATGATCGATGAA-ATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCA.AGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG

GTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA

AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCG

GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG

ACT SEQ ID NO:166 hflt3-94951ink10 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTIAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

WO098/17810 A 1PCTIUS97/20037

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGACTGC

AGTGTCAGCCCGACTCCTCAACCCTGQGCGGTGGGTCAGGAGGTGGATCC

GGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT

CGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG

TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO:167 hflt3-94951jnkl5 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAJ'GAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAA.ACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCALAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGrC CAGACCAACATCTCCCGCC'rCCTGCAGGAGACCTCCGAGCAGCTGGTGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGc

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCA-ACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTT SEQ ID NO:168 hflt3-98991ink10 .seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAcC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAkA.ATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA.CTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGA-ACAACAGTACGTAGAGGGCGG

TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAJ\TCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT

CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT

CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA

AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG

CCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:169 hflt3-98991ink15. seg

GCTAACTGCTCTATAATGATCGATGZAJATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAJAGATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

WO098/17810 A1IJPCT1US97/20037

ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA

CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC

CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCC

TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT

TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC

CAG SEQ ID NO:170 hflt3-28291ink6 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCA.ATTCTGA.AGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCA.AGAATTCCGGGAAA.AACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTrCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCT1CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGA

CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC

GTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO:171 hflt3-28291ink7 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACA.ACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCC PCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCA.AACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCA

GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA

TCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO:172 hflt3-28291inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACc3TTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG-

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGG

GGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT

CCGACTTCGCTGTCAAAkTCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 173 W0 9817810 PCTIUS97/20037 /144 hflt3-28291ink2l..seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGA.ACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG

GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG

GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA

GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC

TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG

AGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCT

CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAA SEQ ID NO:174 hflt3-34351ink6.seq GCTAACTGCTCTATAATGATCGA'rGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGCAAAA.ACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC

CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC

GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGATCCGGAGGTACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA

AGATTACCCAGTCACCGTG SEQ ID NO:175 hflt3-34351ink7 .seq

GCTAACTGCTCTATA.ATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC

CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TCCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC

GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGATCCGGAGGTGGCACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAA.AATCCGTGAGCTGTCTGACTACCTGCT

TCAAGATTACCCAGTCACCGTG SEQ ID NO:176 hflt3-34351ink13 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

WO098/17810 "41 6 PCT/US97/20037

TCATCATCAAGGCAGGTGACTGGCAGTTCCGGGAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGACACAGTACGTJAGAGGGCGG

TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCACATGGCCGCCTCCAJAC

CTGCAGOACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TGC'rGGAGCGCGTGAACACGGAGATACACTTTGTCACCA.TGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCALACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTC

GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACTGC

TCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA

GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 177 hflt3-34351jnk2l seq

GCTAACTGCTCTATATGATCGATGATTATACATCACTTAAGAGACC

ACCTAACCCTTTGCTGGACCCG.CACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGACCTTCGACTCCAACCTGCTCGCATTCGTAGG

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJA

TCTACAGAGGCGCAGATCGAAATAGT

TATCTOGTTACCCTTGAGCAAGCGCAGG1ACACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGTCCAJATCTCTACTATCAACCCGT

CTCCTCCGTCTAAGAATCTCATATCTCCAACATGGCCGCCTCCAAC

CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCGCTGGATGGAGCGGCTCAIAGACTGTCGCTGGGTCCAAGATGCAAGGCT

TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT

CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC

GCCAGAAC'rTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG

CTCAGGGGGAGGTAGTGGTAGGACTGCTCCTTCCACACAGCCCCATCTC

CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG

ATTACCCAGTCACCGTG SEQ ID NO:178 hflt3-62631jnk6 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAGAGACC

ACTACTTCGACGAAACCATTAGCTGT

TCCTGATGGAACGAACCTTCGAJACTCCA-kCCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAGTTCCGGGAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACACAGTACGTAGAGGGCCG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAATCTCCAAAJCATGGCCGTCGCTGGG

TCCAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGT

CACCAAATGTGCCTT'TCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACT

GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTTCAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA

CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC

AGCGCTGGATGGAGCGCTCAAGACT SEQ ID NO: 179 hflt3-62631jnk7 .seq

GCTAACTGCTCTATAATGATCGATGATTATACATCACTTALGAGACC

ACCTAACCCTTTGCTGGACCCAACAACCTCAATTCTGMAGACATGGATA

TCCTGATGGAACGA.AACCTTCGAACTCCAJCCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTCCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAGTTCCGGGJAMACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATATCTCCAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

WO098/17810 IkPCT/US97/20037

TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGG

ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATC

CGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCACCGTGGCCTC

CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG

CACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO:1BO hflt3-62631inkl3 .seq GCACGTTTAGTdTAATTCTATA-GGC

ACTACTTCGACGAACTAATTAGCTGT

TCTAGACAACTGATCACTCCCTCT-G

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAJ,

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJA

TCATCATCAAGGCAGGTGACTGGCAGTTCCGGG)AAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGACACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGA1ATCTCATAAATCTCCAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGG

GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA

CCCAGTCACCGTGGCCTCCA-CCTGCAGGACGAGGAGCTCTGCGGGGGCC

TCGCGTGCTGAACCGAGACGTAGC SEQ ID NO: 181 hflt3-62631ink2l.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAGAGACC

ACTACTTCGACGAAACCATTAGCTGT

TCCTGATGGAACGAAACCTTCGAACTCCAACCTGCTCGCATTCGTAAGG

GCGCACCTGAAGACAGATAGATCTGA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJA

TCTACAGAGGCGCAGATCGAAATAGT

TATCTGGTTACCCTTGAGCAAGCGCAGGACACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCA-CCCGT

CTCCTCCGTCTAA.AGAATCTCATAATCTCCAAAJCATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG

GTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA1A.ATCCGTGAGCT

GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTC

AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC

TGGATGGAGCGGCTCAAGACT SEQ ID NO: 182 hflt3-9 4951jnk6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTA-AAGAGACC

ACCTACCCTTTGCTGGACCCGAACAACCTCATTCTGAJ\GACATGGATA

TCCTGATGGACGACCTTCGACTCCACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAT

CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT

CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCA-GATGCA

AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAJATGTG

CCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO.:183 hflt3-94951jnk7.seq WO 98/17810 PCTIUS97/20037

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGAGACC

ACTACTTCGACG.CACCATTAGCTGT

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAAcAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAJ\CCCGT

CTCCTCCGTCTAAAGAATCTCATAA\TCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACC

CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAJA

AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG

CCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC

CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT

GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT

GTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO:184 hflt3-94951inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGAGACC

ACTACTTCGACGAAACCATTAGCTGT

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCGCACCTGAAGACAGATAGATCTGA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCTACAGAGGCGCAGATCGAAATAGT

TATCTGGTTACCCTTGAGCAAGCGCAGGACACAGTAGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAJACCCGT

CTCCTCCGTCTAAAGAATCTCATAAAI'CTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCA

GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC

CTCCGACTTCGCTGTCAAAATCCGTGAGCTG'rCTGACTACCTGCTTCAAG

ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG

GGCCTCTGGCGGCTGGTCCTrGGCACAGCGCTGGATGGAGCGGCTCAAGAC

TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA

TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO:185 hflt3-94951ink21 .seq

GCTAACTGCTCTATAATGATCGATGAA.ATTATACATCACTTAAAGAGACC

ACTACTTCGACGAAACCATTAGCTGT

TCCTGATGGAACGAA.ACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAJACCCGT

CTCCTCCGTCTAAAGAATCTCATATCTCCAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGG-TACCCAGGACTG

CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG

AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC

CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA

GCCGAGACGTAGCGTGTGTCAAGAGC

TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCWATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTT SEQ ID NO:186 hflt3-98991ink6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCCTTAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACG'rAGAGGGCGG

TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

WO098/17810 PCTIUS97/20037

CTCCTCCGTCTAAGAATCTCATAATCTCCAAACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTC

CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAJAJAJTCCGTGAGCTGTC

TGACTACCTGCTTCAAkGATTACCCAGTCACCGTGGCCTCCAACCTGCAGG

ACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGA

GCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCC

CCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:187 hflt3-98991jnk7 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACTACTTCGACG-CACCATTAGCTGT

TCCTGATGGAACGACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCTACAGAGGCGCAGATCGAAATAGT

TATCTGGTTACCCTTGAGCAGCGCAGGACACAGTACGTAGAGGGCGG

TGGAAGCTCCCCGGGTGAJCCGTCTGGTCCJATCTCTACTATCACCCGT

CTCCTCCGTCTAAGAATCTCATAATCTCCACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC

TTCCALACACAGCCCCATCTCCTCCGACTTCGCTGTC~AAACCGTGAGCT

GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC

AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC

TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAJAGATGCAAGGCTTGCT

GGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGC

CCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:188 hflt3-98991ink13.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACTACTTCGACGAACTATCG-GCTGT

TCCTGATGGAACGAACCTTCGACTCCAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCpJATTCTTCGTA3A

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC-CCCGT

CTCCTCCGTCTAAGAATCTCATATCTCCACATGGCCACCAACATC

'rCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCT1GGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAJAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:189 hflt3-98991ink21 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTA.GAGACC

ACCTAACCCTTTGCTGGACCGACACCTCATTCTGA-GACATGGATA

TCCTGATGGAACGAACCTTCGACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAGTTCCGGGAAACTGACGTTC

TATCTGGTTACCCTTGAGCAGCGCAGGAACACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGMCCGTCTGGTCCATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAATCTCCAACATGGcCACcAAXCATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA

CAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACT

ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAG

GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA

GCGGCTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCG

WO 98/17810 PCTIUS97120037

TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAG SEQ ID NO:190 pMON32390

GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGT

CCGCCCCGCCATGTCTACATCAGATCTGCCTGTGATCAAGTGTGTTT

TATATAAGAATATATATGGATACTAA

CCCATGGTATCAGAATCCCCGGAAGACCTCGGGTGTGCGTTGAGACCCCA

GAGCTCAGGGACAGTGTACGIAAGCTGCCGCTGTGGAAGTGGATGTATCTG

CTTCCATCACACTGCAAGTGCTGGTCGATGCCCCAGGG-CATTTCCTGT

CTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTT

ACAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAATGACAGACCC

AAGCTGGAGAATACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACA

ATATTGTTTACAGTGAGTATAGATACCCTGCTTTAACATTAGAG

ACCTTACTTTAGAAJJTGGAAAACCAGGACGCCCTGGTCTGCATATCTG

AGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGATTCACAGGGG

GAAAGCTGTAAAGAAGAAGTCCAGCTGTTGTTAAGGAGGAAAGT

GCTTCATGAATTATTTGGGATGGACATAAGGTGCTGTGCCAGAAATGAA3C TGGGCAGGGAATGCACCAGGCTGTTCACATAGATCTATCZA,2ACTCCT

CAGACCACATTGCCACAATTATTTCTTAJ\AGTAGGGACCCTTATGGAT

AAGGTGCAAAGCTGTTCATGTGAACCATGGATTCGGGCTCACCTGGGAAT

TAGAAAACAAAOCACTCGAGGAGGGCAACTACTTTGAGATGAGTACCTAT

TCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGT

GGCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCA

GTCAATCAGCTTTGGTTACCATCGTAGAAAGGGATTTATAAATGCTACC

AATTCAAGTGAAGATTATGAAATTGACCAATATGAGAGTTTTGTTTTTC

TGTCAGGTTTAAAGCCTACCCACmATCAGATGTACGTGGACCTTCTCTC

GAAATCATTTCCTTGTGAGCAAGGGTCTTGATACGGATACAGCATA

TCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGC

AGAAGTAGCATTCAAAGTAGTATTAA

GGAAACCTCAAGTGCTCGCAGAAGCATCGGCAJAGTCAGGCGTCCTGTTTC

TCGGATGGATACCCATTACCATCTTGGACCTGGAGAGTGTTCAGACAA

GTCTCCCAACTGCACAGAGAGATCACAGAAGGAGTCTGTAGAGG

CTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACTCTAAACATG

AGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAJTTCCCT

TGGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTT

TCATCCAAGACAACGAATTCATCATCCTGGGCCTGTTCGGCCTCCTGCTG

TTGCTCACCTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAG

GAAGAATCCCCTCTGGCCAAGTGTCCCAGACCCAGCTCACAGCAGCCTGG

GCTCCTGGGTGCCCACAATCATGGAGGAGGATGCCTTCCAGCTGCCCGGC

CTTGGCACGCCACCCATCACCAGCTCACAGTGCTGGAGGAGGATGAA

GAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTCC

CCACTC'rGGTCCAGACCTATGTGCTCCAGGGGGACCCA4GAGCAGTTTCC

ACCCAGCCCCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCA

GCTGCTGGGCAGCCCCACAAGCCCAGGGCCAGGGCACTA'rCTCCGCTGTG

ACTCCACTCAGCCCCTCTTGGCGGGCCTCACCCCCAGCCCCAGTCCTAT

GAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTGGTAACCCCAGC

CCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCACTTCCCCC

TCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTC SEQ ID NO: 191 pMON3 0329. seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCGTCTTTAGAGAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

.CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGC'rGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAATGGAAGCTGGAjATGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGC3CAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG

CGTGTGGGCCAATTGTGTCAGTCAGTGTGGGGGA

ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG

ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT

CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:1-92 pMON32l 7 3.seq WO098/17810 4oPCTIUS97/20037

GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGG'rGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT

CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAGAATCTCATAATCTCCACATGGCTACC

CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT

GACTACCTGCTTCAAGATTACCCAGTCACCGTGCCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG

GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG

ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC

CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG

CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG

CCCGACTCCTCA.ACCCTG SEQ ID NO:193 pMON32175.seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA.TGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCATGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT

CCACCATTACCTTCCGCAAGACCTATTCACTGTC

CCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTT'AGAGCAJAGTGAGGAAG

ATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAG

GAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAG

GCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTG

CAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC

GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACC

CAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC

CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTTTACGCCACCTTGCGCAGCCC SEQ ID NO:194 pMON322O4.seq

GCTACACCATTGGGCCC'TGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG

AGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGGACTGCTCTTTTCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG

CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC

ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG

ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT

CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAG

GGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCT

AAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC

TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAG

ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC

ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG

AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 195 pMON32205 .seq

GCTAACTGCTCTATATGATCGATGATTATACATCACTTAAGAGACCACCTGCACCTTTGCTG

GACGAACTATAGAAGCCATCGTGCGACTCATCAA

CTGGGTCTAGCGCAACTGAATCTAGATAGATCTG

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCA.GGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACTTCTATCTGGTTACCCTTGAGCP1AGCGCAGGCA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGOTCCAATCTCTACTATCAAC

CCTTCCGCAAATTAAACCCACTGCCCGATCCTTA

CACAGCCCCATCTCCTCCGACTTCGCTGTCp.AAATCCGTGAGCTGTCTGACTACCTCTTCAAGAT

TACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC

CTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAG

WO098/17810 /5fPCTjyUS97/20037

CGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC

TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC

TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG

TAGAAGCGGAGTCCGTACCTTGCATTTCACACGC

CCTCCGTCTAAAGAATCTCATAATCTCCA-CATGGCTACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAJAGATGCAGGCTTGCTGGAGCGCGTG

AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC

ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG

SEQ

ID NO:196 pMON32208 .seq

GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCCTGTCAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG;AGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCJAAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGT

CCACCATTACCTTCCGCAAGACCTATTCACTGTC

CCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAGTGAGAAG

ATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAG

GCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTG

CAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC

CAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC

CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTACGTAGAG

GGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCT

AAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAJSCACAGCCCCATCTCC

TCGCTGTTAATCTACGCGATCTCTAGTACATACT

GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAG

ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC

ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG

AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:197 pMONJ 5767 .seq/PMON32191 .seq

GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGA

GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCT

CTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAJAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGAGATACACTTTGTCACCATGTGCCTT

TCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGCCTGGAGCTGCA

GTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGG

CGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCJA

GTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC

CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCC

CCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCT

TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAJGGGATATCCCCCGAGTTGGGTCCCACCTTGGA

CACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGCTGGGAAT

GGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC

AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA

CCTTGCGCAGCCG SEQ ID NO:198 pMON32397.seq GCTAACTGCTCTAThATGATCGATGAAATTATACATCACTTAA-GAGACCACCTAACCCTTTGCTG

GACGAACTATCGAAAGAACTAGACACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGT

AATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCCGATACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAkGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGT WO 98/17810 PCTIUS97/20037

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCCTGTCA.

ATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO:199 pMON32398.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAGAGACCACCTACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAAJTGCATCAGGTATTGAGGCATTCTTCGT

A-TCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAATGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCCGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGT

GGGTCAGGAGGTGGATCCGGAGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAJ\ SEQ ID NO:200 pMON32399 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATACGACGACCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAGCACTTAGAJ

JATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCA

GGGCGCAATCGGAACGCTTTTTGTCCTACACCGA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTG-CCGTCTGGTCCAATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAATCTCCXACATGGCCGCCTCCACCTGCAGACGAG

GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCIAGACTGTC

GCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTGTCACCATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA-ACATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCAGCCCGACTCCTCAJACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO:201 pM0N35700.seq

GCTAACTGCTCTATAATGATCGATGATTATACATCACTAGAGACCACCTACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAGACATGGATATCCTGATGGACGACCTTCGAACTCCAAC

CTGCTCGCATTCGTAAGGGCTGTCAGCACTTAGAJA3ATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCA'rGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA

GGTGACTGGCAAGATTCCGGGAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CAACAGTACGTAGAGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAGAATCTCATAATCTCCAACATGGCCCCTCCACCTGCAGGACGAG

GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCAAATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA.CATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAGJ-ACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC

CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO:202 pMON357O1,seq

GCTAACTGCTCTATAATGATCGATGATTATACATCACTTAAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAGACATGGATATCCTGATGGCGACCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA

GGGCGCAATCGGAACGCTTTTTGTCCTACACCGA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCTTCCGCAAATTAAACCCACTGCTGTGTCAAGA

GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG

GCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC

TCCTCAACCCTGGGCGGTGGCTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACAC

AGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTAC

CCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO:203 pMON3 5702 .seq WO 98/1 7810 113 PCT/US97/20037

GCTAACTGCTCTATAATGATCGATGATTATACATCACTT-AGAGACCACCTACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJATCATCATCAAGGCA

GrGCGCAATCGGAACGCTCACGTACTGrCACCGA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAGAATCTCATAATCTCC1-CATGGCCGTCGCTGGTCCAGATGCA,

GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA.TGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAGACCACATCTCCCCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG

GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC

TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGAC

TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTAC

CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 204 pMON35703 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAGAGACCACCTACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGCCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAGATCTCATAA~.ATCTCCAAACATGGCCCGCTTCGTCCAGACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGALGCCCTGGATCACTCGCCAGAA~C

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGT

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA

ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC

GAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACT

GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAJ

TGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID N0:205 pMON3 5704.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAJ.AGAGACCACCTAACCCTTTGCTG

GACGAACTA'TTAGCTGTTCGTGAGACTCACCAA

CTCCCTCTAGCGCACCTGAATCTAGATAGATCTG

ATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCTTCCGCAAATTAAACCCACTGCGTCTCGCACT

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGTG-GCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGT

GGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATCGGCTTGCTGGAGCGCGTGACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 206 pMON35705.seq

GCTAACTGCTCTATAATGATCGATGATTATACATCACTTAGAGACCACCTACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCACCATGTCTGCCCTCTGCCACGGCCGCkCCCTCTCGACATCCATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAGAATCTCATAATCTCCACATGGCCACCACATCTCCCGCCTCCTG

CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGC

CTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGT

ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC

GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC

AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:207 pMON3 5706. seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAGAGACCACCTACCCTTTGCTG

GACCCGAACAACCTCATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGI'ATTGAGGCAATTCTTCGT

AATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CACATACTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCTGGTCCAATCTCTACTATCAJAC

CCTTCCGCAAATTAAACCCACTGC~AcTTCGCCT WO 98/17810 64 PCT1US97/20037

CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGC

CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT

GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAJACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG

ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC

AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:208 pMON35733 .seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTAGAGACCACCTA-CCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT

ATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCA-GGCA

GGTGACTGGCAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAAC

CCTTCCGCAAATTAAACCCACTGTCATTCAAGAA

CTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAJAATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGC'rGAAGCCCTGGATCACTCGCCAGPJACTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC

SEQ ID NO:209 pMON3 5734.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAGAGACCACCTAACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCA

CTGCTCGCATTCGTAGGGCTGTCAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGT.

AATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCGGGTGACCGTCTGGTCCAJATCTCTACTATCAAC

CCTTCCGCAAATTAAACCCACTGCACGAGTAGGT

TGTGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGTCACCAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGC'rTCGTCCAGACCAJACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT

GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC

GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA3AGATTACCCAGTCACCGTGGCCTCC SEQ ID NO:210 pMON35735.seq

GCTAACTGCTCTATAATGATCGATGATTATACATCACTTAAGAGACCACCTACCCTTTGCTG

GACGAACTATCGAAAGAATCGTGAGACTCACCAA

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAJATTCTTCGT

A.TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJTCATCATCAAGGCA

GGTGACTGGCAAGATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCGCGCAGGAA

CACGAGAAGCGGAGTCCGGGACTTGCATTTCACA

CCGTCTCCTCCGTCTAA-AGAATCTCATAAATCTCCAACATGGCTCTGCAGGATGAGGAJACTGTGC

GGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC

AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCTTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA-CATCTCCCGCCTCCTGCAGGAGACCTCCGAG

CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT

CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC

TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCACCGTGGCCTCCAJAC

SEQ ID NO:211 pMON3 5736. seq

GCTAACTGCTCTATAATGATCGATGA.ATTATACATCACTTAGAGACCACCTACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCGCCTTCGACTCCAAAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAG~AAAGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGGAAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCMATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCTCAGATGAGAGCTGTGTGGT

GGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAG

ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAGTGCCTTTCAGCCC

CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG

CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG

WO 98/17810 PCT1US97120037

CCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA

GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCMACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

SEQ ID NO:212 pM4ON35738 .seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTJ-AAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCtdTCAAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGT ATCTCCACCATGTCTGCCCTCTGCCACGGCCGCACCCTdTCGACATCCAATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAJATCTCTACTATCA.C

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCTGAGAJCTGTGTGGTCGTCTG

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAA

GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG

GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC

TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA

GGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC

CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC

SEQ ID NO:213 pMON3 5739. seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAJAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCCCTTCGACTCCAAAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGA.AATGCATCAGGTATTGAGGC11ATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAJATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGTTACCCTTGAGCAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAGATCTCATAAATCTCCAACATGGCTGAGCTGTGTGGTGGCCTGTGG

CGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGC

TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACTCGCCAAAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCC

TCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGT

AGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJCCTGCAGGACGAG

SEQ ID NO:214 pMON3 5740. seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCGCCTTCGJACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCAATTCTTCGT

AACCACAGCGCTTCAGCGCCCCCAACATACTAGC

GGTGACTGGCAAGAATTCCGGGAI1ACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA,

CACGAGAAGCGGAGTCCGGGACTTGCATTTCACA

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAJ.ACATGGCTCTGTGCGGTGGTCTGTGGCGT

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

SEQ ID NO:215 pMON35741.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAJAGAGACCACCTACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCGCCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAAC

CCTTCCGCAAATTAAACCALCTGTCATTCAAGAA

CTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGOAGCGGCTCAAGACTGTCGCT

GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCTCAGGG'GAGG-TAGTGGTACCCAGGACTGCTCCTTCCAJACACAGCCCCATCTCCTCCGAC

WO 98/17810 40PCTIUS97/20037

TCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC

SEQ ID NO:216 pMON35742.seq

GCTAACTGCTCTATAATGATCGATGAATTATACATCACTTAAGAGACCACCTAACCCTTTGCTG

GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCAAAC

CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGT

AATCTCCAACCATGTCTGCCCO'TGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCA

GGTGACTGGCAAGAATTCCGGGAAAACGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCTTCCGCAAATTAAACCA-CTGTAGTAGATTCG

GGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAG

ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCC

CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCGGGAGACCTCCGAGCAG

CCGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG

CCCGACTCCTCA-ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA

GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

SEQ ID NO:217 pMON3 5743 .seq

GCACGTTTAGTGTAATTCACCTAGGCACACCTGT

GACCCGAACAACCTCAATTCTGGACATGGATATCCTGATGGCGACCTTCGACTCCAC

CTGCTCGCATTCGTAAGGGCTGTCAGCACTTAGAATGCATCAGGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAA

CACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAATCTCCAACATGGCTCTGTGCGGTGGTCTGTGGCGT

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAJJATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAGATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG

SEQ ID NO:218 pMON32179 .seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAA.TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCTGGTCCAATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAGAATCTCATATCTCCACATGGCTACTGCTCTATATGATCGAT

GAATTCTATAAAACCTACCTGTGCCACACCATTA

GAAGAACTAGACAACTGACCAACGTGATGAGGTT

AAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCACCATGTCTGCCCTCT

GCAGCGACTTGCTCACTATAGCGTATGAGATCGA

AACGCTCACGTACCTACACCGACAA SEQ ID NO: 219 pMQN357O7 .seq

GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGOACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGA

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGA'rTACCCAGTCACCGTGGCCTCCAMCCTGCAGTACGTAGAGGGC

GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCTA

GAATCTCATAAATCTCCAACATGGCTACTGCTCTATAATGATCGATGAATTATACATCACTTA

AAAACCTACTTCGACGAAACCATTAGCTGTTCGT

GACAACTGATCACTCCCTTGAGGTTAGATAAATC

TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCT

CGACATCCAATCATCATCAAGGCAGGTGACTGGCAGA-TTCCGGGAJAAACTGACGTTCTATCTG

GTTACCCTTGAGCAAGCGCAGGACAACAG SEQ ID NO:220 WO 98/17810 PCTIUS97/20037 pMON3 5708 .seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

CACTTAGAAAATGCATCAGGTATTGAGGCAJTTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAJACACAG SEQ ID NO: 221 pMON3 5709. seq

GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJ\CACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGTCTCATAATCTCCAACATGGCTACTGC

TCTATAATGATCGATGATTATACATCACTTAAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGCCTTCGACTCCAACCTGCTCGCA

TTCGTAAGGGCTGTCAGCACTTAGATGCATCAGGTATTGAGGCLTTCTTCGTATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAGGCAGGTGACTGG

CAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG

SEQ ID NO:222 pMON3 5710. seq

GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCCTGCTGGAGCGCGTGA3ACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCCTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTCTAAGAATCTCATAATCTCCAACATGGCTACTGCTCTATATGATCGATGAA

CACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAJACACAG SEQ ID NO: 223 pM0N35711.seq

GCGGATGAGGAGCTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGGGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCJAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATATCTCCAACATGGCTAACTGC

TCTATAATGATCGATGAATTATACATCACTTAAGAGACCACCTJACCCTTTGCTGGACCCGAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCW-ACCTGCTCGCA

TTCGTAAGGGCTGTCAGCACTTAGAAGCATCAGGTATTGAGGCA-TTCTTCGTAATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAGGCAGGTGACTGG

CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAACAACAG

SEQ ID NO:224 pMON3 5719. seq

GGCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG

GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCGGGTCCAAGATGCAGGCTT

GCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTG

WO098/17810 PCTIUS97/20037

TCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGCCGCT

GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTC

AACCCTGGGCGGTGGGTCAGGAGGTGGGT1CAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAJATCCTGAGCTGTCTGACTACCTGCT

TCAATACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCAACCC

GTCTCCTCCGTCTAAAGAATCTCATATCTCCAAACATGGCTACTGCTCTATATGATCGATGA

AATTCTATAAAACCTACTTGTGCCACACCATTAG

CATGGATATCCTGATGGAACGAACCTTCGAACTCCACCTGCTCGCATTCGTAGGGCTGTCAA

GCACTTAGAAAATGCATCAGTATTGAGGCATTCTTCGTATCTCCACCATGTCTGCCCTCTGC

CACGGCCGCACCCTCTCGACATCOAATCATCATCAAGGCAGGTGACTGGCAGTTCCGGGAAAA

ACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACAACAG SEQ ID NO :225 pMON35720.seq

GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC

TGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTGCTGGAGCGCGTGAACACG

GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGC

CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCA

GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACC

GTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA.ATCTCTACTATCA-CCCG

TCTCCTCCGTCTAAAGAATCTCATATCTCCACATGGCTAACTGCTCTATAATGATCGATGAA

ATAAACCTAGGCACACCTTCGACGAACTATCGAA

ATGGATATCCTGATGGAACGACCTTCGACTCCACCTGCTCGCATTCGTALGGGCTGTCA-G

CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACAACAG SEQ ID NO: 226 pM0N 35721.seq

GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC

AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG

CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGC

CTGGAGCTGCAGPGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT

GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAGGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTICCTGGCACAGCGCTGGATGGAGCGGCTCAG

ACTTACGTAGAGGGCGGTGGAGGCTCCCCGGTGACCGTCTGGTCCLTCTCTACTATCAACCCG

TCCTCTTAGACCTATTCAAAGCACGTTTAGTGTA

ATTATACATCACTTAGAGACCACCTAACCCTTTGCTGGACCCGCCCTCATTCTGA-GAC

ATGGATATCCTGATGGAACGAACCTTCGAACTCCAACCTGCTCGCATTCGTAGGGCTGTAG

CACTTAGAAATGCATCAGGTATTGAGGCATTCTTCGTAJATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTAGTTTTGTCCTACACCGACAA SEQ ID NO:227 pMON3 5722 .seq

GCCTCCOAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAJXATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCTGGTCCAATCTCTACTATCA-CCCG

TCCTCTTAGACCT-ACCAAAGCACGTTTAGTGTA

ATAAACCTAGGCACACCTTCGACGAACTATCGAA

ATGGATATCCTGATGGAACGACCTTCGACTCCAACCTGCTCGCATTCGTAAGGGCTGTCAAG

CACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG SEQ ID NO:228 pMON35723 .seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCCGAG

CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT

CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC

ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAJ.TCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA-CCTGCAGGACGAGGAGCTCTGC

GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAJAGACTGTCGCTGGGTCC

AGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCAATGTGCCTTTCAG

CCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCG

TCTCCTCCGTCTAAGAATCTCATmTCTCCACATGGCTACTGCTCTATATGATCGATGAA

ATAAACCTAGGCACACCTTCGACGAACTATCGAA

WO 9817810PCTIUJS97/20037

CACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGTAATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAACAJCAG SEQ ID NO: 229 pMON3 5725 .seq

GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC

ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGT

GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTYGCTGTCAAAJATCCGTGAGCTGTCTGACTACCTGCTTCA-GATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTG

AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTCTAAGAATCTCATATCTCCAACATGGCTACTGCTCTATATGATCGATGAA

ATAAACCTAGGCACACCTGTGCCACCTATCGAA

ATGTTCGTGAGACTCACCCACTCCCTCTAGCGCA

CACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG SEQ ID NO: 230 pMON3 5726 .seq

GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCG-AGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTT

CAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTG

CTGGAACGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

TTTTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCG

TCTCCTCCGTCTAAGAATCTCATATCTCCACATGGCTACTGCTCTATATGATCGAGAA

ATAAACCTAGGCACACCTGTGCCAC-CTATCGAA

ATGTTCGTGAGACTCACCCACTCCCTCTAGCGCA

CATAAATCTAGATAGATCTCTACCACAGCGCTTC

ACGCCtCCCAACATACTAAGAGGCGCAATCGGAA CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG SEQ ID NO: 231 pMON35744.seq

GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGACACGGAG

ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC

ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAG

AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAJCCCTGGGCGGTGGGTCAGGA

GGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC

CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAA

GATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGJACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAGATCTCATATCTCCAACATGGCTACTGC

TCAATACAGATAAACCTAAAACCTACTTCGACGA

AACCATTAGCTGTTCGTGACAACTGATCACTCCC

TTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTXCGACATCCATCATCATCAAGGCAGGTGACTGG

CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG

SEQ ID NO:232 pMON3 5745. seq

GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGTGGCGCTGAGCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGT

GGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAA

CACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT

TACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGPJACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCACG

TCTATAATGATCGATGAAATTATACATCACTTAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCAACCTGCTCGCA

TTGAGGTTAGATAAATCTCGTTGGCATTCTACCA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAGCAGGTGACTGG

CAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGACACAG

__SEQ ID NO:233 WO 9817810PCTIUJS97/20037 PMON3 5746. seq

GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGOCGGCTGGTCCTGGCACAGCGCTTGATGGAG

CGGCTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACAC

TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCC

CGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTC

TCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGG~GGTGGGTCAGGAGGTGGG

TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC

AGCCCCATCTCCTCCGACTTCCTGTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTAC

CCAGTCACCGTGGCCTCCAACTAGTAGAGGGCGGTGGAGGCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATATCTCCAACATGGCTACTGC

TCTATAATGATCGATGAAATTATACATCACTTAGAGACCACCTAACCCTTTGCTGGACCCGA.C

AACCATTAGCTGTTCGTOACAACTGATCACTCCC

TTCGTAAGGGCTGTCAAGCACTTAGTGCATCAGGTATTGAGGCAATTCTTCGTATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCAGGTGACTGG

CAAGAATTCCGGGAAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGAACAACAG

SEQ ID NO:234 pMON3 5747. seq

GCGCAAGATGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAGACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCCCCGTCTGATCTCATATCTCCAACATGGCTACTGC

TCTATAATGATCGATGAATTATACATCACTTAAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGACTCCAACCTGCTCGCA

TTGAGGTTAGATAAATCTCGTTGGCATTCTACCA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCMGGCAGGTGACTGG

CAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG

SEQ ID NO:235 pMON3 5748. seq

GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG

ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGTCACC

AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG

CAGGCTCACGTGGCCGACCTGTATGCGATCCCGG

CTGGAGCTGCAGTGTCAGCCCGACTCCTCAJACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT

GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACC

GTGGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCACG

TCTATAATGATCGATGAAATTATACATCACTTAAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGACCTTCGAACTCCAACCTGCTCGCA

TTGAGGTTAGATAAATCTCGTTGGCATTCTACCA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCC-TCATCATCAGCAGGTGACTGG

CAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACACAG

SEQ ID NO:236 pMON35749.seq

GCTCTGTGCGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGALCACGGAGATACACTTTGTCACCAJ\ATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCT6CTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTAcCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATAATCTCCAACATGGCTACTC

TCAATACAGATAAACCTAAAACCTACTTCGACGA

ACCTCATTCTGAAGACATGGATATCCTGATGGACGACCTTCGACTCCACCTGCTCGCA

TTCGTAAGGGCTGTCA1GCACTTAGAATGCATCAGGTATTGAGGCLTTCTTCGTAATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAGGCAGGTGACTGG

CAAGAATTCCGGGAAACTGACGTTCTATCTGGTTACCCTTGAGCAGCCAGGACACAG

SEQ ID NO:237 pMON'3575 seq WO 98/17810 04PCTIUS97/20037

GCACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA-TGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCACG

TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC

AACCATTAGCTGTTCGTGACAACTGATCACTCCC

TTGAGGTTAGATAAATCTCGTTGGCATTCTACCA

CCATGTCTGCCCTCTGCCACCGCCGCACCCTCTCGACATCCAATCATCATCAGGCAGGTGACTGG

CAAGAATTCCGGGAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGACAACAG

SEQ ID NO:238 pM0N35769.seq

GCTCTGTGTGGCGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA

CATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGA3AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCGGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCACG

TCTATATGATCGATGAATTATACATCACTTAAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAGACATGGATATCCTGATGGCGACCTTCGLCTCCAACCTGCTCGCA

TTCGTAAGGGCTGTCAAGCACTTAGTGCATCAGGTATTGAGGCAATTCTTCGTATCTCCAA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCATCATCATCAAGGCAGGTGACTGG

CAAGAATTCCGGGAIACTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG

SEQ ID NO:239 PMON35771.seq

GCCTCCAAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGJAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCACACAGCCCCATCCCTCCGACTTCGCTGTCAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTrCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCG

TCCTCTTAGACCTATTCACT(CACGTTTAGTGTA

ATAAACCTAGGCACACCTTCGACGAACTATCGAA

ATGGATATCCTGATGGAACGACCTTCGACTCCACCTGCTCGCATTCGTAAGGGCTGTCAAG

CACTTAGAAAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG SEQ ID NO:240 pM0M35774.seq

GCTCAAGATGATGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGAAQACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACC

CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT

GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGTACGTAGAGGGCGGTGGAGGC

TCCCCGGGTGAACCTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCTAGATCTCAT

AATCTCCAACATGGCTAACTGCTCTATATGATCGATGAATTATACATCACTTAAGAGACCA

CCACCTGTGCCACACCATCGAAAGAACTAGACAA

CTTCGAACTCCACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAATGCATCAGGTATT

GAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCA

ATACTAGCGTATGAGATCGGAACGCTCACGTACT

GAGCAAGCGCAGGAACAACAG SEQ ID NO:242.

pM0N35775.seq GCCCAAGA'rGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCA-GACTGTCGCTGGGTCCAAGATGCAJAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAGAACTTCTCC

WO 98/17810 PCTIUS97/20037

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA

CTCGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC

GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC

CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGJACCGTCTGGTCCJATCTCTACTATCAACCCG

TCTCCTCCGTCTAAGAATCTCATWTCTCCACATGGCTACTGCTCTATATGATCGATGAA

ATAAACCTAGGCACACCTTCGACGAACTATCGAA

ATGGATATCCTGATGGAACGAACCTTCGACTCCAAJCCTGCTCGCATTCGTAAGGGCTGTCAAG

CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTATCTCCACCATGTCTGCCCTCTGCC

ACGCCCCCCAACATACTAAGAGGCGCAATCGGAA

CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO:242 pMON3 5776. seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJCTTICTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA

CTCGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCA

GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAGATCTCATATCTCCAACATGGCTACTGC

TCTATAATGATCGATGATTATACATCACTTAAGAGACCACCTACCCTTTGCTGGACCCGAAC

AACCTCAATTCTGAAGACATGGATATCCTGATGGCGCCTTCGLCTCCAACCTGCTCGCA

TTCGTAAGGGCTGTCAAGCACTTAGAATGCATCAGGTATTGAGGCATTCTTCGTATCTCCAJA

CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCLTCATCATCAGGCAGGTGACTGG

CAAGAATTCCGGGAAAAACTGACTTCTATCTGGTTACCCTTGAGCAGCGCAGGACACAG

SEQ ID NO:243 pMON32 169. seq/pMON4000 seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAA~CTCCATAGCGGCCTTTTCCTCTACCAGGGG

C'TCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGALTGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCC12GGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCGGGTGACCGTCTGGTCCATCTCTACTATCACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAACATGGCTGATGAGAAJCTGTGTGTGGTCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAJAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:244 pMON32 188. seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAJCTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAACATGGCAATCGCAGACGAGGAGCTGTGCGGGGGC

CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGACGGCTCAGACTGTCGCTGGGTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC

CCCAGCTGTCTTCGCTTCGTCCAGATCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG

GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC

GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG

GGAGGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTCA

ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTICC SEQ ID NO: 245 pMON32273 .seq WO098/17810 PCTIUS97/20037

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAMGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGAATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCCGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAATCTCCAACATGGCCCCCCCCAGCGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAMGCCCTGGATCACTCGC

CAGACTTCTCCCGGTGCCTG~AGCTGCATGTCAGCCCG

ACTCCTCACCCTGGGCGGTGGGTCA

GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTT

CAAGATTACCCAGTCACCGTGGCCTCCAAJCCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATGTGCCTTTCAGCCC SEQ ID NO: 246 pMON35795.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCMACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCtGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCACCCCGTCTCCT

CCGTCTAAAGAATCTCATAATCTCCAAAJCATGGCTCTGCAGGATGAGGACTGTGCGCGGCCTC

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAkGATGCAA

GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG

GCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC

TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA

GGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATC

CGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCCTCCAAC SEQ ID NO: 247 pMON3 5796 .seq

GCTACACCATTGGGCCCTGCCAGCTCCCTCCCCAGAGTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGA-TGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCTTAGACCTATTCACTGTAAAGAACGGGTGCCG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCGACTGTCGCTGGGTCCAGATGCAAGGC

TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG

CTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCC

TCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGT

AGTGGTACCCAGGACTCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO:248 pM0N35797 .seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTICTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCACCCGTCTCCT

CCGTCTAAAGAATCTCATATCTCCAACATGGCTGALGACTGTGTGGTGGTCTGTGGCGGCTG

GTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTG

GAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT

WO 98/17810 PCT1UJS97120037

CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGJAG

CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGT

ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGAC SEQ ID NO: 249 pMON35798.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAACATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGG-A-TGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAACATGGCTGAGCTGTGTGGTGGCCTGTGGCGTCTGGTC

CTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAG

CGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC

TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC

TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG

GGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACC

CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCT

GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAGGACGAG SEQ ID NO: 250 pMON35799.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAQJAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCGCCGACGCGCGTGGCACCAACGCTTCCACGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTGCATTCACCACGCGAATGAACGGAGCCTCCGA

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGOTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAACATGGCTCTGTGCGGTGGTCTGTGGCGTCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGC

GTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC

GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC

GGTGGGTCAGGAGGTGGGTCAGGAGdTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJ\CCTGCAGGACGAGGAG SEQ ID NO: 251 pMON39914.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGACTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTGCATTCACCACGCGAATGAACGGAGCCTCCGA

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGTCTCCT

CCGTCTAAGAATCTCATAAATCTCCAACATGGCTGATGAGcATGTTGGTGGGCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTT

CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:252 pMON39915.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

all ~AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGCCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCJACTCCATAGCGGCCTTTTCCTCTACCAGGGG

WO 98/1 7810 ASPCT1US97120037

CTCCTGCAGGCCCTGGA~GGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAACTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAACATGGCTGATGAGACTGTGTGTGGGCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAJAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCPJATGTGCCTTTCAGCCdCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGC

GGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAG SEQ ID NO:253 pMON3 9916. seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAJCTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCACATGCTGATGAGACTGTGTGGTGGGCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTGCAGT.GTCAGCCCGACTCCTCA

ACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCGCTGGACAACCGCCT

CTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAG SEQ ID NO:254 pMON35712 .seq

GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGTCCAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTdAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTT

CAA SEQ ID NO:255 pMON35713 .seq

GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC

TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAGATGCAAGGCTTGCTGGAGCGCGTGACACG

GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC

CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGjTGGGTCA

GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAJACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCJAGATTACCCAGTCACC

GTG SEQ ID NO:256 pMON35714.seq

GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC

AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG

CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGATICACTCGCCAGAACTTCTCCCGGTGC

CTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT

GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG

ACT SEQ ID NO:257 PMON3 5715. seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGCAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG

WO 98/17810 PCTIUS97/20037

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCT

GGG SEQ ID NO:258 pMON3 5716. seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGCCTCCTGCAGGAGACCTCCGAG

CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGJXACTTCTCCCGGTGCCTGGAGCTGCAGTGT

CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC

ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTCTGC

GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAJGACTGTCGCTGGGTCC

AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAG

CCC SEQ ID NO:259 pMON35717 .seq

GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAJACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA1A.ATCCGTGAGCTGTCTGACTACCTGCTT

CAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAGATGCA-GGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTT SEQ ID NO!260 pMON3 5718.seq

GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATC

ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGT

GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGCTTGCTGGAGCGCGTG

AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC

GAG SEQ ID NO:261 pMON32 170. seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCAAC

TTGCCGCGTCTCCAACTCGTAGCTAACATAA.GT

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTC'rGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:262 pMON32187 .seq

GCAGATGAAGAACTGTGTGGGGGACTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATWATCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAGTGAGGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

WO 98/1 7810 4TPCTIUS97/20037

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:263 pMON32271 .seq GCTGATGAAGAACTGTGTGd TGGGCTGTGGCGGCTGGTCCTGdCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCALCCCTGCCGCCACCGTGGAGCCCGCGTCCACTC

GGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAOCTGTCTGACTACCTGCTTCAJAGATTACCCAGTC

ACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGC

TCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA.GTCTTTA

GAGCAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGP3AGCTGTGTGCCACCTACAAG

CTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGC

TCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAJACTCCATAGCGGCCTTTTCCTC

TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTG

CAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAJAGACTGGGAATGGCCCCT

GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGG

GTCCTGGTTGCTAGCCATCTGCAGAGCI'TCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCG

CAGCCG SEQ ID NO:264 pMON32272 .seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGJACTTCTCCCGG

TGCCTGGAGCTGCAGTCTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGC

GGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA.TCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGTACGTAGAGGGCGGTGGAGGC

TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCACATGGCTACACCATTGGGCCCTGCCAGCTCCCTG

CCCCAGAGCT'rCCTGCTCAAGTCTTTAGAGCAAGTGAGGPJ\GATCCAGGGCGATGGCGCAGCGCTC

CAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCT

CTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTG

AGCCAACTCCATAGCGGCCTTT-TCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCC

GAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAG

CAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCC

TCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTG

TCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 265 pMON32274 .seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGCCGCCACCGTGGAGCCCGCGTCCACTC

GGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAJGATTACCCAGTCACCGTGGCCTCCAACCTG

TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCA

TTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

CTGGTGCTbGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAO

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTGCCACTTGACGTGAACTGATGCCGCTCGCACA

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 266 pMON3 5751. seq

GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCPJACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGA

WO098/17810 AqPCTIUS97/20037

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAJCCTGCAGTACGTAGAGGGC

GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTA

GAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTC

CTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTG

TGTGCCACC'rACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC

TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCAT

AGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAJGGGATATCCCCCGAGTTGGGTCCC

ACC'rTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAA

CTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAG

CGCGCGAGGCTGTCACACTCGGTCTGGTTGACCT

CTACGCCACCTTGCGCAGCCC SEQ ID NO:267 pMON35752 .seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAATTGTGTCAAGAGCTCTGGGGGAAGAAAATTT

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGGCAGCTGGTGCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATMA.ATCTCCAACATGGCTACACCATTAGGCCCTGCCAGCTCC

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAGTGAGGAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

'rCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGd.AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO;268 pMON35753 .seq

GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAGATCTCATAATCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAAGTGAGGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAJ\GCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCC'rTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTGTACGCCACCTTGCGCAGCCC SEQ ID NO: 269 pMON35754.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG

CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT

CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGATCCGGAGGTGGC

ACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTCA.ATCCGTGAGCTG

TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTCTGC

GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC

AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAG

CCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGJACCGTCTGGTCCAATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCTACACCATTAGGCCCTGCCAGCTCC

GTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGT.TGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO:270 pMON35755.seq WO 98/17810 PCTIUS97/20037

GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGC-GGCTTGCTGGAGCGCGTGACACGGAG

ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC

ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAG

AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGA

GGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC

CAACACAGCCCCATCTCCTCCGACTTCGCTGTCA3ATCCGTGAGCTGTCTGACTACCTGCTTCAA

GATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCATCCGTCTAGAATCTCATJAJATCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAIACTGCTTAGAGCAGTGAGGAJAGATC

CAGGGCGATGGCGCAGCGCTCC AGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 271 pMON3 5756. seq

GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAGACTGTCGCTGGGTCCA-AGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC

TtCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA.AGCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT

GGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAAJ

CAACCACCTCATCCGCAATCTACGCGCACGTCAA

TACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGJACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATAATCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAAGTGAGGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGI'CGTACCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO:-272 pMON3 5757. seq

GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTTGATGGAG

CGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACAC

TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCC

CGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAGAACTTC

TCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGG

TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA-CAC

AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC

CCAGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCAAC

TTGCCGCGTCTCCAACTCTCCATCTGGAGGGAGT

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 273 pMON35758 .seq

GCACTGTGCGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA.CTTCTCCCGGTGCCTGGAG

CTACAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTOTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCAAC

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAJAGTGCTTAGAGCAAGTGAGGI.AGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

WO 98/17810 /foPCT1US97120037

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGA-AGAACTGGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 274 pMON35759 .seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCATGTGCC

TTTCAGCCCCCCCCCAGCTO~'CTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCOGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCOTGGAGGCTCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAACATGGCTACACCATTAGGCCCTGCCAGCTCC

CTGCCCCAGAGCTTCCTGCTCA-AGTGCTTAGAGCAA\GTGAGGAAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:275 pMON3 5760. seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCTGACACGGAGATACACTTTGTCACCAAATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA.CTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGpJACCGTCTGGTCCATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAkACATGGCTACACCATTAGGCCCTGCCAGCTCC

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCA-AGTGAGGAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAACGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:276 pMON3 5761. seq

GCGCTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC

GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATGT

GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAG

ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGTCAGGAGGTGGATCC

GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

AACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCC

TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATTTTTACTATCAACCCGTCTCCTCGTCTGATCTCATAATCTCCACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAAGCTTCCTGCTCAGTGCTTAGAGCAGTGAGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAJAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAJATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTCCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO :277 pMON35762.seq

GCTGAACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT

GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA

TGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAG

GAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTG

WO 98/17810 A4PCTIUS97/20037

GAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA

TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC

TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCpJAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAGGACGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCA-JACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 278 pMONJ 5763. seq

GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG

ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG.ATACACTTTGTCACC

AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG

CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC

CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT

GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACC

GTGGCCTCCAACC'TGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCAAC

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAJAGTGAGGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATcccCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGA-TGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:279 pMON3 5764. seq

GCTCAGGACGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGCCAGAACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCA

GTCACCGTGGCCTCCAAkCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCAAC

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAGTGAGGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 280 pMON35765 -seq

GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGLGCCCTGGATC

ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAJACCCTGGGCGGT

GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTTGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGCTCAAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTG

AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC

CAGTACGTAGAGGGCGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTCTAA-AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAG CAGATGGAAGAkACTGGGAZATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC WO 98/17810 PCT/US97/20037 GCCTCTGCTTTCCAGCGCCGGGCAGGAGGcSGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:281 pMON35766 .seq/pMON32l9O .seq/pMON4000l -seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCT

CCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT

TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC

AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG

AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC

CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA

CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAJAGAACTGGGAATGGCC

CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA

GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT

GCGCAGCCG SEQ ID NO:282 pMON3 5768. seq

GCTCAAGATGAAGAACTGTGCGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGCGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTGATCTCATATCTCCACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAAGTGAGGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

.TTTGCCACCACCATCTGGCAGCAGATGGAAGACTGGGAJTGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 283 pMON3577O.seq

GCGCTGTGTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCJXGACTGTC

GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATAT

GCTTACCCCCGTTTCCTGCAAC-CTTCGCCTCGA

ACCTCCGAGCACCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG

CTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA

GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAG

GACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATC

AACCCGTCTCCTCCGTCTAAGAATCTCATATCTCCAACATGGCTACACCATTAGCCCTGCC

AGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAGTGAGGAJ4GATCCAGGGCGATGGC

GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAQCJAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTC

GGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA

GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGG

ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACC

ATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCG

GCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTC

CTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 284 pMON35772.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTTCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGTGACCGTCTGGTCCATCTCTACTATCAACCCG

TCTCCTCCGTrCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC WO 98/17810 PCTIUS97/20037 '413

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAJGATCCAGGGCGATGGCGCAOCG

CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCC'rGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:285 pMON35773.seq GCTCAGACGAGAACTGTGtGGTGGTCTCTGGCGGCTOGTC~GGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCPAkCCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACC

CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA1TCCGTGAGCTGTCT

GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC

TCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCTAAAGAATCTCAT

AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC

TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGCCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAACTGGGAATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCC SEQ ID NO:286 pMON3 5777 .seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGALCACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA

CTCGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC

GCTGTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCCTCCAAC

CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCALATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATAATCTCCAACATGGCTACACCATTAGGCCCTG.CCAGCTCC

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAGTGAGGAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTG1'GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC

TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC

TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAJAGGGATATCC

CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG

CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG

GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 287 pMON3 5778. seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT6TCTTCGCTTCGTCCAGACCAACATCTCCCGC

CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCC

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA

CTCGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGC

CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA

GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAGATCTCATATCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTGCTTAGAGCAGTGAGGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTrGGGAATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:288 pMON35779.seq

GCTGATCAAGAACTGTGTG'GTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

WO 98/17810 PCT/IUS97/20037 14.

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA~GCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAJCCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGC

GGTGGTTCTGGCGGAGGATCCGGCGGCGGAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAATCCGTGAGCTGTCTGAC

TACCTGCTTCA-AGATTACCCAGTCACCGTGGCCTCC3ACCTGCAGTACGTAGAGGGCGGTGGAGGC

TCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCTAGATCTCAT

AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC

TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAJACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGJATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCC SEQ ID NO:289 pMON3 5780. seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCCC

AGACTGTCGCTGGGTCCAGATGCAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGCGGTGGTCAGGAGGTGGGTCAGGC

GGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCATACGTAGAGGGCGGTGGAGGC

TCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAGAATCTCAT

AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC

TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGCTGGGATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCC SEQ ID NO:290 pMQN35782 .seq

GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGIJACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTC

GGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAJ\TCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCACCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAGATCTCATA-TCTCCAACATGGCTACACCA

TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAAGC'rGTGTGCCACCTACAJ\GCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 291 pMON39908.seq

GCTGATGAGGAGCTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGTAGAGACGGTGTTTCACCGTGTCAGCCAGGATGGTCTAGAT

CTCCTGACCTCGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAJA

ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAGTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCA-CATGGCTACACCATTG

GGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAGTGAGAGATCCAG

GGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACTAACAGCTGTGCCACCCCGAGGAGCTG

GTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTG

CAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCC

CTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTT

GCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGT

WO 98/17810 PCT/tUS97/20037

GCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTG

CAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 292 pMON32275.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA~IGCCCTGGATCACTCGCCAGACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCG

GGGACTTGCATCTTCACACCTTCCGCAAATTAAAC

CCAAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTA

GAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAJAG

CTTCACCAGGTGGTCCGCATTTGCTCCGGTCCGG

TCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC

TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTG

CAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAACTGGGAATGGCCCCT

GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGG

GTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCG

CAGCCCTACGTAGAGGGCGGTGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACTATCAAc

CCTTCCGCAAATTAAACCCACTGACCGATCCTTA

CACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACTACCTGCTTCAGAT

TACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:293 pMON3 57 81. seq GCCACCCAGGACTGCTCCTTTCACACAGCCCCATCTCd

TCCGACTTCGCTGTCAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGAGCCGA

4

GAGC

CCGGACACCCATACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGC

TTCCTGCTCAGTCTTTAGAGCAAGTGAGAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG

CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATC

CCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTC

CATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGG-ATATCCCCCGAGTTGGGC

CCCACCTTGGACACACTGCAGC'rGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAA

GAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC

CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT~CTGCAGAGCTTCCTGGAGGTGTCGTACCGC

GTTCTACGCCACCTTGCGCAGCCCTCTGCAGAJACCGATCTCCGGATACTCATACCAGCCCGCCA

TCCCCGGGTTCTAATCTGCAAGATGAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG

CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAJAGATGCAGGCTTGCTGGAGCGCGTG;AAC

ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGCCTTCGCTTCGTCCAG

ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT

CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:294 pMON357 83 .seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTGGCAGGGGCGCGTGJACACGAGATACACTTTGTCACCATGTGCCTTT

CCGAAGAGCCCGGACACCCATACTAGTCCCCATCTCCGGGTACACCATTGGGCCCTGCCAGCTCC

CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAJAGTGAGAAGATCCAGGGCGATGGCGCAGCG

CTCCAGGAGAAGCTGTGTGCCACTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACT

CTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCT

TGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGALGGGATATCCC

CCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGC

AGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCG

CCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGG

TGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCTGCAGACCGAATCTCCGGATACTCATA

CCAGCCCGCCATCCCCGGGTAAIGGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA

ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:295 pMON32276.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAQATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGA.CTCCTCAJACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTCCTCCTTCCAACACAGCCCC

WO 98/17810 PCT/US97/20037 A 1(p

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT

TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACTAAC

AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG

AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC

CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA

CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGJACTGGGAATGGCC

CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTrGCTTTCCAGCGCCGGGCAGGA

GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT

GCGCAGCCG SEQ ID NO:296 pMON32277.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

,AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCG6CCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAACTGGGATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCA.CCCGTCTCCT

CCGTCTAAAGAATCTCATAALATCTCCAAACATGGCTGATGAAGAJCTGTGTGGTGGTCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAJAGATGCAAGGCTTG

CTGGGG(ACCGGTCCTGCCAACGCTCGCCCCACG

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTCCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGCGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 297 pMON32278 .seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTAGAGCTGCAGTCTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGC'rCCCTGCCCCAGAGCTTCCTGCTCAJAGTCT

TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACTAAC

AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG

AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC

CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA

CTCGTGCTGCATTCACCACGCGAAGAGATGAAGC

CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA

GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCCTTCTACGCCACCTT

GCGCAGCCG SEQ ID NO:298 pMON32279 .seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCGTCTTTAGAGCAAGTG

AGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGTGACCGTCTGGTCCATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAGATGAGAJCTGTGTGGGGGCCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAJATGTGCCTTTCAGCCCCCCCCCAGCTCT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACTCAGGACTGT'TCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAG SEQ ID NO :299 pMON3579O.seq WO 98/17810 PCTIUS97/20037 A.4

GCCACTCAGGACTCCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCP.AJTCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCPJAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCAATCTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAJACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC

GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCG;CTCCAGGAGAAGCTGTGTGCCACT

AACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAkGGCCCTGCAGCTGGCAGGCTGCTTGAGCCACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAJCTGGGAATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCG SEQ ID NO:300 pMON35791 .seq

GCATAGCGTTTCAAACCATTCCGCTGTTAATCTA

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJCCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTT

CAGCCCCCCCCCAGCTCTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC

GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC

TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGAATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCG SEQ ID NO:301 pMON35792 .seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAGATGCAAGGCTTGCTGGAGCGCGTGALCACGGAGATACACTTTGTCACCAAATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG

TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCA

TTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAGTGAGAAGATC

CAGGGCGATGGCGCAGCGCTCCAGGAGAGCTGTGTGCCACTJACAGCTGTGCCACCCCGAGGAG

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGA?.TGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO:302 pMON399O5 .seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAJAJATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJkCTTCTCCCGGTGCCTGGAGCTGCAG

TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC

GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG

TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC

TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG

GCCCCTGCCCTGCAGCCCACCCAGGG'rGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTGCGCAGCCG SEQ ID NO;303 WO 9817810 PCT/US97/20037 pMON3 9906. seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTACCATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGCGCCTGGAGCTGCAG

TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC

GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTG'CCCCAGAGCTTCCTGCTCAAG

TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAJAGCTGTGTGCCACT

AACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAdTCTCTGGGCATCCCCTGGGCTCCC

CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT

TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC

ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCACAGATGGAGCTGGGATG

GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA

GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC

CTTCCAGCCG SEQ ID NO:304 pMON39909.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCACGTCGTGCAGGT

GGTGTTCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT

GCGCAGCCCTCTGGCGGCTCTGGCGGCTCTrCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGA

AAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA-GCTGTGTGCCACCTACAACTGTGCCACCCC

GAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGC

CAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTC

CTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTC

GCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGGCCCCTGCCCTGCAGCCC

SEQ ID NO:305 pMON39910.seq

GCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGTGGTGTTCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCT

GGGCCGCGTTAACTCGTAGCTAAC.GGGAGTCGG

GATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTG

CTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAG

CTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTG

GAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCC

ACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCTACGTAGAGGGC

GGTGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACCCGTCTCCTCCGTCTAAA

GAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGOGGGCCTCTGGCGGCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCLGACTGTCGCTGGGTCC-GATGCAGGCTTGCTGGAGCGC

GTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC

GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC

GGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA-ATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 306 pMON3 5727. seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGAACCCALGGACTGCTCCTTCCAJACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTGACCGTCTGGTCC1AATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATA-ATCTCCA.JCATGGCCGACGAGAGCTCTGCGGGGGCCTC

TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAGATGCAA

GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCC

AGCTGTCTTCGCTTCGTCCAGACCAA~CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG

GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC

WO 98/17810 419 PCT1US97/20037

TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGAC

TGCTCCTTCCACACAGCCCCATCTCCTCCGACTTCGCTG'rCAAATCCGTGAGCTGTCTGACTAC CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 307 pMON32168.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAJACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGdACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCZAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGACCGTCTGGTCCA

ATTTCACACGCCTCTTAGATTAAACCAAAGCACA

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAAATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGAGCTCTGCGGGGGC

CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAGATG

CAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCC

CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG

GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC

GACTCCTCAACCCTG SEQ ID NO:308 pMON32195.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA-ACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAJACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT

TTGGAGGGAGTCGGGTGGCGGTCGAAGTTTCACA

AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG

AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC

CTTCAGGTCGAGCTGAGATTCCGGTGTCACTGCC

CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGAATGGCC

CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA

GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT

GCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGJACCGTCTGGTCCATCTCTACTATC

AACCCGTCTCCTCCGTCTAAGAATCTCATATCTCCAACATGGCTGATGAAGACTGTGTGGT

GGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCGCTGGGTCCAAG

ATGCAAGGCTTGCTGGAGCGCGTGAJCACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCC

CCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG

CTGGTGGCGCTGAAGCCCTGGATCACTCGCCtAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG

CCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA

GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC

AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAJACCTGCAG

SEQ ID NO:309 pMON32196 .seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACPJAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGACTGGGATGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATC'rGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCGGGTGACCGTCTGGTCCAJATCTCTACTATCACCCGTCTCCT

CCGTCTAAGAATCTCATAATCTCCAACATGGCTGATGAGAJCTGTGTGGTGGTCTGTGGCGG

CTGGTCCTGGCACAGCGCTGATGGAGCGGCTCAGACTGTCCTGGTCCAGATGCAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTO

AAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGG7TGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAJATCCGTGAG

CTGTCTGACTACCTGCTTCAGATTACCCAGTCACCGTGGCCTCCACCTGCAGTACGTAGAGGGC

GGTGGAGGCTCCCCGGGTG~cCGTCTGGTCCATCTCTACTATCACCCGTCTCCTCCGTCTJA

GAATCTCATAAATCTCCAAJACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC

GACTTCGCTGTCAA.AATCCGTGAGCTGTCTGACTACCTGCTTCAJAGATTACCCAGTCACCGTGGCC

WO 98/17810 PCT/US97/20037

AO

TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG

GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA

CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTCGTCCAGACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC

TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:310 pMON32197 .seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCC'rGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGA-AGAACTGGGAATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCG'rTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGG'IGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGC

GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA

GAATCTCATAAATCTCCAAACATGGCTGA'rGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTG

GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCA.AGATGCAAGGCTTGCTGGAGCGC

GTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC

GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC

GGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCC'ICCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC

TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 311 pMON322O6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTG

GACCCGAACAACCTCAATGACGAAc3ACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCC AAAC CTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCA GGTATTGAGGCAATTCTTCGT

AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA

GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA

CAACAGTACCTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA.ATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGT

CTGTGGCGGCTGG'rCCTGGCACAGCGCTGGATGGAGCGGCTCALAGACTGTCGCTGGGTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC

CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG

GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC

GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG

GGAGGTAGTGGTACCCAGGACTGCSTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA

ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG

CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA

ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 312 pMON322O7.seq GCTGATrGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTrTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC

GGCTCCAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGG

ATGGAGCGGCTCAGACTGTCGCTGGGTCCA-GATGCA.GGCTTGCTGGAGCGCGTGAACACGGAG

ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC

WO 98/17810 PCTIUS97/20037 ATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAG

AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCACCCTGGGCGGTGGGTCAGGA

GG PGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC

CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAJA

GATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAA

CCGTCTGGTCCAATCTCTACTATCAACCGTCTCCTCCGTCTCGATCTCATAATCTCCAC

ATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAA

GTAGAACAGCAGCCGGTCAGGACGGGCCTCACGG

CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC

CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAJACTCCATAGCGGCCTTTTCCTCTACCAG

GGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTG

GACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAGAACTGGGAATGGCCCCTGCCCTG

CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG

GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC

TGATAAGGATCCGAATTCGGCAGC SEQ ID NO:313 pMON35728 .seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAJCTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAJACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT

GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC.CCTG

CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAJACCGTCTGGTCCA.TCTCTACTATCAJACCCG

ATGGATATCCTGATGGAACGACCTTCGACTCCAACCTGCTCGCATTCGTAGGGCTGTCAAG

CTGACGTTCTATCTGGTTACCCTTGAGCIAGCGCAGGACACAGTACGTAGAGGGCGGTGGAGGC

AAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC

TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAGATGCAAGGCTTGCTGGAGCGCGTGAACACG

GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAJAGCCCTGGATCACTCGC

CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAJ\CCCTGGGCGGTGGGTCA

GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC

TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTCACC

GTGGCCTCCAACCTGCAG SEQ ID NO:314 pMON32183 .seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC

AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAJACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAGATTACCCAGTC

ACGGCTCACGAGATAGTGACCGGGCAATAGCTTC

CCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATC

AAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGAT

GACAAGCAACGTGTGGAAAGGAGAAAACCGCCAC

CATAGAGAGGATTACAACAGTACTCTCCGGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGG

ATATGAGATCATCAGCAACAAACCCGGCACAAAC

ATTAACCAGGCGAGGTCCAGAAGCTCTCCAAGAA

ATGACTAAGAAJACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTG

GATGCACAGGAAAACAATAAGAATACATCGATTA

GGTTATCTTCGAGTAATGAAAG-CGGGAAAAACA

TCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAGAGCTTCTCCCGGACTCCG

GGTAAA SEQ ID NO:315 pMON32 184. seq

GCCACCCAGGACTGCTCCTTTCACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAJATCCGTGAG

CTGTCTGACTAcCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGJACACGGAGATACACTTTGTCACCATGTGCCTTT

CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCACATCTCCCGCCTCCTGCAGGAGACCTCC

GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTTCTCCCGGTGCCTGGAGCTGCAG

TGCGCGCCTACCGATCACTGGCAAGCCCACACCG

CCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG

WO 98/17810 PCTUS97ZOO37

ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAG

GATGACCCAGATGTCCAGATCAGCTGGTTTGTGACCGTGGAGTACACACAGCTCAGACACAA

ACCCATAGAGAGGATTACAACAGTACTCTCCGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGAC

TGAGGGC.GATCATCAGCAACAGCTCACCCTGGG

ACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAGA

GAGATGACTAAGAAACAGGTCACTCTGACCTGCATGTCACAGACTTCATGCCTGAAGACATTTAC

GTGGGACAACGAACGGTAATCAACCGACGCTGCC

GAGTCTCTAGAACACGGGTGAAAGATGTGAGATG

TACTCCTGTTCAGTGGTCCACGAGGGTCTGCACJATCACCACACGACTAAGAGCTTCTCCCGGACT

CCGGGTAAA SEQ ID NO:316 vvn 09/1 oRl n Dt, DT'1US97/21J037 TABLE 3 PROTEIN SEQUENCES PMON2 645 8pep SerProAlaProProAl aCysAspLeuArgVa lLeuSerLysLeuLeuArgAspSerHis ValLeu-i sSerArgLeuSerGlnCys ProGluValHi sProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlrie tGluGluThrLysAla GlnAspI leLeuGlyAlaValThrLeuLeuLeuGluG lyValMe tAlaAlaArgGJlyGln LeuolyProThrCysLeuSerserLeuLeuGlyGln~euSerGlyolnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuolyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlal lePheLeuSerPheGinHi sLeuLeuArgGlyLysVa.Arg PheLeuMetLeuValGlyclyserThrLeuCysValArgjluPhe SEQ ID NO:467 pMON2854Bpep SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHi s ValLeullisSerArgLeuSerrlnCysProGluVal~isProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGle tGluGluThrLysA1 a GlnAsplleLeuGlyAlaValThrLeuLeuLeuoluGlyValMetAlaAlaArgGlycln LeuGlyProThrCysLeuSerSerLeuLeuGlyG lnLeuSerG lyGlnvalArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProG lnGlyArgThrThrAla HisLysAspProAsnAlal lePheLeuSerPheGlnHi sLeuLeuArgGlyLysValArg PheLeuMetLeuVa 1GlyGlySerThrLeuCysValArgGluPheGlyGlyAsr4e tAla SerProAlaProProAlaCysAspLeuArgVa lLeuSerLysLeuLeuArgAspSerHi S ValLeuHisSerArgLeuSerGlnCysProGluValHi.s ProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrG1r4e tGluGluThrLysAla GlnAspI eLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuclyAlaLeuGlnSerLeuLeuGlymhrGlnGly~rgThrThrAlaHisLysAspPro AsnAlal lePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGJlyGlySerThrLeuCysValArg SEQ ID NO:468 pMON2 8500 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer{is ValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlycluTrpLysThrGlniMe tGluGluThrLysAl a GlniAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgolyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGl1nGlyArgThrThrAl a HisLysAspProAsnAlal ePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsrietAlaSer ProAlaPro ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspserHisVaI LeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeu ProAlaValAspPheSerLeuGlyGluTrpLysThrGlnijetGluGluThrLysAlaGln AsplleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu GlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeu GlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHi s LysAspProAsnAlal lePhebeuSerPheGlnHisLeuLeuArgGlyLysValArgPhe Leu~etLeuValGlyGlySerThrLeuCysValArg SEQ ID NO:469 pMON2 8501 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlncysProoluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGle tGluGluThrLysAla GlnAspI leLeuGlyAlaValThrLeuLeuLeuGluclyValMetAlaAlaArgGlyGln LeuclyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnlallePheLeuSerPheGlnjjsLeuLeuArgGlyLysValArg PheLeuMetLeuVa lGlyGlySerThrLeuCysValArgGluPheGlyGlyAsuLMe tAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValH s ProLeuProThrProValLeu LeuProAlaVa1AspPheSerLeuGlyGluTrpLysThrGl1etGluGluThrLysAla GInAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlargGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyclnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProG lnGlyArgThrThrAla HisLysAspProAsnAlal lePheLeuSerPheGlnHi sLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO:470 pMON2 8502 Ser~o~l~roro~a~yssp~u~r~aleu~r~yseu~u~r~sper~s Va~ui~rr~ue~ny~o~ua~sr~ur~rr~le WO 98/17810 PCTfUS97/20037 LeuProAiaVaiAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GinAsp I leLeuGlyAiaValThrLeuLeuLeuGluciyVaiMe tAiaAiaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGiyGlnVaiArgLeuLeu LeuGiyAiaLeuGinSerLeuLeuGlyThrGlnLeuProProGinGlyArgThrThrAia HisLysAspProAsnAialePheLeuSerPheGinHisLeuLeuArgGiyLysValArg PheLeuMe tLeuVaiGlyGlySerThrLeuCysVaiArgGluPheclyGlyAsnGiyGiy AsnMe tAiaSer~roAlaProProAl.aCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisVaiLeuHis SerArgLeuSerGlnCysPr oGluValHis ProLeuProThr ProVa lLeuLeuProAiaValAspPheSerLeuGlyGiuTrpLysThrGlnMe tGiuGiu ThrLysAiaGinAspIlieLeuGiyAiaVaimrLeuLeuLeuGuGyVaMe tAaAia ArgG lyGinLeuGiyProThrCysLeuSerSerLeuLeuGiyG lnLeuSerGiyGinVai ArgLeuLeuLeuGiyAlaLeuGinSerLeuLeuGiyThrGinLeuPro ProGinG iyArg ThrThrAlaHisLysAspProAsnAialePheLeuSerPheGinHisLeuLeuArgGiy SEQ ID NO: 471 13182. Pept Asn Cys Ser Ile Met Ile Asp Gu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val S-er Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Giu Gin Gin Tyr Val Giu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Giu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Giu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Giu Giu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Giu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Giu Gin Val Arg Lys Ile Gin Gly Asp Giy Ala Ala Leu Gin Giu Lys Leu Cys Ala Thr SEQ ID NO:472 13183 .Pept Asn Cys Ser Ile Met Ile Asp Gu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Gly Ile Giu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala Gin Giu Gin Gin Tyr Val Giu Gly Gly Gly Gly Ser Pro Gly Giu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Giu Giu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Giu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala-Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Giu Giu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Vai Leu Val Ala Ser His Leu Gin Ser Phe Leu Giu Val Ser Tyr Arg Val Leu Arg His Leu Aia Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Giu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Giu Lys Leu Cys Ala Thr SEQ ID NO:473 13184. Pept Asn Cys Ser Ile Met Ile Asp Gu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Aso Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Gly Ile Giu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu WO 98/17810 PCTIUS97/20037 Gin Ala Gin Giu Gin Gin Tyr Vai Glu Gly Giy Giy Giy Ser Pro Gly Giy Giy Ser Giy Giy Giy Ser Asn Met Aia Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Aia Asp Phe Aia Thr Thr Ile Trp Gin Gin Met Glu Guu Leu Giy Met Aia Pro Aia Lei Gin Pro Thr Gin Giy Aia Met Pro Aia Phe Ala Ser Ala Phe Gin Arg Arg Aia Giy Giy Vai Leu Vai Aia Ser His Leu Gin Ser Phe LeU Giu Vai Ser Tyr Arg Val Leu Arg His Leu Aia Gin Pro Ser Gly Giy Ser Gly Giy Ser Gin Ser Phe Leu Le Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Giy Asp Giy Ala Ala Leu Gin Guu Lys Leu Cys Aia Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Giy Ile Pro Trp Aia Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Giy Cys Leu Ser Gin Leu His Ser Giy Leu Phe Leu Tyr Gin Cly Leu Leu Gin Ala Leu Giu Gly Ile Ser SEQ ID NO:474 13185.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Le Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Giy Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Giy Asp Trp Gin Giu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Giy Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Le Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Aia Phe Gin Arg Arg Ala Cly Giy Val Le Val Ala Ser His Le Gin Ser Phe Leu Giu Val Ser Tyr Arg Vai Le Arg His Le Ala Gin Pro Ser Gly Cly Ser Giy Gly Ser Gin Ser Phe Le Le Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Cly Ala Ala Le Gin Glu Lys Le Cys Ala Thr Tyr Lys Leu Cys His Pro Giu Clu Leu Val Le Leu Gly His Ser Le Gly Ile Pro Trp Ala Pro Le Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Le His Ser Gly Lei Phe Leu Tyr Gin Gly Lei Leu Gin Ala Lei Giu Cly Ile Ser SEQ ID NO:475 13186.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Le Leu Asp Pro Asn Asn Le Asn Asp Giu Asp Val Ser Ile Le Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Giy Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Aia Cly Asp Trp Gin Glu Phe Arg Glu Lys Le Thr Phe Tyr Leu Vai Thr Leu Glu Gin Ala Gin Giu Gin Gin Tyr Val Glu Gly Gly Cly Giy Ser Pro Cly Gly Cly Ser Gly Gly Gly Ser Asn Met Aia Met Ala Pro Ala Lei Gin Pro Thr Gin Giy Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Cly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Vai Leu Arg His Leu Ala Gin Pro Ser Gly Cly Ser Cly Gly Ser Gin Ser Phe Lei Leu Lys Ser Lei Glu Gin Val Arg Lys Ile Gin Cly Asp Gly Ala Aia Leu Cln Glu Lys Lei Cys Ala Thr Tyr Lys Lei Cys His Pro Glu Glu Lei Val Lei Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Lei Ala Cly Cys Leu Ser Gin Lei His Ser Cly Leu Phe Leu Tyr Gin Cly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Lei Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Le Gly SEQ ID NO:476 13187.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Le Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le Asn Asp Glu Asp Vai Ser Ile Le Met Asp Arg Asn Le Arg Le Pro Asn Le Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Cly Ile Glu Ala Ile Le Arg Asn Le Gin Pro Cys Le Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Aia Gly Asp Trp WO 98/17810 PCT/US97/20037

A%

Gin Gin Gly Ser Leu Gin Phe Ser Glu Lys Leu Cys His Gly Asp Leu Phe Arg Glu Lys Gin Glu Gln Gin Pro Ser Gly Pro Glu Ser His Lys Pro Thr Gin Gly Arg Ala Gly Gly Glu Val Ser Tyr Gly Ser Gly Gly Val Arg Lys Ile Cys Ala Thr Tyr Gly His Ser Leu Ser Gln Ala Leu Gly Leu Phe Leu Ser Pro Glu Leu Ala Asp Phe Ala SEQ ID NO:477 Thr Leu Gly Ser Ser Pro Ala Pro Ser Ala Leu Gin Ala Gin Lys Ser Leu Gin Glu Leu Leu Ser Ser Gin Ala Leu Leu Gin Met Glu 13188.Pept Asn Pro Val Ser Glu Ala Gin Gin Gly Met Leu Val Gin Gly Leu Ile Leu Gin Pro Thr Gin Ile Met Ile Pro Leu Leu Leu Met Asp Arg Ala Val Leu Arg Asn Ser Arg His Arg Glu Lys Glu Gin Gin Ser Gly Gly Phe Ala Ser Ser His Leu His Leu Ala Leu Leu Lys Ala Ala Leu Pro Glu Glu Ala Pro Leu Cys Leu Ser Leu Gin Ala Asp Thr Leu Gln Gln Met ID NO:478 Leu Lys Asp Glu Asn Leu Ser Gly Ser Ala Gly Asp Thr Leu Gly Ser Gin Gly Gly Gly Ser Tyr Gly Gly Lys Ile Thr Tyr Ser Leu Ala Leu Phe Leu Glu Leu Phe Ala Pro Ala 13189.Pept Asn Pro Val Ser Glu Ala Gin Gin Gly Ser Met Leu Val Gin Gly Leu Ile Leu Gin Pro Thr Gin Ile Met Ile Pro Leu Leu Leu Met Asp Arg Ala Val Leu Arg Asn Ser Arg His Arg Glu Lys Glu Gin Gin Ser Gly Pro Ser His Lys Phe Ala Ser Ser His Leu His Leu Ala Leu Leu Lys Ala Ala Leu Pro Glu Glu Ala Pro Leu Cys Leu Ser Leu Gin Ala Asp Thr Leu Gln Gln Met ID NO:479 Leu Lys Asp Glu Asn Leu Ser Gly Ser Ala Gly Asp Thr Leu Gly Ser Ser Pro Gin Gly Gly Gly Ser Tyr Gly Gly Lys Ile Thr Tyr Ser Leu Ala Leu Phe Leu Glu Leu Phe Ala Pro Ala 13190.Pept Asn Cys Ser Ile Met Ile Pro Pro Ala Pro Leu Leu Val Ser Ile Leu Met Asp Ser Phe Val Arg Ala Val Asp Glu Ile Asp Pro Asn Arg Asn Leu Lys Asn Leu Ile His His Leu Lys Arg Asn Leu Asn Asp Glu Asp Arg Leu Pro Asn Leu Glu Glu Asn Ala Ser Gly Ile WO 98/17810 PCT/US97/20037 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO:480 13191.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO:481 13192.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile. Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr SEQ ID NO:482 13193.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile lie His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu WO 98/17810 WO 9817810PCT/US97/20037 Ser Giu Ala Gin Gin Gly Ser His Trp Gly Leu Leu Trp Thr Ala Val Gly Giu Lys Val Arg Ala Ile Leu Arg Pro Ser Arg Phe Arg Glu Gin Giu Gin Pro Ser Gly Giu Ser His Giu Giu Leu Pro Leu Ser Leu Ser Gin Gin Ala Leu Thr Leu Gin Gin Met Glu Gly Ala Met Gly Val Leu Tyr Arg Val Ala Ser Ser Val Arg Lys Cys Ala Thr Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Val Glu Ile Ser Thr Ser Pro Asn Leu Leu Gly Cys Pro Ser His Ser Giy Gly Ile Ser Asp Val Ala Leu Gly Met Aia Phe Ala Aia Ser His Arg His Leu Pro Gin Ser Gin Gly Asp ID NO:483 Ser Gly Ser Aia Giy Asp Thr Leu Gly Ser Ser Pro Lys Leu Gly Ile Gin Leu Tyr Gin Giy Pro Thr Thr Leu Gin Gin Arg Phe Leu Thr Pro Lys Ser Leu Gin 25i90. Pept Asn Pro Val Ser Giu Aia Gin Gin Giy Pro Thr Gin Arg Leu Pro Ser Gin Leu Ser Gin Leu Cys Ser Pro Ala Ser Ile Phe Vai Aia Ile Ala Pro Giu Phe Ala Gin Giy Gly Thr Leu Ile Trp Pro Thr Arg Ala Giu Val Leu Gly Leu Giu Giu Lys Vai Leu Ser Cys Leu His Giu Gly Asp Giu Ile Asp Pro Asn Arg Asn Leu Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Vai Giu Gly Ser Asn Gin Leu Asp Giu Giu Leu Met Pro Ala Leu Val Ala Val Leu Arg Ser Leu Pro Lys Ile Gin Thr Tyr Lys Ser Leu Gly Aia Leu Gin Phe Leu Tyr ID NO:484 pMON25i9i .Pep Asn Cys Ser I.

Pro Pro Aia P.

Val Ser Ile L, Ser Phe Val A: Giu Ala Ile L, Ala Ala Pro S, Gin Giu Phe A- Gin Ala Gin G.

Giy Giu Pro S, Ser Lys Giu S, Pro Thr Leu K~ Thr Ile Trp GI Gin Pro Thr G Arg Arg Aia G.

Leu Giu Val S Pro Leu Gly P: Ser Leu Giu G Gin Giu Lys L, Leu Vai Leu Li Ser Ser Cys P: Gin Leu His S, Leu Giu Gly I Asp Giu Ile Asp Pro Asn Arg Asn Leu Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Val Giu Ile Ser Thr Ser Pro Asn Gin Leu Asp Giu Glu Leu Met Pro Ala Leu Val Ala Val Leu Arg Ser Leu Pro Lys Ile Gin Thr Tyr Lys Ser Leu Gly Ala Leu Gin Phe Leu Tyr ID NO:485 Leu Lys Asp Giu Asn Leu Ser Gly Ser Ala Giy Asp Thr Leu Gly Ser Ser Pro Giu Leu Phe Ala Pro Ala Aia Phe Gin Ser Gin Pro Leu Leu Ala Aia Pro Giu Ala Pro Cys Leu Leu Gin 13194. Pept Asn Cys Ser Ile Met Ile Asp Gu Ile Ile His His Leu Lys Arg WO 98/17810 WO 9817810PCTIUS97/20037 Pro Val Ser Glu Ala Gin Gin Gly Leu Gin Phe Thr Lys Leu Giu Leu Ser Al a Leu Met Asp Pro Asn Arg Asn Leu Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Val Glu Gly Ser Asn Ala Met Pro Val Leu Vai Arg Val Leu Ser Ser Leu Arg Lys Ile Ala Thr Tyr His Ser Leu Gln Ala Leu Leu Phe Leu Pro Glu Leu Asp Phe Ala ID NO:486 Asn Leu Arg Leu Glu, Asn Cys Leu Ile Lys Tyr Leu Gly Gly Met Ala Ala Phe Ala Ser Arg His Pro Gin Gin Gly Lys Leu Gly Ile Gin Leu Tyr Gin Gly Pro Thr Thr Asp Glu Asn Leu Ser Giy Ser Ala Gly Asp Thr Leu Giy Ser Ala Pro Ser Ala Leu Gln Ala Gln Phe Leu Gly Ala His Pro Trp, Ala Gly Cys Leu Leu Leu Asp Trp, Gln 13195 Pept Asn Cys Sej Pro Pro Ali Val Ser Il( Ser Phe Va' Glu Ala 11( Ala Ala Pr( Gln Giu Ph( Gln Ala Gi Gly Glu Pr( Ser Lys Gi Leu Gln Pr( Gin Arg Ar( Phe Leu Gli Thr Pro Let Lys Ser Let Leu Gin Glt Glu Leu Va- Leu Ser Sei Ser Gln Let Ala Leu Gi Leu Gln Let Met Glu Gi Ile Met Pro Leu Leu Met Arg Ala Leu Arg Ser Arg Arg Glu Giu Gin Ser Gly Ser His Thr Gin Ala Gly Val Ser Gly Pro Glu Gin Lys Leu Leu Leu Cys Pro His Ser Gly Ile Asp Val Leu Gly Ile Met Pro Leu Leu Met Arg Ala Leu Arg Ser Arg Arg Giu Glu Gin Ser Gly Phe Ala Ser His His Leu Gin Ser Gly Asp Leu Cys Ile Pro Leu Ala Gin Gly Pro Thr Thr Ile Gin Pro Asp Giu Ile Asp Pro ASn Arg Asn Leu Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Val Giu Ile Ser Thr Ser Pro Asn Ala Met Pro Val Leu Val Arg Val Leu Ser Ser Leu Arg Lys Ile Ala Thr Tyr His Ser Leu Gin Ala Leu Leu Phe Leu Pro Glu Leu Asp Phe Ala ID NO:487 13196. Pept Asn Cys Se Pro Pro Al Val Ser Il Ser Phe Va Giu Ala Il Ala Aia Pr Gln Giu Ph Gin Ala G1: Gly Gly G1 Met Pro Al Leu Val Al Val Leu Ar Ser Leu Pr Lys Ile Gl: Thr Tyr Ly Ser Leu Gi Ala Leu Gi.

Phe Leu Ty Glu Leu Gl Phe Ala Th Pro Ala Le 13197. Pept Asp Giu Ile Asp Pro Asn Arg Asn Leu Lys Asn Leu Leu Gin Pro Pro Ile Ile Leu Thr Phe Tyr Val Glu Gly Ser Asn Ala Phe Gin Gin Ser Phe Gin Pro Thr Leu Leu Lys Aia Ala Leu Pro Giu Glu Ala Pro Leu Cys Leu Ser Leu Gin Ala Asp Thr Leu Gin Gin Met ID NO:488 Leu Lys Asp Glu Asn Leu Ser Gly Ser Ala Gly Asp Thr Leu Gly Ser Gin Gly Giy Gly Ser Tyr Pro Ala Gin Val Leu Cys Leu Gly Pro Ser Ser Gly Ile Ser Val Ala Gly Met WO 98/17810 a50 PCT/US97/20037 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu.Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:489 13198.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO:490 13199.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO:491 WO 98/17810 PCTIUS97/20037 31104. Pep Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Vai Thr Leu Giu Gin Ala Gin Giu Gin Gin Giy Giy Gly Ser Asn Cys Ser Ile Met Ile Asp Giu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Giu Gly Gly Gly Gly Ser Pro Gly Giu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Aia Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg '4 15 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Giu Gin Val Arg Lys Ile Gin Gly Asp Giy Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Giu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Giy Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Giu Leu Giy Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Giu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:492 31105.Pep Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala Gin Glu Gin Gin Giy Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Giu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Vai Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Tyr Val Giu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Giu Giu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Giu Gly Ile Ser Pro Glu Leu Giy Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Giu Glu.Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:493 31106.Pep Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Giu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Aso Ala Ser Gly Ile Giu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Giu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Aia Met Pro Aia Phe Ala Ser Ala Pha Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Set Gln Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Giu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Giu Gly Ile Ser Pro Giu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala WO 98/17810 WO 9817810PCT1US97/20037 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Ala Pro Ala Leu Gin Pro SEQ ID NO:494 Giu Giu Leu Gly Met 31107. Pep Ala Val Cys Pro Ser Phe Al a Al a Gly Pro Thr Ala Val Ser Arg Ala His Gin Leu Pro Asp Ala Asp Trp Leu Glu Ile Met Pro Leu Leu Met Arg Ala Leu Arg Ser Arg Ser Pro Pro Pro Gly Ala Gly Val Tyr Arg Gly Ser Ile Gin Tyr Lys Leu Gly Leu Gin Leu Tyr Leu Gly Ala Thr Ala Leu Arg Giu Lys Glu Gin Gin Ile Ile His Asn Asn Leu Leu Arg Leu Leu Giu Asn Pro Cys Leu le Ile Lys Ser Gly Pro Ser His Lys Phe Ala Ser Ser His Leu His Leu Ala Leu Leu Lys Ala Ala Leu Pro Glu Giu Ala Pro Leu Cys Leu Ser Leu Gin Ala Asp Thr Leu Gin Gin Met ID NO:495 31108. Pep Leu Asp Val Asn His Lys Gin Ser Ala Ser Ser Phe Ser His Leu Al a Pro Ala Cys Leu Asp Gin Pro Asn Asn Asn Leu Arg Asn Leu Glu Gin Pro Cys Ile Ile Ile Thr Phe Tyr Gly Gly Ser Met Ile Asp Leu Tyr Val Pro Ile Ser Lys Ser Pro Ser Ala Phe Leu Gin Ser Ala Gin Pro Lys Ser Leu Leu Gin Giu Glu Leu Val Leu Ser Ser Ser Gin Leu Ala Leu Giu Leu Gin Leu Met Giu Giu Glu Asp Leu Giu Gly Ile Ala Thr Asp Trp Leu Giu Ser Gly His His Gly Gly Pro Ser Thr Gin Ala Gly Val Ser Ser Gly Arg Lys Ala Thr His Ser Gin Ala Leu Phe Pro Giu Asp Phe Ala Pro Met Ala Arg Arg Glu Gin Cys Pro Pro Glu Ala Ala Arg Phe Gly His Trp Gly Leu Leu Trp SEQ ID NO:496 31109. Pep Asn Leu Lys Leu Giy Giu Pro Asn Asn Ser Ser Phe Ser His Leu Ala Pro Ala W 98180A 3 PCTIUS97/20037 Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Giu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Vai Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Giu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:497 31110 Pep Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala GinGlu Gin Gin Giy Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Gu Ilie Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Giy Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Lell Giu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Vai Arg Lys Ilie Gin Giy Asp Gly Ala Ala Leu Gin Giu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Giu Gly Ile Ser Pro Giu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:498 31111.Pep Ala Gly Asp Trp Gin Glu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ilie Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Giu Ser Phe Val Arg Ala Val Lys Asn Leu Giu Asn Ala Ser Gly Ile Giu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Giy Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Giu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Giu Gin Val Arg Lys Ilie Gin Gly Asp Gly Aa Al Le GlnGluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp, Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Giu Giu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO:499 pMONi5981 MetAlaAsnCysSerl leMetI leAspGiulleleHisHisLeuLysArgProProAla ProLeubeuAspProAsnAsnLeuAsnAspGluAspVal1SerIl1eLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGuAsnJlaSer Glyl leGluAlal leLeuArgAsnLeuGlnProCysLeuProserAiaThrAiaAlaPro SerArgHisProllelleleLysAiaGiyAspTrpGinGiuPheArgGiuLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGiuGlnGlnTyrVaiGluGlyGlyGlyGly SerProGiyGluProSerGlyProl leSerThrI ieAsnProSerProProSerLysGlu SerHisLysSerProAsniMetAlaTyrLysLeuCysHis ProGiuGluLeuVaiLeuLeu GlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlrilaLeuGln LeuAlaGiyCysLeuSerGlnLeuHisSerGiyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlyl leSerProGiuLeuGiyProThrLeuAspThrLeuGinLeuAspVai AlaAspPheAlaThrThrl leTrpGlnGliMetGiuGiuLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeurgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu WO09817810 A4PCTIUS97/20037 ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgtys I leGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThr SEQ ID NO:500 pMON15982 Me tAl aAsnCysSerI leMe t 11eAspGluI le I leHisHisLeuLysArgPro ProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspVal1Ser I leLeuMetAspArgAsn LeuArgLeuProAsnbeuGluSerPheValArgAlaVa lLysAsnLeuGluAsnAlaSer G lyl 1eGl1uAl a 11eLeuArgAsnLeuG lnProCysLeuPro SerAl aThrlaAla Pro SerArgHi sPro IleI 1e IleLysAlaGlyAspTrpGlncluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnryrValGluclyGlyGlyGly SerProGlyGlu ProSer~lyProl 11eSerThr I!eAsnPro Ser Pro ProSerLysGlu SerHi sLys SerProAsnletAl aProGluLeuG lyPr oThrL euAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrl eTrpGlnGlnMe tGluG luLeuGlyMetAl aPro AlaLeuGlnProThrclnGlyAlaMetProAlaPheAlaserAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu A rgHi sLeuAlaGlnProGlyGlyGlySerAspMetAl aThrProLeuGlyProAlager SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys IleGlnGlyAsp GlyAlaAlaLeuclnGluLysLeuCysAlaThrTyrLysLeuCysjisProGluGluLeu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAl aGlyCysLeuSrGnLeu-i sSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlyIleSer SEQ ID NO:501 pMONi 5965 MetAlaAsnCysSerl leMetI leAspGluI lel leHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspVal SerIl1eLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaVa lLysAsnLeuGluAsnAlaSer G lyI leG luAl a1eLeuArgAsnLeuGlnProCysLeu ProS erAl aThrAlaA 1a Pro SerArgHisProllellellebysAlaGlyAsprrpclnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlrlAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProG 1yG luProSerG IyProl 11eSerThrl 11eAs nPro Ser Pro ProSerLysGl u SerHi sLys SerProAsnMe tAlaSerAlaPheG lnArgArgAl aGlyG lyVa lLeuVal1 AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlagerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLys IieGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyrLysLeuCysHi sProG luGlubeuValLeuLeuGlyHi s SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuclnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGnGlyLeuLeuG~nAlaLeu GluGlyl leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrl leTrpGlnGlrnMetGluGluLeuGly~etAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAla SEQ ID NO:502 pMON15966 MetAlaAsnCysSerl leMetlleAspGlullelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerI leLeuMetAspArgAsi LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnJ~1aSer GlyT leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAla~laPro SerArgHi sPro IleI IeI leLysAlaclyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly Ser ProGlyGl uProS erG lyPro I IeS erThrl 11eAsnPro Ser Pro ProSerLysGlu SerHi sLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAl aSerAlaPheGlnArgArgAlaGlyG lyValLeuValAlaSerHi sLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAl aThrProLeuGlyProAlaSerSerLeuProG inSerPheLeuLeuLys SerLeuGluGlnValArgLysI leGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuG lyHis SerLeuGlyl e ProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnbeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrpGlnGlniMetGluGluLeuGly SEQ ID NO:503 pMON15967 MetAlaAsnCysSerl leMetI leAspGluI lel leHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsrlAspGluAspVal1Ser I leLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGlusnAlaSer Glyl leGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAla~laPro SerArgHis Pro 11e le leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProl leSerThrI leAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe Gl~gr~al~ya~ua~a~ri~u~~rh~ul~le TyrArgValLeuArgHi sLeuAl aGlnProGlyGlyGlySerAspMetAlaThrProLeu WO098/17810 /oPCTIUS97/20037 GlYProAlaSerSerLeuiProGlnSerPheLeuLeuLysserLeuGluGlnvalArgLys Ile~lnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi s ProGl1uGl1uLeuVa ILeuLeuG lyH is SerLeuGlyI 1eProTrpAl aProLeuSer Ser Cys Pro SerGlnAlaLeuG InLeuAl aGlyCysLeuSerGlnLeuHi sS erGlyLeu Phe Le~rl~ye~ul~ae~u~yl~rr~ue~yr~re AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrI leTrpGlnGlnMetcluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:504 9M0N31112.pep Me~as~se~rie~es~u e leThrliisLeuLysolnProProLeu ProLeuLeuspPheAsnsnLeuAsnGlyGluAspGlspI 11 eLeul~etAspAsnAsn Le~gr~os~ul~ah~n~gl~ly~reGns~ae AlalI eGluSerI leLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPr Th~gisr 1eis1 ~ss~l~pr~nl~er~gy~uh PheTyrLeuLysThrLeuGluAsriJ~1aGlrJ~aGnGlnTyrValGluGlyGlyGlyGly SerProG lyGluProSerGlyPro I leSerThrI leAsnProSerProProSerLysGlu SerI-isLys SerProAsnMe tAlamhrGlnclyAlaMetProAlaPheAlaSerAlaPhe Gl~gr~al~ya~ua~a~ri~u~~rh~ul~le Ty~ga~ur~se~al~o~rl~ye~yl~rl~rh LeuLeuLysSerLeuGluGlnValArgLys I eGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVa iLeuLeuGlyHi sSer LeuGlyl 1 eProTrpAl aProLeu SerSerCys Pro SerG lnA 1 aLeuG~nLeuAl aGly CysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGl1~laLeuGlu GlyI 1 eSerProGluLeuGlyProThrL~uspThrLeuGlnLeuAspValAlaspPhe Al aThrThr I leTrpGlnGlniMe tGluG luLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:505 pMON31113 .pep MetAl aAsnCys erAsn~et I leAspGluI leI leThrHisLeuLysclnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspI leLeuMetGluAsnAsn Le~gr~os~ul~ah~r~gl~ly~re~ns~ae AlaI leGluSerI leLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHis Prole I Il~gs~ys~psnl~er~gy~uh PheTyrLeuLysThrLeuGluAsn~1aG1lnAlaGnGlnTyrValGluGlyGlyGlyGly SerProolyGluProSerGlyPro I leSerThrI leAsnProSerPro ProSerLysGlu SerH is Lys SerProAsn4e tAlaThrGlnG lyAlaMe tProAl aPheA a SerA aPhe Gl~gr~al~ya~ua~a~ri~ulsrh~ul~le Ty~ga~ur~se~al~o~rr~ul~ol~re~ur GlnSerPheLeuLeuLysSerLeuGluclnValArgLys I leG lnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLe GlyHisSerLeuclyI eProTrpAaProLeuSererCys ProSerGn~laLG~ LeuAlaGlyCysLeuSerGlnLeuHisSerolyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGnLeu~spVal AlaAspPheAlaThrThrI leTrpGlnGl1etGluGluLeuG lyMe tAl aPrAl Le GinPro SEQ ID NO:506 pMON3 112.4.pep MetAlaAsnCysSerAsrLetIleAspGluI lelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGrispI 1 eLeuMetGluAsnjsn Le~gr~os~ul~ah~n~gl~ly~re~ns~ae Alal leGluSerI leLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAla~laPro Th~gi~ol~el~gs~y~pr~nl~er~gy~uh PheTyrLeuLysThrLeuoluAs~laGln1 aGinGlnTyrVa 1GluG lyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu SeHi y e r~netlah~n~ylaetPolah~ ~rlah Gl~gr~al~ya~ua~a~ri~ul~rh~ul~le Ty~ga~ur~se~al~o~rl~ye~yl~rl~rh Le~uy~re~ul~lr~s~el~ys~yl~ae~nl LysLeuCysAlaThrTyrLysLeuCysHisProGlucluLeuValLeuLeuGlyHisSe LeuGlyl leProTrpAlaProLeuSerSerCysProSerG1i1aLeuGlnLeu~1aGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuG lnAlaLeuGlu Glyl leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrI leTrpGlnGlrMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:507 pMDN3 1115 .pep MetAlaAsnCysSerAsnitetl leAspGlullelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsr~snLeuAsnGyG1uspGl1spIl1eLeuMetAspAsnJsn WO 98/1 7810 A 6PCTIUS97/20037 LeuArgArgProAsnLeuGluAlaPheAsnrgA1 aValLysSerLeuGlnAsnAl aSer AlalleGluSerleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro Th~gisr~ei l~ss~y~pr~nl~er~gy~uh PheTyrLeuLysThrLeuGluAsnAiaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyPro IleSerThrlleAsnProSerProProSerLysGlu SerHi sLys SerProAsne tAl aThrGlnG lyAl aMet ProAl aPheAl aSerAl aPhe Gl~gr~al~ya~ua~a~ri~ul~rh~ul~le TyrArgVa 1LeuArgHi sLeuAlaGlnProThr ProLeuGlyProAlaSerSerLeu Pro GlnSerPheLeuLeuLys SerLeuGluGlnValArgLys I leG lnGlyAspGlyAlaAla LeGnl~se~sl~ry~seuy~ ~o ul~ua~ue GlyHi sSerLeuGlyI 1 eProTrpAlaProLeuSerSerCys ProSerG lnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHi sSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVaI AlaAspPheAlaThrThrIleTrpGlnGl1etGluluLeuGly~etAlaProAlaLeu GinPro SEQ ID NO:508 pMON2 8505 Al~ny eIl~tIl~plI1e ei~ ~uy~gr~olar LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IleLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aVaJ.LysAsnLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProserAl aThrAlaAlaProSer ArgHi s Pro IleI leIl1eLysAlaGlyAspTrpGJlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 1eSerThrl 11eAsnProSerProProSerLysGluSer HisLysSerProAsniMetGluValHis ProLeuProThr ProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrc1rl4e tGluGluThrLysAlaGlnAspI 1 ebeu GlyAlaValThrLeuLeuLeuGluGlyValMe tAlaAlaArgGlyGlnLeuGlyProThr CysLeuserSerLeuLeuGlyGlnLeuserGlyclnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeualyThrGlnLeuProProGlnGlyArgThrThrAlaHi sLysAspPro As~a ~ee~rh~ni~ue~g yy~ ~gh~uete ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsne tAlaSerProAlaPro Pr~ay~pe~gale~ry ue~g~pe~sa~uiSer ArgLeuSerGlnCysPro SEQ ID NO:509 pMON2 8506 AlaAsnCysSerI leMetI leAspGluI leI leI-isHi sLeuLysArgProProAlaPro LeuLeuAspProAsn~~snLeuAsnAspG luAspValSer IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSercly I lel~a ~ur~ne~nr~y~ur~rlah~al~oe ArgHi sProI 1eI IelIleLysAlaGlyAspTrpGlncluPheArgoluLysLeu~hrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrVaIGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrI leAsnProSerPr cProSerLysGluSer HisLysSerProAsraMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnl~etGluGluThrLysAlaGlrnAspI leLeuGlyAlaValThr LeuLeuGlyGlnLeuSerGlyGlnVa lArgLeuLeuLeuGlyAl aLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn~laIlePhe LeuSerPheGlnHisLeuLeuArgclyLysValArgPheLeuMe tLeuValGlyGlySer ThrLeuCysVa1ArgGluPheGlyGlyAsrj~ tAlaSerProAl aPro ProAlaCysAsp LeuArgValLeuSerLysLeuLeuArgAspser~jisValLeu~j sSerArgLeuserGln CysProGluValHisPro SEQ ID NO:510 pMON2 85 07 AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal1Ser IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluserPheValArgAlaValLysAsnLeuGluAsn~laSeroly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAjaAlaProSer Ar~sr~el~ey~al~p~pl~uh~gl~se~rh TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlniMetGluGluThrLysAlaGlnAspI leLeuGlyAlaVa lThrLeuLeuLeuGlu Gl~le~al~gl~ne~y~oh~se~re~ue~y~ LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsn~~l 1 ePheLeuSerPheGin HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeu~ys~al ArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgVa lLeu Se~se~ur~pe~sa~u~Se~ge~rl~sr~ua HisProLeuProThrPro SEQ ID NO:511 pM0N28508 WO 98/17810 PCTIUS97/20037 Al1 AlaAsnCysSerI IeMet 11eAspGlu 11exlleHisji sLeuLysArgProProAl aPro LeuLeuAspProAsnAsnLeu~ASI1spGluAspVal.SerIleLeu~e tAspArgAsnLeu TyrLeuValThrLeuGluGlnzlaclnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProl leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsr14etAaValAspPheSerLeuGlyGluTrpbysThrGlnetolu GluThrLysAlaGlniAsplleLeuclyAlaValThrLeuLeuLeuGluGlyValMetAla ValArgLeuLeuLeuolyAlaLeuolnSerLeu~~ 0 0 lyThrG inLeuProProGincly ArgThrThrAlauisLysAspProAsnAlaI lePheLeuSerPheGlnuisLeuLeuArg Ar~pe~sa~u~se~ge rlny~ol~liProLeuPro ThrProValLeuLeuPro SEQ ID NO:512 pMON2 8509 AlaAsnCysSerlleMetle pl~el~si~e~sr~or~ar LeuLeuAspProAsnAsnLeuAsnspcluAspValSerIleLeuMetAspArgAsnLeu Ar~ur~ne~uerh~lr aa~s~ne~us~ae~ y I leGluAlale ur~ne~n~oy~ur~rlah~al~o Ar~sr~el~ey~al~pr~nluh~gl~se~rh TyrLeuValThrLeuoluGlli~uaolncluG~nGlnTyrValGluGlyGlyGlyGlySe ProGlyGluProSerGlyProx leSerThrlleAsnProSerP-roProSerLysGluSer HisLysSerProAsniMetAspPheSerLeuGyGurpLysThrG1etGlGlThr LxysAlaGlnAspIleLeulyAlaVal~hrLeuLeuLeuoluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValAr LeuLeuLeuGlyAlaLeulnSerLeuLeuolyThrGlnLeuProProGlnGlyArgThr ThrAlaliisLysAspProAsnAlalePheLeuSerPheolnHisLeuLeuArgolyLys Va lArgPheLeuMetLeuValolyolysermrLeuCysValArg~uPhe~y~y~fl MetAlaSerProAlaProProAlacysAspLeuArgva lLeuSerLysLeuLeuArgAsp 'Sri~le~se~ge~rl~sr~ua~sr~ur~rr ValLeuLeuProAlaVal SEQ ID NO:513 pMON2 8510 AlaAsnCysSerIleMetIleAspcluIleIleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnspG luAspValSerI leLeuMetAspArgAsnLeu Ar~ur~ne~uerh~lr aa~s~ne~us~ae~y Il~ul~ee~gs~u~~o~se~oe~ah~al~oe Arg~isProl lellelleLysAlaolyAspTrpclncluPhe~rgoluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGuGlyGlyGlGlyS ProGlyGluProSerGlyProlleSerThrIleAsnProSerProProSerLysGluSer HisLysSerProAsn}etGlyGluTrpLysThrGl1le tGluGluThrLysAlaGlnAsp IleLeuGlyAlaValThrLeuLeuLeuoluolyValMetAlaAlaArgGlyGlnLeuGly ProThrcysLeuSerSerLeuLeuolyolnLeuSerolyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuolyThrGlnLeuProProolnclyArgThrThrAlaHisLys AspProAsnAlalleh ue~elni~ue~glyy~lr~ee MetLeuValGlyGlySerThrLeuCysVa lArgGluPheolyolyAs,~etAlaSerPro Ala or~ay~s~ur~leue~se u~gs~ri~ lLeu Hi~rr~ue~ny~ol~l~sr~ur~rr~le~ur AlaValAspPheSerLeu SEQ ID NO:514 pMON2 8511 AlaAsnCysSerIleMetIleAspolulleIleHisHisLeuLysArgProProAlaPro Le~uspos~neus pl~pa~rleLeu~e tAspArgAsnLeu ArgLeuProAsnLeuoluSerPheValArgA1 aValLysAsnLeuGluAsn3~1aSerG1 y IleGluAlale ur~ne~n~oy~ur~rlah~al~o ArgHisProl lellel leLysAlaGlyAspTrpclnoiuPheArgoluLysLeuThrPhe TyrLeuValThrLeuGluGnlaGlnGluGlnGlnTyrVaGluGlyGlGlGlySe ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSe HisLysSerProAsniMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSer01 GinVal ge~ue~ylae~ne~ue~y~rl~ur~ol Gl~gh~rl~sy~pr~n~al~ee~rh~ni~ue ArgGlyLysValArgPheLeuMetLeu~~ lGlyGlySerThrLeuCysVa lArgGluPhe GlyGlyAsnetAlaSerProAaProProAaCysAspLergVa1LeuSerLLe Le~gs~ri~le~se~g~ue~ny~ol~li~oe ProThrProVaLeuLeuProAaVaAspPheSerLeuGyGuTrpLThGlmt GluGluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMet AlaAlaArgGlyGlnLeu SEQ ID NO:515 WO098/17810 4 PCTIUS97/20037 pMQN2 8512 AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsn~la 5 erQjy 11 eG luAl a 11ee~gs~ul~oy~ur ~rlah~ r e ArgHisProI leIleIleLysAlaGlyAspTrpGlnGluPheArgoluLjszeuThrPhe TyrLeuValThrLeuGluGln~laGlncluGlnGlnTyrValGluGlyGlyGlyGlySer ProG lyGl uProSerG lyPro I IeSerThr 11eAsnPro SerPro Pro SerLysG 1uSer AspProAsnAl.al lePheLeuSerPheG inHi sLeuLeuArgG lyLysValArgPheLeu Mete~ Gl~ye~re~salrgl~elGl~netlaSe r sValLeu HisSerArgLeuSerGlnCysProGluValHis ProLeuPro'rhrProValLeuLeuPro AlaValAspPheSerL~uGlyGluTrpLysThrG1netGluGluThrLysAlaGl1sp IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyG~nVa JArgLeuLeuLeuGly AlaLeuGlnSerLeuLeu SEQ ID NO:516 pMON28513 AlaAsnCysSerIleMetIleAspGluIleIleHisnisLeuLysArgProProAlaPro Le~us~os~neus pl~pa~rleLeu~etAspArgAsiLeu ArgLeuProAsnLeucluSerPheValArgAlaValLysAsnLeuGluAsnla~er~ly Il~ul~ee~gs~u~~o~se~oe~ah~al~oe Ar~sr~el~ey~al~p~pl~uh~gl~se~rh TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGiyGlyGlySer ProG lyG u Pro SerG lyPro 11e SerThr 11eAsnPro SerProPro SerLysGlu Ser Hi~se~os~tl~gh~r~ai~ss~os~al~ee Se~el~se~ur~yy~l~gh~ue~ua~yl~rh LeuCysVa lArgGluPheGlyGlyAsrnMetAaSerProAlaProProAlaCysAspLeu ArgValLeuSerLyszeuLeuArgAspSerHisValLeuHisSerArgLeurGflnys ProGluValHisr'roLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly GluTrpLysThrGlrnetGluGluThrLysAlaGl1spIleLeuGlyAaValThrLeu LeuLeuGluGlyValMe tAlaAl aArgGlyGlnLeuGlyProThrCysLeuserSerLeu LeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuclnSerLeubeu~ly ThrGlnLeuProProGln SEQ ID NO:517 pMON2 8514 AlaAsnCysSerIleMetIleAspGlulleIleHis~isLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsn~spGluAspValSerI leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsn~laSerGly I leGluAlal ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgoluLysLeuThrPhe TyrLeuValThrLeuGluclnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsrietAlaHi sLysAspProAsnAlal lePheLeuSerPheGinHis LeuLeuArgGlyLysValArgPheLeuMe tLeuValGlyclySerThrLeuCysValArg GluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspserHisValLeuHisSerArgLeuSerGlnCy 5 ProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyG luTrpLysThr GlnMetGluGluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeubeuGluGly ValMe tAl aAlaArgGlyclnLeuGlyProThroysLeu SerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnsereuLeuGlyThrGflnLeuPro ProGlnGJlyArgThrThr SEQ ID NO:518 pMON2 85 AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsn~2spGluAspVa1 Ser IleLeuMetAspArgAsnLeu Arbur~ne~ue~ea~g~aa~ss~ul~nl~rl Ilel al~ur~n~u~~oy~ur~e~ah~al~oe ArgHisProIleIleI leLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGln~laGlnGluGlnolnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnietAspProAsn~laIlePheLeuSerPheclnHisLeuLeurg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe~ly GlyAsriMetAl aSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu~eu Ar~pe~sa~ui~rr~u~rl~sr~ua~sr~ur ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlmetGlu GluThrLysAlaGlnAsplleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla Al~glGne~yr~ry~u~re~ue~y~~ue~yl Va~ge~ue~yl~ul~r~ue~yh~ne~or~nl ArgThrThrAlaHisLys SEQ ID NO:519 WO098/17810 PCTIUS97/20037 pMON2 8516 AlaAsnCysSerIleMetIleAspGueleHis~isLeULYSArgProProAlaPro LeuLeuAspProAsnAsnLeu~snAspGluAspValSerIleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsnLeuGJluAsnAlaSercly I el~al~ur~n~ul~oy~ur~e~ah~al~oe ArgHisProI lellel eLysAlaGlyAspTrpGlnGluPheArgaluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSermhrlleAsnProSerProProSerLysGluer HisLysSerProAsriMetAlal lePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuVa lGlyGlySerThrLeuCysValArgol uPheGlyGlyAsrl~et AlaSerProAl aProProAl aCysAspLeuArgValLeuSerLysLeuLeuArgAspSer .Hsa~ui~rr~ue~ny~ol~li~oe~oh~oa LeuLeuProAlaVa1AspPheSerLeuGlyGluTrpLysThrc1netGuGluThrLys AlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlargoly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAl aLeuclnSerLeuLeuGlyThrGlnbeuProProGlnGlyArgThrThr AlaHisLysAspProAsn SEQ ID NO:520 pMON2 8519 AlaAsnCys Ser leMetI leAspGluI lel leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsn~spGluAspVa1 Ser leLeuMe tAspArgAsnLeu ArgLeuProAsnLeucluSerPheValArgAlaValLysAsnLeuGluAsnla~erGly I leGluAlal ArgHisProIleIleIleLysAlaGlyAspTrpclnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetGluValHisProLeuProThrProValLeuLeuProAlaVaI AspPheSerLeuGlyGluTrpLysThrGl1etGluGluThrLysAlaGl1spIleLeu GlyAlaValThrLeuLeuLeuGluolyValMetAlaAlaArgG lyGlnLeuGJlyProThr CysLeuSerSerLeuLeuclyGlnLeuSerGlyGlnVa lArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlymhrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro As~al~ee~rh~ni~u~ur~yy~lr~ee~te Va~yl~rh~uy~lr~u~el~ne~ae~ol~or AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHj sValLeuHi sSerArg LeuSerGlnCysPro SEQ ID NO:521 pMON2852O AlaAsnCys Ser leMetI leAspGluI lel leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGuspValSerI leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluserPheValArgA1 aValLysAsnLeuGluAsnAlaSercly Il~ul~ee~gs~ul~o~se~oe~ah~al~oe ArgHisProl lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyG1yGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetLeuProThrProValLeuLeuProAl aValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAaGIrJ~spI leLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAl aArgGlyGlnLeuGlyProThrCysLeuserSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAl aLeuGlnSerLeuLeu Gl~rl~ur~ol~yr~r~rl~sy~pr~nl~eh LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheL~e tLeuVaj.GlyGlySer ThrLeuCysValArgoluPheGlyAsnit4etAlaSerProAlaProProAlaCysAspLeu ArgVa lLeuSerLysLeuLetiArgAspSerHi sValLeuHisSerArgLeuSerGlnCys ProGluVal~isPro SEQ ID NO:522 pMON28521 AlaAsnCys SerlleMetlleAspGlullelleHisHisLeuLysArgproProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSenl leLeuMetAspArgAsnLeu Ar~ur~ne~ue~ea~g~aa~ss~ul~nl~rl I leGluAlale ur~neGn~oy~ur~rlah~al~o ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnI~etValLeuLeuProAlaValAspPheSerLeuclyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGnLeuGyProThrCysLeuSerSerLeuLeuGlyQGfl Le~rl~na~ge~ue~y~ae~ne~ue~yhGne ProProGlnGlyArgThrThrAlaHisLysAspProAs 5 ~laI lePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeu~~ iGlyG lySerThrLeuCysVal Ar~uh~ysie~ae~ol~or~av~pe~ga~ue LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerG InCys ProGluValHis Wnagillyaln UJ~O~1'Q1 'US71 037LUtfA 200 ProLeuProThrPro SEQ ID NQ:523 pMON2 8522 AlaAsnCysSer IleMet I IeAspcluI leI leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsr1AspGluAspVa1 Ser leLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluSerPh-eValArgAl aValLysAsnLeuGluAsnAlaSerGly 11 eG luAl a 11eLeuArgAsnLeuG1 nProCys LeuPr oSerAl aThrAlaA a Pro Ser ArgHisProl leI lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyclyGlySer ProGlyGluProSerGlyProl IeSerThrI 1 eAsnProSerProPro SerLyscluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGl1etGlu GluThrLysAlaGlnAspIl1eLeuGlyAl aValThrLeuLeuLeuGluG lyValMetAla AlaArgGlyG lnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerG 1yGJln valArgLeuLeuLeuGlyAlaLeuclnSerLeuLeuGlyThrclnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlaI lePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheojy AsrlMetAlaSerProAlaProFroAlaCysAspLeuArgValLeuserLysLeuLeuArg As~ri~le~se~ge~r~ny~ol~li~oe~oh ProValLeuLeuPro SEQ ID NO:524 pMON2 8523 AlaAsnCysSerIlemetI leAspGJluI leI leHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVaj.SerIleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVa1ArgAlaValLysAsnLeuGuAsnaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer Arg~iisProlI leI leI leLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluclnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrI leAsnProSerProProgSerLysGluSer His Lys Ser ProAsnMetAsp PheS erLeuGlyG luTrpLysThrG lne tGl uG1 uThr LysAlaGlnAspI leLeuGlyAlaVa lThrLeuLeuLeuGluG lyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrG lnLeuProProGlnGlyArgThr ThrAlaHi sLysAspProAsnAla IlePheLeuserPheGlnH i sLeuLeuArgGlyLys ValArgPheLeuMetLeuValGyGySerThrLeuCysValArgGuPheclyAsiet AlaSerProAlaProProAlaCysAspLeu~rgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProcluValHisProLeuProThrProVal LeuLeuProAlaVa. SEQ ID NO:525 pMON2 8524 AlaAsnCysSerI leMetlleAspGlu leI leHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnLAspGluAspVal Ser IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlasercly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAl aThrAlaAlaProSer ArgHi sProl le leI 1eLysAlaclyAspTrpGlnGluPheArgGluLysLeumhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValcluGlyGlyGlyGlySer ProGlyGluProSerGlyProl 11eSerThrl 11eAsnProSerProProSerLysGluSer HisLys SerProAsnietGlyGluTrpbysmhrclnMe tGluGluThrLysAlaG lnAsp I leLeuGlyAl aValThrLeuLeuLeuGluGlyValMe tAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuclyGlnLeuSerGlyGlnValArgLeuLeuLeuGly Al aLeuGlnSerLeuLeuclyThrGlnLeuProProGlnGlyArgThrThrAlaHi SLys AspProAsnAl aI lePheLeuSerPheGlnHi sLeuLeuArgG lyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysvaArgGuPheyAsla~etAla5erProAla Pro ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspserHisValLeuHis Se~ge~r~~sr~ua~s~oe~oh~oa~ue~ol ValAspPheSerLeu SEQ ID NO:526 pMON2852S AlaAsnCysSerI leMet 11eAspGluI 1 eI 1eHisiji sLeuLysArg Pro ProAl aPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal Ser IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVa lArgAl aValLysAsnLeuGluAsnAlaSerGly Il~ul~ee~gs~ul~o~se~oe~ah~al~oe ArgHisProI leI lel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnolnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsrnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnVa1ArgLeuLeuLeuGlyAlaLeuGnserLeuLeualyrhrGlnLeuPrropoGfln Gl~gh~rl~sy~pr~n~al~ee~rhGni~ue ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrbeuCysValArgGluPhe GlyAsniMetAlaSerProAlaProProAl aCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProVa lLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnetGlu 'IUS97/20037 WO 98/17810 PCTfUS97/20037 GluThrLysAlaGliAspI 1eLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlxLeu SEQ ID NO:527 pMON28526 AlaAsnCysSer I leMe tI leAspGluI 1leI 1eHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerl eLeuMetAspArgAsriLeu ArgLeuProAsnLeuGluSerPheVa lArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlal ArgHisProIleIeleIlLysAaGyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValcluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetGlyThrclnLeuProProGlnGlyArgThrThrAlaHi sLys AspProAsnAlal lePheLeuSerPheGinHi sLeuLeuArgGlyLysValArgPheLeu Me~ua~yl~rh~uy~l~gl~el~ne~ae~ol ProProAlaCysAspLeuArgValLeuSerLysLeuLeurgAspSerHisValLeu~is SerArgLeuSerGlnCysProGluVa1HisProLeuProThrProValLeuLeuPro~la ValAspPheSerLeuGlyGluTrpLysThrGln4etGluGluThrLysAlaGlj~ 5 p~le LeuGlyAlaVa lThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro ThrCysLeuserSerLeuLeuGlyGlnLeuserGlyGlnValArgLeuLeuLeuGlyAla LeuGlnSerLeuLeu SEQ ID NO:528 pMON2 8527 AlaAsnCysserIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsriAsnLeuAsnJspGuspValSerI leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsn~laSerGly ArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerclyProI leSerThrl leAsnProSerProProSerLysGluSer Hi~se~os~tl~gh~rl~sy~pr~r~al~ee SerPheGlnHisLeuLeuArgclyLysValArgPheLeuetLeuValGlyGly~erThr LeuCysValArgGluPheGlyAsnMe tAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisserArgLeuSerGlflCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspl leLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAl aAl aArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuc lnSerLeuLeuGlyThr GinLeuProProGln SEQ ID NO:529 pMON28528 AlaAsnCysSerl leMetI leAspGluI lelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsnLeuGluAsnAlaSerGly ArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsn~laIlePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlyserThrLeuCysV 5 lArg GluPheGlyAsniMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLys LeuLeuArgAspSerHi sValLeuHis SerArgLeuSerGlnCys ProGluVaiHi sPro LeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln MetGluGluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyVal MetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerserLeuLeuGlyGlnLeuSer GlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGly~hrGllLeuProPro GlnGlyArgThrThr SEQ ID NO:530 pMON28529 AlaAsnCysSerlleMetl leAspGluI lel leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnsnLeuAsnAspGluspValSerI leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnlaSerGly Il~ul~ee~gs~ul~o~se~oe~ah~al~oe Ar~sr~el~ey~al~p~pl~uh~gl~se~rh TyrLeuValThrLeuGluGlnAlaGlnGluGlnGln~yrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAspProAsnAlal lePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuVa lGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeurg As~ri~le~se~ge~rGny~ol~li~oe~oh ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln4etGluGlu ThrLysAlaGInAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyVal~etAlaAla WO098/17810 20&PCTf1US97120 037 ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyG lnLeuSerGlyGlnVal3 ArgLeuLeuLeuGlyAlaLeuclngerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaflisLys SEQ ID NO:531 pMON28530 AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPh-eValArgAl aValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lellel leLysAlaGlyAspTrpclnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnclnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProl 1eSerThrl leAsnProSerProProSerLysGluger HisLysSerProAsniMetAlal lePheLeuSerPheGlnHisLeuLeuArgolyLysVal ArgPheLeumetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAa SerProAlaProProAlaCysAspLeuArgVa lLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluVal~i sProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGl1i4etGluGlumrLysAla GliAspI leLeuG3yAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuserGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProG lnGlyArgThrThrAla HisLysAspProAsn SEQ ID NO:532 pMON2 8533 AlaAsnCysSerl leMetI leAspGlullelleHisHisLeuLysArgProProAlaPro Le'uLeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgbeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysoluSer HisLysSerProAsniMetGluValHisProLeuProThrProValbeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGnMetuGuThrLysAaGlnJspI leLeu G lyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProolnGlyArgThrThrAlaHi sLysAsppro AsnAlal lePheLeuSerPheGlnHisLeuLeuArgclyLysVa.ArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsri4etAlaSer ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer{isVal LeuHisSerArgLeuSerGlnCysPro SEQ ID NO:533 pMON2 8534 AlaAsnCysSerlleMetlleAspGlullelleHisuisLeuLysArgProProAlaPro LeuLeuAspproAsnAsnLeuAsnAspGluAspVal SerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlamhrAlaAlaProSer ArgHisProIleIleI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsrlMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrG~rnMetGluGluThrLysAlaGlnispIleLeuGlyAlaval~hr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGJlnLeuSerGlyGlnValArgLeubeuLeuGlyAl aLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGyArgThrTh-rAlaHisLysAspProAsnAlaI lePhe LeuSerPheGinHi sLeuLeuArgGlyLysValArgPheLeuMe tLeuValGlyGlySer ThrLeuCysVa lArgGluPheGlyGlyAsnGlyGlyAsflMetAlaSer ProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysProGluValHisPro SEQ ID NO:534 pMON28535 AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspDValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsniAlaSerGly IleGluAlal ArgHisProllellelleLysAlaclyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysoluSer HisLysSerProAsrnMetValLeuLeuProAlaValAspPheSerLeuGlycluTrpLys ThrGlrlMetGluGluThrLysAlaGlnAspIl1eLeuG lyAlaValThrLeuLeuLeuGlu GlyVa lMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGnSerLeuLeuG.yThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlal lePheLeuSerPheGin W 981802o PCT1US97/20037 HisLeuLeuArgGlyLysValArgPheLeuMetLeuValclyG lySerThrLeuCysVal ArgGluPheGlyGlyAsnGlyGlyAsniMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHi sValLeuHis SerArgLeuSerGlnCys ProGluValI-isProLeuProThrPro SEQ ID NO:535 pMON28536 AlaAsnCysSerIleMetIleAspGluI leI leHisflisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal Ser leLeu4e AspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaVaJ.LysAsnLeuGluAsnAlaSeroly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProlle Ilel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGjluGlnAlaGlnGluGlnGlnTyrvalGluclyGlyGlyGlySer ProGlyGluProSerGlyPro I leSerThrI leAsnProSerProProSerLysGluSer HisLysserproAsniMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyvalmetAla Al aArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuclyGlnLeuSerGlyGln Va lArgLeuLeuLeuGlyAlaLeuGlrlSerLeuLeuGlyThrGlriLeuProProGlncly ArgThrThrAla~isLysAspProAsnAlal lePheLeuSerPheGlnHisLeuLeuArg GlybysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgcluPheGly GlyAsnGlyGlyAsniMetAlaSerProAlaProProAl aCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeu-i sSerArgLeuSerGlnCys ProGluVaiHis ProLeuProThrProValLeuLeuPro SEQ ID NO:536 pMON28537 AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeubeuAspProAsnAsnLeuAsnAspGluAspVal Ser leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAspPheSerLeuGlyGluTrpLysmrGlnMetGluGluThr LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyG lnLeuGlyProThrCysLeuSerSerLeuLeuclyGlnLeuSerGlyGlnVa lArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHi sLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyG lySerThrLeuCysValArgGluPheGlyGlyAsn GlyGlyAsniMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuserGlnCysProGluVal-isProLeu ProThrProValLeuLeuProAlaVal SEQ ID NO:537 pMON28 538 AlaAsnCysSerl leMetIleAspGluI leIleHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVai Ser IleLeuie tAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLyszeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnietGlyGluTrpLysThrGliMe tGluGluThrLysAlaGlnAsp I leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerbeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr~hrAlaHisLys AspProAsnAl allePheLeuSerPheGIniisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsbiet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValbeuHisSerArgLeuserGlnCysProGluValHisProzeuProThrProVal LeuLeuProAlaValAspPheSerLeu SEQ ID NO:538 pMON28539 AlaAsnCysSerleietlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal1Ser leLeubietAspArgAsnLeu ArgLeuProAsnLeucluSerPheVa lArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlaIl eLeuArgAsnLeuGlnProCysLeuProserAarhrAla~laProSer ArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyclyGlySer ProGlyGluProSerGlyProI leSerThrI leAsnProSerProProSerLysGluger H-isLys SerProAsietGlyProThrCysLeuSerSerLeuLeuGlyG lnLeuSerGly GlnVa lArgLeuLeuLeuGlyAlaLeuGlnserLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlal lePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgcluPhe WO 98/17810 PCT/US97/20037 204 GlyGlyAsnGlyGlyAsriMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSer~i sValLeuHis SerArgLeuSerGlnCysProGluVa 1 H-is ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuclyGluTrpLys Thr~lrnMetGluGluThrLysAlaGliAspI leLeuGlyAlaVa lThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeu SEQ ID NO:539 pMON2 8540 AlaAsnCysSerl leMetI leAspGluI leT leHisHisLeubysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspcluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVa1ArgAlaVa1LysAsnLeuGluAsn~laSerGly I leGluAl aI leLeuArgAsnLeuGlnProCysLeuProSerAl aThrAlaAlaProSer ArgHisProl lellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuVa lThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyG luProSerG lyPro 11eS erThr 11eAs nProSerPr oPro SerLys GluSer H is Lys SerProAsn~e tGlyThrGlnLeu Pro ProG lnGlyArgThrrhrAl ali s Lys AspProAsnAlaI lePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuVa lGlyGlySerThrLeuCysVa lArgGluPheGlyGlyAsnGlyGlyAsnLMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeurgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGl nMetGluG luThrLys AlaGinAspI 1 eLeuGlyAlaValThrLeuLeuLeuGluGlyVa lMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuG lyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeu SEQ ID NO:540 pMON2 8541 AlaAsnCysSerlleMet I leAspGluI le IleHisHisbeuLysArg Pro ProAl aPro LeuLeuAspProAsnAsnLeuAsnAspGluAspvaI Ser I leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaVaLysAsnLeuGluAsn~1aSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProserAl aThrAlaAlaProSer ArgHis Prol 1e eI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetGlyArgThrThrAlaHisLysAspProAsr1~laIlePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAla CysAspLeuArgValLeuSerLysLeuLeuArgAspserHisVal1LeuHis SerArgLeu SerGlnCysProGluValHi sProLeuProThrProValLeuLeuProAlaValAspPhe SerLeuGlyGluTrpLysThrGlnMetGluGlurhrLysAlaGlniAsplleLeuGlyAla ValThrLeuLeuLeuGluGlyValMe tAlaAlaArgGlyGlnLeuGlyProThrCysLeu SerSerLeuLeuGlyGlnLeuserGlyGlnValArgLeuLeuLeuGlyAlaLeuG inSer LeuLeuGlyThrGlnLeuProProGln SEQ ID NO:541 pMON28542 AlaAsnCysSerl leMet IleAspGluI lel leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal Sen JleLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluserPheValArgAlaVa lLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAjlaAlaProser ArgHisProl lel lel leLysAlaGlyAsp~rpGlncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThnl leAsnProSerProProSerLysGluSer HisLysSerProAsn~etAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlyserThrLeucysvalArg GluPheGlyGlyAsnGlyGlyAsnMe tAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerl-isValLeuHi sSerArgLeuSerGinCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlniMetGluGluThrLysAlaGlnAsplleLeuclyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlylnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAl aLeuG lnSerLeuLeuGlyThr GlnLeuProProGlnGlyArgThrThr SEQ ID NO:542 pMON2 8543 AlaAsnCysSelIeMetIleAspGluI lelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsrlAspGluAspVal Ser 1eLeu~etAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsnLeuGluAsnAlaSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuproSerAlaThrAlaAlaProSer ArgHisProllelleleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluclnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThnl leAsnProSerProProSerLysGluSer HisLysSerProAsrlMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeucysValArgGluPhecly GlyAsnGlyGlyAsniMetAlaSerProAlaProProAlaCysAspLeu~rgVa1LeuSer WO 98/17810 WO 9817810PCTIUS97/20037 LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerolncys ProGluValHis ProLeuProThrProVa lLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGly ValMe tAlaAlaArgGlyGlnLeuG lyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuolyAlaLeuGnSerLeuLeuGyThrjlnLeuPro ProGilnGlyArgThrmhrAlaHisLys SEQ ID NO:543 pMON2 8544 AlaAsnCysSerlleMetI leAspGluI leI leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsrlLeuAsnAspG luAspVal Ser leLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVa lArgAlaValLysAsnLeuGluAsnAl aSerGly I leGluAlal leLeuArgAsnLeuG~nProCysLeuProSerAlaThrAl~al ProSer ArgHi sProlI lel 1el 11eLysAl aGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluclnolnTyrVa1GluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer Hi sLys SerProAsnMetAlaI 1 ePheLeuSerPheG lnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuVallyGlySerThrLeuCysVa lArgGluPheGlyGlyAsriGly GlyAsnMe tAlaSerProAlaProProAl aCysAspLeuArgValLeuSerLysLeuLeu Ar~pe~sa~ui~rr~u~rl~sr~ua~sr~ur ThrProValLeuLeuProAlaVa lAspPheSerLeuGlyGluTrpLysmrGlriMetGlu GiuThrLysAlaGlnAspI leLeuGlyAlaValThrbeuLeuLeuGluGlyValMetAla AlaArgclyGlnLeuGlyProThrCysLeuSerserLeuLeuG lyGlnLeuSerGlyGIn ValArgLeuLeuLeuGlyAl aLeuGlnSerLeuLeuGlyThrG inLeuProProGlnGly ArgThrmhrAlaHisLysAspProAsn SEQ ID NO:544 pMON2 8545 AlaAsnCysSerlleMetl leAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsniAspGluAspValSerIleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVaArgAaVaLysAsnLeuGuAsn~JlaSerGly IleGluAlaIleLeuArgAsnLeuGlnproCysLeuProSerAlaThrAlaAlaProSer ArgHi sProI leI leI 1leLysAl aGlyAspTrpGlnoluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyclySer ProGlyGluProSerGlyProxleSerThrlleAsnProSerProProSerLysGluSer 1-isLys SerProAsniMetAspProAsnAlal lePheLeuserPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValG lyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeu~rgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlijet~lu GluThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeualyGnLeuSerGlyGll ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLys SEQ ID NO:545 pMON32132 SerProAl aProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAsps erHi s Va~ui~rr~ue~ny~o~ua~sr~ur~rr~le LeuProAlaVa1AspPheSerLeuGlyGluTrpLysThrGl1ie tGluGluThrLysAla GlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValmetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerG lyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheclnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlyserThrLeuCysValArg SEQ ID NO: 546 PMON3 2133 SerProAlaProProAlaCysAspLeuArgVa1LeuserLysLeuLeuArgAsp~er~is Va1LeuHisSerArgLeuSerGlnCysProGluVal~js ProLeuProThrProValLeu LeuProAlaVa 1AspPheSerLeuGlyGluTrpLysThrGlni~e tGluGluThrLysAla GlnAspI leLeuGlyAlaValThrLeuLeuLeuGluclyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuserserLeuLeuGlyGlnLeuSerGlyGnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuclyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAl allePheLeuSerPheGlnH isLeuLeuArgGlyLysValArgPheLeumetLeu ValGlyGlySerThrLeuCysValArg SEQ ID NO:547 PMON32 134 SerProAlaProProAlaCysAspLeuArgVa1LeuSerLysLeuLeuArgAspSer~j s Va~ui~rr~ue~nv~o~ua~sr~ur~rr~le LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGl1etGluGuThrLysAla WO 08/17810 pr YUS97/20037 2oG~ GlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyVal~~etAlaAlargGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerG iyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProG lnGlyArgThrThrAla HisLysAspProAsnAlal lePheLeuSerPheGlnHi sLeuLeuArgGlyLysValArg PheLeuMetLeuValGiyGlySerThrLeuCysValArg SEQ ID NO:548 pMON3O237 .pep AlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLysI le ArgGluLeuSerAspTyrLeuLeuGnAspTyrProVaThrValAaSerAslLeuG~f AspGluGluLeuCysGiyAlaLeuTrpArgLeuValLeuAlaG inArgTrpMetGluArg LeuLysThrValAlaGiySerLysMetGinGlyLeuLeuGluArgValAsnThrclul le His PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnI ]eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpI le ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO:549 pMON3O238 .pep AlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProva iThrVa iAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeucluArgValAsnThrcluI le His PheVaiThrLysCysAlaPheGlnProProPro serCysLeuArgPheValGlnThr AsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:550 pMON3O239 .pep AlaThrGlrlAspCysSerPheGlnHisSerProI leSerSerAspPheAlaValLys Ile ArgGluLeuSerAspTyrLeuLeuGn~spTyrProVa lThrValAlaSerAsnLeuGln AspGluGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG inArgTrpMe tGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI le HisPheValThrLysCysAlaPheGinGluThrSerGluGlnLeuValAlaLeuLysPro Trp I eThrArgGInAsnPheSerArgCysLeuGluLeuolnCysGlnProAspSerser ThrLeu SEQ ID NO:551 pMON32329.pep GlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLysTile ArgGiuLeuSerAspTyrLeuLeuGinAspTyrProVaiThrVa iAiaSerAsnLeuGin AspGluGiuLeuCysGiyGiyLeuTrpArgLeuvaiLeuAlacin~rgTrpMetGiuArg LeuLysmrVaAaGySerLysMetiniyLeuLeuGluArgVaiAsnThrGiule HisPheVaiThrbysCysAiaPheGinProProProSerCysLeuArgPheVaiGinThr AsnI ieSerArgLeuLeuGinGiuThrSerGiuGinLeuValAiaLeuLysProTrpIie ThrArgGilAsnPheSerArgCysLeuGiuLeucinCysGinpro SEQ ID N'O:552 pMON3233O .pep GiyThrGinAspCysSerPheGinHisSerProlieSerSerAspPheAiaVaiLysle ArgG iuLeuSerAspTyrLeuLeuGinAspTyrProVaiThrVaiAlaSerAsnLeuGin AspGluGiuLeuCysGlyGlyLeuTrpArgLeuVaiLeu~iaGinArgTrpMetGinArg LeuLysThrVaJ.AiaGlyserLysMetGinGlyLeuLeuGiuArgVaiAsnThrGiux le His PheValThrLysCysAiaPheGinProProProSerCys]LeurgPheVaGlnThr AsnhIeSerArgLeuLeuGinGluThrSerGiuGinLeuValAiaLeuLysProTrple ThrArgcinAsnPheSerArgCysLeuGiuLeuGInCysGinProAspSerSerThrLeu SEQ ID NO:553 pMON3234i .pep AlaThrGliAspCysSerPhecinHisSerProleSerSerAspPheAiaValLyslle ArgGluLeuSerAspTyrLeuLeuGilAspTyrProVa iThrVaiAiaSerAsnLeuGin AspGluGluLeuCysGlyGiyLeuTrpArgLeuVaiLeuAa~lrJ~rgTrp~et~luArg LeuLysThrVaiAiaGlySerLysMetGinGiyLeuLeuciurgVaiAsnThrGiuI ie His PheVa iThrLysCysAiaPheGinProProProserCysLeuArgPheVaiGinThr .AsnI ieSerArgLeuLeuGinGluThrserGjluGinLeuValAlaLeuLysProTrplie ThrArgG inAsnPheSerArgCysLeuGluLeuGinCyscinPro SEQ ID NO:554 pMON32342 .pep WO 98/17810 PCTIUS97/20037 AlaThrGlnAspCysSerPheGlnHis SerProl 11eS erserASpPheAlaVal Lys Ile ArgGluLeuSerAspTyrLeuLeuGinAspTyrProValThrVa lAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMe tGlnGlyLeuLeuGluArgVa lAsnThrGluI 1e His PheVa lThrLysCysAl aPheG lnPro Pro Pro SerCys LeuArgPheValG lnThr AsnI leSerArgLeuLeuGlnGluThrSeroluGlnLeuValAlaLeuLysProTrplle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:555 pMON3232O .pep AlaAspGluGluLeuCysGlyciyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGlu ArgLeuLysThrValA.aGlySerLysMetGlnolyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProserCysLeuArgPheValGln ThrAsnl 1 eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuolnCysG lnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnolyThrcinAspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLysl leArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsriLeuGln SEQ ID NO:556 pMON32321 .pep AlaA 'spGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaliArgTrpMetGlu ArgLeuLysThrValAlaGlyserLysMetGlnGlyLeuLeuG luArgValAsnThrGlu I leHi sPheVa lThrLysCysAlaPheGlnProProProserCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGJluThrserGluolnLeuValAlaLeuLysProTrp Ii eThrArgGlnAsnPheSerArgCysLeuGluLeuGnCysGlnProAspserSerThr LeuSerGlyclyAsnGlySerGlyGlyAsnGlyThrGnAspCys Ser PheGlnHi sSer Prol eSerSerAspPheAlaValLysIleArgoluLeuSerAspTyrLeuLeuGlnsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO:557 pMON32322.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclnArgTrpMetclu ArgLeuLysThrVa lAlaGlySerLysMe tGlnGlyLeuLeuG luArgVaJ.AsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnI leSerArgLeuLeuGlnGluThrSeroluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuoluLeuGlnCysG lnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProlIleSerSerAsp PheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGln SEQ ID NO:558 pMON32323 .pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI 1 eHis PheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnmhrAsnhleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl eThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysolnProAspSerSerThrLeuSerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnclyThrGlnAspCysSerPheGlnHisSerPro I leSerSerAspPheAlaValLysl leArgGluLeuserAspTyrLeuLeuclnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysG lyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 559 pMON32324 .pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrclul leHis PheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyojyAsnGly SerGlyGlyAsnGlyThrGlnAspCysSerPheclnHisSerProlleSerSerAspPhe AlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyolyLeuTrpArgLeuValLeuAlaGl1rg TrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:560 pMON32325 .pep AlaSerLysMetGlnGlyLeuLeucluArgValAsnThrGlulleHisPheValThrLys Cy~ah~nr~r~oe se~g~ea~nh~nleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpi leThrArgGlnAsnPhe WO098/17810 2fPCTIUS97/20037 SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly ThrGlnAspCysSerPheGlnHi s SerProlIleSerSerAspPheAlaValLys I leArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuc1nsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeu LysThrValAlaGly SEQ ID NO:561 pMON32326 .pep AlaProProSerCysLeuArgPheValolnThrAsnI 1eSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGlnAsnPh-eSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyclyAsn GlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAsp PheAlaValLys IieArgcluLeuSerAspTyrLeuLeuGlnAspTyrProValhrVa 1 AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeurrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnolyLeuLeuGluArg ValAsnThrGlulleHiSPheValThrLysCysAlaPheGlnpro SEQ ID NO: 562 pMON32327.pep Ala Pro ProS erCysLeuArgPheVa 1GlnThrAsnl 1 eSerArgLeuLeuG 1nG luThr SerGluGlnLeuValAlaLeuLysProTrpl leThrArgGJ~nAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn GlyThrGlnAspCysSerPheGln-isSerProlleSerSerAspPheAlaValLyslle ArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuvalLeuAlaG lnArgTrpMetGluArg LeuLysThrValAlaGlyserLysMetGlnolyLeuLeuGauArgValAsnThrGlul le HisPheValmhrLysCysAlaPheGlnPro SEQ ID NO:563 pMON32328 .pep AlaProProSerCysLeuArgPheValolnThrAsnl leSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProrrpl leThrArgGlniAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAl aGlriArgTrpMe tGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluleHisPheValThrLys CysAlaPheGInPro SEQ ID NO:564 pMON32348 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu I leHisPhevalThrLysCysAlaPheGlnProProProSerCysLeuArgPheVaGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeulnCysolnProAspSerSerThr LeuSerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerclyThrG~n~spCys SerPheGlnHisSerPro IleSerSerAspPheAlaValLys IlJeArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProvalThrValAlaSerAsnLeuGln SEQ ID NO: 565 pMON3235O .pep AlaAspGluGluLeuCysGlyolyLeuTrpArgLeuVaLeuAaG~nrgTrpMetGlu ArgLeuLysThrValAl aGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysteuArgPheValoln ThrAsnl leSerArgLeuLeuGlnGluThrSercluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThr LeuSerGlyGlySerGlySerGyGySerGyThrG1spCysSerPheGlnxisSer ProlleSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlagerAsnLeuGln SEQ ID NO:566 FLT3N -pep MetAlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlrIAspTyrProValThrVaAaSrAsflLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlpJ~rgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnclyLeuLeuGlurgVaAslThrGlu IleHisPheVa1ThrLysCysAlaPheG~nProProProSerCysLeurgPheValcln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp WO 98/17810 WO 9817810PCTIUS97/20037 I leTh-rArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlInProAspSerSerThr LeuGlyGlyGlySer SEQ ID NO:567 FLT3C.pep GlySerGlyGlyThrGlnAspCysSerPheclnHisSerProl leSerSerAspPheAla ValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa 1LeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluI leHisPheValThrLysCysAlaPheclriProProProSerCysLeuArgPhe ValGinThrAsnI 1eSerArgLeuLeuGlnGluThtSerGluGinLeuValAlaLeuLys ProTrp IleThrArgGlnAsnPheSerArgCysLeucluLeuc lnCysGlnProAspSer SerThrLeu SEQ ID NO:568 FLT7N pep MetAlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgcluLeuSerAspTyrLeuLeuGlnAsp'ryrProValThrValAlaSerAsnLeu G inAspO luGluLeuCysG lyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLys~hrValAlaclySerLysMe tGlnGlyLeuLeuG luArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuclnCysG lnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySer SEQ ID NO:569 FLT4C.pep GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPhe AlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluG luLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrVa 1AlaGJlySerLysMetGlnG lyLeuLeuGluArgVal AsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGinThrAsnI leSerArgLeuLeuGlncluThrSerGl1uGlnLeuValAl aLeu LysProTrpl 1eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeu SEQ ID NO:570 FLT11N.pep MetAlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMe tGlu ArgLeuLysThrValAlaGlySerLysMetGlnclyLeuLeuGluArgValAsnThrGlu I leHi sPheValThrLysCysAl aPheGJlnProProProSerCysLeuArgPheVa 1Gl ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeuLys ProTrp IleThrArgolnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyclySer SEQ ID NO:571 FLT1OC .pep GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHis er Pro IleSerSerAspPheAlaValLysl leArgGluLeugerAspTyrLeuLeuGlnAsp TyrProVaJ.ThrValAlaSerAsnLeuGlnAspcluGluLeuCysGlyGlybeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGlySerLysMe tGln GlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrger GluGlnLeuValAlaLeuLysProTrpI leThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:572 pMON32365.pep AlaAspGluGluLeuCysGlyGlyLeuTrp~rgLeuValLeuAl1aGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuG luArgValAsnThrGlu I leHis PheVa lThrLysCysAl aPheG lnPro Pro ProSerCys LeuArgPheVa lGln ThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThr LeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnH i sSerProl leSerSer AspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGln SEQ ID NO:573 WO 98/17810 PCT/US97/20037 PMON32366 .pep AlaAspGluGluLeucysGiyGlyLeuTrpArgLeuvaLeuAlaGriArgTrpMetGlu ArgLeuLysThrValAlaGiySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu 11 eHis PheVa lThrLysCysAl aPheoinPro Pro Pro SerCysLeuArgPheVa.Gln ThrAsnl leSerArgLeuLeuGlnGluThrSerGiuGJlnLeuValAlaLeuLysProTrp I ieThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlInProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGinHi sSerPro 11 eSer SerAspPheAlaVaiLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO:574 pMON32367 .pep AlaAspGluGluLeuCysGlyG lyLeuTrpArgLeuValLeuAl aGlrlArgTrpMetGlu ArgLeuLysThrValAlaG lySerLys~etGlnGiyLeuLeuGluArgValAsnThrGiu IJleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp -IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHlisSer Prol leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 575 pMON3236B .pep AlaAspG luGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetG lnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnI ieSerArgLeubeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGInAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlrnAspCysSerPhe GInHisSerProlleSerSerAspPheAlaValLysl eArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:576 pMON32369 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu I leHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlrAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlyserGlyGlyGlyThrGliAspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLysl leArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 577 pMON32370.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclnArgTrpme tGlu ArgLeuLysThrVa lAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu I leHisPheValThrbysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys Ii eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO:578 pMON3 0247 .pep AlaAsnCysSerlleMetl leAspGluI lelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal SerlleLeuMe LAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuoluAsnAl aSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnproSerProProSerhysGluSer HisLy sSerProAsniMetAlaThrGlnAspCysSerPheGlnHisSerProl leSerSer AspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAs-nLeuGlnAspGluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAl a GlnArgTrpMetGluArgLeuLysThrValAlaGlyserLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluI leHisPhevalThrLysCysAlaPheGlnProProProSerCys wo 98/17810 WO 9817810PCTIUS97/20037 LeuArgPheValGlnThrAsnl leSerArgLeuLeuG inGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl eThrArgGlnAsnPhe~erArgCysLeuGluLeuGlncysGln Pro SEQ ID NO:579 pMON30248 .pep AlaAsnCysSerleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsr]AspGluAspValSerlleLeuMe LAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaVa1LysAsnLeuGluAsJ~1aSeroly I leGluAlalleLeuArgAsnLeuolnProCysLeuProserAlaTh-rAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpclnGluPheArgGluLysLeumhrPhe TyrLeu\TalThrLeuGluGlnAlaGlnoluGlnGlnTyrVaJ.GluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnfetAlaThrGlniAspCysSerPheGlnHisSerProlleSerSer AspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlriAspTyrProValmhr ValAlaSerAsnLeuclnAspoluGluLeuCysolyAlaLeuTrpArgLeuValLeuAla GlnArgTrpMe tGluArgLeuLysThrValAlaclySerLysMe tGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnmhrAsnhleSerArgLeuLeuolnluThrSerGluGlnLeuVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeu SEQ ID NO:580 pMON32332.pep AlaAsnCysSerl leMetI leAspGluI lel leHisflisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsniAspGluAspVal Ser leLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsnLeuGluAsnAlaSerGly IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHisProl lel lelleLysAlaclyAspTrpolnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrVaiG luGlyGlyGlyGlySer ProGlycluProSerGlyProlleSerThrlleAsnProSerProProSerLyscluSer Hi SLysSerProAsnLMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetG luArgLeuLysThrValAlaGlyserLys~etGlnGlyLeuLeu GluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProser CysLeuArgPheVa iGinThrAsrIl eSerArgLeuLeuGlnG luThrSerGluGlnLeu ValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuolnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerlyGlyAsnGyThrGn~sp CysSerPheGln~isSerProlleSerSerAspPheAlaValLyslleArgoluLeuSer AspTyrLeuLeuGlnAspTyrProValThrva lAlaSerAsnLeuGln SEQ ID NO: 581 pMON32333.pep AlaAsnCysSerI leMetIleAspGluIlelle-isHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal1Ser leLeuMetAspArgAsnLeu ArgLeuProAsnLeuoluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IlecluAlalleLeuArgAsnLeuclnProCysLeuProSerAlaThrAla~laProSer ArgHisProllellelleLysAlaGlyAspprpclnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAl aGlnGluGlnGlnTyrValGluGlyGlyGlyG lySer ProGlyGluProSer~lyProl leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMe tAlaAspGluGluLeuCysclyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluI leHisPhevalThrLysCysAlaPheGlnProProProSer CysLeuArgPhevalGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGlu~lnLeu ValAlaLeuLys ProTrpl leThrArgolrlAsnPheserArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerolyGlyAsnGly'rhrGl1sp CysSerPheG~nHisSerProIleserSerAspPheAaVaLysIe~rgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 582 pMON32334.pep AlaAsnCysSerIleMetIleAspGluIleI leHisflisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal~erl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluserPheValArgAl aValLysAsnLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIleIleIleLysAlaGlyAspTrpGln~luPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaSerLysMetGlnclyLeuLeuG luArgVa lAsnThrGlu I leHisPheValThrLyscysAlaPheGlnProProProSercysLeuArgPheValGln WO 98/17810 PCT[US97/20037 ThrAsnl eSerArgLeuLeuGlnGluThrSerGluGIriLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeulnCysG~nProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisgerPro IleSerSerAsp PheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlacln ArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:583 pMON32335 .pep AlaAsnCysSerIJleMetIleAspGluIleI ieHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IieLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsn~1aSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpolnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnA.aGlnGluGlnGlnTyrValGluGlyG.yGlyGlySer ProGlyGluProSerGlyProI ieSerThrl eAsnProSerProProSerLysG~uSer Hi SLysSerProAsnMetAlaSerLysMetG inGlyLeuLeuG luArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProserCysLeuArgPheValGln ThrAsnI ieSerArgLeuLeuGlncluThrSerGluGinLeuValAlaLeuLysProTrp I ieThrArgGlnAsnPheserArgCysLeuGluLeuGlnCysGlnProAspserserThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGly~hrGiAspCysSerPheGln{isSer Prol leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlrnAsp TyrProVa lThrValAl aSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaolnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 584 pMON32336 .pep AlaAsnCysSerl leMetI leAspGluI lel leHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheVal1rgAlaVal]LysAsnbeuGluAsnAlaSerGly I ieGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuphrPhe TyrLeuValThrLeuGluGlniAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGiyProI leSerThrlleAsnProSerProProSerLysGluSer HisLys SerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArg~rrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuI ValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysbeuG luLeuGlnCys GlnProAspSerSerThrLeuSerolyGlyAsnGlySerGlyGlyAsnGlySerGlyoly AsnGlyThrGlnAspCysSerPheGlnHisSerProl eSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaserAsnLeu Gin SEQ ID NO:585 pMON3 2337 .pep AlaAsnCysSerl leMetIleAspGluIleI leHisHi sLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsniAspGluAspValSerl eLeuMetAspArgAsnLeu ArgLeuProAsnLeuG luSerPheVa lArgAl aValLysAsnLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGnProCysLeuProserAlaphrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGInAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluger HisLysSerProAsnMetAlaProProserCysLeuArgPheValclnThrAsnl leSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrplleThrArgGln AsnPheSerArgCysLeuGluLeuGnCysGlnProAspSerSerThrLeuserGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProl eSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuclnAspTyrProValThrValAlaSerAsnLeu GlniAspGluGluLeuCysclyGlyLeuTrpArgLeuVa lLeuAl aGlrnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlurgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:586 pMON32338 .pep AlaAsnCysSerleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsrnAspGluAspVal Serl eLeuMe tAspArgAsiLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGusnlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lel lel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuVaiThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer WO 98/1 7810 21A3PCT/US97/20037 ProGlyGluProSerGlyPro I leSerThrl leAsnProSerPro Pro SerLysGluS er Hi sLysSerProAsriMetAlaProProSerCysLeuArgPheValGlnThrAsnI leSer ArgLeuLeuGlnGluThrSerGluG lnLeuValAlabeuLys ProTrp IleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnclyThrclnAspCys SerPheolnHisSer ProI 1eSerger AspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuG lrAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla G lnArgTrpMetGluArgLeuLysThrvalAl aGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:587 pMON32339 .pep AlaAsnCysSerIleMetIleAspGluIleIle-isHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspVal Ser leLeuMe tAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsrieuGluAsnAlaSerGly IleGluAlallee gs~ul~oy~u~oe~ah~al~oe ArgHi sPro IleI IeIleLysAlaGlyAspTrpGlnG luPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThnl leAsnProSerProProSerLysGluSer His Lys Ser ProAs nMe tAla ProProSerCysLeuArgPheVa lGl nThrAsnl 11eSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp IleThrArgGln AsnPheSerArgCysLeucluLeuGlnCysb.lnProAspSerSerThrLeuSerclyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHis SerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuVa lLeuAlaGlrArgTrpMetGluArgLeuLysThrVa tAlaGlySerLysMe t GlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGln Pro SEQ ID NO:588 pMON32364 .pep AlaAsnCysSerlleMetlleAspGlullellelisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMe tAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHisLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlamhrAlaAlaProSer ArgHisProlJlellelleLysAlaGlyAspTrpolnoluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThnl leAsnProSerProProSerLysGluSer Hi sLys SerProAsnile tAlaThrGl nAspCysSer PheG lnH is Ser Pro I leSerSer AspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAl aSerAsnLeuGlnAspcluGluLeuCysGlyGlyLeurrpArgLeuVa lLeuAl a GlnArgTrpMetGluArgLeuLysThrValAlaclySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGjinCysGln Pro SEQ ID NO:589 pMON3 2377 .pep AlaAsnCysSerlleMetl leAspGluI tel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProllellelleLysAlaclyAspTrpGlnGluPheArgGtuLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrVatGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer H-isLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProleerSer AspPheAlaValLys IieArgcluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyctyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlyserLysMe tGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPhevalThrLysCysAlaPheGlnProProProserCys LeuArgPheValclnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeu SEQ ID NQ:590 pMON32352 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aVa lLysHisLeuGluAsnAlaSerGly WO 98/1 7810 PCT[US97/20037 I lecluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgI-i sPro le leleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyPro I leSerThrl 1 eAsnProSerProProSerLysGluSer His Lys S er ProAsnMe tAl aAspGluG luLeuCysGl yGlyLeuTrpArgLeuValLeu AlaGlriArgTrpMetGluArgLeuLysThrValAlaclySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluI 1eHis PheVal~hrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAl aLeuLys ProTrpl eThrArgGlrAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 591 pMON32353 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisI-isLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeu~e tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsniAlaSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProl lellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerbysGluSer HisLysserproAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysme tGlnG lyLeuLeu GluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyolyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys Ii eArgGluLeuSerAspTyrLeuLeuclnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO:592 pMON32354 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMe tAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProlIlellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeu~luGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuG luArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis Ser~roI leSerSerAsp PheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlniAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysclyclyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlacly SEQ ID NO:593 pM0N32355 .pep AlaAsnCysgerl leMetI leAspGluIleI leHisHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeu~luAsnAlaSer~ly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlniAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLys SerProAsnMetAlaSerLysMetGlnGlyLeubeuG iuArgvalAsnThrGlu I leHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhevalGln ThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnlAspCysSerPheGlnHjsSer Prol leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 594 pMON32356 .pep WO 98/17810 PCTIUS97/20037 AlaAsnCysSerl leMet IleAspGluI leI leHisHisLeuLySArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHis LeuGluAsnAlaSerGly I leGluAlaI 1 eLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHi sPro 11e leI eLysAlaGlyAspTrpGlnGluPheArgluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 11eSerThrlI leAsnProSerProProSerLysGluser Hi sLysSerProAsnMe tAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu 11 eHi sPheVa lThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheVal1G~n ThrAsnI 1 eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl aLeuLys ProTrp Ii eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLys I leArgGJluLeuSerAsp TyrbeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla Gly SEQ ID NO:595 pMON32357 .pep AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHi sLeuGluAsnAl aSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnG *luPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 1 eSerThrI leAsnProSer ProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnhleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrplleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysclnProAspSerSerThrLeuSerGlyGly AsnG lyThrGlniAspCysSerPheGlnHi sSerPro IleSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGliArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IieHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:596 pMON32358 .pep AlaAsnCysSerI leMe t IleAspGlu le 11eHi sxisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl 1 eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHi sLeuGluAsnAlagerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer Argi-isProl lellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAl aGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 1leSerThrl 11eAsnProSer ProProSertysGluSer His Lys SerProAsnMe tAl aPro Pro SerCysLeuArgPhevalG lnmrAsnI leSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGln AsnPheSerArgCysLeuGluLeucJlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnclyThrGlniAspCys SerPheGinHisSerProl 1 eSerSer AspPheAlaVa iLys IieArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnmhrGlulleHisPheValThrLysCysAlaPheGlnPro SEQ ID IqO:597 pMON32359 .pep AlaAsnCysSerI leMetl leAspGlulle leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMe tAspI 1 eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly 11 eGIluAl aI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAl aProSer ArgHis Pro le le leLysAl aGlyAspTrpGlnGluPheArgGluLysLeuThrphe TyrLeuVa lThrLeuGluGlnAl aGlnGluGlnGlnTyrVa 1GluGlyG lyGlyGlySer ProGlyG luProSerGlyProlIleSerThrl 11eAsnProSer ProProSerLysGluSer Hi sLys SerProAsnMe tAl aPro Pro SerCysLeuArgPheVa 1GlnThrAsn IleSer ArgLeuLeuGlnGluThrgerGluGlnLeuValAl aLeuLys ProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerG lyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlniAspCysSerPheGlnHis SerProI leSerSerAspPheAlaValLys IlIeArgGluLeuSerAspTyrLeuLeuGln AspTyrProVa1ThrValAlaS'erAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgVa lAsnThrGluI leHis PheVa lThrLysCysAlaPheGln Pro SEQ ID NO:598 WO 98/17810 WO 98/78 10PCTIUS97/20037 pMON3236O .pep AlaAsnCys SerleMe tIleAspGluleleHisHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnlaSerGly I leGluAl aI 1eLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHi sPro 11e leI 1eLysAlaGlyAsprrpGlnGluPheArgGluLysLeurhrPhe TyrLeuValThrLeuGluGlnAlaGlnGlucinGlnTyrValGiuGlyGlyGlyGlySer ProGlyGluProSerolyProl leSerThrl eAsnProSerProProSerLysGluSer His Lys Ser ProAsnMe tAl aAspGluGiuLeuCysG lyGlyLeuTrpArgLeuVa lLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaclySerLysMetGlnGlyLeuLeu GluArgValAsnThrGlu~leHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlySerGlySerGlyG lySerGlyThrGlnAsp Cys SerPheGlnHi sSerPro IleSerSerAspPheAlaValLys I leArgGiuLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:599 pMON32362 .pep AlaAsnCysSerlleMetleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHisLeuGluAsnAlaSerG ly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlamrAlaAlaProser ArgHis Pro Ile le IleLysAlaGlyAspTrpGlnG luPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlriAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProG 1yG luProSerGlyProI 11eSerThr 11eAsn Pro Ser ProPro SerLysG luSer Hi sLysSerProAsrnMetAlaAspGluGluLeucysGlyGlyLeu'rrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMe tGlnGlyLeuLeu GluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnhleserArgLeuLeuGlnGluThrSerGluGlnLeu Va lAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlrlProAspSerSerThrLeuSerGlyGlySerGySerGlyGlySerGlySerclycly SerGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys I leArgGJluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaserAsnLeu Gin SEQ ID NO:600 pMON32392 -pep AlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslle ArgGluLeuSerAspTyrLeuLeuGlnAsp'yrProValrhrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn'rhrclul le His PheValThrLysCysAlaPheGlnProProProserCysLeuArgPhevalGlnThr AsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProTyrValGjluGlycly GlyGlySerProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsniMetAlaAsnCysSerl leMetIleAspGluI lel le HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAsp MetAsplleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlyI leGluAlal leLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProl lellel leLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuG luGlnAlaGlnGluGln Gin SEQ ID NO:601 pMON32393 .pep AlaThrGlnAspCysSerPheGnHisSerProlleSerSerAspPheAlaValLyslle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVa lThrVa lAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI le His PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThrLeu TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrI leAsn ProSerProProSerLysGluSerHisLysSerProAsietAlasnCysSerI leMet I leAspGluI lel leHisHisLeuLysArgProProAsnProLeuLeuAspProAsnsn LeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeu AlaPheValArgAlaValLysHisLeuGluAsniAlaSerGayIleGluAlaIleLeuArg WO 98/17810 PCT[US97/20037 AsnLeuGlnProCysLeuProSerA1 aThrAlaAlaProSerArgHi s ProI le Ilel 11e LysAlaGlyAspTrpGlncluPheArgcluLysLeuThrPheTyrLeuValThrLeuGlu GlnAlaGlnGluGlnGln SEQ ID NO:602 pMON32396 .pep AlaAsnCysSerI leMetl leAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAl aProser Prol-is ProI le IleI leLysAlaGlyAspTrpGlnGluPheArgGl uLysLeuThrPhe TyrLeuValThrLeuGluGlnAiaclnGluGlnGlnsryrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 11eSerThrl 11eAsnProSerProProSerLysG luSer I-isLys SerProAsn24etAlaThrGlnAspCysSerPheGlnHiserProI 1eSerSer AspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnclyLeuLeuGlu ArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnluThrSerluGln LeuValAlaLeuLysProTrpI 1 eThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeu SEQ ID NO:603 pMON32371 .pep Al aAsnCys Serl leMetlI leAspGluI 1 eI 1eHisHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnbeuAsnSerGluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHi sLeuGluAsnAlaSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer Arg~is Pro Ile le leLysAlaGlyAspTrpGlnGluPheArgGl uLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProG lyGluProSerGlyPro IleSerThrl eAsnProSerProProSer~ysGluSer Hi sLys SerProAsnLMetAlaAspGluGluLeuCysG lyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrVa lAlaGlySerLysMe tGlnGlyLeuLeu GluArgValAsnThrGlu leHis PheValThrLysCysAlaPhelnProPro ProSer CysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnc luThrSerGluGlnLeu Va lAlaLeuLysProTrplleThrArgclnAsnPheSerArgCysLeuGluLeuGlncys GlnProAspSerSerThrLeUGlyGlyGlySerGlyGlyThrG lnAspCysSerPheGln HisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlagerAsnLeuGln SEQ ID NO:604 pMON32372 .pep Al aAsnCys Ser IleMet IleAspGluI 1e leHi sHi sLeuLysArgProProAsnpro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaVa iLysHi sLeuGluAsnAlaSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlamhrAlaAlaProSer ArgHisProllel lel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeu'rhrPhe TyrLeuValThrLeuGluG~InAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlyger ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysGluSer HisLys SerProAsniMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaolnArgTrpMetGluArgLeuLysmhrValAlaGlySerLysMe tGlnGlyLeuLeu GluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlr~spCysSerPhe GlnHisSerProlleSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 605 pMON32373 .pep AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuA].aPheValArgAlaValLysHisLeuGluAsnAlaseroly I 1eGluAlaIleLeuArgAsnLeuGnProCysLeuProserAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProleSerThrlleAsrlProSerProProSerLyscluSer HisLysSerProAsnMetAlaAspGlucluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlyserLysMe tGlnGlyLeuLeu GluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrpl leThrArgGInAsnPheSerArgCysLeuGluLeuGlnCys WO 98/17810 WO 9817810PCTIUS97/20037 GlnProAspSerSerThrLeuGlyGlyGlySerGlyG iyGlySerGlyGlyThrGInAsp CysSerPheGlnHisSerProleSerSerAspPheAlaValLyslleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 606 pMON32374 .pep AlaAsnCysSerl eMetIleAspGluI leIleHisHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAl aPheVAlArgAl aValLysHi sLeuGluAsnAlaSerGly I leGluAlal eLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHi sProIleI IelleLysAlaGlyAspTrpGlnGiuPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGiyGluProSerGlyProlleSerThrleAsnProSerProProSerLysGluSer Hi SLysSerProAsnMe tAiaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMet.GluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGInThrAsnl leSerArgLeuLeuGlnGluThrSercluGlnLeu ValAlaLeuLys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGiyGlyGlySerGlyGlyclySerGlyGlyGlySercly ThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLyslleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl aSerAsnLeuGln SEQ ID NO:607 pMON32375 .pep A)aAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVaiArgAlaVa lLysHisLeuGluAsnAlaSerGly 11 eG luAl a 11eLeuArgAsnLeuG lnProCysLeu Pro SerAl aThrAlal a Pr oSer ArgHisProl lel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyclySer ProGlyGluProSerGlyProxleSermhrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrVa lAlaG lySerLysMetGlnGlyLeuLeu G luArgVa lAsnThrG lu leH is PheVa lThrLysCysAlaPheGlnProPro Pro Ser CysLeuArgPheValclnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly G lyGI yThrGlnAspCys SerPheGlnH is er Prol 11eSer SerAsp PheAl aVa lLys Ii eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO:608 pMON32376 .pep AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLys~i sLeuGluAsnAl aSerGly IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAl~aPro~er ArgHisProl lelleIJleLysAlaclyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValG luGlyGlyGlyGlySer ProG lyGluProSerGlyPro 11eS erThr 11eAsnProSerPro Pro SerLysG luSer Hi sLysSerProAsriMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrVa lAlaGi ySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlncluThrSerGluGlnLeu ValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuolnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHi sSerProl leSer SerAspPheAllaValLys IleArgcluLeuSerAspTyrLeuLeuGlnAspTyrProVaI ThrValAlaSerAshLeuGln SEQ ID NO:609 pMON32378 .pep AlaAsnCysSerl leMetIleAspGluI lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnserGluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHisLeuGluAsnAlaSerGly Il~ul~ee~gs~ul~o~se~oe~ah~al~oe ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlyger ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer WO 98/17810 WO 8/18 PCT/US97/20037 Hi sLysSerProAsriMetAl aSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHi sPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp Ii eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyThrGlriAspCysSerPheGlnsisSerProlleSerSer AspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuG lnAspTyrProValThr ValAlaSerAsnLeuGlrlAspGluGluLeuCysGlyclyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:610 I0 pMON32 379 .pep AlaAsnCysSerl leMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSeroly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgI-isProllel lelleLysAlaGlyAspTrpGlnoluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProl leSer SerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuclnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuvalLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 611 pMON3238O.pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsriLeuAsnSerGluAspMetAspl leLeuMetG luArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer Hi sLysSerProAsniMetAlaSerLys~etGlnGlyLeuLeuGluArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeUGluLeuG lnCysG lnProAspserSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSer ProlleSerSerAspPheAlaValLyslleArgcluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluoluLeuCysolyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaoly SEQ ID NO: 612 pMON32381.pep AlaAsnCysSerlleMetl leAsp~lul lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHjsLeucluAsniAlaSerGly IleGluAlalleLeuArgAsrlLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaSerLysMetGlnGlyLeuLeuG luArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProserCysLeuArgPheValoln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp Ii eThrArgGlnAsnPheSerArgCysLeuGluLeulnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPhe GlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlualuLeuCysGlyGly LeuTrpArgLeuValLeuAlaGJlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:613 pMON32382.pep AlaAsnCysSerIle~etIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeucluAsnAlaSeroly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer WO 98/17810 PCT/US97/20037 WO 98180 C0S9/03 ArgHisProIleIlelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrvalGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaSerLysMe tGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnIl1eSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCyso lnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyr ProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe t(luArgLeuLysThrVa lAla Gly SEQ ID NO:614 pMON32383.pep AlaAsnCysSerl leMetI leAspGluI lel leHis~isLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeucluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlelleI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLys SerProAsniMetAlaSerLysMetGlnGlyLeuLeuG luArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProserCyszeuArgPheValGln ThrAsnIl1eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp Ii eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGJlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGly SEQ ID NO:615 pMON32384.pep AlaAsnCysSerl leMetI leAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProser ArgHisPro Ilel lel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniletAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaVal Lys IleArgcluLeuSerAspTyrLeuLeuliAspTyrProValThrValAlaserAsi LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnclyLeuLeuGluArgValAsnThr GlulleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:616 pMON32385 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl .eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuoluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGanThrAsnl leSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpI leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThrLeuGlyGlyGly SerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAla ValLys IleArgGluLeuSerAspTyrLeuLeuGlniAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlniArgTrp MetGluArgLeuLysThrValAlaclySerLysMetGlnGlyLeuLeuGluA-gValAsn ThrGlulleHisPheValThrLysCysAlaPheclnPro SEQ ID NO:617 pMON3 2386 .pep WO 98/17810 PCT/US97/20037 AlaAsnCys SerI 1 eMe tI leAspGluI leI leHisHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgmrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAl aThrAlalaProSer ArgHisPro IlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValG luGlyGlyGlyGlySer ProGlyGluProSerGlyProI IeSerThrI leAsnProSerProProSerLysGluSer Hi sLys SerProAsrlMe tAl aPro ProSerCysLeuArgPheVa lGlnThrAsn I leSer ArgLeuLeuclnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuclnCysolnProAspSerSerThrLeuGlyGlyGly SerG lyG lyGlySerGlyGlyThrGlnAspCys Ser PheG lnH isSer Pro 11eSerSer AspPheAl aVal Lys 11 eArgGluLeuSerAspTyrLeuLeuG 1nAspTyrProVa lThr ValAl aSerAsrlLeuGlnAspGluoluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMe tGluArgLeuLysThrValAl aGlySerLysMetGlnGlyLeuLeuolu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnpro SEQ ID NO: 618 pMON32 387 .pep AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMe tAsp IleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly 11 eG luAl aI 1eLeuArgAsnLeuG lnProCysLeuPro SerAl amrAl aAla Pro Sbr ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProG lyG].uProSerGlyProl 11eSerThrl 11eAsnPro Ser Pro Pro SerLySG luSer Hi sLys SerProAsnMetAla Pro ProserCysLeuArg PhevalGlnThrAsnl 11eSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlrnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerbysMetolnGly LeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheolnPro SEQ ID NO:619 pMON32388 .pep AlaAsnCysSerl le~etI leAspGluIJleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaVa lLysHisLeuGluAsnAlaSerGly IleGluAlal leLeuArgAsnLeualnProCysLeuProSerAlaThrAlaAlaProSer ArgH is Pro 11e leI leLysAl aolyAspTrpolnG luPheArgaluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGln'ryrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnietAlaProProSerCysLeuArgPheValGlnThrAsnl leSer ArgLeuLeuGlnGluThrserGluGlnLeuValAlaLeuLysProrrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlncysGlnProAspserSerThrLeuGlyGlyG ly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProl leSerSerAspPheAlAValLys IieArgGluLeuSerAspTyrLeuLeuGln AspTyrProVa lThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLyscysAlaPheGln Pro SEQ ID NO:620 pMON32389 .pep AlaLAsriCysSerl leMetI leAspGluIlelleHisI-isLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSercluAspMetAspl eLeu~4etGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly I leGluAlal eLeuArgAsnLeuGlnProCysLeuProserAlaphrAlaAlaProSer ArgHisProlleleleLysAlaGlyAspTrplnGluPheArgluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaProProSerCysLeuArgPheValGlnThrAsnhleSer ArgLeuLeuGlnGluThrSercluGlnLeuValAlaLeuLysProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeucJlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnl-isSerProl leSerSerAspPheAlaValLys IleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspcluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnA-rgTrpMe tGlu~irgLeuLysThr WO 98/17810 PCTfUS97/20037 ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHi sPheVal ThrLysCysAlaPheGlnPro SEQ ID NO;621 hflt3-28291ink10.pep AlaAsnCysSerl leMet I leAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspI ieLeuMetGJluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly 1 ieGluAlaI leLeuArgAsnLeuGInProCysLeuProSerAl aThrAiaAlaProser ArgHi sProI le 11eI 1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGiuGlyGlyGlyGlySer ProGlyGluProSerGlyProI I eSerThrI leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAiaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnrhrAsnl e SerArgLeuLeuGlnGluThrSerGluGlnLeuValAl aLeuLys ProTrpl leThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyThrGlx-AspCysSerPheGlnHisSerProlleSer SerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGIn SEQ ID NO: 622 hflt3-28291ink15.pep AlaAsnCysSerl eMet I leAspGluI leI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeu~e tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IlecluAlaleLeuArgAsnLeuGlnProCysLeuProSerAlarhrAlaAlaProser ArgHisProllel lel leLysAlaGlyAspTrpGJlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGInAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrI leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaAspTyrProValThrValAlaSerAsnLeuGInAspGlu GiuLeuCysGlyGlyLeuTrpArgLeuVaiLeuAiaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPhe valThrLysCysAlaPheGlnProProProSerCysLeuArgPheValclnThrAsnl le SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrbeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeu Gin SEQ ID NO:623 hflt3-34351ink10.pep AlaAsnCysSerlleMetlleAspGlulelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHi sLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHi sProl lellleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGiyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys lMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnl leS erArgLeuLeuGlnGiu ThrSerGluGlnLeuValAlaLeuLysProTrpl eThrArgGInAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 624 hfilt3-34351ink15.pep AlaAsnCysSerl leMetI leAspGlulleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysi sLeuGluAsnAlaSerGly IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAaThrAlaAlaProSer ArgHisProllellelleLysAlaclyAspTrpGlnGluPheArgciuLysLeumhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI ieSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspcluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysmhrValAlaGlyserLys WO 98/17810 PCT/US97/20037 MetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnl eS erArgLeuLeuGlnGlu ThrSerGluGlnLeuVa lAlaLeuLys ProrrpI leThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuG lyGlyGlySerGlyGlyGlySer GlyG lyG lySerG lyG 1yG 1yThrG lnAspCys Ser PheGlnHis er Pro 11egerSer AspPheAlaValLys IieArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr Val SEQ ID NO:625 hflt3-62631ink10.pep AlaAsnCysSerI leMetI leAspGluI leI leI-isHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGluAsriAlaSercly 11leGJluAlaI IeLeuArgAsnLeuGlnProCysLeuProSerAl aThrAlaAl aProSer ArgHi sPro le 11e 11eLysAlaclyAspTrpGln~luPheArgGI uLysLeuThrPhe TyrLeuValThrLeuGluGlInAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyPro I leSerThrI leAsnProSerProProSerLysGluSer Hi sLys SerProAsnIetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGnProProProSerCysLeu~rg PheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuvalAlaLeu LysProTrp IleThrArgGlnAsnPheSerArgCysLeucluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProlleSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuolnAspoluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 626 hflt3-62631inkl5.pep AlaAsnCysSerl leMetI leAspGluI lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLys~isLeuG luAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysbeuProserAlaThrAlaAlaProSer ArgHisProl lellelleLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLys SerProAsniMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVa1 AsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProserCysLeuArg PheValGlnThrAsnI leSerArgLeuLeuGlnGluThrserGluGlnLeuValAlaLeu Lys ProTrpl lemrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProVa lThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLys Thr SEQ ID NO:627 hflt3-94951ink10.pep AlaAsnCysSerIleMetI leAspclullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lellelleLysAlaGlyAspTrpGlnoluPheArgGluLysLeumhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGlrlAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyclySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu~laGlrgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr~lu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 628 hflt3-94951inkl5.pep AlaAsnCys Serl leMetl 11eAspGluI lel leHisH isLeuLysArg Pro ProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAs[~laSerGay IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer WO 98/17810 PCTIUS97/20037

;ZA

ArgHisProlel6IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGiuGlnAlaGlnGluGlnGlnTyrVaiGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI ieSerThrl eAsnProSerProProSerLysGluSer IisLysSerProAsnLMetAlaArgPheValGlnThrAsnl legerArgLeuLeuGlnGlu ThrSerGiuGlnLeuValAlaLeuLysProTrpl leThrArgGlAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrzeuGlyciyGlySerclyclyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProl leSerSer AspPheAlaValLysI ieArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlniAspGluGluLeuCysGlyGlyLeurrpArgLeuValLeuAla GlnArgTrpMetciuArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheoinProProProSerCys Leu SEQ ID NO:629 hflt3-98991ink10.pep AlaAsnCysSerl leMetI leAspGluIleI leHisHisbeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsp IieLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaVa iLysHi sLeuG 1uA~nAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProlelleleLysAlaGlyAspTrpGlnc~iuPheArgGluLysbeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProIleSerphrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaThrAsnhleSerA 'rgLeuLeuGlnGluThrSerciuGln LeuValAlaLeuLysProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrcin AspCysSerPheGInHisSerProl leSerSerAspPheAlaValLyslleArgGluLeu SerAspTyrLeuLeuG inAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAiaGlnArgTrpMetGluArgLeuLysmhr ValAlaGlySerLysMetGlnGlyLeuLeuoiuArgValAsnThrGluleHisPheVal ThrLysCysAlaPheGinProProProserCysLeuArgPheValGln SEQ ID NO: 630 hflt3-98991inkl5.pep AlaAsnCysSerlleMetl eAspGluI ieleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMe tAsp IieLeuMetGluArgAsnLeu ArgThrProAsnbeuLeuAlaPheValArgAlaValLysHisLeuGiuAsnAlaSerGly IleGluAlalleLeuArgAsnLeucinProCysLeuProSerAiaphrAlaAlaProSer ArgHisProl le lel eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGInGlnTyrValGluGiyGlyGlyGlySer ProGlyGluProSerGlyProI ieSerThrl eAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnl eSerArgLeuLeuGlnGluThrSerGluGln LeuValAiaLeuLysProTrpleThrArgGlnAsnPheserArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaVal Lys IleArgGiuLeuSerAspTyrLeuLeuolnAspTyrProVa'rhrValAlaserAsn LeuGlniAspGluGluLeuCysclyGlyLeuTrpArgLeuVa lLeuAl aGlnArgTrpMe t GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr Glul eHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal Gin SEQ ID NO:631 hflt3-28291ink6.pep AlaAsnCysSerlleMetl leAspGluI ielleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAl aPheValArgAlaValLysHi sLeuG luAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProserAiaThrAlaAlaProser ArgHisProl leIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGiuGlnAlaGlnGluGIncinTyrValGluGlyGiyGlyGlySer ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaAspTyrProValThrValAlaSerAsnLeuGInAspGlu GluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAl aGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVaiAsnThrGlulleHisPhe ValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl le SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpI leThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAla ValLysleArgGluLeuSerAspTyrLeuLeuGln SEQ ID lsO:632 hflt3-28291jnk7 .pep WO098/17810 2sPCTIUS97/20037 AlaAsnCysSerl leMetl 11eAspGluI 1 ell elisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspx leLeuMetGluArgAsnLeu ArgmrProAsnLeuLeuAl aPheValArgAlaValLysHi sLeuGluAsnAl aSercly IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProger ArgHisProllellelleLysAlaGlyAspTrpGlnoluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 11eSerThrl 1 eAsnProSerProProSerLysGluSer H isLys Ser ProAsrnMe tAlaAspTyr Pr oVa lThrVa IA1 aSerAsnLeuG lnspGlu G luLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMe tGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVa.AsnThrGluI leHisPhe Va lThrLysCysAlaPheGlnProProProSerCysLeuArgPhevalGlnThrAsnI le SerArgLeuLeuGlnGluThrSerGluclnLeuValAlaLeuLysProTrpl leThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSermrLeuGlyGly G lyS erGlyG lyG lyThrGlnAspCys SerPheGlnHis er Pro I leSerSerAspPhe A2laValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO:633 hflt3-28291ink13 .pep AlaAsnCys SerI IeMetI leAspGluI 1eI leHi sHi sLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGuAsp~etAspI 1leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly I1 eGluAlaI 1leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlncluPheArgGluLysLeumrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyclyGlyGlySer ProG lyGluProSerGlyProI 11eSerThrI 1 eAsnProSer Pro ProSerLysG luSer HisLysSerProAsnMetAlaAspTyrProValThrValAlagerAsnLeuGlnAspclu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlule-isPhe ValThrbysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuclncluThrSerGluGlnLeuValAlaLeuLys ProTrpI 1leThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlycly GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer Prol leSerSerAspPheAlaValLys IlJeArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO:634 hflt3-28291ink21 .pep AlaAsnCysSerIleMetIJleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGluAsnAlaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser Arg~is Prol lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeumhrPhe TyrLeuValThrLeuGluolnAlaGlnGluGlnGlnTyrValGluGlyGayGlyGlySer ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnletAlavalAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrG luI 11eHi sPheVa lThrLys CysAl aPheG lnPro Pro ProSerCysLeuArg PheValGinThrAsnl leSerArgLeuLeuGlnGluThrSerGluolnLeuValAlaLeu Lys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlncysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyolySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPhe AlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysclyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThr SEQ ID NO:635 hflt3-3435link6 .pep AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAl aPheValArgAlaValLysHi sLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProIleIleI leLysAlaGlyAspTrpGlncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluclnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProgerGlyProl leSerThrlleAsriProSerProProSerLysGluSer H isLysSerProAsniMe tAl aAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnmhrGlul leHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPhevalGlnThrAsn~ leSerArgLeuLeuGlnGlu ThrserGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLys IleArgcluLeu SerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO:636 WO 98/17810 WO 9817810PCT/US97/20037 hflt3-34351ink7 .pep AlaAsnCys SerI leMe tI leAspGlu I leI 1 eHi sHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspI 1 ebeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLys~i sLeuG luAsnAlaSerGly I leGluAlaI 1leLeuArgAs nLeuG lnProCysLeu ProSe rAlaThrAlaA a Pro Ser ArgHisProI leI leI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaclnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGly~luProSerGlyPro IleSerThrI leAsnProSerProProSerLysGluSer H is Lys Ser ProAsnMe tAl aAl a SerAsnLeuGlnAspG 1uGluLeuCysG lyGlyLeu TrpArgLeuValLeuAlaolnArgTrpMetoluArgLeuLysThrValAlaclySerLys Me tGlnGlyLeuLeuGluArgValAsnThrGluI leHi sPheValThrLysCysAlaPhe GlnPro Pro Pro SerCys LeuArg PheValGlnThrAsnI leSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAl aLeuLys ProTrp 11eThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerPro leSerSerAspPheAlaValLysI leArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrVaI SEQ ID NO: 637 hflt3-34351inkl3 .pep AlaAsnCysSerIleMetIleAspcluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa1ArgAlaValLysHisLeuoluAsn~laSercly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnrryrValGluGlyGlyolyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer H is Lys SerProAsnMe tAl aAl aSerAsnLeuGlnAspG luGluL euCysG lyG lyLeu TrpArgLeuValLeuAlaGlnArgTrpMetoluArgLeuLysThrValAlaGlySerLys Me tGlnGlyLeuLeuGluArgValAsnThrGluIl1eHisPheValThrLysCysAlaPhe GlriProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer G lyG lyG lyS erGlyThrG lnAspCys Ser PheGlnHis er Prol I1 eSer SerAsp Phe AlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO:638 hflt3-34351jnk21 .pep AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsniAsnLeuAsnSerGluAspMe tAspIl1eLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGluAsnAlaSerGly IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlalProSer ArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluclnclnTyrValGluGlyclyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsrnMetAlaAlaSerAsnLeuGlrnspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaclnArgTrpMetGluArgLeuLysThrVa lAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValolnThrAsnx leSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLys ProTrplleThrArgGrInAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyger GlyGlyGlySerGlyGlyGlySerGlyClyGlySerGlyThrG1nspCysSerPheGln HisSerProlleSerSerAspPheAlaValLyslIleArgGluLeuserAspTyrLeuLeu GlnAspTyrProValThrVal SEQ ID NO:639 hflt3-62631jnk6 .pep AlaAsnCysSerlleMetl leAsp~lul lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHj sLeuGluAsnAl aSerGly I leGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lel lelleLysAlaGlyAspTrpGlnGluPheArgoluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluG lyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlyserLysMetGlnGlyLeuLeuciuArgVal AsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProserCysLeuArg PheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGln~euValAlaLeu LysProTrpl leThrArgGlnAsnPheSerArgCysLeuoluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyThrGln~spCy 5 SerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu~lnAspTyr WO098/17810 ')-tPCTIUS97/20037 ProValThrValAlaSerAsnLeuGlnAspGluGluLeUCYSGlyGlyLeuTrpArgLeu ValLeuAlaGlriArgTrpMetGluArgLeuLysThr SEQ ID NO:640 hflt3-62631ink7.pep AlaAsnCysSerl leMet IleAspGluI JeI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsp IleLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnteuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgilisProl lel lelleLysAlaGJlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HiisLys SerProAsniMetAlaValAlaGlyserLysMetGlnGlyLeuLeuGluArgVal AsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnhleSerArgLeuLeuGlnoluThrSerGluGlnLeuValAlaLeu Lys ProTrpl eThrArgGlnAsnPheserArgCysLeuGluLeuJlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlyrhrGlnAspCysSer PheGlnHi sSer Prol leSerSerAspPheAlaValLys IleArgGluLeuSerAspryrLeubeuGliAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuvalLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO :641 hflt3-62631ink13 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeubeuAlaPheValArgAlaValLysllisLeuGluAsnAlaSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeurhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGln'ryrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlIleAsriProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaolySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCypLeuArg PheValGlnThrAsnhleserArgLeuLeuGlnGlumhrSercluGnLeuValAlaLeu Lys ProTrpl eThrArgGlnlAsnPheSerArgCysLeuGlubeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerlyGlyGlySerGlyThrGl,Asp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProVa lThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO:642 hflt3-62631ink21 .pep AlaAsnCysSerIleMetIleAspGluI lelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeumhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGn'ryrValGluGlyclyGlyGlySer ProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSerLysoluSer H is Lys SerProAsne tAlaVa lAl aG lySerLysMe tGlnG lyLeuLeuG luArgVa 1 AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeurg Ph~ll~rs~ee~ge~u~nl~re~ul~ua~ae Lys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys~lnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyclySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPhe AlaValLys IieArgcluLeuSerAspTyrLeuLeuGlnAspryrProValThrValAla SerAsnLeuGlnAspGluGuLeuCysGyGyLeuTrpArgLeuVaLe~laGlrg TrpMetGluArgLeuLysThr SEQ ID NO:643 hflt3-94951iik6 .pep AlaAsnCysSerl leMetlleAspGlullelleHisHisLeuLysArgProProAsnpro LeuLeuAspProAsrlAsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHisLeuGluAsnAlaSerGly I leGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlamhrAlaAlaProger ArgHisProIleIleIleLysAlaGlyAspTrpclnGluPheArgGluLysLeu~hrPhe TyrLeuValThrLeuGluG~nAlaclnGluGlnGlnTyrValGluGlyly~1yGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer Hiis Lys SerProAsniMetAlaArgPheValGlnThrAsnIleserArgLeuLeu~lnlu ThrSerGluGlnLeuValAlaLeuLys Pro~rplleThrArgG'lnAsnPheserArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln WO 9 17810 PCTIUS97/20037 22q AspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysI~etGlnGlyLeuLeuGluArgVa lAsnThrGluI leHis PheVaj.

ThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO:644 hflt3-94951ink7 .pep AlaAsnCysSerI leMetlIleAspGlulleI leHisl4isLeu!,ysArgProProAsnPro LeuLeuAspProAsniAsnLeuAsnSerGluAspMetAspl eLeuMe tGluArgAsnLeu ArgmrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGi uAsnAlaSerGly I leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgI-i sPro 1e 1e leLysAlaG lyAspTrpGlncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValolnThrAsnhleSerArgLeuLeuGlnGlu ThrSerGluGlrlLeuValAlaLeuLys Pro~rrpl leThrArgG lnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlyserGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO:645 hflt3-94951inkl3 .pep AlaAsrlCysSerIleMetIleAspGlulleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSercluAspMetAsplleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAl aValLysHi sLeuGi uAsnAl aSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHisProl lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaArgPheValGlnThrAsnhleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlrlAspCysSerPheGlnHisSerProl eSerSerAspPhe AlaValLyslleArgGluLeuSerAspTyrLeuLeuolnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyclyLeurrpArgLeuValLeuAlaGluArg TrpMe tGluArgLeuLysThrValAlaGlySerLysMe tGlnG lyLeuLeuGluArgVal AsnThrGlulleHisPheValThrLysCysAlaPheclnProProProSerCysLeu SEQ ID NO:646 hflt3-94951ink21.pep AlaAsnCysSerl leMetI leAspGluIleI leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnserGluAspMetAsplleLeuMetcluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn~laSerGly I leGluAlal leLeuArgAsnLeuGInProCysLeuProSerAlaThrAlaAlaProser ArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeumhrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAl aArgPheValGlnThrAsnl leSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProlleSerSerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeu GlrAspTyrProValThrValAlaSerAsnLeuGlnAspGluG luLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetcluArgLeuLysThrVa lAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPhe GlnProProProSerCysLeu SEQ ID NO:647 hflt3-98991ink6 .pep Ala-AsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnPro LeuLeuAspproAsnAsnLeuAsnSerGluAsp~etAspl eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn~laSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAJlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProleSerThrlleAsnProSerProProSerLysGluSer Ilud,% QQ/l 1791 n prwtaQrInn, HisLysSerProAsniMetAlaThrAsnhleSerArgt~euLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpl leThrArgGlriAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuG lyGlyGlySerGlyGlyThrGliAspCys SerPhe GlnHisSerPro I leSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGInAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMe LGluArgLeuLysThrValAlaGlySer LysMe tGlnGlyLeuLeuGluArgValAsnThrGluI 1 eHi s PheVa lThrLysCysAla PheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 648 hflt3-98991ink7 .pep Al aAsnCysSer IleMe t IleAspGluI IeI leHi sH isLeuLysArg Pro ProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsplleLeuMe tGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaVAlLysHisLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lel lelleLysAlaGlyAspTrp~lnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnhleSerArgLeuLeuGlnGluThrSerGluGln LeuVa lAl abeuLys ProTrpl 11eThrArgGlrnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrolnAspCysSer PheGlnHi sSerProl leSerSerAspPheAiaValLyslleArgGluLeuSerAspTyr LeuLeuG lnAspTyrProVa lThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 649 hflt3-98991inkl3.pep AlaAsnCysSerl leMetI leAspGluI lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl eLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheVa lArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHis Prol lel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnletAlaThrAsnl leSerArgLeuLeuGlnGluThrSerGluGln LeuVaJ.AlaLeuLysP roTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlInAspCysSerPheGinHisSerProl leSerSerAspPheAlaValLysI le ArgGluLeuSerAspTyrLeuLeuGlniAspTyrProValThrValAl aSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlriArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO:650 hflt3-98991ink21.pep AlaAsnCysSerl leMetIleAsp~lul lel leHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeuMe tcluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnhleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuclnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyG lyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnolyLeu LeuGluArgValAsnThrGluIl1eHi sPheValThrLysCysAl aPheGinProProPro SerCysLeuArgPheValGln SEQ ID NO:651 GlySerThrMet SerArgLeuProValLeuLeuLeuLeuGlnLeuLeuValArgProAlaMetSerThrAsnGln AspLeuProVallleLysCysValLeulleAsnHisLysAsnAsnAspSerSerValGlyLysSerSerSerTyr ProMetValSerGluSerProGluAspLeuGlyCysAlaLeuArgProGlnSerSerGlyThrValTyroluAla AlaAlaVa1GluValAspValSerAlaSerI leThrLeuGlnValLeuValAspAlaProGlyAsnhIeSerCys LeuTrpValPheLysHisSerSerLeuAsnCysGlnproHisPheAspLeuGlruAsnArgclyValValSerMet ltlyr% no/1,79in vv PCTTTSQ7'M0t7 VallleLeuLysMetThrGluThrGlnAlaGlyGluTyrLeuLeuPhelleGlnSerGluAlaThrAsnryrThr 11 eLeuPheThrVal Ser IleArgAsnThrLeuLeuTyrThrLeuArgArgProTyrPheArgbYSMetGluAsn GInAspAlaLeuValCys IleSerGluSerValProGluPro IleValGluTrpValLeuCysAspSerGlnGly GluSerCysLysGluGluSerProAlaValValLysLysGluGluLysValLeuHisGluLeuPheGlyMetAsp I leArgCysCysAlaArgAsnGluLeuGlyArgGluCysThrArgLeuPheThrl leAspLeuAsnGlnThrPro GlnThrThrLeuProGlnLeuPheLeuLysValGlycluPro.LeuTrpl leArgCysLysAlaValHisValAsn HisGlyPheGlyLeuThrTrpGluLeuGluAsnLysAlaLeuGluGluGlyAsnTyrPheGluMetSerThrTyr SerThrAsnArgThrMetl leArglleLeuPheAlaPheValSerSerValAlaArgAsnAspThrGlyTyrTyr ThrCysSerSerSerLysHisProSerGlnSerAlaLeuValThrl2.eValGluLysGlyPheI leAsnAlaThr AsnSerSerGluAspTyrGluleAspGlniTyrGlucluPheCysPheSerValArgPheLysAlaTyrProGln Ii eArgCysThrTrpThrPheSerArgLys SerPheProCysGluclnLysGlyLeuAspAsnGlyTyrSerl le SerLysPheCysAsnHisLysHisGlnProGlyGluTyrllePheHisAlaGluAsnAspAspAlaGlnPheThr LysMetPheThrLeuAsnl leArgArgLysProGlnValLeuAlaGluAlaSerAlaSerclnAlaSerCysPhe SerAspGlyTyrProLeuProSerTrpThrTrpLysLysCys SerAspLysSerProAsnCysThrGluGlul le ThrGluGlyValTrpAsniArgLysAlaAsnArgLysValPheGlyGlnTrpValeerSriSerThrLeuAsrnMet SerGluAlalleLysGlyPheLeuValLysCysCysAlaTyrAsnSerLeuGlyThrSerCysGluThrl leLeu LeuAsnSerProGlyProPheProPhelleGlnAspAsnGluPhellelleLeuGlyLeuPheGlyLeuLeuLeu LeuLeuThrCysLeuCysGlyThrAlaTrpLeuCysCysSer ProAsniArgLysAsnProLeiTrpProSerVal ProAspProAlaHisSerSerLeuGlySerTrpValProThrl leMetGluGluAspAlaPheGlnLeuProGly LeuGlyThrProProllemrLysLeuThrValLeuGluGluAspGluLysLysProValProTrpGluSerHis AsnSerSerGluThrCysGlyLeuProThrLeuValGlnThrTyrValLeuGlnGlyAspProArgAlaValSer ThrGlnProGlnSerGlnSerGlyThrSerAspGlnValLeuTyrGlyGlnLeuLeuGlySerProThrSerPro GlyProGlyHi sTyrLeuArgCysAspSerThrGlnProLeuLeuAl aGJlyLeuThrProSerProLys SerTyr GluAsnLeuTrpPheGlnAlaSerProLeuG lyThrLeuValThrProAlaProSerGlnGluAspAspCysVal PheGlyProLeuLeuAsnPheProLeuLeuGlnGlyl leArgValiiisGlyMetGluAlaLeuGlySerPhe SEQ ID NO:652 pMON30329 .pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLyslle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlabeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMe tProAlaPheAlaSerAlaPheGInArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVal Ser~yrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGJlySerProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsniMetAlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPhe AlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetolnclyLeuLeucluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeu LysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:653 pMON32173 .pep AlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProVa lThrValAl aSerAsnLeuGlnAspGluG luLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlniAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyclyGlyGlySerProGly GluProSerGlyProlleSerThrl leAsnProSerProProSerLysGJluSerHisLysSerProAsnimetAla ThrGlnAspCysSerPheGlnHisSerProlleSerserAspPheAlaValLyslleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProvalThrvalAlaSerAsnLeuGlriAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn I leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpI leThrArgGlniAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:654 pMON32175 .pep AlathrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspcluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaclySerLysMe tGlnGlyLeuLeuGluArg ValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGlnLAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnietAla ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeucluGlnValArgLys IleGin GlyAspGlyAlaLAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSercys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeu SerGlnLeuHi sSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr IieTrpGlnGlnMetGluGluLeuGly WO 98/17810 PTU9/03 PCT/US97/20037 MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerI-isLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:655 pMON32204.pep AlaThrProLeuGlyProAlaSerSerbeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysl le GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlamhrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHi sSerLeuGlyl leProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnbeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyl leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGlucluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerI-isLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro IleSerThrI leAsnProSerProProSer LysGluSerHisLysSerProAsniletAlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPhe AlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlrAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclnArgTrpMetcluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHis PheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyr ValGluGlyGlyGlyGlySerProclycluProSerGlyProI leSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsniMetAlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAla ValLys IleArgGluLeuSerAspTyrLeuLeualnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnmrGluleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnl legerArgLeuLeuGlnGluThrSercJluGlnLeuValAlaLeuLys ProTrpl leThrArgGlnAsnPheserArgCysLeuGluLeuolnCysGlnProAspSerSerThrLeu SEQ ID NO:656 pMON322O5.pep AlaAsnCysSerIleMetI leAspGlullelleHisHisLeuLysArgProProAlaProLeuLeu, spProAsn AsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArg AlaValLysAsnLeuGluAsniAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProl leSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsniMetAlaThrGlnAsp CysSerPheGInHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp~yrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnmhrGlu I leHisPheVal~hrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnhleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgclnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol leSerThrlleAsnProSerProProSerLysGlugerHisLys SerProAsnMetAlaThrGlnAspCys SerPheGlnxisSerProlleSerSerAspPheAlaValLyslleArgGluLeuserAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuolnAspGluGluzeuCysGlyGlyLeuTrpArgLeuValLeuAlacln ArgTrpMetGluArgLeuLysThrValAlaGlyserLysMetGlnGlyLeuLeuGluArgValAsnThrGlul le HisPheValThrLysCysAlaPheclnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl eThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:657 pMON322O8 .pep AlaThrclnAspCysSerPheolnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGliAspGluGluLeuCySGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPhevalThrLysCysAlaPheGlnProProProserCysLeuArgPheValolnThr AsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluclyclyGlyGlySerProGly GluProSerGlyProlleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysl leGln GlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi sProGluGluLeuValLeuLeu GlyHisSerLeuGlyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeu SerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluclyl leSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrphr IleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSer-isLeuGlnSerPheLeuGluVal SerTyrArgVaiLeuArgHisLeuAlaGlnProTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProI leSerThrIleAsnProSerProProSerLys GluSerHisLysSerProAsniMetAlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAla ValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu G2uLeuCysGlyGlybeuTrpArgLeuValLeuAl aGlnArgTrplmetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGlnPrOProPro SerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuG lnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGln-AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:658 WO 98/17810 PCTIUS97/20037 pMON35767 .pep/PMON32191 .pep AlaThrGlnAspCysSerPheGlnHi sSerProI 1leSerSerAspPheAlaValLys 11eArgGluLeuSerAsp TyrLeuLeuGInAspTyrProVai'rhrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGiuArg ValAsnThrGlu I ieHis PheValThrLysCysAlaPheGlnpz-oPrProSercysLeuArgPheValcinrhr AsnI 1 eSerArgLeuLeuGlnGiuThrSerGluGlnLeuValAiaLeuLysProTrplI eThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGiySerAshrMetAiaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu Lys SerLeuG 1uGinValArgLysIleGInoiyAspGlyAlaAlaLeuGlnGlubysLeuCysAlaThrTyrLys LeuCysHis ProGluGluLeuVa lLeuLeuGlyHi sSerLeuG IylIeProTrpAlaProLeugerSerCys Pro SerGirAlaLeuGlnLeuAiaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGln A2laLeuGIluGIyI ieSerProGluLeuGiyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrIleTrpGlnGinLMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuciuValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:659 pMON32397.pep.

AiaAsnCys Serl leMet I eAspGluI 1 eI leHisH i sLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGiuAspMetAspl 1leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHi sLeuGluAsnAlaSerGlyI leGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAl a ThrAlaAlaProSerArgHisProllelelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProI 1 eSerThr IleAsnProSerProProSerLysGiuSerHi sLysSerProAsniMetAlaAspTyrPro ValThrValAlaSerAsnLeuGiAspG iuGluLeuCysGlyG lyLeuTrpArgLeuValbeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGnGlyLeuLeuGluArgVaAsnrhrGiul IleHi s Phe ValThrbysCysAlaPheGlnProProProserCysLeuArgPheValolnThrAsnhleSerArgLeuLeuGln GluThrSerG luGlnLeuVa 1AlaLeuLys ProTrpI 1eThrArgGlnAsnPhegerArgCysLeuoluLeuGln CysGlnProAspSerserThrLeuGlyolyGlySerGlyGlyGlySerGlyGlyThrGInAspCysSerPheGln His SerPro 11eSerSerAspPheAlaValUys I eArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 660 pMON32398 .pep AlaAsnCysSerlleMetlleAspGlulelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg A laVa lLysH isLeuGiluAsnAl aS erG 1yI 1eG luAlaI 1eLeuArgAsnLeuGlnProCysLeu Pro SerAl a ThrAlaAlaProSerArgHis Prol1 e I lel 1 eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuVaiThrLeuGluGlnAlaGlnGluGlnGInTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyPro 11eSerThr 11eAsnPro Ser Pro ProSerLysGiuS erHi s Lys SerProAs nMe tAl aAspTyr Pro Val ThrValAl aSerAsnLeuGInAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrp MetGluArgLeuLysThrValAlaciySerLysMetGlnGlyLeuLeuGluArgVaiAsnThrGluleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGln GluThrSerGluGinLeuVa lAlaLeuLys ProTrplieThrArgGlnAsnPheSerArgCysLeuGiuLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGlnHisSerProl leSerSerAspPheAlaValiys IleArgGiuLeuSerAspTyrLeuLeu Gin SEQ ID NO:661 pMON32399 .pep AlaAsnCysSerl leMetIleAspGluI lel leHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAlaPheVa.Arg AlaValLysHisLeuGiuAsnAiaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAl aA1 aProSerArgHi sPro 11e 11e 11eLysAl aGlyAspTrpG nG uPheArgG 1uLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGinTyrValcluGlyGiyGlyolySerProGlyGiuProSer G lyPro I IeS erThrI 11eAsnPro Ser Pro Pro SerLysGluS er~i sLys Ser ProAsiMe tAl aAl aSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGinArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluleHisPheValThrLysCysAlaPhe GInProProProSerCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnGlumhrSerGluGlnLeu VaiAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGInProAspSerSer ThrLeuGl1yGIyG lySerG lyG lyG lyS erGlyGlyThrGlrnAspCys Ser PheGi1nHis er Pro I IeSerSer Asp PheAl aValILys I IeArgG luLeuSerAspTyrLeuLeuG 1nAspTyrProVa1ThrVal1 SEQ ID NO: 662 *pMON35700.pep AlaAsncysserlleMetleAspGlulleleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGiuAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAl aAla Pro SerArgHi sPro 1 ie 11e 11eLysA1 aGlyAspTrpG lncl uPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGInTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProlleSerThrleAsnProSerProProSerLysGuSer-isLysSerProAsnMetAlaAlaSerAsn WO 98/17810 PCTIUS97/20037 2 3 LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluclnLeu ValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProlleSerSerAspPheAlaValLys IleArgGluLeuSerAspryrLeuLeuGlriAspTyrProvalThr Val SEQ ID NO:663 pMON3 5701 .pep AlaAsnCysSerlleMetl leAspGlullelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlni~aGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrI leAsnProSerProProSerLysoluSerHisLysSerProAsniMetAlaValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGln~luThrSerGluGlnLeuValAlaLeu LysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGliHisSerProlleSerSerAspPheAla ValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 664 pMON35702.pep AlaAsnCysSerlleMetl leAspGluIleI leHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGJluAspMetAspl leLeumetcluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlalleLeuArgAsnLeuclnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProl leSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu Lys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProl le SerSerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspG luGluLeuCysG lyGlyLeuTrpArgLeuVa lLeuAlaGlniArgTrpMe tcluArgLeuLys Thr SEQ ID NO:665 pMON35703 .pep AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGJluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProl lellelleLysAlaclyAspTrpGlnGluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyclyGlyGlySerProGlyGluProSer GlyProl leSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaArgPheVal GlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLyslleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProserCysLeu SEQ ID NO:666 pMON3 5704 .pep AlaAsnCysSerl leMetI leAspGluI lelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllellelleLysAlaGlyAspTrpGlnoluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProlleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnimetAlaArgPheVal GlnThrAsnhleSerArgLeuLeuGlnGluThrSerGlucJ~nLeuValAlaLeuLysProTrplleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGnProAspSerSerThrLeuGlyGly~lySerolyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlniAspTyrProValThrValAlaserAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCys Leu SEQ ID NO:667 pMON3 5705 .pep WO 48/17810 U1A CR1 7R1APCTIUS~97/200f37 !R A AlaAsnCysSerIieMetIleAspGluI ieleHislisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMe tAspI ieLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAlaPheva lArg AlaVaiLysHisLeuGluAsnIlaSerGlyI ieGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAia ThrAlaAlaProSerArgHisProlel leleLysAlaGlyAspTrpcinciuPheArgGluLysLeuThrPhe TyrLeuVaiThrLeuGluGinAiaGlnGluGlnGinTyrVai~luGlyGlyGlySerSerProGlyGluProSer GlyProl eSerThrlleAsnProSerProProSerLysGiuSer~isLysSerProAsnitetAlaThrAsnl le SerArgLeuLeuGlnGiuThrSerGluGlnLeuValAlaLeuLysProTrpl eThrArgGiriAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGiySerGiyGlyGlySerGlyGlyThrGln AspCysSerPheGInHisSer~roIleSerSerAspPheAlaValLysI ieArgGlubeuSerAspTyrLeuLeu GinAspTyrProValThrVaiAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuvalLeu AiaGiriArgTrpMetGiuArgLeuLysThrValAiaGlySerLysMe tGlnGlyLeuLeuGluArgValAsnThr GluIieI-isPheVaThrLysCysAaPheGlnProProProSerCysLeuArgPheVaIGIn SEQ ID NO: 668 pMON357O6.pep AlaAsnCysSerl leMetIleAspGluIleIlel-isHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProserAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpclnGluPheArgGluLysLeumhrPhe TyrLeuVaiThrLeuGluGlnAlaGlnGluGlnGlnTyrvalGluGlyGlyGlyGlySerProGlyGluProSer GlyPro IleSerThrl leAsnProSerProProSerbysGluSerHisLysSerProAsniMetAlaThrAsnhle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerclyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysserPheGlnHisSerProlleserSerAspPheAlaValLyslleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlriArgTrpMetGluArgLeuLysThrValAlaGlySerbysMetGlnGlyLeuLeu GluArgValAsnThrGluI leHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal Gin SEQ ID NO:669 pMON35733 .pep AlaAsnCysSerl leMetI leAspGluI lelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAsp IleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGiuAlaleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllel lelleLysAlaGlyAspTrpGlncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProlieSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsniMetAlaSerAsnLeu GlriAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnlArgTrpMetGluArgtieuLysThrVal AlaGlySerLysmetGlnGlyLeuLeuGluArgValAsnThrolullexisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGiySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAla SEQ ID NO:670 pMON3 5734 .pep AlaAsnCysSerl leMetl leAspGluI lel lelisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAsplleLeu~etGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsniAlaSerGlyI leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllellelleLySAlaGlyAspTrpGlnGluPheArgGlubysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyPro IleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnimetAlaAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul eHis PheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuclnCysclnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLysleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSer SEQ ID NO:671 pMON3S735 .pep AlaAsnCysSerlleMetleAspGlulleleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl eLeuMetoluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeubluASnAlaSerGlyllecluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIldIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlniAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluproSer G lyProl11eSerThr 11eAsnPro SerProPro SerLysGluS erHi sLys SerProAsrie tA aLeuG lAsp GluGluLeuCysGlyGlyLeUTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl aLeu LysProTrpl leThrArgGlnAsnPh-eSerArgCys~euGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer WO98/17810 PCT/US97/20037 pheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGllAspTyr ProVaJ.ThrValAlaSerAsn SEQ ID NO:672 pMQN35736 .pep AlaAsnCys SerI leMetI 11eAspGluI le I leHisHi sLeuLysArgProProAsflProLeubeuAspProAsn AsnLeuAsflSerGluAspMetAspI leLeuMetGluArgAsnLeuArgThrProAsflLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyIeGuAaIleLeuArgAsflLeuGlnrProCysLeuProSerAla ThrAlaAlaProSerArgHisProI lel 1eIleLysAlaGlyAspTrpGlnGJluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGlUGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyPro 11eSerThr 11eAsnProS erProPro SerLysGluS erH i sLysSer ProAsrMetAl aGflAspG lu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGrlArgTrpMe tGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluI lelisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGflAspCysSerPhe GlrHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGllAspTyrPro ValThrValAlaSerAsnLeu SEQ ID NO:673 pMON35738.pep AlaAsnCysSerl leMetlleAspGlullelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsfl AsnLeuAsnSerGluAspMetAspl leLeuMetcluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyI leGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlelleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyG-ySerProGlyGluProSer GlyProl leSerThrlleAsnProSerProProgerLysGluSerHi sLysSerProAsriMetAlaGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMe t GlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlflProProPr~oSerCys LeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp I leThrArgGJnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGllHis SerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAsp SEQ ID NO:674 pMON35739 .pep AlaAsnCysSerl leMetI leAspGluIleI leHisHisLeuLysArgProProAsflProLeuLeuAspProAsfl AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsflLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpG~lGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluG~nAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerPrOAsflMetAlaGluLeuCys G lyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMe tGlr' GlyLeuLeuGluArgValAsnThrGluI leHi sPheValThrLysCysAlaPheGlflProProProSerCysLeu ArgPheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlriAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuG-yGyGlySerGly GlyG2.ySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGllAspCysSerPheGllHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGflAspTyrProValThrVal AlaSerAsnLeuGlnAspGlu SEQ ID NO:675 pMON3 5740 .pep AlaAsnCysSerIleMetIleAspGluIleIleHis~isLeuLysArgProProAsflProLeuLeuAspPrOAsfl AsnLeuAsnSerGluAspMetAspl leLeuMetGluArgAsnLeuArgThrProAsflLeuLeuAlaPheValArg AlaValLysHisLeuGluAsriAlaSerGlyI leGluAlail eLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProl lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeUThrPhe TyrLeuValThrLeuGluGlrlAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GilyProl leSerThrlleAsnProSerProProSerLysGluSerHi sLysSerProAsniMetAlaLeuCysGly GlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysmetGllGly LeuLeuGluArgValAsnThrGlulleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrplleThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGjlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGllHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGlu SEQ ID NO:676 PMON35741 .pep AlaAsncysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnProLeuLeuAspPrOAsl AsnLeuAsnSerGluAspMetAspl leLeumetGluArgAsnLeuArgThrProAsnLeuLeAlaPheVa-Arg AlaVaIlLysHisLeuGluAsnAlaSerGlyI 1eGluAiaIleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProllelleI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProlleSerThrlleAsrlProSerProProSerLysGluSerHisLysSerProAsniMetAlaSerAsflLeu WO 98/17810 PCTIUS97/20037 GlnAspGluGluLeuCysGlyGlyLeUTpArgLeuVaLeuAaGlrlArgTrpMet-GluArgLeuLysThrVa 1 AlaGlySerLysMe tGlnGlyLeuLeuGluArgValAsnThrGluI IleHisPheValThrLysCysAlaPheGln Pro Pro ProS erCys LeuArgPheVa1G lnThrAsn I leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl 1leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerPro I leSerSerAspSerAlaValLys 11eArgGluLeuSerASpTyrLeuLeuGln AspTyrProValThrValAla SEQ ID NO:677 pMON3 5742 .pep AlaAsnCysSerI leMetIleAspGluI lelleHisHi sLeuLysArgProProAsnProLeuLeuAspProAsn AsriLeuAsnSerGluAspMetAspl eLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheVa lArg Al aVa 1Lys Hi sLeuG luAsnAl aSerGlyI 1eGl uAl aI 1eLeuArgAsnLeuG lnProCysLeuPro SerAl a ThrAlaAlaProSerArgHisProllel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer G lyPro 11eSerThr 11eAsnPro Ser ProPr oSerLysG luSerH is Lys Ser ProAsnMe tAlaclrnAspG 1u GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuArgGluThrSerGluG~nProValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeucluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProlleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGllAspryrPro ValThrValAlaSerAsnLeu SEQ ID NO:678 pMON35743.pep AlaAsnCysSerl leMetI leAspGluI lelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspl eLeuMe tGluArgAsnLeuArgThrProAsnLeuLeuAlaPheVa 1Arg AlaValLysHisLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGllPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrVaIlGluGlyGlyGlyGlySerProGlyGluProSer GlyProl leSerThrl leAsnProSerProProSerLysGluSer~isLysSerProAsMetAlaLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlySerLysMetGlflGly LeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr ArgGlnAsnPheSerArgCysLeuGluLeuclnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro I leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGlu SEQ ID NO:679 pMON32179 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIl1eHisPheValThrLysCysAlaPheGll ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeUVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGllProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrvalTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerl leMetI leAspGluIle IleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspl leLeu MetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAl aSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProl lelle 1 leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGllAlaGllGlu GInGln SEQ ID NO:680 pMON35707 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGfl ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVa 1 AlaLeuArgProTrpl leThrArgGlrnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyG lySerGlyGlyThrGlnAspCys SerPheGlriHis SerPro I leSerSerAsp PheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSer LysG luSerHi sLysSerProAsnlMetAlaAsnCys SerI 1eMetl 1eAspGlul lel leHisHisLeuLysArg Pro ProAsnProLeuLeuAsp ProAsnAsnLeuAsnSerG IuAspMe tAspl 1 eLeuMe tGluArgAsflLeuArg ThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlaI leLeuArg AsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProlleIleIleLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO:681 pMON3 5708 .pep WO 98/17810 WO 9817810PCTIUS97/20037 Al aAspGluGluLeuCysGlyclyLeuTrpArgLeuVa lLeuAl aGlrnArgTrpMetGluArgLeuLysThrVa 1 AlaGlySerLysMetclnGlyLeuLeuGluArgvalAsnThrGluleHisPheValThrLysCysAlaPheGln Pro Pro ProSerCys LeuArgPheVal1G inThrAsn I 1 eSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpI 1leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGl1spCysSerPheGlnHisSer ProI leSerSerAspPheAlaValLyS I eArgGluLeuSerAspTyrLeuLeuGl1spTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro 11 eSerThrlIleAsn Pro SerPro Pr oSerLysG1uSerH isLys SerProAsn~JetAl aAsnCys er I leMet I leAspGluI leI le Hi sHi sLeuLysArgProProAsnProLeuLeuAspProAssnLeusnSercluspMetAspI 11eLeuMet G luArgAsnLeuArgThrProAsnLeuLeU~laPheVa lArgAlaValLysHi sLeuGluAsn~laSerclyI le GluAlaI 1leLeuArgAsnLeuGlnProCysLeuPro SerAlaThrAl aAlaProSerArg.{sProI 1 eIleI le LysAlaGlyAspTrpGlnGluPheArgGluLysLeumhrPheTyrLeuValThrLeuGluGln~aGllG luG in Gin SEQ ID NO:682 pMON35709.pep AlaAspGluGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAiaGlnArgTrpMetGluArgLeuLysThrVal AlaGiySerLysMetGinGiyLeuLeuGluArgValAsnThrGluIieHisPheVaiThrLysCysAlaPheGln Pro Pro Pro SerCys LeuArgPheVa 1GinThrAsnl 11eSerArgLeuLeuGinGluThrserGluGlnLeuVal AlaLeuLys ProTrp 11eThrArgGlnAsnPheserArgCysLeuGiuLeuGincysGlnProAspSerSerThr LeuGiyGiyGlySerGlyGlyGlySerGiyGiyGlySerGlyGlyGiySerciyGlyGlySerGlyThrGinsp CysSerPheGlnHisSerProl ieSerSerAspPheAlaVaiLys IieArgGiuLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGiuGlyGiyGlyGiySerProGlyGluProSerGly ProIlieSerThrl I eAsnProSerProProSerLysGluSerHisLys SerProAsnMe tAiaAsnCys Serl 11e MetIi1eAspGluIl11 ieHisHi sLeuLysArgPro ProAsnProLeuLeuAspProAsisnLeusnSerGlu AspMetAspIieLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAlaPheVaiArgAlaValLysHisLeu GluAsnAiaSerGlyI ieGiuAiaI leLeuArgAsnLeuGlnProCysLeuProSerAiaThrAiaAlaProSer ArgHisProlelleleLysAlaGlyAspTrpGinGluPheArgciuLysLeuThrPheTyrLeuValThrLeu GiuGinAiaGinGluGinGin SEQ ID NO:683 pMON3 5710 .pep AiaAspGluGluLeuCysGiyGlyLeuTrpArgLeuValLeuAlaGlirgTrpMetGluArgLeuLysThrVal AiaGiySerbysMetGinGiyLeuLeuGiuArgVaiAsnThrGlulieHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgLeuVaiGinThrAsnI 1 eSerArgLeuLeuGinGiuThrSerGiucinLeuVai AlaLeuLys ProTrpI 1ieThrArgGlniAsnPheSerArgCysLeuGluLeuGlnCysGinProAspserSerThr LeuGiyGlyGlySerGiyGiyGlySerGiyGlyGlySerGlyGyGyThrGn3~spCysSerPheGlnHisSer ProI IeSerSerAspPheA aVa 1 Lys 11eArgGiuLeuSerAspTyrLeuLeuGinjspTyrProValThrVa 1 AiaSerAsnLeuGlnTyrVaiGluGlyGiyGlyGiySerProGlyGluProSerGlyPro 11eSerThrlieAsn ProserPro ProSerLysGiluSerH isLys erProAsnetAl aAsnCys erI leMe t 11eAspGiul lel 1le HisHi sLeuLysArg Pro ProAsnProLeuLeuAspProAsn~s nLeuAsnSerGluspMe tAspI leLeuMe t GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAl aValLysHisLeuGluAsinJljaSerGlyI 1le GiuAial IeLeuArgAsnLeuGlnProCysLeuPro SerAi aThrAl aA aPro SerArgHis Pro I le le le LysAi aGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGl1i1aGinGluGln Gin SEQ ID NO:684 pMON357ii .pep AlaAspGluGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGiyArgLeuLysThrVal AiaGilySerLysMetGlnGlyLeuLeuGiuArgValAsnThrG lulileHisPheVaiThrLysCysAlaPheGin Pro ProPro SerCysLeuArgPheVa lGl nThrAsnl 1 eSerArgLeuLeuGlnGiuThrSerGluGlnLeuVa 1 AlaLeuLys ProTrpI leThrArgGlrlAsnPheserArgCysLeuGiuLeuolnCysGlnProAspSerserThr LeuGiyGlyGlySerGlyGlyGlySerGlyGlyGiySerGiyGlyGiySerGlyGlyGlySerGlyThrGl1sp CysSerPheGlnHi sSerProI 1ieSerSerAspPheAi aVal Lys IieArgGluLeuSerAspTyrLeuLeuGin AspTyrProVaiThrVaiAlaSerAsnLeuGInTyrValGiuGlyGiyGiyGlySerProGlyGluproSerGly ProI leSerThrI leAsnProSerProProSerLysGIuSerHisLys erProAsnjetAlasnCysSerI le MetI ieAspGluIl eIieHisHisLeuLysArgProProAsnProLeuLeuAspProAsnsnLeusnerGlu AspMe tAspl leLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAiaPheValArgAlaValLysHi sLeu GiuAsnAiaSerGiyI 1eGluAlaI leLeuArgAsnLeuGinProCysLeuProserAlaThrAia-Aiaproser ArgHi sProl lell1e IieLysAlaGlyAspTrpGinGiluPheArgGluLysLeuThrPheTyrLeuValThrLeu GiuGlnAiaGlnGluGlnGln SEQ ID NO:685 pMON3 5719 .pep MetAlaAspTyrProVaimrVaiAlaSerAsnLeuGinAspG luGluLeuCysGiyGiyLeuTrpArgLeuVal LeuAlaGinArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGinGlyLeuLeuGlurgVaAsn ThrGluI 1eHi sPheVa lThrLysCysAl aPheG InPro Pro Pro SerCysLeurgPheValG lnThrAsnI le SerArgLeuLeuGlnGiuThrSerGluGinLeuVaiAj aLeuLys ProTrplieThrArgGInAsnPheSerArg CysLeuGluLeuGinCysGinProAspSerSerThrLeuGlyGlyGlySerGiyGlyGlySerGlyGiyGlySer GlyGlyciyThrG lnpspCys er PheGlnHis er Pro I eserserAspPheAlaVaiLys I eArgGiuLeu SerAspTyrLeuLeuGlnTyrVaiGluGiyGlyGlyGiySerProGlyGluProSerGlyProI I eSerThrl 1 e AsnProSerProProSerLysGiuSerHisLysSerProAsnMe tAlaAsnCys erI 1eMe t IleAspGilIle I IeHisHisLeuLysArgProProAsnProLeuLeuAspProAsn~snLeuz~snSerG1uspMetAspI ieLeu Me tGiuArgAsnLeuArgThrProAsnLeuLeuAaPheVaArgAaVaLysHisLeuGus~aSerGly 1IleGiluAlaleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAaAaProSerArgH s Pro le Ile WO 98/17810 WO 9817810PCT/US97/20037 I ieLysAiaGiyAspTrpGinGiuPheArgGiuLysLeumbrPheryrLeuvaiThrLeuciucinAla~lnGlu GinGin SEQ ID NO:68E pMON3572O -pep AiaAiaSerAsnLeuGinAspciuGiuLeuCysGiyGyLeuTrpArgLeuVaLeuAaaGlnArgTrpMetolu Ar~uy~ra~al~ry~ ~nl~ueu ur~ ~nh~uIl~ h~lh LysCysAlaPheGlnProProProSercysLeuArgPhevaiG inThrAsni ieSerArgLeuLeucinoiuThr SerGiuGinLeuVaiAiaLeuLysProTrpIieThrArgGinAsnPheSerArgCysLeuGiuLeucinCysGln ProAspSerSerThrLeuGiyGiy'GiySetGiyGiysiySerGlyiyGySeriyGylyThrn~spCys SerPhecinHi sSerProl 1ieSerSerAspPheAiavai1Lys I1 eArgGiuLeuSerAspTyrLeuLeuclnAsp Tyr ProVaiThrVailTyrVaiGi uGlyGlyGiyGiyS erProcilyGluProSerGiyPrOl 1leSerThrl i eAsn Pro Ser ProPro SerLysGi userHi sLys serProAsl~e tAi aAsncys serl i eMetIlieAspclul leIle HisHisLeuLysArgProProAsnProLeuLeuAspProAsssnLeuAsnSerGuAspMe tAspl 11eLeuMet GiuArgAsnLeuArgThrProAsnLeuLeuAlaPheVailArgAlavaiLysHisLeuaiuAsnAiaSerGiyle GiuAiaIileLeuArgAsnLeuGinProCysLeuProSerAiaThrAiaAiaProS~rArg~is proIileI leI le LysAiaGiyAspTrpGinGiuPheArgGiuLysLeuThrpheTyrLeuvaiThrLeuGluGjnAla~lnGluGln Gin SEQ ID NO:687 p14ON3572l.pep AiaVaiAiaGiySerLysMetGinciyLeuLeuoiuArgvaiAsnThrGiulleHisphevaiThrLysCysAia PheGilnPro Pro ProSercysLeuArg Pheva iGoinThrAsnl 1 eSerArgLeuLeuclncluThrSerG loGin LeuVaiAiaLeuLys ProTrpIlieThrArgGinAsnPheSerArgCysLeuGiuLeuGincyscinProAspSer SerThrLeuGiyGiyGiySerGiyGiyGiySeroiyGiyGiySerGlyGiyGiyThrGin~spcysSerPheGin Hi sSerPro i eSerSerAspPheAiaValLys 11 ieArgGiuLeuSerAspTyrLeuLeuGliAspTyrProvai ThrVa iAiaSerAsnLeuGinAspGiuGiuLeucysGiyGiyLeuTrpArgLeuvaibeuA acinArgTrpMet GiuArgLeuLysThrTyrVaiGiuGiyGiyGlyGiyserProGiycluProserGiyprolieserThrlieAsn ProSerProProSerLysGiuSerlisLysSerProAsnI4etAiaAsnCysSerIieMetIleAspGiuIieIie HisHisLeuLysArgProProAsnProLeuLeuAspproAsnAsnLeuAsnSerGiuAspMecAspleLeu~et GiuArgAsnLeuArgThrProAsnLeuLeuAaPheVaArgAlaVaLys-isLeuoiuAsniAiaSerciyle GluAlalieLeuArgAsnLeuGlnProCysLeuproSerAaThrAaAaproserArg-isprol leT lelle LysAiaciyAspTrpGlnGiuPheArgGiuLysLeuThrPbeTyrLeuvaiThrLeuGiuG InAisGinGiuGin Gin SEQ ID NO:688 pMON3 5722 .pep AiaSerLysMetGinGiyLeuLeuGiuArgvaiAsnThrciulieHisPheVaiThrLyscysAiaPheGinPro ProProSerCysLeuArgPhevaiGinThrAsnl leSerArgLeuLeuGinGluThrSerGiuGinLeuVaiAia LeuLys ProTrplieThrArgGinAsnPheSerArgCysLeuG luLeuG inCyscinProAspSerSerThrLeu GiyGiyGiySerciyGiyciySerGiyGiyGiySerGlyGiyc iyThrGinAspcysSerPhecinHisSerPro IieSerSerAspPheAiaVaiLysleArgGiuLeuSerAspTyrLeuLeuoinAspTyrProVaiThrVaiAia SerAsnLeuGinAspGiuGiuLeuCysGyGyLeuTrpArgLeuvaLeuAaGIn1rgTrpMe tGiuArgLeu LysThrVaiAiaGiyTyrvaiGiuciyGiyGiyoiySerProGlyGiuProserGiyProl ieSerThrleAsn ProSerProProSerLysciuSerllisLysSerProAsnMetAlaAsncysSerleMetleAspGiulele HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGiuAspMetAspleLeuMet GiuArgAsnLeuArgThrProAsnLeuLeuAiaPheVaiArgAaVaLys~isLeuGiuAsnAiaSerGiyle GluAaleLeuArgAsnLeucinProCysLeuProSerAlaThrAiaAiaProSerArgHisProlelelie LysAl aG iyAspTrpGinciuPheArgG iuLysLeuThrPheTyrLeuvaiThrLeuGiusinAiaGinG loGin Gin SEQ ID NO:689 pMONJ 5723 -pep AiaProProSerCysLeuArgPhevaiGlnmhrAsnlieSerArgLeuLeuGinGiuThrSerGiuGinLeuVai AlaLeuLys ProTrplieThrArgG inAsnPheSerArgCysLeuoluLeuGinCysGinproAspSerSerThr LeuGlyGiy GlySerGiyGiyGiySerGlyGiyGiySerGiyGlyGlymrGnAspCysSerPheGinHisSer ProlIleSerSerAspPheAi aVaiLySleArgGluLeuSerAspTyrLeuLeuGinLAspTyrproVaiThrVal1 AlaSerAsnLeuGinAspGiuGiuLeuCysGiyGiyLeuTrpArgLeuVaiLeuAiaGin~rgTrpMetGiuArg LeuLysThrVaiAiaciySerLysMetGinGiyheuLeuGiuArgvaiAsnThrGiul leHi sPheVa iThrLys CysAiaPheGlnProTyrvaiGiuGiyGiyGiyGiySerProGlyGiuProSerGiyProleSerThrleAsn ProSerProProSerLysGiuSerHisLysSerProAsl~etAiaAsncysSerl leMetI ieAspGiul leIle HisHisLeuLysArgProProAsnProLeuzeuAspProAsnAsnLeuAsnSerGiuAspMetAspl leLeuMet GiuArgAsnLeuArgThrProAsnLeuLeuAiaPheVaArgAlaVaLysisLeuGuAsna~iSerGiylie GluAlalieLeuArgAsnLeuGinProcysLeuProSerAiaThrAiaAiaProSerArgxis Prol let lele LysAiaGiyAspTrpGinGiuPheArgGiuLysLeuThrPheTyrLeuVaiThrLeuGiuGinfl aGinoiuGin Gin SEQ ID NO:690 pHON35725 .pep AiaThrAsnhieSerArgLeuLeuGinGiuThrSerGiuGinLeuvalAiaLeuLysProTrpleThrArgGin AsnPheSerArgCysLeuGiuLeuGinCysGinProAspSerSerThrLeuGiyGiyGiySerGlyGiyGiySer GiyGiyGiySerGlyGiyGyThrGnAspCysSerPheGinHisSerProI leSerSerAspPheAlavaiLys Ii eArgGiuLeuSerAspTyrheuLeuGinAkspTyrProvaimhrVaiAiaserAsnLeuGinAspGiuGiuLeu CYsGiyGiyLeuTrpArgLeuVaiLeuAiaGinj~rgTrpMetGluArgLeuLysThrVaiAiaGiySerLysMet GinGiyLeuLeuGiuArgvaiAsnThrGiuleiisPhevaiThrLyscysAiaPheGinProProPrbSerCys WO 98/17810 WO 9817810PCTIUS97/20037 LeuArgPheValGlnTyrValGiuGiyciyGlyGiySerProGlyciuProSerGlyProleSerThrI ieAsn ProSerProProSerLysGiuSerHisLysSerProAsnMetAlaAsncysserl eMetlieAspGiuI lel le HisHisLeuLysArgProProAslProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAsp leLeumet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAiaVaiLysHisLeuGluAsnAiaSerGlyl le GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProleleIle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGuG~nAlaGlnGluGln Gin SEQ ID NO:691 pMON35726 .pep AiaArgPheVaiGlnThrAsnlieSerArgLeuLeuGlnGluThrSerciuGinLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGiuLeuGlncysGInProAspSerSerThrLeuciyGlyGlySer GlyGlyGiySerGlyGlyGySerGyGyGyThrGnAspCysSerPheGnHisSerProIleSerSerAsp PheAlaVa2lLysI ThArgGluLeuSerAspTyrLeuLeuGinLAspTyrProValThrValAlaSerAsnLeuGln AspGiuGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGInrgTrpMetGluArgLeuLysThrValAla GiySerLysMetGlnGiyLeuLeuGluArgVaiAsnThrGiul leHi sPheVaiThrLysCysAlaPheoinPro ProProSerCysPheTyrVaiGiuGlyGlyoiyGlySerProGiyGiuProSerGiyProl leSerThrlieAsn ProSerProProSerLysGluSerHisLysSerProAspJ~etAiaAsnCysSerIleMetIleAspGluI leIl e HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGiuAspMetAsplleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAiaPheVaiArgAaVaLysHiseuGuAsnAlaSerGlyI le GluAlalieLeuArgAsnLeuGinProCysLeuProSerAiaThrAi aAlaProSerArgHisProlel leIle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGln~1aGlnGluGln Gin SEQ ID NO:692 pMO N35744.pep AlaSerAsnLeucinAspGiuGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGiyLeuLeuGiuArgVaiAsnThrGlulleHisPhevalimrLys CysAlaPheclnProProProSerCysLeuArgPheValGlnThrAsnhIeSerArgLeuLeuGInGlumhrSer GluGinLeuVaiAiaLeuLysProTrpl leThrArgGinAsnPheSerArgCysLeuGluLeuGlnCysGinPro AspSerSerThrLeuGlyGiyGiySerGlyGiyGiySerGlyGlyGiySerGlyGlyciySerciyGlyGiySer GiyThrGlnAspCysSerPheGinHisSerProlleSerSerAspPheAlaValLyslleArgGiuLeuSerAsp TyrLeuLeuGinAspTyrProValThrValAiaTyrValGluGiyGiyGlyGiySerProGiyGluProSerGly Prol ieSerThrlieAsnProSerProProSerLysGiuSerHisLysSerProAsnMetAiaLAsnCysSerIle MetIieAspGiuIieIieHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeu~snSerGiu AspMetAsplieLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAiaPheVaiArgAiaVaiLysHisLeu GiuAsnAlaSerGlyleGluAlalieLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAiaProSer ArgHisProleleleLysAlaGiyAspTrpGlnGiuPheArgGiuLysLeuThrPheTyrLeuValThrLeu GiuGlnAiaGinGiuGinGln SEQ ID NO:693 pMON35745 .pep AiaAsnLeuGinAspGluGiuLeuCysGiyGiyLeuTrpArgLeuVa iLeuAiaGlnArgTrpMetGiuArgLeu LysThrVaiAlaGiySerLysMetGlnGiyLeuLeuGluArgValAsnThrGiul ieHisPheValThrLysCys AiaPheGlnProProProSerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGinGluThrSerGiu GlnLeuValAlaLeuLysProTrplieThrArgGinAsnPheSerArgCysLeuGluLeuGinCysGlnProAsp SerSerThrLeuGiyGiyGiySerGiyGlyGlySerGlyGlyGiySerGlyGlyGlySerGlyGlyGiySerGiy ThrGinAspCysSerPheGlnHisSerProleSerSerAspPheAiaVaiLys IieArgGluLeuSerAspTyr LeuLeuGinAspTyrProVaiThrVaiAlaSerTyrValGluGiyGlyGiyGlySerProGiyGiuProSerGly ProIleSerThrIleAsnProSerProProSerLysGuSerHisLysSerProAs3i4etAiaAsnCysSerIie MetI ieAspGlul leleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAsplieLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAiaPheVaiArgAiaValLysHisLeu GiuAsnAiaSerGiyleGiuAlaleLeuArgAsnLeuGinProCysLeuProSerAiaThrAiaAiaProSer ArgHisProleleleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GiuGinAlaGinGiuGinGin SEQ ID NO:694 pMON3 5746 .pep AiaLeuGinAspGlu~iuLeucysGiyGlyLeuTrpArgLeuValLeuAaGnArgLeuMetGluArgLeuLys ThrVaiAiaGiySerLysMetGlnGiyLeuLeuGluArgValAsnThrGluleHisPheValThrLysCysAia PheGinProProProSerCysLeuArgPhevaiGlnThrAsnlieSerArgLeuLeuGlnGluThrSerGiuGin LeuVaiAlaLeuLysProTrpleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer Ser~hrLeuGlyGlyGiySerGlyGlyGiySerGlyGlyGlySerGiyGlyGiyserGlyGiyGiySerGlyThr GinAspCysSerPheGinHisSerProlieSerSerAspPheAlaValLyslieArgGiuLeuSerAspTyrLeu LeuGinAspTyrProVaiThrVaiAiaSerAsnTyrValGjluGlyGlyGlyGlySerProGlyGluProSerGly Prol eSerThrl leAsnProSerProProSerLysGiuSerHisLysSerProAsnMetAiaAsnCysserl le MetleAspGiuleleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspl leLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAiaPheVaiArgAiaValLysHisLeu GiuAsnAlaSerGiyleGluAlaleLeuArgAsnLeuGlnProcysLeuProSerAiaThrAiaAlaProSer ArgHisProleleleLysAlaGiyAspTrpGinGiuPheArgGluLysLeuThrPheTyrLeuValThrLeu GiuGInAlaGinGiuGinGin SEQ ID NO:695 pMON3 5747 .pep WO 98/17810 WO 9817810PCT[US97/20037 AlaclnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGJlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPhe GlnProPro Pro SerCysLeuArgPheVa1G lnThrAs Il leserArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGiyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspeysSerPheGlnHisSerProI leSer SerAspPheAl aVa 1Lys 11eArgGluLeu SerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProserGly ProI leSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsniMetAlaAsnCysSerlle MetI leAspGluIleI leHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu Asp~etAspI leLeuMetGluArgAsrlLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlyI leGluAlaI 1 eLeuArgAsnLeuG lrProCysLeu ProSerAlaThrAl aAla Pro Ser ArgHisPro lelleI leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluG~nGln SEQ ID NO:696 pMON35748..pep AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLys ProTrp IleThrArgGlrnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlrnAspCys Ser PheG lnHi sSer Prol 11eSerS erAspPheAl aVa 1 Lys 11eArgGluLeuSerAspTyrLeuLeuG 1riAsp TyrProValThrValAlaSerAsnLeuGlrnAspTyrValGluGlyGlyGlyGlySerProGlyG luProSerGly Prol leSerThrlleAsnProSerProProSerLyscluSerHisLysSerProAsnMetAlaAsnCysSerlle Met 11eAspGlul leI leHi sHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu Asp~etAspl leLeuIetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlyI leGluAlal leLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHis Pro IleI lel leLysAlaGlyAspTrpG lnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGJluGlnGln SEQ ID NO:697 pMON3 5749 .pep Ala LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySer LysMe tG lnG lyLeuLeuG luArgVa lAsnThrG 1u 11eH is PheVa lThrLysCysA1 aPheGlnPrO Pro Pro SerCysLeuArgPhevalGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe G IrH is SerPr o 1 leSer SerAsp PheAl aVal1Lys 11eArgGluLeuSerAspTyrLeuLeuG lnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProlleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetI leAspGluIleIleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAsp IleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHi sLeu G luAs nAl aSerGlyI 1 eG luAl a 11eLeuArgAsnLeuG lnProCysLeuPro SerAlaThrAl aAl aPro ser ArgHi s Pro Ile 1 leI leLysAlaG lyAspTrpGlnGluPheArgG luLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO:698 pMON3575O .pep Al aLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnG luThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProI 1 eSerS erAspPheAl aVa 1Lys 11eArgGl uLeuSerAspTyrLeuLeuG lnAspTyr Pro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProI leSerThrl 1leAs nProSer Pro Pro SerLysGl uSerHi sLys SerProAsnMe tAl aAsnCys SerI le MetI leAspGlullel leHisHisLeuLysArgProProAsnProLeuLeiAspProAsnAsnLeuAsnSerGlu AspMetAspl leLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlavalLysHisLeu GluAsnAlaSerGlyIleGluAlaI leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl lel lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGIn SEQ ID NO:699 pMON3 5769 .pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclnArgTrpMetGluArgLeuLysrhrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIl1eHi sPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGlurhrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGlniAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrclnAspCysSerPhe GlnHisSerProl leSerSerAspPheAlaValLysI eArgGluLeuSerAspTyrLeuLeuG InAspTyr Pro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol11eSerThr1eAsnProSerPro ProSerLysG u SerHi sLysSer ProAsnMe tAl aAsnCys Ser I le Met IieAspGluI leIl eHisHi sLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspDI leLeuMetGluArgAsnLeuArgThrProAsnbeuLeuAlaPheValArgAlaValLysHisLeu GIluAsnAlaSerGlyI leGluAlal leLeuArgAsnLeuclnProCysLeuProSerAlaThrAlaAlaProSer WO 98/17810 PCTIUS97/20037 24A1 ArgHisProIleIlelleLysAiaGJlyAspTrpGinGiuPheArgGiuLysLeuThrPhepyrLeuValThrLeu GiuGinAiaGinGiuGinoin SEQ ID NO:700 pMONJ 5771 .pep AiaSerLysMetGinGiyLeuLeuciuArgVaiAsnThrGiul eHisPheVaiThrLysCysAiaPheGinPro LeuLys ProTrplieThrArgcinAsnPheSerArgCysLeuGiuLeuoilCysGinProAspSerserThrLeu GlyGiyGiySerGiyGiyGlySerGlyGiyGiySerGlyGyGlyThrGlpAspCysSerPheGlnHisSerPro SerAsnLeuGinAspGiuGluLeuCysGiyGlyLeuTrpArgLeuValLeuAlaGInrgTrpMetGluArgLeu LysThrVaiAlaGiyTyrVaiGiuGlyGiyGiyGiySerProGiyGluProSerGiyProl leSerThrlieAsn ProSerProProSerLysGiugerHisLys SerProAsn~etAi aAsnCysSerlieMetleAspGiul leI Ile HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGiuAspMetAspIleLeuMet GiuArgAsnLeuArgThrProAsnLeuLeuAiaPheValArgAiaVaiLysHisLeuGiuAsn~iaSerGyI 1e GluAlal ieLeuArgAsnLeuGlnProCysLeuProSerAiaThrAiaAiaProserArgHisProI iellelie LysAiaGiyAspTrpGlnGiuPheArgGuLysLeuThrPheTyrLeuVaThrLeuGuir~acn~lu~ in Gin SEQ ID pMON35774.pep AlaGinAspAspGiuLeuCysGiyGiyLeuTrpArgLeuVaLeuAaGnArgrrpMetGluArgLeuLysThr VaiAiaGiySerLysMetGlnGiyLeuLeuGluArgValAsnThrGiuleHisPheValThrLysCysAiaPhe Gin~roProProSerCysLeuArgPheVaiGlnThrAsnlieSerArgLeuLeuGinGiuThrSerciucinLeu ValAlaLeuLys ProTrpl 1 eThrArgGinAsnPheSerArgCysLeuGiuLeuGinCysGlnProAspSerSer ThrLeuGlyGiyGiySerGiyGiyGiySerGlyGiyGlySerGlyGlyGiySerGiyGlyGiySerGlyGlyGly SerGiyGiyGiySerGiyThrGinAspCys Ser PheGlnHisSerProI 1ieSerSerAspPheAlaVaiLys I Ie ArgGiuLeuSerAspTyrLeuLeuGinAspTyr ProVa lThrValAiaSerAsnLeuTyrVaiGiuG lyGlyGly GiySerProGiyGiuProSerGiyProlieSerThrlleAsrlProSerProProSerLysGiuSerHisLysSer ProAsnimetAiaAsnCysSerleMetleAspGiuleleHisHisLeuLysArgProProAsnProLeuLeu AspProAsrnAsnLeuAsnSerGiuAspMetAsp I eLeuMetGiuArgAsnLeuArgThrProAsnLeuLeuAla PheVaiArgAiaVaiLysHisLeuGiuAsnAiaSerGiylieGiuAialieLeuArgAsnLeuGlnProCysLeu ProSerAiaThrAiaAiaProserArgHisProl le lelieLysAiaGiyAspTrpGinGiuPheArgGiuLys LeuThrPheTyrLeuVaiThrLeuGiuGin~iaGinGiuGlnGin SEQ ID NO:702 PMON3 5775 .pep Al~ns~ul~uy~yl~ur~ge~le~a~~gr~tl~ge~sh VaiAiaGiySerLysMetGinGlyLeuLeuGiuArgVaAsnThrGiuleHisPheValThrLysCysAiaPhe GlnProProProSerCysLeuArgPheValGinThrAsnlieSerArgLeuLeuGinGluThrSerGiuGlnLeu VaiAi aLeuLys ProTrp I ieThrArgGinAsnPheserArgCysLeuGiuLeuGinCysGinProAspSerSer ThrLeuProProProTrpserProArgProLeuoiyAiaThrAi aProThrThrGinAspCysSerPheGinHis SerProleSerSerAspPheAiaVaLysleArgGuLeuSerAspTyrLeuLeuGinAspTyrProValThr VaiAlaSerAsnLeuTyrValGiuGiyGiyGiyGiySerProGiyGiuProSerGiyProlegerThrl leAsi ProSerProProSerLysGiuSerHisLysSerProAsrij.etAaAsnCysSerI ie~et IieAspGiuI Ie Ile HisHisLeuLysArgProProAsnProLeuLeuAspProAsnsnLeuAsnSerG iuAspMe tAspl leLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheVa lArgAl aValLysHisLeuGiuAsn~iaSerGilyI 1e GiuAialeLeuArgAsnLeuGinProCysLeuProSerAlarhrAiaAiaProSerArgHisProlelelie LysAiaGlyAspTrpGinGluPheArgGiuLysLeuThrPheTyrLeuVaThrLeuGluGln~aGlGlGl Gin SEQ ID NO:703 pMON35776 .pep AiaGliAspGiuGluLeuCysGiyGiyLeuTrpArgLeuValLeuAiaGlirgTrpMetGluArgLeuLysThr VaiAiaGiySerLysMetGinGiyLeuLeuGiuArgValAsnThrGiulieHisPheVaiThrLysCysAi aPhe GilnPro Pro ProSerCys LeuArg Pheva1GlnhrAs n i eSerArgLeuLeuGinGiuThrSerGiuGinLeu VaiAiaLeuLys ProTrplieThrArgGinAsnPheSerArgCysLeuGiuLeuGnCysGnProAspSerser ThrLeuProProProTrpSerProArgProLeuGiyAi aThrAi aProThrAiaGiyGinProProLeuThrGin AspCysSerPheGinHisSerProleSerSerAspPheAjlaValLyslieArgGiuLeuSerAspTyrLeuLeu GinAspTyrProVaiThrVaiAiaSerAsnLeuTyrValGiuGiyGiyGiyGiySerProGiyGiuProSerGly Pro 11eSerThr I eAsnProSerProProSerLysGuSerHi sLys SerProAsetAasnCys SerIi1e MetleAspGulieIlieHisHisLeuLysArgProProAsnPro)LeuLeuAspProAspJsnLesnSerGiu AspMetAspl eLeuMetGiuArgAsnLeuArgThrProAsnLeuLeu~liaPheVaiArgAiaVaiLysHisLeu GiuAsnAiaSerGiylieGiuAialieLeuArgAsnbeuGlnProCysLeuProSerAiaThrAiaAiaProSer ArgHi sPro I Ielei eLysAiaGiyAspTrpGlnGluPheArgGiuLysLeuThrPheTyrLeuVaiThrLeu GiuGinAlaGinGiuGinGIn SEQ ID NO:704 pMON32169 .pep/pMON40000 pep AiaThrProLeuGiyProAiaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGiuGinValArgLys Ile GinGiyAspGiyAiaAiaLeuGinGiuLysLeuCysAi aThrTyrLysLeuCysHis ProGiuGiuLeuVaiLeu LeuGlyHisSerLeuGlyleProTrpAlaProLeUSerSerCYSProSerGlnAlaLeuGinLeuAlaGiyCys LeuSerGinLeuHisSerGlyLeuPheLeuTyrGinGlyLeuLeuGinAlaLeuGiuGlyleSerproGluLeu GiyProThrLeuAspThrLeuGinLeuAspValAiaAspPheAi aThrThrI ieTrpGlnGlnMetGiuGiuLeu GlyMetAiaProAiaLeuGInProThrGinGlyAiaMe t ProAi aPheAiaSerAlaPheGinArgArgAlaGly WO 98/17810 PCTfUS97/20037 GiyValLeuValAlaSerHisLeuGlnSerPheLeuGuValSerTyrArgVaLeuArgHisLeuAaGInPr.

TyrValG iuG lyGlyGiyGiyS erProG lyGlu ProSerG lyPro I IeSerThr I eAsnPr oSerPro Pro Ser Lys Gi1uSerH isLys Ser ProAsniMe tAlaAspGi1uGluLeuCysG iyGiyLeuTrpArgLeuVa ILeuAl aG ln ArgTrpMetGiuArgLeuLysThrVaiAiaciySerLysMetGlnGybeuLeuGluArgValAsnThrGiule His PheValThrLysCysAi aPheGilnPro Pro ProSerCys LeuArgPheVai1GinThrAsn 11eSerArgLeu LeuGlnGluThrserGiuGinLeuVaiAiaLeuLys ProTrp IieThrArgG inAsnPheSerArgCysLeuGiu LeuGinCysGlnProAspSerSerThrLeuGiyGiyGlySerGiyGiyGlySerGiyGiyGiySerGlyGlyGly SerGiyGiyGiySerGiyThrGliAspCys SerPheGlnHis sSerProIlieSerSerAspPheAiaVaiLys Ile ArgGiuLeuSerAspTyrLeuLeuGinAspTyrProVaiThrVaiAaSerAsnLeucin SEQ ID NO:705 pMON321BR .pep AiaThrProLeuGiyProAiaSerSerLeuProGinSerPheLeuLeuLysSerLeuciuGlnVaiArgLys Ile GlnrliyAspGiyAiaAiaLeuGlnGluLysLeuCysAiaThrTyrLysLeuCysHi sProGiuGiuLeuVa iLeu LeuGiyHisSerLeuGiyleProTrpAlaProLeuSerSerCysProSerGinAiaLeuGlnLeuAiaGiyCys LeuSerGinLeuHisSerGiyLeuPheLeuTyrGilGiyLeuLeuGinAiaLeuciuGlyl leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGnGlpl4etGluoiuLeu GiyMetAlaProAiaLeuGinProThrGinGiyAiaMetProAlaPheAiaSerAlaPhecinArgArgAiaGly GiyVaiLeuValAlaSerxisLeuGlnSerPheLeuGiuVaiSerTyrArgValLeuArgHisLeuAlaGInPro TyrVaiGiuGiyGiyGiyGiySerProGlyGiuProSerGlyProleSermrleAsnProSerProProSer LysGiuSerHi sLysSerProAsniMetAiaAsnLeuGinAspGiuGluLeuCysGiyGlyLeuTrpArgLeuVai LeuAiaGinArgTrpMetGiuArgLeuLysThrVaiAiaG lySerLysMe tGinGiyLeuLeuGiuArgVaiAsn ThrGiuI ieHisPheVaiThrLysCysAiaPheGlnProProProSerCysLeuArgPheVaiGlnl leAsnI le SerArgLeuLeuGInGiuThrSerGiuGinLeuValAiaLeuLys ProTrplieThrArgGInAsnPheSerArg CysLeuGluLeuGinCysGinProAspSerSerThrLeuGlyGiyGlySerGlyGlyGiySerGiyGiyGiySer GiyGiyGiySerGiyGlyGlySerGlyThrGinAspCysSerPheGinHisSerProIleSerSerAspPheAa ValiLys 11eArgG luLeuSerAspTyrLeuLeuGilnAspTyr ProVaimrVa, Ai aSer SEQ ID NO:706 pMON32273.pep AiaThrProLeuGlyProAlaSerSerLeuProGinserPheLeuLeuLysSerLeuGiuGinValArgLys lie GlnGiyAspGiyAlaAiaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGiuGiuLeuValLeu LeuGlyHis SerLeuGlylieProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAiaGiyCys LeuSerGlnLeuHisserGlyLeuPheLeuTyrGinGiyLeubeuGlnAlaLeuGiuGlylleSerProGiuLeu GiyProThrLeuAspThrLeuGlnLeuAspVaAaAspPheAaThrTirl eTrpGinGiriMetGiuGiuLeu GiyMetAlaProAiaLeuGinProThrGinciyAlaMetProAiaPheAlaSerAlaPheGlnArgArgAlaGly GiyVaiLeuVaiAlaSerHisLeuGlnSerPheLeuGiuValSerTyrArgValLeuArgHi sLeuAiaGlnPro TyrValGiuGiyGiyGiyGlySerProGiyGiuProSerGiyProl ieSerThrl leAsnProSerProProSer LysGluSerHisLysSerProAsniMetAiaProProserCysLeuArgPheVaiGlnThrAsnlieSerArgLeu LeuGinGiuThrSerciuGlnLeuVaiAiaLeuLys ProTrpleThrArgGlnAsnPheSerArgCysLeuciu LeuGinCysGlnProAspSerSerThrLeuGiyGlyclySerGiyGiyGlySerGlyGiyGlySerGiyGlyGly SerGiyGiyGiySerGiymhrGinAspCysSerPheoinHi sSerProlleSerSerAspPheAiaVaiLys le ArgGiuLeuSerAspTyrLeuLeuGiriAspTyrProVaiThrVaiAlaSerAsnLeuGliAspoiuGiuLeuCys GiyG iyLeuTrpArgLeuVaiLeuAiaGinArgTrpMetGiuArgLeuLysThrVaiAiaGiySerLysMetGin GiyLeuLeuGluArgVaiAsnmrGule-isPheVaiThrLysCysAiaPheGnPro SEQ ID NO:707 pMON35795 .pep AiaThrProLeuGlyProAiaSerSerLeuProGinserPheLeuLeuLysSerLeuGluGinValArgLysle GinGiyAspGlyAlaAlaLeuGinGluLysLeuCysAiaThrTyrLysLeuCysHisProGiuGluLeuVaiLeu LeuGlyHisSerLeuGlyIleProTrpAlaProLeugerSerCysProSerGln~iaLeuGlnLeuAlaGlyCys LeuSerGinLeuHisSerGiyLeuPheLeuTyrGinGlyLeuLeuGinAlaLeuGiuGiyl eSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrleTrpGnGnmetGluGluLeu GlyMetAlaProAlaLeuGinProThrGInGlyAlaMetProAlaPheAlaSerAlaPheGiArgArgAlaGly GlyValLeuValAlaSerl-isLeuGnSerPheLeuGluValSerTyrArgVaiLeuArgHisLeu~laGlnPro TyrVaiGiuGiyGiyGiyGlySerProGiyGiuProSerGlyPro I eSerThrl eAsnProSerProProSer LysGluSerHisLysSerProAsniMetAlaLeuGlnAspGluaiuLeuCysGlyGlyLeuTrpA-rgLeuValLeu AiaGlnArgTrpMetGluArgLeuLysThrVaiAi aGiySerLysMetGinGlyLeuLeuGiuArgVaiAsnThr GiuleHisPheVaiThrLysCysAlaPheGinProProProserCysLeuArgPheVaiGinThrAsnhIeSer ArgLeuLeuGinGiuThrSerGluGlnLeuValAiaLeuLys ProTrplieThrArgcinAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGiyGlySerGiyGlyGlySerGly GiyGiySerGlyGiyGiySerGlyThrGinAspCysSerPheGinHisSerProlieSerSerAspPheAiaVai LysIleArgGluLeuSerAspTyrLeuLeuGln~spTyrProValThrValAlaSerAsn SEQ ID NO: 708 pMON3 5796 .pep AiaThrProLeuGlyProAiaSerSerLeuProGlngerPheLeuLeuLys SerLeuGluGlnValArgLys le GlnGlyAspGlyAiaAiaLeuGlnGluLysLeuCysAiaThrTyrLysLeuCysHisProGluGluLeuValbeu LeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGln~laLeuGInLeu~iaGlyCys LeuSerGinLeuHisSerGiyLeuPheLeuTyrGlnGiyLeuLeuGlAaLeuGluGiylieSerProGiuLeu GlyProThrLeuAspThrLeuGinbeuAspVaAlaAspPheAlaThrThrl eTrpGinGlnMetGiuGiuLeu GlyMetAlaProAiaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGln~rgArgAlaGly GlyValLeuValAiaSerHisLeuGinSerPheLeuGluVa.SerTyrArgValLeuArgHisLeuAlaGlnPro TyrVaiGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThrlleAsnProSerProProSer WO 98/17810 PCT/US97/20037 LysGiuSerHisLys SerProAsnMe tAiaGliAspGluGiuLeuCysGlyoiyLeuTrpArgLeuVaiLeuAia GlnArgTrpMetGiuArgLeuLysThrValAaGlySerLysMetGinciyLeuLeuGuArgVaAsiThrGlu I ieHis PheVaiThrLysCysAiaPheGinProProProSerCysLeuArgPheVaiGinmhrAsnI 1ieSerArg LeuLeuGinGluThrSerGiuGinLeuVaiAi aLeuLys ProTrplieThrArgGinAsnPheSerArgCysLeu GluLeuGinCysGlnProAspSerSerThrLeuGiyGiyGiySerGiyGiyGlySerGlyGiyGlySerGiyGiy GlySerGiyGiyGiySerGiyThrGintAspCys SerPheGinHi sSerProlieSerSerAspPheAiaVaiLys IieArgGiuLeuSerAspTyrLeuLeuGinAspTyrProVaiThrValAiaSerAsnLeu SEQ ID NO: 709 pMON35797 .pep AiaThrProLeuciyProAiaSerSerLeuProGinSerPheLeuLeuLysserLeuGluGinValArgLys le GinGiyAspGlyAiaAlaLeuGlnGluLysLeuCysAaThrTyrLysLeuCys-isProGluGiuLeuValLeu LeuGlyH is SerLeuGlyl 1 eProTrpAlaProLeuSerSerCys Pro SerGinAl aLeuGinLeuAi aGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrcinGlyLeuLeuGinAiaLeuciuclylieSerProGluLeu GiyProThrLeuAspThrLeuGInLeuAspValAiaAspPheAiaThrThrleTrpGniletGiuGluLeu GiyMetAiaProAiaLeuGlnProThrGlnGiyAlaMetProAiaPheAlaSerAlaPheGinArgArgAlaGly GiyVaiLeuValAlaSerHisLeuGlnSerPheLeuGluVai SerTyrArgValLeuArgHisLeuAiaGinPro TyrValGiuGiyGlyGlyGiySerProGiyGiuProSerGlyProleSerThrl leAsnProSerProProSer LysGiluSerH is Lys SerProAsnMe tAi aGuG luLeucys G yGiyLeuTrpArgLeuVaiLeuAl aG nArg TrpMetGiuArgLeuLysThrVaiAiaGlySerLysMetGlnGiyLeuLeuiuArgValAsnThrciul leHis PheVaiThrLysCysAi aPheG lnPro Pro ProSerCysLeuArgPheVaiGinmhrAsnl 1 eS erArgLeuLeu GinGiuThrSerGluGlnLeuVaiAiaLeuLys ProTrp IleThrArgGinAsnPheSerArgCysLeuGiuLeu GinCysGInProAspSerSerThrLeuGiyGlyGiySerGlyGiyGiySerGlyGiyGlySerGiyclyGlyger GlyG lyGilySerGlyThrG nAspCys Ser PheGlnH is Ser Pro 11e SerSerAspPheAi aVa ILys I leArg GiuLeuSerAspTyrLeuLeuGlnAspTyrProVaiThrVaiAlaSerAsnLeuGliAsp SEQ ID NO: 710 pMON35798 .pep AlaThrProLeuGiyProAlaSerSerLeuProGlnserPheLeuLeuLysserLeuGluGinVaiArgLysl le GlnGlyAspGlyAiaAl aLeuGlnGluLysLeuCysAiaThrTyrLysLeuCysji sProGluGluLeuVaiLeu LeuG lyH is SerLeuGlyl 11eProTrpAl aProLeuS erSerCys Pro SerG 1nA 1aLeuGl nLeuA laG lyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGiyLeuLeuGlnAiaLeuGluGlyl leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlieTrpGlnGlnl~etGluGiuLeu GlyMetAlaProAlaLeuGlnPrcThrGinGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVaiserTyrArgVaLeuArglisLeuAlaGlnPro 'yrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProleSerThrl leAsnProSerProProSer LysG luSerHi sLys Ser ProAsn4e tAi aGl uLeuCysGlyG lyLeurrpArgLeuVa ILeuAl aGlnArgTrp MetGluArgzeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrplieThrArgGlnAsnPh-eSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGiyGlyGlySerGlyGlyGlySerGiyGlyGlySerGly G lyGilySerGilyThrGlriAspCys Ser PheGlnH is Ser Pro i eSer SerAsp PheAl aVailLys 11eArgG lu LeuSerAspTyrLeuLeuGlnAspTyrProVaiThrValAlaSerAsnLeuGlnAspGiu SEQ ID NO:711 pMON35799.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuoiuGinValArgLys le GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlamhrTyrLysLeuCysHisProGiuGluLeuValLeu LeuGiyHi sSerLeuGlyI 1e ProTrpAi aProLeuS erSerCys Pro SerGlnAi1aLeuGilnLeuAl aG lyCys LeuSerGinLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGiriAlaLeuGiuGyleSerProGuLeu GlyProThrLeuAspThrLeuGinLeuAspVaiAlaAspPheAiamhrThrleTrpGnGlnMetGluGluLeu GlyMetAlaProAiaLeuGinProThrGnGyAaMetProAaPheAaSerAaPheGl-ArgArgAiaGly GiyVaiLeuVaiAlaSerHisLeuGinSerPheLeuGiuVai SerTyrArgValLeuArgHisLeuAiaGinPro TyrVaiGiuGlyGiyGiyGiySerProGiyGluProSerGlyProxIeSerThrlieAsnProSerProProSer LysGiuSerHi sLysSerProAsniMetAlaLeuCysGlyGlyLeuTrpArgLeuVaiLeuA aGinArgTrpMet GiuArgLeuLysThrVaiAiaGlySerLysMetGinGiyLeuLeuGluArgValAsnThrGiul leHisPheVal ThrLysCysAiaPheGlnProProProSerCysLeuArgPhevaiGinThrAsnlieSerArgLeuLeuGinGlu ThrSerGiuGinLeuVaiAiaLeuLys ProTrpleThrArgGlnAsnPheSerArgCysLeuGiubeuGInCys GlnProAspSerSermhrLeuGlyGiyGySerGlyGlyGiySerGiyGyGySerGlyGiyGiySerGlyGly GiySerGiyThrcinAspCysSerPheGinHisSerProleSerSerAsppheAiaVaiLysleArgGluLeu SerAspTyrLeuLeuGinAspTyrProVaiThrVaiAiaSerAsnLeuGinAspGluGiu SEQ ID NO :712 pMON39914 .pep AlaThrProLeuciyProAiaSerSerLeuProGinSerPheLeuLeuLysSerLeuGluGinvalArgLys le GInGiyAspGlyAlaAiaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCys~isProGiuGiuLeuValLeu LeuGlyHisSerLeuGlyl eProTrpAiaProLeuSerSerCysProSerGlnAlaLeuGinLeuAlaGiyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGiyLeuLeuGli~laLeuGiuGlylleSerProGluLeu GlyProThrLeuAspThrLeuGinLeuAspVaiAlaAspPheAi aThrThrlieTrpGinGiriMetGiuGiuLeu GiyMetAiaProAlaLeuGlnProThrGinGlyAiaMetProAlaPheAaSerAaPheGnAxrgArgAiaGiy GiyVaiLeuValAiaSerHisLeuGlnSerPheLeuGiuVai SerTyrArgVaiLeuArgHisLeuAiaGinPro TyrVaiGluGiyGlyGiyGiySerProGyGuProSerGlyProleSerrhrlieAsnProSerProProger LysGIuSerHisLys SerProAsnMetAiaAspGluGluLeuCysGlyGiyLeuTrpArgLeuVa iLeuAiaGin ArgTrpMetGluArgLeuLysThrvaiAiaGiySerLysMetoilnGlyLeuLeuGiuArgVaiAsnThrGlul le HisPheVaiThrLysCysAlaPheGlnProProProSerCysLeuArgPhevalGlnThrAsnlieSerArgLeu WO 98/17810 PCTIUS97/20037 21411f LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlriAsnPheSerArgCysLeuGlu LeuGlnCysolnProAspSerSerThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThr ThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLys IleArgGluLeuSerAspTyr LeuLeuGlInAspTyrProValThrValAlaSerAsnbeuGln SEQ ID NQ:713 pMON3 9915 .pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysserLeuGluGlnValArgLys le GlnGiyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrbysLeuCysHisProclucluLeuValLeu LeuGlyflisSerLeuclylleProTrpAlaProLeuSerSerCysProSerGlrlAlaLeu~lnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrclnGlyLeubeuGliAlaLeuGluGlyl leSerPro~luLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpclnGlnlmetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGliArgArgAlaGly GiyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerclyProleSermhrlleAsnProSerProProSer LysGiuSerHi sLysSerProAsnMe tAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrVa lAlaGlySerLysMetGiG lyLeuLeuGluArgValAsnThrGlul le His PheValmhrLysCysAlaPheGlnProProProSerCysLeuArgPheValclnThrAsnl eSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlriAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGiyGiyGlySerolyGlyGlySerGlyGlyGlySerGlyGlyGly SerGiyGlyGlySerGlyGlyGlySerGlyGlyciySerGlyThrGliAspCysSerPheGlnHisSerProl le SerSerAspPheAl aVaiLys IleArgGluLeuSerAspTyrLeuLeuGinAspTyrProValThrValAi aSer AsnLeuGln SEQ ID NO:714 pMON39916.pep AlaThrProLeuGlyProAiaserSerLeuProolnserPheLeubeuLysSerLeuGluoinValArgLys le GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHis SerLeuGlylieProTrpAlaProLeuSerSerCysProSerGlinAiaLeuGinLeuAiaciyCys LeuSerGinLeuHisSerGiyLeuPheLeuTyrGlnGlyLeuLeuGnAaLeuGiuGiyleSerProGluLeu GlyProThrLeuAspThrLeucinLeuAspVaiAlaAspPheAaThrThrleTrpirilinMetGluGluLeu GiyMetAlaProAlaLeuGinProThrGInGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAiaGly GiyValLeuValAlaSerHisLeuGnSerPheLeuGuValSerryrArgVaLeuArg-isLeuAlaGlnPro TyrVaiGluGiyGiyGiyGiySerProGlyGluProSerGiyProlieSerThrl eAsnProSerProProSer LysGIuSerHisLysgerProAsnMe tAlaAspGiuGluLeuCysGlyGiyLeuTrpArgLeuVaiLeuAl aGIn ArgTrpMetGiuArgLeubysThrValAiaGiyserLysMetGinGlyLeuLeuciuArgVaiAsnThrGlul le HisPheVaiThrLysCysAiaPheGinProProProserCysLeuArgPheValGlnThrAsnl leSerArgLeu LeuGilGluThrSerGiucinLeuVaiAlaLeuLysProTrpleThrArgGlnAsnPheSerArgCysLeuGlu LeuGinCysGlnProAspSerserThrLeuProProProTrpSerProArgProLeuGlyAaThrAaProrhr AlaGlyGinProProLeuThrGlnAspCysSerPheGinHisSerProleSerSerAspPheAiaValLyslle ArgGluLeuSerAspTyrLeuLeuGliAspTyrProVaiThrValAiaSerAsnLeuGln SEQ ID NO: 715 pMON35712 .pep AiaAspTyrProVaiThrVaiAiaSerAsnLeuGinAspGluGiuLeuCysGlyGiyLeuTrpArgLeuVa iLeu AiaGlnArgTrpMetGluArgLeuLysThrVaiAlaGiySerLysMe tGinGiyLeuLeuGluArgValAsnThr GluleHisPheVaiThrLysCysAiaPheGlnProProProSerCysLeuArgPheVaiGlnThrAsnlieSer ArgLeuLeuGInGiuThrSerGluGInLeuVaiAlaLeuLys ProTrplieThrArgGlnAsnPheSerArgCys LeuGluLeuGinCysGinProAspSerSerThrLeuGlyGlyGlySerGlyGiyGlySerGlyGlyGlySerGly GiyGlyThrGinAspCysSerPheGinuisSerProl leSerSerAspPheAlaValLys I eArgGiuLeuSer AspTyrLeuLeuGin SEQ ID NO:716 pMON35713 .pep AlaAlaSerAsnLeuGlnAspGluGiuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGiyserLysMetGlnGlyLeuLeucluArgValAsnThrGlulieHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGinThrAsnhleSerArgLeuLeuGlnGluThr SerGiuGlnLeuValAlaLeuLys ProTrpl eThrArgGlnAsriPheSerArgCysbeuGluLeuGinCysGln ProAspSerSermrLeuGyGyGySerGyGlyGlySerGyiyGlySerGlyGyGlyThrGr]AspCys SerPheGlnHisSerProlleSerSerAspPheAlaValLys I eArgGluLeuSerAspTyrLeuLeuGinAsp TyrProValThrVal SEQ ID NO:717 pMON3 5714 .pep AlavalAlaGlySerLysMetGlnGlyLeuLeucluArgValAsnThrGlulleHisPhevalThrLysCysAla PheG lnProPro Pro SerCys LeuArgPheVa lGinThrAsnl 11eSerArgLeuLeuGlnGluThrSerGiuGln LeuValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerclyGlyGySerGlyGyGlySerGyGyGyThrGln~jspCysSerPheGln His SerProl11eSerSerAspPheAlaValLyslIleArgGluLeuSerAspTyrLeuLeuGlniAspTyrProVaI ThrValAlaSerAsnLeuolnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GiuArgLeuLysThr.SEQ ID NO:718 pMON3 5715 .pep WO 98/17810 PCTIUS97/20037 245 AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHis PheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlncluThrSercluGlnLeuValAla LeuLysProTrpl leThrArg~lnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHjisSerPro IleSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaolnArgTrp~e tGluArgLeu LysThrValAlaGly SEQ ID NO:719 pMON3 5716 .pep AlaProProSerCysLeuArgPheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpI leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspserserThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGyGlyThrG.nAspCysSerPheGlnHisSer Pro 11eSerS erAspPheAl aVal Lys 11eArgG luLeuSerAspTyrLeuLeuG lnAspTyrProVa lThrVal AlaSerAsnLeuGlrlAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGrInArgTrpMetnluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHi sPheValThrLys CysAlaPheGinPro SEQ ID NO:720 pMONJ 5717 .pep AlaArgPheValGlnThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProI leSerSez-Asp PheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetcluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHis PheValThrLysCysAlaPheGlnPro ProProSerCysLeu SEQ ID NO:721 pMON35718 .pep AlaThrAsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyclySerGlyclyGlySer G lyG lyGlySerGlyG lyGlyThrG lnAspCys Ser PheGlnH is SerPro 11eSerSerAspPheAl aVa 1Lys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGln SEQ ID NO:722 pMON3217O.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlniArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrolulleHisPheValThrLysCysAlaPheGln Pro Pro Pro SerCysLeuArgPheValG lnThrAsnlI leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerclyclyGlySerclyThrGlnAsp CysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeuserAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyolySerProGlyGluProSerGly ProI leSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnimetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysI leGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuclyHisSerLeu GlyI leProTrpAlaProLeuSerSerCys Pro SerGl1nAlaLeuGlnLeuAl aG lyCys LeugerGlnLeuHi s SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAl aLeuGluG lyl leSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlriMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 723 pMON32 187 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlrnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeu~luArgValAsnThrolulleHisPheValThrLysCysAlaPheGln Pro Pro ProSerCysLeuArgPheVa1G lnThrAsn 11eSerArgLeuLeuclnG 1uhrS erGluG lnLeuVa 1 Al aLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyclySerGlyGlyGlySerGlyGlyGlySerGlyrhrGlrAsp CysSerPheGlnHisSerProlleSerSerAspPheAlaValLysleArgGluLeuSerAspTyrLeuLeuoln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluG lyGlyGlyGlySerProclyGluProSerGly Prol 11eSerThrl 11eAsnProS erProPr oSerLysGl uSerH isLys SerProAsnrme tAl aThrProLeuGly ProAlaSerSerbeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysl leGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis FroGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrG inGlyLeuLeuGlnAl aLeuGluGlyl eSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl eTrpGlnGletGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlniArgArgAlaGlyGlyvalLeuValAla SerHisLeuGlnSerPheLeuGluValSerryrArgValLeuA-rgHisLeuAlaclnPro SEQ ID NO: 724 WO 98/17810 WO 9817810PCT[US97/20037 pMON32271 .pep AlaAspGluGluLeuCysclyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVaI AlaGlySerLysMetGlnGJlyLeuLeuGluArgValAsnmhrGlulleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuProPro ProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyalnProProLeuThrGlr~sp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGlu GluLeuValLeuLeuGlyHi sSerLeuGlyI 1 eProTrpAlaProLeuSerSerCys ProSerGlnlAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrolnGlyLeuLeuGlnAlaLeuGluGlyl le SerProGluLeuGlyProThrLeuAsprhrLeuGlnLeuAspValAlaAspPheAlaThrrhrl leTrpGlnGln MetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGln ArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnserPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnPro SEQ ID NO:725 pMON32 272 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrVa.

AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnmhrG lulleHisPheValThrLysCysAlaPhecln ProPro ProSerCysLeuArgPheValGlnphrAsnl leSerArgLeuLeuGlnGluThrgerGluGlnLeuVaI AlaLeuLysProTrpl leThrArgGlniAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlymrGlnAspCysSerPhe~lnHisSerPro IleSerSerAsppheAlaValLys IleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyolyGly GlySerProGlyGlyGlySerGlyGlyGlySerAsriMetAlaThrProLeuGlyProAlaSerSerLeuProGln SerPheLeuLeuLysSerLeuGluclnValArgLys IleGlnclyAspclyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeu SerSerCys ProSerGlniAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGln GlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGln'roThrGlnGlyAla Me tProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa iLeuValAlaSer-i sbeuGlnSerPheLeu GluValS-erTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:726 pMON32 274 -pep AlaAspGluG luLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMe tGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPhevalThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrgerGluGlnLeuVal AlaLeuLys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuPro Pro ProTrpSerProArgProLeuclyAlaThrAlaProThrThrGllAspCys SerPheGinHis Ser ProlleSerSerAspPheAlaValLyslleArgGluLeuserAspryrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnmetAlaThr ProLeuGilyProAlaSerSerLeuProGlnserPheLeuLeuLysserLeuGluGlnValArgLys IleGlnGly AspGlyAlaAlaLeuGlnGluLysLeuCysAl aThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly HisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlniAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeu~yrGlnGlyLeuLeuGlnAlaLeuluGlyleSerProG.uLeuGlyPro ThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlamrhrThrleTrplGlnfl1etGluGluLeuGlyMet AlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheliArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeulaGlnPro

SEQ

ID NO:727 pMON\3 5751 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAl.aGlnArgTrpMetGluArgLeuLysThrVal Al aGlySerLysMetGlnGlyLeuLeuGluArgValAsnmhrGlul leHi sPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuArgProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspserSermhr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAsp PheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValmhrValAlaserAsnLeuGln TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThrl leAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProG~nSerPheLeuLeu LysCysLeuGluclnValArgLys IleGlnGlyAspGlyAla-AlaLeuGlnGluLysLeuCysAlaThrTyrLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnG lyLeuLeuGra Al aLeuGluGlyl eSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAl aThr ThrlleTrpGlnGlnlMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyclyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:728 pMON3 5752 .pep wn OR/I 721 Ik virrvitycooWlinnioT AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclr~rgTrpMetGluArgLeuLysThrval AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPhevalGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVaI AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyclySerGlyGyGyThrGn~spCysSerPheGlnHisSer Pr~ee~rs~el~ly~er~ue~rs~re~ul~py~oa~ra AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProI leSerThrl leAsn ProSerProProSerLysGluSerHisLysSerProAsn4etAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysl leGlnGlyAspGlyAlaAlaLeuGlncluLysLeu CysAlaThrTyrLysLeuCysHisProoluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVaI AlaAspPheAlaThrThrl eTrpGlnGlnMetGluGluLeuolyMetAlaProAlaLeuGlnProThrclnGly Al~tr~ah~ae~ah~nr~gl~yl~le~ll~ri~ul~rh LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:729 pMON35753 .pep AlaAspGluGluLeuCysolyGlyLeuTrpArgLeuValLeuAlaGlw~rgTrpMetGluArgLeuLysThrVaI AlaolySerLysMetolnGlyLeuLeuoiuArgValAsnThrolulleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlncluThrSerGluGlnLeuVal AlaLeuLysProTrpl leThrArgolnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThr LeuGlyGlyGlySerGlyGlyGlySerclyalyGlySerGlyGlyGlySerGlyolyolySerGlyThrGl1sp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol leSerThrIleAsnProSerProProSerLysG~uSerHisLysSerProAsnetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysl leGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGlihGluLeuVaJ.LeuLeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGln~laLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGln~laLeuGluGlyIleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAl.aThrThr IieTrpGlnGlniMetGluGluLeuGlyMetAlaProAl a LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGl1rgArgAaGlylyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValValArgHisLeuAlaGlnPro SEQ ID NO: 730 pMON35754.pep AlaProProSerCysLeuArgPhevalGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl leThrArgclnAsnPheSerArgCysLeuo luLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGyGyGyThr1InJspCysSerPheGinHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl1spTyrProValThrVaI Al aSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu~laGlnrgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnolyLeuLeuGluArgvalAsnThrGlulleHisPheValThrLys CysAlaPheGlnProTyrvalGluGlyGlyGlyGlySerProGlyGluProSerGlyProl leserThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsniMetAlaThrProLeuGlyProAlaSerSerValPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleolnGlyAspGlyAlaAlaLeuGlncluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerreuGlyl leProTrpAlaPro LeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHi sSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrl leTrpGlnGlrlI'etGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyclyValLeuValAlaserHisLeuGlnSerPhe LeuGluValserTyrArgvallleArgHisLeuAlaGlnPro SEQ ID NO: 731 pMON3 5755 .pep AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGl1rgTrpMetclurg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlurgVaAsnThrGluleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpI leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlylyGlySer GlyThrGlnAspCysSerPheolnHisserProlleSerSerAspPheAlaValLyslleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGlySerProclyGluProSerGly ProIleSerThrI leAsnProSerHisProSerLysGluSerHisLysSerProAsnldetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluclnValArgLys IleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGlpJlaLeuGlnLeu~laGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI JeSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGl1rgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeurgHisLeuAlaGnPro SEQ ID NO: 732 pMON3 5756 .pep AlaAsnLeuGlnAspGluGluLeuCysGyolyLeuTrpArgLeuVaLe~1aGl1rgTrpMetGlurgLeu LysThrValAlaGlySerLysMetGnGlyLeuLeuGu.rgValAsnThrGluI leHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPhevalnThrAsflleSerArgLeuLeu~1lnGluThrSerGlu WO 98/17810 WO 9817810PCTIUS97/20037 GlnLeuValAlaLeuLys ProTrpI 1 eThrArgGlnAsnPheSerArgCysLeuGluLeuGllCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyclyGlySerGlyGlyGlySerGly ThrclnAspCys erPheGlnHisSerProI leSerSerAspPheAlaValLys I IeArgGlubeuSerAspTyr LeuLeuGlnAspTyrProValmhrValAlaSerTyrValGl uGlyGlyGlyGlySerProGlyGluProSeroly Pro 11eSerThr I eAsnProS erPro ProSerLys GluSerHisLys SerPr oAse tAl aThrProLeuG ly ProAlaSerSerLeuProclnSerPheLeuLeuLysCysLeuoluGlnValArgLys I leGlnGlyAspGlyAla AlaLeuGlnGJluLysLeuCysAlamrTyrLysLeuCysHi s ProGluGluLeuValLeuLeuGlyHis erLeu Glyl leProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnclyLeuLeuGlnAlaLeuGluclyI 1leSerProGluLeuGlyPromhrLeuAsp ThrLeuGlnLeuAspVa1AlaAspPheAlaThrThr I eTrpGlnGlrletGluGluLeuGlyMetAI aProAla Le~nr~rl~yl~tr~ah~ae~ah~nr~gl~yl~le~ll SerHisLeuclnSerPheLeuo luValSerTyrArgVallleArgHisLeuAlaGlnPro SEQ ID NO: 733 pMON3 5757 .pep AlaLeuGlniAspGluGluLeuCysGlyclyLeuTrpArgLeuValLeuAlaGl1rgLeuMe tGluArgLeuLys Th~ll~ye~se~nl~ue~ur~ls~rl~ei~ea~ry~sl PheGlnProProProSerCysLeuArgPhevalolnThrAsnr leSerArgLeuLeuclnGluThrserGluGln LeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeulnCysolnProAspser SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCys SerPheG lnHis er Pro 11eSerSerAspPheAl aVa ILys I1 eArgGl uLeuS erAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol 11eSerThr 11eAsnPro Ser ProProSerLysG luSerH isLys SerProAse tAl aThrProLeuG ly ProAlaSerSerLeur'roolnSerPheLeuLeuLysCysLeuGluclnvalArgLys IleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCys ProSerGlnAl aLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyl leSerProGluLeuGlyPromhrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlIeTrpGlnGlrietGluGluLeuGlymetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGl1rgArgAlaGlyGlyValLeuValAla SerHisbeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 734 pMON3575B .pep AlaLeuCysGlyGlyLeullrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGlySer LysMe tG lnGlyLeuLeuG 1uArgVa lAsnThrGlulIleH isPheVa lThrLysCysAl aPheGlnProPro Pro SerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuvaJ.AlaLeuLys ProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGl1spCysSerPhe G lnHi sSer Prol11eSerSerAsp PheAlaVa lLys 11leArgGluLeuSerAspTyrLeuLeuG lnAspTyrPro ValThrValAlaSerAsnLeuGlrlAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Proll1eSerThrl 1leAsnProSerProProSerLyscluSerHisLysSerProAsnetAlaThrProLeuGly ProAlaSerSerLeuProcGlnSerPheLeuLeuLysCysLeuGluGlnValArgLys IleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlIyll1eProTrpAl aProLeuSerSerCys Pro SerG lnAl aLeuGl1nLeuAl aG IyCys LeuSerG lnLeuH is SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlarhrThrl leTrpGlnGlrlMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPeGlnkrgArgAlaGlyGlyValLeuValAla SerI-isLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:735 pMON35759.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHi sPheValThrLysCysAlaPheGlnPro Pro ProSerCys LeuArgPheVa1G lnThrAsnI 1e SerArgLeuLeuG lnG luThr SerG luGlnLeuVa lAl a LeuLysProTrpl leThrArgGlniAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyclyGly~hrGlnAspCysSerPheGlnHisSerPro 11leSer SerAspPheAlaVal Lys 11eArgG luLeu SerAspTyrLeuLeuGpJ~spTyrProVa lThrVa1AI a SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeu Lys ThrValAl aGlyTyrVa lGluGlyG lyG lyGlySerProG lyG 1uProgerG lyPro 11eS erThrl11eAsn ProSerProProSerLysGluSerHisLysSerProAsn~jetAlaThrProLeuGlyProAlagerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLy 3 Leu CysAlaThrTyrLysbeuCysHisProoluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCys ProSerclnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerolyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyx leSerProGluLeuGlyPromrLeuAspThrLeuGlnLeuAspVa.

AlaAspPheAlaThrThrlleTrpGlnGlrMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisIeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 736 pMON3 5760.pep AlaSerLysMetGlnGlyLeuLeuGlurgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGl~nGluThrSerGluGlnLeuValAla LeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlncysGlnProAspSerserThrLeu GlyGlyGlySerGlyGlyGlySerGlyclyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro 11leSer SerAsp PheAlaVal1Lysl 11eArgGluLeuSerAspTyrLeuLeuGli2spTyrProVa lThrValAl a SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVaLe~laGlrgTrp~etGlurgLeu WO 98/17810 PCT[US97/20037 LysThrValAlaGJlyTyrVa1GluG lyGlyGlyGlySerProGlyGluProSerGlyPro I leSerThrl leAsn Pro SerPr oProSerLysG 1uSerHi sLys SerProAsnMe tAl aThr ProLeuG lyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGlu~lnValArgLysl le~lnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly-isSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerlnLeuHis~erGlyLeUPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuGllLeuAspVaI AlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGJlyValLeuValAlaSerHisLeu~lnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO :737 pMON3 5761. pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGlySer Lysb~etGlnGlyLeuLeuGluArgValAsnThrGluI leHi sPhevalThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyserGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProl leSerSerAsnPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlniAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProllePheThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGllValArgLys IleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlriAlaLeuGluGlyl leSerProGluLeuGlyProThrbeuAsp ThrLeuGlnLeuAspValAlaiAspPheAlaThrThrI leTrpGlnG ln~etGluGluLeuGlyMetAlaProAl a LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAl aPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:738 pMON35762 .pep AlaGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnLArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIl eHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProrrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnLAspGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol leSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnmetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeubeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrpGlnG lnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGllArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 739 pMON3 5763 .pep AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrG lul leHisPheValThrLysCysAlaPheGllPro ProProSerCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerluGllLeuValAla LeuLys ProTrpIl1eThrArgGlnAsnPheSerArgCysLeuGluLeuolnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGinHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol 11eSerThrl 1leAsnProSer Pro Pro SerLysG luS erHis Lys SerProAsniMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi sProGluGluLeuValLeuLeuGlyHisSerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGnLfeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnlaLeuGluGlyI 1eSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaLMetProAlaPheAlaSerAl aPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 740 pMON35764.pep AlaGlnAspGluGluLeuCysGlyGlyL euTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLyscysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnll1eserArgLeuLeuGlnGluThrSerGluGllLeu ValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsPSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGll AspCys Ser PheG lnH is Ser Pro 11eSer SerAspPheAl aValLys IleArgGl uLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Pro I leSerThrl leAsnProSerProProSerLysGluSerHi sL-vsSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla WO 98/17810 PCT/US97/20037 AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi sProC luGluLeuValLeuLeu~lyHis serLeu Glyl I eProTrpAlaProLeuSerSerCysProSerGlnAl aLeuG LeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAl aLeuGluGlyIl eSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspVa lAlaAspPheAlaThrThr IleTrpGlnGlnMetGluGluLeuGlyMe tAlaProAl a LeuGlnProThrG~nGlyAlaMe tProAlaPheA a SerAl aPheG lnrgArgAlaGlyGlyValLeuVa lAla SerHisLeuG~nSerPheLeuGluValSerTyrArgValLeuArgHisLeu~1aGlnPro SEQ ID NO: 741 pMON3 5765 .pep AlaThrAsnhleSerArgLeuLeuG~nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr~rgGln AsnPheSerArgCysLeuGluLeuGnCysGnProAspSerSerThrLeuGyGyGySerc1lyySer GlyG lyGl yS erG lyGlyG lyThrG lriAspCys Ser PheG lnHis Ser Prol 11eSerSerAsp PheAl aValbys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAaaSerAsnLeuGl1sp~luGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnA-gTrpMe tGluArgLeuLysThrValAl aGlySerLysMet G lnGlyLeuLeuGI uArgVa lAs nThrG lu IleHi s PheVa lThrLysCysAl aPheGlnPro Pro ProSerCys LeuArgPheValGlnTyrValGluGlyGlyolyGlySerProGlyGluProSerGlyProIeSerThrIleAsfl ProS er Pro ProSerLysG luS er~i sLys Ser ProAse tAlaThrProLeuG lyProAl aSerSerLeuPro GlnserPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyl leProTrpAlaPro LeuSerSerCys ProSerGlnAlaLeuGlnLeuAl aGlyCysLeuiSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGlulylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrIleTrpGlnGlniMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHi sLeuGinSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:742 pMON35766 .pep/pMON3219O .pep/pMON40001 pep AlaAspGluGluLeuCysolyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArgLeuLysThrVaI AlaGlySerLysMetGlI-GlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGln ProPro Pro SerCysLeuArg PheVa lGlnThrAsnl 11eS erArgLeuLeuG lnGluThr serG luG InLeuVa 1 AlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuG luLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrc1nsp CysSerPheGlnHisSerProI leSerSerAspPheAlaValLysl leArgGluLeuserAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsndetAlaThrProLeuclyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu GlnValArgLys IleGlnGlyAspGlyAlaAlaLeuGlnG 1uLysLeuCysAlaThrTyrLysLeuCysHis Pro G luG IuLeuVal LeuLeuGlyH is e rLeuGly 1 leProTrpAl aProLeuSer SerCys Pro SerGl nAl aLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGl1~laLeuGluGly I leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl eTrpGln GlnmetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaserHisLeuGlnSerPheLeuGluValSerTyrArgValLeurg HisLeuAlaGlnPro SEQ ID NO:743 pMON3 5768 .pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlrlArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlullexisPheValThrLysCysAlaPhe G lnPro Pro ProSerCysLeuArgPheVal1GlnThrAsnl eSerArgLeuLeuGlnGluThrserGluGlnLeu ValAlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProl leSerSerAspSerAlaValLyslleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyclySerProGlyGluProSerGly Prol leSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLys IleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlyIleProTrpAlaProLeuSerSerCysProSerG1lj~1aLeuG~nLeu~laGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrmhr IleTrpGlnGlnMetGluGluLeuGly~etAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAl aPheG lnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPbeLeuGluValSerTyrArgValLeuArisLeup~1aGlnPro SEQ ID NO:744 pMON3577O .pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaolArrgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThr~luI leHi sPheValThrLysTyrAlaPheclnProProPro SerCysLeuArgPheValc~lnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerserThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrG1lj~spCysSerPheG~nisSerPro I leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAse tAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysl leGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyl leProTrp AlaProLeuSerSerCysProSerGlrlAlaLeuGlnLeuAl aGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuclnAlaLeuGluclylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeu WO 98/17810 WO QR17810PCT11N97/20037 AspValAlaAspPheAlaThrThrl leTrpGlnGlnMetGluGlULeuGlyMetAlaProAlaLeuGlnProThr GlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGln SerPheLeuGluValSerTyrArgValLeuArgHisLeuAjlaGlnPro SEQ ID NO: 745 pMON35772.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGaul leHi sPheValThrLysCysAlaphealnPro ProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl a LeuLys ProTrp IieThrArgGlniAsnPhePheArgCysLeuGJluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrcln~spCysSerPheGlnHisSerPro I leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGl]AspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlylyLeurrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyolyGlySerProGlyGluProSerGlyPro IleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnl~etAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluolnValArgLysI eGlnGyAspGlyAlaAlaLeucln~luLysLeu CysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuoly leProTrpAlaPro LeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeugerGlnLeuHi sSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuclnLeuAspVal AlaAspPheAlaThrThrIleTrpGlnclnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheolnArgArgAlaGlyGlyValLeuValAlaserHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 746 pMON3 5773 .pep AlaG lnAspGluGluLeuCysclyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThr ValAlaolySerLysMetGlnGlyLeubeuGluArgValAsnThrGluleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValjlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerser ThrLeuGlyGlyGlySerGlyGlyGlySerGly~lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGln~lisSerProlleSerSerAspPheAlaValLyslle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl aSerAsnLeuTyrVa iGluGlyGlyGly G lySer ProG lyGluPro SerG lyPro 11eS erThr I leAsnPro Se rProProSerLysG lSer-is Lys Ser ProAsrlMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCys~isProGluclu LeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGln~laLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGnGyLeuLeGnzlaLeuGlualyI leSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlniet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMe tProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyVaJ.LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO:747 pMON3 5777 .pep AlaGlnAspGluGluLeuCysGlyclyLeuTrpArgLeuValLeuAlaolnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHi sPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuolnCysolnProAspSerser ThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHis SerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuTyrValGluGlyGlyGlyGlygerProGlyGluProSerGlyProlleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsniMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLyslleGlnGlyAspGlyAlaAlaLeuclnoluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyl leProTrpAlaPro LeuSerSerCysProSerGlniAlaLeuGlnLeuAlaolyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGJluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrl leTrpGlnGlniMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 748 pMON35778.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa1lLeuAlaGlpJ~rgTrpMetGlurgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHi sPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspserSer ThrLeuPro ProProTrpSerProArgProLeuolyAlaThrAlaProThrAlaolyGlnProProLeuThrGln AspCysSerPheGlnHi aSerProl leSerSerAspPheAlaValbys IleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol leSerThrl leAsnProSerProProSerLysGluSerHisbysSerProAsL~etAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLyscysLeuGluGlnValArgLys IleGlnGlyAspGlyAl a AlaLeuGlnGluLysLeuCysAl aThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHis SerLeu Glyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlnMetGluGluLeuGlyMetAlaProAla WO 98/17810 PCTfUS97/20037 !Z52, LeuGlnProThrclnclyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaclyclyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerryrArgValL~uArgHisLeuAlaGlnPro SEQ ID NO: 749 pMON35779 .pep AlaAspGlucluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetcluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGln Pro ProPro SerCysLeuArgPheVa 1GlnThrAsnI 1 eS erArgLeuLeuG lnG 1uThr SerG luGlnLeuVa 1 AlaLeuLys ProTrpI leThrArgGlrlAsnPheSerArgCysLeuG luLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProxleSerSerAspPheAlaValLys IleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl aSerAsnLeuGlnTyrvalGluGlyG lyGly GlySerProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluserHisLysSer ProAsnMetAlaThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLyslleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluolu LeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeugerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeulnl~laLeuoluGlyI leSer ProGluLeuGlyProThrLeuAspmhrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuG~nProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGl1rg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnserPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGinPro SEQ ID NO:750 pMON35780 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAl aGlnArgTrpMe tGluArgProLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValclnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgcysLeuGluLeulncysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerlyThrGlnAspCysSerPheGlnHisSerProlleserserAspPheAlaValLyslleArg GluLeuSerAspTyrLeuLeuclnAspTyrProValThrValAl aSerAsnLeuGlnTyrValGluGlyGlyGly GlySerProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSeriisLysSer ProAsnMetAlaThrProLeuolyProAl aSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGyHisSerLeuGyIleProTrpAlaProLeuSerSerCysProSerGln~aLeuGlnLeu AlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAl aLeuGluGJlyIl1eSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr IieTrpGlnGlre t GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheG~rnJrg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGinPro SEQ ID NO;751 pMONJ 5782 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnrgTrpMetGluArgLeuLysrhrVal AlaclySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSeroluolnLeuVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysolnProAspserserThr LeuPro Pro ProTrpS erProArgProLeuGlyAlaThrAl aProThrA 1 aG lyG lnPr oProLeuThrG lnAsp CysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyclyThrProGlyGluProgerGly Pro I leSerThrl leAsnProSerProProSerLysGluSer-i sLysSerProAsniMetAlaThrProLeuGly ProAlaSerSerLeuProGlnserPheLeuLeuLysCysLeuGluGlnValArgLys IleGlnGlyAspGlyAla AlaLeuGlnGlubysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisgerLeu Glyl leProTrpAlaProLeuSerSeriZysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlriMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAl aMe tProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValserTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:752 pMON399O8.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVaLe~laGl1rgTrpMetGlurgLeuLysThrVaI AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGli ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnproValGluThrVal PheHisArgValSerGlnAspGlyLeuAspLeuLeuThrSerThrGln~spCysSerPheGlnHisSerProI le SerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnTyrValGluGlyG lyGlyG ySer ProGl yG lyG ySerG lyGlyGlySerAse tAl aThr Pro LeuGlyProAlaSerSerLeuProGlnSerPheLeuLeULySSerLeuGluGlnValArgLys IleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGauLeuValLeuLeuGlyHis SerLeuGlyl leProTrpAlaProLeuSerSerCysProSerGn~aLeuGnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlriluaLeuGluGlylleSerProGluLeuGlyProThr LeuAspThrLeuGlnLeuj~spValAlaAspPheAlaThrThr~ 1eTrpGlnGlnLMetGluGluLeuGlyMetAla ProAlaLeuGlnProThrGlnGlyAlaMe tProAlaPheAlaSerAlaPheGlnArgArgAlaclyG lyValLeu WO 0-/1 7810 PCTIU1S97/200137 253 ValAlaSerHi sLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 753 pMON32275.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrolulleHisPheValThrLysCysAlaPhecln ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuclnCysGlnProAspSerSerThr LeuTyrValGluGlyGlyGlyGlySerProGlyGluProSer~lyProlleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsn-MetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeu~luGlnValArgLys IleGlnGlyAspGlyAlaAlaLeuG2.nGluLysLeuCysAlaThrTyr LysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlyl leProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeu GlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAs~pThrLeuGlnLeuAspValAlaAspPheAla ThrThr IleTrpGlnGlrnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAla~etProAla PheAl aSerAlaPheGlniArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlngerPheLeuGluVal Ser TyrArgValLeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro IleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSer PheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGln SEQ ID NO:754 pMON35781 .pep AlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLysl leArgcluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnGluProLysSerProAspThrHi sThrSer ProProSerProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGInVal ArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlyllePr6TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrclnGlyLeuLeuGlnAlaLeucluGlyl leSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl eTrpolnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAl aPheAlaSerAlaPheGlnArg* ArgAlaGlyGlyValLeuValAlaSerHisLeuGnSerP-eLeuGluVal SerTyrArgValLeuArgHisLeu AlaGlnProSerAlaGluProLysSerProAspThrHisThrSerProProSerProGlySerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlybeuLeuGluArgValAsnThrolul leHis PheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:755 pMON35783 .pep AlaThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLyslIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnG.yTrpGlnGlyArg ValAsnThrGlulleHisPheValThrLysCysAlaPheProLysSerProAspThrHisThrSerProProSer ProGlyThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuzeuLys SerLeuGluGlnValArgLys I leGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyl leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrleTrpGlnGlrl~etGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlniArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeucluValSerTyrArgValLeuArgHisbeuAlaGlnPro SerAlaG luProLys Ser ProAspThrHisThr Ser Pro ProSer ProGlyLysAlaPheG lnProPro ProSer CysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpI leThrArgGlnAsnPheSerArgCysLeuGluLeuGnCysGlnProAspSerSerThrLeu SEQ ID NO: 756 pMON32276 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaclnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysSerAlaPheGln ProPro Pro SerCysLeuArgPheVaJG lnThrAsnI 1 e SerArgLeuLeuG lnG luThr SerGluG lnLeuVal1 AlaLeuLys ProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp SerSerPheGlnHisSerProlleSerserAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu G lnValArgLysI 11eG lnGlyAspGlyAlaAl aLeuG lnG luLys LeuCysAlaThrAsnLys LeuCysH is Pro GluGluLeuValLeuLeuGlyHisSerLeuGlyI leProTrpAlaProLeuSerSerCysProSerGlrnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAl aLeuGluGly I leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl eTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe WO 98/1 7810 PCT1US97/20037 GinArgArgAlaGiyGiyValLeuValAi aSerHi sLeuGinSerPheLeuGiuVal SerTyrArgVaiLeuArg HisLeuAiaGlnPro SEQ ID NO:757 pMON32277 .pep AlaThrProLeuGlyProAiaSerSerLeuProGilnSerPheLeuLeuLysSerLeuGiuGinValArgLys 11ie 0GiyAspGiyAlaAiaLeuGinGluLysLeuCysAi aThrTyrLysLeuCysHisProGiuGiuLeuVaiLeu LeuGlyHi sSerLeuGly lieProTrpAiaProLeu.SerSerCys Pro SerGinAiaLeuG lnLeuAiaoiyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGyLeuLeGriAlaLeuGiuGlylieSerProGJluLeu GlyProThrLeuAspThrLeuGnLeuAspVaAaAspPheAlaThrThIeTrpGnlnGI'nIetGluGluLeu GiyMetAiaProAiaLeuGlnProThrGinGiyAlaMe tProAiaPheAlaSerAiaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVaiLeuArgHisLeuAlaGlnPro TyrVaiGJluGlyGiyGiyoiySerProGlyoiuProSerGiyProlleSerThrlleAsnProSerProProser LysG luSerHi sLys SerProAsniMe tAiaAspGiluGiluLeuCysG lyGiyLeuTrpArgLeuVa 1LeuAi aG ln ArgTrpMetGiuArgLeuLysThrVaiAlaGlySerLysMetGinGlyLeuLeuGluArgValAsnThrGiule His PheVaiThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGInThrAsnl leSerArgLeu LeuGlnGiuThrSerGiuGinLeuValAlaLeuLysProTrpl leThrArgoinAsnPheSerArgCysLeuGlu LeuGinCysGinProAspSerSerThrLeuGlyGlyGlySerGlyGlyGiySerGiyGlyGlySerGlyGlyGly SerGlyGJlyGiySerGiyThrGlnAspSerSerPheGinHisSerProl leSerSerAspPheAlaVaiLyslle ArgGluLeuSerAspTyrLeuLeuclnAspTyrProVaiThrValAlaSerAsnLeuGln SEQ ID NO: 758 pMON32278 .pep AlaAspoluGiuLeuCysGlyolyLeuTrpArgLeuValLeuAlaoinArgTrpMet~luArgLeuLysThrVal AiaGiySerLysMetGlnGiyLeuLeuGluArgVaiAsriThroiuleHisPheVaiThrLysCysAlaPheGln ProPro Pro SerSerLeuArgPheVa lGlnThrAsnl 11eSerArgLeuLeuGlnGiuThrSerGluGriLeuVal AiaLeuLysProTrplieThrArgGinAsnPheSerArgCysLeuGluLeuGinSerGinProAspSerSerThr LeuGlyGlyGiySerGiyGiyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProlieSerSerAspPheAlaVaiLys IleArgGiuLeuSerAspTyrLeuLeuoln AspTyrProValThrValAlaSerAsnLeuGinTyrValGiuGiyGiyGiyGlySerProGlyGiyGiySerGly GiyGiySerAsniMetAlaThrProLeuoiyProAiaSerSerLeuProGInSerPheLeuLeuLys SerLeuGlu GlnValArgLys IleGinGlyAspGlyAlaAiaLeuolnGluLysLeuCysAlaThrAsnLysLeuCysHisPro GluoluLeuVaiLeuLeuGlyHisSerLeuGiylleProTrpAiaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAiaGlyCysLeuSerGinLeuHisSerGiyLeuPheLeuTyrGlnGiyLeuLeuGlnAiaLeuGluGly IieSerProGluLeuGiyProThrLeuAspThrLeuGinLeuAspValAlaAspPheAlaThrmhrlleTrpGln GliMetGluGluLeuoiyMetAlaProAlaLeuGlnProThrGinGlyAlaMetProAlaPheAiaSerAiaPhe GinLArgArgAlaoiyGlyVaiLeuValAlaSerHisLeuolnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAiaGlnPro SEQ ID NO:759 pMON32279.pep AlaThrProLeuolyProAiaSerSerLeuProclnSerPheLeuLeuLysSerLeuGiuGlnVaiArgLys le GlnclyAspGiyAiaAiaLeuGlnGluLysLeuCysAiaThrTyrLysLeuCysHisProGluGiuLeuValLeu LeuGlyHisSerLeuGlyl leProTrpAiaProLeuSerSerCysProSerGinAiaLeuGinLeuAiaGlyCys LeuSerolnLeuHisSeroiyLeuPheLeuTyrGinGiyLeuLeuGInAiaLeuGiuGlylieSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAl aAspPheAiaThrThrI leTrpoinGlnMetGluGiuLeu GiyMetAiaProAlaLeuGlnProThrGInGlyAlaMetProAlaPheAlaSerAiaPhecinArgArgAlaGly GiyVaiLeuValAlaSerHisLeuGinSerPheLeuoiuVai SerTyrArgValLeuArgHisLeuAiaGlnPro TyrValGluGiyGiyGiyGlySerProGlyGluProSerGlyProl ieSerThrlieAsnProSerProProSer LysoiuSerHisLysSerProAsnMetAiaAspoluciuLeuCysciyoiyLeuTrpArgLeuValLeuAlaGin ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetoinGiyLeuLeuGiuArgVaiAsnThrGlulie HisPheVa1ThrLysCysAiaPheGInProProProS~rSerLeuArgPheValGlnThrAsnI ieSerArgLeu LeuGinGiuThrSerGiuGlnLeuVaiAlaLeuLysProTrplieThrArgoinAsnPheSerArgCysLeuGlu LeuGinSeroinProAspSerSerThrLeuGiyGlyGiySerGlyGlyGlySerGiyGiyGiySerGlyGiyGly SerGlyGlyGiySerGiyThrGliAspCysSerPheGinHi sSerProleSerSerAspPheAlaVaiLys Ile ArgGluLeuSerAspTyrLeuLeuGinAspTyrProValThrVaiAlaSerAsnLeuGin SEQ ID NO: 760 pMON3 5790 .pep AlaThrGlnAspSerSerPheGlnHisSerProlleSerSerAspPheAiaVaiLysleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrVaiAiaSerAsnLeuGlnAspGiuGluLeuCysGlyGiyLeuTrpArg LeuVaiLeuAlaGinArgTrpMetGluArgLeuLysThrValAiaoiySerLysMetGlnGiyLeuLeuGluArg VaiAsnThrGluI ieHisPheValThrLysSerAlaPheGinProProProSerCysLeuArgPheValGlnThr AsnI ieSerArgLeuLeuGinGluThrSerGiuGlnLeuVaiAlaLeubysProTrplleThrArgGlnAsnPhe SerArgCysLeuGiuLeuGlnCysGlnProAspSerSerThrLeuTyrVaiGiuGlyGiyGlyoiySerProGiy GiyGiySerG lyGiyGiySerAsnl~etAiaThrProLeuGiyProAiaSerSerLeuProGlnSerPheLeuLeu LysSerLeuoluGInValArgLys I eGinGiyAspGiyAiaAlaLeuGinGluLysLeuCysAlaThrAsnLys LeuCysHisProGiuGluLeuValLeuLeuGlyHisSerLeuGiyleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGinLeuAlaGlyCysLeuSerGlnLeuHisSerGiyLeuPheLeuTyrGlnGlyLeuLeuGin AlaLeuGiuGlylieSerProGiuLeuGiyProThrLeuAspThrLeuGlnLeuAspVaiAiaAspPheAiaThr ThrI leTrpGlnGinMetGluGluLeuGiyMetAiaProAiaLeuGinProThrGinGiyAiaMetProAiaPhe AlaSerAiaPheGinArgArgAiaGlyGlyValLeuVaiAiaSerHisLeuGlnSerPheLeuoluValSerTyr ArgValLeuArgHisLeuAiaolnPro SEQ ID NO:761 pM0N35791.pep WO 98/17810 WO 9817810PCTIUS97/20037 AlaThrGlnAspCysSerPheGlnlisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlniAspcluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThr AsnI leSerArgLeuLeuGlnGluThrserGluGlnLeuValAlaLeuLys ProTrpl eThrArgGlnAsnPhe SerArgCysbeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlyl leSerProGluLeuGlyProThrLeuAspThrLeuclnLeuAspValAlaAspPheAlaThr ThrI leTrpGlnGlnletGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:762 pMON3 5792.pep AlaThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValbys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGInAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlySerLysMetGlnG lyLeuLeuGluArg ValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnI leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnTyrValGluGlyGlyGIlyGlySerProGlyGlyGlySerGlyGlyGlySerAsn MetAl aThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHis ProGluGluLeuVaI LeuLeuGlyHisSerLeuGlyl leProTrpAllaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyl leSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA.aThrThr IleTrpGlnGlniMetGluGlu LeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGJlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln Pro SEQ ID NO:763 pM0N39905 .pep AlaThrGlnAspCy(sSerPheGlnHisSerProlleSerSerAspPheAlaValLysl leArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeualnAspGluGluLeuCysGlyGlyLeuTrpArg LeuVa lLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuclnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsriMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu Lys SerLeuGluGlnValArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGInAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhebeuTyrGlnGlyLeuLeuGln AlaLeuGluGlyl leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:764 pMON3 9906 .pep AlaThralnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluI leHisPheValThrLysCysAlaPheclnProProProSerCysLeuArgPheValGlnThr AsnhleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPhe SerArgArgLeucluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerolyGlyG lySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysl leGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLys LeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlyl leProTrpAlaProLeuSerSerCysPro SerGlrnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlyl eSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVa lAlaAspPheAlaThr ThrI leTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPr SEQ ID NO:765 pMON39909.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGinGlyLeuLeuGluArg-ValAsnThrGluI leHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGllLeuVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeucluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp WO 98/17810.

PCTIUS97/20037 CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGJlnTyrValGluG1yGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsr ~etAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlrnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluVal.SerTyrArgValLeuArgHisLeuAl aGlnProSerGly GlySerGlyGlySerGlnSerPheLeuLeuLys SerLeuGluGlnValArgLys IleGllG lyAspGlyAlaAl a Leu~ln~luLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGly I IeProTrpAl aProLeuS erSerCys Pro SerG lnAl aLeuGlnLeuAl aGlyCys LeuSerG lLeuHi sSer GlyLeuPheLeuTyrGln~lyLeuLeuGlriAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrhr I leTrpGlriGlnMetGluGluLeuGlyMetAlaProAlaLeu GinPro SEQ ID NO:766 pMON3 9910 .pep AlaThrGlnGlyAlaMetProAl aPheAlaSerAJlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHis LeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySer GlnSerPheLeuLeuLysSerLeuGluGlnValArgLys I leGlnGlyAspGlyAlaAlaLeuGlflGluLysLeu CysAlaThrTyrLysLeuCysHis ProGluGluLeuVa lLeuLeuGlyHis SerLeuGlyI 1eProTrpAlaPro LeuSerSerCys Pro SerG lnAlaLeuGlnLeuAl aGlyCysLeu SerGlnLeuHi s SerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThrLeuG lnLeuAspVa 1 AlaAspPheAl.aThrThr IleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTyrValGlu GlyGlyGlyGlySerProGlyGluProSerGlyProI IeSerThr I leAsnProSerProPro SerLysGluSer His Lys SerProAsnMe tAl aAspGluGluLeuCysGlyG lyLeuTrpArgLeuVa 1LeuAl aGlnArgTrpMe t GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAslThrGlulleHisPheVaI ThrLysCysAlaPheGlnProPro ProSerCysLeuArg PheVa iGInThrAsni 1eSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlniAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHi sSerPro I I eSerSerAspPheAlaValLyslIleArgGluLeu SerAspTyrbeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 767 pMON35727.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAl aGlnArgTrpMe tGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGll ProProProSerCysLeuArgPheValGlnThrAsnl eSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGllPrOAsSSrSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGllHisSer Pro IleSerSerAspPheAlaValLys 11eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa 1 AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI 11eSerThrlIleAsn ProSerProProSerLysG lu SerHi sLys Ser ProAsn~e tAl aAspGluG luLeuCysG lyo lyLeUTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGlul IeHi sPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGllThr AsnI leSerArgLeuLeuGlncluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 768 pMON32 168 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGllLeUVal AJlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGllAsp CysSerPheGlnHisSerProlleSerSerAspPheAlaValLysleArgGluLeuSerAspTyrLeuLeuGfl AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly Prol leSerThrl 1 eAsnProSerProProSerLysGluSerHi sLysSerProAsrMetAlaThrGllAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGllAsf TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGyGlyLeuTrpArgLeuValLeuAlaGll ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsflThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGllThrAsllleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGlU LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:769 pMON32195 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlflGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGll ProProProserCysLeuArgPheValGlnThrAsnhleSerArgLeuLeuolnGluThrSerGluGlnLeuVal AlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuoluLeuGlnCysolnProASpSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGllAsp CysSerPheGlnHisSerProlleSerSerAsppheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrVa lGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsrnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu WO 98/17810 PCT/US97/20037 WA ORI7R1 PCTUS972003 GlnValArgLys IleGlnG lyAspGlyAl aAlaLeuGlnGluLysLeuiCysAlaThrTyrLysLeuCysHi sPro GluGluLeuValLeuLeuGlyHis SerLeuGlyI leProTrpAlaProLeuSerSerCys ProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly 11 eSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrI 1 eTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGliGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThrIleAsn Pro Ser Pro ProSerLysG luserH isLys Ser ProAsnMe tAlaAspG luG 1uLeuCysGlyGlyLeuTrpArg LeuvalLeuAlaGlr]ArgTrpMetGiuArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGlul leHi sPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnI 1eSerArgLeuLeuGln~luThrSercluGlnLeuVa lAlaLeuLys Pro~rpI leThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerolyGlyGlySerGlyGly GlySerGlyGiyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProI leSerSerAsp PheAl aVa lLys I leArgGluLeuSerAspTyrLeuLeuGlniAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:770 pMON32196 .pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys 11ie GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi sProGluGluLeuValLeu LeuGlyHisSerLeuGlyI leProTrpAlaProLeuSerSerCysProSerGlniAlaLeuG lnLeuAl aGlyCys LeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGiuGlyI leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl eTrpGlnGlniMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSer LysG luSerHisLys SerProAsnldetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrVa iAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu le His PheValThrLysCysAi aPheGInProPro ProSerCysLeuArgPheValGllThrAsnl leSerArgLeu LeuGlnGluThrSerGluGlnLeuVa lAlaLeuLys ProTrp IleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlniAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLysle ArgO luLeuSerAspTyrLeuLeuGlnAspTyrProVa lThrValAlaSerAsnLeuGlnTyrvalGluGlyGly GlyGlySerProGlyGluProSerGlyProIleSerThrI leAsnPro SerProPr oSerLysG luSerHi sLys SerProAsniMetAlaThrGlnAspCysSerPheGlnHisSerProleSerSerAspPheAlaValLys lleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProVa lThrVa lAlaSerAsnLeuGlniAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaclnArgTrpMetoluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluI IeH is PheValThrLysCysAla PheGlnPro Pro ProSerCysLeuArg PheValGlnThrAsnhleSerArgLeubeuGlnoluThrSerluolnLeuValAlaLeuLysProTrplleThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln-ProAspSerSerThrLeu SEQ ID NO:771 pMON32 197 .pep AlaThrProLeuGlyProAlaSergerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys Ile GlnGlyAspGiyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeu LeuGlyHisSerLeuGlyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrclnolyLeuLeuGlnAlaLeuGluGlyl leSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspVa lAlaAspPheAlaThrThr IleTrpGlnGlniMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuolnSerPheLeuGluValserTyrArgValLeuArgHisLeuAlaGlnPro TyrVa lGluG lyGlyG lyGlySer ProG lyGlu Pro SerG lyProI 11eSerThr I IeAsnProSerPro ProSer LysGluSerHisLysSerProAsnMetAlaAspoiuGluLeuCysGlylyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaolySerLysMe tGlnGlyLeuLeuGluArgValAsnThrGluI le His PheValThrLysCysAlaPheolnProProProSerCysLeuArgPheValolnThrAsnI leSerArgLeu LeuGlnGluThrSeroluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAsp)TyrProVa lThrValAlaSerAsnLeuGlnTyrValGlUGlyGly GlyGlySerProGlyGluProSerGlyProI leSerThrl eAsnProSerProProSerLysGluSerHisLys SerProAsniMe tAlaAspGluGluLeuCysclyclyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaolySerLysMetolnolyLeuLeuoluArgValAsnThrGlul ellis PheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValjinThrAsnl leSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpI leThrArgGiriAsnPheSerArgCysLeuGluLeuGlnCysGllPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyolyserGlyGlyGlyserGlyGlyGlySer G lyThrGlnAspCys Ser PheGlnHi sSerPro IleSer SerASpPheAlaVa 1Lys 11eArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 772 pMON32206 .pep AlaAsnCysSerIleMetIleAspGluIleIleHislijisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArg AlaValLysAsnLeuGluAsnAlaSerGlyI leGlu~laI leLeuArgAsnLeuGflProCysLeuProSerAla ThrAl aAl aProSerArgHis Pro IleI leI leLysAIlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlrnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyPro IleSerThrI leAsnProSerPro Pro SerLysGluSerHisLysSerProAsnMetAlaAspGluGlu Wn Go 11 Wl n 00 IlTQ~flPCTJIJS97/20037 LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlflArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsflThrGluIleHisPheValThrLysCysAlaPheGllProProProSer CysLeuArgPheValGlnThrAsllleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpI leThrArgGlnAsnPheSerArgCysLeuGluLeuG~lCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlAspCysSerPheGll His SerProl leSerSerAspPheAlaValLysl leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThr I leAsnProSerProProSerLysGluSerHisLysSerProAsflMetAlaAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysmrValAlaGlySerLysMe tGlnGlyLeuLeu GluArgValAsnThrGlul leHisPhevalThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnI IeSerArgLeuLeuclnGluThrSerG luGlnLeuValAlaLeuLys ProTrp 1eThrArgGll AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyclySerGlyGlyGlySer GlyGlyGlySerGlyclyGlySerclyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProlleSer SerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGin SEQ ID NO:773 pMON32 207 .pep AlaAspGluGluLeuCysclyGlyLeuTrpArgLeuValLeuAlaGllArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAslThrGluIleHisPheValThrLysCysAlaPheGll ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuVal Al aLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyrhrGllAsp Cys SerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGllArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeubeuGluArgValAsnThrGlul le-i s PheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerclyThrGlnAspCysSerPheGllHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProVa lThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGlyProlleSerThrlleAsnProSerProProSerLys~luSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGllValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGlUGluLeuValLeu LeuGlyHisSerLeuGlyl leProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlnietGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGllArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlGllPro STPSTPGlySerGluPheGlySer SEQ ID NO:774 pMON35728 .pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGllArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGll ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGllLeuVal AlaLeubys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGrlASpCysSerPheGllHisSer ProlleSerSerAspPheAlaValLyslleArg~luLeuSerAspTyrLeuLeuGlnAspTyrProValThrval AlaSerAsnLeuGlnTyrvalGluGlyGlyGlyGlySerProGlyGluProSerGlyProlleSerThrl leAsn ProSerProProSerLysGluSerHisLysSerProAsniMetAlaAsnCysSerI leMetlleAspGlullelle Hi siisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsflSerGluAspMetAspIl1eLeuMe t GluArgAsnLeuArgThrProAsnLeuLeuAlaPheVal ArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIle LysAlaGlyAspTrpGllGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGllAlaGllGluGll GlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProl leSerThrlleAsnProSerProPro SerLysGiuSerHi sLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuVa lLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsflThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAslhleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysgerPheGln-isSerProlleSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuclnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:775 pMON32l83 .pep Al aAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa 1 AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlul leHisPheValThrLysCysAlaPheGll ProProProSerCysLeuArgPheValGlnThrAsnl leSerArgLeuLeuGlncluThrSerGluGllLeuVal AlaLeuLysProTrpl lemhrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyThrGrlAsp CysSerPheGlnHisSerProl leSerSerAsPPheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnGluPheLysLeuGluProArgGlyProThrl leLysProCys WO 98/17810 PCTIUS97/20037 ProProCysLysCysProAlaProAsnLeuLeuGlyGlyProSerValPhelePheProProLyslleLysAsp ValLeuMetIleSerLeuSerProIleValThrCysValValValAspValSerGluAspAspProAspValGln I leSerTrpPheValAsnAsnValGluValHisThrAlaGlnThrGlnThrHisArgGluAspTyrAsnSerThr LeuArgAlaValSerAlaLeuProIleGlnHisGlnAspTrpMetSerGlyLysGluPheLysCysLysValAsn AsnLysAspLeuProAlaProlleGluArgThrIleSerLysProLysGlySerValArgAlaProGlnValTyr ValLeuProProProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThrAspPheMetPro GluAspI leTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGluProValLeuAsp SerAspGlySerTyrPheMetTyrSerLysLeuArgValGluLysLysAsnTrpValGluArgAsnSerTyrSer CysServalValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrProG.yLys SEQ ID NO:776 pM0N32184 .pep AlaThrGlniAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGlulleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhevalGlnThr AsnI leSerArgLeuLeuGlnGluThrSerGluGJ~nLeuValAlaLeuLysProTrp IleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGluPheLysLeuGluProArgGlyProThr ileLysProCysProProCysLysCysProAlaProAsnLeuLeuG2.yGlyProSerValPhellePheProPro LyslleLysAspValLeuMetlleSerLeuSerProlleValThrCysValValValAspValSerGluAspAsp ProAspValGlnI leSerTrpPheValAsnAsnValGluValHisThrAlaGlnThrGlnThr-isArgGluAsp TyrAsnSerThrLeuArgAlaValSerAlaLeuProl leGlriHisGlnAspTrpMetSerGlyLysGluPheLys CysLysValAsnAsnbysAspLeuProAlaProlleGluArgThrl leSerLysProLysGlySerValArgAla ProGlnValTyrValLeuProProProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThr 'Asp PheMetProGluAspIleTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGlu ProValLeuAspSerAspGlySerTyrPheMe tTyrSerLysLeuArgValGluLysLysAsnTrpValGluArg AsnSerTyrSerCysSerValValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrPro GlyLys SEQ ID NO:777 WO 98/17810 PCT/US97/20037 2p The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

EXAMPLE i Construction of parental BHK expression vector A. Removal of AflIII site from mammalian expression plasmid.

A new mammalian expression vector was constructed to accept NcoI-HindIII or AflIII-HindIII gene fragments in-frame and 3' to the hIL-3 receptor agonist pMON13146 (WO 94/12638) gene and a mouse IgG2b linker fragment.

First, the single AflIII site was removed from pMON3934, which is a derivative of pMON3359. pMON3359 is a pUC18based vector containing a mammalian expression cassette.

The cassette includes a herpes simplex viral promoter IE110 (-800 to +120) followed by a modified human IL-3 signal peptide sequence and an SV40 late polyadenylation (poly-A) signal which has been subcloned into the pUC18 polylinker (See Hippenmeyer et al., Bio/Technology, 1993, pp.1037-1041). The modified human IL-3 signal sequence, which facilitates secretion of gene products outside of the cell, is flanked by a BamHI site on the 5' end and a unique NcoI site on the 3' end.

A unique HindIII site is 3' to the NcoI site and 5' to the poly-A sequence. The DNA sequence encoding the signal peptide is shown below (restriction enzyme sites are indicated above). The ATG (methionine) codon within the NcoI site is in-frame with the initiator ATG of the signal peptide (underlined); WO 98/17810 PCTIUS97/20037 BamHI NcoI (SEQ ID NO:857) The single AflIII site was removed from pMON3934 by digestion with AflIII followed by filling in the overhangs by addition of a DNA polymerase and nucleotides. The digested DNA fragment was purified via Magic PCR Clean up kit (Promega) and ligated with T4 DNA ligase. The ligation reaction was transformed into m and the cells were plated onto LB-agar plus ampicillin. Individual colonies were screened for the loss of the AflIII site by restriction analysis with AflIII and HindIII which results in a single fragment if the AflIII site was removed. The resulting plasmid was designated pMON30275.

B. Transfer of hIL-3 receptor agonist pMON13416/IgG2b cassette into pMON30275.

The NcoI-HindIII fragment (ca. 425 bp) from pMON30245 was ligated to the NcoI-HindIII fragment (ca.

3800 bp) of the pMON30275. pMON30245 (WO 94/12638) contains the gene coding for hIL-3 receptor agonist pMON13416 joined to a mouse IgG2b hinge fragment.

Immediately 3' to the IgG2b hinge and 5' to the HindIII site is an AflIII site. Genes can be cloned into the AflIII-HindIII sites as NcoI-HindIII or AflIII-HindIII fragments in frame with the hIL-3 variant pMON13416/IgG2b hinge to create novel chimeras. The NcoI site and the AflIII site have compatible overhangs and will ligate but both recognition sites are lost. The plasmid, pMON30304 containing the DNA sequence of (SEQ ID NO:1), coding for hIL-3 variant pMON13416 joined with a mouse IgG2b hinge region, was a result of this cloning.

WO 98/17810 PCT/US97/20037 EXAMPLE 2 Construction of an intermediate plasmid containing one copy of the c-mpl ligand (1-153) cene of the dimer template In order to generate a plasmid DNA with the coding sequence of c-mpl (1-153) ligand followed by a unique EcoRI restriction site, the gene is isolated via reverse transcriptase/polymerase chain reaction (RT/PCR). Human fetal (lot #38130) and adult liver (lot #46018) A+ RNA are obtained from Clontech (Palo Alto, CA) for source of c-mpl ligand messenger RNA (mRNA). The first strand cDNA reactions are carried out using a cDNA Cycle T Kit obtained from Invitrogen (San Diego, CA). In the RT reaction, random primers and oligo dT primer are used to generate cDNA from a combination of human and fetal liver mRNA. For amplification of c-mpl ligand gene fragment encoding amino acids 1-153, the RT product serves as the template for PCR with a combination of the primers, Forward primer: c-mplNcol (SEQ ID NO:317) and Reverse primer: Ecompl. The c-mplNcol primer anneals to the c-mpl ligand gene (bases #279-311 based on c-mpl ligand sequence from Gene bank accession #L33410 or de Sauvage et al., Nature 369: 533-538 (1994)) and encodes a NcoI restriction enzyme site immediately 5' to the first codon (Ser+l) of c-mpl ligand. The NcoI restriction enzyme site codes for methionine and alanine codons prior to Ser+l and includes codon degeneracy for the Ala codon and the first four codons (Ser, Pro, Ala, Pro) of c-mpl ligand. The Ecompl primer anneals to bases #720-737 of c-mpl ligand and encodes an EcoRI site (GAATTC) in-frame with the c-mpl ligand gene immediately following Arg-153. The EcoRI site creates Glu and Phe codons following Arg-153. The ca. 480 bp PCR product was purified, digested with NcoI and EcoRI and ligated to the NcoI-EcoRI vector fragment of pMON3993 (ca. 4550 WO 98/17810 PCT/US97/20037 pMON3993 was a derivative of pMON3359 (described in Example The human IL-3 signal peptide sequence, which had been subcloned as a BamHI fragment into the unique BamHI site between the IE110 promoter and poly-A signal, contains an NcoI site at its 3' end and is followed by a unique EcoRI site. The plasmid, pMON26458 containing the DNA sequence of (SEQ ID NO:2), coding for c-mpl ligand amino acids 1-153 (SEQ ID N0:467), was the result of this cloning.

EXAMPLE 3 Construction of the parental plasmids containing the second genes of the dimer templates For amplification of c-mpl ligand gene fragments starting at amino acid 1 (Ser) with a termination codon following amino acid 153 (Arg), the RT reaction from Example 2 serves as the template for PCR with a combination of the following primers; c-mplNcol (SEQ ID NO:317) (forward primer) and c-mplHindIII (SEQ ID NO:319) (reverse primer). The c-mplNcol (SEQ ID NO:317) primer is described in Example 2. The c-mplHindIII (SEQ ID NO:319) primer, which anneals to bases #716-737 of cmpl ligand, adds both a termination codon and a HindIII restriction enzyme site immediately following the final codon, Arg 53 Two types of PCR products are generated from the RT cDNA samples, one with a deletion of the codons for amino acids 112-115 and one without the deletion of these codons. The c-mpl ligand PCR products (ca. 480 bp) are digested with NcoI and HindIII restriction enzymes for transfer to a mammalian expression vector, pMON3934. pMON3934 is digested with NcoI and HindIII (ca. 3800 bp) and will accept the PCR products.

wn 8/17810 PCT/US97/20037

.T

Plasmid, pMON32132 (SEQ ID NO:84), coding for c-mpl ligand amino acids 1-153 (SEQ ID N0:546) was a result of this cloning. Plasmid, pMON32134 (SEQ ID NO:86), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:548) was a result of this cloning. Plasmid, pMON32133 (SEQ ID coding for c-mpl ligand amino acids 1-153 with a deletion of codons 112-115 (A112-115) (SEQ ID NO:547) was also a result of this cloning.

EXAMPLE 4 Generation of PCR dimer template 5L with a 112-115 deletion in the second c-mpl ligand gene A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32133 (containing a deletion of amino acids 112-115) along with the EcoRI/AflIII 5L synthetic oligonucleotide linker (SEQ ID NO:322) and 5L-3' (SEQ ID NO:323).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32133, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32133 will ligate as well. Plasmid, pMON28548, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:3) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMet (SEQ ID NO:783) linker to amino acids 1-153 c-mpl ligand that contains a deletion of amino acids 112-115 (SEQ ID NO:468).

EXAMPLE Generation of PCR dimer template 4L W( 98/17810 PCT/US97/20037 A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 4L synthetic oligonucleotide linker (SEQ ID NO:320) and 4L-3' (SEQ ID NO:321).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. The plasmid, pMON28500, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:4) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyAsnMetAla (SEQ ID NO:223) linker (4L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:469).

EXAMPLE 6 Generation of PCR dimer template A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 5L synthetic oligonucleotide linker (SEQ ID NO:322) and 5L-3' (SEQ ID NO:323).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. Plasmid, pMON28501 is a result of the cloning and contains the DNA sequence of (SEQ ID NO:4) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMet (SEQ ID NO:783) linker (5L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:470).

WO 98/17810 PCT/US97/20037 EXAMPLE 7 Generation of PCR dimer templates 8L A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32134 along with the EcoRI/AflIII 8L synthetic oligonucleotide linker (SEQ ID NO:324) and 8L-3' (SEQ ID NO:325).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32134, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32134 will ligate as well. Plasmid, pMON28502 is a result of the cloning which contains the DNA sequence of (SEQ ID NO:6) and encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnGlyGlyAsnMetAla (SEQ ID N0:224) linker (8L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:471).

EXAMPLES 8-44 Generation of novel c-mpl ligand genes with new Nterminus and C-terminus A. PCR generation of genes encoding novel c-mpl ligand receptor agonists.

Genes encoding novel c-mpl ligand receptor agonists were generated using Method III (Horlick et al., Prot.

Eng. 5:427-433, 1992 The PCR reactions were carried out using dimer templates, pMONs 28500, 28501, 28502 or 28548 and one of the sets of synthetic primer sets below (The first number refers to the position of the first amino acid in the original sequence. For example, the WO 98/17810 PCT/US97/20037 31-5' and 31-3' refers to the 5' and 3' oligo primers, receptively, for the sequence beginning at the codon corresponding to residue 31 of the original sequence.).

31-5' (SEQ ID NO:326) and 31-3' (SEQ ID NO:327), 35-5' (SEQ ID NO:328) and 35-3' (SEQ ID N0:329), 39-5' (SEQ ID NO:330) and 39-3' (SEQ ID NO:331), 43-5' (SEQ ID NO:332) and 43-3' (SEQ ID NO:333), 45-5' (SEQ ID NO:334) and 3' (SEQ ID N0:335), 49-5' (SEQ ID N0:336) and 49-3' (SEQ ID NO:337), 82-5' (SEQ ID NO:338) and 82-3' (SEQ ID NO:339), 109-5' (SEQ ID NO:340) and 109-3' (SEQ ID NO:341), 115-5' (SEQ ID N0:342) and 115-3' (SEQ ID NO:343), 120-5' (SEQ ID N0:344) and 120-3' (SEQ ID NO:345), 123-5' (SEQ ID N0:346) and 123-3' (SEQ ID NO:347), 126-5' (SEQ ID N0:348) and 126-3' (SEQ ID NO:349).

The templates and oligonucleotide sets used in the PCR reactions are shown in Table 4. The products that were generated were about 480 bp and were purified via Magic PCR Clean up kits (Promega).

B. Subcloning of novel c-mpl receptor agonist gene products into mammalian expression vector for generation of chimeras.

The c-mpl receptor agonist gene PCR products were digested with NcoI and HindIII or AflIII and HindIII restriction enzymes (ca. 470 bp) for transfer to a mammalian expression vector. The expression vector, pMON30304, was digested with NcoI and HindIII (ca. 4200 bp) and accepts the PCR products as NcoI-HindIII or AflIII-HindIII fragments. The restriction digest of the PCR product and the resulting plasmids are shown in Table 4.

WO 98/17810 PCTIUS97/20037 TABLE 4 PCR PCR Product Resulting Breakpoint Example PCR Product Restriction Linker Plasmid in c-mpl template Primer Digest pMON ligand set Example 8 pMON28501 31 NcoI/HindIII 5L 28505 30-31 Example 9 pMON28501 35 AflIII/HindI 5L 28506 34-35

II

Example 10 pMON28501 39 NcoI/HindIII 5L 28507 38-39 Example 11 pMON28501 43 NcoI/HindIII 5L 28508 42-43 Example 12 pMON28501 45 NcoI/HindIII 5L 28509 44-45 Example 13 pMON28501 49 NcoI/HindIII 5L 28510 48-49 Example 14 pMON28501 82 NcoI/HindIII 5L 28511 81-82 Example 15 pMON28501 109 NcoI/HindIII 5L 28512 108-109 Example 16 pMON28501 116 NcoI/HindIII 5L 28513 115-116 Example 17 pMON28501 120 NCol/HindIII 5L 28514 119-120 Example 18 pMON28501 123 NcoI/HindIII 5L 28515 122-123 Example 19 pMON28501 126 NcoI/HindIII 5L 28516 125-126 Example 20 pMON28500 31 NcoI/HindIII 4L 28519 30-31 Example 21 pMON28500 35 AflIII/HindI 4L 28520 34-35

II

Example 22 pMON28500 39 NcoI/HindIII 4L 28521 38-39 Example 23 pMON28500 43 NcoI/HindIII 4L 28522 42-43 Example 24 pMON28500 45 NcoI/HindIII 4L 28523 44-45 Example 25 pMON28500 49 NcoI/HindIII 4L 28524 48-49 Example 26 pMON28500 82 NcoI/HindIII 4L 28525 81-82 'Example 27 pMON28500 109 NcoI/HindIII 4L 28526 108-109 Example 28 pMON28500 116 NcoI/HindIII 4L 28527 115-116 Example 29 pMON28500 120 NcoI/HindIII 4L 28528 119-120 Example 30 pMON28500 123 NcoI/HindIII 4L 28529 122-123 Example 31 pMON28500 126 NcoI/HindIII 4L 28530 125-126 Example 32 pMON28502 31 NcoI/HindIII 8L 28533 30-31 Example 33 pMON28502 35 AflIII/HindI 8L 28534 34-35

II

Example 34 pMON28502 39 NcoI/HindIII 8L 28535 38-39 Example 35 pMON28S2 43 NcoI/RindIII 8L 28536 42-43 WO 98/17810 WO 9817810PCTIUS97/20037 TABLE 4 cont.

PCR PCR Product Resulting Breakpoint Example PCR Product Restriction Linker Plasmid in c-mpl template Primer Digest pMON ligand set Example 36 pMON28502 45 I'coI/HindIII 8L 28537 44-45 Example 37 pM0N28502 49 NcoI/HindIII 8L 28538 48-49 Example 38 pMON28502 82 NcoI/HindIII 8L 28539 81-82 Example 39 pM0N28502 109 NcoI/HindIII 8L 28540 108-109 Example 40 pM0N28502 116 Nool/HindIll SL 28541 115-116 EXAMPLE 41 pM0N28502 120 NcoI/HindIII BL 28542 119-120 Example 42 pMON28502 123 NcoI/HindIII 8L 28543 122-123 Example 43 pM0N28502 126 NcoI/HindIII 8L 28544 125-126 Example 44 pM0N28548 123 NcoI/HindIII 5L 28545 122-123 EXAMPLE 4 Construction of PMON15960 Construction of pMONl596O, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding G-CSF Ser" with a new N-terminus and Cterminus. Plasmid pACYCl77 (Chang, A.C.Y. and Cohen, S N. J. Bacteriol. 134:1141-1156, 1978) DNA was digested with restriction enzymes IiindIII and BamHI, resulting in a 3092 base pair HindIII, Bam}{I fragment.

Plasmid, pMON13037 (WO 95/21254), DNA was digested with BglII and FspI, resulting in a 616 base pair BglII, FspI fragment. A second sample of plasmid, pMON13037, DNA was digested with NcoI and HindIII, resulting in a 556 base pair NcoI, HindIIT fragment. The synthetic DNA oligonucleotides lGGGSfor (SEQ ID NO:380) and 1GGGSrev (SEQ ID NO:381) were annealed to each other, and then digested with'AflIII and FspI, resulting in a 21 base pair AflIII, FspI fragment. The restriction fragments WO 98/17810 PCTIUS97/20037 were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on anpicillin-containing plates.

Plasmid DNA was isolated and analyzed by restriction analysis to confirm the correct insert.

EXAMPLE 46 Construction of DMON15981 Construction of pMON15981, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SiaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 38 stop (SEQ ID NO:369) and 39 start (SEQ ID NO:368) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs.

Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E.

coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15981, contains the DNA sequence of (SEQ ID NO:78) which encodes the following amino acid sequence: MetAlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProcysLeuProSerAlaThrAlaAlaPro SerArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProerGlyProlleSerThrleAsnProSerProProSerLysGlu SerHisLysSerProAsrxMetAlaTyrLysLeuCysHiisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSercysProSerGlnAlaLeuGln LeuAlaGlycysLeuSerGlnLeuHisSerGiyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVa1 WO 98/17810 WO 9817810PCTIUS97/20037 AlaAspPheAlaThrThrl eTrpGlnGlnMetGuG-uLeuGlyMetAlaProAlaLeu G 1nProThrGlnGlyAl aMet ProAl aPheAl aSerAlaPheG lnArgArgAl aGlyGly ValLeuValAlaSeriisLeuGinSerPheLeuGluVal SerTyrArgValLeuArgHi s LeuAlaGlnProGlyGlyGlySerAspMet.AlaThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLys SerLeuGluGflnVaArgLysI1eG1lG1yAspG1.yAla AlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:500) EXAMPLE 47 Construction of iDMON15982 Construction of pMON15982, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SinaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 96 stop (SEQ ID NO:371) and 97 start (SEQ ID NO:370) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindlII, NcoI fragment of 558 base pairs.

Plasmid, pMONl3181, DNA was digested with HindIII and AflIIl, resulting in a HindIZL, AflII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E.

coi K-12 strain cr1101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15982, contains the DNA sequence of (SEQ ID NO:79) which encodes the following amino acid sequence: MetAlaAsncysSerlleMetl leAspGluI leIleHisHi *sLeuLysArgProProAla ProLeuLeuAspProAsnAsriLeuAsriAspGluAspValSerl leLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsflLeuG-uAsfAlaSer GlyIleGluAlaIleLeuArg AsnLeuGlnProcysLeuProSerAlaThrAlaAlaPro SerArgHisProl lelleT leLysAlaGlyAspTrpG lnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyG-yGly SerProGlyGluPro~erGlyProl leSerThrIleAsnProSerProProSerLysGlu SerHi sLysSerProAsniMetAlaProGluLeuGlyProThrLeuAspThrLeuGllLeu AspValAlaAspPheAlaThrThrIleTrpGlnGflMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGllArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuG1 uVal SerTyrArgValLeu ArgHi sLeuAlaGlnProGlyGlyGlySerAspMetAlaThrPrOLeuGlyProAlaSer SerLeuProGlnSerPheLeuLeuLysSerLeuGluGl2nValArgLys IleGlnGlyAsp WO 98/17810 212 PCTIUS97/20037 GlyA 1aA1 aLeuG 1nG 1uLys LeuCysAl aThrTyr Lys LeuCysHi s ProGluGluLeu ValLeuLeuGlyHisSerLeuGlyl eProTrpAlaProLeuSerSerCys ProSerGin AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHi s SerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlyIleSer (SEQ ID NO: 501) EXAMPLE 48 Construction of oMON15965 Construction of pMON15965, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SinaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 142 stop (SEQ ID NO:377) and 141 start (SEQ ID NO:376) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindTII, NcoI fragment of 558 base pairs.

Plasmid, pMON13l81, DNA was digested with HindIII and AflIII, resulting in a HindlII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E.

coli K-12 strain JMl0l. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15965, contains the DNA sequence of (SEQ ID which encodes the following amino acid sequence: MetAlaAsnCysSerIleMetIleAspGlulleIleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspVal~erl leLeuMetAspArgAsl LeuArgLeuProAsflLeuGluSerPheVa lArgAl aValLysAsnLeuGluAsnAla~er Glyl lecluAlalleLeuArgAsnbeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGlULysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGlu~lnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysG.u SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGinSerPheLeuGluVal SerTyrArgValLeuArgHi sLeuAlaGll ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGll~er PheLeuLeuLys~erLeuGlu~lnValArgLysl leGlnGlyAspGlyAlaAlaLeuGll GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis Se rLeuG 1yI leProTrpAla ProLeuSe rSerCys Pro SerG 1nA1 aLeuGllLeuAl a WO 98/17810 WO 9817810PCTIUS97/20037 GlycysLeuSerGlnLeu~isSerGlyLeuPheLeuTyrGllGlyLeuLeuGllAlaLeu GluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGllPro ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:502) EXAMPLE 49 Construction of p)MON15966 Construction of pMON15966, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SinaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 126 stop (SEQ ID NO:372) and 125 start (SEQ ID NO:373) as primers,, resulting in the amp lification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs.

Plasmid, pMONl3181, DNA was digested with HindIII and AflITI, resulting in a HindIII, AflITI fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E.

coi K-12 strain JMl0l. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15966, contains the DNA sequence of (SEQ ID NO:81) which encodes the following amino acid sequence: MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspVal~erl leLeuMetAspArgAsfl LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAslLeuGluAsflAlaSer GlyI leGluAlaI leLeuArgAsnLeuGlnProcysLeuProSerAl aThrAlaAl aPro SerArgHi sProI le11e I leLysAl aGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuVa lThrLeuGluGlnAl aGinGluG lnGlnTyrValGluGlyGlyGlyGly SerProGlyGluPro~erGlyProI leSerThrI leAsnProSerProProSerLysGlu SerHi sLys Ser ProAsnMetAlaMetAlaProAlaLeuG lnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgisLeuAaGnProGyGlyGlY SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLys IeGnGyAspG yAaAaLeuGnGuLysLeuCys AlaThrTyrLysLeuCysHi s ProGluGluLeuValLeuLeuGlyHisSerLeuGlyI le WO 98/17810 WO 9817810PCT/US97/20037 ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnbeuAlaGlyCysLeuSer GlnLeu~is SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIl)eSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrPGlnGlnMetGluGluLeuGly (SEQ ID N0:503) EXAMPLE Construction of pOMON15967 Construction of pMON15967, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Pilasmid, pMON15960, DNA was digested with restriction enzyme SinaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 132 stop (SEQ ID NO:375) and 133 start (SEQ ID NO:374) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindlII, NcoI fragment of 558 base pairs.

Plasmid, pMON13181, DNA was digested with HindIII and Af1III, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the-ligation reaction mixture was used to transform E.

coi K-12 strain JMl0l. Transformant bacteria were selected on ampic ill in-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15967, contains the DNA sequence of (SEQ ID NO: 82) which encodes the following amino acid sequence: MetAlaAsnCysSerlleMetleAspGlulelelisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsflAl aSer Glyl leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProllellelleLysAlaGlyAspTrpGlnoluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProG lyGlu Pro SerGl1yProl 11eSerThr 11 eAsnProSer Pro ProSerLysGlu SerHi sLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu GlyProAl aSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys Ii eGlnGlyAspGlyAlaAlaLeuGlnGluLysLeucysAlaThrTyrLysLeucysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlyl leProTrpAlaProLeuSerSer WO 4/17810 PCT/IUS97/20037

VV

CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:504 EXAMPLE 51 Construction of pMON13180, an intermediate plasmid used for constructing plasmids that contain DNA sequence encoding multi-functional hematopoietic receptor aqonists.

Plasmid, pMON13046 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4018 base pair vector fragment. The 4018 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) in which the base pair XmaI-SnaBI insert fragment is not retained.

The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:378) and glyxa2 (SEQ ID NO:379), were designed to remove sequence encoding a factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends.

The primers, Glyxal and glyxa2, were annealed in annealing buffer (20mM Tris-HCl pH7.5, 10 mM MgCl 2 mM NaCl) by heating at 70 0 C for ten minutes and allowed to slow cool. The 4018 base pair XmaI-SnaBI fragment from pMON13046 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates.

Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13180 (SEQ ID NO:88).

WO 98/17810 PCTIUS97/20037 EXAMPLE 52 Construction of pMON13181, an intermediate plasmid used for constructing plasmids that contain DNA sequences encodin multi-functional hematopoietic receptor aqonists.

Plasmid, pMON13047 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4063 base pair vector fragment. The 4063 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) in which the base pair XmaI-SnaBI insert fragment is not retained.

The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:378) and glyxa2 (SEQ ID NO:379), were designed to remove sequence encoding the factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends.

Glyxal and glyxa2 were annealed in annealing buffer by heating at 700C for ten minutes and allowed to slow cool. The 4063 base pair XmaI-SnaBI fragment from pMON13047 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates.

Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13181 (SEQ ID NO:87).

EXAMPLE 53 _W JdmA4 1T A1 t AA

W

O 98/17810 21-1 PCT/US97/20037 Construction of pMON13182 The new N-terminus/C-terminus gene in pMON13182 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:368) and L-ll start (SEQ ID N0:364).

Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:369) and L-1 stop (SEQ ID N0:365). The fulllength new N terminus/C-terminus G-CSF Ser 17 gene was created and amplified from the annealed Fragments Start and Stop using primers 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13182.

E. coli strain JM101 was transformed with pMON13182 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13182, contains the DNA sequence of (SEQ ID NO:17) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg WO 98/17810 2 PCT/US97/20037 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gln Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID NO:472) EXAMPLE 54 Construction of PMON13183 The new N-terminus/C-terminus gene in pMON13183 was created using Method I as described in Materials and Methods. "Fragment Start" was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 39 start (SEQ ID N0:368) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 38 stop (SEQ ID N0:369) and L-11 stop (SEQ ID NO:365). The full-length new N terminus/Cterminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic WO 98/17810 PCT/US97/20037 DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13183.

E. coli strain JM101 was transformed with pMON13183 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13183, contains the DNA sequence of (SEQ ID NO:18) which encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly Ser His Trp Gly Leu Leu Trp Thr Ala Val Ser Arg Cys Pro Ser Phe Ala Ala Glu Ala Glu Lys Pro Ala Cys Leu Asp Gin Gin Gly Ser Gly Lys Ile Pro Leu Arg Leu Ser Arg Glu Ser Ser Glu Leu Ser Ala Leu Met Ala Val Arg Ser Gin Met Leu Met Ala Arg Arg Glu Gin Gly His Leu Ser Gin Leu Gin Glu Met Leu Val Gin Gly Ile Leu Asp Val Asn His Lys Gin Pro Lys Val Ser Leu Glu Leu Glu Pro Val Leu Ser Asp Asp Asp Arg Lys Leu Pro Leu Tyr Ile Ser Leu Cys His Gly Asp Leu Ala Ala Arg Phe Gly Glu Pro Asn Asn Gin Ile Thr Val Ser Pro Leu Pro Ser Ile Val Gly Phe Ser His Leu Ala His Leu Leu Asn Leu Lys Leu Gly Asn Ala Ser Ala Phe Glu Phe Pro Ala Gin Gin Ser Gin His Asn Pro Ala Pro Ala Val Gly Pro Tyr Leu Leu Leu Leu Ala Ala Phe Ser Pro Leu Glu Leu Asp Asn Ser Ser Gly Thr Gly Ser Lys Gly Gin Tyr Gly Thr Leu Gin Phe Ser Glu Lys Lys Glu Leu Gly Ala Asp Leu Ser Pro Leu Ile Leu Gin Pro Thr Gin Arg Leu Gly Gin Leu Arg Asp Glu Ile Thr Trp Glu Pro Pro Cys Pro Ala Gly Thr Ile Pro Arg Glu Gly Val Cys Ala Thr (SEQ ID N0:473) EXAMPLE Construction of pMON13184 The new N-terminus/C-terminus gene in pMON13184 was created using Method I as described in Materials and WO 98/17810 PCT/US97/20037 Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:370) and L-l1 start (SEQ ID NO:364).

Fragment Stop was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and L-11 stop (SEQ ID NO:365). The fulllength new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13184.

E. coli strain JM101 was transformed with pMON13184 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13184, contains the DNA sequence of (SEQ ID NO:19) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu WO 98/17810 PCT/US97/20037 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID N0:474) EXAMPLE 56 Construction of pMON13185 The new N-terminus/C-terminus gene in pMON13185 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:370) and L-11 start (SEQ ID NO:364).

Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and L-11 stop (SEQ ID NO:365). The fulllength new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, WO 98/17810 PCT/US97/20037 Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13185.

E. coli strain JM101 was transformed with pMON13185 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13185, contains the DNA sequence of (SEQ ID NO:20) which encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly Ser Pro Thr Gin Arg Leu Gly Gin Leu Leu Pro Ser Ile Cys Pro Ser Phe Ala Ala Glu Ala Glu Lys Thr Ile Pro Arg Glu Gly Val Cys Gly Ser Gly Ser Ser Ile Ala Pro Ile Leu Val Arg Ile Leu Pro Ser Phe Arg Gin Glu Pro Ser Glu Ser Leu Asp Trp Gin Thr Gin Ala Gly Val Ser Ser Gly Arg Lys Ala Thr His Ser Gin Ala Leu Phe (SEQ ID Met Ile Leu Leu Met Asp Ala Val Arg Asn Arg His Glu Lys Gin Gin Gly Pro His Lys Thr Leu Gin Met Gly Ala Gly Val Tyr Arg Gly Ser Ile Gin Tyr Lys Leu Gly Leu Gin Leu Tyr NO:475) Asp Asp Arg Lys Leu Pro Leu Tyr Ile Ser Gin Glu Met Leu Val Gin Gly Leu Ile Leu Gin Glu Pro Asn Asn Gin Ile Thr Val Ser Pro Leu Glu Pro Val Leu Ser Asp Cys Pro Ala Gly Ile Asn Arg Glu Cys Ile Tyr Gly Ile Met Val Gly Phe Ser His Leu Ala Pro Ala Cys Leu His Leu Leu Asn Leu Lys Leu Gly Asn Ala Ala Met Ala His Leu Leu Ala Glu Pro Leu Gin Lys Glu Leu Gly Ala Asp Leu Ser Pro Leu Ala Ala Phe Ser Pro Leu Glu Val Ser Leu Glu EXAMPLE 57 Construction of DMON13186 The new N-terminus/C-terminus gene in pMON13186 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:372) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from WO 98/17810 PCT/US97/20037 G-CSF Ser 17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:373) and L-1 stop (SEQ ID NO:365) The full-length new N terminus/C-terminus G-CSF Ser" 1 gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13186.

E. coli strain JM101 was transformed with pMON13186 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13186, contains the DNA sequence of (SEQ ID NO:21) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu WO 98/17810 24 PCT/US97/20037 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:476) EXAMPLE 58 Construction of pMON13187 The new N-terminus/C-terminus gene in pMON13187 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:372) and L-1 start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser" 1 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:373) and L-ll stop (SEQ ID N0:365).

The full-length new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13187.

WO 98/17810 PCT/US97/20037 E. coli strain JM101 was transformed with pMON13187 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13187, contains the DNA sequence of (SEQ ID NO:22) which encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly Ser Leu Gin Phe Ser Glu Lys Leu Cys His Gly Asp Met Leu Met Ala Arg Arg Glu Gin Gly His Gin Gly Ser Gly Lys Thr Ser Ala Phe Glu Phe Ile Leu Asp Val Asn His Lys Gin Pro Lys Gly Gly Tyr Gly Ile Tyr Leu Leu Leu Leu Ala Asp Asp Arg Lys Leu Pro Leu Tyr lie Ser Ala Val Arg Ser Gin Lys Gly Gin Tyr Gly Thr Ile Asn Leu Leu Pro Ile Phe Glu Thr Asn Pro Val Leu Ser Asp Cys Pro Ala Gly Thr lie Lys Glu Leu Gly Ala Asp Leu Ser Pro Pro Ala Gin Gin Ser Gin Leu Ser Gin Leu Gin Glu Arg Asp Glu Ile Thr Trp Glu Pro Pro Ala Phe Ser Pro Leu Glu Val Ser Leu Glu Leu Glu Leu Gly (SEQ ID NO:477) EXAMPLE 59 Construction of pMON13188 The new N-terminus/C-terminus gene in pMON13188 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 7 sequence in pMON13037 using the primer set, 133 start (SEQ ID N0:374) and L-11 start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser' 7 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and L-1l stop (SEQ ID N0:365).

The full-length new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

WO 98/17810 :2 PCT/US97/20037 The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13188.

E. coli strain JM101 was transformed with pMON13188 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13188, contains the DNA sequence of (SEQ ID NO:23) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu WO 98/17810 2% PCT/US97/20037 Gin Pro (SEQ ID N0:478) EXAMPLE Construction .of pMON13189 The new N-terminus/C-terminus gene in pMON13189 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 1 sequence in pMON13037 using the primer set, 133 start (SEQ ID N0:374) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and L-ll stop (SEQ ID NO:365).

The full-length new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5( cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13189.

E. coli strain JM101 was transformed with pMON13189 for protein expression and protein isolation from inclusion bodies.

WO 98/17810 2? PCT/US97/20037 The plasmid, pMON13189, contains the DNA sequence of acid (SEQ ID NO:24) sequence: which encodes the following amino Asn Pro Val Ser Glu Ala Gin Gin Gly Ser Met Leu Val Gin Gly Leu lie Leu Gin Pro Cys Pro Ser Phe Ala Ala Glu Ala Glu Lys Pro Val Leu Ser Asp Cys Pro Ala Gly Thr Ser Ala Ile Val Ile Pro Phe Gin Pro Glu Ala Ala Arg Phe Gly His Trp Gly Leu Leu Ile Pro Leu Arg Leu Ser Arg Glu Ser Ser Phe Ser His Leu Ala Pro Ala Cys Leu Asp Asp Asp Arg Lys Leu Pro Leu Tyr Ile Ser Ala Gin Gin Ser Gin Leu Ser Gin Leu Gin Glu Glu Pro Asn Asn Gin Ile Thr Val Ser Pro Phe Ser Pro Leu Glu Val Ser Leu Glu Leu Glu Ile Asn Leu Leu Pro Ile Phe Glu Thr Asn Gin Phe Ser Glu Lys Leu Cys His Gly Asp Leu lie Asn Arg Glu Cys lie Tyr Gly lie Met Arg Leu Gly Gin Leu Leu Pro Ser Ile Val Gly His Leu Leu Asn Leu Lys Leu Gly Asn Ala Arg Glu Gly Val Cys Gly Ser Gly Ser Ala Met His Asn Pro Ala Pro Ala Val Gly Pro Thr Ala Val Ser Arg Ala His Gin Leu Pro Asp Ala Leu Asp Asn Ser Ser Gly Thr Gly Ser Gin Gly Ser Gly Lys Thr Ser Ala Phe Glu Phe Pro Lys Glu Leu Gly Ala Asp Leu Ser Pro Gly Gly Tyr Gly Ile Tyr Leu Leu Leu Leu Ala Ala Arg Asp Glu Ile Thr Trp Glu Pro Pro Ala Val Arg Ser Gin Lys Gly Gin Tyr Gly Thr Leu Thr. Ile Trp Gin Gin Gin Pro (SEQ ID N0:479) EXAMPLE 61 Construction of pMON13190 The new N-terminus/C-terminus gene in pMON13190 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:376) and L-l1 start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:377) and L-ll stop (SEQ ID NO:365).

The full-length new N terminus/C-terminus G-CSF Ser 1 gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate WO 98/17810 2 PCT/US97/20037 plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13190.

E. coli strain JM101 was transformed with pMON13190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13190, contains the DNA sequence of (SEQ ID NO:25) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:480) EXAMPLE 62 WO 98/17810 PCT/US97/20037 Construction of pMON13191 The new N-terminus/C-terminus gene in pMON13191 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 1 7 sequence in pMON13037 using the primer set, 142 start (SEQ ID N0:376) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 141 stop (SEQ ID N0:377) and L-ll stop (SEQ ID N0:365).

The full-length new N terminus/C-terminus G-CSF Ser" gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON13191.

E. coli strain JM101 was transformed with pMON13191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13191, contains the DNA sequence of (SEQ ID NO:26) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg wnoQ/1an 10 PCrTnlQ/Ts7/nn7 294 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:481) EXAMPLE 63 Construction of pMON13192 The new N-terminus/C-terminus gene in pMON13192 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:368) and P-bl start (SEQ ID NO:366).

Fragment Stop was created and amplified from G-CSF Ser 1 7 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:369) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser 1 7 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% WO 98/17810 PCT/US97/20037 2z TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 17 gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13192.

E. coli strain JM101 was transformed with pMON13192 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13192, contains the DNA sequence of (SEQ ID NO:27) which encodes the following amino acid sequence: 13192.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu WO98/17810 93 PCT/US97/20037 Lys Leu Cys Ala Thr (SEQ ID N0:482) EXAMPLE 64 Construction of pMON13193 The new N-terminus/C-terminus gene in pMON13193 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 39 start (SEQ ID N0:368) and P-bl start (SEQ ID N0:366).

Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:369) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 17 gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct WO 98/17810 PCT/US97/20037 insertion of the new gene. The resulting plasmid was designated pMON13193.

E. coli strain JM101 was transformed with pMON13193 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13193, contains the DNA sequence of (SEQ ID NO:28) encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly Ser His Trp Gly Leu Leu Trp Thr Ala Val Gly Glu Lys Met Leu Met Ala Arg Arg Glu Gin Gly His Leu Ser Gin Leu Gin Glu Met Leu Val Ser Lys Thr lie Asp Leu Asp Asp Arg Val Lys Asn Leu His Pro Lys Leu Gin Tyr Pro lie Lys Ser Val Leu Ser Cys Leu His Glu Gly Leu Asp Glu Leu Pro Ala Val Ala Leu Arg Leu Pro Ile Gin (SEQ ID Glu Ile Pro Asn Asn Leu Asn Leu Gin Pro lie Ile Thr Phe Val Glu Ser Thr Pro Asn Leu Gly Pro Ser Ser Gly Ile Ser Val Ala Gly Met Phe Ala Ser His His Leu Gin Ser Gly Asp N0:483) Leu Asp Asn Ser Ser Gly Thr Gly Ser Lys Gly Gin Tyr Gly Thr Leu Gin Phe Thr Lys Leu Arg Asp Glu Ile Thr Trp Glu Pro Pro Cys Pro Ala Gly Thr Ile Pro Arg Glu Leu Leu Glu EXAMPLE Construction of pMON25190 The new N-terminus/C-terminus gene in pMON25190 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:370) and P-bl start (SEQ ID NO:366).

Fragment Stop was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and P-bl stop (SEQ ID N0:367). Fragment WO 98/17810 PCT/US97/20037 Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" 1 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 17 gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25190.

E. coli strain JM101 was transformed with pMON25190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25190, contains the DNA sequence of (SEQ ID NO:29) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro.Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr WO 98/17810 PCTIUS97/20037 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Let Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID N0:484) EXAMPLE 66 Construction of PMON25191 The new N-terminus/C-terminus gene in pMON25191 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:370) and P-bl start (SEQ ID N0:366).

Fragment Stop was created and amplified from G-CSF Ser 1 7 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser 7 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 17 gene was isolated using Geneclean (BiolOl, Vista, CA). The WO 98/17810 PCT/US97/20037 intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25191.

E. coli strain JM101 was transformed with pMON25191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25191, contains the DNA sequence of (SEQ ID NO:30) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:485) WO 98/17810 PCT/US97/20037 EXAMPLE 67 Construction of pMON13194 The new N-terminus/C-terminus gene in pMON13194 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:372) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:371) and P-bl stop (SEQ ID N0:367).

Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI- HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser 1 7 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 1 gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct WO 98/17810 PCT/US97/20037 insertion of the new gene. The resulting plasmid was designated pMON13194.

E. coli strain JM101 was transformed with pMON13194 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13194, contains the DNA sequence of (SEQ ID NO:31) which encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly Leu Gin Phe Thr Lys Leu Glu Leu Ser Ala Leu Met Cys Pro Ser Phe Ala Ala Glu Ala Gly Gin Arg Leu Pro Ser Gin Leu Ser Gin Leu Gin Glu Ser Ala Ile Val Ile Pro Phe Gin Gly Pro Arg Glu Leu Leu Glu Val Ser Leu Glu Leu Glu Met Leu Met Ala Arg Arg Glu Gin Gly Gin Gly Ser Pro Gin Leu Leu Pro Ser Ile Val Gly Ile Asp Leu Asp Asp Arg Val Lys Asn Leu His Pro Lys Leu Gin Tyr Gly Gly Gly Ala Gly Val Tyr Arg Ala Ser Val Arg Cys Ala Gly His Ser Gin Gly Leu Ser Pro Ala Asp (SEQ ID Glu Ile Pro Asn Asn Leu Asn Leu Gin Pro Ile Ile Thr Phe Val Glu Ser Asn Met Pro Leu Val Val Leu Ser Leu Lys lie Thr Tyr Ser Leu Ala Leu Phe Leu Glu Leu Phe Ala NO:486) His Leu Leu Asn Leu Lys Leu Gly Ala Phe Ser His Gin Gly Leu lie Leu Gin Pro Thr His Asn Pro Ala Pro Ala Val Gly Met Ala His Leu Ser Asp Cys Pro Ala Gly Thr lie Leu Asp Asn Ser Ser Gly Thr Gly Ala Ser Leu Ala Phe Gly His Trp Gly Leu Leu Trp Lys Glu Leu Gly Ala Asp Let Ser Pro Ala Gin Gin Leu Ala Pro Ala Cys Leu Asp Gin EXAMPLE 68 Construction of pMON13195 The new N-terminus/C-terminus gene in pMON13195 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 7 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:372 and P-bl start (SEQ ID NO:366).

Fragment Stop was created and amplified from G-CSF Ser 7 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:373) and P-bl stop (SEQ ID N0:367). Fragment WO GuIl 1791 I'T/n7/O nn27 rT U 7W1AQUfl sqI J. Al IJb7 11 UUJ I 0300 Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser 1 7 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser" gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13195.

E. coli strain JM101 was transformed with pMON13195 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13195, contains the DNA sequence of (SEQ ID NO:32) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile. Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr WO 98/17810 PCT/US97/20037 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:487) EXAMPLE 69 Construction of pMON13196 The new N-terminus/C-terminus gene in pMON13196 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:374) and P-bl start (SEQ ID NO:366).

Fragment Stop was created and amplified from G-CSF Ser 7 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and P-bl stop (SEQ ID N0:367). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser" gene was isolated using Geneclean (BiolOl, Vista, CA). The WO 98/17810 PCT/US97/20037 intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5o cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13196.

E. coli strain JM101 was transformed with pMON13196 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13196, contains the DNA sequence of (SEQ ID NO:33) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:488) WO 98/17810 PCT/US97/20037 3o3 EXAMPLE Construction of DMON13197 The new N-terminus/C-terminus gene in pMON13197 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser 17 sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:374) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser 7 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and P-bl stop (SEQ ID NO:367).

Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI- HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser" gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct WO 98/17810 PCT/US97/20037 Qo4 insertion of the new gene. The resulting plasmid was designated pMON13197.

E. coli strain JM101 was transformed with pMON13197 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13197, contains the DNA sequence of (SEQ ID NO:34) which encodes the following amino acid sequence: Asn Pro Val Ser Glu Ala Gin Gin Gly His Trp Gly Leu Leu Trp Thr Ala Val Gly Glu Lys lie Asp Leu Asp Asp Arg Val Lys Asn Leu His Pro Lys Leu Gin Tyr Gly Gly Val Leu Ser Cys Leu His Glu Gly Leu Asp Glu Leu Pro Ala Val Ala Leu Arg Leu Pro lie Gin (SEQ ID Glu lie Pro Asn Asn Leu Asn Leu Gin Pro lie Ile Thr Phe Val Glu Ser Asn Leu Gly Pro Ser Ser Gly Ile Ser Val Ala Gly Met Phe Ala Ser His His Leu Gin Ser Gly Asp N0:489) His Leu Leu Asn Leu Lys Leu Gly Ala Ser Ala Phe Glu Phe Pro Ala Gin Gin Leu Ala Arg Asp Glu Ile Thr Trp Glu Pro Cys Pro Ala Gly Thr Ile Pro Arg Glu Leu Leu Glu EXAMPLE 71 Construction of oMON13198 The new N-terminus/C-terminus gene in pMON13198 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:376) and P-bl start (SEQ ID NO:366).

Fragment Stop was created and amplified from.G-CSF Ser 17 sequence in pMON13037 using the primer set, 141 stop WO 98/17810 PCT/US97/20037 (SEQ ID NO:377) and P-bl stop (SEQ ID N0:367). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 17 gene was isolated using Geneclean (BiolOl, Vista, CA). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13198.

E. coli strain JM101 was transformed with pMON13198 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13198, contains the DNA sequence of (SEQ ID NO:35) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile WO 98/17810 PCT/US97/20037 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr. Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:490) EXAMPLE 72 Construction of pMON13199 The new N-terminus/C-terminus gene in pMON13199 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser" sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:376) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser1 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:377) and P-bl stop (SEQ ID NO:367).

Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI- HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser" gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the fulllength new N-terminus/C-terminus G-CSF Ser 1 7 gene was isolated using Geneclean (BiolOl, Vista, CA). The WO 98/17810 PCT/US97/20037 intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI).

The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13199.

E. coli strain JM101 was transformed with pMON13199 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13199, contains the DNA sequence of (SEQ ID NO:36) which encodes the following amino acid sequence: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:491) WO 98/17810 PCT/US97/20037 3cj7 EXAMPLE 73 Construction of tandemly-duplicated plasmid template, Syntanl To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, Syntanl, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, Llsyn.for (SEQ ID NO:352) and Llsyn.rev (SEQ ID N0:353), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and Clal ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaI (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl).

A portion of the ligation reaction was used to transform E. coli strain DH5( cells (Life Technologies, Gaithersburg, MD). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntanl and contains the DNA sequence of (SEQ ID NO:7).

EXAMPLE 74 Construction of tandemly-duplicated template, svntan3.

WO 98/17810 PCT/US97/20037 To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, syntan3, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L3syn.for (SEQ ID NO:354) and L3syn.rev (SEQ ID NO:355), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and SnaBI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaI (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl).

A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan3 and contains the DNA sequence of (SEQ ID NO:8).

EXAMPLE Construction of pMON31104 The new N-terminus/C-terminus gene in pMON31104 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using WO 98/17810 PCT/US97/20037 9Ao the primer set 35 start (SEQ ID N0:356) and 34 rev (SEQ ID NO:357).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector,pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31104.

E. coli strain JM101 was transformed with pMON31104 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31104, contains the DNA sequence of (SEQ ID NO:9) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly WO 98/17810 PCT/TS97/'i07 Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:492) EXAMPLE 76 Construction of pMON31105 The new N-terminus/C-terminus gene in pMON31105 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using the primer set 70 start (SEQ ID NO:358) and 69 rev (SEQ ID NO:359).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31105.

WO 98/17810 PCT/US97/20037 3A2/ E. coli strain JM101 was transformed with pMON31105 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31105, contains the DNA sequence of (SEQ ID NO:10) which encodes the protein with the following amino acid sequence: Asn Leu Lys Leu Asn Pro Val Ser Gly Pro Thr Ala Val Ser Arg Ala His Gin Leu Pro Asp Ala Ala Pro Ala Val Cys Pro Ser Phe Gly Ser Gin Gly Ser Gly Lys Thr Ser Ala Phe Glu Phe Pro Glu Ala Gin Gin lie Leu Asp Val Glu Lys Pro Val Leu Ser Asp Cys Pro Ala Gly Thr Ile Pro Ala Ile Ala Pro Glu Phe Ala Gin Asp Glu Asp Pro Arg Asn Lys Asn Pro Ser Glu Ser Ala Phe Ala Ser Arg His Phe Leu Gly Ala His Pro Trp Ala Gly Cys Leu Leu Leu Asp Trp Gin (SEQ ID Leu Arg Ser Arg Arg Glu Glu Gin Ile lie Asn Asn Leu Arg Leu Glu Gly Pro His Lys Ala Ser His Leu Leu Ala Leu Lys Ala Leu Glu Glu Pro Leu Leu Ser Gin Ala Thr Leu Gin Met NO: 493) Asn His Lys Gin His Leu Leu Tyr lie Ser Ala Gin Gin Ser Gin Leu Ser Gin Leu Gin Glu EXAMPLE 77 Construction of pMON31106 The new N-terminus/C-terminus gene in pMON31106 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using the primer set 91 start (SEQ ID NO:360) and 90 rev (SEQ ID NO:361).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a wn R81Tn7R10 prT/ITS7/ n 007

VY

34 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4' DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31106.

E. coli strain JM101 was transformed with pMON31106 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31106, contains the DNA sequence of (SEQ ID NO:11) which encodes the protein with the following amino acid sequence: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala WO 98/17810 PCTUS97/20037 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO;494) EXAMPLE 78 Construction of pMON31107 The new N-terminus/C-terminus gene in pMON31107 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using the primer set 101 start (SEQ ID NO:362) and 100 rev (SEQ ID NO:363).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested The DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert.

The resulting plasmid was designated pMON31107.

E. coli strain JM101 was transformed with pMON31107 for protein expression and protein isolation from inclusion bodies.

WO 98/17810 PCT/US97/20037 The plasmid, pMON31107, contains the DNA sequence of (SEQ ID NO:12) which encodes the following amino acid sequence: Ala Val Cys Pro Ser Phe Ala Ala Gly Pro Thr Ala Val Ser Arg Ala His Gin Leu Pro Asp Ala Gly Thr Ser Ala Ile Val Ile Pro Gly Ser Gin Gly Ser Gly Lys Thr Ser Ala Phe Glu Phe Pro Asp Leu Ile Pro Leu Arg Leu Ser Ser Pro Gly Gly Tyr Gly Ile Tyr Leu Leu Leu Leu Ala Ala Glu Ala Asp Asp Arg Lys Leu Pro Glu Lys Pro Val Leu Ser Asp Cys Pro Ala Gly Thr Ile Pro Phe Arg Gln Glu Glu Ile Pro Asn Asn Leu Asn Leu Gin Pro lie Ile Pro Ser Glu Ser Ala Phe Ala Ser Arg His Phe Leu Gly Ala His Pro Trp Ala Gly Cys Leu Leu Leu Asp Trp Gin (SEQ ID Glu Lys Gin Gin Ile His Asn Leu Arg Leu Glu Asn Cys Leu Ile Lys Gly Pro His Lys Ala Ser His Leu Leu Ala Leu Lys Ala Leu Glu Glu Pro Leu Leu Ser Gin Ala Thr Leu Gin Met NO:495) Leu Gly His Asn Pro Ala Pro Tyr Ile Ser Ala Gin Gln Ser Gin Leu Ser Gin Leu Gin Glu Thr Gly Leu Asp Asn Ser Ser Val Ser Pro Phe Ser Pro Leu Glu Val Ser Leu Glu Leu Glu Phe Gly Lys Glu Leu Gly Ala Glu Thr Asn Gin Phe Ser Glu Lys Leu Cys His Gly Asp Leu Tyr Ser Arg Asp Glu Ile Thr Gly lie Met Arg Leu Gly Gln Leu Leu Pro Ser Ile Val Gly Leu Asn Pro Val Ser Glu Ala Gly Asn Ala Arg Glu Gly Val Cys Gly Ser Gly Ser Ala Met EXAMPLE 79 Construction of pMON31108 The new N-terminus/C-terminus gene in pMON31108 was created using Method III as described in Materials and Methods. The full length new Nterminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set start (SEQ ID NO:356) and 34 rev (SEQ ID N0:357).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression WO 98/17810 PCT/US97/20037 vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31108.

E. coli strain JM101 was transformed with pMON31108 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31108, contains the DNA sequence of (SEQ ID NO:13) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:496) WO 98/17810 PCT/US97/20037 EXAMPLE Construction of. MON31109 The new N-terminus/C-terminus gene in pMON31109 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 70 start (SEQ ID N0:358) and 69 rev (SEQ ID NO:359).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31109.

E. coli strain JM101 was transformed with pMON31109 for protein expression and protein isolation from inclusion bodies.

WO 98/17810 PCT/US97/20037 The plasmid, pMON31109, contains the DNA sequence of (SEQ ID NO:14) which encodes the following amino acid sequence: Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:497) EXAMPLE 81 Construction of PMON31110 The new N-terminus/C-terminus gene in pMON31110 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 91 start (SEQ ID NO:360) and 90 rev (SEQ ID NO:361).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified WO 98/17810 PCT/US97/20037 digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31110.

E. coli strain JM101 was transformed with pMON31110 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31110, contains the DNA sequence of (SEQ ID NO:15) which encodes the following amino acid sequence: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:498) WO 98/17810 PCT/US97/20037 EXAMPLE 82 Construction of pMON31111 The new N-terminus/C-terminus gene in pMON31111 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 101 start (SEQ ID N0:362) and 100 rev (SEQ ID NO:363).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and.the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, MD).

Transformant bacteria were selected on ampicillincontaining plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31111.

E. coli strain JM101 was transformed with pMON31111 for protein expression and protein isolation from inclusion bodies.

WO 98/17810 PCT/US97/20037 &y4 The plasmid, pMON31111, contains the DNA sequence of (SEQ ID NO:16) which encodes the following amino acid sequence: Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:499) EXAMPLE 83 Construction of pMON31112 Construction of pMON31112, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222 (WO 94/12639, US serial 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:350) and WO 98/17810 WO 9817810PCTIUS97/20037 SYNNOXA2.REQ (SEQ ID NO:351) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMONl3l89. A portion of the ligation mixture was then transformed into E. coi K-12 strain JMl0l. Transforinant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pNON3lll2, contains the DNA sequence of (SEQ ID NO:37) which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetIieAspGluleleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspolnAspl leLeuMetAspAsriAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaVaLysSerLeuGlnsJ~laSerAlaIleGluSerI ieLeu LysAsnLeuLeuProcysbeuProLeuAlaThrAiaAllaProThrArgHisProlleHislleLys AspG lyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaG in AlaGinGJlnTyrVaiGiuGiyGlyG2yGlySerProGlyGluProSerGlyProlleSerThrl le AsnProSerProPro~erLysoiuSerHisLys SerProAsnMetAlaThrGlnGlyAiaMet Pro AlaPheAia~erAlaPheGinArgArgAlaGlyGlyValLeuvaAiaSerHi sLeuGinSerPhe LeuGluVal~erTyrArgValLeuArg-isLeuAlaGlnProSerolyGlySerGlyGiySerGln SerPheLeuLeuLysSerLeuciuolnvalArgLysl leGlnGiyAspGiyAlaAiaLeuGlnGlu LysLeucysAiaThrTyrLysLeucysHisProoluGiuLeuvaiLeuLeuGlyHi sSerLeuGly I leProTrpAlaProLeuSerSercys ProSerGriAl aLeuGlnLeuAlaGlycysLeuSerGln LeuHi sSerGiyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeulu~iylleSerProGiuLeu GlyProThrLeuAspThrLeuGinLeuAspValAiaAspPheAlaThrThrleTrpGinGlnMet GluGluLeuGlyMetAlaProAlaLeuGinPro (SEQ ID NO:505) Construction of p)MON3lll3 Construction of pMON3l113, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hTL-3 receptor and G-CSF receptor. Plasmid, pMON13 197 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, US serial 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base WO 98/17810 .32 3 WO 98/78 10PCTIUS97/20037 pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:350) and SYNNOXA2.REQ (SEQ ID NO:351) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JMl0l. Transformant bacteria were selected on aipicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON3lll3, contains the DNA sequence of (SEQ ID NO:38) which encodes the following amino acid sequence: MetAlaAsnCys~erAsnMetl leAspGluIleI leThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnolyoluAspolnAspleLeuMetluAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlriAsnAlaSerAlaIleGluSerIleLeu LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProllellelleArg AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuluAsnAlaoln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProl leSerThrl le AsnPro~erProPro~erLysGluSerHisLys SerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheclnArgArgAlaGlyolyValLeuValAlaSerHisLeuGlnserPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnvalArgLysI leGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHis SerLeuGlyl leProTrpAlaProLeuSersercysProsero lnAlaLeuGlnLeuAlaclycys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGn31yLeuLeuGln~1aLeuGluGlyIleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 506) EXAMPLE Construction of iDMON31114 Construction of pMON3lll4, a plasmid containing DNA sequence encoding a multi-functional hematop oietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and IW41% GO111191A Vr'1rrIr74Q"P)nn'XI7

WV

~1JI o/I'llA r'I~vnfin2'?tso, *2J37 purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, US serial 08/411,796), was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID N0:350) and SYNNOXA2.REQ (SEQ ID NO:351) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13189. A portion of the ligation mixture was then transformed into coi K-12 strain JMl0l. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31114, contains the DNA sequence of (SEQ ID NO:39) which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetlleAspGlullel leThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsriAsnLeuAsnGlyGluAspGlnAspl leLeuMetGluAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalleGluSerlleLeu LysAsnLeuLeuProcysLeuProLeuAlaThrAlaAlaProThrArgHisProllellelleArg AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProI leSerThrlle AsnProSerProProSerLysGluSerHi SLysSerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHi sLeuAlaGlnProSerGlyGlySerGlyGlySerGln SerPheLeuLeuLysSerLeuGluGlnValArgLys IleGinG lyAspGlyAlaAlaLeuGlnGlu LysLeucysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHi sSerLeuGly Il.eProTrpAlaProLeuSerSercys ProSerGlnAlaLeuGlnLeuAlaGlycysLeuSerGln LeuHisSerGlyLeuPhebeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:507) EXAMPLE 86 Construction of pDMON31115 WO 98/17810 WO 9817810PCTIUS97/20037 Construction of pMON3lll5, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMQN13197 DNA was digested with restriction' enzy -mes NcoI And XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222, was digested with NcoI and EcoRT resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:350) and SYNNOXA2.REQ (SEQ ID NO:351) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JMlO1. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON3l1l5, contains the DNA sequence of (SEQ ID NO:40) which encodes the following amino acid sequence: MetAlaAsncysSerAsnMetlleAspGlul lelleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspl lebeuMetAspAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlal leGluSerI leLeu LysAsnLeuLeuProcysLeuProLeuAlaThrAlaAlaProThrArgHisProl leHis IleLys AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrI le AsnProSerProProSerLysG.uSerHisLys SerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlriArgArgAlaGlyGlyValLeuValAlaSerHi sLeuGlnSerPhe LeuGluVal SerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLyslleGlnGlyAspGlyAlaAla LeuGlnGluLysLeucysAlaThrTyrLysLeucysHis ProGluGluLeuValLeubeuGlyHis SerLeuGlyl leProTrpAlaProbeuSerSercysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyl leSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrl leTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 508) WO 98/17810 PCT/US97/20037 EXAMPLE 87 Determination of the in vitro activity of multifunctional hematopoietic receptor aconist proteins The protein concentration of the multi-functional hematopoietic receptor agonist protein can be determined using a sandwich ELISA based on an affinity purified polyclonal antibody. Alternatively the protein concentration can be determined by amino acid composition analysis. The bioactivity of the multifunctional hematopoietic receptor agonist can be determined in a number of in vitro assays. For example a multi-functional hematopoietic receptor agonist which binds the hIL-3 receptor and G-CSF receptor can be assayed in cell proliferation assays using cell lines expressing the hIL-3 and/or G-CSF receptors. One such assay is the AML-193 cell proliferation assay. AML-193 cells respond to IL-3 and G-CSF which allows for the combined bioactivity of the IL-3/G-CSF multi-functional hematopoietic receptor agonist to be determined. Another such assay is the TF1 cell proliferation assay.

In addition other factor dependent cell lines, such as M-NFS-60 (ATCC. CRL 1838) or 32D which are murine IL- ,3 dependent cell line, may be used. The activity of IL-3 is species specific whereas G-CSF is not, therefore the bioactivity of the G-CSF component of the IL-3/G-CSF multi-functional hematopoietic receptor agonist can be determined independently. Cell lines, such as BHK or murine Baf/3, which do not express the receptor for a given ligand can be transfected with a plasmid containing a gene encoding the desired receptor. An example of such a cell line is BaF3 transfected with the hG-CSF receptor (BaF3/hG-CSF). The activity of the multi-functional hematopoietic receptor agonist in these cell lines can be compared with hIL-3 or G-CSF alone or together. The bioactivity of examples of multi- WO 98/17810 PCTYUS97/20037 functional hematopoietic receptor agonists of the present invention assayed in the BaF3/hG-CSF cell proliferation and TFl cell proliferation assays is shown in Table 5 and Table 6. The bioactivity of the multifunctional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMON13056 (WO 95/21254) which has IL-3 and G-CSF receptor binding activity. The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3/c-mpl cell proliferation and TF1 cell proliferation assays is shown in Table 7 and Table 8.

WO 98/17810 PCT/US97/20037 TABLE CELL PROLIFERATIVE ACTIVITY OF DUAL IL-3/G-CSF RECEPTOR AGONISTS BaF3/hG-CSF receptor cell TF1 pMON proliferation assay cell proliferation assay relative activity relative activity 13182 0.015 1.1 13183 0.02 nd 13184 0.01 0.3 13185 0.023 0.36 13186 0.36 0.45 13187 0.07* 0.26 13188 0.64 1.3 13189 0.58 1.37 13190 0.045 1.2 13191 0.14 2.7 13192 0.09 2.2 13193 0.06 25190 nd nd 25191 0.43 1.2 13194 nd nd 13195 1.3 4.3 13196 0.66 13197 0.6 0.77 13198 0.6 13199 nd nd 15982 0.7 1.9 15981 0.068 1.2 15965 0.7 0.82 15966 0.36 1.48 15967 0.62 1.37 nd not determined The bioactivity of the multi-functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMON13056. n=3 or greater WO 98/17810 PCT/US97/20037 TABLE 6 CELL PROLIFERATIVE ACTIVITY OF DUAL IL-3/G-CSF RECEPTOR AGONISTS pMON BaF3/hG-CSF receptor TF1 cell proliferation assay cell proliferation assay relative activity relative activity 31104 31105 31106 31107 nd nd 31108 31109 31110 nd nd 31111 nd nd 31112 31113 31114 31115 31116 nd nd 31117 nd nd nd not determined t The bioactivity (n=l hematopoietic receptor activity compared with indicates that. the pMON13056.

or 2) of the multi-functional agonist is expressed as relative a standard protein pMON13056.

molecule was comparable to WO 98/17810 WO 9817810PCT/US97/20037 TABLE 7 CELL PROLIFERATION ACTIVITY pHON cell proliferation cell proliferation 28505 28506 2 8507 28508 28509 28510 28511 28512 28513 28514 28519 28520 28521 28522 28523 28524 28525 28526 28533 28534 28535 28536 28537 28538 28539 28540 28541 28542 28543 28544 28545 *Activity measured in the Baf3 cell line transfected with the c-mpl receptor, relative to c-mpl ligand (1- 153).

t Activity measured relative to pMON13056.

In a similar manner other factor dependent cell lines known to those skilled in the art can be used to measure the bioactivity of the desired multi-functional hematopoietic receptor agonist. The methylcellulose WO98/17810 PCT/US97/20037 assay can be used to determine the effect of the multifunctional hematopoietic receptor agonists on the expansion of the hematopoietic progenitor cells and the pattern of the different types of hematopoietic colonies in vitro. The methylcellulose assay can provide an estimate of precursor frequency since one measures the frequency of progenitors per 100,000 input cells. Long term, stromal dependent cultures have been used to delineate primitive hematopoietic progenitors and stem cells. This assay can be used to determine whether the multi-functional hematopoietic receptor agonist stimulates the expansion of very primitive progenitors and/or stem cells. In addition, limiting dilution cultures can be performed which will indicate the frequency of primitive progenitors stimulated by the multi-functional hematopoietic receptor agonist.

WO 98/17810 WO 9817810PCT/US97/20037 3321 8 pMON IL-3 agonist activity c-mol reecptor agonist (AML cell proliferation activity assay) (Baf/3-c-xnpl cell proliferation assay 28505 28506 28507 28508 28509 28510 28511 28512 28513 28514 28515 28519 28520 28521 28522 28523 28524 28525 28526 28527 L 28528 28529 WO 98/17810 PCT/US97/20037 33able 8 cot) Table R (r~nnt' 28535 28539 28540 28541 28542 28545 28551 28571 EXAMPLE 88 G-CSF variants which contain single or multiple amino acid substitutions were made using PCR mutagenesis techniques as described in WO 94/12639 and WO 94/12638.

These and other variants amino acid substitutions, insertions or deletions and N-terminal or C-terminal extensions) could also be made, by one skilled in the art, using a variety of other methods including synthetic gene assembly or site-directed mutagenesis (see Taylor et al., Nucl. Acids Res., 13: 7864-8785 [1985]; Kunkel et al., Proc. Natl. Acad. Sci. USA, 82: 488-492 [1985]; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, [19891, (WO 94/12639) and (WO 94/12638)). These substitutions can be made one at a time or in combination with other amino acid substitutions, and/or deletions, and/or insertions and/or extensions. After sequence verification of the changes, the plasmid DNA can be transfected into an appropriate mammalian cell, insect cell or bacterial strain such as E. coli for production. Known variants of G-CSF, which are active, include substitutions at positions 1 (Thr to Ser, Arg or Gly, 2 (Pro to Leu), 3 (Leu to Arg or Ser) and 17 (Cys to Ser) and deletions of amino acids 1-11 (Kuga et al. Biochemicla and wO ro/I 781N PCTnI9O7/0fn37 334 Biophysical Research Comm. 159:103-111 (1989)). These G- CSF amino acid substitution variants can be used as the template to create the G-CSF receptor agonists in which a new N-terminus and new C-terminys are created.

Examples of G-CSF amino acid substitution variants are shown in Table 9.

EXAMPLE 89 Bioactivity determination of G-CSF amino acid substitution variants The G-CSF amino acid substitution variants can be assayed for cell proliferation activity using the Baf/3 cell line transfected with the human G-CSF receptor. The bioactvity of examples of G-CSF amino acid substitution variants is shown in Table 9 relative to native human G- CSF. A indicates a comparable activity to native and a indicates significantly reduced or no measurable activity.

WO 98/17810 335 WO 9817810PCTIUS97/20037 TABLE 9 CELL PROLIFERATION ACTIVITY OF G-CSF VARIANTS IN BAF3 r(PT.. T.TWMV TRAN!~FECTED WTTH THE HETMAN G-C5~F REC"PPTOP aa position native aa mutant aa activity 13 13 13 13 16 16 16 16 18 18 18 18 18 19 19 19 19 19 19 22 22 22 22 24 24 24 Phe Phe Phe Phe Lys Lys Lys Lys Leu Leu Leu Leu Leu Glu Glu Glu Glu Glu Glu Arg Arg Arg Arg Ile Ile Ile Ser His Thr Pro Pro Ser Thr His Pro Thr His Cys Ile Ala Thr Arg Pro Leu Ser Tyr Ser Ala Thr Pro Leu Tvr WO 98/17810 WO 9817810PCT1US97/20037 TABLE 9 cont.

aa position native'aa mutant aa activity Asp Ala Al a Lys His His His His His His His His His Pro Pro Pro Pro Pro Pro Pro Pro Pro Glu .Glu Leu Leu Leu Leu Leu Leu *Gly Ile Leu Ser Gly Thr Val1 Lys Trp Al a Arg *Cys Leu Arg Asp Val Al a His Gin Trp Gly Thr Ala Arg Thr Phe Arg Ser His His WO 98/17810 WO 9817810PCTIUS97/20037 TABLE 8 cont.

aa position native aa mutant aa activity 67 67 67 104 104 108 108 108 108 108 108 115 115 115 144 144 144 144 144 146 147 156 156 156 Gin Gin Gin Gin Gin Gin Gin Asp Asp Leu Leu Leu Leu Leu Leu Thr Thr Thr Phe Phe Phe Phe Phe Arg Arg His His His Lys Leu Cys Pro Leu Arg Ser Gly Val1 Ala Val1 Arg Gly Trp Gin His Leu Aia His Arg Pro Leu Giu Gin Gin Asp Ser Glv WO' 9817810 niPCTIUS97/20037 TABLE 8 conit.

aa position native aa mutant aa activity 159 Ser Arg 159 Ser Thr 159 Ser Tyj.r 159 Ser- Val 159 Ser Gly 162 Glu Gly 162 Glu Trp 162 Glu Leu 163 Val Arg 163 Val Ala 163 Val Gly 165 Tyr Cys nd 169 Ser Leu 169 Ser Cys 169 Ser Arg 170 His Arg 170 His Ser *activity relative to native hG-CSF nd not determined wn O/1i7Rn PCT/IS97/2f037

V

EXAMPLE Isolation of cDNA encoding flt3 liqand Three flt3 ligand clones were amplified from human bone morrow poly A+ RNA (Clontech) using NCOFLT, HIND160, and HIND165 PCR primers (according to the manufacturer's suggested conditions). These amplified PCR products were gel purified and cloned into the BHK expression vector pMON5723 generating pMON30237 (NCOFLT HIND160), pMON30238 (NCOFLT HIND165), and a deletion clone pMON30239 (NCOFLT HIND165). The deletion in pMON30239 is of amino acid residues 89 through 106.

EXAMPLE 91 Sequence rearranged flt3 receptor agonists were constructed using several methods and linker types. The first set of constructs containing the linker peptide (SerGlyGlyAsnGly)X (where X 1, 2, or 3) with the breakpoints 39/40, 65/66, and 89/90 were made using a two step PCR process described by Mullins et al. in which the front half and the back half of each final sequence rearranged molecule is made separately in the first PCR step, then the paired products of the first reaction step are combined in a second PCR step and extended in the absence of exogenous primers.

For example, to make the three 89/90 breakpoint precursor molecules with SerGlyGlyAsnGly SEQ ID N0:786, SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID N0:787, and SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:788 amino acid linkers (pMON32326, pMON32327 and pMON32328 respectively), six initial PCR products were generated. The following primer pairs were used in the first step PCR reaction: a) 89For/L5B; b) 89For/L10B; c) 89For/L15B; d) 89Rev/L5A; e) 89Rev/L10A; and f) WO 98/17810 PCT/US97/20037 34o 89Rev/L15A. The identical approach was used to make pMON32321 (39/40 breakpoint, primer pairs 39For/L10B and 39Rev/L10A) and pMON32325 (65/66 breakpoint, primer pairs 65For/L5B and 65Rev/L5A) precursors. Except as noted below, all subsequent PCR reactions utilized the components of the PCR Optimizer Kit (Invitrogen) and amplification conditions according to the manufacturers suggested protocol. Reactions were set up as follows: pmol of each primer, 10 ul of 5X Buffer B [300 mM Tris-HCl (pH 10 mM MgCl 2 75 mM (NH 4 )2SO 4 5 U Taq polymerase, and 100 ng of heat denatured DNA (in this example pMON30238) template were combined, and brought to 45 ul final volume with dH20. Reactions were preincubated for 1-5 minute at 80 0 C, then 5 ul of 10 mM dNTP added to each reaction, and heat denatured for 2 minutes at 94 0 C prior to amplification in a Perkin Elmer model 480 DNA thermal cycler. Seven DNA amplification cycles were done under the following conditions: heat denature for one minute at 940C, two minutes annealing at 65 0 C, followed by a three minute extension at 720C.

Twenty three additional cycles consisting of a one minute heat denaturation at 940C followed by a four minute annealing/extension at 72 0 C were done, followed by a final 7 minute extension cycle at 720C. With the exception of pMON32328, the PCR amplification products were run out on a 1.2% TAE agarose gel, and the appropriate size bands (the major amplification product) were excised and purified using Geneclean II (Bio 101).

Samples were resuspended in 10 ul dH20. The amplication products for pMON32328 were purifed directly using a Wizard PCR Clean UP kit (Promega), and DNA eluted in ul dH20.' The method to construct the precursors of pMON32322 (39/40 breakpoint, primer pairs 39For/L5B and 39Rev/L5A) was modified by increasing the amount of template to 1 ug, and by changing the PCR amplification conditions as follows: six cycles of 94 0 C, 1 minute, 65 0 C for 2 1% nnil jao1n o~mrrmn~r~~~~- W y7I1 ii iow rP II/US// uu37 minute, and 720C for 2 1/2 minutes, followed by cycles of 94 0 C for 1 minute, 70 0 C for 2 minutes, and 720C for 2 minutes, followed by a single 720C extension cycle for seven minutes.

The second PCR step utilized the gel-purified precursors from the first PCR step as a combination of primer/template as follows: 5 ul each of each precursor molecule for pMON32328 the PCR products from primer pairs 89For/L5B and 89Rev/L5A), 10 ul of Buffer B, 5 U of Taq polymerase, and 24 ul dH20. The reactions were heated for five minutes at 800C, 5 ul of mM dNTP was added, and the reactions heat denatured for 94 0 C for two minutes. DNA amplification conditions were as follows: 15 cycles of 940C for one minute, 690C for two minutes, followed then by a three minute extension at 72°C. To allow for complete extension, the last cycle was followed by a single extension step at 720C for seven minutes. The 80 deg incubation time was reduced to two minutes and the number of cycles was decreased to ten cycles for pMON32325 (PCR products 65For/L5B and 65Rev/L5A). PCR reaction products of the appropriate size were gel purified on a 1.2 TAE agarose gel using Geneclean II. For pMON32322 (39For/L5B and 39Rev/L5A) the annealing temperature was reduced to 68 0 C, and the extension time reduced to two minutes. In addition, the PCR product was purified using a Wizard PCR Clean Up kit (Promega) according to the suppliers suggested protocol. The second PCR step was modified for pMON32326 (PCR products of 89For/L15B and 89Rev/L15A) as follows. Three sets of PCR reactions were set up identically as above, except for the sample buffer type (either 5X buffer B, D, or J PCR Optimizer Kit). Composition of buffers D and J differ from buffer B only by pH or [MgC1 2 The [MgCl 2 for buffer D is mM, whereas the pH of buffer J is 9.5. The protocol was modified by increasing the number of PCR cycles 20, and ul aliquots were withdrawn at the end of cycles WO 98/17810 PCT/US97/20037 and 20. Five uls of each aliquot timepoint were analyzed for the presence of amplfied material on a 1.2% TBE agarose gel. The remainder of the buffer B, D, and J PCR reaction mixtures were pooled and subsequently purified using the Wizard PCR Clean Up Kit protocol.

The DNA was eluted in 50 ul dH 2

O.

The purified samples from the second step PCR reaction were digested with NcoI/HindIII using one of two standardized digestion conditions. For Geneclean II purified samples, 10 ul of DNA were digested in a 20 ul reaction with 7.5 U each of NcoI/HindIII for two hours at 37 0 C, and gel purified on a 1.1% TAE agarose gel again with Geneclean II. Ligation-ready samples were resuspended in 10 ul dH 2 0. For pMON32322, 20 ul of sample was digested in a 50 ul reaction volume with each of NcoI and HindIII for 3 hour at 37 0 C. 0.1 volume 3M NaOAc (pH 5.5) and 2.5 volume of EtOH were added, mixed, and stored at -200C overnight. The DNA was recovered by pelleting for 20 minutes at 13,000 rpm 4 0 C in a Sigma Mk 202 microfuge. The DNA pellet was rinsed with chilled 70% EtOH, lyophilized, and resuspended in 10 ul dH 2 0.

EXAMPLE 92 An alternate approach was used to construct pMON32320 (39/40 breakpoint, fifteen amino acid linker), pMON32323 (65/66 breakpoint, fifteen AA linker), and pMON32324 (65/66 breakpoint, ten amino acid linker). New primers L15D, L15E) were designed to incorporate BamHI restriction site in the primer that was inframe to allow cloninng into the BamHI site and maintain the proper reading frame. PCR reaction conditions for the first step were performed identically to that described for pMON32322, except that the following set of primer pairs were used: 65For/L15D and 65Rev/L15E (pMON32324); WO 98/17810 PCT/US97/20037 39For/L15D and 39Rev/Ll5C (pMON32320); and 65For/L15D and 65Rev/L15C (pMON32323). The PCR reaction products were purified using a Wizard PCR Clean Up kit as described, and eluted in 50 ul dH 2 0. Samples were digested with either NcoI/BamHI (39For/L15D and 65For/L15D) or BamHI/HindIII (39Rev/Ll5C, 65Rev/L15C, and 65Rev/Ll5E). Restriction digests were performed as follows: 10 ul of purified PCR reaction products, 3 ul of 10X universal restriction buffer, 15 U of either NcoI or HindIII, 15 U of BamHI, in a final reaction volume of ul. Reactions were incubated for 90 minutes at 370C, and the PCR products gel purified on a 1.1% TAE agarose gel using Geneclean II. Ligation-ready DNA was resuspended in 10 ul dH 2 0.

Inserts were ligated to NcoI/ HindIII digested pMON3977 (BHK mammalian expression vector) that had been treated with shrimp alkaline phosphatase (SAP) either in a three way (pMON32320, pMON32323, or pMON32324) or a two way (pMON32321, pMON32322, pMON32325, pMON32326, pMON32327 and pMON32328) ligation reaction as follows: 2.5 ul of insert (2 ul of each primer pair amplicon for pMON32320, pMON32323, and pMON32324) was added to 50 ng of vector in a ten ul reaction using standard ligation conditions. Two ul of each reaction was transformed with 100 ul of chemically competent DH5a cells (Gibco/BRL) following the manufacturers suggested protocol. Twenty five ul and 200 ul aliquots were plated out on LB plates containing 50 ug/ml ampicillin and incubated overnight. Isolated colonies were picked and DNA prepared from 50 ml overnight cultures using Qiagen DNA midiprep kits. DNA was quantitated by absorbance at A260/A280, and verified for correct insert size by agarose gel electrophoresis following digestion of 1 ug template with NcoI/HindIII restriction endonucleases. Samples containing inserts of the predicted size were sequenced in both orientations using WO 98/17810 PCT/US97/20037 vector-specific primers using an automated fluorescent DNA sequencer model 373A (Perkin Elmer ABI).

Sequencing reactions were done in 20 ul reaction volumes using a Perkin Elmer model 480 DNA thermal cycler as follows: one ug of template, 3.2 pmol primer, 1 ul DMSO, ul Taq terminator dyedeoxy premix Perkin Elmer ABI) were combined, and subjected to 25 cycles of sequencing amplification as follows: 30 seconds at 94 0

C,

second annealing at 50 0 C, followed by a four minute extension cycle at 60 0 C. Samples were purified using Centri-Sep spin columns (Princeton Separations) following the manufacturers suggested protocol, lyophized, and submitted for sequence analysis. Samples containing the predicted amino acid sequence were selected for analysis and assigned pMONnumbers.

EXAMPLE 93 A similar approach used to construct pMON32320, pMON32323, and pMON32324 was utilized to introduce the second linker type (SerGlyGlySerGly)X where x 2 or 3, into two sequence rearranged sequences containing the 39/40 breakpoint (pMON32348 and 32350). The primer pairs were as follows: for pMON32348 the combinations of 339For2/339Rev3 and 339Rev2/339-10For3 and for pMON32350 the combinations of 339For2/339Rev3 and 339Rev2/339- 15For3 were used to create three PCR amplification products. Each PCR amplification was set up as follows: to 100 ng of heat denatured pMON32320, 50 pmol of each primer pair, 10 ul of 5X Buffer B, 5 U of Taq polymerase and dH 2 O was added to a final volume of 45 ul.

Reactions were preincubated as described before.

Fifteen amplification cycles were done under the following conditions: heat denature at 94 0 C, one minute, followed by a two minute annealing step at 70 0 C, and a three minute extension at 72 0 C. After the last cycle, a single 72 deg extension step of 7 minutes was done.

The PCR amplification products of primer pairs WO 98/17810 PCT/US97/20037 339For2/339Rev3, 339Rev2/339-10For3, and 339Rev2/339- 15For2 were purified using a Wizard PCR Clean Up kit (Promega), and eluted in 50 ul dH 2 O. NcoI/BamHI digests for the 339For2/339Rev3 primer pair as follows: 8 ul of DNA template was mixed with 2 ul universal restriction buffer and 10 U each of NcoI and BamHI in a ul reaction volume, and incubated for 90 minutes at 37 0 C. The digestion products was purified using the Geneclean II direct purification protocol, and ligation ready DNA resuspended in 10 ul dH20. The restriction digests and subsequent purification for the 339Rev2/339- 10For3 and 339Rev2/339-15For2 amplification products were done identically as described for the 339For2/339Rev3 amplicon, except that 10 U of HindIII was substituted for NcoI. Standard ligations were done by adding to 50 ng NcoI/HindIII/SAP-treated, gel purified pMON3977, 0.5 ul 339For2/Rev3 amplicon, 1 ul of either 339Rev2/339-10For3 (pMON32348) or 339Rev2/339- 15For3 (pMON32350) amplicons, 5U T4 DNA ligase, and 1 ul 10 X ligase buffer in a 10 ul reaction volume for minutes at ambient temperature. Subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 94 A third type of linker, with a variable (GlyGlyGlySer)X repeat motif, was incorporated into another set of sequence rearranged flt3 receptor agonists from modularly constructed templates. These linker lengths were; 6 AA linker (GlyGlyGlySerGlyGly SEQ ID NO:792), 7 AA linker (GlyGlyGlySerGlyGlyGly SEQ ID N0:793), AA linker (GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID N0:794), 13 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:795), 15 AA linker WO 98/17810 PCT/US97/20037 (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO:796); and 21 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGly SEQ ID NO:797) amino acid residues. These modular templates, each comprising a dimer of hflt3 ligand separated by a BamHI-containing linker of unique length, were constructed as follows. Six intermediate PLASMID templates, FL3N, FL7N, FL11N, FL3C, FL4C, and FL10C, were constructed by PCR using paired primers and pMON30238 as template using cycling conditions similar to those employed for pMON32322. Per reaction, 50 pmol of each primer was added to 100 ng of heat-denatured template and the reactions assembled as described for pMON32322. Cycle conditions were as follows: seven cycles of 94 0 C, one minute; two minutes at 65 0 C, and minutes at 72 0 C; followed by ten cycles of one minute at 94 0 C, two minutes at 70 0 C, and 2.5 minutes at 72 0 C. A single seven minute extension at 72 0 C completed the cycling reactions. The primer pairs used to construct each intermediate were; N-term/FLN3 (FL3N); N-term/FLN7 (FL7N); N-term/FLNll (FL11N); C term/FLC3 (FL3C); Cterm/FLC4 (FL4C); and C-term/FLC10 (FL10C). The PCR amplification products were purified with Wizard PCR Clean Up kits (Promega) and eluted in 50 ul dH 2

O.

Purified DNA for the first subset, FL3N, FL7N, and FL11N, were digested with NcoI/BamHI, gel purified as described previously, and ligated to NcoI/BamHI/Saptreated pSE420 vector DNA (Invitrogen). Intermediate templates of the second subset, FL3C, FL4C, and were constructed in an identical manner except HindIII was utilized instead of NcoI. Subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE WO 98/17810 PCT/US97/20037 To make the final six templates, the two subsets of intermediates in pSE420 were digested with either NcoI/BamHI (FL3N, FL7N, FL11N-subset 1) or BamHI/HindIII (FL3C, FL4C, FL10C-subset 2) and gel purified using Geneclean II as described previously. One intermediate amplicon from each subset were ligated to NcoI/HindIII/SAP-treated pMON3977 per reaction and transformed in DH5a cells as described previously using the following combinations to generate specific linker lengths: six AA linker (FL3N and FL3C), seven AA linker (FL3N and FL4C), ten AA linker (FL7N and FL3C), thirteen AA linker (FL3N and FL10C), fifteen AA linker (FL11N and FL4C), and 21 AA linker (FL11N and FL10C). DNA was prepared 50 ml overnight cultures from single colonies from each of the six combination as described above, analyzed for correct insert size by NcoI/HindIII restriction analysis, and used as template.

Primer pairs 39For/39Rev (39/40 breakpoint); 65For/65Rev (65/66 breakpoint) and 89For/89Rev (89/90 breakpoint) were used to PCR amplify each templates as described for pMON32322, except 75 pmol of each primer was used.

Amplification conditions were modified as follows: six cycles of 94 0 C for one minute, 2 minutes at 70 0 C, minutes at 72 0 C; followed by nine cycles of 94 0 C for one minute, and three minutes at 72 0 C. After the last cycle, a final extension of six minutes at 72 0 C allowed ample time for full extension of products.

Samples were purified using a Wizard PCR Clean Up kit as described, and double digested with NcoI/HindIII.

These amplification products were purified again using a Wizard PCR Clean Up kit. In addition, all six different linker length molecules for the 39/40 breakpoint were cloned into NcoI/HindIII/SAP-treated pMON3977 as single proteins (pMON32365, pMON32366, pMON32367, pMON32368, pMON32369 and 32370). Subsequent steps leading to final DNA sequence confirmation were done as described above.

WO 98/17810 PCTIUS97/20037 EXAMPLE 96 Genes encoding multi-functional chimeric receptor agonist molecules consisting of an IL-3 receptor agonist, of pMON13416 (WO 94/12638) joined via an IgG2b linker to either native flt3 ligand or sequence rearranged flt3 receptor agonists, Examples 91-93, were constructed. Inserts containing the desired sequence rearranged flt3 receptor agonists molecule were isolated from the parental plasmid as a NcoI/HindIII restriction fragment and ligated to pMON30304 digested with AflIII/Hind III/SAP Subsequent steps leading to final DNA sequence confirmation were done as described above.

The resulting plasmids, containing the DNA sequences encoding multi-functional chimeric molecules comprising an IL-3 receptor agonist (from pMON13416) and a sequence rearranged flt3 receptor agonist are indicated in Table 9.

Table 9 Resulting Plasmid pMON30247 pMON30248 pMON32332 pMON32333 pMON32334 pMON32335 pMON32336 pMON32337 pMON32338 pMON32339 hflt3 ligand permutein precursors pMON30237 pMON30238 pMON32321 pMON32320 pMON32325 pMON32324 pMON32323 pMON32328 pMON32327 pMON32326 EXAMPLE 97 WO 98/17810 PCT/US97/20037 Genes encoding multi-functional chimeric receptor agonist molecules consisting of an IL-3 receptor agonist, of pMON13288 (WO 94/12638) joined via an IgG2b linker to either native flt3 ligand or sequence rearranged flt3 receptor agonists, Examples 91-93, were constructed. Inserts containing the desired sequence rearranged flt3 receptor agonists molecule were isolated from the parental plasmid as a NcoI/HindIII restriction fragment and ligated to pMON30311 digested with AflIII/Hind III/SAP Subsequent steps leading to final DNA sequence confirmation were done as described above.

The resulting plasmids, containing the DNA sequences encoding multi-functional chimeric molecules comprising an IL-3 receptor agonist (from pMON13288) and a sequence rearranged flt3 receptor agonist are indicated in Table Resulting Plasmid pMON32364 pMON32377 pMON32352 pMON32353 pMON32354 pMON32355 pMON32356 pMON32357 pMON32358 pMON32359 pMON32360 pMON32362 pMON32396 Table Flt3 ligand precursors pMON30237 pMON30238 pMON32321 pMON32320 pMON32325 pMON32324 pMON32323 pMON32328 pMON32327 pMON32326 pMON32348 pMON32350 pMON30239 EXAMPLE 98 WO 98/17810 PCT/US97/20037 Two chimeric molecules with the sequence rearranged hflt3 receptor agonist component at the N-terminus of the chimeric molecule were constructed via PCR using pMON32360 and pMON32362 plasmid DNA as the template and primer pairs N-term/134rev and N-term/139 rev to replace the stop codon at the C terminus of the native flt3 ligand molecules with an inframe SnaBI restriction site.

Reaction mixtures were set up as described previously for pMON32322. Cycle conditions and were as follows: seven cycles of 940C, one minute, 65 0 C, two minutes, and 720C 2 1/2 minutes and an additional 10 amplification cycles were performed in which the annealing temperature was elevated from 65 0 C to 700C. Samples were purified using the Wizard PCR Purification kit and protocol, and eluted in 50 ul dH20, 20 ul of each sample was digested with NcoI and SnaBI. Plasmid, pMON26431, DNA was digested with NcoI and SnaBI and ligated with the NcoI/SnaBI digested PCR reactions. Transformation of competent DH5a cells and subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 99 Five additional hflt3 ligand breakpoints were made using the indicated primers 28/29(28For/28Rev), 34/35(34For/34Rev), 62/63 (62For/62Rev), 94/95 (94For/94Rev), and 98/99 (98For/98Rev) to amplify the ten and fifteen amino acid linker (GlyGlyGlySer)x as described above. The resulting PCR products were digested with NcoI/HindIII and ligated into pMON30311, digested with AflIII/HindIII/SAP as described previously. Transformation of competent DH5a cells and subsequent steps leading to final DNA sequence confirmation were done as described above.

WO 98/17810 PCT/US97/20037 EXAMPLE 100 For enhanced expression of sequence rearranged hflt3 receptor agonists in E. coli, N-terminal specific primers coding for degenerate codons were used to reengineer both the 1-134 and 1-139 forms of native hflt3 ligand in the E. coli expression vector pMON5723.

Primer pairs FH3AFor/SCF.rev (Ala2) and Flt23For/SCF (Gly2) were used to PCR amplify a N-terminal degenerate mixture of sequences encoding native flt3 ligand using reaction conditions as described for pMON23222, except that the number of amplification cycles was reduced to fifteen cycles of 1 minute at 95 0 C, 2 minutes at 55 0

C,

and 2 1/2 minutes at 72 0 C. Amplicons were purified using Wizard PCR Clean up kit (Promega), and eluted in ul dH 2 O. Restriction digestion with NcoI/HindIII and subsequent gel purification using Geneclean II was performed as previously described. Inserts were ligated to NcoI/HindIII/SAP-treated, gel-purified pMON5723 plasmid DNA, and transformed into competent cells as previously described. Aliquots of transformed cells were plated out on LB agarose media plates containing 75 ug/mL spectinomycin, incubated for 14-16 hours at 37 0 C, and colonies counted. After confirmation of colonies, the remainder of each transformation mixture was incubated overnight (14-16hr) at 370C in 2 x 5 mL of LB media containing 75 ug/mL spectinomycin. Miniprep DNA was prepared using a Wizard DNA 373A Miniprep kit (Promega) following the recommended protocol. Purified miniprep DNA was eluted in 50 ul dHO0, and 1-2 ul used to transform chemically competent MON207 cells. 25 and 200 ul aliquots were plated out on LB media plates containing 75 ug/mL spectinomycin, and incubated for 12-15 hours at 37 0

C.

40-50 well-isolated colonies representing each original primer pair were selected and streaked out on WO 98/17810 PCT/US97/20037 LB/spectinomycin master plates, and incubated an additional 4-6 hours at 370C.

Individual sequence rearranged hflt3 receptor agonist clones were screened for E. coli expression in a 96 well microtiter format to select for improved expression levels. Per well, 100 ul of minimal M9 media (including 1% casamino acids) was inoculated by a single colony 50 isolates were analyzed for each hflt3 PCR primer pair), and incubated at 370C at 200 rpm for 3-4 hr (I=0) and induced by addition of 5 ul/well of Img/mL freshly prepared Nalidixic acid (in 0.1 N NaOH). After an additional four hours incubation at 37 0 C approximately 5-10 ul aliquots were withdrawn from each well, and analyzed by light microscopy for the presence of refractile bodies, and the results scored as a approximate percentage of cells containing refractile bodies to the total number of cells. The clones having the highest expression levels were selected for 10 mL benchtop scale expression studies as follows. Five mL overnight cultures were grown in LB media in the presence of 75ug/mL spectinomycin at 370C. To 10 mL freshly prepared minimal M9 (with 1% casamino acids) in 125 mL shake flasks, inoculation with sufficient overnight cells to achieve an initial reading of Klett units was done, and then incubated for 3-4 hours at 370C with shaking until a density of -110-150 Klett units was reached and induced with 50 ul of freshly prepared Nalidixic acid (10 mg/mL in 0.1 N NaOH). One mL aliquots were removed and the cells pelleted for one minute in a microfuge. The supernatants were removed by aspiration and the pellets stored at -200C until ready for SDS-PAGE analysis. The remainder of the induced cells were incubated for an additional four hours at 370C with shaking, after this time point cell density (in Klett units) was measured. A one mL aliquot was removed from each sample, pelleted and stored as described above. Another 5-10 ul WO 98/17810 53 PCTUS97/20037 aliquot was removed from each flask and analyzed by light microscopy for the presence of refractile bodies.

Pelleted samples were resuspended in a volume (in ul) of 2X loading buffer (including 1% B-mercaptoethanol) equal to the 1=4 Klett value, boiled for 5 minutes, and 6-7 ul loaded on a 12% or 14% Tris-Glycine SDS polyacrylamide gel (Novex) and electrophoresed for 90 minutes at volts. Gels were fixed, stained and prepared for drying according the suggested protocol (Novex). Clones were selected at this point for scale up fermentation based upon enhanced expression levels of a single induced protein band corresponding to the predicted size when compared to the I=0 samples.

Midiprep DNA was also prepared from selected clones expressing high level of induced protein as described previously and steps leading to final DNA sequence confirmation were done exactly as described above.

These clones were designated pMON32329, pMON32330, pMON32341, and pMON32342 EXAMPLE 101 A set of multi-functional receptor agonist chimeric molecules comprising an IL-3 receptor agonist (from pMON13288) and native flt3 ligand were also constructed for expression in E. coli. The genes encoding the multi-functional receptor agonist chimeric molecules from pMON32364 and pMON32377 were released from the parental vector by digestion with NcoI/Hind III and ligated to pMON5677 vector, transformed into MON207 cells, and single isolates picked, as described above.

These constructs were designated pMON32394 (insert from pMON32364) and pMON32395 (insert from pMON32377).

EXAMPLE 102 WO 98/17810 4 PCT/US97/20037 A truncated Flt3 receptor was isolated as a 1.4Kb PCR product using 50pmol of the primers FLTAFLS1 and FLTR1N with approximately 10ng of the plasmid pMON27184 as the template. The primers were designed to produce an AflIII restriction site just 5' to the first Asn codon of the mature coding sequence, as well as an EcoRI restriction site just 5' to the putative transmembrane region. The reaction was digested with AflIII and EcoRI using standard reaction conditions and ligated into the NcoI/EcoRI digested plasmid pMON26458. This plasmid contains the following DNA sequence: 5'

GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACT

CCTGGTCCGCCCCGCCATGGCTAAAGCTT 3' SEQ ID NO:857, encoding the IL-3 signal sequence. This sequence contains a BamHI restriction site on the 5' end, and includes the ATG methionine as the first amino acid of the signal sequence 3' to the BamHI site. This signal sequence is cleaved by the cell, leaving a 5' Met/Ala generated by fusing the NcoI site from the signal sequence fused to the AflIII site of the receptor produced in the PCR reaction. The entire truncated form of the receptor along with the IL-3 signal sequence could be cut back out of the vector as a BamHI/EcoRI digest (hIL3L/hFflt3R).

The catalytic domain of pMON30298 (hG-CSFR) was reengineered to create an in frame EcoRI restriction site at the transmembrane/cytoplasmic bound via PCR as follows. To 0.5 ug of heat denatured pMON30298, 100 pmole each of primers HGCFfor and HGCFrev, 10 ul of buffer J, 5U of Taq polymerase, and dH20 were added to a final volume of 45 ul as described. PCR amplification was done as follows: six cycles (one minute at 94 0 C, two minutes at 64 0 C, and three minutes at 70 0 followed by nine cycles (one minute at 94 0 C, four minutes at 70 0

C).

A final one minute extension of seven minutes at 70 0

C

was done. Ten ul of each PCR reaction were gel purified using Geneclean II as described previously, and eluted WO 98/17810 3 PCTUS97/20037 in 10 ul dH 2 O. Samples were digested with 10U each of EcoRI and HindIII in 20 ul reactions for 90 minutes at 37 0 C. Samples were gel purified again (Geneclean II) as described previously, and eluted in 10 ul dH 2 O. Two ul of insert were ligated to 50 ng of NcoI/HindIII/phosphatased pSE420 vector in a 10 ul reaction as described previously. Transformation of competent DH5a cells and subsequent. steps leading to final DNA sequence confirmation were done exactly as described above. Selected clones were then sequenced to verify the presence of the in frame EcoRI site as well as confirmation of the correct G-CSFR catalytic domain DNA sequence. Clones containing the predicted sequence were digested with EcoRI/HindIII as described previously and gel purified. Purified inserts of the hG-SCFR (EcoRI/HindIII) and hIL3L/hFlt3R (BamHI/EcoRI) fragments were ligated to BamHI/HindIII/phosphatased pcDNA 3.1 vector (Invitrogen). Transformation of competent DH5a cells and subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 103 Additional genes encoding sequence rearranged Flt3 ligands were constructed using the dimer template intermediates previously described. For sequence rearranged flt3 receptor agonists having the fifteen amino acid linker (GlyGlyGlySer),GlyGlyGly SEQ ID NO:795, the dimer intermediates Flt4C.seq and FltllN.seq were used as template. Breakpoints corresponding to Flt3 3 ligand amino acid residues 28/29, 34/35, 62/63, 94/95, and 98/99, were constructed using a PCR based approach using a PCR Optimizer kit (Invitrogen) and the following primer pairs; FL29For/FL29Rev, FL35For/FL35Rev, FL63For/FL63Rev, FL95For/FL95Rev, FL99For/FL99Rev as WO 98/17810 3 PCT/US97/20037 described IN Example 94. Amplification conditions were as follows: seven cycles of 94 °C for 1 min, 62 °C for 2 min, and 2.5 min at 70 oC; twelve cycles of 94 OC for 1 min, 68 °C for 2 min, and 70 OC for 2.5 min; followed by a final cycle of 7 min at 72 OC. PCR products corresponding to the predicted insert size were digested with NcoI and HindIII, and gel purified as described previously using Gene Clean II (Bio 101) following the manufacturer's suggested protocol. Samples were resuspended in 10 ul final volume with dH20. Inserts were cloned as single genes into the mammalian expression vector pMON3934 (NcoI/HindIII/SAP treated) and designated pMON35712, pMON35713, pMON35714, pMON35715, pMON35716, pMON35717 and pMON35718 respectively.

Genes encoding chimeric proteins comprising an IL-3 receptor agonist encoded by pMON13288 (WO 94/12638) herein referred to as "IL-3 receptor agonist and sequence rearranged Flt3 ligand were prepared by cloning the purified, restriction-digested PCR products of the 28/29, 34/35, 62/63, 94/95, and 98/99 breakpoint primer pairs into AflIII/HindIII/SAP-treated pMON30311. The resulting plasmids were designated pMON32398, pMON35700, pMON35702, pMON35704, and pMON35706 respectively. In addition, the same primer pairs were used in conjunction with the dimer template intermediates Flt7N.seq and Flt3C.seq to construct the ten amino acid linker (GlyGlyGlySer) 2 GlyGly SEQ ID NO:793, forms of these IL-3 receptor agonist I/Flt3L chimeric proteins; pMON32397, pMON32399, pMON35701, pMON35703, and pMON35705 respectively.

EXAMPLE 104 Genes encoding IL-3 receptor agonist I/Flt3L chimeric proteins containing the 21 amino acid residue linker WO 98/17810 PCT/US97/20037 (GlyGlyGlySer),Gly SEQ ID N0:796 were constructed using a similar PCR approach using the dimer template intermediates FltllN.seq and FltlOC.seq and the following primer pairs; Flt36/36Rev, Flt37/37Rev, Flt38/38Rev, Flt39/39Rev, Flt41/41Rev, Flt42/42Rev, and Flt43/43Rev. These primer pairs correspond to the following Flt3 ligand breakpoints 35/36; 36/37; 37/38; 38/39; 40/41; 41/42; and 42/43 (the 39/40 breakpoint was previously constructed as pMON32376) and were used for PCR amplification using the following cycle conditions: seven cycles of 94 OC for 1 min, 66 OC for 2 min, and 2.5 min at 70 0 C; fifteen cycles of 94 OC for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 OC using the Invitrogen PCR Optimizer kit (Buffer Following DNA sequence confirmation these constructs were designated pMON35733, pMON35734, pMON35735, pMON35736, pMON35738, pMON35739, pMON35740, pMON35741, pMON35742 and pMON35743 respectively. PCR incorporation errors resulted in two single amino acid substitutions of the sequence rearranged Flt3 chimeric partner (pMON35741, 35/36 breakpoint; and pMON35743, 42/43 breakpoint) and one construct (pMON35742, 38/39 133 breakpoint) containing two amino acid substitutions Q 133 100 100 112 112 to R and Q to R and L to P in the Flt3L moiety, constructed and tested as part of this serieS.

Additional Flt3L/IL-3 receptor agonist I chimeric proteins in which the alternate Flt3L breakpoints corresponding to Flt3 ligand amino acid residues 28/29, 34/35, 62/63, 65/66, 89/90, 94/95, and 98/99 previously described were also constructed with the fifteen amino acid linker (GlyGlyGlySer) 3 GlyGlyGly templates FLt4C and FLtllN. PCR reaction mixtures were similar to those described in Example 103, except that reverse primers encoding the C-terminus of the sequence rearranged Flt3 moieties were modified by replacing the HindIII restriction site with a SnaBI recognition sequence. PCR WO 98/17810 PCT/US97/20037 amplification cycle parameters were as follows: seven cycles of 94 OC for 1 min, 66 OC for 2 min, and 2.5 min at 70 oC; fourteen cycles of 94 oC for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 oC.

PCR clean up, restriction digestion and purification were done as described previously. Inserts were ligated to NcoI/SnaBI/SAP-treated pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 receptor agonist I moiety) as follows: 50ng treated vector, insert (10:1 insert:vector), 1 unit of T4 DNA ligase (Gibco BRL), and 1 ul 10X ligase buffer in a 10 ul reaction volume.

Ligations were incubated for one hour at ambient temperature, then 2 ul of each ligation were removed and used to transform 100 ul of chemically competent DH1OB (alternatively, DH5a) cells (Gibco BRL) following the manufacturer's suggested protocol. One fifth and 1/25th volumes of each transformation mixture were plated out on LB agar plates supplemented with the appropriate antibiotic markers and incubated overnight (14-16 hours) at 37 OC. Isolated colonies were picked, and DNA prepared using the Qiagen midiprep protocol as described previously.

Sequence analysis of selected clones were confirmed for 28/29 breakpoint (pMON35719), 34/35 breakpoint (pMON35720), 62/63 breakpoint (pMON35721), 65/66 breakpoint (pMON35722), 89/90 breakpoint (pMON35723), and 98/99 breakpoint (pMON35725). pMON35726 contains a single amino acid substitution (Leu94 to Phe94) for the 94/95 breakpoin. Flt3L/IL-3 receptor agonist I chimeric constructs with a Flt3L breakpoint of 39/40 and varying amino acid linker lengths of 10, 15, and 21 AA are represented by pMON35707, pMON35708, pMON35709, pMON35710 and pMON35711. These constructs were generated by PCR amplification of one of the following templates; pMON32373, pMON32375, or pMON32376, and the Flt3Lspecific primer pair 39N TERM-1/SNAB1C TERM. Standard WO 98/17810 PCT/US97/20037 PCR reaction mixtures were set up as previously described, and DNA product amplified using the following parameters: seven cycles of 94 OC for 1 min, 62 OC for 2 min, and 2.5 min at 70 twelve cycles of 94 OC for 1 min, 68 OC for 2 min, and 70 oC for 2.5 min; followed by a final cycle of 7 min at 72 OC. PCR products corresponding to the predicted insert size were digested to completion with NcoI and SnaBI, gel purified, and cloned as described previously into the mammalian expression vector pMON26431 (Ncol/SnaBI/SAP treated) as Flt3L/IgG2b/IL-3 receptor agonist I chimeric proteins.

Two of these constructs contained PCR incorporation errors in the sequence rearranged Flt3 chimeric partner 96 which resulted in single amino acid substitutions F to 96 58 58 L and E to G (pMON35710 and pMON35711).

EXAMPLE 105 Another series of chimeric proteins, sequence rearranged Flt3L/IL-3 receptor agonist I with the breakpoints corresponding to Flt3 ligand amino acid residues 35/36, 36/37, 38/39, 40/41, 41/42, 42/43 and 65/66 previously described and a 21 amino acid linker were also constructed using selected IL-3 receptor agonist I/sequence rearranged Flt3L constructs as template (see Table 11 below). One exception was that a fifteen amino acid linker template (pMON35715) was used to construct the 65/66 breakpoint, pMON35771.

WO 98/17810 PCT/US97/20037 Table 11 Flt3L/IL-3 receptor agonist I IL-3 receptor agonist I/Flt3L Construct template Flt3L Primer Pair breakpoint pMON35744 pMON35733 35/36 Flt36/36Rev' pMON35745 pMON35734 36/37 Flt37/37Rev' pMON35746 pMON35735 37/38 Flt38/38Rev' pMON35747 pMON35736 38/39 Flt39/39Rev' pMON35748 pMON35738 40/41 Flt41/41Rev' pMON35749 pMON35739 41/42 Flt42/42Rev' pMON35750 pMON35740 42/43 Flt43/43Rev' pMON35769 pMON35743 42/43 Flt43/43Rev' pMON35771 pMON35715 65/66 65For/66SnaBI Primer pairs encoding the same restriction sites as those used to construct pMON35719-35725 were utilized.

The reverse primers 36Rev', 37 Rev', 38 Rev', 39 Rev', 41 Rev', 42 Rev', and 43 Rev', were used to create the in frame SnaBI site. The same forward primers Flt36, Flt37, Flt38, Flt39, Flt41, Flt42 and Flt43 were used.

PCR reaction mixtures were identical to those described previously, however, with the exception of pMON35771, amplification conditions were modified as follows: 18 cycles of 94 OC for 1 min, 68 OC for 2 min, and 70 °C for 2.5 min; followed by a single extension cycle at °C for 7 minutes. For pMON35771, amplification conditions were as follows: six cycles of 94 OC for 1 min, 66 OC for 2 min, and 2.5 min at 70 OC; fifteen cycles of 94 OC for 1 min, and 70 OC for 4 min; followed by a final cycle of 7 min at 72 OC. Flt3-specific PCR amplification products were restriction digested, purified, and cloned into pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 'receptor agonist I moiety) as described in Example 104.

1 wuO 9117mi1 36P /CI rY/720037 One variant, pMON32179, was constructed as a 34/40 breakpoint using the PCR primer pair Flt40/34Rev and dimer template intermediates FltllN.seq and FltlOC.seq.

PCR amplification conditions and subsequent cloning were identical to that used to clone pMON35771.

Three additional Flt3L/IL-3 receptor agonist I chimera (38/39 breakpoint) were designed and constructed to test the effects of alternate linker lengths and composition.

Using pMON35709 as template, the GlySer linker length was expanded to encompass 29 amino acid residues with the motif (GlyGlyGlySer),Gly using the primer pairs BamForl/38Rev (reaction product referred to as PCR A) and Flt38/BamRevl (reaction product referred to as PCR The amplification conditions were as follows: six cycles of 94 OC for 1 min, 66 OC for 2 min, and 2.5 min at 70 oC; fifteen cycles of 94 OC for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 OC.

The resulting PCR products were cleaned up using a Promega PCR clean up kit, and digested with either NcoI/BamHI (PCR A) or BamHI/SnaBI (PCR gel purified and ligated to pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 receptor agonist I moiety) as described previously. The resulting construct was sequenced confirmed and designated pMON35774. In comparison, pMON35775 and 35776 different in that the GlySer linker was replaced by native Flt3L amino acid residues 140-154 (pMON35775) or 140-160 (pMON35776) containing a single amino acid substitution.

PCR reaction conditions were identical as described for pMON35774, except the following primer pairs were used: 38For/Navfor and 38Rev/NavRevS (pMON35775); and 38For/Navfor and 38Rev/NavRevL (pMON35776). KasI was substituted for BamHI, otherwise the cloning steps of these PCR amplification products were identical to those employed for pMON35774. Sequence analysis revealed PCR induced errors in multiple isolates for both pMON35775 and 35776. To obtain the final correct sequences, it was necessary to redigest selected subclones with WO 98/17810 PCT/US97/20037 NarI/SnaBI and NcoI/NarI, and use these gel purified fragments to redone the desired constructs.

Several Flt3L dimer chimeric molecules were also constructed for testing as BHK transients. pMON32173, consisting of two native Flt3L molecules linked by an IgG2b linker, was assembled from two pre-existing molecules as follows: the NcoI/SnaBI Flt3L-containing insert from pMON32393 was ligated to gel purified, NcoI/SnaBI cut, pMON32377 in which the IL-3 receptor agonist I chimeric partner had been released.

Similarly, pMON35727 (39/40 breakpoint, fifteen amino acid linker) was assembled using the Flt3L insert from pMON35708 (as an NcoI/SnaBI insert) to gel purified pMON32375 in which the IL-3 receptor agonist I chimeric partner had been excised. The third Flt3L dimer, pMON32168, (39/40 breakpoint, 21 amino acid linker) was assembled as follows: the NcoI/SnaBI insert from pMON32165 coli equivalent of pMON35709, assembled by subcloning the NcoI/BamHI fragment from pMON32163 and the BamHI/HindIII fragment of pMON35709 into NcoI/HindIII-digested pMON5723). The NcoI/SnaBI insert from pMON32165 (Flt3L 1-139 (39/40)L21) and the SnaBI/HindIII insert (IgG2b/Flt3L 1-139 (39/40)L21) from pMON32376 were subcloned into the E. coli production vector pMON5723, creating pMON32167. The NcoI/HindIII insert from pMON32167 was then subcloned into pMON30304, and designated pMON32168.

EXAMPLE 106 A series of trimeric molecules, each consisting of two Flt3L moieties and a single copy of IL-3 receptor agonist I or IL-3 receptor agonist II (an IL-3 receptor agonist encoded by pMON13416 (WO 94/12638) herein referred to as "IL-3 receptor agonist were also constructed from pre-existing molecules using restriction digested, gel purified fragments. pMON35728 WO 98/17810 was assembled using the NcoI/EcORI (Flt3L/IgG2b/IL-3 receptor agonist I) insert from pMON32375 and the EcoRI/HindlII (TL-3 receptor agonist I/IgG2b/Flt3L) insert from pNON35708. The two fragments were then religated to NcoI/HindIII/SAP-treated mammalian expression vector pMON3934 and subcloned as described previously. pMON32205 (IL-3 receptor agonist TI/IgG2B/Flt3 l-139/IgG2B/Flt3 1-139) was assembled' by ligating the NcoI/HindIII fragment from pMON32173 into the AflIII/HindlII site of pMON30304. A similar approach was used to construct pMON32206 (IL-3 receptor agonist II/IgG2b/Flt3L (3 9/40) L21/IgG2b/Flt3L (39/40)L21) The NcoI/HindIII fragment from pMON32167 was gel and subcloned into the AflI.11/Hind III-digested pMON30304 (which contains the IL-3 receptor agonist II/IgG2b-moiety). The plasmid pMON32207 (Flt3L (39/40)L21/IgG2b/Flt3L (39/40)L21)/G-CSF) was assembled by subcloning the gel purified NcoI/HindIII insert from pMON32170 into the intermediate pMON32198 (AflIIl/HindlII).

pMON32208 (Flt3L l-139/IgG2b/G-CSF/IgG2b/Flt3L1-139) was assembled by subcloning the gel purified SnaBI insert from pMON30320 (as IgG2b/G-CSF) into SnaBIdigested/SAP-treated pMON32173. pMON32204 was assembled by subcloning the NcoI/HindIII insert from pMON32173 into AflIII/HindIII-digested pMON30309 (which contains G-CSF/IgG2b) pMON32195 (Flt3L l-139(39/40)L21/IgG2b/G- CSF/Flt3L 1-139(39/40)L21) was constructed by subcloning the NcoI/SacI insert from pMON32190 and the SacI/HindIII fragment from pMON32171 into NcoI/HindIIT-digested pMON303O4. pMON32196 (G-CSF/IgG2b/Flt3L 1- 139(39/40)L21/IgG2b/Flt3L 1-139) was assembled by subcloning the NcoI/AflIII fragment from pMON30309 (as G-CSF/IgG2b) into NcoI/SAP-treated pMON32168 (Flt3L 1- 139(39/40)L21/IgG2b/Flt3L 1-139) and confirming orientation by DNA sequence and restriction analysis.

PMON32197 (G-CSF/IgG2b/Flt3L l-139(39/40)L21/IgG2b/Flt3L 1-139 (39/40)L21) was constructed by subcloning the WO 98/17810 PCT/US97/20037 NcoI/HindIII insert of pMON32167 (Flt3L 1- 139(39/40)L21/IgG2b/Flt3L 1-139 (39/40)L21) into the AflIII/HindIII site of pMON30309 (G-CSF/IgG2b).

EXAMPLE 108 A series of Flt3L containing molecules was constructed as BHK transients by replacing IL-3 receptor agonist I or IL-3 receptor agonist II with G-CSF as the chimeric partner. For chimeric proteins expressed transiently and made using the BHK vector pMON3934, the G-CSF moiety could either encode Ser or Cys at position 17. For molecules used for either E. coli expression or expressed non-transiently in mammalian expression systems, position 17 of the G-CSF partner encoded Ser exclusively. Chimera of native Flt3L and G-CSF were made as BHK expression constructs in both orientations: G-CSF/IgG2b/Flt3L (pMON30329) and Flt3L/IgG2b/G-CSF (pMON32175). pMON30329 was assembled by subcloning the Flt3L 1-139 insert from pMON30238 (as a NcoI/Hind III digest) into pMON30309 (which contains G-CSF/IgG2b) digested with AflIII/HindIII, whereas pMON32175 was constructed using the gel-purified NcoI/SnaBI insert from pMON32393 to NcoI/SnaBI-digested pMON26420 (which contains the IgG2b/G-CSF gene). A third native G- CSF/Flt3L chimeric molecule, pMON32191, differs from pMON32175 in that it has a GlySer linker in place of the IgG2b chimeric linker and was designed for E.coli expression. pMON32191 was assembled using the same gelpurified NcoI/SnaBI insert from pMON32393 into NcoI/SnaBI-digested pMON31123 (which contains the GlySer/G-CSF gene). The BHK equivalent, pMON35767, was assembled by subcloning the gel-purified NcoI/HindIII chimeric gene from pMON32191 into the BHK vector pMON3934.

WO 98/17810 WO 9817810PCT/US97/20037 EXAMPLE 109 Two series of sequence rearranged Flt3L chimera were constructed by replacing the IL-3 receptor agonist I component with G-CSF. The first set, with the orientation G-C8F/IgG2B/ sequence rearranged Flt3L, were essentially assembled as follows: pMON30329 (G- CSF/IgG2B/Flt3L 1-139) was digested with SnaBI/HindIII, and the vector-containing G-CSF moiety gel-purified as described above. SnaBI/HindIII-digested inserts from the appropriate IL-3 receptor agonist I/Flt3L constructs shown below in Table !2were then pMON3 0329 (SnaBI/HindIII).

subcloned into Table 12 G-CSF/IgG2b/Flt3L constructs and agonist I analogues their IL-3 receptor Flt3L breakipoint 35/36L21 89/90L21 37/38L21 38/39L21 40/41L21 41 /42L2 1 42/43L21 PMON (G-CSF) pMON32188 pMON32273 pMON3 5795 pMON35796 pMON3 57 97 pMON35798 pMON35799 DMON (IL-3 receptor agonist I) pMON3 5733 pMON32389 pMON3 5735 pMON35736 pMON35738 pMON3 5739 pMON3 5740 pMON32169 CG-CSF/IgG2b/Flt3L 1-139 (39/40)L21) was assembled using the NcoI/BaxWHI insert from pMON32163 and the BamHI/HindIII insert from pMON32370 subcloned into the AflIII/HindIII-digested pM0N303O9. Three molecules in this series have no direct IL-3 receptor agonist I counterparts. The first, pMON39914, was assembled using the BHK expression vector~pMON30309 (which contains G- CSF/TgG2b) digested with AflIII/HindIII, and the Flt3 1- 139 (39/40)L29 insert from pMON32243 (as NcoI/HindIII) For pMON39915, the Flt3L 1-154 (39/40) gene from WO 98/17810 WO 9817810PCTIUS97/20037 pMON32242 (as a NcoT/HindIII insert) was subcloned into the parental vector pMON30309. pMON39916 was assembled exactly as for pMON39915, except that the Flt3L 1-160 (39/40) insert from pMON32252 was utilized. pMONs 32242, 32243, and 32252 are E. coli expression constructs containing a nonchimeric, sequence, rearranged Flt3L gene (as NcoI/HindIII) Finally, the insert from pMON35799 was subcloned into pMON5723 (as an NcoI/HindIII fragment) for expression in E. coli. This E. coli production plasmid was designated pMON399O4.

EXAMPLE 110 Many of the second series of G-CSF chimera with the orientation Flt3L/IgG2b/G-CSF were also constructed from their IL-3 receptor agonist I analogues as indicated below in Table 13.

Table 13 Flt3L /IgG2b/G-CSF constructs and agonist I analogues their IL-3 receptor Flt3L break-point TpMON (G-CSF) DMON(IL-3 receptor agonist V) 39/40L10 39/40L15 39 /4 L21 89/90L15 35/36L21 36/37L21 37/38L21 34 /35L15 65/66L15 98/99L15 pMON3 5751 pMON3 5752 pMON3 5753 pMON3 5754 pMON3 5755 pMON3 5756 PMON3 5757 pMON3 5759 pMON35760 pMON3 57 65 pMON357 07 pMON3 5708 pMON3 5709 pMON3 5723 pMON3 5744 pMON3 5745 pMON3 5746 pMON3 5720 pMON3 5722 pMON3 5725 These constructs were assembled using NcoI/SnaBIdigested pMON36113 (a DHK vector containing the IgG2b/G-

V

VIJ 98/17810 .361 IPCi.T/Uy IILUUS CSF gene) and specific NcoT/SnaBI-digested sequence rearranged Flt3L inserts from the Flt3L/IL-3 receptor agonist I chimneric proteins in Table above. The resulting plasmids were designated pMON32170, pMON32B7l, pMON32271, pMON32172, pMON32174, pMON35751, pMON35752, pMON35753, pMON35754, pMON35755, pMON35756, pMON35757, pMON35758, pMON35759, pMON35760, pMON35761, pMON35762, pMON35763, pMON35764, pMON35765, pMON35766, pMON35767, pMON35768, pM0N35770, pMON35772, pMON35773, pMON35777, pMON35778, pMON35779, pMON35780, pMON35782 and pMON39908 pMON35777 and pMON35778 were constructed by PCR and assembled from the same NcoI/NarI and NarI/SnaBI inserts as described for pMON35775 and pM0N35776, except that NcoI/SnaBI-digested pI40N35751 was used as the parental vector containing the IgG2b/G-CSF gene. To construct the 39/40 breakpoint equivalent of pM0N35778, the primer pair Flt4O/SnaBI C-term was used to re-amplify pMON35778 template. Amplification conditions were done as described previously for pMON3577l, except the initial Tnelwas lowered from 66 to 55 0 C. The resulting construct was designated pM0N35782 (Flt3 1-160 (39/40)/IgG2b/G-CSF).

pMON32170 (Flt3L l-139(39/40)L21/IgG2B/G-CSF) was assembled using the NcoI/SnaBI insert from pMON32165 ligated into NcoI/SnaBI-digested pMON26430 (which contains IgG2B/G-CSF) pM0N35764 (Flt3L (38/39)L2l/IgG2b/G-CSF) was cloned as follows: the sequence rearranged Flt3L insert was PCR amplified using as template pM0N35736 and the primer pair Flt39/39Rev.

Amplification conditions were identical to those employed for pMON3 5771, except the initial Tanneai was lowered from 66 to 56 0 C. The NcoI/SnaBI digested PCR amplification was subcloned into NcoI/SnaBI-digested pMON35754 containing the IgG2b/G-CSF gene. pMON35768 (Flt3L (38/39)L21/IgG2b/G-CSF) has a mutation at residue 7T 7'rv TCn nn v (Ser to Phe) of the Flt3 chimeric partner.

pMON35762 (Flt3 template pMON35739), pMON35763 (Flt3 template 35738), pMON35758 (Flt3 template 35740), pMON35770 (pMON35743 as Flt3L template were constructed 125 exactly as described for pMON35764. pMON35772 a S to F12 mutant of the sequence rearranged Flt3 gene in pMON35760, was cloned by PCR using pMON35715 as Flt3 template and the primer pairs 65For/65SnaBI. PCR cycle conditions were identical to that used to amplify the Flt3 genes from pMON35733, pMON35734, pMON35735 and 133 pMON35736 described previously. pMON35761 is a Q to R mutant of the sequence rearranged Flt3L gene in pMON35758. pMON35773 (Flt3L 1-139 (38/39)L29/IgG2B/G- CSF) was cloned as described previously for pMON35774, except pMON26430 (NcoI/SnaBI/SAP-treated) containing the IgG2b/G-CSF gene was used as parental vector.

To construct the 39/40 breakpoint equivalent, pMON35773 was used as template in a PCR amplification reaction with the primer pair Flt40/SnaBI C-term. Amplification was done exactly as described previously for pMON35771.

The NcoI/SnaBI-digested amplification product was subcloned into pMON26430 (NcoI/SnaBI/SAP-treated), resulting in pMON35779 (Flt3L 1-139 (39/40)L29/IgG2B/G- CSF). pMON35780 is a variant of pMON35779 and encodes a single amino acid mutation (L to P in the sequence rearranged Flt3 chimeric partner. pMON32190 (Flt3L 1- 139 (39/40)L21/GS/G-CSF) contains an alternate GlySer chimeric linker which replaces the IgG2b linker of pMON32170. The NcoI/SnaBI fragment Flt3L gene from pMON32165 (Flt3L 1-139 (39/40)L21/IgG2b/IL-3 receptor agonist I in the E. coli expression vector pMON5723) was subcloned into NcoI/SnaBI-digested pMON31123. The BHK expression equivalent, pMON35766, was constructed by subcloning the entire Flt3L/GlySer/G-CSF chimeric insert as an NcoI/HindIII fragment into pMON3934.

WO 98/17810 PCT/US97/20037 pMON39908 is similar to pMON35779, except the Flt3L amino acid residues 133-160 have been replaced by the amino acid sequence, VETVFHRVSQDGLDLLTS SEQ ID N0:798, which is homologous to an alternate splice variant of Flt3L (Genbank accession number HSU29874). pMON32190 was used as a PCR template with the following sets of primer pairs Flt40/XbaRev and SnaBICterm/XbaFor.

Amplification conditions were done as described previously for pMON35771, except the initial Tanneal was lowered from 66 to 64 OC. Both gel-purified PCR amplification products were digested with either NcoI/XbaI (Flt40/XbaRev PCR product) or XbaI/SnaBI (SnaBICterm/XbaFor PCR product) and subcloned into pMON26430 (NcoI/SnaBI/SAP-treated). pMON32273 (Flt3L 1- 139 (39/40)L21/IgG2b/G-CSF) was constructed by PCR of pMON35777 with the primer pairs FltConNco/Grev to reamplify the 38/39 Flt3L moiety as 39/40. The purified amplicon was digested with NcoI/SnaBI, and subcloned into the NcoI/SnaBI-digested pMON32191, and designated pMON32259 (for E. coli production). For BHK expression, the NcoI/HindIII insert from pMON32259 was subcloned into pMON3934 (NcoI/HindIII).

EXAMPLE 103 Another series of chimeric proteins were constructed in which the Flt3L partner contained one or two Cys mutations (Table XIA and XIB). pMON35790 (Flt3L 1- 4 4 85 139(C S C S )/GS/G-CSF (Serl7)), was constructed by PCR using pMON32191 as template and the primer pairs ClFor/C3Rev and C3For/139Rev in two 93 93 132 reactions. pMON35791 (Flt3L 1-139(C S C 132 S )/GS/G-CSF (Serl7)), was also constructed by PCR using pMON32191 as template and the primer pairs C5For/C6Rev and C5Rev/N-term. Amplification conditions WO 98/17810 PCT/US97/20037 were done as described previously for pMON35771, except the initial Tanea was lowered from 66 to 64 OC. A second round of PCR was done using the amplicons (10 ul each) from the first round, and the PCR products were then purified, digested with NcoI/SnaBI, and subcloned into NcoI/SnaBI -digested pMON32191. PCR amplification conditions for the second round were modified as follows: the initial Taneal was increased to 68 0 C, and the number of cycles increased from 6 to 15. No additional amplification was required. These 4 4 85 constructs, pMON35787 (C S C S and pMON35788 93 93 132 132 (C S C S were used for E. coli expression.

The BHK expression equivalents, pMON35790 and 35791, were constructed by subcloning the correctly mutated Flt3L/GlySer/G-CSF chimeric inserts as NcoI/HindIII 132 fragments into pMON3934. pMON35792 (Flt3L 1-132(C 132 S )/GlySer/G-CSF (Serl7)) was constructed by PCR using pMON32191 as template and the primer pair FLDlRev/FltNTerm.

132 132 pMON39905 (Flt3L 1-139(C S )/GlySer/G-CSF (Serl7)) was constructed by PCR using pMON32191 as template and the primer pair FLMlRev/FltNTerm. pMON39906 (Flt3L 1- 127 127 32 132 139(C S C S )/GlySer/G-CSF (Serl7)) contains a single amino acid substitution at residue 127 of the sequence rearranged Flt3L partner, a result of a PCR induced error during the PCR amplification of pMON39905.

4 4 pMON32276 (Flt3L 1-139 (39/40)L21(C S C -4 S )/GlySer/G-CSF (Serl7)) was constructed by two rounds of PCR. Three initial amplicons were generated: PCR1 (pMON32190 template and primer pairs G10L/85N); PCR 7 (pMON32190 template and primer pairs 4N/85S); and PCR 4 (pMON32198 template and primer pairs 4S/3605Rev). For the second round, PCR1, 4 and 7 were re-amplified in a combined mixture, resulting in PCR A. PCR A was v V098/17810 9 PCTUS97ZOO37 purified, digested with NcoT/.SnaBI, and subcloned in pMON30277 (GlySer/G-CSF) The next three constructs were generated in a similar manner. pMON32277 (G-CSF 4 4 85 (Serl7)/IgG2B/Flt3L 1-139 (39/40)L21 (C _4 S C _4 S first round PCR generated three initial amplicons: PCRl (pMON32190 template and primer pairs GlOL/85N); PCR 7 (pMON32190 template and primer pairs 4N/85S); and 2CR 6 (pMON32169 template and primer pairs 4S/3605Rev). For the second round, PCR1, 6 and 7 were re-amplified in a combined mixture, resulting in PCR B. PCR B was purified, digested with NcoI/HindIII, and subcloned into Ncol/HindIII-digested pMON30309 (G-CSF(Serl7) /IgG2B).

93 93 132 pMON32278 (Flt3L 1-139 (39/40)L21 (C -S C -4 S 12)/GlySer/G-CSF (Serl7)) first round PCR generated three initial amplicons: PCR2 (pMON32190 template and primer pairs GlOL/93N); PCR 8 (pMON32190 template and primer pairs 132N/93S); and PCR 3 (pMON32198 template and primer pairs 132S/3605Rev). For the second round, PCR2, 3 and 8 were re-amplified in a combined mixture, resulting in PCR C. PCR C was purified, digested with NcoI/SnaBT, and subcloned in pMON30277 (GlySer/G-CSF).

93 pMON32279 G-CSF (Serl7)/IgG2B/FlL3L 1-139 (39/40)L21 (C -S93/ C13 -4 S12 first round PCR generated three initial amplicons: PCR2 (pMON3219O template and primer pairs GlOL/93N); PCR 8 (pMON32190 template and primer pairs 132N/93S); and PC R 5 (pMON32169 template and primer pairs 132S/3605Rev). For the second round, PCR2, 5 and 8 were re -amplified in a combined mixture, resulting in PCR D. PCR D was purified, digested with NcoI/HindIII, and subcloned into NcoI/HindIII-digested pMON30309 (G-CSF(Serl7)/IgG2B).

EXAMPLE 112 pMON39909 (Flt3L l-139(39/40)L21/GS/G- CSF(Serl7)(133/132)) is one of two Flt3/G-CSF chimeric WO 98/17810 PCT/US97/20037 proteins in which both proteins the sequenced are rearranged. The NcoI/AflIII fragment'from pMON32198 comprising the Flt3L 1-139(39/40)L21/GlySer gene was subcloned into NcoI/SAP-treated pMON25187 coli production plasmid containing a single copy of G- CSF(Serl7)(133/132)). Following DNA sequence confirmation, the chimeric insert was subcloned into pMON3934 as an NcoI/HindIII fragment and designated pMON39909. pMON39910 (G-CSF(Serl7)(133/132/ IgG2B/Flt3L 1-139(39/40)L21) was constructed by PCR using pMON25187 as template and the primer pair GPForl/GPRev2.

Amplification conditions were identical to those utilized for pMON39908. NcoI/SnaBI-digested G- CSF(Serl7) (133/132) was subcloned into the NcoI/SnaBI site of pMON32376 containing the IgG2B/Flt3L 1-139 (39/40)L21 gene.

EXAMPLE 113 pMON40000 is the production plasmid modified from pClneo (Promega) containing G-CSF(Serl7)/GlySer/Flt3L 1-139 (39/40)L21 for expression in NSO cells (pMON32169 is the BHK equivalent). pMON40000 contains the CMV IE promoter/enhancer element, an IL-3 leader sequence immediately upstream of CSF(Serl7)/GlySer/Flt3L 1-139 (39/40)L21, truncated thymidine kinase promoter, late poly A signal sequence, and several DNAse 1 hypersensitive regions (part of IgH 3 min LCR).

WO 98/17810 WO 9817810PCT/US97/20037 3413 EXAMPLE 114 Bioactivity of multi-functional chimeric hematopoietic receptor acoonists Table 14 IN VITRO MULTI -FUNCTIONAL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS BIOASSAY Clone RAF3/FLT3L BAF3/FLT3L CPU-GM Colonies Proliferation' Prolif eration, pMON30247 pMON32169 pMON3 2175 pMON32190 pMON32191 pMON32333 pMON32342 pMON32352 pMON3236O pMON35766 pMON40000 pMON40002' Legend Compa 2Compa Analy Decreased potency (right shifted) compared to control Equivalent potency to control (within 2 fold) Increased potency (left shifted) compared to control ired Lred Lred 'zed control: pMON3 0247 control: pMON32352 appropriate coaddition control pool of clones pMON40000 and pMON40002 WO 98/17810 f WO 9817810PCT[US97/20037 EXAMPLE 115 Bioactivity determination EX VIVO MULTI -FUNCTION~AL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS BIOASSAY Clone Hematopoietic Ex Vivo Expansion 1Dendritic Cell Ex Vivo Expansion' Fold Neutrophil Mega- Fold Function Expansion Precursors karyocyte Expansion Precursors pMON32175 pMON32191 pMON32360 11-3 receptor agonist I, MFR agonist I, MFR agonist II 11-3 receptor agonist I, MFR agonist I, MFR agonist II, pMON3 0247 11-3 receptor agonist I, MFR agonist.

I, MFR agonist II, pMON3 2360 11-3 receptor agonist. I, MFR agonist I, MFR agonist II, pMON32333 11-3 receptor agonist. I, MFR agonist I, MFR agonist II, pMON3 2191 11-3 receptor agonist I, MFR agonist I, MFR WO 98/17810 5 PCT/US97/20037 agonist II, pMON32175 MFR agonist

II,

pMON32191 pMON30247 pMON32352 Legend: Decreased activity compared to IL-3, IL-6, SCF,G-CSF (literature control) Equivalent activity to IL-3, IL-6, SCF,G-CSF ((literature control)(within Increased activity compared to IL-3, IL-6, SCF,G-CSF (literature control) Culture Condition: X-Vivo 10 Media, 37'C, 5% CO 2 11 day incubation 2 Legend: Decreased activity compared to GM-CSF, TNFa, SCF (literature control) Equivalent activity to GM-CSF, TNFa, SCF ((literature control)(within Increased activity compared to GM-CSF, TNFa, SCF (literature control) Culture Condition: IMDM-20 Media supplemented with 100 ng/ml GM-CSF, 100 ng/ml TNFa, 20 ng/ml SCF, at 37 0 C/5% CO, for 18-22 days MFR agonist I pMON31140 (WO 95/21197) MFR agonist II pMON28571 (WO 97/12985) Hematopoietic Ex Vivo Expansion Assay CD34 enriched progenitor cells from human bone marrow were isolated and cultured at 5x10 4 cells/ml in X-Vivo 10 1% HSA with test cytokines and controls to assess cytokine expansion potential. Cells were expanded and replated at 5xl0'cells/ml with new media and cytokines around day 5 depending on cell growth.

On day 10 cells were harvested and characterized.

Cells were collected from the plates and diluted to a concentration of 1x10 6 cells/ml. Total cell expansion was determined and cells were characterized for hematopoietic progenitor cells by CFU Pre- and Post Expansion in methylcellulose (Stem Cell Technologies, MethocultHCC3534) Expanded cells were also characterized by flow cytometry for lineage specific WO 98/17810 PCT/US97/20037 phenotyping: CDllb(PE)/CD15(FITC), CD34 (FITC), CD41a (FITC).

Dendritic Cell Ex Vivo Expansion Assay CD34' enriched progenitor cells from human bone marrow were isolated and cultured at 2xl0 5 cells/ml in FCS with test cytokines and controls to assess expansion potential. Cells were expanded and replated at 5x10 4 cells/ml with new media and cytokines around day 5 depending on cell growth. On day 18-22 cells were harvested and characterized.

Total cell expansion was determined expanded cells were characterized by flow cytometry for lineage specific phenotyping: HLA-DR+(PE)/CDla+(FITC), CD86+(PE)/CDla+(FITC), CD19-(FITC). Dendritic cell fold expansion was determined as the total cellular expansion x HLA-DR+/CDla+. The functional activity of the cells was determined using a 1-way mixed lymphocyte reaction. Washed, irradiated cultured dendritic cells were added in graded doses to allogeneic responder peripheral blood mononuclear cells in 96-well microtiter plates. The ability of the dendritic cells to serve as antigen presenting cells was determined by the degree of proliferation stimulated in the responding cell preparations, as measured by H thymidine incorporation.

4r WO 98/17810 PCT/US97/20037 EXAMPLE 116 Receptor Binding Table 16 Receptor Binding Analyses: Compound Flt3-Fc G-CSFR IL-3R" K, (nM) IC 0 (nM) IC,, (nM) pMON32342 26 7 1000 pMON30247 36 7 6.6 pMON32360 45 17 26 (2) pMON32352 56 "5 13 4 pMON32191 37 14 0.33 0.01 11-3 receptor 1000 1.3 "0.2 agonist II 11-3 receptor 1000 3.7 "0.6 agonist I G-CSF 0.69 0.08 100 Data are expressed as .the mean "SEM from at least three experiments determined in triplicate, except pMON 32360 where only experiments have been completed.

The affinity of the Flt-3 agonist containing chimeric molecules was evaluated in receptor binding assays.

BIACORE analysis was performed by directly immobilizing Flt3-Fc and the Kd value computed from determining the association and dissociation rate constants. Competitive binding assays were utilized for evaluating the interactions of the chimeric molecules with either the G-CSF receptor transfected in BaF3 cells or the subunit of the IL-3 receptor expressed in BHK cells. The competition assays using these cells employed an agonist-specific radioligand and IC 0 values were generated for the competing chimeras using logit-log analysis of dose-response curves.

WO 98/17810 PCTIUS97/20037 EXAMPLE 117 In vivo bioactivitv Tablel7 MURINE IN VIVO MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS ASSAY DATA Clone Peripheral Blood Spleen I-Ab'/CDllc I-Ab/CD8' I-Ab/CDlc" I-Ab'/CD8 CFU-GM /Spleen DC cells/ul blood DC cells/Spleen (x 106) Fold Increase pMON30247 ND ND 33.5 23.8 78 pMON32342 ND ND 8.0 4.5 2 pMON32360 ND ND 64.5 37.5 183 pMON32191 17,089 2,379 133.5 78.9 53 C57BL/6 mice were injected s.c. with pMON30247, pMON32342 or pMON32360 (150 ug/day) or pMON32191(200ug/day) or Mouse Serum Albumin (MSA, 200 ug/day) for 10 days. On Day 11 terminal bleeds were done via cardiac puncture. Leucocytes counts were obtained on whole blood. Peripheral blood leucocytes were obtained by gradient centrifugation (Histopaque) followed by ammonium chloride lysis to further remove erythrocytes. Cells were stained for flow cytometery using direct fluorescein or phycoerythrin conjugated monoclonal antibodies (Pharmingen). Prior to staining non-specific Fc receptor binding was blocked using FcBlock (Pharmingen). Cells were analyzed on a FacScan flow cytometer (Becton/Dickinson).

Percent postive cells were determined by integration and phenotype enumeration was calculated based on WBC count. Spleens from treated animals were removed aseptically, teased apart, in RPMI media with needles. A cell suspension was obtained using the flat end of a 5cc syringe plunger followed by filtration through a cotton plug to remove clumps.

WO 98/17810 PCT/US97/20037 Erythrocytes were removed by ammonium chloride lysis, cells were washed, resuspended and counted using a Coulter counter (Coulter Electronics). Cells were prepared for flow cytometry as described above.

Phenotype was expressed as number of cells/spleen based on the percent of cells with a postive phenotype and total spleen WBC count. CFU cultures were obtained by plating 1.5 x 10 5 splenic cells/lml in triplicate wells of methylcellulose with murine cytokines w/o erythropoietin (Stem Cell Technologies). Cultures were incubated for 10 days at 37 0 C and counted on an inverted microscope. A CFU was defined as a colony of cells with >50 cells. The fold increase of CFU/spleen was determined (total number of CFU/Spleen of test compound/total number of CFU/Spleen of MSA control). MSA control values for peripheral blood were 15 and 347 cells/ul for I- Ab /CD11c' and I-Ab+/CD8' respectively. MSA control values for the splenic leucocytes were 2 and 1 x 106 cells/spleen for I-Ab/CD11c' and I-Ab/CD8' respectively.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

More details concerning the molecular biology techniques, protein purification and bioassays can be found in WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and WO 96/23888, are hereby incorporated by reference in their entirety.

WO 98/17810 PCTIUS97/20037 All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

WO 98/17810 PCT/US97/20037 SEQUENCE LISTING GENERAL INFORMATION APPLICANT: G. D. Searle (ii) TITLE OF THE INVENTION: Multi-functional Chimeric Hematopoietic Receptor Agonists (iii) NUMBER OF SEQUENCES: 865 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: G. D. Searle Co.

STREET: P.O. Box 5110 CITY: Chicago STATE: IL COUNTRY: U. S. A.

ZIP: 60680 COMPUTER READABLE FORM: MEDIUM TYPE: Diskette COMPUTER: IBM Compatible OPERATING SYSTEM: DOS SOFTWARE: FastSEQ for Windows Version (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE: 22-OCT-1997

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: 60/029,629 FILING DATE: 25-OCT-1996 (viii) ATTORNEY/AGENT INFORMATION: NAME: Bennett, Dennis A REGISTRATION NUMBER: 34,547 REFERENCE/DOCKET NUMBER: C-2994 (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: 314-737-6986 TELEFAX: 314-737-6972

TELEX:

INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 439 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGT 439 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 4 1 WO 98/17810 .3 FZPCT1US97/20037 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TCCCCAGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

TTtCTGATGC

CACCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC.

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

TGAC'CTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

GTCCTCAGTA AACTGCTTCG GAGGTTCACC CTTTGCCTAC TGGAAAACCC AGATGGAGGA CTGGAGGGAG TGATGGCAGC GGGCAGCTTT CTGGACAGGT CAGCTTCCTC CACAGGGCAG TTCCA.ACACC TGCTCCGAGG TGCGTCAGGG AATTC

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

A.AAGGTGCGT

INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCCCCAGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

TTCCTGATGC

TCTCCCGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

AATGCCATCT

GTAGGAGGGT

CACCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

TCCTGAGCTT

CCACCCTCTG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CCAACACCTG

CGTCAGG

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC

TGCGTCAGGG

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGGGCAGGA

CTCCGAGGAA

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

TGCTCCGAGG

AATTCGGCGG

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CCACAGCTCA

AGGTGCGTTT

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

AA.AGGTGCGT

CAACATGGCG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

CAAGGATCCC

CCTGATGCTT

INFORMATION FOR SEQ ID NO:4: Wi SEQUENCE CHARACTERISTICS: LENGTH: 936 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO;4: TCCCCAGCTC CACCTGCTTG GTCCTTCACA GCAGACTGAG CTGCCTGCTG TGGACTTTAG CAGGACATTC TGGGAGCAGT CTGGGACCCA CTTGCCTCTC CTTGGGGCCC TGCAGAGCCT CACAAGGATC CCAATGCCAT TTCCTGATGC TTGTAGGAGG CCCGCTCCGC CTGCTTGTGA CTTCACAGCA GACTGAGCCA CCTGCTGTGG ACTTTAGCTT GACATTCTGG GAGCAGTGAC GGACCCACTT GCCTCTCATC GGGGCCCTGC AGAGCCTCCT AAGGATCCCA ATGCCATCTT CTGATGCTTG TAGGAGGGTC

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

CCTCCGAGTC

GTGCCCAGAG

GGGAGAATGG

CCTTCTGCTG

CCTCCTGGGG

TGGAACCCAG

CCTGAGCTTC

CACCCTCTGC

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC

TGCGTCAGGG

CTCAGTAAAC

GTTCACCCTT

AAAACCCAGA

GAGGGAGTGA

CAGCTTTCTG

CTTCCTCCAC

CAACACCTGC

GTCAGG

AA.CTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

TGCTCCGAGG

AATTCGGCAA.

TGCTTCGTGA

TGCCTACACC

TGGAGGAGAC

TGGCAGCACG

GACAGGTCCG

AGGGCAGGAC

TCCGAGGAAA

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

AAAGGTGCGT

CATGGCGTCT

CTCCCATGTC

TGTCCTGCTG

CAAGGCACAG

GGGACAACTG

TCTCCTCCTT

CACAGCTCAC

GGTGCGTTTC

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 939 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 4 WO 98/17810 ?'3 PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:

TCCCCAGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

TTCCTGATGC

AATTCGGCGG

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

TGCTCCGAGG

939

CACCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

CAACATGGCG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

AAAGGTGCGT

TGACCT(

CCAGTG(

CTTGGG2

GACCCT'

ATCCCTC

CCTTGG

CTTCCT(

GTCCAC(

480 540 600 660 720 780 840 900 CCGA GTCCTCAGTA AACTGC' CCCA GAGGTTCACC CTTTGC( k.GAA TGGAAAACCC AGATGGj E'CTG CTGGAGGGAG TGATGG( 2CTG GGGCAGCTTT CTGGAC %ACC CAGCT DCCTC CACAGG( 3AGC TTCCAACACC TGCTCC( =CC TGCGTCAGG TCTCCCGCTC CGCCTGCTTG GTCCTTCACA GCAGACTGAG CTGCCTGCTG TGGACTTTAG CAGGACATTC TGGGAGCAGT CTGGGACCCA CTTGCCTCTC CTTGGGGCCC TGCAGAGCCT CACAAGGATC CCAATGCCAT TTCCTGATGC TTGTAGGAGG

TTCG

CTAC

rGGA

CAGC

AGGT

GCAG

GAGG

TGACTCC

ACCTGTC

GACCAAC

ACGGGGI

CCGTCTC

GACCAC2

AAAGGTC

~CAT ~CTG 600 ~GCA 660 ~CAA 720 ~CTC 780 GCT 840 ;CGT 900 93 9G

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC

TGCGTCAGG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 948 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:.

TCCCCAGCGC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

TTCCTGATGC

AACATGGCGT

GACTCCCATG

CCTGTCCTGC

ACCAAGGCAC

CGGGGACAAC

CGTCTCCTCC

ACCACAGCTC

AAGGTGCGTT

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

CCCCAGCGCC

TCCTTCACAG

TGCCTGCTGT

AGGACATTCT

TGGGACCCAC

TTGGGGCCCT

ACAAGGATCC

TCCTGATGCT

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

GCCTGCTTGT

CAGACTGAGC

GGACTTTAGC

GGGAGCAGTG

TTGCCTCTCA

GCAGAGCCTC

CAATGCCATC

TGTAGGAGGG

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC!

TGCGTCAGGG

GACCTCCGAG

CAGTGCCCAG

TTGGGAGAAT

ACCCTTCTGC!

TCCCTCCTGG

CTTGGAACCC

TTCCTGAGCT

TCCACCCTCT

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

TGCTCCGAGG

AATTCGGCGG

TCCTCAGTAA

AGGTTCACCC

GGAAAACCCA

TGGAGGGAGT

GGCAGCTTTC

AGCTTCCTCC

TCCAACACCT

GCGTCAGG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

AAAGGTGCGT

CAACGGCGGC

ACTGCTTCGT

TTTGCCTACA

GATGGAGGAG

GATGGCAGCA

TGGACAGGTC

ACAGGGCAGG

GCTCCGAGGA

INFORMATION FOR SEQ ID NO:7: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 688 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATGGCTAAC

AC!CTTTGCTG

CCTTCGACTT

AGGTATTGAG

CTCTCGACAT

GTTCTATCTG

TATAATGATC

GAACAACCTC

CCTGGAGAGC

TCTTCGTAAT

CATCATCAAG

CCTTGAGCAA

TGCTCTATAA

GACCCGAACA

CCAAACCTGG

GCAATTCTTC

CCAATCATCA

GTTACCCTTG

GATGAAATTA

AATGACGAAG

TTCGTAAGGG

CTCCAACCAT

GCAGGTGACT

GCGCAGGAAC

TGATCGATGA

ACCTCAATGA

AGAGCTTCGT

GTAATCTCCA

TCAAGGCAGG

AGCAAGCGCA

TACATCACTT

ACGTCTCTAT

CTGTCAAGAA

GTCTGCCCTC

GGCAAGAATT

AACAGTAC

AATTATACAT

CGAAGACGTC

AAGGGCTGTC

ACCATGTCTG

TGACTGGCAA

GGAACAACAG

AAAGAGACCA

CCTGATGGAC

CTTAGAAAAT

TGCCACGGCC

CCGGGAAA

CACTTAAAGA GACCACCTGC TCTATCCTGA TGGACCGAAA AAGAACTTAG AAAATGCATC CCCTCTGCCA CGGCCGCACC GAATTCCGGG AAAAACTGAC GGTGGTGGCT CTAACTGCTC CCTGCACCTT TGCTGGACCC CGAAACCTTC GACTTCCAAA GCATCAGGTA TTGAGGCAAT GCACCCTCTC GACATCCAAT CTGACGTTCT ATCTGGTTAC INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: CA) LENGTH: 712 base pairs TYPE: nucleic acid WO 98/17810 3?g4 WO 9817810PCT/US97/20037 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CATGGCTAAC TGCTCTATAA TGATCGATGA ACCTTTGCTG GACCCGAACA ACCTCAATGA

CCTTCGACTT

AGGTATTGAG

CTCTCGACAT

GTTCTATCTG

CAGCGGCGGC

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CCAAACCTGG

GCAATTCTTC

CCAATCATCA

GTTACCCTTG

GGTTCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGt

AGAGCTTCGT

GTAATCTCCA

TCAAGGCAGG

AGCAAGCGCA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AATTATACAT

CGAAGACGTC

AAGGGCTGTC

ACCATGTCTG

TGACTGGCAA

GGAACAACAG

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCA.AGCGcAc.

CACTTAAAGA

TCTATCCTGA

AAGAACTTAG

CCCTCTGCCA

GAATTCCGGG

GGTGGTGGCT

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

GACCACCTGC

TGGACCGAAA

AAAATGCATC

CGGCCGCACC

AAAAACTGAC

CTGGCGGTGG

ACTTAALAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

AC

INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 975 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATGGCTCTGG ACCCGAACAA CTTCGACTTC CAAACCTGGA GGTATTGAGG CAATTCTTCG TCTCGACATC CAATCATCAT TTCTATCTGG TTACCCTTGA ATAATGATCG ATGAAATTAT GGCGGTGGAG GCTCCCCGGG CCGTCTAAAG AATCTCATAA GCCTCTGCTT TCCAGCGCCG CTGGAGGTGT CGTACCGCGT TCTCAGAGCT TCCTGCTCAA GCGCTCCAGG AGAAGCTGTG CTCGGACACT CTCTGGGCAT CAGCTGGCAG GCTGCTTGAG CAGGCCCTGG AAGGGATATC GTCGCCGACT TTGCCACCAC CTGCAGCCCT AATAA CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGc CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGG ACATCACTTA AAGAGACCAC TGAACCGTCT GGTCCAATCT ATCTCCAAAC ATGGCTACCC GGCAGGAGGG GTCCTGGTTG TCTACGCCAC CTTGCGCAGC GTCTTTAGAG CAAGTGAGAA TGCCACCTAC AAGCTGTGCC CCCCTGGGCT CCCCTGAGCT CCAACTCCAT AGCGGCCTTT CCCCGAGTTG GGTCCCACCT CATCTGGCAG CAGATGGAAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

GTGGTGGCTC

CTGCACCTTT

CTACTATCAA

AGGGTGCCAT

CTAGCCATCT

CCTCTGGCGG

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

TAACTGCTCT

GTACGTAGAG

CCCGTCTCCT

GCCGGCCTTC

GCAGAGCTTC

CTCTGGCGGC

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

INFORMATION FOR SEQ ID NO:lO: SEQUENCE CHARACTERISTICS: LENGTH: 975 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1O:

ATGGCTAATG

GCCACGGCCG

CGGGAAAAAC

GGCTCTAACT

CCTTTGCTGG

CTTCGACTTC

GGCGGTGGAG

CCGTCTAAAG

GCCTCTGCTT

CTGGAGGTGT

TCTCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCT

CATCAGGTAT

CACCCTCTCG

TGACGTTCTA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

GCTCCCCGGG

AATCTCATAA

TC!CAGCGCCG

CGTACCGCGT

TC!CTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

AATAA

TGAGGCAATT

ACATCCAATC

TCTGGTTACC

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TGAACCGTCT

ATCTCCAAAC

GGCAGGAGGG

TCTACGCCAC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CTTCGTAATC TCCAACCATG ATCATCAAGG CAGGTGACTG CTTGAGCAAG CGCAGGAACA ATTATACATC ACTTAAAGAG GAAGACGTCT CTATCCTGAT AGGGCTGTCA AGAACTTAGA GGTCCAATCT CTACTATCAA ATGGCTACCC AGGGTGCCAT GTCCTGGTTG CTAGCCATCT CTTGCGCAGC CCTCTGGCGG CAAGTGAGAA AGATCCAGGG AAGCTGTGCC ACCCCGAGGA CCCCTGAGCT CCTGCCCCAG AGCGGCCTTT TCCTCTACCA GGTCCCACCT TGGACACACT CAGATGGAAG AACTGGGAAT

TCTGCCCTCT

GCAAGAATTC

ACAGGGTGGT

ACCACCTGCA

GGACCGAAAC

ATACGTAGAG

CCCGTCTCCT

GCCGGCCTTC

GCAGAGCTTC

CTCTGGCGGC

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

7 WO 98/17810 PCT[US97/20037 INF'ORMATION FOR SEQ ID NO:11: SEQUENCE CHARACTERISTICS: LENGTH: 975 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1l: ATGGCTGCAC CCTCTCGACA TCCAATCATC GAAAAACTGA CGTTCTATCT GGTTACCCTT TCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATGACGAA CGACTTCCAA ACCTGGAGAG CTTCGTAAGG ATTGAGGCAA TTCTTC!GTAA TCTCCAACCA GGCGGTGGAG GCTCCCCGGG TGAACCGTCT CCGTCTA.AAG AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT TCTACGCCAC TCTCAGAGCT TCCTGCTCA.A GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG TGCCACCTAC CTCGGACACT CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG CCAACTCCAT CAGGCCCTGG AAGGGATATC CCCCGAGTTG GTCGCCGACT TTGCCACCAC CATCTGGCAG CTGCAGCCCT AATAA

ATCAAGGCAG

GAGCAAGCGC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

GGTCCAATCT

ATGGCTACCC

GTCCTGGTTG

CTTGCGCAGC

CAAGTGAGAA

AAGCTGTGCC

CC CCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

GTijACTGGCA AGAATTCCGG AGGAACALACA GGGTGGTGGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

C!TGCCACGGC

CTACTATCAA

AGGGTGCCAT

CTAGCCATCT

C!CTCTGGCGG

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CTACGTAGAG

CCCGTCTCCT

GCCGGCCTTC

GCAGAGCTTC

CTCTGGCGGC

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG,

GCAGCTGGAC

GGCCCCTGCC

120 180, 240 300 360 420 480 540 600 660 720 780 840 900 960 975 INFORMATION FOR SEQ ID NO:12: SEQUENCE CHARACTERISTICS: LENGTH: 975 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAGCAAGCGC AGGAACAACA GGGTGGTGGC ATACATCACT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA CCGAAACCTT GCTGTCAAGA ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC CGCACCCTCT GGCGGTGGAG GCTCCCCGGG TGAACCGTCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT TCTACGCCAC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG TGCCACCTAC CTCGGACACT CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG CCAACTCCAT CAGGCCCTGG AAGGGATATC CCCCGAGTTG GTCGCCGACT TTGCCACCAC CATCTGGCAG CTGCAGCCCT AATAA

GAAAAACTGA

TCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

GGTCCAATCT

ATGGCTACCC

GTCCTGGTTG

CTTGCGCAGC

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

CGTTCTATCT

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CTACTATCAA

AGGGTGCCAT

CTAGCCATCT

CCTCTGGCGG

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

GGTTACCCTT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GTACGTAGAG

CCCGTCTCCT

GCCGGCCTTC

GCAGAGCTTC

CTCTGGCGGC

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG,

GCAGCTGGAC

GGCCCCTGCC

INFORMATION FOR SEQ ID NO:l3: SEQUENCE CHARACTERISTICS: LENGTH: 999 base pairs TYPE: nucleic acid (C).STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATGGCTCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

AGCGGCGGCG

CCACCTGCAC

ATCTCTACTA

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTTCTAACTG

CTTTGTAC!GT

TCAACCCGTC

CCTCAATGAC

GAGCTTCGTA

TAATCTCCA.A

CAAGGCAGGT

GCAAGCGCAG

CTCTATAATG

AGAGGGCGGT

TCCTCCGTCT

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGG

ATCGATGAAk

GGAGGCTCCC

AAAGAATCTC

CTATCCTGAT GGACCGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC A.ATTCCGGGA AAAACTGACG GTGGTGGCTC TGGCGGTGGC TTATACATCA CTTAAAGAGA CGGGTGAACC GTCTGGTCCA ATAAATCTCC AAACATGGCT WO 98/17810

ACCCAGGGTG

GTTGCTAGCC

CAGCCCTCTG

AGAAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

CCATGCCGGC

ATCTGCAGAG

GCGGCTCTGG

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GAATGGCCCC

CTTCGCCTCT

CTTCCTGGAG

CGGCTCTCAG

CGCAGCGCTC

GCTGCTCGGA

CCTGCAGCTG

CCTGCAGGCC

GGACGTCGCC

TGCCCTGCAG

GCTTTCCAGC

GTGTCGTACC

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

CCCTAATAA

PCT1UJS97/20037 GCCGGGCAGG AGGGGTCCTG 540 GCGTTCTACG CCACCTTGCG 600 TCAAGTCTTT AGAGCAAGTG 660 TGTGTGCCAC CTACAAGCTG 720 GCATCCCCTG GGCTCCCCTG 780 TGAGCCAACT CCATAGCGGC 840 TATCCCCCGA GTTGGGTCCC 900 CCACCATCTG GCAGCAGATG 960 999 INFORMATION FOR SEQ ID NO:14: SEQUENCE CHARACTERISTICS: LENGTH: 999 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATGGCTAATG

GCCACGGCCG

CGGGAAAAAC

GGCTCTGGCG

CATCACTTA-A

GTCTCTATCC

GTCAAGAACT

ATCTCTACTA

ACCCAGGGTG

GTTGCTAGCC

CAGCCCTCTG

AGAAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

CATCAGGTAT

CACCCTCTCG

TGACGTTCTA

GTGGCAGCGG

AGAGACCACC

TGATGGACCG

TAGAATACGT

TCAACCCGTC

CCATGCCGGC

ATCTGCAGAG

GCGGCTCTGG

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GAATGGCCCC

TGAGGCAATT

ACATCCAATC

TCTGGTTACC

CGGCGGTTCT

TGCACCTTTG

AAACCTTCGA.

AGAGGGCGGT

TCCTCCGTCT

CTTCGCCTCT

CTTCCTGGAG

CGGCTCTCAG

CGCAGCGCTC

GCTGCTCGGA

CCTGCAGCTG

CCTGCAGGCC

GGACGTC!GCC

TGCCCTGCAG

CTTCGTAATC

ATCATCAAGG

CTTGAGCAAG

AACTGCTCTA

CTGGACCCGA

CTTCCAAACC

GGAGGCTCCC

AAAGAATCTC

GCTTTCCAGC

GTGTCGTACC

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

CCCTAATAA

TCCAACCATG TCTGCCCTCT CAGGTGACTG GCAAGAATTC CGCAGGAACA ACAGGGTGGT TAATGATCGA TGAAATTATA ACAACCTCAA TGACGAAGAC TGGAGAGCTT CGTAAGGGCT CGGGTGAACC GTCTGGTCCA ATAAATCTCC AAACATGGCT GCCGGGCAGG AGGGGTCCTG GCGTTCTACG CCACCTTGCG TCAAGTCTTT AGAGCAAGTG TGTGTGCCAC CTACAAGCTG GCATCCCCTG GGCTCCCCTG TGAGCCAACT CCATAGCGGC TATCCCCCGA GTTGGGTCCC CCACCATCTG GCAGCAGATG INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 999 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID,

ATGGCTGCAC

GAAAAACTGA

TCTGGCGGTG

CACTTAAAGA

TCTATCCTGA

AAGAACTTAG

CCCTCTGCCA

ATCTCTACTA

ACCCAGGGTG

GTTGCTAGCC

CAGCCCTCTG

AGAAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

CCTCTCGACA.

CGTTCTATCT

GCAGCGGCGG

GACCACCTGC

TGGACCGAAA

AAAATGCATC

CGGCCTACGT

TCAACCCGTC

CCATGCCGGC

ATCTGCAGAG

GCGGCTCTGG

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GAATGGCCCC

TCCAATCATC

GGTTACCCTT

CGGTTCTAAC

ACCTTTGCTG

CCTTCGACTT

AGGTATTGAG

AGAGGGCGGT

TCCTCCGTCT

CTTCGCCTCT

CTTCCTGGAG

CGGCTCTCAG

CGCAGCGCTC

GCTGCTCGGA

CCTGCAGCTG

CCTGCAGGCC

GGACGTCGCC

TGCCCTGCAG

ATCAAGGCAG

GAGCAAGCGC

TGCTCTATAA

GACCCGAACA

CCAAACCTGG

GCAATTCTTC

GGAGGCTCCC

AAAGAATCTC

GCTTTCCAGC

GTGTCGTACC

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

CCCTAATAA

GTGACTGGCA AGAATTCCGG AGGAACAACA GGGTGGTGGC TGATCGATGA AATTATACAT ACCTCAATGA CGAAGACGTC AGAGCTTCGT AAGGGCTGTC GTAATCTCCA ACCATGTCTG CGGGTGAACC GTCTGGTCCA ATAAATCTCC AAACATGGCT GCCGGGCAGG AGGGGTCCTG GCGTTCTACG CCACCTTGCG TCAAGTCTTT AGAGCAAGTG TGTGTGCCAC CTACAAGCTG GCATCCCCTG GGCTCCCCTG TGAGCCAACT CCATAGCGGC TATCCCCCGA GTTGGGTCCC CCACCATCTG GCAGCAGATG INFORMATION FOR SEQ ID NO:16; Ci) SEQUENCE CHARACTERISTICS: LENGTH: 999 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9/1780 3 19.PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATGGCTGCAG

GAGCAAGCGC

TGCTCTATAA

GACCCGAACA

CCAAACCTGG

GCAATTCTTC

CCAATCATCA

ATCTCTACTA

ACCCAGGGTG

GTTGCTAGCC

CAGCCCTCTG

AGAAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

GTGACTGGCA

AGGAACAACA

TGATCGATGA

ACCTCA-ATGA

AGAGCTTCGT

GTAATCTCCA

TCAAGTACGT

TCAACCCGTC

CCATGCCGGC

ATCTGCAGAG

GCGGCTCTGG

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GAATGGCCCC

AGAATTCCGG

GGGTGGTGGC

A.ATTATACAT

CGAAGACGTC

AAGGGCTGTC

ACCATGTCTG

AGAGGGCGGT

TCCTCCGTCT

CTTCGCCTCT

CTTCCtGGAG

CGGCTCTCAG

CGCAGCGCTC

GCTGCTCGGA

CCTGCAGCTG

CCTGCAGGCC

GGACGTCGCC

TGCCCTGCAG,

GAAAAACTGA

TCTGGCGGTG

CACTTAAAGA

TCTATCCTGA

A.AGAACTTAG

CCCTCTGCCA

GGAGGCTCCC

AAAGAATCTC

GCTTTCCAGC

GTGTCGTACC

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

CCCTAATAA

CGTTCTATCT

GC!AGCGGCGG

GACCACCTGC

TGGACCGAAA

AAAATGCATC

CGGCCGCACC

CGGGTGAACC

ATAAATCTCC

GCCGGGCAGG

GCGTTCTACG

TCAAGTCTTT

TGTGTGCCAC

GCATCCCCTG

TGAGCCAACT

TATCCCCCGA

CCACCATCTG

GGTTACCCTT

CGGTTCTAAC

ACCTTTGCTG

CCTTCGACTT

AGGTATTGAG

CTCTCGACAT

GTCTGGTCCA.

AAACATGGCT

AGGGGTCCTG

CCACCTTGCG

AGAGCAAGTG

CTACAAGCTG

GGCTCCCCTG

CCATAGCGGC

GTTGGGTCCC

GCAGCAGATG

INFORMATION FOR SEQ ID NO:17: SEQUENCE CHARACT ERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GAGCTGGTGC

AGCCAGGCCC'

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

CGCCGGGCAG

CGCGTTCTAC

CTCAAGTCTT

CTGTGTGCCA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

TGCTCGGACA

TGCAGCTGGC

TGCAGGCCCT

ACGTCGCCGA

CCCTGCAGCC

GAGGGGTCCT

GCCACCTTGC

TAGAGCAAGT

CCTAATA.A

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CTCTCTGGGC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

AACATGGCTT

ATCCCCTGGG

ACTTAAAGAG ACCACCTGCA CTATCCTGAT GGACCGAAAC AGA.ACTTAGA AAATGCATCA CC!TCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC ACAAGCTGTG CCACCCCGAG CTCCCCTGAG CTCCTGCCCC ATAGCGGCCT TTTCCTCTAC TGGGTCCCAC CTTGGACACA AGCAGATGGA AGAACTGGGA CCTTCGCCTC TGCTTTCCAG GCTTCCTGGA GGTGTCGTAC GCGGCTCTCA GAGCTTCCTG GCGCAGCGCT CCAGGAGAAG AGGCTGCTTG AGCCAACTCC GGAAGGGATA TCCCCCGAGT CTTTGCCACC ACCATCTGGC CACCCAGGGT GCC.ATGCCGG GGTTGCTAGC CATCTGCAGA GCAGCCCTCT GGCGGCTCTG GAGAAAGATC CAGGGCGATG INFORMATION FOR SEQ ID NO:18: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

CAAGTGAGAA

TAA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CCTCTGGCGG

AGATCCAGGG

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA.

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

ACTATCAACC

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

C!GTCTCCTCC

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

TCCTGCTCAA

AGAAGCTGTG

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

GTCTTTAGAG

TGCCACCTAA

CTCTGGCGGC. TCTCAGAGCT CGATGGCGCA GCGCTCCAGG WO 98/17810 WO 9817810PCT/US97120037 INFORMATION FOR SEQ ID NO:19: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GACACACTGC

CTGGGAATGG

TTCCAGCGCC

TCGTACCGCG

TTCCTGCTCA

GAGAAGCTGT

TCTCTGGGC.A

GGCTGCTTGA

GAAGGGATAT

GCTCTATAAT GATCGATGAA.

ACCCGAACAA CCTCAATGAC CAAACCTGGA GAGCTTCGTA CAATTCTTCG TAATCTCCAA CAATCATCAT CAAGGCAGGT TTACCCTTGA GCAAGCGCAG GTGGTTCTGG CGGCGGCTCC AGCTGGACGT CGCCGACTTT CCCCTGCCCT GCAGCCCACC GGGCAGGAGG GGTCCTGGTT TTCTACGCCA CCTTGCGCAG AGTCTTTAGA GCAAGTGAGA GTGCCACCTA CAAGCTGTGC TCCCCTGGGC TCCCCTGAGC GCCAACTCCA TAGCGGCCTT

CCTAATAA

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

AACATGGCTC

GCCACCACCA

CAGGGTGCCA

GCTAGCCATC

CCCTCTGGCG

AAGATCCAGG

CACCCCGAGG

TCCTGCCCCA

TTCCTCTACC

ACTTAAAGAG ACCACCTGCA CTATCCTGAT GGACCGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC CCGAGTTGGG TCCCACCTTG TCTGGCAGCA GATGGAAGAA TGCCGGCCTT CGCCTCTGCT TGCAGAGCTT CCTGGAGGTG GCTCTGGCGG CTCTCAGAGC GCGATGGCGC AGCGCTCCAG AGCTGGTGCT GCTCGGACAC GCCAGGCCCT GCAGCTGGCA AGGGGCTCCT GCAGGCCCTG INFORMATION FOR SEQ ID Ci) SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTCC

CGCCACCTTG

TTAGAGCAAG

ACCTACAAGC

TGGGCTCCCC

CTCCATAGCG

TAA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

ACTTTGCCAC

CCACCCAGGG

TGGTTGCTAG

CGCAGCCCTC

TGAGAAAGAT

TGTGCCACCC

TGAGCTCCTG

GCCTTTTCCT

GATCGATGAA ATTATACATC CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGC CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGT TCCAATCTCT ACTATCAACC GGCTCCCGAG TTGGGTCCCA CACCATCTGG CAGCAGATGG TGCCATGCCG GCCTTCGCCT CCATCTGCAG AGCTTCCTGG TGGCGGCTCT GGCGGCTCTC CCAGGGCGAT GGCGCAGCGC CGAGGAGCTG GTGCTGCTCG CCCCAGCCAG GCCCTGCAGC CTACCAGGGG CTCCTGCAGG

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

CCTTGGACAC

AAGAACTGGG

CTGCTTTCCA

AGGTGTCGTA

AGAGCTTCCT

TCCAGGAGAA

GACACTCTCT

TGGCAGGCTG

CCCTGGAAGG

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAA-AGAA

ACTGCAGCTG

AATGGCCCCT

GCGCCGGGCA

CCGCGTTCTA

GCTCAAGTCT

GCTGTGTGCC

GGGCATC CCC

CTTGAGCCAA

GATATCCTAA

INFORMATION FOR SEQ ID NO:21: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

ACCCAGGGTG

GTTGCTAGCC

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

CCATGCCGGC

ATCTGCAGAG

GATCGATGAA ATTATACATC

CCTCAATGAC

GAGCTTCGTA

TAATCTCCA-A

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CTTCGCCTCT

CTTCCTGGAG

GAAGACGTCT

AGGGCTGTCA

CCATGTC!TGC

GACTGGCAAG

GAACAACAGT

AACATGGCTA

GCTTTCCAGC

GTGTCGTACC

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

TGGCCCCTGC

GCCGGGCAGG

GCGTTCTACG

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

,GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

CCTGCAGCCC

AGGGGTCCTG

CCACCTTGCG

WO 98/17810 WO 9817810PCTIUS97/20037

CAGCCCTCTG

AGAAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

GCGGCTCTGG

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GATAATAA

CGGCTCTCAG

CGCAGCGCTC

GCTGCTCGGA

CCTGCAGCTG

CCTGCAGGCC

GGACGTCGCC

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

TCAAGTCTTT

TGTGTGCCAC

GCATCCCCTG

TGAGCCAACT

TATCCCCCGA

CCACCATCTG

AGAGCA.AGTG

CTACAAGCTG

GGCTCCCCTG

CCATAGCGGC

GTTGGGTCCC

GCAGCAGATG

INFORMATION FOR SEQ ID NO:22: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRAflDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

CCGGCCTTCG

CAGAGCTTCC

TCTGGCGGCT

GATGGCGCAG

CTGGTGCTGC

CAGGCCCTGC

GGGCTCCTGC

CAGCTGGACG

TAA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

CCTCTGCTTT

TGGAGGTGTC

CTCAGAGCTT

CGCTCCAGGA

TCGGACACTC

AGCTGGCAGG

AGGCCCTGGA

TCGCCGACTT

GATCGATGAA

CCTCA-ATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTATGGCC

CCAGCGCCGG

GTACCGCGTT

CCTGCTCAAG

GAAGCTGTGT

TCTGGGCATC

C'rGCTTGAGC

AGGGATATCC

TGCCACCACC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

ACTATCAACC

CCTGCCCTGC

GCAGGAGGGG

CTACGCCACC

TCTTTAGAGC

GCCACCTACA

CCCTGGGCTC

CAACTCCATA

CCCGAGTTGG

ATCTGGCAGC

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

AGCCCACCCA

TCCTGGTTGC

TTGCGCAGCC

AAGTGAGAAA

AGCTGTGCCA

CCCTGAGCTC

GCGGCCTTTT

GTCCCACCTT

ACCACCTGCA

GGACCGAAAc

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGGTGCCATG

TAGCCATCTG

CTCTGGCGGC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

AGATGGAAGA ACTGGGATAA INFORMATION FOR SEQ ID NO:23: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

ATGGCTAACT

CCTTTGCTGG

CTTCGA.CTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TTCGCCTCTG

TTCCTGGAGG

GGCTCTCAGA

GCAGCGCTCC

CTGCTCGGAC

CTGCAGCTGG

CTGCAGGCCC

GACGTCGCCG

GCCCTGCAGC

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CA.ATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

CTTTCCAGCG

TGTCGTACCG

GCTTCCTGCT

AGGAGAAGCT

ACTCTCTGGG

CAGGCTGCTT

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CCGGGCAGGA

CGTTCTACGC

CAAGTCTTTA

GTGTGCCACC

CATCCCCTGG

GAGCCAACTC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

AACATGGCTA

GGGGTCCTGG

CACCTTGCGC

GAGCAAGTGA

TACAAGCTGT

GCTCCCCTGA

CATAGCGGCC

TTGGGTCCCA

CAGCAGATGG

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CCCAGGGTGC

TTGCTAGCCA

AGCCCTCTGG

GAAAGATCCA

GCCACCCCGA

GCTCCTGCCC

TTTTCCTCTA

CCTTGGACAC

AAGAACTGGG

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

CATGCCGGCC

TCTGCAGAGC

CGGCTCTGGC

GGGCGATGGC

GGAGCTGGTG

CAGCCAGGCC

CCAGGGGCTC

ACTGCAGCTG

A.ATGGCCCCT

TGGAAGGGAT ATCCCCCGAG ACTTTGCCAC

CACCATCTGG

CCTAATA.A

INFORMATION FOR SEQ ID NO:24: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: ATGGCTAACT GCTCTATAAT GATCGATGA ATTATACATC ACTTAAAGAG ACCACCTGCA WO 98/1 7810

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

CAGCGCCGGG

TACCGCGTTC

CTGCTCAAGT

AAGCTGTGTG

CTGGGCATCC

TGCTTGAGCC

GGGATATCCC

GCCACCACCA

TAA

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

CAGGAGGGGT

TACGCCACCT

CTTTAGAGCA

CCACCTACAA

CCTGGGCTCC

AACTCCATAG

CCGAGTTGGG

TCTGGCAGCA

390 CCTCAATGAC GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA AGAACTTAGA TAATCTCCAA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GGCTACCCAG GGTGCCATGC CGGCCTTCGC CCTGGTTGCT AGCCATCTGC AGAGCTTCCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTGTGCCAC CCCGAGGAGc TGGTGCTGCT CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA CGGCCTTTTC CTCTACCAGG GGCTCCTGCA TCCCACCTTG GACACACTGC AGCTGGACGT GATGGAAGAA CTGGGAATGG CCCCTGCCCT PCT/US97/20037 GGACCGAAAC 120 AAATGCATCA 180 GGCCGCACCC 240 AAAACTGACG 300 CGGTGGAGGC 360 GTCTAAAGAA 420 CTCTGCTTTC 480 GGAGGTGTCG 540 TCAGAGCTTC 600 GCTCCAGGAG 660 CGGACACTCT 720 GCTGGCAGGC 780 GGCCCTGGAA 840 CGCCGACTTT 900 GCAGCCCTAA 960 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GGAGGGGTCC

CGCCACCTTG

TTAGAGCAAG

ACCTACAAGC

TGGGCTCCCC

CTCCATAGCG

GAGTTGGGTC

TGGCAGCAGA

CCGGCCTTCG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

TGGTTGCTAG

CGCAGCCCTC

TGAGAAAGAT

TGTGCCACCC

TGAGCTCCTG

GCCTTTTCCT

CCACCTTGGA

TGGAAGAACT

CCTAATAA

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CCATCTGCAG

TGGCGGCTCT

CCAGGGCGAT

CGAGGAGCTG

CCCCAGCCAG

CTACCAGGGG

CACACTGCAG

GGGAATGGCC

ATTATACATC ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GGACCGAAAC AGGGCTGTCA AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGTGGAGGC AACATGGCTT CTGCTTTCCA GCGCCGGGCA AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC GTGCTGCTCG GACACTCTCT GGGCATCCCC GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCTGCAGG CCCTGGAAGG GATATCCCCC CTGGACGTCG CCGACTTTGC CACCACCATC CCTGCCCTGC AGCCCACCCA GGGTGCCATG INFORMATION FOR SEQ ID NO:26: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GCTAGCCATC

CCCTCTGGCG

AAGATCCAGG

CACCCCGAGG

TCCTGCCCCA

TTCCTCTAC!C

TTGGACACAC

GAACTGGGAA

TAA

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

TGCAGAGCTT

GCTCTGGCGG

GCGATGGCGC

AGCTGGTGCT

GCCAGGCCCT

AGGGGCTCCT

TGCAGCTGGA

TGGCCCCTGC

GATCGATGAA ATTATACATC CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGC CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGT TCCAATCTCT ACTATCAACC GGCTTCTGCT TTCCAGCGCC CCTGGAGGTG TCGTACCGCG CTCTCAGAGC TTCCTGCTCA AGCGCTCCAG GAGAAGCTGT GCTCGGACAC TCTCTGGGCA GCAGCTGGCA GGCTGCTTGA GCAGGCCCTG GAAGGGATAT CGTCGCCGAC TTTGCCACCA CCTGCAGCCC ACCCAGGGTG ACTTAAAGAG ACCACCTGCA CTATCCTGAT GGACCGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC CGTCTCCTCC GTCTAAAGAA GGGCAGGAGG GGTCCTGGTT TTCTACGCCA CCTTGCGCAG AGTCTTTAGA GCAAGTGAGA GTGCCACCTA CAAGCTGTGC TCCCCTGGGC TCCCCTGAGC GCCAACTCCA TAGCGGCCTT CCCCCGAGTT GGGTCCCACC CCATCTGGCA GCAGATGGAA CCATGCCGGC CTTCGCCTAA INFORMATION FOR SEQ ID NO:27: SEQUENCE CHARACTERISTICS: 4 i WO 98/17810 .334 LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: PCTIUS97/20037

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GAGCTGGTGC

AGCCAGGCCC

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

CGCCGGGCAG

CGCGTTCTAC

AGCTTCCTGC

CAGGAGAAGC

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

TGCTCGGACA

TGCAGCTGGC

TGCAGGCCCT

ACGTCGCCGA

CCCTGCAGCC

GAGGGGTCCT

GCCACCTTGC

TCAAGTCTTT

TGTGTGCCAC

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CTCTCTGGGC

AGGCTGCTTG

GGAAGGGATA

CTTTGCCACC

CACCCAGGGT

GGTTGCTAGC

GCAGCCCACA

AGAGCAAGTG

CTAATAA

ATTATACATC ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GGACCGAAAC AGGGCTGTCA AGAACTTAGA AAATGCATCA CCATGTCTGC CCTC!TGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGTGGAGGC AACATGGCrT ACAAGCTGTG CCACCCCGAG ATCCCCTGGG CTCC!CCTGAG CTCCTGCCCC AGCCAACTCC ATAGCGGCCT TTTCCTCTAC TCCCCCGAGT TGGGTCCCAC CTTGGACACA ACCATCTGGC AGCAGATGGA AGAACTGGGA GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGAAAGATCC AGGGCGATGG CGCAGCGCTC INFORMATION FOR SEQ ID NO:28: SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO; 28:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

TCTTTAGAGC

GCCACCTAAT

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CCACACCATT

AAGTGAGAAA

AA

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCA-A

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

GGGCCCTGCC

GATCCAGGGC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

ACTATCAACC

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC!

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

AGCTCCCTGC

GATGGCGCAG

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

.TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

CCCAGAGCTT

CGCTCCAGGA

ACCACCTGCA

GGACCGAALAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

CCTGCTCAAG

GAAGCTGTGT

INFORMATION FOR SEQ ID NO:29: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GACACACTGC

CTGGGAATGG

TTCCAGCGCC

TCGTACCGCG

CCCCAGAGCT

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

AGCTGGACGT

CCCCTGCCCT

GGGCAGGAGG

TTCTACGCCA

TCCTGCTCAA

GATCGATGAA ATTATACATC CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGC! CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGT CGGCGGCTCC AACATGGCTC CGCCGACTTT GCCACCACCA GCAGCCCACC CAGGGTGCCA GGTCCTGGTT GCTAGCCATC CCTTGCGCAG CCCACACCAT GTCTTTAGAG CAAGTGAGAA

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CCGAGTTGGG

TCTGGCAGCA

TGCCGGCCTT

TGCAGAGCTT

TGGGCCCTGC

AGATCCAGGG

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

TCCCACCTTG

GATGGAAGAA

CGCCTCTGCT

CCTGGAGGTG

CAGCTCCCTG

CGATGGCGCA

wn l1 2I1 nlf 3921 r LIl GCGCTCCAGG AGAAGCTGTG TGCCACCTIAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CTAATAA INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID 1S97/20037 780 840 900 927

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTCC

CGCCACCTTG

CTCA.AGTCTT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCTAAT

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTCG

CTCCAAACAT

ACTTTGCCAC

CCACCCAGGG

TGGTTGCTAG

CGCAGCCCAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AA

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTCCCGAG

CACCATCTGG

TGCCATGCCG

CCATCTGCAG

ACCATTGGGC

GAGAAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

ACTATCAACC

TTGGGTCCCA

CAGCAGATGG

GCCTTCGCCT

AGCTTCC!TGG

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACTTAAAGAG ACCACCTGCA CTATCCTGAT GGACCGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC CGTCTCCTCC GTCTAAAGAA CCTTGGACAC ACTGCAGCTG AAGAACTGGG AATGGCCCCT CTGCTTTCCA GCGCCGGGCA AGGTGTCGTA CCGCGTTCTA CCCTGCCCCA GAGCTTCCTG GCGCAGCGCT CCAGGAGAAG TGCTGCTCGG ACACTCTCTG CCCTGCAGCT GGCAGGCTGC TCCTGCAGGC CCTGGAAGGG INFORMATION FOR SEQ ID NO:31: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: ATGGCTAACT GCTCTATAAT CCTTTGCTGG ACCCGAACAA CTTCGACTTC CAAACCTGGA GGTATTGAGG CAATTCTTCG TCTCGACATC CAATCATCAT TTCTATCTGG, TTACCCTTGA TCCCCGGGTG GTGGTTCTGG ACCCAGGGTG CCATGCCGGC GTTGCTAGCC ATCTGCAGAG CAGCCCACAC CATTGGGCCC GAGCAAGTGA GAAAGATCCA TACAAGCTGT GCCACCCCGA GCTCCCCTGA GCTCCTGCCC CATAGCGGCC TTTTCCTCTA TTGGGTCCCA CCTTGGACAC CAGCAGATGG AAGAACTGGG

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CTTCGCCTCT

CTTCCTGGAG

TGCCAGCTCC

GGGCGATGGC

GGAGCTGGTG

CAGCCAGGCC

CCAGGGGCTC

ACTGCAGCTG

ATAATAA

ATTATACATC

GAAGACGTCT

AGGGCTGTCA.

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

AACATGGCTA

GCTTTCCAGC

GTGTCGTACC

CTGCCCCAGA

GCAGCGCTCC

CTGCTCGGAC

CTGCAGCTGG

CTGCAGGCCC

GACGTC-GCCG

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

ALATTCCGGGA

ACGTAGAGGG

TGGCCCCTGC

GCCGGGCAGG

GCGTTCTACG

GCTTCCTGCT

AGGAGAAGCT

ACTCTCTGGG

CAGGCTGCTT

TGGAAGGGAT

ACTTTGCCAC

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

CCTGCAGCCC

AGGGGTCCTG

CCACCTTGCG

CAAGTCTTTA

GTGTGCCACC

CATCCCCTGG

GAGCCAACTC

ATCCCCCGAG

CACCATCTGG

INFORMATION FOR SEQ ID NO:32: SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: Single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG, ACCCGAACAA CCTCAATGAC GAJ\GACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCA CCATGTCTGC CCTCTGCCAC GGCCGCACCC WO098/17810 TCTCGACATC CAATCATCAT TTCTATCTGG TTACCCTTGA TCCCCGGGTG AACCGTCTGG TCTCATAAAP CTCCAAACAT CCGGCCTTCG CCTCTGCTTT CAGAGCTTCC TGGAGGTGTC GGCCCTGCCA GCTCCCTGCC ATCCAGGGCG ATGGCGCAGC CCCGAGGAGC TGGTGCTGCT TGCCCCAGCC AGGCCCTGCA CTCTACCAGG GGCTCCTGCA GACACACTGC AGCTGGACGT CTGGGATAAT AA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTATGGCC

CCAGCGCCGG

GTACCGCGTT

CCAGAGCTTC

GCTCCAGGAG

CGGACACTCT

GCTGGCAGGC

GGCCCTGGA.A

CGCCGACTTT

GACTGGcAAG

GA.ACAACAGT

ACTATCAACC

CCTGCCCTGC

GCAGGAGGGG

CTACGCCACC

CTGCTCAAGT

AAGCTGTGTG

CTGGGCATCC

TGCTTGAGCC

GGGATATCCC

GCCACCACCA

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

AGCCCACCCA

TCCTGGTTGC

TTGCGCAGCC

CTTTAGAGCA

CCACCTACAA

CCTGGGCTCC

AACTCCATAG

CCGAGTTGGG

TCTGGCAGCA

PCT/US97/20037 AA.AACTGACG 300 CGGTGGAGGC 360 GTCTAAAGAA 420 GGGTGCCATG 480 TAGCCATCTG 540 CACACCATTG 600 AGTGAGAAAG 660 GCTGTGCCAC 720 CCTGAGCTCC 780 CGGCCTTTTC 840 TCCCACCTTG 900 GATGGAAGAA 960 INFORMATION FOR SEQ ID NO:33: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs, TYPE: nucleic acid STRALNDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ATGGCTAACT

CCTTTGC.TGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TTCGCCTCTG

TTCCTGGAGG

GCCAGCTCCC

GGCGATGGCG

GAGCTGGTGC

AGCCAGGCCC

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

CTTTCCAGCG

TGTCGTACCG

TGCCCCAGAG

CAGCGCTCCA

TGCTCGGACA

TGCAGCTGGC

TGCAGGCCCT

ACGTCGCCGA

CCCTGCAGCC

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CCGGGCAGGA

CGTTCTACGC

CTTCCTGCTC

GGAGAAGCTG

CTCTCTGGGC

AGGCTGCTTG

GGAAGGGATA

CTTTGCCACC

CTAATAA

ATTATACATC ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GGACCGAAAC AGGGCTGTCA AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGTGGAGGC AACATGGCTA CCCAGGGTGC CATGCCGGCC GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC CACCTTGC!GC AGCCCACACC ATTGGGCCCT AAGTCTTTAG AGCAAGTGAG AAAGATCCAG TGTGCCACCT ACAAGCTGTG CCACCCCGAG ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAACTCC ATAGCGGCCT TTTCCTCTAC TCCCCCGAGT TGGGTCCCAC CTTGGACACA ACCATCTGGC AGCAGATGGA AGAACTGGGA INFORMATION FOR SEQ ID NO:34: SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: ATGGCTAACT GCTCTATAAT CCTTTGCTGG ACCCGAACAA CTTCGACTTC CAAACCTGGA GGTATTGAGG CAATTCTTCG TCTCGACATC CAATCATCAT TTCTATCTGG TTACCCTTGA TCCCCGGGTG AACCGTCTGG TCTCATAAAT CTCCAAACAT CAGCGCCGGG CAGGAGGGGT TACCGCGTTC TACGCCACCT CAGAGCTTCC TGCTCAAGTC CTCCAGGAGA AGCTGTGTGC GGACACTCTC TGGGCATCCC CTGGCAGGCT GCTTGAGCCA GCCCTGGAAG GGATATCCCC GCCGACTTTG CCACCACCAT CAGCCCTAAT AA

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCA.ATCTCT

GGCTACCCAG

CCTGGTTGCT

TGCGCAGCCC

TTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

ACTATCAACC

GGTGCCATGC

AGCCATCTGC

ACACCATTGG

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

ACTTAAAGAG ACCACCTGCA CTATCCTGAT GGACCGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC CGTCTCCTCC GTCTAAAGAA CGGCCTTCGC CTCTGCTTTC AGAGCTTCCT GGAGGTGTCG GCCCTGCCAG CTCCCTGCCC TCCAGGGCGA TGGCGCAGCG CCGAGGAGCT GGTGCTGCTC GCCCCAGCCA GGCCCTGCAG TCTACCAGGG GCTCCTGCAG ACACACTOCA GCTGGACGTC TGGGAATGGC CCCTGCCCTG INFORMATION FOR SEQ ID Wi SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single If I WO 98/17810 394 PCT[US97/20037 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

GGAGGGGTCC

CGCCACCTTG

CTCAAGTCTT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

GTGGTTCTGG

TGGTTGCTAG

CGCAGCCCAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

CGGCGGCTCC

CCATCTGCAG

ACCATTGGGC

GAGAAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTAATAA

ATTATACATC!

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GAACAACAGT

AACATGGCTT

AGCTTCCTGG

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCI'GCCAC

AATTCCGGGA

ACGTAGAGGG

CTGCTTTCCA

AGGTGTCGTA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCC!CTGCA

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GCGCCGGGCA

CCGCGTTCTA

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

INFORMATION FOR SEQ ID NO:36: SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: ATGGCTAACT GCTCTATAAT CCTTTGCTGG ACCCGAACAA CTTCGACTTC CAAACCTGGA GGTATTGAGG CAATTCTTCG TCTCGACATC CAATCATCAT TTCTATCTGG TTACCCTTGA TCCCCGGGTG AACCGTCTGG TCTCATAAAT CTCCAAACAT GCTAGCCATC TGCAGAGCTT COCACACCAT TGGGCCCTGC CAAGTGAGAA AGATCCAGGG AAGCTGTGCC ACCCCGAGGA CCCCTGAGCT CCTGCCCCAG AGCGGCCTTT TCCTCTACCA GGTCCCACCT TGGACACACT CAGATGGAAG AACTGGGAAT TTCGCCTA.AT AA

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GGCTTCTGCT

CCTGGAGGTG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC!

GACTGGCAAG

GAACAACAGT

ACTATCAACC

TTCCAGCGCC

TCGTACCGCG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

ACTTAAAGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTC!CGGGA

ACGTAGAGGG

CGTCTCCTCC

GGGCAGGAGG

TTCTACGCCA

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

ACCACCTGCA

GGACCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGTCCTGGTT

CCTTGCGCAG

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

INFORMATION FOR SEQ ID NO:37: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGGCTAACT

CCGCTGCTGG

CTTCGTCGTC

GCAATTGAGA

ACGCGACATC

TTCTATCTGA

TCCCCGGGTG

TCTCATAAAT

CAGCGCCGGG

TACCGCGTTC

CTGCTCAAGT

AAGCTGTGTG

CTGGGCATCC

TGCTTGAGCC

GGGATATCCC

GCTCTAACAT

ACTTCAACAA

CAAACCTCGA

GCATTCTTAA

CAATCCATAT

AAACCTTGGA

AACCGTCTGG

CTCCAAACAT

CAGGAGGGGT

TACGCCACCT

CTTTAGAGCA

CCACCTACAA

CCTGGGCTCC

AACTCCATAG

CCGAGTTGGG

GATCGATGAA

CCTCA.ATGGT

GGCATTCAAC

AAATCTCCTG

CAAGGACGGT

GAACGCGCAG

TCCAATCTCT

GGCTACCCAG

CCTGGTTGCT

TGCGCAGCCC

AGTGAGAAAG

GCTGTGCCAC

CCTGAGCTCC

CGGCCTTTTC

TCCCACCTTG

ATCATCACCC

GAAGACCAAG

CGTGCTGTCA

CCATGTCTGC!

GACTGGAATG

GCTCAACAGT

ACTATCAACC

GGTGCCATGC!

AGCCATCTGC

TCTGGCGGCT

ATCCAGGGCG

CCCGAGGAGC

TGCCCCAGCC

CTCTACCAGG

GACACACTGC

ACCTGAAGCA

ATATCCTAAT

AGTCTCTGCA

CGCTAGCCAC

AATTCCGTCG

ACGTAGAGGG

CGTCTCCTCC

CGGCCTTCGC

AGAGCTTCCT

CTGGCGGCTC

ATGGCGCAGC

TGGTGCTGCT

AGGCCCTGCA

GGCTCCTGCA

AGCTGGACGT

GCCACCGCTG

GGACAATAAC

GAATGCATCA

GGCCGCACCC

TAAACTGACC

CGGTGGAGGC

GTCTAAAGAA

CTCTGCTTTC

GGAGGTGTCG

TCAGAGCTTC

GCTCCAGGAG

CGGACACTCT

GCTGGCAGGC

GGCCCTGGAA

CGCCGACTTT

Wvy IN /IlIoIu 3.55 CIU GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA

TAA

S97/20037 INFORMATION FOR SEQ ID NO:38: SEQUENCE CHARACTERISTICS: LENGTH: 972 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: ATGGCTAACT GCTCTAACAT CCGCTGCTGG ACTTCAACAA CTTCGTCGTC CAAACCTCGA GCAATTGAGA GCATTCTTAA ACGCGACATC CAATCATCAT TTCTATCTGA AAACCTTGGA TCCCCGGGTG AACCGTCTGG TCTCATAAAT CTCCAAACAT CAGCGCCGGG CAGGAGGGGT TACCGCGTTC TACGCCACCT CAGAGCTTCC TGCTCAAGTC CTCCAGGAGA AGCTGTGTGC GGACACTCTC TGGGCATCCC CTGGCAGGCT GCTTGAGCCA GCCCTGGAAG GGATATCCCC GCCGAC!TTTG CCACCACCAT CAGCCCTAAT AA GATCGATGAA ATCATCACCC

CCTCAATGGT

GGCATTCAAC

AA.ATCTCCTG

CCGTGACGGT

GAACGCGCAG

TCCAATCTCT

GGCTACCCAG

CCTGGTTGCT

TGCGCAGCCC

TTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GAAGACCAAG

CGTGCTGTCA

ACCTGAAGCA GCCACCGCTG ATATCCTGAT GGAAA.ATAAC AGTCTCTGCA GAATGCATCA CCATGTCTGC CCCTGGCCAC GACTGGAATG AATTCCGTCG GCTCAACAGT ACGTAGAGGG ACTATCAACC CGTCTCCTCC GGTGCCATGC CGGCCTTCGC AGCCATCTGC AGAGCTTCCT ACACCATTGG GCCCTGCCAG GTGAGAAAGA TCCAGGGCGA CTGTGCCACC CCGAGGAGCT CTGAGCTCCT GCCCCAGCCA GGCCTTTTCC TCTACCAGGG CCCACCTTGG ACACACTGCA ATGGAAGAAC TGGGAATGGC

GGCCGCACCC

TAAACTGACC

CGGTGGAGGC

GTCTAAAGA.A

CTCTGCTTTC

GGAGGTGTCG

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

INFORMATION FOR SEQ ID NO:39: SEQUENCE CHARACTERISTICS: LENGTH: 963 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ATGGCTAACT

CCGCTGCTGG

CTTCGTCGTC

GCAATTGAGA

ACGCGACATC

TTCTATCTGA

TC!CCCGGGTG

TCTCATAAAT

CAGCGCCGGG

TACCGCGTTC

CTGCTCAAGT

AAGCTGTGTG

CTGGGCATCC

TGCTTGAGCC

GGGATATCCC

GCCACCACCA

TAA

GCTCTAACAT GATCGATGAA ACTTCAACAA CCTCAATGGT CAAACCTCGA GGCATTCA.AC GCATTCTTAA AAATCTCCTG CAATCATCAT CCGTGACGGT AAACCTTGGA GAACGCGCAG AACCGTCTGG TCCAATCTCT CTCCAAACAT GGCTACCCAG CAGGAGGGGT CCTGGTTGCT TACGCCACCT TGCGCAGCCC CTTTAGAGCA AGTGAGAAAG CCACCTACAA GCTGTGCCAC CCTGGGCTCC CCTGAGCTCC AACTCCATAG CGGCCTTTTC CCGAGTTGGG TCCCACCTTG TCTGGCAGCA GATGGAAGAA

ATCATCACCC

GAAGACCAAG

CGTGCTGTCA

CCATGTCTGC

GACTGGAATG

GCTCAACAGT

ACTATCAACC

GGTGCCATGC

AGCCATCTGC

TCTGGCGGCT

ATCCAGGGCG

CCCGAGGAGC

TGCCCCAGCC

CTCTACCAGG

GACACACTGC

CTGGGA.ATGG

ACCTGAAGCA

ATATCCTGAT

AGTCTCTGCA

CCCTGGCCAC

AATTCCGTCG

ACGTAGAGGG

CGTCTCCTCC

CGGCCTTCGC

AGAGCTTCCT

CTGGCGGCTC

ATGGCGCAGC

TGGTGCTGCT

AGGCCCTGCA

GGCTCCTGCA

AGCTGGACGT

CCCCTGCCCT

GCCACCGCTG

GGAAAATAAC

GAATGCATCA

GGCCGCACCC

TAAACTGACC

CGGTGGAGGC

GTCTAAAGAA

CTCTGCTTTC

GGAGGTGTCG

TCAGAGCTTC

GCTCCAGGAG

CGGACACTCT

GCTGGCAGGC

GGCCCTGGAA

CGCCGACTTT

GCAGCCCTAA

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 970 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATGAA TTCCGTCGTA AACTGACCTT WO 98/17810 WO 9817810PCT/UJS97/20037 CTATCTGAAA ACCTTGGAGA ACGCGCAGGC CCCGGGTGA.A CCGTCTGGTC CAATCTCTAC TCATAAATCT CCAAACATGG CTACCCAGGG GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCGCGTTCTA CGCCACCTTG CGCAGCCCAC GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT CCAGGAGAAG CTGTGTGCCA CCTACALAGCT ACACTCTCTG GGCATCCCCT GGGCTCCCCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CGACTTTGCC ACCACCATCT GGCAGCAGAT

GCCCTAATAA

TCAACAGTAC GTAGAGGGCG TATCAACCCG TCTCCTCCGT TGCCATGCCG GCCTTCGCCT CCATCTGCAG AGCTTCCTGG ACCATTGGGC CCTGCCAGCT GAGAAAGATC CAGGGCGATG GTGCCACCCC GAGGAGCTGG GAGCTCCTGC CCCAGCCAGG CCTTTTCCTC TACCAGGGGC CACCTTGGAC ACACTGCAGC GGAAGAACTG GGAATGGCCC

GTGGAGGCTC

CTAAAGAATC

CTGCTTTCCA

AGGTGTCGTA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGC.A

INFORMATION FOR SEQ ID NO:41: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTTAGCT

GGAGCAGTGA

TGCCTCTCAT

CAGAGCCTCC

AA±GCCATCT

GTAGGAGGGT

CCTGCTTGTG

AGACTGAGCC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGA

TGGGAGAATG

CCCTTCTGCT

CCCTCCTGGG

TTGGAACCCA

TCCTGAGCTT

CCACCCTCTG

ACCTCCGAGT

AGTGCCCA

CGATGAAATT

CAATGACGAA

CTTCGTA-AGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

.AATCTCTACT

GGTTCACCCT

GAAAACCCAG

GGAGGGAGTG

GCAGCTTTCT

GCTTCCTCCA

CCAACACCTG

CGTCAGGGAA

CCTCAGTAAA

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TTGCCTACAC

ATGGAGGAGA

ATGGCAGCAC

GGACAGGTCC

CAGGGCAGGA

CTCCGAGGAA

TTCGGCGGCA

CTGCTTCGTG

TAAAGAGACC

TCCTGATGGA.

ACTTAGAAAA

CTGCCACGGC

TCC!GGGAAAA

TAGAGGGCGG

CTCCTCCGTC

CTGTCCTGCT

CCAAGGCACA

GGGGACAACT

GTCTCCTCCT

CCACAGCTCA

AGGTGCGTTT

ACATGGCGTC

ACTCCCATGT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCCTGCTGTG

GGACATTCTG

GGGACCCACT

TGGGGCCCTG

CAAGGATCCC

CCTGATGCTT

TCCCGCTCCG

CCTTCACAGC

INFORMATION FOR SEQ ID NO:42: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC!

GGAGAATGGA

CTTCTGCTGG

CTCCTGGGGC

GGAACCCAGC

CTGAGCTTCC

ACCCTCTGCG

CTCCGAGTCC

TGCCCAGAGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGTT

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCACA

AACACCTGCT

TCAGGGAATT

TCAGTAAACT

TTCACCCT

CGATGAAATT

CAATGACGAA

CTTCGTA.AGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGA.

AATCTCTACT

GCCTACACCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAAAG

CGGCGGCAAC

GCTTCGTGAC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCCTGCTGC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

ATGGCGTCTC

TCCCATGTCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

CTGCTGTGGA.

ACATTCTGGG

GACCCACTTG

GGGCCCTGCA

AGGATCCCAA

TGATGCTTGT

CCGCTCCGCC

TTCACAGCAG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTTTAGCTTG

AGCAGTGACC

CCTCTCATCC

GAGCCTCCTT

TGCCATCTTC

AGGAGGGTCC

TGCTTGTGAC

ACTGAGCCAG

INFORMATION FOR SEQ ID NO:43: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCTIUJS97/20037 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC! CGTCTGGTCC CATAAATCTC CAAACATGGT ACCCAGATGG AGGAGACCAA GGAGTGATGG CAGCACGGGG CTTTCTGGA.C AGGTCCGTCT CCTCCACAGG GCAGGACCAC CACCTGCTCC GAGGAAAGGT AGGGAATTCG GCGGCAACAT AGTAAACTGC TTCGTGACTC CACCCTTTGC CTACACCT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCTGCTGCCT

GOCACAGGAC

ACAACTGGGA

CCTCCTTGGG

AGCTCACAAG

GCGTTTCCTG

GGCGTCTCC

CCATGTCCTT

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GCTGTGGACT

ATTCTGGGAG

CCCACTTGCC

GCCCTGCAGA

GATCCCAATG

ATGCTTGTAG

GCTCCGCCTG

CACAGCAGAC

TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TTAGCTTGGG AGAATGGAAA CAGTGACCCT TCTGCTGGAG TCTCATCCCT CCTGGGGCA.G GCCTCCTTGG AACCCAGCTT CCATCTTCCT GAGCTTCCAA GAGGGTCCAC CCTCTGCGTC CTTGTGACCT CCGAGTCCTC TGAGCCAGTG CCCAGAGGTT INFORMATION FOR SEQ ID NO:44: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

AGGACCACAG,

GGAAAGGTGC

GGCAACATGG

CGTGACTCCC

ACACCTGTCC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTA.A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

CACAGGACAT

AACTGGGACC

TCCTTGGGGC

CTCACAAGGA

GTTTCCTGAT

CGTCTCCCGC

ATGTCCTTCA

TGCTGCCT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TGTGGACTTT

TCTGGGAGCA

CACTTGCCTC

CCTGCAGAGC

TCCCAATGCC

GCTTGTAGGA

TCCGCCTGCT

CAGCAGACTG

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

AGCTTGGGAG

GTGACCCTTC

TCATCCCTCC

CTCCTTGGAA

ATCTTCCTGA

GGGTCCACCC

TGTGACCTCC

AGCCAGTGCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

C!TGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

C!TCCTCCGTC

AATGGAAAAC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCAGATGGAG

TGCTGGAGGG AGTGATGGCA TGGGGCAGCT TTCTGGAC!AG CCCAGCTTCC TCCACAGGGC GCTTCC!AACA CCTGCTCCGA TCTGCGTCAG GGAATTCGGC GAGTCCTCAG TAAAC*TGCTT CAGAGGTTCA CCCTTTGCCT INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

ATGGCGTCTC

TCCCATGTCC

GTCCTGCTGC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGA

ACATTCTGGG

GACCCACTTG

GGGCCCTGCA

AGGATCCCAA

TGATGCTTGT

CCGCTCCGCC

TTCACAGCAG

CTGCTGTG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTTTAGCTTG

AGCAGTGACC

CCTCTCATCC

GAGCCTCCTT

TGCCATCTTC

AGGAGGGTCC

TGCTTGTGAC

ACTGAGCCAG

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GGAGAATGGA

CTTCTGCTGG

CTCCTGGGGC

GGAACCCAGC

CTGAGCTTCC

ACCCTCTGCG

CTCCGAGTCC

TGCCCAGAGG

TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT C!TGCCACGGC CGCACCCTCT TCCGGGAAAA -ACTGACGTTC

TAGAGGGCGG

C!TCCTC!CGTC

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCACA

AACACCTGCT

TCAGGGAATT

TCAGTAAACT

TTCACCCTTT

TGGAGGCTCC

TAAAGAATCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAAAG

CGGCGGCAAC

GCTTCGTGAC

GCCTACACCT

INFORM4ATION FOR SEQ ID NO:46: WO 98/17810 WO 9817810PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 907 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCGGTTAC CCTTGAGCAA CGGGGAACCG TCTGGTCCAA TAAACTCCAA ACATGGGAGA CTGGAGCAGT GACCCTTCTG CTTGCTCTCA TCCCTCCTGG GCAGGCCTCC TTGGAACCCA AATGCATCTT CCTGAGCTTC TAGGGGGTCC ACCCTCTGCG TGCTGTGACC TCCGAGTCCT CTGACCAGTG CCCAGAGGTT

TTAGTTG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

GCGCAGGAAC

TCTCTACTAT

ATGGAAAACC

CTGGAGGGAG

GGCAGCTTTC

GCTTCCTCCA

CAACACCTGC

TCAGGGAATT

CAGTAAACTG

CACCCTTTGC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

AACAGTACGT

CAACCCGTCT

CAGATGGAGG

TGATGGCAGC

TGGACAGGTC

CAGGGCAGGA

TCCGAGGAAA

CGGCGGCAAC

CTTCGTGACT

CTACACCTGT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

AGAGGGCGGT

CCTCCGTCTA

AGACCAAGGC

ACGGGGACAA

CGTCTCCTCC

CCACAGCTCA

GGTGCGTTTC

ATGGCGTCTC

CCCATGTCCT

CCTGCTGCCT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

GGAGGCTCCC

AAGAATCTCA

ACAGGACATT

CTGGGACCCA

TTGGGGCCCT

CAAGGATCCC

CTGATGCTTG

CCGCTCCGCC

TCACAGCAGA

GCTGTGGACT

INFORMATION FOR SEQ ID NO:47: SEQUENCE CHARACTERISTICS: LENGTH: 917 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC!

CATAAATCTC

CAGGTCCGTC

GGCAGGACCA

CGAGGAAAGG

GGCGGCAACA.

CTTCGTGACT

CCTACACCTG

GAGGAGACCA

GCAGCACGGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTA.A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

TCCTCCTTGG

CAGCTCACAA

TGCGTTTCCT

TGGCGTCTCC

CCCATGTCCT

TCCTGCTGCC

AGGCACAGGA

GACAACT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

ACCCACTTGC

GGCCCTGCAG

GGATCCCAAT

GATGCTTGTA

CGCTCCGCCT

TCACAGCAGA

TGCTGTGGAC!

CATTCTGGGA

ATACATCACT

GACGTCTCTA

GCTGTCAAGA.

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTCATCCC

AGCCTCCTTG

GCCATCTTCC

GGAGGGTCCA

GCTTGTGACC

CTGAGCCAGT

TTTAGCTTGG

GCAGTGACCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGC!CACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCC!TCCGTC

TCCTGGGGCA

GAACCCAGCT

TGAGCTTCCA

CCCTCTGCGT

TCCGAGTCCT

GCCCAGAGGT

GAGAATGGAA

TTCTGCTGGA

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTTTCTGGA

TCCTCCACAG

ACACCTGCTC

CAGGGAATTC

CAGTAAACTG

TCACCCTTTG

AACCCAGATG

GGGAGTGATG

INFORMATION FOR SEQ ID NO:48: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRAN~DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GATCCCAATG

ATGCTTGTAG

GCTCCGCCTG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

CCATCTTCCT

GAGGGTCCAC

CTTGTGACCT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

AACCCAGCTT

GAGCTTCCAA

CCTCTGCGTC

CCGAGTCCTC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CCTCCACAGG

CACCTGCTCC

AGGGAATTCG

AGTAAACTGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCAGGACCAC

GAGGAAAGGT

GCGGCAACAT

TTCGTGACTC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

AGCTCACAAG

GCGTTTCCTG

GGCGTCTCCC

CCATGTCCTT

ft

WO'

CACACCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG, GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTT INFORMATION FOR SEQ ID NO:49: SEQUENCE CHARACTERISTICS.

LENGTH: 918 base pairs TYPE: nucleic acid STRAINDEDNES9: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: JS97/20037 720 780 840 900 918

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AGCTTCCAAC

CTCTGCGTCA

CGAGTCCTCA

CCAGAGGTTC

GAATGGAAAA

CTGCTGGAGG

CTGGGGCAGC

ACCCAGCTTC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

ACCTGCTCCG

GGGAATTCGG

GTAAACTGCT

ACCCTTTGCC

CCCAGATGGA

GAGTGATGGC

TTTCTGGACA

CTCCACAG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CAGGACCACA

AGGAAAGGTG

CGGCAACATG

TCGTGACTCC

TACACCTGTC

GGAGACCAAG

AGCACGGGGA

GGTCCGTCTC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GCTCACAAGG

CGTTTCCTGA.

GCGTCTCCCG

CATGTCCTTC

CTGCTGCCTG,

GCACAGGACA

CAACTGGGAC

C'1'CPT('cC(,

TAAAGAGACC

TCCTGATGGA

ACTTAGAAA.A

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

ATCCCAATGC

TGCTTGTAGG

CTCCGCCTGC

ACAGCAGACT

CTGTGGACTT

TTCTGGGAGC

CCACTTGCCT

CCCTGCAGAG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CATCTTCCTG

AGGGTCCACC

TTGTGACCTC

GAGCCAGTGC

TAGCTTGGGA

AGTGACCCTT

CTCATCCCTC

CCTCCTTGGA

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA-AC

CATAAATCTC

CTGCTCCGAG

GAATTCGGCG

AAACTGCTTC

CCTTTGCCTA.

CAGATGGAGG

GTGATGGCAG

TCTGGACAGG

CCACAGGGCA

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GAAAGGTGCG

GCAACATGGC

GTGACTCCCA

CACCTGTCCT

AGACCAAGGC

CACGGGGACA

TCCGTCTCCT

GGACCACA

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TCACAAGGAT

TTTCCTGATG

GTCTCCCGCT

TGTCCTTCAC

GCTGCCTGCT

ACAGGACATT

ACTGGGACCC

CCTTGGGGCC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CCCAATGCCA

CTTGTAGGAG

CCGCCTGCTT

AGCAGACTGA

GTGGACTTTA

CTGGGAGCAG

ACTTGCCTCT

CTGCAGAGCC!

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCTTCCTGAG

GGTCCACCCT

GTGACCTCCG

GCCAGTGCCC

GCTTGGGAGA

TGACCCTTCT

CATCCCTCCT

TCCTTGGAAC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTTCCAACAC

CTGCGTCAGG

AGTCCTCAGT

AGAGGTTCAC

ATGGAAAACC

GCTGGAGGGA

GGGGCAGCTT

CCAGCTTCCT

INFORMATION FOR SEQ ID NO:51: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT WO 98/17810

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GGAAAGGTGC

GGCAACATGG

CGTGACTCCC

ACACCTGTCC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

AGGACCACAG

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGA

GTTTCCTGAT

CGTCTCCCGC

ATGTCCTTCA

TGCTGCCTGC

CACAGGACAT

AACTGGGACC

TCCTTGGGGC

CTCACAAG

4v GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT TCCCAATGCC ATCTTCCTGA GCTTGTAGGA GGGTCCACCC TCCGCCTGCT TGTGACCTCC CAGCAGACTG AGCCAGTGCC TGTGGACTTT AGCTTGGGAG TCTGGGAGCA GTGACCCTTC CACTTGCCTC TCATCCCTCC CCTGCAGAGC CTCCTTGGAA

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCTTCCAACA

TCTGCGTCAG

GAGTCCTCAG

CAGAGGTTCA

AATGGAAAAC

TGCTGGAGGG

TGGGGCAGCT

CCCAGCTTCC

PCTIUJS97/20037 ACTGACGTTC 300 TGGAGGCTCC 360 TAAAGAATCT 420 CCTGCTCCGA 480 GGAATTCGGC 540 TAAACTGCTT 600 CCCTTTGCCT 660 CCAGATGGAG 720 AGTGATGGCA 780 TTCTGGACAG 840 TCCACAGGGC 900 INFORMATION FOR SEQ ID NO:52: SEQUENCE CHARACTERISTICS: LENGTH: 918 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGTTTCCTGA.

GCGTCTCCCG

CATGTCCTTC

CTGCTGCCTG

GCACAGGACA

CAACTGGGAC

CTCCTTGGGG

GCTCACAAGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGCTTGTAGG

CTCCGCCTGC

ACAGCAGACT

CTGTGGACTT

TTCTGGGAGC

CCACTTGCCT

CCCTGCAGAG

ATCCCAAT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CATCTTCCTG

AGGGTCCACC

TTGTGACCTC

GAGCCAGTGC

TAGCTTGGGA

AGTGACCCTT

CTCATCCCTC

CCTCCTTGGA

ATACATCACT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA CCGAAACCTT GCTGTCAAGA ACTTAGAAAA TGCATCAGGT TGTCTGCC!CT CTGCCACGGC CGCACCCTCT TGGCAAGAAT TCCGGGAAAA ACTGACGTTC CAACAGTACG TAGAGGGCCG TGGAGGCTCC ATCAACCCGT CTCCTCCGTC TAAAGAATCT AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CTCTGCGTCA GGGAATTCGG CGGCAACATG CGAGTCCTCA GTAAACTGCT TCGTGACTCC CCAGAGGTTC ACCCTTTGCC TACACCTGTC GAATGGAAAA CCCAGATGGA GGAGACCAAG CTGCTGGAGG GAGTGATGGC AGCACGGGGA CTGGGGCAGC TTTCTGGACA GGTCCGTCTC ACCCAGCTTC CTCCACAGGG CAGGACCACA INFORMATION FOR SEQ ID NO:53: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTTAGCT

GGAGCAGTGA

TGCCTCTCAT

CAGAGCCTCC

AATGCCATCT

GTAGGAGGGT

GCTTGTGACC

CTGAGCCAGT

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGA

TGGGAGAATG

CCCTTCTGCT

CCCTCCTGGG

TTGGAACCCA

TCCTGAGCTT

CCACCCTCTG

TCCGAGTCCT

GCCCA

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

GGTTCACCCT

GAAAACCCAG,

GGAGGGAGTG

GCAGCTTTCT

GCTTCCTCCA

CCAACACCTG

CGTCAGGGAA

CAGTAAACTG

ATACATCACT TAAAGAGACC GACGTCTCTA TCCTGATGGA GCTGTCA.AGA. ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC TTGCCTACAC CTGTCCTGCT ATGGAGGAGA CCAAGGCACA ATGGCAGCAC GGGGACAACT GGACAGGTCC GTCTCCTCCT CAGGGCAGGA CCACAGCTCA CTCCGAGGAA AGGTGCGTTT TTCGGCAACA TGGCGTCTCC CTTCGTGACT CCCATGTCCT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCCTGCTGTG

GGACATTCTG

GGGACCCACT

TGGGGCCCTG

CAAGGATCCC

CCTGATGCTT

CGCTCCGCCT

TCACAGCAGA

INFORMATION FOR SEQ ID N0:54: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GGAGAATGGA

CTTCTGCTGG

CTCCTGGGGC

GGAACCCAGC

CTGAGCTTCC

ACCCTCTGCG

CGAGTCCTCA

CCAGAGGTTC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGTT

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCACA

AACACCTGCT

TCAGGGAATT

GTAAACTGCT

ACOCT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

GCCTACACCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAAAG

CGGCAACATG

TCGTGACTCC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCCTGCTGC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

GCGTCTCCCG

CATGTCCTTC

TAA.AGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT CTGCTGTGGA CTTTAGCTTG ACATTCTGGG AGCAGTGACC GACCCACTTG CCTCTCATCC GGGCCCTGCA GAGCCTCCTT AGGATCCCAA TGCCATCTTC TGATGCTTGT AGGAGGGTCC CTCCGCCTGC TTGTGACCTC ACAGCAGACT GAGCCAGTGC INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCTAACTGCT CTATA.ATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGT ACCCAGATGG AGGAGACCAA GGAGTGATGG CAGCACGGGG CTTTCTGGAC AGGTCCGTCT CCTCCACAGG GCAGGACCAC CACCTGCTCC GAGGAAAGGT AGGGAATTCG GCAACATGGC AAACTGCTTC GTGACTCCCA CCTTTGCCTA CACCT CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CCTGCTGCCT GCTGTGGACT GGCACAGGAC ATTCTGGGAG ACAACTGGGA CCCACTTGCC CCTCCTTGGG GCCCTGCAGA AGCTCACAAG GATCCCAATG GCGTTTCCTG ATGCTTGTAG GTCTCCCGCT CCGCCTGCTT TGTCCTTCAC AGCAGACTGA TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TTAGCTTGGG AGAATGGAAA CAGTGACCCT TCTGCTGGAG TCTCATCCCT CCTGGGGCAG GCCTCCTTGG AACCCAGCTT CCATCTTCCT GAGCTTCCAA GAGGGTCCAC CCTCTGCGTC GTGACCTCCG AGTCCTCAGT GCCAGTGCCC AGAGGTTCAC INFORMATION FOR SEQ ID NO:56: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCA-A

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

AGGACCACAG

GGAAAGGTGC

AACATGGCGT

GACTCCCATG

CCTGTCCTGC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAAR

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

CACAGGACAT

AACTGGGACC

TCCTTGGGGC

CTCACAAGGA

GTTTCCTGAT

CTCCCGCTCC

TCCTTCACAG

TGCCT

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT TGTGGACTTT AGCTTGGGAG TCTGGGAGCA GTGACCCTTC CACTTGCCTC TCATCCCTCC CCTGCAGAGC CTCCTTGGAA TCCCAATGCC ATCTTCCTGA GCTTGTAGGA GGGTCCACCC GCCTGCTTGT GACCTCCGAG CAGACTGAGC CAGTGCCCAG TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT AATGGAAAAC CCAGATGGAG TGCTGGAGGG AGTGATGGCA TGGGGCAGCT TTCTGGACAG CCCAGCTTCC TCCACAGGGC GCTTCCAACA CCTGCTCCGA TCTGCGTCAG GGAATTCGGC TCCTCAGTAA ACTGCTTCGT AGGTTCACCC TTTGCCTACA INFORMATION FOR SEQ ID NO:57: WO 98/17810 WO 9817810PCT[US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57;

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

GCGTCTCCCG

CATGTCCTTC

CTGCTGCCTG

CTATAATGAT CGATGAAATT CGAACAACCT CAATGACGAA ACCTGGAGAG CTTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CAAACATGGA CTTTAGCTTG ACATTCTGGG AGCAGTGACC GACCCACTTG CCTCTCATCC GGGCCCTGCA GAGCCTCCTT AGGATCCCAA TGCCATCTTC TGATGCTTGT AGGAGGGTCC CTCCGCCTGC TTGTGACCTC ACAGCAGACT GAGCCAGTGC

CTGTG

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GGAGAATGGA

CTTCTGCTGG

CTCCTGGGGC

GGAACCCAGC

CTGAGCTTCC

ACCCTCTGCG

CGAGTCCTC.A

CCAGAGGTTC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCACA

AACACCTGCT

TCAGGGAATT

GTAXACTGCT

ACCCTTTGCC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAAAG

CGGCAACATG

TCGTGACTCC

TACACCTGTC

INFORMATION FOR SEQ ID NO:58: Wi SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATTCTGGGAG

CCCACTTGCC

GCCCTGCAGA.

GATCCCAATG

ATGCTTGTAG

CCGCCTGCTT

AGCAGACTGA

GTGGACTTTA

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

CAGTGACCCT

TCTCATCCCT

GCCTCCTTGG

CCATCTTCCT

GAGGGTCCAC

GTGACCTCCG

GCCAGTGCCC

GCTTG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG,

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

AGAATGGAAA

TCTGCTGGAG

CCTGGGGCAG

AACCCAGCTT

GAGCTTCCAA

CCTCTGCGTC

AGTCCTCAGT

AGAGGTTCAC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

ACCCAGATGG

GGAGTGATGG

CTTTCTGGAC

CCTCCACAGG

CACCTGCTCC

AGGGAATTCG

AAACTGCTTC

CCTTTGCCT.A

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AGGAGACCAA

CAGCACGGGG

AGGTCCGTCT

GCAGGACCAC

GAGGAAAGGT

GCAACATGGC

GTGACTCCCA

CACCTGTCCT

ACCTGCACCT

CCGA.A.ACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGCACAGGAC

ACAACTGGGA

CCTCCTTGGG

AGCTCACAAG

GCGTTTCCTG

GTCTCCCGCT

TGTCCTTCAC

GCTGCCTGCT

INFORMATION FOR SEQ ID NO:59: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGG CAGGTCCGTC TCCTCCTTGG GGCAGGACCA CAGCTCACAA CGAGGAAAGG TGCGTTTCCT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

ACCCACTTGC

GGCCCTGCAG

GGATCCCAAT

GATGCTTGTA

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTCATCCC

AGCCTCCTTG

GCCATCTTCC

GGAGGGTCCA

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGq,

CTCCTCCGTC

TCCTGGGGCA

GAACCCAGCT

TGAGCTTCCA

CCCTCTGCGT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTTTCTGGA

TCCTCCACAG

ACACCTGCTC

CAGGGAATTC

WO 98/17810 43 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG GCACGGGGAC AACTG PCTIUS97/20037 TAAACTGCTT 720 CCCTTTGCCT 780 CCAGATGGAG 840 AGTGATGGCA 900 915 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGG GATCCCAATG CCATCTTCCT ATGCTTGTAG GAGGGTCCAC CCGCCTGCTT GTGACCTCCG AGCAGACTGA GCCAGTGCCC GTGGACTTTA GCTTGGGAGA CTGGGAGCAG TGACCCTTCT ACTTGCCTCT CATCCCTCCT CTGCAGAGCC TCCTT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

AACCCAGCTT

GAGCTTCCAA

CCTCTGCGTC

AGTCCTCAGT

AGAGGTTCAC

ATGGAAAACC

GCTGGAGGGA

GGGGCAGCTT

ATACATCACT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA CCGAAACCTT GCTGTCAAGA ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC CGCACCCTCT TGGCAAGAAT TCCGGGAAAA ACTGACGTTC CAACAGTACG TAGAGGGCGG TGGAGGCTCC ATCAACCCGT CTCCTCCGTC TAAAGAATCT CCTCCACAGG GCAGGACCAC AGCTCACAAG CACCTGCTCC GAGGAAAGGT GCGTTTCCTG AGGGAATTCG GCAACATGGC GTCTCCCGCT AAACTGCTTC GTGACTCCCA TGTCCTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT CAGATGGAGG AGACCAAGGC ACAGGACATT GTGATGGCAG CACGGGGACA ACTGGGACCC TCTGGACAGG TCCGTCTCCT CCTTGGGGCC INFORMATION FOR SEQ ID NO:61: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6l:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AGCTTCCAAC

CTCTGCGTCA

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCt

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

ACCTGCTCCG

GGGAATTCGG

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CAGGACCACA

AGGAAAGGTG

CAACATGGCG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

ATACATCACT TAAAGAGACC GACGTCTCTA TCCTGATGGA GCTGTCAAGA ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC GCTCACAAGG ATCCCAATGC CGTTTCCTGA TGCTTGTAGG TCTCCCGCTC CGCCTGCTTG GTCCTTCACA GCAGACTGAG CTGCCTGCTG TGGACTTTAG CAGGACATTC TGGGAGCAGT CTGGGACCCA CTTGCCTCTC CTTGGGGCCC TGCAGAGCCT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CATCTTCCTG

AGGGTCCACC

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

INFORMATION FOR SEQ ID NO:62: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT WO 98/17810

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGCTCCGAG

GAATTCGGCA

CTGCTTCGTG

TTGCCTACAC

ATGGAGGAGA

ATGGCAGCAC

GGACAGGTCC

CAGGGCAGGA

404

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GAAAGG'rGCG

ACATGGCGTC

ACTCCCATGT

CTGTCCTGCT

CCAAGGCACA

GGGGACAACT

GTCTCCTCCT

CCACA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TCACAAGGAT

TTTCCTGATG

TCCCGCTCCG

CCTTCACAGC

GCCTGCTGTG

GGACATTCTG

GGGACCCACT

TGGGGCCCTG

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CCCAATGCCA

CTTGTAGGAG

CCTGCTTGTG

AGACTGAGCC

GACTTTAGCT

GGAGCAGTGA

TGCCTCTCAT

CAGAGCCTCC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCTTC!CTGAG

GGTCCACCCT

ACCTCCGAGT

AGTGCCCAGA

TGGGAGAATG

CCCTTCTGCT

CCCTCCTGGG

TTGGAACCCA

PCTIUJS97/20037 ACTGACGTTC 300 TGGAGGCTCC 360 TAAAGAATCT 420 CTTCCAACAC 480 CTGCGTCAGG 540 CCTCAGTAAA 600 GGTTCACCCT 660 GAAAACCCAG 720 GGAGGGAGTG 780 GCAGCTTTCT 840 GCTTCCTCCA 900 915 INFORMATION FOR SEQ ID NO: 63: Wi SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CTATAATGAT CGATGAAATT CGAACAACCT CAATGACGAA ACCTGGAGAG CTTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGA GGAAAGGTGC GTTTCCTGAT AACATGGCGT CTCCCGCTCC GACTCCCATG TCCTTCACAG CCTGTCCTGC TGCCTGCTGT ACCAAGGCAC .AGGACATTCT CGGGGACAAC TGGGACCCAC CGTCTCCTCC TTGGGGCCCT ACCACAGCTC ACAAG

TCCCAATGCC

GCTTGTAGGA

GCCTGCTTGT

CAGACTGAGC

GGACTTTAGC

GGGAGCAGTG

TTGCCTCTC!A

GCAGAGCCTC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

ATCTTCCTGA

GGGTCCACCC

GACCTCCGAG

CAGTGCCCAG

TTGGGAGAAT

ACCCTTCTGC

TCCCTCCTGG

CTTGGAACCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCTTCCAACA

TCTGC!GTCAG

TCCTCAGTAA

AGGTTCACCC

GGAAAACCCA

TGGAGGGAGT

GGCAGCTTTC

AGCTTCCTCC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCTCCGA

GGAATTCGGC

ACTGCTTCGT

TTTGCCTACA

GATGGAGGAG

GATGGCAGCA

TGGACAGGTC

ACAGGGCAGG

INFORMATION FOR SEQ ID NO:64: SEQUENCE CHARACTERISTICS: LENGTH: 915 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGTTTCCTGA

TCTCCCGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGCTTGTAGG

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAAT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CATCTTCCTG

AGGGTCCACC

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

AGCTTCCA\C

CTCTGCGTCA

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

ACCTGCTCCG

GGGAATTCGG

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

AGGAAAGGTG

CAACATGGCG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACAGCT

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATGACGAA GACTTCCAAA CCTGGAGAGC TTCGTAAGGG TGAGGCAATT CTTCGTAATC TCCAACCATG CATCCAATCA TCATCAAGGC AGGTGACTGG TGGTTACCCT TGAGCAAGCG CAGGAACAAC TAACCGTCTG, GTCCAATCTc TACTATCAAC TCTCCAAACA TGGAGGTTCA CCCTTTGCCT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GTGACCCTTC TGCTGGAGGG AGTGATGGCA TCATCCCTCC TGGGGCAGCT TTCTGGACAG CTCCTTGGAA. CCCAGCTTCC TCCACAGGGC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA.

GGGTCCACCC TCTGCGTCAG GGAATTCGGC CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AGCAGACTGA GCCAGTGCCC A

ATACATCACT

GACGTCTCTA

CTGTCAAGAA

TCTGCCCTCT

CAAGAATTCC

AGTACGTAGA

CCGTCTCCTC

ACACCTGTCC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

AGGACCACAG

GGAA.AGGTGC

GGCAACGGCG

AAACTGCTTC

TAAAGAGACC

TCCTGATGGA

CTTAGAAAAT

GCCACGGCCG

GGGAAAAACT

GGGCGGTGGA

CGTCTAAAGA

TGCTGCCTGC

CACAGGACAT

AACTGGGACC

TCCTTGGGGC.

CTCACAAGGA

GTTTCCTGAT

GCAACATGGC

GTGACTCCCA

ACCTGCACCT

CCGAAACCTT

GCATCAGGTA

CACCCTCTCG

GACGTTCTAT

GGCTCCCCGG

ATCTCATAAA

TGTGGACTTT

TCTGGGAGCA

CACTTGCCTC

CCTGCAGAGC

TCCCAATGCC

GCTTGTAGGA

GTCCCCAGCG

TGTCCTTCAC

INFORMATION FOR SEQ ID NO: 66: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GGAGAATGGA

CTTCTGCTGG

CTCCTGGGGC

GGAACCCAGC

CTGAGCTTCC

ACCCTCTGCG

GCTTGTGACC

CTGAGCCAGT

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGTT

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCACA

AACACCTGCT

TCAGGGAATT

TCCGAGTCCT

GCCCAGAGGT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

GCCTACACCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAAAG

CGGCGGCAAC

CAGTAAACTG

TCACCCT

ATACATCACT

GACGTCTCTA

GCTGTCAIIGA.

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCCTGCTGC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

GGCGGCAACA

CTTCGTOACT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

CTGCTGTGGA

ACATTCTGGG

GACCCACTTG

GGGCCCTGCA

AGGATCCCAAk

TGATGCTTGT

TGGCGTCCCC

CCCATGTCCT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTTTAGCTTG

AGCAGTGACC

CCTCTCATCC

GAGCCTCCTT

TGCCATCTTC

AGGAGGGTCC

AGCGCCGCCT

TCACAGCAGA

INFORMATION FOR SEQ ID NO: 67: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCCAGATGG

GGAGTGATGG

CTTTCTGGAC

CCTCCACAGG

CACCTGCTCC

AGGGAATTCG

CGAGTCCTCA

CCAGAGGTTC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCT'rCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC.

CAAACATGGT

AGGAGACCAA

CAGCACGGGG

AGGTCCGTCT

GCAGGACCAC

GAGGAAAGGT

GCGGCAACGG,

GTAAACTGCT

ACCCTTTGCC

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCTGCTGCCT

GGCACAGGAC

ACAACTGGGA

CCTCCTTGGG

AGCTCACAAG

GCGTTTCCTG

CGGCAACATG

TCGTGACTCC

TACACCT

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GCTGTGGACT

ATTCTGGGAG

CCCACTTGCC

GCCCTGCAGA

GATCCCAATG

ATGCTTGTAG

GCGTCCCCAG

CATGTCCTTC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TTAGCTTGGG

CAGTGACCCT

TCTCATCCCT

GCCTCCTTGG,

CCATCTTCCT

GAGGGTCCAC

CGCCGCCTGC

ACAGCAGACT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

AGAATGGAAA

TCTGCTGGAG

CCTGGGGCAG

AACCCAGCTT

GAGCTTCCAA

CCTCTGCGTC

TTGTGACCTC

GAGCCAGTGC

INFORMATION FOR SEQ ID NO:68: WO 98/17810 WO 9817810PCTIUS97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC GAGACCAAGG CACAGGACAT GCACGGGGAC AACTGGGACC GTCCGTCTCC TCCTTGGGGC AGGACCACAG CTCACAAGGA GGAAAGGTGC GTTTCCTGAT GGCAACGGCG GCAACATGGC AAACTGCTTC GTGACTCCCA CCTTTGCCTA CACCTGTCCT CGATGAAATT ATACATCACT C2\ATGjACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG

AATCTCTACT

TGTGGACTTT

TCTGGGAGCA

CACTTGCCTC

CCTGCAGAGC

TCCCAATGCC

GCTTGTAGGA

GTCCCCAGCG

TGTCCTTCAC

GCTGCCT

ATCAACCCGT

AGCTTGGGAG

GTGACCCTTC

TCATCCCTCC

CTCC!TTGGAA

ATCTTCCTGA

GGGTCCACCC

CCGCCTGCTT

AGCAGACTGA

TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGJ CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT AATGGAAAAC CCAGATGGAG TGCTGGAGGG AGTGATGGCA TGGGGCAGCT TTCTGGACAG CCCAGCTTCC TCCACAGGGC GCTTCCAACA CCTGCTCCGA TCTGCGTCAG GGAATTCGGC GTGACCTCCG AGTCCTCAGT GCCAGTGCCC AGAGGTTCAC INFORMATION FOR SEQ ID NO:69: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AAGGCACAGG

GGACAACTGG

CTCCTCCTTG

ACAGCTCACA

GTGCGTTTCC

GGCGGCAACA

CTTCGTGACT

CCTACACCTG

CTATAATGAT CGATGAAATT ATACATCACT CGAACAACCT CAATGACGAA GACGTCTCTA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT TCATCATCAA GGCAGGTGAC TGGCAAGAAT CCCTTGAGCA AGCGCAGGA-A CAACAGTACG CGTCTGGTCC AATCTCTACT ATCAACCCGT CAAACATGGA CTTTAGCTTG GGAGAATGGA ACATTCTGGG AGCAGTGACC CTTCTGCTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC GGGCCCTGCA GAGCCTCCTT GGAACCCAGC AGGATCCCAA TGCCATCTTC CTGAGCTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TGGCGTCCCC AGCGCCGCCT GCTTGTGACC CCCATGTCCT TCACAGCAGA CTGAGCCAGT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAACCCAGAT

AGGGAGTGAT

AGCTTTCTGG

TTCCTCCAC!A

AACACCTGCT

TCAGGGAATT

TCCGAGTCCT

GCCCAGAGGT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGGAGACC

GGCAGCACGG

ACAGGTCCGT

GGGCAGGACC

CCGAGGAA.AG

CGGCGGCAAC

CAGTAAACTG

TCACCCTTTG

TCCTGCTGCC

TGCTGTG

INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATTCTGGGAG

CCCACTTGCC

GCCCTGCAGA.

CTATAATGAT CGATGAAATT CGAACAACCT CAATGACGAA ACCTGGAGAG CTTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAp. GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CAAACATGGG AGAATGGAAA CAGTGACCCT TCTGCTGGAG TCTCATCCCT CCTGGGGCAG GCCTCCTTGG AACCCAGCTT

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

ACCCAGATGG

GGAGTGATGG

CTTTC!TGGAC

CCTCCACAGG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAA

TAGAGGGCGG

CTCCTCCGTC

AGGAGACCAA

CAGCACGGGG

AGGTCCGTCT

GCAGGACCAC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGCACAGGAC

ACAACTGGGA

CCTCCTTGGG

AGCTCACAAG

wu 0/ iu 1w4oq PCTII GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTC.A GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC

TACACCTGTC

CTGCTGCCTG CTGTGGACTT TAGCTTG INFORMATION FOR SEQ ID NO: 71: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: tingle TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: JS9120037 720 780 840 900 927

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC!

CATAAATCTC

CAGGTCCGTC

GGCAGGACCA

CGAGGAAAGG

GGCGGCAACG

AGTAAACTGC

CACCCTTTGC

ACCCAGATGG

GGAGTGATGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA~

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

TCCTCCTTGG

CAGCTCACAA

TGCGTTTCCT

GCGGCAACAT

TTCGTGACTC

CTACACCTGT

AGGAGACCAA

CAGCACGGGG

CGATGAAATT ATACATCACT TAAAGAGACC CAATGACGAA GACGTCTCTA TCCTGATGGA CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC GGCAGGTGAC TGGCAAGAAT

TCCGGGAAAA

AGCGCAGGAA CAACAGTACG TAGAGGGCGG AATCTCTACT ATCAACCCGT CTCCTCCGTC ACCCACTTGC CTCTCATCCC TCCTGGGGCA GGCCCTGCAG AGCCTCCTTG GAACCCAGCT GGATCCCAAT GCCATCTTCC

TGAGCTTCCA

GATGCTTGTA GGAGGGTCCA CCCTCTGCGT GGCGTCCCCA GCGCCGCCTG CTTGTGACCT CCATGTCCTT CACAGCAGAC

TGAGCCAGTG

CCTGCTGCCT GCTGTGGACT TTAGCTTGGG GGCACAGGAC ATTCTGGGAG CAGTGACCCT

ACAACTG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTTTCTGGA

TCCTCCACAG

ACACCTGCTC

CAGGGAATTC

CCGAGTCCTC

CCCAGAGGTT

AGAATGGAAA

TCTGCTGGAG

INFORMATION FOR SEQ ID NO: 72; SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GCTAACTGCT

TTGCTGGAC!C

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GATCCCA.ATG

ATGCTTGTAG

GCGTCCCCAG

CATGTCCTTC

CTGCTGCCTG

GCACAGGACA

CAACTGGGAC

CTCCTTGGGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGG

CCATCTTCCT

GAGGGTCCAC

CGCCGCCTGC

ACAGCAGACT

CTGTGGACTT

TTCTGGGAGC

CCACTTGCCT

CCCTGCAGAG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

AACCCAGCTT

GAGCTTCCAA

CCTCTGCGTC

TTGTGACCTC

GAGCCAGTGC

TAGCTTGGGA

AGTGACCCTT

CTCATCCCTC

CCTCCTT

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CCTCCACAGG

CACCTGCTCC

AGGGAATTCG

CGAGTCCTCA

CCAGAGGTTC

GAATGGAAAA

CTGCTGGAGG

CTGGGGCAGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCAGGACCAC

GAGGAAAGGT

GCGGCAACGG

GTAAACTGCT

ACCCTTTGCC

CCCAGATGGA

GAGTGATGGC

TTTCTGGACA

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

AGCTCACAAG

GCGTTTCCTG

CGGCAACATG

TCGTGACTCC

TACACCTGTC

GGAGACCAAG

AGCACGGGG.

GGTCCGTCTC

INFORMATION FOR SEQ, ID NO:73: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC

ACCTGCACCT

TTGCTGGACC CGAACAACCT CAATGACGAJA GACGTCTCTA TCCTGATGGA

CCGAAACCTT

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA

TGCATCAGGT

ATTGAGGCAA TTCTTCGTAA. TCTCCAACCA TGTCTGCCCT CTGCCACGGC

CGCACCCTCT

WO 98/17810

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AGCTTCCAAC

CTCTGCGTCA

TGTGACCTCC

AGCCAGTGCC

AGCTTGGGAG

GTGACCCTTC

TCATCCCTCC

CTCCTTGGA.A

140)

TCATCATCAA

CCCT'rGAGCA

CGTCTGGTCC

CAAACATGGG

ACCTGCTCCG

GGGAATTCGG

GAGTCCTCAG

CAGAGGTTCA

AATGGAAAAC

TGCTGGAGGG

TGGGGCAGCT

CCCAGCTTCC

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CAGGACCACA

AGGAAAGGTG

CGGCAACGGC

TAAACTGCTT

CCCTTTGCCT

CCAGATGGAG

AGTGATGGCA

TTCTGGACAG

TCCACAG,

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GCTCACAAGG

CGTTTCCTGA

GGCAACATGG

CGTGACTCCC

ACACCTGTCC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

ATCCCAATGC

TGCTTGTAGG

CGTCCCCAGc

ATGTCCTTCA

TGCTGCCTGC

CACAGGACAT

AACTGGGACC

TCCTTGGGGC

PCT1UJS97/20037 ACTGACGTTC 300 TGGAGGCTCC 360 TAAAGAATCT 420 CATCTTCCTG 480 AGGGTCCACC 540 GCCGCCTGCT 600 CAGCAGACTG 660 TGTGGACTTT 720 TCTGGGAGCA 780 CACTTGCCTC 840 CCTGCAGAGC 900 INFORMATION FOR SEQ ID NO:74: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGCTCCGAG

GAATTCGGCG

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTA-A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GAAAGGTGCG

GCAACGGCGG

AACTGCTTCG

CTTTGCCTA.C

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CACAGGGCAG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCA6ACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TCACA.AGGAT

TTTCCTGATG

CAACATGGCG

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

GACCACA

ATACATCACT TAAAGAGACC GACGTCTCTA TCCTGATGGA GCTGTCAAGA ACTTAGAAAA TGTCTGCCCT

CTGCCACGGC

TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CCCAATGCCA TCTTCCTGAG CTTGTAGGAG GGTCCACCCT TCCCCAGCGC CGCCTGCTTG GTCCTTCACA GCAGACTGAG CTGCCTGCTG TGGACTTTAG CAGGACATTC TGGGAGCAGT CTGGGACCCA CTTGCCTCTC CTTGGGGCCC TGCAGAGCCT

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTTCCAACAC

CTGCGTCAGG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

INFORMATION FOR SEQ ID Wi SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS* single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GGAAAGGTGC

GGCAACGGCG

AAACTGCTTC

CCTTTGCCTA

CAGATGGAGG

GTGATGGC.AG

TCTGGACAGG

CCACAGGGCA

CTATAATGAT CGATGAAATT CGAACAACCT CAATGACGAA ACCTGGAGAG

CTTCGTAAGG

TTCTTCGTAA.

TCTCCAACCA

TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC

AATCTCTACT

CAAACATGGA TCCCAATGCC GTTTCCTGAT GCTTGTAGGA GCAACATGGC

GTCCCCAGCG

GTGACTCCCA

TGTCCTTCAC

CACCTGTCCT GCTGCCTGCT AGACCAAGGC ACAGGACATT CACGGGGACA

ACTGGGACCC

TCCGTCTCCT

CCTTGGGGCC

GGACCACAGC TCACAAG ATACATCACT TAAAGAGACC GAC!GTCTCTA TCCTGATGGA GCTGTCAAGA ACTTAGAAAA TGTCTGCCCT

CTGCCACGGC

TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC ATC!TTCCTGA GCTTCCAACA GGGTCCACCC TCTGCGTCAG CCGCCTGCTT GTGACCTCCG AGCAGACTGA GCCAGTGCCC GTGGACTTTA GCTTGGGAGA CTGGGAGCAG TGACCCTTCT ACTTGCCTCT CATCCCTCCT CTGCAGAGCC TCCTTGGAAC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCTCCGA.

GGA.ATTCGGC

AGTCCTCAGT

AGAGGTTCAC

ATGGAAAACC

GCTGGAGGGA

GGGGCAGCTT

CCAGCTTCCT

INFORMATION FOR SEQ ID NO:76: SEQUENCE CHARACTERISTICS: LENGTH: 927 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCT/US97/20037 ,4o.9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGTTTCCTGA

GGCAACATGG

CGTGACTCCC

ACACCTGTCC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

AGGACCACAG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGCTTGTAGG

CGTCCCCAGC

ATGTCCTTCA

TGCTGCCTGC

CACAGGACAT-

AACTGGGACC

TCCTTGGGGC

CTCACAAGGA

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTA.AGG GCTGTCAAGA.

TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CATCTTCCTG AGCTTCCAAC AGGGTCCACC CTCTGCGTCA GCCGCCTGCT TGTGACCTCC CAGCAGACTG AGCCAGTGCC TGTGGACTTT AGCTTGGGAG TCTGGGAGCA GTGACCCTTC CACTTGCCTC TCATCCCTCC CCTGCAG.AGC CTCCTTGGAA

TCCCAAT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCAC!GGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

ACCTGCTCCG

GGGAATTCGG

GAGTCCTCAG

CAGAGGTTCA

AATGGAAAAC

TGCTGGAGGG

TGGGGCAGCT

CCCAGCTTCC

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

AGGAAAGGTG

CGGCAACGGC

TAAACTGCTT

CCCTTTGCCT

CCAGATGGAG

AGTGATGGCA

TTCTGGACAG

TCCACAGGGC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 INFORMATION FOR SEQ ID NO:77: SEQUENCE CHARACTERISTICS: LENGTH: 906 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GGAAAGGTGC

GGCAACATGG

CGTGACTCCC

ACACCTGTCC

GAGACCAAGG

GCACGGGGAC

GTCCGTCTCC

CACAAG

CTATAATGAT CGATGAAATT ATACATCACT CGAACAACCT CAATGACGAA GACGTCTCTA ACCTGGAGAG CTTCGTA.AGG GCTGTCAAGA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT TCATCATCAA GGCAGGTGAC TGGCAAGAAT CCCTTGAGCA AGCGCAGGAA CAACAGTACG CGTCTGGTCC AATCTCTACT ATCAACCCGT CAAACATGGA TCCCAATGCC ATCTTCCTGA GTTTCCTGAT GCTTGTAGGA GGGTCCACCC CGTCTCCCGC TCCGCCTGCT TGTGACCTCC ATGTCCTTCA. CAGCAGACTG AGCCAGTGCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG CACAGGACAT TCTGGGAGCA GTGACCCTTC AACTGGGACC CACTTGCCTC TCATCCCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCTTCCAACA

TCTGCGTCAG

GAGTCCTCAG

CAGAGGTTCA

AATGGAAAAC

TGCTGGAGGG

TGGGGCAGCT

CCCAGGGCAG

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCTCCGA

GGAATTCGGC

TAAACTGCTT

CCCTTTGCCT

CCAGATGGAG

AGTGATGGCA.

TTCTGGACAG,

GACCACAGCT

INFORMATION FOR SEQ ID NO:78:.

SEQUENCE CHARACTERISTICS:' LENGTH: 993 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

CCCCAGAGCT

GCGCTCCAGG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CCGGCGGCGG

TCCTGCTCAA

AGAAGCTGTG

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GTCTTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

CTCTGACATG

GTCTTTAGAG

TGCCACCTAA

ATTATACATC ACTTAAAGAG GAAGACGTCT CTATCCTGAT AGGGCTGTCA AGAACTTAGA CC.ATGTCTGC CCTCTGCCAC GACTGGCAAG AATTCCGGGA GAACAACAGT ACGTAGAGGG ACTATCAACC CGTCTCCTCC CTGTGCCACC CCGAGGAGCT CTGAGCTCCT GCCCCAGCCA GGCCTTTTCC TCTACCAGGG CCCACCTTGG ACACACTGCA ATGGAAGAAC TGGGAATGGC GCCTCTGCTT TC!CAGCGCCG CTGGAGGTGT CGTACCGCGT GCTACACCAT TAGGCCCTGC CAAGTGAGGA AGATCCAGGG

TAA

ACCACCTGCA

GGATCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

CAGCTCCCTG

CGATGGCGC!A

WO98/17810//A INFORMATION FOR SEQ ID NO:79: SEQUENCE CHARACTERISTICS: LENGTH: 993 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: PCT/US97/20037

ATGGCTAACT

CCTTTGC!TGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTCC

CGCCACCTTG

TCCCTGCCCC

GGCGCAGCGC

GTGCTGCTCG

GCCCTGCAGC

CTCCTGCAGG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

ACTTTGCCAC

CCACCCAGGG

TGGTTGCTAG

CGCAGCCCGG

AGAGCTTCCT

TCCAGGAGAA

GACACTCTCT

TGGCAGGCTG

CCCTGGAAGG

GATCGATGAA

CCTCAATGAC

GAGCTTCGTA

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GTCTCCCGAG

CACCATCTGG

TGCCATGCCG

CCATCTGCAG

CGGCGGCTCT

GCTCAAGTCT

GCTGTGTGCC

GGGCATCCCC

CTTGAGCCAA

GATATCCTAA

ATTATACATC

GAAGACGTCT

AGGGCTGTCA

CCATGTCTGC

GACTGGCAAG

GA.ACAACAGT

ACTATCAACC

TTGGGTCCCA

CAGCAGATGG

GCCTTCGCCT

AGCTTCCTGG

GACATGGCTA

TTAGAGCAAG

ACCTACAAGC

TGGGCTCCCC

CTCCATAGCG

TAA

ACTTAA-AGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

CCTTGGACAC

AAGAACTGGG

CTGCTTTCCA

AGGTGTCGTA

CACCATTAGG

TGAGGALAGAT

TGTGCCACCC

TGAGCTCCTG

GCCTTTTCCT

ACCACCTGCA

GGATCGAA.AC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

ACTGCAGCTG

AATGGCCCCT

GCGCCGGGCA

CCGCGTTCTA

CCCTGCCAGC

CCAGGGCGAT

CGAGGAGCTG

CCCCAGCCAG

CTACCAGGGG

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 993 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GCTAGCCATC

CCCGGCGGCG

TTCCTGCTCA

GAGAAGCTGT

TCTCTGGGCA

GGCTGCTTGA

GAAGGGATAT

TTTGCCACCA

ACCCAGGGTG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

TGCAGAGCTT

GCTCTGACAT

AGTCTTTAGA

GTGCCACCTA

TCCCCTGGGC

GCCAACTCCA

CCCCCGAGTT

CCATCTGGCA

CCATGCCGGC

GATCGATGAA ATTATACATC ACTTAALAGAG CCTCAATGAC GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA AGAACTTAGA TAATCTCCAA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG CCTGGAGGTG TCGTACCGCG TTCTACGCCA GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCAAGTGAGG AAGATCCAGG GCGATGGCGC CAAGCTGTGC CACCCCGAGG AGCTGGTGCT TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT TAGCGGCCTT TTCCTCT.ACC AGGGGCTCCT GGGTCCCACC TTGGACACAC TGCAGCTGGA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CTTCGCCTAA. TAA

ACCACCTGCA

GGATCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGTCCTGGTT

CCTTGCGCAG

GCCCCAGAGC

AGCGCTCCAG

GCTCGGACAC

GCAGCTGGCA

GCAGGCCCTG

CGTCGCCGAC

CCTGCAGCCC

INFORMATION FOR SEQ ID NO:81: SEQUENCE CHARACTERISTICS: LENGTH: 993 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

GATCGATGAA ATTATACATC CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGC CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGT TCCAATCTCT ACTATCAACC GTCTATGGCC CCTGCCCTGC

ACTTAA-AGAG

CTATCCTGAT

AGAACTTAGA

CCTCTGCCAC

AATTCCGGGA

ACGTAGAGGG

CGTCTCCTCC

AGCCCACCCA

ACCACCTGCA

GGATCGAAAC

AAATGCATCA

GGCCGCACCC

AAAACTGACG

CGGTGGAGGC

GTCTAAAGAA

GGGTGCCATG

"I WO 98/17810

CCGGCCTTCG

CAGAGCTTCC

TCTGACATGG

TCTTTAGAGC

GCCACCTACA

CCCTGGGCTC

CAACTCCATA

CCCGAGTTGG

ATCTGGCAGC

CCTCTGCTTT

TGGAGGTGTC

CTACACCATT

AAGTGAGGAA

AGCTGTGCCA

CCCTGAGCTC

GCGGCCTTTT

GTCCCACCTT

AGATGGAAGA

4,/ CCAGCGCCGG GCAGG-AGGGG GTACCGCGTT CTACGCCACC AGGCCCTGCC AGCTCCCTGC GATCCAGGGC GATGGCGCAG CCCCGAGGAG CTGGTGCTGC CTGCCCCAGC CAGGCCCTGC CCTCTACCAG GGGCTCCTGC GGACACACTG CAGCTGGACG ACTGGGATAA TAA PCT/US97/20037 TCCTGGTTGC TAGCCATCTG 540 TTGCGCAGCC CGGCGGCGGC 600 CCCAGAGCTT CCTGCTCAAG 660 CGCTCCAGGA GAAGCTGTGT 720 TCGGACACTC TCTGGGCATC 780 AGCTGGCAGG CTGCTTGAGC 840 AGGCCCTGGA AGGGATATCC 900 TCGCCGACTT TGCCACCACC 960 993 INFORMATION FOR SEQ ID NO:82: SEQUENCE CHARACTERISTICS: LENGTH: 993 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

ATGGCTAACT

CCTTTGCTGG

CTTCGACTTC

GGTATTGAGG

TCTCGACATC

TTCTATCTGG

TCCCCGGGTG

TCTCATAAAT

CAGCGCCGGG

TACCGCGTTC

GGCCCTGCCA

ATCCAGGGCG

CCCGAGGAGC

TGCCCCAGCC

CTCTACCAGG

GACACACTGC

CTGGGAATGG

GCTCTATAAT

ACCCGAACAA

CAAACCTGGA

CAATTCTTCG

CAATCATCAT

TTACCCTTGA

AACCGTCTGG

CTCCAAACAT

CAGGAGGGGT

TACGCCACCT

GCTCCCTGCC

ATGGCGCAGC

TGGTGCTGCT

AGGCCCTGCA.

GGCTCCTGCA

AGCTGGACGT

CCCCTGCCCT

GATCGATGAA

CCTCAATGAC

GAGCTTCGT.A

TAATCTCCAA

CAAGGCAGGT

GCAAGCGCAG

TCCAATCTCT

GTCTACCCAG

CCTGGTTGCT

TGCGCAGCCC

CCAGAGCTTC

GCTCCAGGAG

CGGACACTCT

GCTGGCAGGC

GGCCCTGGAA.

CGCCGACTTT

GCAGCCCTAA

ATTATACATC ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GGATCGAAAC AGGGCTGTCA AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGTGGAGGC ACTATCAACC CGTCTCCTCC GTCTAAAGAA GGTGCCATGC CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT GGAGGTGTCG GGCGGCGGCT CTGACATGGC TACACCATTA CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCTTGAGCC AACTCCATAG CGGCCTTTTC GGGATATCCC CCGAGTTGGG TCCCACCTTG GCCACCACCA TCTGGCAGCA GATGGAAGAA

TAA

INFORMATION FOR SEQ ID NO:83: SEQUENCE CHARACTERISTICS: LENGTH: 1027 base pairs TYPE: nucleic acid STRAI\DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: ATGGCTACAC CATTGGGCCC GAGCAAGTGA GGAAGATCCA TACAAGCTGT GCCACCCCGA GCTCCCCTGA GCTCCTGCCC CATAGCGGCC TTTTCCTCTA TTGGGTCCCA CCTTGGACAC CAGCAGATGG AAGAACTGGG GCCTTCGCCT CTGCTTTCCA AGCTTCCTGG AGGTGTCGTA GACATGGCTA CACCATTGGG TTAGAGCAAG TGAGGAAGAT ACCTACAAGC TGTGCCACCC TGGGCTCCCC TGAGCTCCTG CTCCATAGCG GCCTTTTCCT GAGTTGGGTC CCACCTTGGA TGGCAGCAGA TGGAAGAACT TAGCCATCTG CAGAGCTTCC

CTGATAA

TGCCAGCTCC

GGGCGATGGC

GGAGCTGGTG

CAGCCAGGCC

CCAGGGGCTC

ACTGCAGCTG

AATGGCCCCT

GCGCCGGGCA

CCGCGTTCTA

CCCTGCCAGC

CCAGGGCGAT

CGAGGAGCTG

CCCCAGCCAG

CTACCAGGGG

CACACTGCAG

GGGAATGGCC

TGGAGGTGTC

CTGCCCCAGA

GCAGCGCTCC

CTGCTCGGAC

CTGCAGCTGG

CTGCAGGCC

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTC

CGCCACCTTG

TCCCTGCCCC

GGCGCAGCGC

GTGCTGCTCG

GCCCTGCAGC

CTCCTGCAGG

CTGGACGTCG

CCTGCCCTGC

GTACCGCGTT

GCTTCCTGCT CAAGTCTTTA AGGAGAAGCT GTGTGCCACC ACTCTCTGGG CATCCCCTGG CAGGCTGC!TT GAGCCAACTC TGGAAGGGAT ATCCCCCGAG ACTTTGCCAC CACCATCTGG CCACCCAGGG TGCCATGCCG TGGTTGCTAG CCATCTGCAG CGCAGCCCGG CGGCGGCTCT AGAGCTTCCT GCTCAAGTCT TCCAGGAGAA GCTGTGTGC!C GACACTCTCT GGGCATCCCC TGGCAGGCTG CTTGAGCCAA CCCTGGALAGG GATATCCCCC CCGACTTTGC CACCACCATC AGCCCACCCA TCCTGGTTGC CTACGCCACC TTGCGCAGCC 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1027 INFORMATION FOR SEQ ID NO:84: SEQUENCE CHARACTERISTICS: LENGTH: 459 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TCTCCCGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

CACAAGGATC

TTCCTGATGC

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC

TGCGTCAGG

A.ACTGCTTCG TGACTCCCAT CTTTGCCTAC ACCTGTCCTG AGATGGAGGA GACCAAGGCA TGATGGCAGC ACGGGGACAA CTGGACAGGT CCGTCTCCTC CACAGGGCAG GACCACAGCT TGCTCCGAGG AAAGGTGCGT INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 447 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

TCTCCCGCTC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC

AATGCCATCT

GTAGGAGGGT

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

TCCTGAGCTT

CCACCCTCTG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CCAACACCTG

CGTCAGG

GTCCTCAGTA

GAGGTTCACC

TGGAAAACCC

CTGGAGGGAG

GGGCAGCTTT

CAGGGCAGGA

CTCCGAGGAA

AACTGCTTCG

CTTTGCCTAC

AGATGGAGGA

TGATGGCAGC

CTGGACAGGT

CCACAGCTCA

AGGTGCGTTT

TGACTCCCAT

ACCTGTCCTG

GACCAAGGCA

ACGGGGACAA

CCGTCTCCTC

CAAGGATCCC

CCTGATGCTT

INFORMATION FOR SEQ ID NO:86: SEQUENCE CHARACTERISTICS: LENGTH: 459 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

TCCCCAGCGC

GTCCTTCACA

CTGCCTGCTG

CAGGACATTC

CTGGGACCCA

CTTGGGGCCC,

CACAAGGATC

TTCCTGATGC

CGCCTGCTTG

GCAGACTGAG

TGGACTTTAG

TGGGAGCAGT

CTTGCCTCTC

TGCAGAGCCT

CCAATGCCAT

TTGTAGGAGG

TGACCTCCGA

CCAGTGCCCA

CTTGGGAGAA

GACCCTTCTG

ATCCCTCCTG

CCTTGGAACC

CTTCCTGAGC

GTCCACCCTC

GTCCTCAGTA

GAGGTTCACC

TGGAAA'ACCC

CTGGAGGGAG

GGGCAGCTTT

CAGCTTCCTC

TTCCAACACC

TGCGTCAGG

AACTGCTTCG TGACTCCCAT CTTTGCCT.AC ACCTGTCCTG AGATGGAGGA GACCAAGGCA TGATGGCAGC ACGGGGACAA CTGGACAGGT CCGTCTCCTC CACAGGGCAG GACCACAGCT TGCTCCGAGG AAAGGTGCGT INFORMATION FOR SEQ ID NO:87: SEQUENCE CHARACTERISTICS: LENGTH: 464 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87;

CCATGGCTAA

CACCTTTGCT

ACCTTCGACT

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GCTCCCCGGG

AATCTCATAA

CTGCTCTATA ATGATCGATG GGACCCGAAC AACCTCAATG TCCAAACCTG GAGAGCTTCG GGCAATTCTT CGTAATCTCC TCCAATCATC ATCAAGGCAG GGTTACCCTT GAGCAAGCGC TGAACCGTCT GGTCCAATCT ATCTCCAAAC ATGTAAGGTA AAATTATACA TCACTTAAAG ACGAAGACGT CTCTATCCTG TAAGGGCTGT CAAGAACTTA AACCATGTCT GCCCTCTGCC GTGACTGGCA AGAATTCCGG AGGAACAACA GTACGTAGAG CTACTATCAA CCCGTCTCCT CCGCATGCA GCTT

AGACCACCTG

ATGGATCGA.A

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

GGCGGTGGAG

CCGTCTAAAG

INFORMATION FOR SEQ ID NO:88: SEQUENCE C HARACTERISTICS: LENGTH: 419 base pairs TYPE: nucleic acid WO 98/17810 WO~/ 1803 PCTJIUS97/20037 STRANDEDNESS: single TOPOLOGY: linear 0 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

CCATGGCTAA

CACCTTTGCT

ACCTTCGACT

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GCTCCCCGGG

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

TGGTGGTTCT

ATGATCGATG

AACCTCAATG

GAGAGCTTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

GGCGGCGGCT

AAATTATACA

ACGAAGACGT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA,

CCAACATGTA

TCACTTAAAG AGACCACCTG CTCTATCCTG ATGGATCGAA CAAGAACTTA GAAAATGCAT GCCCTCTGCC ACGGCCGCAC AGAATTCCGG GAAAAACTGA GTACGTAGAG GGCGGTGGAG AGGTACCGCA TGCAAGCTT INFORMATION FOR SEQ ID NO:89: SEQUENCE CHARACTERISTICS: LENGTH: 405 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GCCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGC

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CCAACACAGC

GCTTCAAGAT

GCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 420 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID

GCCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

INFORMATION FOR SEQ ID NO:91: SEQUENCE CHARACTERISTICS: LENGTH: 366 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GCCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

TGGATCACTC

ACCCTG

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGC!TGGGTC

CCAAATGTGC

GCCAGAACTT

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGGAG

CTCCCGGTGC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

ACCTCCGAGC

CTGGAGCTGC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

AGCTGGTGGC

AGTGTCAGCC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

GCTGAAGCCC

CGACTCCTCA

INFORMATION FOR SEQ ID NO:92: SEQUENCE CHARACTERISTICS:.

LENGTH: 405 base pairs TYPE: nucleic acid STRANDEDNESS: single ~0 WO 98/17810 414 PCT/US97/20037 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

GGAACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ATTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCC,

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

INFORMATION FOR SEQ ID NO:93: SEQUENCE CHARACTERISTICS: LENGTH: 420 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

GGTACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ATTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CCAACACAGC CCCATCTCCT CCGACTTCGC GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CCTCTGGCGG CTGGTCCTGG CACAGCGCTG CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CTTTCAGCCC CCCCCCAGCT

GTCTTCGCTT

GGAGACCTCC GAGCAGCTGG

TGGCGCTGAA

GTGCCTGGAG CTGCAGTGTC

AGCCCGACTC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

INFORMATION FOR SEQ ID NO:94: SEQUENCE CHARACTERISTICS: LENGTH: 405 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ACTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CCAACACAGC CCCATCTCCT CCGACTTCGC GCTTCAAGAT TACCCAGTCA

CCGTGGCCTC

CCTCTGGCGG CTGGTCCTGG

CACAGCGCTG

CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GTGCCTGGAG CTGCAGTGTC AGCCC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 420 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCCACTCAGG ACTGCTCTTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATGTGC AACATCTCCC

GCCTCCTGCA

ACTCGCCAGA

ACTTCTCCCG

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CCCATCTCCT CCGACTTCGC TACCCAGTCA

CCGTGGCCTC

CTGGTCCTGG CAC!AGCGCTG GGCTTGCTGG AGCGCGTGAA CCCCCCAGCT GTCTTCGCTT

GAGCAGCTGG'TGGCGCTGAA

CTGCAGTGTC AGCCCGACTC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

INFORMATION FOR SEQ ID NO:96: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 98/ 7810PCT[US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: GCCGACGAGG AGCTCTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGTCTGGAG GTAACGGATC TCCTTCCAAC ACAGCCCCAT TACCTGCTTC AAGATTACCC

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG,

GCAGGAGACC

CCGGTGCCTG

CGGTGGCAAT

CTCCTCCGAC

AGTCACCGTG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGGAGCGGCG

TTCGCTGTCA

GCCTCCAACC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAAATGGAAC

AAATCCGTGA

TGCAG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

INFORMATION FOR SEQ ID NO:97: SEQUENCE CHARACTERISTICS: LENGTH: 450 base pairs TYPE: nucleic acid (C)-STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCAGGCG

CCCATCTCCT

TACCCAGTCA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAACGGCAG

CCGACTTCGC

CCGTGGCCTC

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGAGGTAAT

TGTCAAAATC

CAACCTGCAG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCACCCAGG

CGTGAGCTGT

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACTGCTCCTT

CTGACTACCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG,

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

INFORMATION FOR SEQ ID NO:98: SEQUENCE CHARACTERISTICS: LENGTH: 435 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGCG

TTCGCTGTCA

GCCTCCAACC

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GCAACGGCAC

AAATCCGTGA

TOCAG

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CCAGGACTGC

GCTGTCTGAC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

TCCTTCCAAC

TACCTGCTTC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACAGCCCCAT

AAGATTACCC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTCCTCCGAC

AGTCACCGTG

INFORMATION FOR SEQ ID NO:99: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

GCCTCCAAGA.TGCA.AGGCTT

TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGCA TCCCGGTGCC TGGAGCTGCA TCCGGTGGCA ATGGGAGCGG ATCTCCTCCG ACTTCGCTGT CCAGTCACCG TGGCCTCCAA GTCCTGGCAC AGCGCTGGAT

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAAATGGA

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

AGATACACTT TGTCACCAAA AGACCAACAT CTCCCGCCTC GGATCACTCG CCAGAACTTC CCCTGTCTGG AGGTAACGGA GCTCCTTC!CA ACACAGCCCC ACTACCTGCT TCAAGATTAC GCGGGGGCCT CTGGCGGCTG

CTGGG

INFORMATION FOR SEQ ID NO:l00: SEQUENCE CHARACTERISTICS: LENGTH: 450 base pairs WO 98/17810 14 6 WO 9817810PCTIUS97/20037 TYPE: nucleic acid STRANDEDNESS:.single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l0: GCCTCCAAGA TGCAAGGCTT TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGCA TCCCGGTGCC TGGAGCTGCA TCCGGAGGTA ATGGCACCCA GCTGTCAAA.A TCCGTGAGCT TCCAACCTGC AGGACGAGGA TGGATGGAGC GGCTCAAGAC

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

GGACTGCTCC

GTfCTGACTAC

GCTCTGCGGG

TGTCGCTGGG

GTGAACACGG

CGCTTCGTcc

CTGAAGCCCT

GACTCCTCAA

TTCCAACACA

CTGCTTCAAG

GGCCTCTGGC

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGTCTGG

GCCCCATCTC

ATTACCCAGT

GGCTGGTCCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

AGGTAACGGA

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

INFORMATION FOR SEQ ID NO:l0l: SEQUENCE CHARACTERISTICS: LENGTH: 435 base pairs TYPE: nucleic acid STRAI\DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: GCCTCCAAGA TGCAAGGCTT TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGCA TCCCGGTGCC TGGAGCTGCA ACGCAGGACT GCTCCTTCCA GAGCTGTCTG ACTACCTGCT GAGGAGCTCT GCGGGGGCCT AAGACTGTCG CTGGG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

GTGAACACGG AGATACACTT TGTCACCAAA CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGAAGCCCT GGATCACTCG CCAGAACTTC GACTCCTCAA CCCTGTCTGG CGGCAACGGC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC INFORMATION FOR SEQ ID NO:102: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID'NO:102:

GCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGGAGCGGTG

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

GTGAACACGG

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAAATGGAAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC-

GACTGTCGCT

TGTCACCAAA

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

TCCTTCCAAC!

TACCTGCTTC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC!

CCCGCCTCCT

AGAACTTCTC

GTAACGGCAG

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCC

GCAGGAGACC

CCGGTGCCTG

TGGTGGCAAT

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

GCTGGAGCGC

INFORMATION FOR SEQ ID NO:103: SEQUENCE CHARACTERISTICS: LENGTH: 450 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

GCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

ACCAACATCT

ATCACTCGCC

CTGTCAGGCG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCGCCTCCT GCAGGAGACC AGAACTTCTC CCGGTGCCTG GTAACGGCAG TGGAGGTAAT CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA INFORMATION FOR SEQ ID NO:104: WO 98/17810 WO 9817810PCTIUS97/20037 Wi SEQUENCE CHARACTERISTICS: LENGTH: 435 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

GCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

TCCTTCCAAC

TACCTGCTTC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCC

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

GCTGGAGCGC

ACCAACATCT

ATCACTCGCC

CTGTCTGGCG

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

GTGAACACGG

CCCGCCTCCT

AGAACTTCTC

GCAACGGCAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

GCAGGAGACC

CCGGTGCCTG

GCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

INFORMlATION FOR SEQ ID NO:105: SEQUENCE CHARACTERISTICS: LENGTH: 451 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

CCCCATCTCC

TTACCCAGTC

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAGTGGATC

TCCGACTTCG

ACCGTGGCCT

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CGGAGGTTCT

CTGTCAAAAT

CCAACCTGCA

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCAACCCAG

CCGTGAGCTG

G

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GACTGCTCCT

TCTGACTACC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

TCCAACACAG

TGCTTCAAGA

INFORMATION FOR SEQ ID NO:-106: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nudleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGcC

CTGTCTGGAG

TCCTTCCAAC

TACCTGCTTC

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAGTGGATC

ACAGCCCCAT

AAGATTACCC

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CGGTGGCAGT

CTCCTCCGAC

AGTCACCGTG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGGAGCGGCG

TTCGCTGTCA.

GCCTCCAACC

TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC GATCTGGA.AC CCAGGACTGC AAATCCGTGA GCTGTCTGAC

TGCAG

INFORMATION FOR SEQ ID NO;l07: Wi SEQUENCE CHARACTERISTICS: LENGTH: 437 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

CCATGGCCAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

AGACCAACAT

GGATCACTCG

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TCCTTCCAAC ACAGCCCCAT TACCTGCTTC AAGATTACCC GGGGGCCTCT GGCGGCTGGT GGGTCCAAGA TGCAAGGCTT TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGCA TCCCGGTGCC TGGAGCTGCA CTCCTCCGAC TTCGCTGTCA AGTCACCGTG GCCTCCAACC CCTGGCACAG CGCTGGATGG GCTGGAGCGC GTGAACACGG CAGCTGTCTT CGCTTCGTCC GCTGGTGGCG CTGAAGCCCT GTGTCAGCCC GACTCCTCAA WO98/17810 CCqTGGGCGG TGGATC INFORMATION FOR SEQ ID NO:108; SEQUENCE CHARACTERISTICS: LENGTH: 436'base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108: PCTIUS97/20037

GGATCCGGAG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

ACGGAGATAC

GTCCAGACCA

CCCTGGATCA

TCAACCCTGT

GTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACTGT

ACTTTGTCAC

ACATCTCCCG

CTCGCCAGAA

AAGCTT

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

CGCTGGGTCC

CAAATGTGCC

CCTCCTGCAG

CTTCTCCCGG

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

AAGATGCAAG

TTTCAGCCCC

GAGACCTCCG

TGCCTGGAGC

CCATCTCCTC CGACTTCGCT ACCCAGTCAC CGTGGCCTCC TGGTCCTGGC ACAGCGCTGG GCTTGCTGGA GCGCGTGAAC CCCCCAGCTG TCTTCGCTTC AGCAGCTGGT GGCGCTGAAG TGCAGTGTCA GCCCGACTCC INFORMATION FOR SEQ ID NO:10'9: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 449 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109: CCATGGCCAC CCAGGACTGC AAATCCGTGA GCTGTCTGAC TGCAGGACGA GGAGCTCTGC AGCGGCTCAA GACTGTCGCT AGATACACTT TGTCACCAAA AGACCAACAT CTCCCGCCTC GGATCACTCG CCAGAACTTC CCCTGGGCGG TGGGTCAGGA

TCCTTCCA-AC

TACCTGCTTC

GGGGGCCTCT

GGGTCCA-AGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

GGTGGATCC

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

INFORMATION FOR SEQ ID NO:llO: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 439 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:llO:

GGATCCGGAG

GCTGTCAAAA

TCCAACCTGC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

GTGGCACCCA

TCCGTGAGCT

AGGACGAGGA

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGTAAGCTT-

GGACTGCTCC

GTCTGACTAC

GCTCTGCGGG

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

TTCCAACACA

CTGCTTCAAkG

GGCCTCTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCT~fl

GCCCCATCTC

ATTACCCAGT

GGCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

INFORMATION FOR SEQ ID NO:lll: SEQUENCE CHARACTERISTICS: LENGTH: 461 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:lll: CCATGGCCAC CCAGGACTGC TCCTTCCAAC! ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG WO 98/17810

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

4/19 PCT/US97/20037 TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300 CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360 CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420 TGGGTCAGGA GGTGGGTCAG GAGGTGGATC C 461 INFORMATION FOR SEQ ID NO:ll2: SEQUENCE CHARACTERISTICS: LENGTH: 457 base pairs TYPE: nucleic acid STRANDEDNESS; single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG,

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GTGGCTCAGG GGGAGGTAGT CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA GTCTTCGCTT CGTCCAGACC TGGCGCTGAA GCCCTGGATC AGCCCGACTC CTCAACCCTG

GGTACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TAAGCTT

ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAAGAT TCTGCGGGGG CCTCTGGCGG TCGCTGGGTC CAAGATGCAA CCAAATGTGC CTTTCAGCCC GCCTCCTGCA GGAGACCTCC ACTTCTCCCG GTGCCTGGAG INFORMATION FOR SEQ ID NO:113: SEQUENCE CHARACTERISTICS: LENGTH: 438 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

GACTTCGCTG

GTGGCCTCCA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GATCCGGAGG

TCAAAATCCG

ACCTGCAG

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TACCCAGGAC

TGAGCTGTCT

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

TGCTCCTTCC

GACTACCTGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

AACACAGCCC

TTCAAGATTA

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CATCTCCTCC

CCCAGTCACC

INFORMATION FOR SEQ ID NO;114: SEQUENCE CHARACTERISTICS: LENGTH: 441 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCGACTTCG

ACCGTGGCCT

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GATCCGGAGG

CTGTCAAAAT

CCAACCTGCA

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGCACCCAG

CCGTGAGCTG

G

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GACTGCTCCT

TCTGACTACC

TGGCACAGCG CTGGATGGAG TGGAGCGC!GT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC TCCAACACAG CCCCATCTCC TGCTTCA-AGA TTACCCAGTC INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 450 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG WO 98/17810

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

CCCATCTCCT

TACCCAGTCA

420 PCTIUS97/20037

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

CCGACTTCGC

CCGTGGCCTC

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGATCCGGA

TGTCAAAATC

CAACCTGCAG

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTACCCAGG

CGTGAGCTGT

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACTGCTCCTT

CTGACTACCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

INFORMATION FOR SEQ ID NO:l16: SEQUENCE CHARACTERISTICS: LENGTH: 459 base pairs TYPE: nucleid acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116: GCCGACGAGG AGCTCTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGGGCGGTG GATCCGGAGG CAACACAGCC CCATCTCCTC CTTCAAGATT ACCCAGTCAC

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCA.G

GCAGGAGACC

CCGGTGCCTG

TGGCTCAGGG

CGACTTCGCT

CGTGGCCTCC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGAGGTAGTG

GTCAAAATCC

AACCTGCAG

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GTACCCAGGA

GTGAGCTGTC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTGCTCCTTC

TGACTACCTG

INFORMATION FOR SEQ ID NO:117: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCAC

AAATCCGTGA

TGCAG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

INFOR1MATION FOR SEQ, ID NO:ll8: SEQUENCE CHARACTERISTICS: LENGTH: 483 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAG

AGCTCTGCGG

CTGTCGCTGG,

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

GGGCCTCTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCCGAGCAGC CCGGTGCCTG GAGCTGCAGT TGGGTCAGGA GGTGGATCCG CTTCCAACAC AGCCCCATCT CCTGCTTCAA GATTACCCAG

TGGCACAGCG

TGGAGCGCGT

GCTGCCTTCG,

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG,

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

INFORMATION FOR SEQ ID NO:119: SEQUENCE CHARACTERISTICS: LENGTH: 843 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 4 PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l19:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAGACCMA

CCTGGATCAC

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCCAGGAC

TG.AGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

CATCTCCCGC

TCGCCAGAAC

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGCTCCTTCC

GACTACCTGC

TGCGGGGCGC

GCTGGGTCCA

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AACACAGCCC

TTCAAGATTA

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CATCTCCTCC

TCTGGCGGCT GGTCCTGGCA AGATGCAAGG CTTGCTGGAG TTCAGCCCCC CCCCAGCTGT AGACCTCCGA GCAGCTGGTG GCCTGGAGCT GCAGTGTCAG INFORMATION FOR SEQ ID NO:120: SEQUENCE CHARACTERISTICS: LENGTH: 858 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCCGACTCCT

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAGACCAA

CCTGGATCAC

CAACCCTG

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CACCCAGGAC TGCTCCTTCC TGAGCTGTCT GACTACCTGC CGAGGAGCTC TGCGGGGCGC CAAGACTGTC GCTGGGTCCA CTTTGTCACC AAATGTGCCT CATCTCCCGC CTCCTGCAGG TCGCCAGAAC TTCTCCCGGT TAAAGAdACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT AACACAGCCC CATCTCCTCC TTCAAGATTA CCCAGTCACC TCTGGCGGCT GGTCCTGGCA AGATGCAAGG CTTGCTGGAG TTCAGCCCCC CCCCAGCTGT AGACCTCCGA GCAGCTGGTG GCCTGGAGCT GCAGTGTCAG INFORMATION FOR SEQ ID NO:121: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTG.A

CAGCCCGACT

TGCTCCTTCC

GACTACCTGC

CTATP.ATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AACACAGCCC

TTCAAGATTA

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CGACGAGGAG CTCTGCGGGG GCTCAAGACT GTCGCTGGGT ACACTTTGTC ACCAAATGTG CAACATCTCC CGCCTCCTGC CACTCGCCAG AACTTCTCCC GTCAGGCGGT AACGGCAGTG CATCTCCTCC GACTTCGCTG CCCAGTCACC GTGGCCTCCA TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAJA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GAGGTAATGG

TCAAAATCCG

ACCTGCAG

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CACCCAGGAC

TGAGCTGTCT

INFORMATION FOR SEQ ID NO:122: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs WO 98/17810 PCTIUS97/20037 1/2Z TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC GCACAGCGCT GGATGGAGCG GAGCGCGTGA ACACGGAGAT TGTCTTCGCT TCGTCCAGAC GTGGCGCTGA AGCCCTGGAT CAGCCCGACT CCTCAACCCT AATGGAACCC AGGACTGCTC ATCCGTGAGC TGTCTGACTA

CAG

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CGACGAGGAG CTCTGCGGGG GCTCAAGACT GTCGCTGGGT ACACTTTGTC ACCAAATGTG CAACATCTCC CGCCTCCTGC CACTCGCCAG AACTTCTCCC GTCTGGAGGT AACGGATCCG CTTCCAACAC AGCCCCATCT CCTGCTTCAA GATTACCCAG TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT GCCTCTGGCG GCTGGTCCTG CCAAGATGCA AGGCTTGCTG CCTTTCAGCC CCCCCCCAGC AGGAGACCTC CGAGCAGCTG GGTGCCTGGA GCTGCAGTGT GTGGCAATGG GAGCGGCGGA CCTCCGACTT CGCTGTCAAA TCACCGTGGC CTCCAACCTG INFORMATION FOR SEQ ID NO:123; SEQUENCE CHARACTERISTICS: LENGTH: 873 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGACTTCCAA ACCTGGAGAG ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGTCTGGCG GCAACGGCAC TTCGCTGTCA AAATCCGTGA GCCTCCAACC TGCAGGACGA CGCTGGATGG AGCGGCTCAA

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

GCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

ATACATCACT TAAAGAGACC GACGTCTCTA TCCTGATGGA GCTGTCAAGA ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA TCCTTCCAAC ACAGCCCCAT TACCTGCTTC AAGATTACCC GGGGGCCTCT GGCGGCTGGT

GGG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

INFORMATION FOR SEQ ID NO:124: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAACGGATC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CGGAGGTAAT

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

ATACATCACT TAAAGAGACC GACGTCTCTA TCCTGATGGA GCTGTCAAGA ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA GGCACCCAGG ACTGCTCCTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGCTGGG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

WO 98/17810 423 PCT/US97/20037 INFORMATION FOR SEQ ID NO:125: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

TCCTTCCAAC!

TACCTGCTTC

GGGGGCCTCT

GGG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAACGGATC

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CGGTGGCAAT

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCT1GCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGGAGCGGCG

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAA.ATGGAAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

INFORMATION FOR SEQ ID NO:126: SEQUENCE CHARACTERISTICS: LENGTH: 873 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

AACGGCACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

AGGACTGCTC

TGTCTGACTA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CCCCCCCAGC TGTCTTCGCT CGAGCAGCTG GTGGCGCTGA GCTGCAGTGT CAGCCCGACT CTTCCAACAC AGCCCCATCT CCTGCTTCAA GATTACCCAG GGGCCTCTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCC TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTC!CGTC TAAAGAATCT TCGTCCAGAC CAACATCTCC AGCCCTGGAT CACTCGCCAG CCTCA-ACCCT GTCTGGCGGC CCTCCGACTT CGCTGTCAAA TCACCGTGGC CTCCAACCTG TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG INFORMATION FOR SEQ ID NO:127: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCA-A

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

CGATGAAATT

CAATGACGAA

CTTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

TAAAGAGACC ACCTGCACCT TCCTGATGGA CCGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG' TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TCGTCCAGAC CAACATCTCC AGCCCTGGAT CACTCGCCAG CCTCAACCCT GTCAGGCGGT q WO 98/17810 AACGGCAGTG GAGGTAATGG CACCCAGG) GACTTCGCTG TCAAAATCCG TGAGCTGTC GTGGCCTCCA ACCTGCAGGA CGAGGAGC' CAGCGCTGGA TGGAGCGGCT CAAGACTGr CGCGTGAACA CGGAGATACA CTTTGTCAC 2. PCT/US97/20037 C TGCTCCTTCC AACACAGCCC CATCTCCTCC 660 'T GACTACCTGC TTCAAGATTA CCCAGTCACC 720 P'C TGCGGGGGCC TCTGGCGGCT GGTCCTGGC.A 780 P'C GCTGGGTCCA AGATGCAAGG CTTGCTGGAG, 840 "C A.AATGTGCCT TTCAGCCC R88 INFORMATION FOR SEQ ID NO:128: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATGACGAA CGACTTCCAA ACCTGGAGAG CTTCGTA.AGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC CCCCCCCAGC CGCCTCCTGC AGGAGACCTC CGAGCAGC!TG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT AACGGCAGTG GTGGTAATGG GAGCGGCGGA AGCCCCATCT CCTCCGAC!TT CGCTGTCAAA.

GATTACCCAG TCACCGTGGC CTCCAACCTG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CAAGGCTTGC TGGAGCGCGT GAACACGGAG

CCC!

ATACATCACT

GACGTCTCTA

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

AATGGAACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AGGACTGCTC

TGTCTGACTA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GTCTGGAGGT

CTTCCA.ACAC

CCTGCTTCA.A

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

INFORMATION FOR SEQ ID NO:129: SEQUENCE CHARACTERISTICS:.

LENGTH: 843 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA.AC

CATAAATCTC

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

COGAGATACA

TCCAGACCAA

CCTGGATCAC

CGATGAAATT ATACATCACT CAATTCTGAA GACATOGATA ATTCGTAAGG GCTdTCAAGC TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT GACTCAGGAC TGTTCTTTCC TGAGCTGTCT GACTACCTGC CGAGGAGCTC TGCGGGGGCC CAAGACTGTC GCTGGGTCCA CTTTGTCACC AAATGTGCCT CATCTCCCGC CTCCTGCAGG TCGCCAGAAC TTCTCCCGGT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

AGACCTCCGA

GCCTGGAGCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

CTTGCTGGAG

CCCCAGCTGT

GCAGCTGGTG

GCAGTGTCAG

INFORMATION FOR SEQ ID NO:130: SEQUENCE CHARACTERISTICS: LENGTH: 858 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCP.A TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAXT TCCGGGAAAA ACTGACGTTC WO 98/17810 WO 9817810PCT[US97/20037 4J2 S-

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCCGACTCCT

CCCTTGAGCA AGCGCAGGAA

CGTCTGGTCC

CAAACATGGC

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAGACCAA

CCTGGATCAC

CAACCCTG

AATCTCTACT

AACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

CATCTCCCGC

TCGCCAGAAC

CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTC!CGTC TGCTCTTTTc AACACAGCCC GACTACCTGC TTCAAGATTA TGCGGGGGCC TCTGGCGGCT GCTGGGTCCA AGATGCAAGG AAATGTGCCT TTCAGCCCCC CTCCTGCAGG AGACCTCCGA TTCTCCCGGT GCCTGGAGCT

TGGAGGCTCC

TAAAGAATCT

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA.

CTTGCTGGAG

CCCCAGCTGT

GCAGCTGGTG

GCAGTGTCAG

INFORMATION FOR SEQ ID NO:131: SEQUENCE CHARACTERISTICS: LENGTH: 843 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l31:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA.

ACTTCTCCCG

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG,

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA GTCTTCCCT CGTCCAGACC TGGCGCTGAA GCCCTGGATC AGCCCTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT TAATGATCGA TGAAATTATA ACAACCTCAA TTCTGAAGAC TGCTCGCATT CGTAAGGGCT TTCGTAATCT CCAACCATGT TCATCAAGGC AGGTGACTGG TTGAGCA.AGC GCAGGAACAA INFORMATION FOR SEQ ID NO:132: Wi SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

TGCTCCTTCC

GACTACCTGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CCAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AACACAGCCC

TTCAAGATTA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GTCAGGC!GGT

CATCTCCTCC

CCCAGTCACC

ATACATCACT TAAAGAGACC ACCTAACCCT GACATGGATA TCCTGATGGA ACGAAACCTT

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

AACGGCAGTG

GACTTCGCTG

GTGGCCTCCA

ACTTAGA-AAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT GCCTCTGGCG GCTGGTCCTG CCAAGATGCA AGGCTTGCTG CCTTTCAGCC CCCCCCCAGC AGGAGACCTC CGAGCAGCTG GGTGCC!TGGA GCTGCAGTGT GAGGTAATGG CACCCAGGAC TCAAAATCCG TGAGCTGTCT

ACCTGCAG

INFORMATION FOR SEQ ID NO:133: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT WO 98/17810 WO 9817810PCTIUS97/20037

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

AATGGAACCC

ATCCGTGAGC

CAG

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AGGACTGCTC

TGTCTGACTA

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GTCTGGAGGT

CTTCCAACAC

CCTGCTTCAA

GACATGGATA TCCTGATGGA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

AACGGATCCG

AGCCCCATCT

GATTACCCAG

ACTTAGAAAA

CTGCC.ACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GTGGCAATGG

CCTCCGACTT

TCACCGTGGC

ACGAAAcCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

GAGCGGCGGA

CGCTGTCAAA

CTCCAACCTG

INFORMATION FOR SEQ ID NO:l134: SEQUENCE CHARACTERISTICS: LENGTH: 873 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGCG

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA-

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GCAACGGCAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCA-ACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

GCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

TCCTTCCAAC

TACCTGCTTC

GGGGGCCTCT

GGG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

INFORMATION FOR SEQ ID NO:135: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAACGGATC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

CGGAGGTAAT

TGTCAAAATC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCACCCAGG

CGTGAGCTGT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAA.A

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGC!GT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCdCGA

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAACCTGCAG GACGAGGAGC GATGGAGCGG CTCAAGACTG INFORMATION FOR SEQ ID NO:136: Wi SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 4 WO 98/17810 PCTIUS97/20037 /12-7c (Xi) SEQUENCE DESCRIPTION: SEQ ID NO; 136:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTCTGGAG

TCCTTC!CAAC

TACCTGCTTC!

GGGGGCCTCT

GGG

CTATAkATGAT CGAACA4cCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GTAACGGATC

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

CGATGAAATT

ATACATCACT

CAATTCTGAA GACATGGATA ATTCGTAAGG GCTGTCA-AGC TCTCCAACCA

TGTCTGCCCT

GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCC!GAGCAGC CCGGTGCCTG GAGCTGCAGT CGGTGGCAAT GGGAGCGGCG CTCCTCCGAC TTCGCTGTCA AGTCACCGTG

GCCTCCAACC

CCTGGCACAG CGCTGGATGG TAAAGAGACC ACCTAACCCT TCCTGATGGA

ACGAAACC'TT

ACTTAGAAAA

TGCATCAGGT

CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTc TAGAGGGCGG TGGAGGCTCC CTCCTCC!GTC! TAAAGAATCT TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCC!AG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC GAAATGGAAC

CCAGGACTGC

AAATCCGTGA GCTGTC!TGAC TGCAGGACGA GGAGCTCTGc! AGCGGCTCAA GACTGTCGCT INFORMATION FOR SEQ ID NO: 137; SEQUENCE CHARACTERISTICS: LENGTH; 873 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:137: GCTAACTGCT

CTATAATGAT

TTGCTGGACC

CGAACAACCT

CGAACTCCAA ACCTGCTCGC ATTGAGGCAA

TTCTTCGTAA

CGACATCCAA TCATCATCAA TATCTGGTTA

CCCTTGAGCA

CCGGGTGAAC CGTC!TGGTCC CATAAATCTC CAAACATGGC CGCCTCCTGC AGGAGACCTC AACTTCTCCC GGTGCCTGGA AACGGCACGC AGGACTGCTC ATCCGTGAGC TGTCTGACTA CAGGACGAGG

AGCTCTGCGG

CGGCTCAAGA CTGTCGCTGG ATACACTTTG

TCACCAAATG

CGATGAAATT

CAATTCTGA-A

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC!

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CTTCCAACAC

CCTGCTTCAA

GGGCCTCTGG

GTCCAAGATG

TGCCTTTC!AG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

AGCCCCATCT

GATTACCCAG

CGGCTGGTCC

CAAGGCTTGC

CCC!

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

TGGAGCGCGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GTCTGGC!GGC

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

GAACACGGAG

INFORMATION FOR SEQ ID NO:138: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC7

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

AACGGCAGTG

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GAGGTAATGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

ATACATCACT

GACATGGATA

GCTGTCA-AGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

TAAAGAGACC

TCC!TGArGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC!

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GTCAGGCGGT

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

CTTGCTGGAG

GTGGCGCTGA AGCCCTGGAT CAGCCCGACT CCTCAACCCT TGCTCCTTCC AACACAGCCC GACTACCTGC TTCAAGATTA TGCGGGGGCC TCTGGCGGCT GCTGGGTCCA AGATGCAAGG AAATGTGCCT TTCAGCCr INFORMATION FOR SEQ ID NO:139: WO 98/17810 42 IF PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION! SEQ ID NO:139:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

AACGGCAGTG

AGCCCCATCT

GATTACCCAG

CGGCTGGTCC

CAAGGCTTGC

CCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GTGGCAATGG

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

TGGAGCGCGT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

GAGCGGCGGA

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

GAACACGGAG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

AATGGAACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

TAAAGAGACC ACCTAACCCT TCCTGATGGA

ACGAAACCTT

ACTTAGAAAA

TGCATCAGGT

CTGCCACGGC

CGCACCCTCT

TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC

TAAAGAATCT

TCGTCCAGAC CAACATCTCC AGCCCTGGAT CACTCGCCAG CCTCAACCCT GTCTGGAGGT AGGACTGCTC CTTCCAACAC TGTCTGACTA CCTGCTTCA AGCTCTGCGG

GGGCCTCTGG

CTGTCGCTGG

GTCCAAGATG

TCACCAA.ATG TGCCTTTCAG INFORMATION FOR SEQ ID NO:140: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

TGCTCCTTCC

GACTACCTGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CCAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AACACAGCCC

TTCAAGATTA

CGATGAAATT

CAATTCTGAAp

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GTCTGGAGGT

CATCTCCTcC

CCCAGTCACC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG,

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

AGTGGATCCG

GACTTCGCTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GAGGTTCTGG

TCAAAATCCG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CACCCAGGAC

TGAGCTGTCT

GTGGCCTCCA ACCTGCAG INFORMA~TION FOR SEQ ID NO:141: SEQUENCE CHARACTERISTICS; LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

GCTAACTGCT

TTGCTGGACC

CGAACTCCA

ATTOAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCA.AGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GTCTGGAGGT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TAAAGAGACC

ACCTAACCCT

TCCTGATGGA. ACGAAACCTT ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCOG ATCAACCCGT CTCCTCCGTC CTCTGCGGGG GCCTCTGGCG GTCGCTGGGT CCAAGATGCA ACCAAATGTG

CCTTTCAGCC

CGCCTCCTGC AGGAGACCTC AACTTCTCCC GGTGCCTGGA AGTGGATCCG GTGGCAGTGG

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

GAGCGGCGGA

1. 1.

WO QR17810b 1pir TCTGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG

CAG

INFORMATION FOR SEQ ID NO:142: SEQUENCE CHARACTERISTICS: LENGTH: 858 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142: YUS97/20037 840 900 903

GCCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

CCGTCTCCTC

ATCGATGAAA

CTCAATTCTG

GCATTCGTAA

AATCTCCAAC

AAGGCAGGTG

CAAGCGCAGG

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

CGTCTAAAGA

TTATACATCA

AAGACATGGA

GGGCTGTCAA

CATGTCTGCC

ACTGGCAAGA

AACAACAG

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CTCCCCGGGT

ATCTCATAAA

CTTAAAGAGA

TATCCTGATG

GCACTTAGAA

CTCTGCCACG

ATTCCGGGAA

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GAACCGTCTG

TCTCCAAACA

CCACCTAACC

GAACGAAACC

AATGCATCAG

GCCGCACCCT

AAACTGACGT

CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA GTCTTCGCTT CGTCCAGACC TGGCGCTGAA GCCCTGGATC AGCCCGACTC CTCAACCCTG GTCCAATCTC TACTATCAAC TGGCTAACTG CTCTATAATG CTTTGCTGGA CCCGAACAAC TTCGAACTCC AAACCTGCTC GTATTGAGGC AATTCTTCGT CTCGACATCC AATCATCATC TCTATCTGGT TACCCTTGAG INFORMATION FOR SEQ ID NO:143: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143 GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGAACTCCAA ACCTGCTCGC ATTGAGGCAA TTCTTCGT.A CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC GCACAGCGCT GGATGGAGCG GAGCGCGTGA ACACGGAGAT TGTCTTCGCT TCGTCCAGAC GTGGCGCTGA AGCCCTGGAT CAGCCCGACT CCTCAACCCT CACAGCCCCA TCTCCTCCGA CAAGATTACC CAGTCACCGT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT GGGCGGTGGA TCCGGAGGTA CCCAGGACTG CTCCTTCCAA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT GGCCTCCAAC CTGCAG INFORMATION FOR SEQ ID NO:144: SEQUENCE CHARACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

ATACATCACT TAAAGAGACC ACCTAACCCT GACATGGATA TCCTGATGGA ACGAAACCTT GCTGTCAAGC ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC CGCACCCTCT TGGCAAGAAT TCCGGGAAAA ACTGACGTTC CAACAGTACG TAGAGGGCGG TGGAGGCTCC ATCAACCCGT CTCCTCCGTC TAAAGAATCT CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG WO 98/17810

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

CAACACAGCC

CTTCAAGATT

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

CCATCTCCTC

ACCCAGTCAC

430 GCTCAAGACT GTCGCTGGGT ACACTTTGTC ACCAAATGTG CAACATCTCC CGCCTCCTGC CACTCGCCAG AACTTCTCCC GGGCGGTGGA TCCGGAGGTG CGACTTCGCT GTCAAAATCC CGTGGCCTCC AACCTGCAG PCTIUS97/20037 CCAAGATGCA AGGCTTGCTG CCTTTCAGCC CCCCCCCAGC AGGAGACCTC CGAGCAGCTG GGTGCCTGGA GCTGCAGTGT GCACCCAGGA CTGCTCCTTC GTGAGCTGTC TGACTACCTG INFORMATION FOR SEQ ID NO:145: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID

GCTAACTGCT.

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

TGCTCCTTCC

GACTACCTGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AACACAGCCC

TTCAAGATTA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG

CATCTCCTCC

CCCAGTCACC

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTTCGC!TG

GTGGCCTCCA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGC!G

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GATCCGGAGG

TCAAAATCCG

ACCTGCAG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TACCCAGGAC

TGAGCTGTCT

INFORMATION FOR SEQ ID NO;146: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTICGCT

GTGGCGCTGA

CAGCCCGACT

ACCCAGGACT

GAGCTGTCTG

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTAAGG TTCTTCGTA.A TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

GCTCCTTCCA

ACTACCTGCT

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GGGCGGTGGA

ACACAGCCCC

TCAAGATTAC

ATACATCACT

GACATOGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCCGGAGGTG

ATCTCCTC!CG

CCAGTCACCG

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GCTCAGGGGG

ACTTCGCTGT

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

AGGTAGTGGT

CAAAATCCGT

TGGCCTCCAA CCTGCAG INFORMATION FOR SEQ ID NO:147: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CTATAATGAT CGATGAAATT ATACATCPCT TAAAGAGACC ACCTAACCCT CGAACAACCT CAATTCTGAA GACATOGATA TCCTGATGGA ACGAAACCTT ACCTGCTCGC ATTCGTAAGG GCTGTCA.AGC ACTTAGAAAA TGCATCAGGT TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT WO 98/17810 WO 981781 PCTIUS97/20037

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

GGTGGCACCC

ATCCGTGAGC

CAG

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AGGACTGCTC

TGTCTGACTA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG,

CTTCCAACAC

CCTGCTTCAA

TGGCA.AGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG;

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

AGCCCCATCT

GATTACCCAG

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GG3TGCCTGGA

GGTCAGGAGG

CCTCCGACTT

TCACCGTGGC

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGATCCGGA

CGCTGTCAA.A

CTCCAACCTG

300 360 420 480 540 600 660 720 780 840 900 903 INFORMATION FOR SEQ ID NO:148: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

GGTGGCTCAG

TCCGACTTCG

ACCGTGGCCT

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTA.AGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CAAACATGGC CGACGAGGAG GGATGGAGCG GCTCAAGACT ACACGGAGAT ACACTTTGTC TCGTCCAGAC CAACATCTCC AGCCCTGGAT CACTCGCCAG CCTCAACCCT GGGCGGTGGG GGGGAGGTAG TGGTACCCAG CTGTCAAAAT CCGTGAGCTG CCAACCTGCA G

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTGCTCCT

TCTGACTACC

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT GCCTCTGGC!G GCTGGTCCTG CCAAGATGCA AGGCTTGCTG CCTTTCAGCC CCCCCCCAGC AGGAGACCTC CGAGCAGCTG GGTGCCTGGA GCTGCAGTGT GGTCAGGAGG TGGATCCGGA TCCAACACAG CCCCATCTCC TGCTTCAAGA TTACCCAGTC INFORMATION FOR SEQ ID NO:149: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTC!C

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GATCCGGAGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC!

GAGCTGCAGT

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTC!G

TGGTGGCGCT

GTCAGCCCGA

AACACAGCCC

TTCAAGATTA

TCTGGCGGC!T

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

INFORMATION FOR SEQ ID NO:150: SEQUENCE CHARACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRAI'DEDNESS: single TOPOLOGY: linear WO 98/17810 4f 3- WO 9817810PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCA.A

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCGACTTCG

ACCGTGGCCT

GCACAGCGCT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTC!TGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GATCCGGAGG

CTGTCAAAAT

CCAACCTGCA

GGATGGAGCG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGCACCCAG

CCGTGAGCTG

GGACGAGGAG

GCTCAAGACT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GACTGCTCCT

TCTGACTACC

CTCTGCGGGG

GTCGCTGGG

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

TCCAACACAG

TGCTTCAAGA

GCCTCTGGCG

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCCCATCTCC

TTACCCAGTC

GCTGGTCCTG

INFORMATrION FOR SEQ ID NO:151: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC CTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGATCCGGA CCCATCTCCT CCGACTTCGC TGTCAAAATC TACCCAGTCA CCGTGGCCTC CAACCTGCAG CTGGTCCTGG CACAGCGCTG GATGGAGCGG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

INFORMATION FOR SEQ ID NO:152: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

CTATAATGAT CGATGAAATT ATACATCACT CGAACAACCT CAATTCTGAA GACATGGATA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC TTCTTCGTAA TCTCCAACCA TGTCTGCCCT TCATCATCAA GGCAGGTGAC TGGCAAGAAT CCCTTGAGCA AGCGCAGGAA CAACAGTACG CGTCTGGTCC AATCTCTACT ATCAACCCGT CAAACATGGC CTCCAAGATG CAAGGCTTGC TCACCAAATG TGCCTTTCAG CCCCCCCCCA CCCGCCTCCT GCAGGAGACC TCCGAGCAGC AGA.ACTTCTC CCGGTGCCTG GAGCTGCAGT GATCCGGAGG TGGCTCAGGG GGAGGTAGTG CCATCTCCTC CGACTTCGCT GTCAAAATCC ACCCAGTCAC CGTGGCCTCC AACCTGCAGG TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAA.A

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACTGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

CGCTGGG

INFORM~ATION FOR SEQ ID NO:153: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid WO 98/17810 It33 WO 9817810PCT/US97/20037 STRA IDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCA.AC

TACCTGCTTC

GGGGGCCTCT

GGG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

ATACATCACT TA.AAGAGACC GACATGGATA TCCTGATGGA

GCTGTCAAGC

TGTCTGC!CCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCAC

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

AAATCCGTGA GCTGTCTGAC TGCAGGACGA GGAGCTCTGC AGCGGCTCAA GACTGTCGCT INFORMATION FOR SEQ ID NO:154: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG,

AGTGGTACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTA.A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGCTCTGCGG

CTGTCGCTGG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

GGGCCTCTGG

G

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

CGGCTGGTCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

INFORMATION FOR SEQ ID NO:155: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCA\

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCCGGAGGTA

AAAATCCGTG

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTA.A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

CCCAGGACTG

AGCTGTCTGA

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CTCCTTCCAA

CTACCTGCTT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCA.ACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

CACAGCCCCA

CAAGATTACC

TGGCGGCTGG,

ATGCAAGGCT

CAGCCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

TCTCCTCCGA

CAGTCACCGT

TCCTGGCACA

TGCTGGAGCG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGA

CTTCGCTGTC

GGCCTCCAAC

GCGCTGGATG

CGTGAACACG

WO 98/17810 WO 9817810PCTIUS97/20037 434 INFORMATION FOR SEQ ID NO:156: SEQUENCE CHARACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCCGGAGGTG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

ACGGAGATAC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GCACCCAGGA

GTGAGCTGTC

ATGAGGAGCT

TCAAGACTGT

ACTTTGTCAC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

CGCTGGGTCC

CAAATGTGCC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

AAGATGCAAG

TTTCAGCCC

TAAAGAGACC

TCCtGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

CCATCTCCTC

ACCCAGTCAC

TGGTCCTGGC

GCTTGCTGGA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGA

CGACTTCGCT

CGTGGCCTCC

ACAGCGCTGG

GCGCGTGAAC

INFORMATION FOR SEQ ID NO:157: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l57:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTTCGCTG

GTGGCCTCCA.

CAGCGCTGGA

CGCGTGAACA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GATCCGGAGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCC

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

CTTGCTGGAG

INFORMATION FOR SEQ ID NO:158: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCCGGAGGTG

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CAAACATGGC CCCCCCCAGC AGGAGACCTC CGAGCAGCTG GGTGCCTGGA GCTGCAGTGT GCTCAGGGGG AGGTAGTGGT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

ACCCAGGACT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

GCTCCTTCCA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGA

ACACAGCCCC

WO 98/17810

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

TTGCTGGAGC

ACTTCGCTGT CAAAATCCGT TGGCCTCCAA CCTGCAGGAC AGCGCTGGAT GGAGCGGCTC GCGTGAACAC GGAGATACAC 426 PCT/US97/20037 GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720 GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780 AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840 TTTGTCACCA AATGTGCCTT TCAGCCC 897 INFORMATION FOR SEQ ID NO:l59: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

AGCCCCATCT

GATTACCCAG

CGGCTGGTCC

CAAGGCTTGC

CCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GGTCAGGAGG

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

TGGAGCGCGT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGATCCGGA

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

GAACACGGAG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

GGTGGCACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

AGGACTGCTC

TGTCTGACTA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG

CTTCCAACAC

CCTGCTTCAA

AGCTCTGCGG GGGCCTCTGG CTGTCGCTGG GTCCAAGATG TCACCAAATG TGCCTTTCAG INFORMATION FOR SEQ ID NO:160: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTGCTCCT

TCTGACTACC

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGGAGACCTC

GGTGCCTGGA

GGTCAGGAGG

TCCAACACAG

TGCTTCAAGA

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

CGATGAAATT ATACATCACT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGATCCGGA

CCCCATCTCC

TTACCCAGTC

GCTGGTCCTG

AGGCTTGCTG

C

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

GGTGGCTCAG

TCCGACTTCG

ACCGTGGCCT

GCACAGCGCT

GAGCGCGTGA

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

GGGGAGGTAG

CTGTCAAAAT

CCAACCTGCA

GGATGGAGCG

ACACGGAGAT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG

TGGTACCCAG

CCGTGAGCTG

GGACGAGGAG

GCTCAAGACT

ACACTTTGTC

INFORMATION FOR SEQ ID NO:161: Wi SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA ATTGAGGCAA TTCTTCGTA-A TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGA-AT TCCGGGAAAA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

I 1 WO098/17810 434 PCT/US97/20037

TATCTGGTTA

CCGGGTGAAc

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

TCCGACTTCG

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGATCCGG

CTGTCAAAAT

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTACCCAG

CCGTGAGCTG

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GACTGCTCCT

TCTGACTACC

TAGAGGGCGG

CTCCTCCGTC

CCTCCAACCT

GCTGGATGG.A

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

TCCAACACAG

TGCTTCAA

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CCCCATCTCC

INFORMATION FOR SEQ ID NO:162: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162;

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CACAGCCCCA

CAA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

TCTCCTCCGA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

OGATTACOCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CTTCGCTGTC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AAAATCCGTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

CCTCCAACCT

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGCCGGT

CTCCTTCCAA

CTACCTGCTT

INFORMATION FOR SEQ It) NO:163: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTACCC

ATCCGTGAGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

AGGACTGCTC

TGTCTGACTA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGCCTCCAAC!

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTTCCAACAC

CCTGCTTCAA

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

AGCCCCATCT

GATTACCCAG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCTCCGACTT

TCACCGTG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGATCC

CGCTGTCAAA

INFORMATION FOR SEQ ID NO:164: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164: WO 98/17810

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

GACTTCGCTG

GTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

431

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAr

CAACAGTACG

ATCAACCCGT

CTGCAGGACG,

GAGCGGCTCA

GAGATACACT

CAGACCA.ACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

WO 9817810PCTIUS97/20037 TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAAGGCGG

CTCCTCCGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CATCTCCTCC

CCCAGTCACC

INFORMATION FOR SEQ ID NO:165: SEQUENCE CHARACTERISTICS: LENGTH; 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

CTATAATGAT

CGAACA.ACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

CCATCTCCTC

ACCCAGTCAC

TGGTCCTGGC

CGATGAKATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

CGACTTCGC!T

CGTGGCCTCC

ACAGCGCTGG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGATCCGGAG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAGGCTTGCT

CCC CCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

INFORMATION FOR SEQ ID NO:166: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION:,SEQ ID NO:166:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

CAGGACTGCT

CTGTCTGACT

GAGCTCTGCG

ACT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

CCTTCCAACA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

CAGCCCCATC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TCCTCCGACT

GTCACCGTGG

CTGGCACAGC

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT AAGGCTTGCT GGAGCGCGTG CCCCCCCCAG CTGTCTTCGC CCGAGCAGCT GGTGGCGCTG AGCTGCAGTG TCAGCCCGAC GTGGATCCGG AGGTGGCACC TCGCTGTCAA AATCCGTGAG CCTCCAACCT GCAGGACGAG GCTGGATGGA GCGGCTCAAG ACCTGCTTCA AGATTACCCA GGGGCCTCTG GCGGCTGGTC INFORMATION FOR SEQ ID NO:167: SEQUENCE CHARACTERISTICS; LENGTH: 888 base pairs TYPE: nucleic acid ~r WO 98/17810 PCTIUS97/20037 STRAflDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N'O: 167:.

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

AGGACTGCTC

TGTCTGACTA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CGATGAAATT ATACATCACT CAATTCTGAA GACATGGATA ATTCGTAAGG GCTGTCAAGC TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CCGCTTCGTC CAGACCAACA GCTGAAGCCC TGGATCACTC CGACTCCTCA ACCCTGGGCG CTTCCAACAC AGCCCCATCT CCTGCTTCAA. GATTACCCAG GGGCCTCTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA

TAAAGAGACC

TCCTGATGGA

ACTI'AGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGATCC

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

GAACACGGAG

INFORMATION FOR SEQ ID NO:168: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168!

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC!

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAGACCAACA.

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

TAAAGAGACC ACCTALACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC

TAGAGGGCGG

CTCCTCCGTC

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAG3CCCCC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

CTTGCTGGAG

CCCCAGCTGT

INFORMATION FOR SEQ ID NO:169: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA. TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC CACCAACATC CTGGTGGCGC TGAAGCCCTG GATCACTCGC TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GACTGCTCCT TCCAACACAG CCCCATCTCC TCTGACTACC TGCTTCAAGA TTACCCAGTC CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GTCGCTGGGT CCAAGATGCA AGGCTTGCTG ACCAAATGTG CCTTTCAGCC CCCCCCCAGC

ATACATCACT

GACATOGATA

GC!TGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

TCCGACTTCG

ACCGTGGCCT

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTGGATCCGG

CTGTC!AAAAT

CCAACCTGCA

GGATGGAGCG

ACACGGAGAT

TCGTCCAG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAAGCTCC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

AGGTACCCAG

CCGTGAGCTG

GGACGAGGAG

GCTCAAGACT

ACACTTTGTC

WO 98/17810 43 g WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AAAATCCGTG

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCTTCCAA

CTACCTGCTT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CACAGCCCCA

CAAGATTACC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

TCTCCTCCGA

CAGTCACCGT

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CTTCGCTGTC

GGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

INFORMATION FOR SEQ ID NO:171: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA.AC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

GTCAAAATCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTACCCAGGA

GTGAGCTGTC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

CTGCTCCTTC

TGACTACCTG

ATACATCACT TAAAGAGACC ACCTAACCCT GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC GTCACCGTGG CCTCCAACCT CTGGCACAGC GCTGGATGGA CTGGAGCGCG TGAACACGGA AGCTGTCTTC GCTTCGTCCA CTGGTGGCGC TGAAGCCCTG TGTCAGCCCG ACTCCTCAAC CAACACAGCC CCATCTCCTC

CTTCAA

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CGACTTCGCT

INFORMATION FOR SEQ ID NO:172: SEQUENCE CHRACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

ATACATCACT TAAAGAGACC ACCTAACCCT GACATGGATA TCCTGATGGA ACGAAACCTT GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC GTCACCGTGG CCTCCAACCT CTGGCACAGC GCTGGATGGA CTGGAGCGCG TGAACACGGA AGCTGTCTTC GCTTCGTCCA

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

WO 98/17810 440

PCI

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

GCTGTCAAAA

TGCAGGAGAC CTCCGAGCAG CCCGGTGCCT GGAGCTGCAG GTGGCACCCA GGACTGCTCC TCCGTGAGCT GTCTGACTAC CTGGTGGCGC TGAAGCCCTG GATCACTCGC TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT TTCCAACACA GCCCCATCTC CTCCGACTTC

CTGCTTCAA

AUS97/20037 720 780 840 879 INFORMATION FOR SEQ ID NO:173: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA.AC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

CCCATCTCCT

CTATAATGAT

CGAACAACCT

ACCTGCTC!GC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGCTCAGG

CCGACTTCGC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

GGGAGGTAGT

TGTCAAAATC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGTACCCAGG

CGTGAGCTGT

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA. TGCATCAGGT CTGCC.ACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT CCTCCAACCT GCAGGACGAG GCTGGATGGA GCGGCTCAAG TGAACACGGA GATACACTTT GCTTCGTCCA GACCAACATC TGAAGCCCTG GATCACTCGC ACTCCTCAAC CCTGGGCGGT ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAA INFORMATION FOR SEQ ID NO:174: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAkAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

CGA.ACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCT

TCCTCCGACT

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

CCTCCAACCT

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

AATCCGTGAG

INFORMATION FOR SEQ ID NO:175: SEQUENCE CHARACTERISTICS: LENGTH: 869 base pairs TYPE: nucleic acid STRANDEDNESS; single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NQ:175:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

WO 98/1 7810

CCGGGTGAAC

CATAAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

CCTTCCAACA

ACCTGCTTCA

CGTCTGGTCC AATCTCTACT CAAACATGGC CGCCTCCAAC TCCTGGCACA GCGCTGGATG TGCTGGAGCG CGTGAACACG CCAGCTGTCT TCGCTTCGTC AGCTGGTGGC GCTGAAGCCC AGTGTCAGCC CGACTCCTCA CAGCCCCATC TCCTCCGACT AGATTACCCA GTCACCGTG 44/

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCA-ACA

TGGATCACTC

ACCCTGGGCG

TCGCTGTCAA

CTCCTC!CGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGA-ACTT

GTGGATCCGG

AATCCGTGAG

PCT/US97120037 TAAAGAATCT 420 CGGGGGCCTC 480 TGGGTCCAAG 540 ATGTGCCTTT 600 CCTGCAGGAG 660 CTCCCGGTGC 720 AGGTACTGCT 780 CTGTCTGACT 840 869 INFORMATION FOR SEQ ID NO:176: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 872 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC TGGCGGCTGG TCCTGGCACA ATGCAAGGCT TGCTGGAGCG CAGCCCCCCC CCAGCTGTCT ACCTCCGAGC AGCTGGTGGC CTGGAGCTGC AGTGTCAGCC GCTCCTTCCA ACACAGCCCC ACTACCTGCT TCAAGATTAC

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

ATCTCCTCCG

CCAGTCACCG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

ACTTCGCTGT

TG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTC!CGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGATCCGG

CAAAATCCGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGCACT

GAGCTGTCTG

INFORMATION FOR SEQ ID NO:177: Wi SEQUENCE CHARACTERISTICS: LENGTH: 890 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l77: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGAACTCCAA ACCTGCTCGC ATTGAGGCAA TTCTTCGTAA.

CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC TGGCGGCTGG TCCTGGCACA ATGCAAGGCT TGCTGGAGCG CAGCCCCCCC CCAGCTGTCT ACCTCCGAGC AGCTGGTGGC CTGGAGCTGC AGTGTCAGCC GGGGGAGGTA GTGGTACTGC AAATCCGTGA GCTGTCTGAC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

TCCTTCCAAC

TACCTGCTTC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

ACAGCCCCAT

AAGATTACCC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

C!TCCTCCGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCC!GCCT

GCCAGAACTT

GTGGATCCGG

CTCCTC!CGAC

AGTCAC!CGTG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGCTCA

TTCGCTGTCA-

INFORMATION FOR SEQ ID NO:17B: SEQUENCE CHARACTERISTICS: LENGTH: 917 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT WO 98/17810 CGAACTCCAA ACCTGCTCGC ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC TGGCGGCTGG TCCTGGCACA ATGCAAGGCT TGCTGGAGCG CAGCCCCCCC CCAGCTGTCT ACCTCCGAGC AGCTGGTGGC CTGGAGCTGC AGTGTCAGCC GGAGGTGGAT CCGGAGGTGG GCCCCATCTC CTCCGACTTC ATTACCCAGT CACCGTG

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTCAGGGGGA

GCTGTCAAAA

4 4L

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGTAGTGGTA

TCCGTGAGCT

PCTIUS97/20037 ACTTAGAAAA TGCATCAGGT 180 CTGCCACGGC CGCACCCTCT 240 TCCGGGAAAA ACTGACGTTC 300 TAGAGGGCGG TGGAGGCTCC 360 CTCCTCCGTC TAAAGAATCT 420 AGGAGCTCTG CGGGGGCCTC 480 AGACTGTCGC TGGGTCCAAG 540 TTGTCACCAA ATGTGCCTTT 600 TCTCCCGCCT CCTGCAGGAG 660 GCCAGAACTT CTCCCGGTGC 720 GTGGGTCAGG AGGTGGGTCA 780 GGACTGCTCC TTCCAACACA 840 GTCTGACTAC CTGCTTCAAG 900 INFORMATION FOR SEQ ID NO:179: ()SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

ACTTCGCTGT

TGGCCTCCAA

AGCGCTGGAT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

ATCCGGAGGT

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG,

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACT

TAA.AGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA.

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA.

.AAGCCCTGGA

TCCTCAACCC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

ATCCGGAGGT

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC TCCAAGATGC AAGGCTTGCT GCCTTTCAGC CCCCCCCCAG CAGGAGACCT CCGAGCAGCT CGGTGCCTGG AGCTGCAGTG GGCACCCAGG ACTGCTCCTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG

CTCAAGACT

ACCTA6ACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

INFORMATION FOR SEQ ID NO:181: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 WO 9817810PCT/US97/20037 443 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTAAGG TTCTTCGtAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA CGTCTGGTCC AATCTCTACT CAAACATGGC CGTC!GCTGGG TACACTTTGT CACCAAATGT CCAACATCTC CCGCCTCCTG TCACTCGCCA GAACTTCTCC TGGGCGGrGG ATCCGGAGGT AACACAGCCC CATCTCCTCC TTCAAGATTA CCCAGTCACC TCTGGCGGCT GGTCCTGGCA ATACATOACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC TCCAAGATGC AAGGCTTGCT GCCTTTCAGC CCCCCCCCAG CAGGAGACCT CCGAGCAGCT CGGTGCCTGG AGCTGCAGTG GGCTCAGGGG GAGGTAGTGG GACTTCGCTG TCAAAATCCG GTGGCCTCCA. ACCTGCAGGA CAGCGCTGGA TGGAGCGGCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

TACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACT

INFORMATION FOR SEQ ID NO:182: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

GGGGGAGGTA

GCTGTCAAAA

TCCAACCTGC

TGGATGGAGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

GTGGTACCCA

TCCGTGAGCT

AGGACGAGGA

GGCTCAAGAC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

GGACTGCTCC

GTCTGACTAC

GCTCTGCGGG

T

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TTCCAACACA

CTGCTTCAAG

GGCCTCTGGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGC!CACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAGGCTTGC!T

CCC COCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

GGCTGGTCC!T

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGCCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

INFORMATION FOR SEQ ID NO:183: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

GCTAACTGCT

TTGCTGGAC!C

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GACTGCTCCT

TCTGACTACC

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CTATAATGAT

CGAACAACCT

ACCTGC!TCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

TCCAACACAG

TGCTTCAAGA

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CCCCATCTCC

TTACCCAGTC

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAGACCAACA,

TGGATCACTC.

ACCCTGGGCG

TCCGACTTCG

ACCGTGGCCT

GCACAGCGCT

GAGCGCGTGA

TGTCTT

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAA-A TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA. ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TCTC!CCGCCT CCTGCAGGAG GCCAGAACTT CTCCCGGTGC GTGGATCCGG AGGTACCCAG CTGTCAAAAT CCGTGAGCTG CCAACCTGCA GGACGAGGAG GGATGGAGCG GCTCAAGACT ACACGGAGAT ACACTTTGTC INFORMATION FOR SEQ ID NO:184: Ci) SEQUENCE CHARACTERISTICS: WO 98/17810 WO 9817810PCTIUS97/20037 LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

CAGGACTGCT

CTGTCTGACT

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

CCTTCCAACA

ACCTGCTTCA

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGccc

CGACTCCTCA

CAGCCCCATC

AGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CAGACCAACA TCTCCCGCCT TGGATCACTC GCCAGAACTT ACCCTGGGCG GTGGATCCGG TCCTCCGACT TCGCTGTCAA GTCACCGTGG CCTCCAACCT CTGGCACAGC GCTGGATGGA CTGGAGCGCG TGAACACGGA

AGCTGTCTT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGCACC

AATCCGTGAG

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

INFORMATION FOR SEQ ID NO:185: SEQUENCE CHARACTERISTICS:, LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGGGGAGGTA

GCTGTCAAAA

TCCAACCTGC

TGGATGGAGC

AACACGGAGA

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

GTGGTACCCA

TCCGTGAGCT

AGGACGAGGA

GGCTCAAGAC

TACACTTTGT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

GGACTGCTCC

GTCTGACTAC

GCTCTGCGGG

TGTCGCTGGG

CACCAAATGT

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CAGACCAACA TCTCCCGCC!T TGGATCACTC GCCAGAACTT ACCCTGGGCG GTGGATCCGG TTCCAACACA GCCCCATCTC CTGCTTCAAG ATTACCCAGT GGCCTCTGGC GGCTGGTCCT TCCAAGATGC AAGGCTTGC!T GCCTTTCAGC CCCCCCCCAG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

GGAGCGCGTG

CTGTCTT

INFORMATION FOR SEQ ID NO:186: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

GCTAACTGCT

TTGCTGGACC

CGAACTCCA.A

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

CACAGCCCCA

CAAGATTACC

TGGCGGCTGG

ATGCAAGGCT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCTCCTCCGA

CAGTCACCGT

TCCTGGCACA

TGCTGGAGCG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTCAGGGGGA

CTTCGCTGTC

GGCCTCCAAc

GCGCTGGATG

CGTGAACACG

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAA.GC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC CAGACCAACA TCTC!CCGCC!T TGGATCACTC GCCAGAACTT ACCCTGGGCG GTGGGTCAGG GGTAGTGGTA CCCAGGACTG AAAATCCGTG AGCTGTCTGA.

CTGCAGGACG AGGAGCTCTG GAGCGGCTCA AGACTGTCGC GAGATACACT TTGTCACCAA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CTCCTTCCAA.

CTACCTGCTT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

WO098/17810 1/ q!5 CAGCCCCCCC CCAGCTGTCT T INFORMATION FOR SEQ ID NO:187: SEQUENCE CHARACTERISTICS: LENGTH: 876 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187: PCTIUS97/20037

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA.AC!

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

AAGATGCAAG

TTTCAGCCCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

CCATCTCCTC

ACCCAGTCAC

TGGTCCTGGC

GCTTGCTGGA

CCCCCAGCTG

CGATGA.AATT ATACATCACT CAATTCTGAA GACATGGATA ATTCGTAAGG GCTGTCAAGC TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAAGCTCC

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

CGACTTCGCT

CGTGGCCTCC

ACAGCGCTGG

GCGCGTGAAC

TCTTCGCTTC

ATCAACCCGT

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

ACGGAGATAC

GTCCAG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACTGT

ACTTTGTCAC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

CGCTGGGTCC

CAAATGTGCC

INFORMATION FOR SEQ ID NO:188: SEQUENCE CHARACTERISTICS: LENGTH: 879 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

GCTAACTGCT

TTGCTGGAC!C

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

TTCCAACACA

CTGCTTCAAG

GGCCTCTGGC

TCCA.AGATGC

GCCTTTCAGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

GCCCCATCTC

ATTACCCAGT

GGCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CGATGAAATT ATACATCACT CAATTCTGAA GACATGGATA ATTCGTAAGG GCTGTCAAGC TCTCCAACCA TGTCTGCCCT

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

GGAGCGCGTG

CTGTCTTCGC

TGGCAAGAAT

CAACAGTACG

ATCA.ACCCGT

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

GCTGTCAAAA

TCCAACCTGC

TGGATGGAGC

AACACGGAGA

TTCGTCCAG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTGGCACCCA

TCCGTGAGCT

AGGACGAGGA

GGCTCAAGAC

TACACTTTGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAAGCTCC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

GGACTGCTCC

GTCTGACTAC

GCTCTGCGGG

TGTCGCTGGG

CACCAAATGT

INFORMATION FOR SEQ ID NO:189: SEQUENCE CHARACTERISTICS: LENGTH: 897 base pairs TYPE: nucleic acid STRANDEDNESS; single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAA.ATCTC

CTGGTGGCGC

TGTCAGCCCG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGA.AGCCCTG

ACTCCTCAAC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC

CAGAACTTCT

GGATCCGGAG

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAALA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAAGCTCC CTCCTCCGTC TAXAGAATCT TGCAGGAGAC CTCCGAGCAG CCCGGTGCCT GGAGCTGCAG GTGGCTCAGG GGGAGGTAGT 1 1- WO 98/17810 GGTACCCAGG ACTGCTCCTT CCAACACAGC CGTGAGCTGT CTGACTACCT GCTTCAAGAT GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA CACTTTGTCA CCAAATGTGC CTTTCAGCCC W,4 0 PCTIUS97/20037 CCCATCTCCT CCGACTTCGC TGTCAAAATC 660 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 720 CTGGTCCTGG CACAGCGCTG GATGGAGCGG 780 GGCTTGCTGG AGCGCGTGAA CACGGAGATA 840 CCCCCCAGCT GTCTTCGCTT CGTCCAG 897 INFORMATION FOR SEQ ID NO:190; SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAP.

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA

CCTCCAACCT

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

AATCCGTGAG

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

G

ATACATCACT

GACATOGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

INFORMATION FOR SEQ ID NO:191: SEQUENCE CHARACTERISTICS: LENGTH: 2247 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GGATCCACCA

ATGTCTACAA

GATTCATCAG

GGGTGTGCGT

GATGTATCTG

CTCTGGGTCT

GGAGTTGTTT

TTTATTCAGA

CTGCTTTACA

TGCATATCTG

GAAAGCTGTA

TTATTTGGGA

CTGTTCACAA

GTAGGGGAAC

ACCTGGGAAT

TCAACAAACA

GACACCGGAT

ATCGTAGAAA

TATGAAGAGT

ACCTTCTCTC

TCCAAGTTTT

GATGCCCAAT

GAAGCATCGG

TGGAAGAAGT

AATAGAAAGG

AGTGAAGCCA

TGTGAGACGA

ATCATCCTGG

CTCTGTTGCA

AGCAGCCTGG

CTTGGCACGC

CCCTGGGAGT

TGAGCCGCCT

ATCAAGATCT

TGGGGAAGTC

TGAGACCCCA

CTTCCATCAC

TTAAGCACAG

CCATGGTCAT

GTGAAGCTAC

CATTAAGAAG

AGAGCGTTCC

AAGAAGAAAG

TGGACATAAG

TAGATCTAAA

CCTTATGGAT

TAGAAAACAA.

GAACTATGAT

ACTACACTTG

AGGGATTTAT

TTTGTTTTTC

GAAAATCATT

GCAATCATAA

TTACCAAAAT

CAAGTCAGGC

GTTCAGACAA

CTAACAGAAA

TAAAAGGGTT

TCCTTTTAAA

GCCTGTTCGG

GCCCCAACAG

GCTCCTGGGT

CACCCATCAC

CCCATAACAG

GCCCGTCCTG CTCCTGCTCC GCCTGTGATC AAGTGTGTTT ATCATCATAT CCCATGGTAT GAGCTCAGGG ACAGTGTACG ACTGCAAGTG, CTGGTCGATG, CTCCCTGAAT TGCCAGCCAC TTTGAAAATG ACAGAAACCC CAATTACACA ATATTGTTTA ACCTTACTTT AGAAAAATGG AGAGCCGATC GTGGAATGGG TCCAGCTGTT GTTAAAAAGG GTGCTGTGCC AGAAATGAAC TCAAACTCCT CAGACCACAT AAGGTGCAAA GCTGTTCATG AGCACTCGAG GAGGGCAACT ACGGATTCTG TTTGCTTTTG, TTCCTCTTCA AAGCATCCCA AAATGCTACC AATTCAAGTG TGTCAGGTTT AAAGCCTACC TCCTTGTGAG CAAAAGGGTC GCACCAGCCA GGAGAATATA GTTCACGCTG AATATAAGAA GTCCTGTTTC TCGGATGGAT GTCTCCCAAC TGCACAGAAG AGTGTTTGGA CAGTGGGTGT CCTGGTCAAG TGCTGTGCAT CTCTCCAGGC CCCTTCCCTT CCTCCTGCTG, TTGCTCACCT GAAGAATCCC CTCTGGCCAA GCCCACAATC ATGGAGGAGG CAAGCTCACA GTGCTGGAGG CTCAGAGACC TGTGGCCTCC

AACTCCTGGT

TAATCAATCA

CAGAATCCCC

AAGCTGCCGC

CCCCAGGGAA

ATTTTGATTT

AAGCTGGAGA

CAGTGAGTAT

AAAACCAGGA

TGCTTTGCGA

AGGAAAAAGT

TGGGCAGGGA

TGCCACAATT

TGAACCATGG

ACTTTGAGAT

TATCATCAGT

GTCAATCAGC

CCGCCCCGCC

TAAGAACAAT

GGAAGACCTC

TGTGGAAGTG

CATTTCCTGT

ACAAAACAGA

ATACCTACTT

AAGAAATACC

CGCCCTGGTC

TTCACAGGGG

GCTTCATGAA

ATGCACCAGG

ATTTCTTAAA

ATTCGGGCTC

GAGTACCTAT

GGCAAGAAAC

TTTGGTTACC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 AAGATTATGA AATTGACCAA CACAAATCAG ATGTACGTGG TTGATAACGG ATACAGCATA TATTCCATGC AGAAAATGAT GGAAACCTCA AGTGCTCGCA ACCCATTACC ATCTTGGACC

AGATCACAGA

CGAGCAGTAC

ACAATTCCCT

TCATCCAAGA

GCCTCTGTGG

GTGTCCCAGA

ATGCCTTCCA

AGGATGAAAA

CCACTCTGGT

AGGAGTCTGG

TCTAAACATG

TGGCACATCT

CAACGAATTC

AACTGCCTGG

CCCAGCTCAC

GCTGCCCGGC

GAAGCCGGTG

CCAGACCTAT

WO 98/17810

GTGCTCCAGG

GATCAGGTCC

CTCCGCTGTG

GAGAACCTCT

GAGGACGACT

CATGGGATGG

4 4 GGGACCCAAG AGCAGTTTCC ACCCAGCCCC AATCCCAGTC TTTATGGGCA GCTGCTGGGC AGCCCCACAA GCCCAGGGCC ACTCCACTCA GCCCCTCTTG GCGGGCCTCA CCCCCAGCCC GGTTCCAGGC CAGCCCCTTG GGGACCCTGG TAACCCCAGC GTGTCTTTGG GCCACTGCTC AACTTCCCCC TCCTGCAGGG AGGCGCTGGG GAGCTTC PCT/US97/20037 TGGCACCAGC 1980 AGGGCACTAT 2040 CAAGTCCTAT 2100 CCCAAGCCAG 2160 GATCCGGGTC 2220 2247 INFORMATION FOR SEQ ID NO:192: SEQUENCE CHARACTERISTICS: LENGTH: 1047 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

TTGCTGGAGC

CCCAGCTGTC

CAGCTGGTGG

CAGTGTCAGC

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

ACTTCGCTGT

TGGCCTCCAA

AGCGCTGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG,

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

ACCCAGGACT

GAGCTGTC!TG

GAGGAGCTCT

AAGACTGTCG

TTTGTCACCA

ATCTCCCGCC

CGCCAGAACT

TCCTGCTCAA

AGA.AGCTGTG

CTCTGGGCAT

GCTGC!TTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

GC!TCCTTCCA.

ACTACCTGCT

GCGGGGGCCT

CTGGGTCCAA

AATGTGC!CTT

TC!CTGCAGGA

TCTCCCGGTG

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 INFORMATION FOR SEQ ID NO:193: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 942 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

CCGTCTCCTC

TTCCAACACA

CTGCTTCAAG

GGCCTCTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

ACTGCTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

CGTCTAAAGA

GCCCCATCTC

ATTACCCAGT

GGCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CTCCCCGGGT

ATCTCATAAA

CTCCGACTTC

CACCGTGGCC

GGCACAGCGC

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG,

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GAACCGTCTG

TCTCCAAACA

GCTGTCAAAA

TCCAACCTGC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

CCGACTTCGC

CCGTGGC!CTC

CACAGCGCTG

AGCGCGTGAA

GTC!TTC!GCTT

TGGCGCTGAA

AGCCCGACTC

GTCCAATCTC

TGGCTACCCA

TCCGTGAGCT

AGGACGAGGA

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TG

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

TACTATCAAC

GGACTGCTCC

GTCTGACTAC

GCTCTGCGGG

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

INFORMATION FOR SEQ ID NO:194: SEQUENCE CHARACTERISTICS: CA) LENGTH; 1047 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGAC!TTCGC TGTCAAAATC t~ WO 98/1 7810 PCTIUS97/20037

CGTGAGCTGT

GACGAGGAGc

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

CCGTCTCCTC

GCCAGCTCCC

GGCGATGGCG

GAGCTGGTGC

AGCCAGGCCC

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

CGCCGGGCAG

CGCGTTTTAC

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

CGTCTAAAGA

TGCCCCAGAG

CAGCGCTCCA

TGCTCGGACA

TGCAGCTGGC

TGCAGGCCCT

ACGTCGCCGA

CCCTGCAGCC

GAGGGGTCCT

GCCACCTTGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CTCCCCGGGT

ATCTCATAAA

CTTCCTGCTC

GGAGAAGCTG

CTCTCTGGGC

AGGCTGCTTG

GOAAGGGATA

CTTTGCCACC

CACCCAGGGT

GGTTGCTAGC

GCAGCCC

TACCCAGTCA

CTGGTCCTGG,

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GAACCGTCTG,

TCTCCAAACA

AAGTGCTTAG

TGTGCCACCT

ATCCCCTGGG

AGCCAACTCC

TCCCCCGAGT

ACCATCTGGC

GCCATGCCGG

CATCTGCAGA

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTCCAATCTC

TGGCTACACC

AGCAAGTGAG

ACAAGCTGTG

CTCCCCTGAG

ATAGCGGCCT

TGGGTCCCAC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCATGGATC

CTCAACCCTG

TACTATCAAC

ATTAGGCCCT

GAAGATCCAG

CCACCCCGAG

CTCCTGCCCC

TTTCCTCTAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 AGCAGATGGA AGAACTGGGA CCTTCGCCTC TGCTTTCCAG GCTTCCTGGA GGTGTCGTAC INFORMiATION FOR SEQ ID NO:195: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1569 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

TTGCTGGAGC

CCCAGCTGTC

CAGCTGGTGG

CAGTGTCAGC

CCGTCTGGTC

CCAAACATGG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

ACGGAGATAC

GTCCAGACCA

CCCTGGATCA

TCAACCCTG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

ACTTCGCTGT

TGGCCTCCAA

AGCGCTGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

CAATCTCTAC

CTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACTGT

ACTTTGTCAC

ACATCTCCCG

CTCGCCAGAA

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTGTAC

TATCAACCCG

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

CGCTGGGTCC

CAAATGTGCC

CCTCCTGCAG

CTTCTCCCGG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

ACTCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

TTTGTCACCA

ATCTCCCGCC

CGCCAGAACT

GTAGAGGGCG

TCTCCTCCGT

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

AAGATGCAAG

TTTCAGCCCC

GAGACCTCCG

TGCCTGGAGC

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

GCTCTTTTCA

ACTACCTGCT

GCGGGGGCCT

CTGGGTCCAA

AATGTGCCTT

TCCTGCAGGA

TCTCCCGGTG

GTGGAGGCTC

CTAAAGAATC

CCATCTCCTC

ACCCAGTCAC

TGGTCCTGGC

GCTTGCTGGA

CCCCCAGCTG

AGCA.GCTGGT

TGCAGTGTCA.

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

CCCGGGTGAA

TCATAAATCT

CGACTTCGCT

CGTGGCCTCC

ACAGCGCTGG

GCGCGTGAAC

TCTTCGCTTC

GGCGCTGAAG

GCCCGACTCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1569 INFORMATION FOR SEQ ID NO:196: SEQUENCE CHARACTERISTICS: LENGTH: 1380 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO.196:

GCTAACTGCT

TTGCTGGACC

CGACTTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GACTTCGCTG

CTATAATGAT

CGAACAACCT

ACCTGGAGAG

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCAAAATCCG

CGATGAAATT ATACATCACT CAATGACGAA GACGTCTCTA CTTCGTAAGG GCTGTCAAGA TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT CACTCAGGAC TGCTCTTTTC! TGAGCTGTCT GACTACCTGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AACACAGCCC

TTCAAGATTA

ACCTGCACCT

CCGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CATCTCCTCC

CCCAGTCACC

WO 98/17810

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCCGACTCCT

CCAATCTCTA

GCTACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAGACCAA

CCTGGATCAC

CAACCCTGTA

CTATCAACCC

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

CATCTCCCGC

TCGCCAGAAC

CGTAGAGGGC

GTCTCCTCCG

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

14,-9

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

GGTGGAGGCT

TCTAAAGAAT

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

AGACCTCCGA

GCCTGGAGCT

CCCCGGGTGA

CTCATAAATC

CCGACTTCGC

CCr-TGGCCTC PCT/tUS97/20037 GGTCCTGGCA 600 CTTGCTGGAG 660 CCCCAGCTGT 720 GCAGCTGGTG 780 GCAGTGTCAG 840 ACCGTCTGGT 900 TCCAAACATG 960 TGTCAAAATC 1020 CAACCTGCAG 1080 CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA GTCTTCGCTT CGTCCAGACC TGGCGCTGAA GCCCTGGATC AGCCCGACTC CTCAACCCTG 1140 1200 1260 1320 1380 INFORMATION FOR SEQ, ID NO:197: SEQUENCE CHARACTERISTICS: LENGTH: 1569 base pairs TYPE: nucleic acid STRAN'DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

1569 420

TACTATCAAC

ATTGGGCCCT

AA.AGATCCAG

CCACCCCGAG

CTCCTGCCCC

TTTCCTCTAC

CTTGGACACA

AGAACTGGGA

TGCTTTCCAG

GGTGTCGTAC

CCCGGGTGAA

TCATAAATCT

CGACTTCGCT

CGTGGCCTCC

ACAGCGCTGG

GCGCGTGAAC

TCTTCGCTTC

GGCGCTGAAG

GCCCGACTCC

1569 ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GALACCGTCTG GTCCAATCTC 480 CCGTCTCCTC CGTCTAAAGA. ATCTCATAAA TCTCCAAACA TGGC 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCA 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAA( 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCC( 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAG( 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGG' 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCA( 900 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTT( 960 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTT( 1020 CGCGTTCTAC GCCACCTTGC GCAGCCCTAC GTAGAGGGCG GTGG 1080 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAJ 1140 CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCAT( 1200 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCC~ 1260 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGT( 1320 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTT( 1380 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCC( 1440 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCA 1500 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCA( 1560 TCAACCCTG

TACACC

%.GTGAG

CTGTG

CCTGAG

CGGCCT

ECCCAC

~ATGGA

CGCCTC

CCTGGA

kGGCTC

~AATC

CTCCTC

k'GTCAC

CCTGGC

GCTGGA

CAGCTG

GCTGGT

GTGTCA

INFORMATION FOR SEQ ID NO:198: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1003 base pairs TYPE: nucleic acid STRA1NDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

GGCCACTCAG

CCGTGAGCTG

GGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GTACGTAGAG

TACACCATTG

AGTGAGAAAG

GCTGTGCCAC

GACTGCTCTT

TCTGACTACC

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

GGCGGTGGAG

GGCCCTGCCA

ATCCAGGGCG

CCCGAGGAGC

TTCAACACAG

TGCTTCAAGA

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GCTCCCCGGG

GCTCCCTGCC

ATGGCGCAGC

TGGTGCTGCT

CCCCATCTCC

TTACCCAGTC

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGTGGTTCT

CCAGAGCTTC

GCTCCAGGAG

cGGAcACTCT TCCGACTTCG CTGTCAAAAT ACCGTGGCCT CCAACCTGCA GCACAGCGCT GGATGGAGCG GAGCGCGTGA ACACGGAGAT TGTCTTCGCT TCGTCCAGAC GTGGCGCTGA AGCCCTGGAT CAGCCCGACT CCTCAACCCT GGCGGCGGCT CCAACATGGC CTGCTCAAGT CTTTAGAGCA AAGCTGTGTG CCACCTACAA CTGGGCATCC CCTGGGCTCC WO 98/17810

CCTGAGCTCC

CGGCCTTTTC

TCCCACCTTG

GATGGAAGAA

CGCCTCTGCT

CCTGGAGGTG

TGCCCCAGCC

CTCTACCAGG

GACACACTGC

CTGGGAATGG

TTCCAGCGCC

TCGTACCGCG

AGGCCCTGCA

GGCTCCTGCA

AGCTGGACGT

CCCCTGCCCT

GGGCAGGAGG

TTCTACGCCA

GCTGGCAGGC

GGCCCTGGAA

CGCCGACTTT

GCAGCCCACC

GGTCCTGGTT

CCTTGCGCAG

TGCTTGAGCC

GGGATATCCC

GCCACCACCA

CAGGGTGCCA

GCTAGCCATC

CCG

PCTIUS97/20037 AACTCCATAG 720 CCGAGTTGGG 780 TCTGGCAGCA 840 TGCCGGCCTT 900 TGCAGAGCTT 960 1003 INFORMATION FOR SEQ ID NO:199: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

GAGCTCTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

TCCGACTTCG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGGGCCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGATCCGG

CTGTCAAAAT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCA-ACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTACCCAG

CCGTGAGCTG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GACTGCTCCT

TCTGACTACC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCC ACGGC

TCCGGGAAAA

TAGAGGGCGG

C!TCCTC!CGTC

CCTCCAACCT

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGC!CCTG

ACTCCTCAAC

TCCAACACAG

TGCTTCAA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CCCCATCTCC

INFORMATION FOR SEQ ID NO:200: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200: GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGAACTCCAA ACCTGCTCGC ATTGAGGCAA TTCTTCGTAA CGACATCCAA TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC GAGCTCTGCG GGGGCCTCTG ACTGTCGCTG GGTCCAAGAT GTCACCAAAT GTGCCTTTCA TCCCGCCTCC TGCAGGAGAC CAGAACTTCT CCCGGTGCCT GGGTCAGGAG GTGGGTCAGG CACAGCCCCA TCTCCTCCGA.

CAA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGATTACCCA

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CTTCGCTGTC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GTCACCGTGG

CTGGCAC!AGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AAAATCCGTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAA.A

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

C!CTCCAACCT

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCAGGACGAG

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCTTCCAA

CTACCTGCTT

INFORMATION FOR SEQ ID NO:201: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTA-AGG TTCTTCGTAA TCTCCAACCA ATACATCACT TAAAGAGACC ACCTAACCCT GACATGGATA TCCTGATGGA ACGAAACCTT GCTGTCAAGC ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC CGCACCCTCT WO 98/17810

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTACCC

ATCCGTGAGC

TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA

CGTCTGGTCC

CAAACATGGC

TCCTGGCACA.

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

AGGACTGCTC

TGTCTGACTA

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTTCCAACAC

CCTGCTTCAA

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

AGCCCCATCT

GATTACCCAG

PCTIUS97/20037 TCCGGGAAMA ACTGACGTTC 300 TAGAGGGCGG TGGAGGCTCC 360 CTCCTC!CGTC TAAAGAATCT 420 AGGAGCTCTG CGGGGGCCTC 480 AGACTGTCGC TGGGTCCAAG 540 TTGTCACCAA ATGTGCCTTT 600 TCTCCCGCCT CCTGCAGGAG 660 GCCAGAACTT CTCCCGGTGC 720 GTGGGTCAGG AGGTGGATCC 780 CCTCCGACTT CGCTGTCAAA 840 TCACCGTG 888 INFORMATION FOR SEQ ID NO:202; SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

GACTTCGCTG

GTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGCCTCCAAC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TAAAGAGACC ACCTAACCCT TCCTGA.TGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCC.ACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAAGGCGG TGGAGGCTCC

CTCCTCCGTC

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TAAAGAATCT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CATCTCCTCC

CCCAGTCACC

INFORMATION FOR SEQ ID NO:203: SEQUENCE CHARACTERISTICS: LENGTHO 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

CAACACAGCC

CTTCAAGATT

CTCTGGCGGC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

CCATCTCCTC

ACCCAGTCAC

TGGTCCTGGC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG,

GAACTTCTCC

GTCAGGAGGT

CGACTTCGCT

CGTGGCCTCC

ACAGCGCTGG

ATACATCACT TAAAGAGACC GACATGGATA TC!CTGATGGA

GCTGTCA.AGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGATCCGGAG

GTCAAAATCC

AACCTGCAGG

ATGGAGCGGC

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

A.AGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTACCCAGGA

GTGAGCTGTC

ACGAGGAGCT

TCAAGACT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

CTGCTCCTTC

TGACTACCTG

CTGCGGGGGC

INFORMATION FOR SEQ ID NO:204: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204: WO 98/17810 WO 9817810PCT/US97/20037 4 GCTAACTGCT CTATAATGAT TTGCTGGACC CGAACAACCT CGAACTCCAA ACCTGCTCGC ATTGAGGCAA TTCTTCGTAA CGACATCCA-A TCATCATCAA TATCTGGTTA CCCTTGAGCA CCGGGTGAAC CGTCTGGTCC CATAAATCTC CAAACATGGC AACACGGAGA TACACTTTGT TPCGTCCAGA CCAACATCTC AAGCCCTGGA TCACTCGCCA TCCTCAACCC TGGGCGGTGG CAGGACTGCT CCTTCCAACA CTGTCTGACT ACCTGCTTCA GAGCTCTGCG GGGGCCTCTG

ACT

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

CAGCCCCATC

AGATTACCCA

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TCCTCCGACT

GTCACCGTGG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

TCjGCTGTCAA

CCTCCAACCT

GCTGGATGGA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

AGGTGGCACC

AATCCGTGAG

GCAGGACGAG

GCGGCTCAAG

GCGGCTGGTC CTGGCACAGC INFORMATION FOR SEQ ID NO:205: SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTACCC

ATCCGTGAGC

CAGGACGAGG

CGGCTCAAGA

ATACACTTTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

AGGACTGCTC

TGTCTGACTA

AGCTCTGCGG

CTGTCGCTGG

TCACCAAATG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTTCCAACAC

CCTGCTTCAA'

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

AGCCCCATCT

GATTACCCAG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCTCCGACTT

TCACCGTGGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGATCC

CGCTGTCAAA

CTCCAACCTG

CTGGATGGAG

GAACACGGAG

INFORMATION FOR SEQ ID NO:206: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCA.A

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

GACTTCGCTG

GTGGCCTCCA

CAGCGCTGGA

CGCGTGAACA

CTT

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAAACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TCTCCCGCCT CCTGCAGGAG GCCAGAACTT CTCCCGGTGC GTGGGTCAGG AGGTGGGTCA AACACAGCCC CATCTCCTCC TTCAAGATTA CCCAGTCACC TCTGGCGGCT GGTCCTGGCA AGATGCAAGG CTTGCTGGAG TTCAGCCCCC CCCCAGCTGT INFORMATION FOR SEQ ID NO:207: Wi SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs WO 98/17810 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207: PCT/US97/20037

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

GACTGCTCCT

TCTGACTACC

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

TCCAACACAG

TGCTTCAAGA

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

CCCCATCTCC

TTACCCAGTC

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC!

CAGAACTTCT

GGGTCAGGAG

TCCGACTTCG

ACCGTGGCCT

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGCAGGAGAC

CCCGGTGCCT

GTGGATCCGG

CTGTCAAAAT

CCAACCTGCA

GGATGGAGCG

ACACGGAGAT

TCGTCCAG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAAGCTCC

TAAAGAATCT

CTCCGAGCAG

GGAGCTGCAG

AGGTACCCAG

CCGTGAGCTG

GGACGAGGAG

GCTCAAGACT

ACACTTTGTC

INFORMATION FOR SEQ ID NO:208: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AA.AATCCGTG

CTGCAGGACG

GAGCGGCTCA

GAGATACACT

CAG

CTATAATGAT

CGAAC AACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

AGGAGCTCTG

AGACTGTCGC

TTGTCACCAA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

CACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCTTCCAA

CTACCTGCTT

CGGGGGCCTC

TGGGTCCAAG

ATGTGCCTTT

ATACATOACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TCCCGCCTCC!

CAGAACTTCT

GGGTCAGGAG

CACAGCCCCA

CAAGATTACC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

TAAAGAGACC ACCTAACCCT TCCTGATGGA ACGAA.ACCTT ACTTAGAAAA TGCATCAGGT CTGCCACGGC CGCACCCTCT TCCGGGAAAA ACTGACGTTC TAGAGGGCGG TGGAGGCTCC CTCCTCCGTC TAAAGAATCT TGCAGGAGAC CTCCGAGCAG CCCGGTGCCT GGAGCTGCAG GTGGGTCAGG AGGTGGATCC TCTCCTCCGA CTTCGCTGTC CAGTCACCGT GGCCTCCAAC TCCTGGCACA GCGCTGGATG TGCTGGAGCG CGTGAACACG CCAGCTGTCT TCGCTTCGTC INFORMATION FOR SEQ ID NO:209: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

CTATAATGAT CGATGAAATT ATACATCACT CGAACAACCT CAATTCTGAA GACATGGATA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC TTCTTCGTA-A TCTCCAACCA TGTCTGCCCT TCATCATCAA GGCAGGTGAC TGGCAAGAAT CCCTTGAGCA AGCGCAGGAA CAACAGTACG CGTCTGGTCC AATCTCTACT ATCAACCCGT CAAACATGGC TTCTAATCTG CAAGATGAAG TGGCACAGCG CTGGATGGAG CGGCTCAAGA TGGAGCGCGT GAACACGGAG ATACACTTTG GCTGTCTTCG CTTCGTCCAG ACCAACATCT TGGTGGCGCT GAAGCCCTGG ATCACTCGCC GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC CCTCCGACTT CGCTGTCAAA ATCCGTGAGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCC!ACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

AGCTGTGCGG

CTGTC!GCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

WO 98/17810 GATTACCCAG TCACCGTGGC C 4'.,P PCT/US97/20037 INFORMATION FOR SEQ ID NO:210: Wi SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs -TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGA.AC

CATAAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

CTATAATGAT CGATGAAATT CGAACAACCT CAATTCTGAA ACCTGCTCGC ATTCGTAAGG TTCTTCGTAA TCTCCAACCA TCATCATCAA GGCAGGTGAC CCCTTGAGCA AGCGCAGGAA

CGTCTGGTCC

CAAACATGGC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

AATCTCTACT

CAACCTGCAA

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAA.GC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC GATGAAGAGC TGTGTGGGGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATGTGC AACATCTCCC GCCTCCTGCA.

ACTCGCCAGA ACTTCTCCCG GGCGGTGGGT CAGGAGGTGG GGTACCCAGG ACTGCTCCTT CGTGAGCTGT CTGACTACCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

INFORMATION FOR SEQ ID NO:211: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGAC!C CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGG'rCC AATCTCTACT CATAAATCTC CAAACATGGC TCTGCAGGAT GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC TTGCTGGAGC GCGTGAACAC GGAGATACAC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC CAGCTGGTGG CGCTGAAGCC CTGGATCACT CAGTGTCAGC! CCGACTCCTC AACCCTGGGC TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ATCTCCTCCG ACTTCGCTGT CAAAATCCGT CCAGTCACCG TGGCCTCCAA C

ATACATCACT

GACATGGATA

GCTGTCA-AGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GAGGAACTGT

AAGACTGTCG

TTTGTCACCA

ATCTCCCGCC

CGCCAGA.ACT

GGTGGGTCAG

ACCCAGGACT

GAGCTGTCTG

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GCGGCGGCCT

CTGGGTCCAA

AATGTGCTTT

TCCTGCAGGA

TCTCCCGGTG

GAGGTGGGTC

GCTCCTTCCA

ACTACCTGCT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CTGGCGGC!TG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

AGGAGGTGGA

ACACAGCCCC

TCAAGATTAC

INFORMA~TION FOR SEQ ID NO:212: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGT-

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TCAAGATGAA

ATACATCACT TAAAGAGACC GACATGGATA TCCTGATGGA GCTGTCAAGC ACTTAGAAAA TGTCTGCCCT CTGCCACGGC TGGCAAGAAT TCCGGGAAAA CAACAGTACG TAGAGGGCGG ATCAACCCGT CTCCTCCGTC GAGCTGTGTG GTGGTCTCTG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCGGCTGGTC

WO 98/17810

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTcAGccCG

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

GCTGGATGGA.

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA

CCTCCAACCT

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

AATCCGTGAG

G

19 65

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

PCTIUS97/20037 GCAAGGCTTG 540 GCCCCCCCCC 600 CTCCGAGCAG 660 GGAGCTGCAG 720 AGGTGGATCC '780 CAGCCCCATC 840 AGATTACCCA 900 INFORMATION FOR SEQ ID NO:213: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC TGAAGAACTG CAGCGCTGGA. TGGAGCGGCT CAAGACTGTC CGCGTGAACA CGGAGATACA CTTTGTCACC CTTCGCTTCG TCCAGACCAA CATCTCCCGC GCGCTGAAGC CCTGGATCAC TCGCCAGAAC CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGCTCAGGGG GAGGTAGTGG TACCCAGGAC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GTGGCCTCCA ACCTGCAGGA C

ATACATCACT

GACATGGATA

GCTGTCAAGC!

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

TGTGGTGGTC

GCTGGGTCCA

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

GGAGGTGGGT

TGCTCCTTCC

GACTACCTGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

TGTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

AGACCTCCGA

GCCTGGAGCT

CAGGAGGTGG

AACACAGCCC

TTCAAGATTA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGTCCTGGCA

CTTGCTGGAG

CCCCAGCTGT

GCAGCTGGTG

GCAGTGTCAG

ATCCGGAGGT

CATCTCCTCC

CCCAGTCACC

INFORMATION FOR SEQ ID NO.214: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

TCAGGGGGAG

TTCGCTGTCA

GCCTCCAACC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTA.A

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

AGCGGCTCAAk

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GTAGTGGTAC

AAATCCGTGA

TGCAGGACGA

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TGAGCTGTGT

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAAAACTTC

TGGGTCAGGA

CCAGGACTGC

GCTGTCTGAC

G

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GGTGGCCTGT

GGGTCCAAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

GGTGGGTCAG

TCCTTCCAAC!

TACCTGCTTC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GGCGTCTGGT

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

GAGGTGGATC

ACAGCCCCAT

AAGATTACCC

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

CCTGGCACAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CTCCTCCGAC

AGTCACCGTG

INFORMATION FOR SEQ ID NO:215: Wi SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO :215: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT WO 98/17810

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

GGGGGAGGTA

GCTGTCAAA.A

TCCAACCTGC

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

GTGGTACCCA

TCCGTGAGCT

AGGACGAGGA

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TCTGTGCGGT

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

GGACTGCTCC

GTCTGACTAC

G

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

GGTCTGTGGC

TCCALAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TTCCAACACA

CTGCTTCALAG

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GTCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

PCTIUS97/20037 ACGAAACCTT 120 TGCATCAGGT 180 CGCACCCTCT 240 ACTGACGTTC 300 TGGAGGCTCC 360 TAAAGAATCT 420 GGCACAGCGC 480 GGAGCGCGTG 540 CTGTCTTCGC 600 GGTGGCGCTG 660 TCAGCCCGAC 720 AGGTGGCTCA 780 CTCCGACTTC 840 CACCGTGGCC 900 921 INFORMATION FOR SEQ ID NO:216: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRAN~DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

GCTAACTGCT

TTGCTGGAC!C

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCA.GT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA.

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTC

TCACCGTGGC

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

AATCTCTACT

TTCTAATCTG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GA.AGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAA.A

C

ATACATCACT

GACATGGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CAAGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCC!ACGGC

TCCGGGAAAA.

TAGAGGGCGG

CTCCTCCGTC

AGCTGTGCGG

CTGTC!GCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

INFORMATION FOR SEQ ID NO:217: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY; linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

GCTAACTGCT

TTGCTGGAC!C

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CCGGTGGCGC

TGTCAGCCCG

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CGTCTGGTCC

CAAACATGGC

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCA.A

CCTCCAACCT

CGATGAAATT ATACATCACT CAATTCTGAA GACATGGATA ATTCGTAAGG GCTGTCAAGC TCTCCAACCA TGTCTGCCCT GGCAGGTGAC TGGCAAGAAT AGCGCAGGAA CAACAGTACG AATCTCTACT ATCAACCCGT TCAAGATGAA GAACTGTGCG GCGGCTCAAG ACTGTCGCTG GATACACTTT GTCACCAAAT GACCAACATC TCCCGCCTCC GATCACTCGC CAGAACTTCT CCTGGGCGGT GGGTCAGGAG TAGTGGTACC CAGGACTGCT AATCCGTGAG CTGTCTGACT

G

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

CTCCTCCGTC

GTGGTCTCTG

GGTCCAAGAT

GTGCCTTTCA

TGCGGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GCGGCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG,

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

INFORMATION FOR SEQ ID NO:218: Wi SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPEt nucleic acid WO 98/178 10 PCTIUS97/20037 STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

CCGGGTGAAC

CATAAATCTC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

A.AGCCCTGGA

TCCTCAACCC

GGGGGAGGTA

GCTGTCAAGA

TCCAACCTGC

CTATAATGAT CGATGAAATT ATACATCACT CGAACAACCT CAATTCTGAA GACATGGATA ACCTGCTCGC ATTCGTAAGG GCTGTCA.AGC TTCTTCGTAA TCTCCAACCA TGTCTGCCCT TCATCATCAA GGCAGGTGAC TGGCAAGAAT CCCTTGAGCA AGCGCAGGAA CAACAGTACG

CGTCTGGTCC

CAAACATGGC

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

GTGGTACCCA

TCCGTGAGCT

AGGACGAGGA

AATCTCTACT

TCTGTGCGGT

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

GGACTGCTCC

GTCTGACTAC

ATCAACCCGT

GGTCTGTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TTCCAACACA

CTGCTTCAAG

TA.AAGAGACC

TC!CTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TAGAGGGCGG

dTCCTCCGTC

GTCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

TGGAGGCTCC

TAAAGAATCT

GGCACAGCGC

GGAGCGCGTG,

CTGTCTTCGC

GGTGGCGCTG

TCGGCCCGAC

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

INFORMATION FOR SEQ ID NO:219: SEQUENCE CHARACTERISTICS: LENGTH: 906 base pairs TYPE: nucleic acid STR.ANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

GGTGGAGGCT

TCTAAAGAAT

ATACATCACT

GACATOGATA

GCTGTCAAGC

TGTCTGCCCT

TGGCAAGAAT

CAACAG

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

CCCCGGGTGA

CTCATAAATC

TAAAGAGACC

TCCTGATGGA

ACTTAGAAAA

CTGCCACGGC

TCCGGGAAAA

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

ACCGTCTGGT

TCCAAACATG

ACCTAACCCT

ACGAAACCTT

TGCATCAGGT

CGCACCCTCT

ACTGACGTTC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

CCAATCTCTA

GCTAACTGCT

TTGCTGGACC

CGAACTCCAA

ATTGAGGCAA

CGACATCCAA

TATCTGGTTA

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGTA

CTATCAACCC

CTATAATGAT

CGAACAACCT

ACCTGCTCGC

TTCTTCGTAA

TCATCATCAA

CCCTTGAGCA

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CGTAGAGGGC

GTCTCCTCCG

CGATGAAATT

CAATTCTGAA

ATTCGTAAGG

TCTCCAACCA

GGCAGGTGAC

AGCGCAGGAA

INFORMATION FOR SEQ ID NO:220:.

Wi SEQUENCE CHARACTERISTICS: LENGTH: 888 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

GCGGATGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

CCCATCTCCT

TACCCAGTCA

GAACCGTCTG

TCTCCAAACA

CCACCTAACC

GAACGAAACC

AATGCATCAG

GCCGCACCCT

AAACTGACGT

AGCTGTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

CCGACTTCGC

CCGTGGCCTC

GTCCAATCTC

TGGCTAACTG

CTTTGCTGGA

,TTCGAACTCC

GTATTGAGGC

CTCGACATCC

TCTATCTGGT

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGATCCGGA

TGTCAAAATC

CAACCTGCAG

TACTATCAAC

CTCTATAATG

CCCGAACAAC

AAACCTGCTC

AATTCTTCGT

AATCATCATC

TACCCTTGAG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTACCCAGG

CGTGAGCTGT

TACGTAGAGG

CCGTCTCCTC

ATCGATGAAA

CTCAATTCTG

GCATTCGTAA

AATCTCCAAC

AAGGCAGGTIG

CAAGCGCAGG

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

ACTGCTCCTT

CTGACTACCT

GCGGTGGAGG

CGTCTAAAGA

TTATACATCA

AAGACATGGA

GGGCTGTCAA

CATGTCTGCC

ACTGGCAAGA

AACAACAG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAGGCCCTGG

CTCCTCAACC

CCAACACAGC

GCTTCAAGAT

CTCCCCGGGT

ATCTCATAAA

CTTAAAGAGA

TATCCTGATG

GCACTTAGAA

CTCTGCCACG

ATTCCGGGAA

WO 98/17810 WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID NO:221: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

AGCTGTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

CGGCTGGTCC!

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCtCCAACC

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGAAC

AAATCCGTGA

TGCAGTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

INFORMATION FOR SEQ ID NO:222: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

GCAGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

AGCTGTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

CTCCGTCTAA

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

TGGCACAGCG

TGGAGCGCGT

GCTGTC!TTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTC!GAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:223: Wi SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

GCGGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGAGGCTCCC

AGCTGTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

CGGGTGAACC

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG,

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

GTCTGGTCCA

CGGCTGGTCC

CAAGGCCTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

ATCTCTACTA

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGAAC

AAATCCGTGA

TGCAGTACGT

TCAACCCGTC

CTGGATGGAG

GAACACGGAG

CCTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC!

AGAGGGCGGT

TCCTCCGTCT

WO 98/17810

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

AACTGCTCTA TAATGATCGA CTGGACCCGA ACAACCTCAA ACTCCAAACC TGCTCGCATT GAGGCAATTC TTCGTAATCT CATCCAATCA TCATCAAGGC CTGGTTACCC TTGAGCAAGC PCTIUJS97/20037 TGAAATTATA 600 TTCTGAAGAC 660 CGTAAGGGCT 720 CCAACCATGT 780 AGGTGACTGG 840 GCAGGAACAA 900 INFORMATION FOR SEQ ID NO; 224: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:224: GCGGATGAGG AGCTGTGTGG TGGCCTCTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA AGTGGTACCC AGGACTGCTC CTTCCAACAC ATCCGTGAGC TGTCTGACTA CCTGCTTCAA CAGTACGTAG AGGGCGGTGG AGGCTCCCCG AACCCGTCTC CTCCGTCTAA AGAATCTCAT ATGATCGATG AAATTATACA TCACTTAAAG AACCTCAATT CTGAAGACAT GGATATCCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA CGTAATCTCC AACCATGTCT GCCCTCTGCC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAGCAAGCGC AGGAACAACA G

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CC!TCCGACTT

TC!ACCGTGGC

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

CTGGATGGGG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:225: SEQUENCE CHARACTERISTICS: LENGTH: 904 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225: GGCCGATTAC CCAGTCACCG CTGGCGGCTG GTCCTGGCAC GATGCAAGGC TTGCTGGAGC TCAGCCCCCC CCCAGCTGTC GACCTCCGAG CAGCTGGTGG CCTGGAGCTG CAGTGTCAGC AGGAGGTGGA TCCGGAGGTG CGACTTCGCT GTCAAAATCC TGGAGGCTCC CCGGGTGAAC TAAAGAATCT CATAAATCTC ACATCACTTA AAGAGACCAC CATGGATATC CTGATGGAAC TGTCAAGCAC TTAGAAAATG TCTGCCCTCT GCCACGGCCG GCAAGAATTC CGGGAAAAAC

ACAG

TGGCCTCCAA

AGCGCTGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

GCACCCAGGA

GTGAGCTGTC

CGTCTGGTCC

CAAACATGGC

CTAACCCTTT

GAAACCTTCG

CATCAGGTAT

CACCCTCTCG

TGACGTTCTA

CCTGCAGGAC

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTGGGC

CTGCTCC!TTC

TGACTACCTG

AATCTCTACT

TAACTGCTCT

GCTGGACCCG

AACTCCAAAC

TGAGGCAATT

ACATCCAATC

TCTGGTTACC

GAGGAGCTCT

AAGACTGTCG

TTTGTCACCA

ATCTCCCGCC

CGCCAGAACT

GGTGGGTCAG

CAACACAGCC

CTTCAATACG

ATCAACCCGT

ATAATGATCG

AACAACCTCA

CTGCTCGCAT

CTTCGTAATC

ATCATCAAGG

CTTGAGCAAG

GCGGGGGCCT

CTGGGTCCAA

AATGTGCCTT

TCCTGCAGGA

TCTCCCGGTG

GAGGTGGGTC

CCATCTCCTC

TAGAGGGCGG

CTCCTCCGTC

ATGAAATTAT

ATTCTGAAGA

TCGTAAGGGC

TCCAACCATG

CAGGTGACTG

CGCAGGAACA

INFORMATION FOR SEQ ID NO:226: Wi SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226: GCCGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCA.AGG CTTGCTGGAG WO 98/17810

CGCGTGAACA

CTTCGCTTCG

GCGCTGAAGC

CCCGACTCCT

GGCACCCAGG

CGTGAGCTGT

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

4'6f2 PCTIUS97/20037

CGGAGATACA

TCCAGACCAA

CCTGGATCAC

CAACCCTGGG

ACTGCTCCTT

CTGACTACCT

CGGGTGAACC

ATAA-ATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

CTTTGTCACC

CATCTCCCGC

TCGCCAGAAC

CGGTGGGTCA

CCAACACAGC

GCTTCAAGAT

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

GGAGGTGGGT

CCCATCTCCT

TACCCAGTCA

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

TTCAGCCCCC CCCCAGCTGT AGACCTCCGA GCAGCTGGTG GCCTGGAGCT GCAGTGTCAG CAGGAGGTGG ATCCGGAGGT CCGACTTCGC TGTCAAAATC CCGTGTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT TAATGATCGA TGAAATTATA ACAACCTCAA TTCTGAAGAC TGCTCGCATT CGTAAGGGCT TTCGTAATCT CCAACCATGT TCATCAAGGC AGGTGACTGG TTGAGCAAGC GCAGGAACAA INFORMATION FOR SEQ ID NO:227: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

GCCGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CACAGCCCCA

CAGGATTACC

TGGCGGCTGG

GGAGGCTCCC

AA.AGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

TCTCCTCCGA

CAGTCACCGT

TCCTGGCACA

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CTTCGCTGTC

GGCCTCCAAC

GCGCTGGATG

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AAAATCCGTG

CTGCAGGACG

GAGCGGCTCA

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

AGGAGCTCTG

AGACTTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCTTCCA.A

CTACCTGCTT

CGGGGGCCTC

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

INFORMATION FOR SEQ ID NO:228: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:228: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC GGAGGCTCCC CGGGTGAACC GTCTGGTCCA AAAGAATCTC ATAA.ATCTCC AAACATGGCT CATCACTTAA AGAGACCACC TA.ACCCTTTG, ATGGATATCC TGATGGAACG AAACCTTCGA GTCAAGCACT TAGAAAATGC ATCAGGTATT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CAAGAATTCC GGGAAAAACT GACGTTCTAT

CAG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACt

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAA-ACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGCTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

INFORMATION FOR SEQ ID NO:229: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single WO98/17810 1164 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:229: PCTIUS97/20037 GCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA GGTGGATCCG GAGGTGGCAC TTCGCTGTCA AAATCCGTGA GCCTCCAACC TGCAGGACGA CGCTGGATGG AGCGGCTCAA GTGAACACGG AGATACACTT GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CATCACTTAA AGAGACCACC ATGGATATCC TGATGGAACG GTCAAGCACT TAGAAAATGC CTGCCCTCTG CCACGGCCGC CAAGAATTCC GGGAAAAACT

CAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCGTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

GCTGGAGCGC

AGAGGGGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTG6

GCAGGAACAA

INFORMATION FOR SEQ ID NO:230: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

GCCACCAACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

CCTGCAGGAG ACCTCCGAGC CTCCCGGTGC CTGGAGCTGC AGGTGGGTCA GGAGGTGGAT CATCTCCTCC GACTTYGCTG CCCAGTCACC GTGGCCTCCA GGTCCTGGCA CAGCGCTGGA CTTGCTGGAG CGCGTGAACA CCCCAGCTGT CTTCGCTTCG GTCTGGTCCA ATCTCTACTA AAACATGGCT AACTGCTCTA TAACCCTTTG CTGGACCCGA AAACCTTCGA ACTCCAAACC ATCAGGTATT GAGGCAATTC ACCCTCTCGA CATCCAATCA GACGTTCTAT CTGGTTACCC

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAGTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

C2) INFORMATION FOR SEQ ID NO:231: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 903 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear.

(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

GCCCGCTTCG

GCGCTGAAGC

CCCGACTCCT

GGCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

TCCAGACCAA

CCTGGATCAC

CAACCCTGGG

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAA.ATGTGC

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

CATCTCCCGC CTCCTGCAGG AGACCTCCGA TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG CCAACACAGC CCCATCTCCT CCGACTTCGC GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CCTCTGGCGG CTGGTCCTGG CACAGCGCTG CAAGATGCAA GGCTTGCTGG AACGCGTGAA CTTTCAGCCC CCCCCCAGCT GTTTTTACGT GTCTGGTCCA ATCTCTACTA TCAACCCGTC AAACATGGCT AACTGCTCTA TAATGATCGA TAACCCTTTG CTGGACCCGA ACAACCTCAA AAACCTTCGA ACTCCAAACC TGCTCGCATT ATCAGGTATT GAGGCAATTC TTCGTAATCT ACCCTCTCGA CATCCAATCA TCATCAAGGC GACGTTCTAT CTGGTTACCC TTGAGCAAGC

GCAGCTGGTG

GCAGTGTCAG

ATCCGGAGGT

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

WO 98/17810 PCT/US97/20037 INFORMATION FOR SEQ ID NO:232:.

SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

GCTTCAA.ATC

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

TCAGGGGGAG

TTCGCTGTCA

GCCTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

TGCAGGATGA

AGCGGCTCAA

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GTAGTGGTAC

AAATCCGTGA

AGGGCGGTGG

CTCCGTCTAA

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

AGAGCTGTGC

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

CCAGGACTGC

GCTGTCTGAC

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCCGTGCC

GGTGGGTCAG

TCCTTCCAAC

TACCTGCTTC

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC!

GAAAAACTGA

GGCGGCTGGT

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

GAGGTGGATC

ACAGCCCCAT

AAGATTACCC

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

CCTGGCACAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CTCCTCCGAC

AGTCACCGTG

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:23.

SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233: GCTAATCTGC AAGATGAGGA GCTGTGCGGG

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

GGGGGAGGTA

GCTGTCAAAA

TCCTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

GTGGTACCCA

TCCGTGAGCT

AGGGCGGTGG

CTCCGTCTAA.

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

GGACTGCTCC

GTCTGACTAC

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G.

GCCCTCTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG,

GGGTCAGGAG

TTCCAACACA.

CTGCTTCAAG,

GGTGAACCGT'

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

GGCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GGCACAGCGC

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

CTCTACTATC

CTGCTCTATA

GGACCdGALAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:234: Wi SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

GCGCTGCAGG

ATGGAGCGGC

ACGGAGATAC

GTCCAGACCA

CCCTGGATCA

TCAACCCTGG

GGAGGTAGTG

GTCAAAATCC

AACTACGTAG

ATGAAGAGCT

TCAAGACTGT

ACTTTGTCAC

ACATCTCCCG

CTCGCCAGAA

GCGGTGGGTC

GTACCCAGGA

GTGAGCTGTC

AGGGCGGTGG

GTGTGGCGGC

CGCTGGGTCC

CAAATGTGCC

CCTCCTGCAG

CTTCTCCCGG

AGGAGGTGGG

CTGCTCCTTC

TGACTACCTG

AGGCTCCCCG

CTCTGGCGGC

AAGATGCAAG

TTTCAGCCCC

GAGACCTCCG

TGCCTGGAGC

TCAGGAGGTG

CAACACAGCC

CTTCAAGATT

GGTGAACCGT

TGGTCCTGGC

GCTTGCTGGA

CCCCCAGCTG

AGCAGCTGGT

TGCAGTGTCA

GATCCGGAGG

CCATCTCCTC

ACCCAGTCAC

CTGGTCCAAT

ACAGCGCTTG

GCGCGTGAAC

TCTTCGCTTC

GGCGCTGAAG

GCCCGACTCC

TGGCTCAGGG

CGACTTCGCT

CGTGGCCTC!C

CTCTACTATC

WO 98/17810

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

463

CTCCGTCTAA

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

AAATCTCCAA

AGACCACCTA.

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

ACATGGCTAX

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

PCT/US97/20037 CTGCTCTATA 600 GGACCCGAAC 660 TCCAAACCTG 720 GGCAATTCTT 780 TCCAATCATC 840 GGTTACCCTT 900 INFORMATION FOR SEQ ID NO:235: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:235: GCGCAAGATG AGGAACTGTG GAGCGGCTCA AGACTGTCGC GAGATACACT TTGTCACCAA CAGACCAACA TCTCCCGCCT TGGATCACTC GCCAGAACTT ACCCTGGGCG GTGGGTCAGG GGTAGTGGTA CCCAGGACTG AAAATCCGTG AGCTGTCTGA.

CTGTACGTAG AGGGCGGTGG AACCCGTCTC CCCCGTCTAA.

ATGATCGATG AAATTATACA AACCTCAATT CTGAAGACAT CTCGCATTCG TAAGGGCTGT CGTAATCTCC AACCATGTCT ATCAAGGCAG GTGACTGGCA GAGCAAGCGC AGGAACAACA.

TGGTGGTCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CTCCTTCCAA

CTACCTGCTT

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

TGGCGGCTGG

ATGCALAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

CACAGCCCCA

CAAGATTACC

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCTCCTCCGA

CAGTCACCGT

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTCAGGGGGA

CTTCGCTGTC

GGCCTCCAAC

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:236: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:236: GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA CACTTTGTCA 'CCAAATGTGC CTTTCAGCCC AACATCTCCC GCCTCCTGCA GGAGACCTCC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG, GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CGTGAGCTGT CTGACTACCT GCTTCAAGAT GACTACGTAG AGGGCGGTGG AGGCTCCCCG AACCCGTCTC CTCCGTCTAA AGAATCTCAT ATGATCGATG AAATTATACA TCACTTAAAG AACCTCAATT CTGAAGACAT GGATATCCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA CGTAATCTCC AACCATGTCT GCCCTCTGCC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAGCAA.GCGC AGGAACAACA. G

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

CACAGCGCTG

AGCGCGTGAA

GTCTTC!GCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGAC!TTCGC

CCGTGGCCTC

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:237: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:.

GCTCTGTGCG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG, TGAACACGGA GATACACTTT WO098/17810 44

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

GTGCCTTTCA GCCCCCCCCC TGCAGGAGAC CTCCGAGCAG CCCGGTGCCT GGAGCTGCAG GTGGGTCAGG AGGTGGATCC CCTTCCA.ACA CAGCCCCATC ACCTGCTTCA AGATTACCCA AGGGCGGTGG AGGCTCCCCG CTCCGTCTAA AGAATCTCAT AAATTATACA TCACTTAAAG CTGAAGACAT GGATATCCTG TAAGGGCTGT CAAGCACTTA AACCATGTCT GCCCTCTGCC GTGACTGGCA AGAATTCCGG AGGAACA.ACA G

AGCTGTCTTC

CTGGTGGCGC

TGTCAGC!CCG

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA

CCTCCAACCT

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

PCTIUS97/20037 GACCAACATC 180 GATCACTCGC 240 CCTGGGCGGT 300 TAGTGGTACC 360 AATCCGTGAG 420 GCAGGACGAG 480 CTCTACTATC 540 CTGCTCTATA 600 GGACCCGAAC 660 TCCAAACCTG 720 GGCAATTCTT 780 TCCAATCATC 840 GGTTACCCTT 900 921 INFORMATION FOR SEQ ID NO:2 3 8 SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

GCACTGTGTG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

GTGGTCTGTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

AGGGCGGTGG

CTCCGTCTA.A

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

GCGTCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

CTGGCACAGC GCTGGATGG.A GCGGCTCAAG CTGGAGCGCG TGAACACGGA GATACACTTT AGCTGTCTTC GCTTCGTCCA GACCAACATC CTGGTGGCGC TGAAGCCCTG GATCACTCGC TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGAGGTGGCT CAGGGGGAGG TAGTGGTACC TCCTCCGACT TCGCTGTCAA. AATCCGTGAG GTCACCGTGG CCTCCAACCT GCAGGACGAG GGTGAACCGT CTGGTCCAAT CTCTACTATC AAATCTCCAA ACATGGCTAA CTGCTCTATA AGACCACCTA ACCCTTTGCT GGACCCGAAC ATGGAACGAA ACCTTCGAAC TCCAAACCTG GAAAATGCAT CAGGTATTGA GGCAATTCTT ACGGCCGCAC CCTCTCGACA TCCAATCATC GAAAAACTGA CGTTCTATCT GGTTACCCTT INFORMATION FOR SEQ ID NO:239: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

GCTCTGTGTG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

GCGGTCTGTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

AGGGCGGTGG

CTCCGTCTAA

AAATTATACA

CTGAAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

GCGTCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCGGCCCG

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

GCTGGATGGA

TGA-ACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA.

CCTCCAACCT

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

GATCCGTGAG

GCAGGACGAG

CTCTACTATC

CTGCTCTATA.

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:240: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single WO 98/17810 WO 9817810PCT/US97/20037 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240: GCCTCCAAGA TGCAAGGCTT TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGC!A TCCCGGTGCC TGGAGCTGCA GGTGGGTCAG GAGGTGGATC ATC!TCCTCCG ACTTCGCTGT CCAGTCACCG TGGCCTCCAA GTCCTGGCAC AGCGCTGGAT GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CATCACTTAA AGAGACCACC ATGGATATCC TGATGGAACG GTCAAGCACT TAGAAAATGC CTGCCCTCTG CCACGGCCGC CAAGAATTCC GGGAAAAACT

CAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGOTOT

AAGACTGTCG

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGCTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

GTCTGGTCCA ATCTCTACTA AAACATGGCT AACTGCTCTA TAACCCTTTG CTGGACCCGA AAACCTTCGA ACTCCAAACC ATCAGGTATT GAGGCAATTC ACCCTCTCGA CATCCAATCA GACGTTCTAT CTGGTTACCC INFORMATION FOR SEQ ID NO:24l: SEQUENCE CHARACTERISTICS: LENGTH: 945 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

GCTCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGAAGCGGAG

CCCATCTCCT

TACCCAGTCA

CCGTCTGGTC

CCAAACATGG

CCTAACCCTT

CGAAACCTTC

GCATCAGGTA

GCACCCTCTC

CTGACGTTCT

ATGAGCTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

GTGGCTCTGG

CCGACTTCGC

CCGTGGCCTC

CAATCTCTAC

CTAACTGCTC

TGCTGGACCC

GAACTCCAAA

TTGAGGCAAT

GACATCCAAT

ATCTGGTTAC

TGGTGGTCTC TGGCGGCTGG TGGGTCCAAG ATGCAAGGCT ATGTGCCTTT CAGCCCCCCC CCTGCAGGAG ACCTC!CGAGC CTCCCGGTGC CTGGAGCTGC AGGTGGGTCA GGCGGTGGTT GGGAGGTAGT GGTACCCAGG TGTCAAAATC CGTGAGCTGT CAACCTGTAC GTAGAGGGCG TATCAACCCG TCTCC!TCCGT TATAATGATC GATGAAATTA GAACAACCTC AATTCTGAAG CCTGCTCGCA TTCGTAAGGG TCTTCGTAAT CTCCAACCAT CATCATCAAG GCAGGTGACT CCTTGAGCAA GCGCAGGAAC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CTGGCGGAGG

ACTGCTCCTT

CTGACTACCT

GTGGAGGCTC

CTAAAGAATC

TACATCACTT

ACATGGATAT

CTGTCAAGCA

GTCTGCCCTC

GGCAAGAATT

AACAG

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

ATCCGGCGGC

CCAACACAGC

GCTTCAAGAT

CCCGGGTGAA

TCATAAATCT

AAAGAGACCA

CCTGATGGAA

CTTAGAAAAT

TGCCACGGCC

CCGGGAAAAA

INFOR1MATION FOR SEQ ID NO:242: SEQUENCE CHARACTERISTICS: LENGTH: 903 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

GCCCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGCCGC

TGCTCCTTCC

GACTACCTGC

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAG

AAGAACTGTG TGGTGGCCTC AGAC!TGTCGC TGGGTCCAAG TTGTCACCAA ATGTGCCTTT TCTCCCGCCT CCTGCAGGAG GCCAGAACTT CTCCCGGTGC CACCGTGGAG CCCGCGTCCA AACACAGCCC CATCTCCTCC TTCAAGATTA CCCAGTCACC CGGGTGAACC GTCTGGTCCA.

ATAAATCTCC AAACATGGCT AGAGACCACC TAACCCTTTG TGATGGAACG AAACCTTCGA TAGAAAATGC .ATCAGGTATT CCACGGCCGC ACCCTCTCGA GGGAAAAACT GACGTTCTAT

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

CTCGGCGCCA

GACTTCGCTO

GTGGCCTCCA

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAACC

GAGGCAATTC

CATCCAATCA

CTGGTTACCC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGCACCGAC

TCAAAATCCG

ACCTGTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCAITT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

AGAGGGCGGT

TCCTCCGTCT

TGAAATTATA

TTCTGAAGAC

CGTAAGGGCT

CCAACCATGT

AGGTGACTGG

GCAGGAACAA

WO 98/17810 WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID NO: 243: SEQUENCE CHARACTERISTICS: LENGTH: 921 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

GCCCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGCCGC

CCGCCTCTGA

AAAATCCGTG

CTGTACGTAG

AACCCGTCTC

ATGATCGATG

AACCTCAATT

CTCGCATTCG

CGTAATCTCC

ATCAAGGCAG

GAGCAAGCGC

AAGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

CACCGTGGAG

CCCAGGACTG

AGCTGTCTGA

AGGGCGGTGG

CTCCGTCTAA.

AAATTATACA

CTGALAGACAT

TAAGGGCTGT

AACCATGTCT

GTGACTGGCA

AGGAACAACA

TGGTGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

CCCGCGTCCA

CTCCTTCCAA

CTACCTGCTT

AGGCTCCCCG

AGAATCTCAT

TCACTTAAAG

GGATATCCTG

CAAGCACTTA

GCCCTCTGCC

AGAATTCCGG

G

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

CTCGGCGCCA

CACAGCCCCA

CAAGATTACC

GGTGAACCGT

AAATCTCCAA

AGACCACCTA

ATGGAACGAA

GAAAATGCAT

ACGGCCGCAC

GAAAAACTGA

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGCACCGAC

TCTCCTCCGA

CAGTCACCGT

CTGGTCCAAT

ACATGGCTAA

ACCCTTTGCT

ACCTTCGAAC

CAGGTATTGA

CCTCTCGACA

CGTTCTATCT

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CGCTGGACAA

CTTCGCTGTC

GGCCTCCAAC

CTCTACTATC

CTGCTCTATA

GGACCCGAAC

TCCAAACCTG

GGCAATTCTT

TCCAATCATC

GGTTACCCTT

INFORMATION FOR SEQ ID NO:244: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244: GCTACACCAT TGGGCCCTGC CAAGTGAGAA AGATCCAGGG AAGCTGTGCC ACCCCGAGGA CCCCTGAGCT CCTGCCCCAG AGCGGCCTTT TCCTCTACCA GGTCCCACCT TGGACACACT CAGATGGAAG AACTGGGA.AT TTCGCCTCTG CTTTCCAGCG TTCCTGGAGG TGTCGTACCG GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CTGGTCCTGG CACAGCGCTG GGCTTGCTGG AGCGCGTGAA CCCCCCAGCT GTCTTCGCTT GAGCAGCTGG TGGCGCTGAA CTGCAGTGTC AGCCCGACTC GGATCCGGAG GTGGCTCAGG CCCATCTCCT CCGACTTCGC TACCCAGTCA CCGTGGCCTC

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

TGTGTGGTGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CAGGAGGTGG

ACTGCTCCTT

CTGACTACCT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:245: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

TCCTGCTCA.A

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

WO 98/17810 CAGATGGAAG AACTGGGAAT TTCGCCTCTG CTTTCCAGCG TTCCTGGAGG TGTCGTACCG GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CTCTGGCGGC TGGTCCTGGC AAGATGCAAG GCTTGCTGGA TTTCAGCCCC CCCCCAGCTG GAGACCTCCG AGCAGCTGGT TGCCTGGAGC TGCAGTGTCA TCAGGAGGTG GATCCGGAGG CAACACAGCC CCATCTCCTC CTTCAAGATT ACCCAGTCAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCA

ACAGCGCTGG

GCGCGTGAAC

TCTTCGCTTC

GGCGCTGAAG

GCCCGACTCC

TGGCTCAGGG

CGACTTCGCT

CGTGGCCTCC

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

AATCTGCAAG

ATGGAGCGGC

ACGGAGATAC

GTCCAGATCA

CCCTGGATCA

TCAACCCTGG

GGAGGTAGTG

GTCAAAATCC

PCTIU

CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGAGC AGCCCTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT ACGAGGAGCT GTGCGGGGGC TCAAGACTGT CGCTGGGTCC ACTTTGTCAC CAAATGTGCC ACATCTCCCG CCTCCTGCAG CTCGCCAGAA CTTCTCCCGG GCGGTGGGTC AGGAGGTGGG GTACCCAGGA CTGCTCCTTC GTGAGCTGTC TGACTACCTG S97/20037 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO: 246: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

GCCTCCTGCA

ACTTCTCCCG

CAGGAGGTGG

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

CAGCTCCCTG CCCCAGAGCT CGATGGCGCA GCGCTCCAGG GCTGGTGCTG CTCGGACACT CCAGGCCCTG CAGCTGGCAG GGGGCTCCTG CAGGCCCTGG GCAGCTGGAC GTCGCCGACT GGCCCCTGCC CTGCAGCCCA CCGGGCAGGA GGGGTCCTGG CGTTCTACGC CACCTTGCGC GTCTGGTCCA ATCTCTACTA AAACATGGCC CCCCCCAGCT GGAGACCTCC GAGCAGCTGG GTGCCTGGAG CTGCAGTGTC GTCAGGAGGT GGATCCGGAG CCAACACAGC CCCATCTCCT GCTTCAAGAT TACCCAGTCA CCTCTGGCGG CTGGTCCTGG CAAGATGCAA GGCTTGCTGG

CTTTCAGCCC

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA INFORMATION FOR SEQ ID NO:247: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGAGGTGGAT

TGGGCCCTGC

AGATCCAGGG

ACtCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTCAGGGGGA

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

CTGCAGGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGTAGTGGTA

AAAATCCGTG

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

AGGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCCAGGACTG

AGCTGTCTGA

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

CGGCGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CTCCTTCCAA

CTACCTGCTT

120 180 240 300 360 420 480 540 600 660 780 840 900 960 1020 1080 1110 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC CAAGATTACC CAGTCACCGT GGCCTCCAAC INFORMATION FOR SEQ ID NO:248: WO 98/17810 PCTIUS97/20037 1169 Wi SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG,

GGAGGCTCCC

AAAGAATCTC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCC!CA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

CAAGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACcCC

ATCCGTGAGC

TCCTGCTCAA.

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

AGCTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TGGTCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 TGTCTGACTA CCTGCTTCAA INFORMATION FOR SEQ ID NO:249: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid* STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

GTCCTGGCAC

TTGCTGGAGC

CCCAGCTGTC

CAGCTGGTGG

CAGTGTCAGC

TCCGGAGGTG

ATCTCCTCCG

CCAGTCACCG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

AGCGCTGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

GCTCAGGGGG

ACTTCGCTGT

TGGCCTCCAA

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTGGGC

AGGTAGTGGT

CAAAATCCGT

CCTGCAGGAC

CCCCAGAGCT TCCTGCTCAA GCGCTCCAGG AGAAGCTGTG CTCGGACACT CTCTGGGCAT CAGCTGGCAG GCTGCTTGAG CAGGCCCTGG AAGGGATATC GTCGCCGACT TTGCCACCAC CTGCAGCCCA CCCAGGGTGC GGGGTCCTGG TTGCTAGCCA CACCTTGCGC AGCCCTACGT ATCTCTACTA TCAACCCGTC GAAGAACTGT GTGGTGGTCT AAGACTGTCG CTGGGTCCAA TTTGTCACCA AATGTGCCTT ATCTCCCGCC TCCTGCAGGA CGCCAGAACT TCTCCCGGTG GGTGGGTCAG GAGGTGGGTC ACCCAGGACT GCTCCTTCCA GAGCTGTCTG ACTACCTGCT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

GTGGCGGCTG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

AGGAGGTGGA

ACACAGCCCC

TCAAGATTAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID N0:250: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

WO 98/17810

GGTCCCACCT

CAGA'rGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGCACAGC

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGC:CCG

GGAGGTGGCT

TCCTCCGAC!T

GTCACCGTGG

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG,

TCGCTGTCAA

CCTCCAACCT

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

AATCCGTGAG

GCAGGACGAG

PCTIUS97/20037

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GAGCTGTGTG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

TTGCCACCAC CATCTGGCAG CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGAGC AGCCCTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT GTGGCCTGTG GCGTCTGGTC GGTCCAAGAT GCAAGGCTTG GTGCCTTTCA GCCCCCCCCC TGCAGGAGAC CTCCGAGCAG CCCGGTGCCT GGAGCTGCAG GTGGGTCAGG AGGTGGATCC CCTTCCAACA CAGCCCCATC ACCTGCTTCA AGATTACCCA 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID N0:251: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

OCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTGA

CAGCCCGACT

GGTGGCTCAG

TCCGACTTCG

ACCGTGGCCT

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

GGGGAGGTAG

CTGTCAAAAT

CCAACCTGCA

CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA CGATGGCGCA GCGCTCCAGG AGAAGCTGTG GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCAGGCCCTG CAGCTGGCAG, GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG AAGGGATATC GCAGCTGGAC GTCGCCGACT TTGCCACCAC GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA CGTTCTACGC CACCTTGCGC AGCCCTACGT GTCTGGTCCA ATCTCTACTA TCAACCCGTC AAACATGGCT CTGTGCGGTG GTCTGTGGCG GCTCAAGACT GTC!GCTGGGT CCAAGATGCA ACACTTTGTC ACCAAATGTG CCTTTCAGCC CAACATCTCC CGCCTCCTGC AGGAGACCTC CACTCGCCAG AACTTCTCCC GGTGCCTGGA GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGTACCCAG GACTGCTCCT TCCAACACAG CCGTGAGCTG TCTGACTACC TGCTTCAAGA

GGACGAGGAG

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGATCCGGA

CCCCATCTCC

TTACCCAGTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:252: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRAINDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GCCACCGCAC

GCTGTCAAAA

TCCAACCTGC

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

CGACCACCCA

TCCGTGAGCT

AG

CAGCTCCCTG CCCCAGAGCT CGATGGCGCA GCGCTCCAGG GCTGGTGCTG CTCGGACACT CCAGGCCCTG CAGCTGGCAG GGGGCTCCTG CAGGCCCTGG GCAGCTGGAC GTC!GCCGACT GGCCCCTGCC CTGCAGCCCA CCGGGCAGGA GGGGTCCTGG CGTTCTACGC CACCTTGCGC GTCTGGTCCA ATCTCTACTA AAACATGGCT GATGAAG1AAC GATGGAGCGG CTCAAGACTG CACGGAGATA CACTTTGTCA CGTCCAGACC AACATCTCCC GCCCTGGATC ACTCGCCAGA CTCAACCCTG CCGCCACCGT GGACTGCTCC TTCCAACACA GTCTGACTAC CTGCTTCAAG

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

TGTGTGGTGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GGAGCCCGCG

GCCCCATCTC

ATTACCCAGT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

GCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

TCCACTCGGC

CTCCGACTTC

CACCGTGGCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 WO 98117810 WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID NO:253: SEQUENCE CHARACTERISTICS: LENGTH: 1134 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCC CCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGTTCTGGCG

CAGGACTGCT

CTGTCTGACT

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GAGGATCCGG

CCTTCCAACA

ACCTGCTTCA

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

CGGCGGAAGC

CAGCCCCATC

AGATTACCCA

CCCCAGAGCT

GCGCTCCAG

CTCGGACACT

CAGCTGGCAd

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTPTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGAGGTGGCT

TCCTCCGACT

GTCACCGTGG

TCCTGCTCAA GTCTTTAGAG AGAAGCTGTG TGCCACCTAC CTCTGGGCAT CCCCTGGGCT GCTGCTTGAG CCAACTCCAT AAGGGATATC CCCCGAGTTG TTGCCACCAC CATCTGGCAG CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGAGC AGCCCTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT TGTGTGGTGG, GCTGTGGCGG TCGCTGGGTC CAAGATGCAA CCAAATGTGC CTTTCAGCCC GCCTCCTGCA GGAGACCTCC ACTTCTCCCG GTGCCTGGAG CAGGAGGTGG GTCAGGCGGT CTGGGGGAGG TAGTGGTACC TCGCTGTCAA AATCCGTGAG CCTCCAACCT GCAG 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1134 INFORMATION FOR SEQ ID NO:254: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:254: GCTACACCAT TGGGCCCTGC CAAGTGAGAA AGATCCAGGG AAGCTGTGCC ACCCCGAGGA CCCCTGAGCT CCTGCCCCAG AGCGGCCTTT TCCTCTACCA GGTCCCACCT TGGACACACT CAGATGGAAG AACTGGGAAT TTCGCCTCTG CTTTCCAGCG TTCCTGGAGG TGTCGTACCG GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CTGGTCCTGG CACAGCGCTG GGCTTGCTGG AGCGCGTGAA CCCCCCAGCT GTCTTCGCTT GAGCAGCTGG TGGCGCTGAA CTGCAGTGTC AGCCCGACTC GCCACCGCAC CGACCGCTGG CCCATCTCCT CCGACTTCGC TACCCAGTCA CCGTGGCCTC

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

ACAACCGCCT

TGTCAAAATC

CAACCTGCAG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

CCGCCACCGT

CTGACCCAGG

CGTGAGCTGT

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

A.AGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

TGTGTGGTGG

TC!GCTGGGTC

CCAAATGTGC

GCCTCCTGCA

AC7TTCTCCCG

GGAGCCCGCG

ACTGCTCCTT

CTGACTACCT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCC CGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

GCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

TCCACTCGGC

CCAACACAGC

GCTTCAAGAT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:255: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25-5:

GCCGATTACC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG WO 98/17810 4-1 PCT[US97/20037 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAA.

INFORMATION FOR SEQ ID NO:256: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:

GCCGCCTCCA.

CAGCGCTGGA

CGCGTGAACA

CTTCGCTTCG

GCGCTGA.AGC

CCCGACTCCT

GGCACCCAGG

CGTGAGCTGT

ACCTGCAGGA CGAGGAGCTC TGGAGCGGCT CAAGACTGTC CGGAGATACA CTTTGTCACC TCCAGACCAA CATCTCCCGC CCTGGATCAC TCGCCAGAAC CAACCCTGGG CGGTGGGTCA ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAAGAT

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

GGAGGTGGGT

CCCATCTCCT

TACCCAGTCA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

AGACCTCCGA

GCCTGGAGCT

CAGGAGGTGG

CCGACTTCGC

CCGTG

GGTCCTGGCA.

CTTGCTGGAG

CCCCAGCTGT

GCAGCTGGTG

GCAGTGTCAG

ATCCGGAGGT

TGTCAAAATC

INFORMATION FOR SEQ ID NO:257: SEQUENCE CHAR~ACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

GCCGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CACAGCCCCA

CAAGATTACC

TGGCGGCTGG

GGTCCAAGAT

GTGCC.TTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

TCTCCTCCGA

CAGTCACCGT

TCCTGGCACA

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CTTCGC!TGTC

GGCCTCCAAC

GCGCTGGATG

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC

TGTCAGCCCG

GGAGGTGGCA

AAAATCCGTG

CTGCAGGACG

GAGCGGCTCA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CCCAGGACTG

AGCTGTCTGA

AGGAGCTCTG

AGACT

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

CTCCTTCCAA

CTACCTGCTT

CGGGGGCCTC

INFORMATION FOR SEQ ID NO:258: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

GCCTCCALAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

GGTGGGTCAG

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

GAGGTGGATC

ACTTCGCTGT

TGGCCTCCAA

AGCGCTGGAT

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGG

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

ACACAGCCCC

TCAAGATTAC

CTGGCGGCTG

INFORMATION FOR SEQ ID NO:259: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC WO 98/17810

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

CGCTGGA'rGG

GTGAACACGG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCC

PCTIUS97/20037 CCGGTGCCTG 120 TGGGTCAGGA 180 CTCCTCCGAC 240 AGTCACCGTG 300 CCTGGCACAG 360 GCTGGAGCGC 420 465 INFORMATION FOR SEQ ID NO:260: SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260: GCCCGCTTCG TCCAGACCAA GCGCTGAAGC CCTGGATCAC CCCGACTCCT CAACCCTGGG GGCACCCAGG ACTGCTCCTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATGTGC

CATCTCCCGC

TCGCCAGAAC

CGGTGGGTCA

CCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

CTCCTGCAGG

TTCTCCCGGT

GGAGGTGGGT

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

AGACCTCCGA GCAGCTGGTG GCCTGGAGCT GCAGTGTCAG CAGGAGGTGG ATCCGGAGGT CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA

GTCTT

INFORMATION FOR SEQ ID NO:261; Wi SEQUENCE CHARACTERISTICS: LENGTH: 465 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

GCCACCAACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

CCTGCAGGAG ACCTCCGAGC CTCCCGGTGC CTGGAGCTGC AGGTGGGTCA GGAGGTGGAT CATCTCCTCC GACTTCGCTG CCCAGTCACC GTGGCCTCCA GGTCCTGGCA CAGCGCTGGA CTTGCTGGAG CGCGTGAACA CCCCAGCTGT CTTCGCTTCG

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCAAAATCCG

ACCTGCAGGA

TGGAGCGGCT

CGGAGATACA

TCCAG

GCTGAAGCCC

CGACTCCTCA

CACCCAGGAC

TGAGCTGTCT

CGAGGAGCTC

CAAGACTGTC

CTTTGTCACC

INFORM~ATION FOR SEQ ID NO:262: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC.

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TGGTCTGTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCCGAGCAGC

CCGGTGCCTG

TGGGTCAGGA

CTTCCA-ACAC

CCTGCTTCAA

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

CTCAAGTCTT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACA.AGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

ACCATTGGGC

GAGAAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 CCTGGAAGGG ATATCCCCCG CGACTTTGCC ACCACCATCT GCCCACCCAG GGTGCCATGC CCTGGTTGCT AGCCATCTGC WO 98/17810 0 TACCGCGTTC TACGCCACCT TGCGCAGCCC INFORMATION FOR SEQ ID NO:263: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:263: PCTIUS97/20037 1110 GCAGATGAAG AACTGTGTGG GGGACTGTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA AGTGGTACCC AGGACTGCTC CTTCCAACAC ATCCGTGAGC TGTCTGACTA CCTGCTTCAA.

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG AACCCGTCTC CTCCGTCTAA AGAATCTCAT CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CAGGGCGATG GCGCAGCGCT CCAGGAGAAG GAGGAGCTGG TGCTGCTCGG ACACTCTCTG CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC! TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ACACTGCAGC TGGACGTCGC CGACTTTGCC GGAATGGCCC CTGCCCTGCA GCCCACCCAG CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT TACCGCGTTC TACGCCACCT TGCGCAGCCC

CGTCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGA.ACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

TGGCACAGCG

TGGAGC!GCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGTC!CAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCA.AA

CTCOAACCTG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120.

180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:264: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1062 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION; SEQ ID N0:264:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGCCGCCAC

CCTCTGACCC

ATCCGTGAGC

TACGTAGAGG

ACACCATTGG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

CGTGGAGCCC

AGGACTGCTC

TGTCTGACTA

GCGGTGGAGG,

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGC!GCCG

CGTACCGCGT

TGGGCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

GCGTCCACTC

CTTCCAACAC

CCTGCTTCAA

CTCCCCGGGT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG,

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCGCCACCG

AGCCCCATCT

GATTACCCAG

GGTGGTTCTG

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

TGGCACAGCG

TGGAGCGCGT

GCTGTC!TTCG

TGGTGGCGCT

GTCAGCCCGA

CACCGACCGC

CCTcCGACTT

TCACCGTGGC

GCGGCGGCTC

TGCTCAAGTC

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

TGGACAACCG

CGCTGTCAAA

CTCCAACCTG

CAACATGGCT

TTTAGAGCA-A

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1062 INFORMATION FOR SEQ ID NO:265; SEQUENCE CHARACTERISTICS: CA) LENGTH: 1089 base pairs CB) TYPE: nucleic acid CC) STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:265: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG WO 98/17810

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGCGGAGGTG

ATCTCCTCCG

CCAGTCACCG

GGTTCTGGCG

AGCTTCCTGC

CAGGAGAAGC

CACTCTCTGG

GCAGGCTGCT

CTGGAAGGGA

GACTTTGCCA

CCCACCCAGG

CTGGTTGCTA

GCGCAGCCG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

GCTCTGGGGG

ACTTCGCTGT

TGGCCTCCAA

GCGGCTCCAA

TCAAGTCTTT

TGTGTGCCAC

GCATCCCCTG

TGAGCCAACT

TATCCCCCGA

CCACCATCTG

GTGC!CATGCC

GCCATCTGCA

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGC

AGGTAGTGGT

CAAAATCCGT

CCTGCAGTAC

CATGGCTACA

AGAGCAAGTG

CTACAAGCTG

GGCTCCCCTG,

CCATAGCGGC

GTTGGGTCCC

GCAGCAGATG

GGCCTTCGCC

GAGCTTCC!TG

TCCGAGCAGC

GAGCTGCAGT

GGTGGTTCTG

ACOCAGGACT

GAGCTGTCTG

GTAGAGGGCG

CCATTGGGCC

AGGAAGATCC

TGCCACCCCG

AGCTCCTGCC

CTTTTCCTCT

ACCTTGGACA

GAAGAACTGG

TCTGCTTTCC

GAGGTGTCGT

TGGTGGCGCT

GTCAGCCCGA

GCGGAGGATC

GCTCCTTCCA

ACTACCTGCT

GTGGAGGCTC

CTGCCAGCTC

AGGGCGATGG

AGGAGCTGGT

CCAGCCAGGC

ACCAGGGGCT

CACTGCAGCT

GAATGGCCCC

AGCGCCGGGC

ACCGCGTTCT

PCTIUS97/20037 GA.AGCCCTGG 240 CTCCTCAACC 300 CGGCGGCGGA 360 ACACAGCCCC 420 TCAAGATTAC 480 CCCGGGTGGT 540 CCTGCCCCAG 600 CGCAGCGCTC 660 GCTGCTCGGA 720 CCTGCAGCTG 780 CCTGCAGGCC 840 GGACGTCGCC 900 TGCCCTGCAG 960 AGGAGGGGTC 1020 ACGCCACCTT 1080 1089 INFORMATION FOR SEQ ID NO:266: SEQUENCE CHARACTERISTICS: LENGTH: 1044 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGCCGCCAC

TCCTTCCAAC!

TACCTGCTTC

GGCTCCCCGG

AGCTCCCTGC

GATGGCGCAG

CTGGTGCTGC

CAGGCCCTGC

GGGCTCCTGC

CAGCTGGACG

GCCCCTGCCC

CGGGCAGGAG

GTTCTAC!GCC

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

CGTGGAGCCC

ACAGCCCCAT

AAGATTACCC

GTGGTGGTTC

CCCAGAGCTT

CGCTCCAGGA

TCGGACACTC

AGCTGGCAGG

AGGCCCTGGA

TCGCCGACTT

TGCAGCCCAC

GGGTCCTGGT

ACCTTGCGCA

TGGGCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

GCGTCCACTC

CTCCTCCGAC

AGTCACCGTG

TGGCGGCGGC

CCTGCTCA.AG

GAAGCTGTGT

TCTGGGCATC

CTGCTTGAGC

AGGGATATCC

TGCCACCACC

CCAGGGTGCC

TGCTAGCCAT

GCCG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCGCCACCG

TTCGCTGTCA

GCCTCCAACC

TCCAACATGG

TCTTTAGAGC

GCCACCTACA

CCCTGGGCTC

CAACTCCATA

CCCGAGTTGG

ATCTGGCAGC

ATGCCGGCCT

CTGCAGAGCT

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCC!CGA

CACOGACCAC

AAATCCGTGA

TGTACGTAGA

CTACACCATT

AAGTGAGRAA

AGCTGTGCCA

CCCTGAGCTC

GCGGCCTTTT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG,

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

GGGCGGTGGA

GGGCCCTGCC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1044 GTCCCACCTT GGACACACTG AGATGGAAGA ACTGGGAATG TCGCCTCTGC TTTCCAGCGC TCCTGGAGGT GTCGTACCGC INFORMATION FOR SEQ ID NO:267: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1077 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:267: GCGGATGAGG AGCTGTGCGG TGGCCTCTGG CGGCTCAAGA CTGTCGCTGG, GTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGATCCGGA CCCATCTCCT CCGACTTCGC TGTCAAAATC TACCCAGTCA CCGTGGCCTC CAACCTGCAG GAACCGTCTG GTCCAATCTC TACTATCAAC TCTCCAAACA TGGCTACACC ATTAGGCCCT AAGTGCTTAG AGCAAGTGAG GAAGATCCAG TGTGCCACCT ACAAGCTGTG CCACCCCGAG ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAACTCC ATAGCGGCCT TTTCCTCTA.C TCCCCCGAGT TGGGTCCCAC CTTGGACACA ACCATCTGGC AGCAGATGGA AGAACTGGGA GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CATCTGCAGA GCTTCCTGGA GGTGTCGTAC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTACCCAGG

CGTGAGCTGT

TACGTAGAGG

CCGTCTCCTC

GCCAGCTCCC

GGCGATGGCG

GAGCTGGTGC

AGCCAGGCCC

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

CGCCGGGCAG

CGCGTTCTAC

TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAGGCCCTGG GTCAGCCCGA CTCCTCAACC ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAAGAT GCGGTGGAGG CTCCCCGGGT CGTCTAAAGA ATCTCATAAA TGCCCCAGAG CTTCCTGCTC CAGCGCTCCA GGAGAAGCTG TGCTCGGACA CTCTCTGGGC TGCAGCTGGC AGGCTGCTTG TGCAGGCCCT GGAAGGGATA ACGTCGC!CGA CTTTGCCACC CCCTGCAGCC CACCCAGGGT GAGGGGTCCT GGTTGCTAGC GCCACCTTGC GCAGCCC 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1077 f 11 WO 98/17810 f/g..

INFORMATION FOR SEQ ID NO:268: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:268: PCT/US97/20037 GCCGACGAGG AGCTGTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGGGCGGTG GGTCAGGAGG TCCTTCCAAC ACAGCCCCAT TACCTGCTTC AAGATTACCC GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CAGAGCTTCC TGCTCAAGTG CTCCAGGAGA AGCTGTGTGC GGACACTCTC TGGGCATCCC CTGGCAGGCT GCTTGAGCCA GCCCTGGAAG GGATATCCCC GCCGACTTTG CCACCACCAT CAGCCCACCC AGGGTGCCAT GTCCTGGTTG CTAGCCATCT CTTGCGCAGC CC

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCAC

AAATCCGTGA

TGCAGTACGT

TCAACCCGTC

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

AGAGGGCGGT

TCCTCCGTCT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 INFORMATION FOR SEQ ID NO:269: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:269: GCAGACGAGG AGCTGTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGGGCGGTG GGTCAGGAGG AGTGGTACCC AGGACTGCTC ATCCGTGAGC TGTCTGACTA CAGTACGTAG AGGGCGGTGG AACCCGTCTC CTCCGTCTAA CCTGCCAGCT CCCTGCCCCA CAGGGCGATG GCGCAGCGCT GAGGAGCTGG TGCTGCTCGG CCCAGCCAGG CCCTGCAGCT TACCAGGGGC TCCTGCAGGC ACACTGCAGC TGGACGTCGC GGAATGGCCC CTGCCCTGCA CAGCGCCGGG CAGGAGGGGT TACCGCGTTG TACGCCACCT

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

CTCA.AGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:270: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

GCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC

''I

f WO 98/17810 TTCGCTGTCp.

GCCTCCAACC

CGCTGGATGG

GTGAACACGG

GGAGGCTCCC

AAAGAATCTC

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

CGGGTGAACC

ATAAATCTCC

TGCTCAAGTG

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

cc

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

TACCTGCTTC

GGGGGCCTCT

GGGTCCA-AGA

TGTGCCTTTC

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

AAGATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCGTACGT

TCAACCCGTC

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

PCT/US97/20037 AGTCACCGTG 300 CCTGGCACAG 360 GCTGGAGCGC 420 AGAGGGCGGT 480 TCCTCCGTCT 540 CTCCGTGCCC 600 TGGCGCAGCG 660 GGTGCTGCTC 720 GGCCCTGCAG 780 GCTCCTGCAG 840 GCTGGACGTC 900 CCCTGCCCTG 960 GGCAGGAGGG 1020 TATACGCCAC 1080 1092 INFORMATION FOR SEQ ID NO:271: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESSt single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

GCTTCAAATC

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

TCAGGGGGAG

TTCGCTGTCA

GCCTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

TGCAGGATGA

AGCGGCTCAA

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GTAGTGGTAC

AAATCCGTGA

AGGGCGGTGG

ATCCGTCTAA.

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

AGAGCTGTGC

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

CCAGGACTGC

GCTGTCTGAC

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

GGTGGGTCAG

TCCTTCCAAC

TACCTGCTTC

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

GGCGGCTGGT CCTGGCACAG TGCAAGGCTT GCTGGAGCGC AGCCCCCCCC CAGCTGTCTT CCTCCGAGCA GCTGGTGGCG TGGAGCTGCA GTGTCAGCCC

GAGGTGGATC

ACAGCCCCAT

AAGATTACCC

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

CGGAGGTGGC

CTCCTCCGAC

AGTCACCGTG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:272: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

GCTAATCTGC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA.

TCCTCAACCC

GGGGGAGGTA

GCTGTCAAAA

TCCTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTA

AAGATGAGGA

GGCTCAAGAC

TACACTTTGT

CCAACATCTC

TCACTCGCCA

TGGGCGGTGG

GTGGTACCCA

TCCGTGAGCT

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

GCTGTGCGGG

TGTCGCTGGG

CACCAAATGT

CCGCCTCCTG

GAACTTCTCC

GTCAGGAGGT

GGACTGCTCC

GTCTGACTAC

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GGCCTCTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGGTGCCTGG

GGGTCAGGAG

TTCCAACACA

CTGCTTCAAG

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGCTGGTCCT

AAGGCTTGCT

CCCCCCCCAG

CCGAGCAGCT

AGCTGCAGTG

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GGCACAGCGC

GGAGCGCGTG

CTGTCTTCGC

GGTGGCGCTG

TCAGCCCGAC

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 GCCCACCCAG GGTGCCATGC CCTGGTTGCT AGCCATCTGC

TGCGCAGCCC

WO 98/17810 INFORMATION FOR SEQ ID NO:273: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273: PCTIUS97120037

GCGCTGCAGG

ATGGAGCGGC

ACGGAGATAC

GTCCAGACCA

CCCTGGATCA

TCAACCCTGG

GGAGGTAGTG

GTCAAAATCC

AACTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

ATGAAGAGCT

TCAAGACTGT

ACTTTGTCAC

ACATCTCCCG

CTCGCCAGAA

GCGGTGGGTC

GTACCCAGGA

GTGAGCTGTC

AGGGCGGTGG

GTGTGGCGGC

CGCTGGGTCC

CAAATGTGCC

CCTCCTGCAG

CTTCTCCCGG

AGGAGGTGGG

CTGCTCCTTC

TGACTACCTG

AGGCTCCCCG

CTCTGGCGGC

AAGATGC.AAG

TTTCAGCCCC

GAGACCTCCG

TGCCTGGAGC

TCAGGAGGTG

CAACACAGCC

CTTCAAGATT

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

TGGTCCTGGC ACAGCGCTTG GC!TTGCTGGA. GCGCGTGAAC! CCCCCAGCTG TCTTCGCTTC AGCAGCTGGT GGCGCTGAAG TGCAGTGTCA GCCCGACTCC GATCCGGAGG TGGCTCAGGG CCATCTCCTC CGACTTCGCT ACCCAGTCAC CGTGGCCTCC CTGGTCCAAT CTCTACTATC ACATGGCPAC ACCATTAGGC TAGAGCAAGT GAGGAAGATC CCTACAAGCT GTGCCACCCC GGGCTCCCCT GAGCTCCTGC TCCATAGCGG CCTTTTCCTC AGTTGGGTCC CACCTTGGAC GGCAGCAGAT GGAAGAACTG CGGCCTTCGC CTCTGCTTTC AGAGCTTCCT GGAGGTGTCG CTCCGTCTAA AGAATCTCAT CCCTGCCCCA GAGCTTCCTG GCGCAGCGCT CCAGGAGAAG TGCTGCTCGG ACACTCTCTG CCCTGCAGCT GGCAGGCTGC TCCTGCAGGC CCTGGAAGGG TGGACGTCGC CGACTTTGCC CTGCCCTGCA GCCCACCCAG CAGGAGGGGT CCTGGTTGCT TACGCCACCT TGCGCAGCCC 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:274: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:

GCACTGTGCG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

GTGGTCTGTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC!

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

GCGTCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTACAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

CTGGCAC!AGC GCTGGATGGA CTGGAGCGCG TGAACACGGA AGCTGTCTTC GCTTCGTCCA CTGGTGGCGC TGAAGCCCTG TGTCAGCCCG ACTCCTCAAC GGAGGTGGCT CAGGGGGAGG TCCTCCGACT TCGCTGTCAA GTCACCGTGG CCTCCAACCT GGTGAACCGT CTGGTCCAAT AAATCTCCAA ACATGGCTAC CTCAAGTGCT TAGAGCAAGT CTGTGTGCCA CCTACAAGCT GGCATCCCCT GGGCTCCCCT TTGAGCCAAC TCCATAGCGG ATATCCCCCG AGTTGGGTCC ACCACCATCT GGCAGCAGAT GGTGCCATGC CGGCCTTCGC AGCCATCTGC AGAGCTTCCT

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

AATCCGTGAG

GCAGGACGAG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:275: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO;275: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC WO 98/17810

TCCCGGTGCC

GGTGGGTCAG

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

GGAGGCTCCC

AAAGAATCTC

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGA.AG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

TGGAGCTGCA

GAGGTGGATC

ACTTCGCTGT

TGGCCTCCAA.

AGCGCTGGAT

CGGGTGAACC

ATAAATCTCC

TGCTCAAGTG

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

cc

GTGTCAGCCC

CGGAGGTGGC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

Il~,

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTC!G

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGCTACGT

TCAACCCGTC

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

PCT/US97/20037 TGGGTCAGGA 240 ACACAGCCCC 300 TCAAGATTAC 360 CTGGCGGCTG 420 AGAGGGCGGT 480 TCCTCCGTCT 540 CTCCCTGCCC 600 TGGCGCAGCG 660 GGTGCTGCTC 720 GGCCCTGC.AG 780 GCTCCTGCAG 840 GCTGGACGTC 900 CCCTGCCCTG 960 GGCAGGAGGG 1020 TCTACGCCAC 1080 1092 INFORMATION FOR SEQ ID NO:276: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:276: GCCTCCAAGA TGCAAGGCTT TGTGCCTTTC AGCCCCCCCC CTGCAGGAGA CCTCCGAGCA TCCCGGTGCC TGGAGCTGCA GGTGGGTCAG GAGGTGGATC ATCTCCTCCG ACTTCGCTGT CCAGTCACCG TGGCCTCCAA GTCCTGGCAC AGCGCTGGAT GGAGGCTCCC CGGGTGAACC AAAGAATCTC ATAAATCTCC CAGAGCTTCC TGCTCAAGTG CTCCAGGAGA AGCTGTGTGC GGACACTCTC TGGGCATCCC CTGGCAGGCT GCTTGAGCCA GCCCTGGAAG GGATATCCCC GCCGACTTTG CCACCACCAT CAGCCCACCC AGGGTGCCAT GTCCTGGTTG, CTAGCCATCT CTTGCGCAGC CC

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGCTACGT

TCAACCCGTC

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

ACACAGCCCC

TCAAGATTAC

CTGGC!GGCTG

AGAGGGCGGT

TCCTCCGTC!T

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 INFORMATION FOR SEQ ID NO:277: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

GCGCTGTGTG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

CAGGACTGCT

CTGTCTGACT

GAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

GTGGTCTGTG

GGTCCAAGAT

GTGCCTTTCA

TGCAGGAGAC

CCCGGTGCCT

GTGGGTCAGG

CCTTCCAACA

ACCTGCTTCA

AGGGCGGTGG

CTCCGTCTA.A

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TC!CTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

GCGTCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGCAG

GGAGCTGCAG

AGGTGGATCC

CAGCCCCATC

AGATTACCCA

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

CTGGCACAGC!

CTGGAGCGCG

AGCTGTCTTC

CTGGTGGCGC!

TGTCGGCCCG

GGAGGTGGCT

TCCTCCAACT

GTCACCGTGG

GGTGAACCGT

AAATCTCCA.A

CTCAAGTGCT

CTGTGTGCC!A

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC!

AGCCATCTGC

GCTGGATGGA

TGAACACGGA

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

CAGGGGGAGG

TCGCTGTCAA.

CCTCCAACCT

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

TAGTGGTACC

GATCCGTGAG

GCAGGACGAG

TTTTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 WO 98/17810 TACCGCGTTC TACGCCACCT TGCGCAGCCC PCT[US97/20037 1110 INFORMATION FOR SEQ ID NO:278: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRiPTION: SEQ ID NO:278:

GCTGAACTGT

AAGACTGTCG

TTTGTCACCA

ATCTCCCGCC

CGCCAGAACT

GGTGGGTCAG

ACCCAGGACT

GAGCTGTCTG

GAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

GTGGTGGTCT

CTGGGTCCAA

AATGTGCCTT

TCCTGCAGGA

TCTCCCGGTG

GAGGTGGGTC

GCTCCTTCCA

ACTACCTGCT

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

GTGGCGTCTG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

AGGAGGTGGA

ACACAGCCCC

TCAAGATTAC

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

GTCCTGGCAC

TTGCTGGAGC

CCCAGCTGTC

CAGCTGGTGG,

CAGTGTCAGC

TCCGGAGGTG

ATCTCCTCCG

CCAGTCACCG

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

AGCGC!TGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

GCTCAGGGGG

ACTTCGCTGT

TGGCCTCCAA

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTGGGC

AGGTAGTGGT

CAAAATCCGT

CCTGCAGGAC

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:279: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRAI DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

GCTGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

GACTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

TGTGTGGTGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CAGGAGGTGG

ACTGCTCCTT

CTGACTACCT

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

CCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:280: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280: GCTCAGGACG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG WO 98/17810

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGTAGTGGTA

AAAATCCGTG

CTGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCCAGGACTG

AGCTGTCTGA

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGC!T

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CTCCTTCCAA.

CTACCTGCTT

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

CAGCCCCCCC CCAGCTGTCT ACCTCCGAGC AGCTGGTGGC CTGGAGCTGC AGTGTCAGCC GGAGGTGGAT CCGGAGGTGG CACAGCCCCA TC!TCCTCCGA.

CAAGATTACC CAGTCACCGT GGTGAACCGT CTGGTCCAAT AAATCTCCAA ACATGGC'rAC CTCAAGTGCT TAGAGCAAGT CTGTGTGCCA CCTACAAGCT GGCATCCCCT GGGCTCCCCT TTGAGCCAAC TCCATAGCGG ATATCCCC!CG AGTTGGGTCC ACCACCATCT GGCAGCAGAT GGTGCCATGC CGGCCTTCGC AGCCATCTGC AGAGCTTCCT PCTLJS97/20037 TCGCTTCGTC 180 GCTGAAGCCC 240 CGACTCCTCA 300 CTCAGGGGGA 360 CTTCGCTGTC 420 GGCCTCCAAC 480 CTCTACTATC 540 ACCATTAGGC 600 GAGGAAGATC 660 GTGCCACCCC 720 GAGCTCCTGC 780 CCTTTTCCTC 840 CACCTTGGAC 900 GGAAGAACTG 960 CTCTGCTTTC 1020 GGAGGTGTCG 1080 1110 INFORMATION FOR SEQ ID NO:281: SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:-

GCCACCAACA

TGGATCACTC

ACCCTGGGCG

TGCTCCTTCC

GACTACCTGC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

GGAGGCTCCC

AAAGAATCTC

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

AACACAGCCC

TTCAAGATTA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

CGGGTGAACC

ATAAATCTCC

TGCTCAAGTG

AGCTGTGTGC

TGGGCATC!CC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

cc

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CATCTCCTCC

CCCAGTCACC

GGTCCTGGCA

CTTGCTGGAG

CCCCAGCTGT

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC GACTTTGCTG TCAAAATCCG TGAGCTGTCT GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC CAGCGCTGGA TGGAGCGGCT CAAGACTGTC CGCGTGA.ACA CGGAGATACA CTTTGTCACC CTTCGCTTCG TCCAGTACGT AGAGGGCGGT ATCTCTACTA TCAACCCGTC TCCTCCGTCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG GGCCTTTTCC TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA GCTGGACGTC ATGGAAGAAC TGGGAATGGC CCCTGCCCTG GCCTCTGCTT TCCAGCGC!CG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT TCTACGCCAC 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 INFORMATION FOR SEQ ID NO:.282: SEQUENCE CHARACTERISTICS: LENGTH: 1065 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG,

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CAAGGCTTGC TGGAGCGCGT GAACACGGAG CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA GGTGGATCCG GAGGTGGCTC AGCCCCATCT CCTCCGACTT GATTACCCAG TCACCGTGGC GGTGGTGGTT CTGGCGGCGG CCCCAGAGCT TCCTGCTCAA GCGCTCCAGG AGAAGCTGTG CTCGGACACT CTCTGGGCAT CAGCTGGCAG GCTGCTTGAG CAGGCCCTGG AAGGGATATC GTCGCCGACT TTGCCACCAC CTGCAGcCCA CCCAGGGTGC GGGGTCCTGG TTGCTAGCCA

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCCAACATG

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 WO 98/17810 Z/ F4 PCT/US97/20037 1065 TTCCTGGAGG *TGTCGTACCG CGTTCTAC!GC CACCTTGCGC AGCCG INFORMATION FOR SEQ ID NO: 283: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:-

GCTCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGTAGTGGTA

AAAATCCGTG

CTGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

AAGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

CCCAGGACTG

AGCTGTCTGA

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CGGTGGTCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

CTCCTTCCAA

CTACCTGCTT

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGC!TGC

GGAGGCGGAT

CACAGCCCCA

CAAGATTACC

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

TCCTGGCAC!A

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGGAGGTGG

TCTCCTCCGA

CAGTCACCGT

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CTCAGGGGGA

CTCCGCTGTC

GGCCTCCAAC

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 CTGCCCTGCA GCCCACCCAG CAGGAGGGGT CCTGGTTGCT TACGCCACCT TGCGCAGCCC INFORMATION FOR SEQ ID, NO: 284: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1098 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:

GCGCTGTGTG

ACTGTCGCTG

GTCACCAAAT

TCCCGCCTCC

CAGAACTTCT

GGGTCAGGAG

TTCCAACACA

CTGCTTCAAG,

GGCGGTGGAG

CCGTCTAAAG;

CTGCCCCAGA

GCAGCGCTCC

CTGCTCGGAC!

CTGCAGCTGG

CTGCAGGCCC

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTCC

CGCCACCTTG

GTGGCCTGTG

GGTCCAAGAT

ATGCCTTTCA

TOCAGGAGAC

CCCGGTGCCT

GTGGATCCGG

GCCCCATCTC

ATTACCCAGT

GCTCCCCGGG

AATCTCATAA

GCTTCCTGCT

AGGAGAAGCT

ACTCTCTGGG

CAGGCTGCTT

TGGAAGGGAT

ACTTTGCCAC

CCACCCAGGG

TGGTTGCTAG

CGCAGCCC

GCGTCTGGTC

GCAAGGCTTG

GCCCCCCCCC

CTCCGAGC!AG

GGAGCTGCAG

AGGTGGCTCA

CTCCGACTTC

CACCGTGGCC

TGAACCGTCT

ATCTCCAAAC

CAAGTGCTTA

GTGTGCCACC

CATCCCCTGG

GAGCCAACTC

ATCCCCCGAG

CACCATCTGG

TGCCATGCCG

CCATCTGCAG

CTGGCAC!AGC GCTGGATGGA CTGGAGCGCG TGAACACGGA

AGCTGTCTTC

CTGGTGGCGC

TGTCGGCCCG

GGGGGAGGTA

GCTGTCA-AGA

TCCAACCTGC

GGTCCAATCT

ATGGCTACAC

GAGCAAGTGA

TACAAGCTGT

GCTCCCCTGA

CATAGCGGCC

TTGGGTCCCA

CAGCAGATGG

GCCTTCGCCT

AGCTTCCTGG

GCTTCGTCCA

TGAAGCCCTG

ACTCCTCAAC

GTGGTACCCA

TCCGTGAGCT

AGGACGAGGA

CTACTATCAA

CATTAGGCCC

GGAAGATCCA

GCCACCCCGA

GCTCCTGCCC

TTTTCCTCTA

CCTTGGACAC

AAGAACTGGG

CTGCTTTCCA

AGGTGTCGTA

GCGGCTCAAG

GATACACTTT

GACCAACATC

GATCACTCGC

CCTGGGCGGT

GGACTGCTCC

GTCTGACTAC

GTACGTAGAG

CCCGTCTCCT

TGCCAGCTCC

GGGCGATGGC

GGAGCTGGTG

CAGCCAGGCC

CCAGGGGCTC

ACTGCAGCTG

AATGGCCCCT

GCGCCGGGCA

CCGCGTTCTA

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1098 INFORMATION FOR SEQ ID NO; 28 Ci SEQUENCE CHARACTERISTICS: CA) LENGTH: 1092 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:285: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC WO 98/17810

CTGCAGGAGA

TTCCGGTGCC

GGTGGGTCAG

ATCTCCTCCG

CCAGTCACCG

GTCCTGGCAC

GGAGGCTCCC

AAAGAATCTC

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

CCTCCGAGCA

TGGAGCTGCA

GAGGTGGATC

ACTTCGCTGT

TGGCCTCCAA

AGCGCTGGAT

CGGGTGAACC

ATAAATCTCC

TGCTCAAGTG

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

cc

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CAAAATCCGT

CCTGCAGGAC

GGAGCGGCTC

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

CTGAAGCCCT

GACTCCTCAA

ACCCAGGACT

GAGCTGTCTG

GAGGAGCTCT

AAGACTGTCG

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

GGATCACTCG

CCCTGGGCGG

GCTCCTTCCA

ACTACCTGCT

GCGGGGGCCT

CTGGCTACGT

TCA-ACCCGTC

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

PCT/US97/20037 CCAGAACTTC 180 TGGGTCAGGA 240 ACACAGCCCC 300 TCAAGATTAC 360 CTGGCGGCTG 420 AGAGGGCGGT 480 TCCTCCGTCT 540 CTCCCTGCCC 600 TGGCGCAGCG 660 GGTGCTGCTC 720 GGCCCTGCAG, 780 GCTCCTGCAG 840 GCTGGACGTC 900 CCCTGCCCTG 960 GGCAGGAGGG 1020 TCTACGCCAC 1080 1092 INFORMATION FOR SEQ ID NO:286: SEQUENCE CHARACTERISTICS: LENGTH: 1134 base pairs TYPE: nucleic acid STRANDEDNESS: 'single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:

GCTCAAGACG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGGGCG

GGAAGCGGAG

CCCATCTCCT

TACCCAGTCA

CCGTCTGGTC

CCAAACATGG

TGCTTAGAGC

GCCACCTACA

CCCTGGGCTC

CAACTCCATA

CCCGAGTTGG

ATCTGGCAGC

ATGCCGGCCT

CTGCAGAGCT

AAiGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

GTGGGTCAGG

GTGGCTCTGG

CCGACTTCGC

CCGTGGCCTC

CAATCTCTAC

CTACACCATT

AAGTGAGGAA

AGCTGTGCCA

CCCTGAGCTC

GCGGCCTTTT

GTCCCACCTT

AGATGGAAGA

TCGCCTCTGC

TCCTGGAGGT

TGGTGGTCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

AGGTGGGTCA

GGGAGGTAGT

TGTCAAAATC

CAACCTGTAC

TATCAACCCG

AGGCCCTGCC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

GGACACACTG

ACTGGGAATG

TTTCCAGCGC

GTCGTACCGC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

GGCGGTGGTT

GGTACCCAGG

CGTGAGCTGT

GTAGAGGGCG

TCTCCTCCGT

AGCTCCCTGC

GATGGCGCAG

CTGGTGCTGC

CAGGCCCTGC

GGGCTCCTGC

CAGCTGGACG

GCCCCTGCCC

CGGGCAGGAG

GTTCTACGCC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CTGGCGGAGG

ACTGCTCCTT

CTGACTACCT

GTGGAGGCTC

CTAAAGAATC

CCCAGAGCTT

CGCTCCAGGA

TCGGACACTC

AGCTGGCAGG

AGGCCCTGGA

TCGCCGACTT

TGCAGCCCAC

GGGTCCTGGT

ACCTTGCGCA

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

ATCCGGCGGC

CCAACACAGC

GCTTCAAGAT

CCCGGGTGA.A

TCATAAATCT

CCTGCTCAAG

GAAGCTGTGT

TCTGGGCATC

CTGCTTGAGC

AGGGATATCC

TGCCACCACC

CCAGGGTGCC

TGCTAGCCAT

GCCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1134 INFORMATION FOR SEQ ID NO:287: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1092 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:

GCCCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGCCGC

TGCTCCTTCC

GACTACCTGC

GGAGGCTCCC

AAAGAATCTC

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

AAGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

CACCGTGGAG

AACACAGCCC

TTCAAGATTA

CGGGTGAACC

ATAAATCTCC

TGCTCAAGTG

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

TGGTGGCCTC

TGGGTCCAAG

ATGTGCCTTT

CCTGCAGGAG

CTCCCGGTGC

CCCGCGTCCA

CATCTCCTCC

CCCAGTCACC

GTCTGGTCCA

AAACATGGCT

CTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCCC

ACCTCCGAGC

CTGGAGCTGC

CTCGGCGCCA

GACTTCGCTG

GTGGCCTCCA

ATCTCTACTA

ACACCATTAG

GTGAGGAAGA

CTGTGCCA.CC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGC!TGGTGGC

AGTGTCAGCC

CCGCACCGAC

TCAAAATCCG

ACCTGTACGT

TCAACCCGTC

GCCCTGCCAG

TcCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CACOCAGGAC

TGAGCTGTCT

AGAGGGCGGT

TCCTCCGTCT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 WO 98/17810 PCT/1 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CC INFORMATION FOR SEQ ID NO:288: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:288: tS97/20037 1080 1092

GCCCAAGATG

GAGCGGCTCA

GAGATACACT

CAGACCAACA

TGGATCACTC

ACCCTGCCGC

CCGCCTCTGA

AAAATCCGTG

CTGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

AAGAACTGTG

AGACTGTCGC

TTGTCACCAA

TCTCCCGCCT

GCCAGAACTT

CACCGTGGAG

CCCAGGACTG

AGCTGTCTGA

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

TGGTGGCCTC TGGCGGCTGG TGGGTCCAAG ATGCAAGGCT ATGTGCCTTT CAGCCCCCCC CCTGCAGGAG ACCTCCGAGC CTCCCGGTGC CTGGAGCTGC CCCGCGTCCA CTCGGCGCCA CTCCTTCCAA CACAGCCCCA CTACCTGCTT CAAGATTACC AGGCTCCCCG GGTGAACCGT AGAATCTCAT AAATCTCCAA GAGCTTCCTG CTCAAGTGCT CCAGGAGAAG CTGTGTGCCA ACACTCTCTG GGCATCCCCT GGCAGGCTGC TTGAGCCAAC CCTGGAAGGG ATATCCCCCG CGACTTTGCC ACCACCATCT GCCCACCCAG GGTGCCATGC CCTGGTTGCT AGCCATCTGC

TGCGCAGCCC

TCCTGGCACA

TGCTGGAGCG

CCAGCTGTCT

AGCTGGTGGC

AGTGTCAGCC

CCGCACCGAC

TCTCCTCCGA

CAGTCACCGT

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GCGCTGGATG

CGTGAACACG

TCGCTTCGTC

GCTGAAGCCC

CGACTCCTCA

CGCTGGACAA

CTTCGCTGTC

GGCCTCCAAC

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:289: SEQUENCE CHARACTERISTICS: LENGTH: 1134 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGCGGAGGTG

ATCTCCTCCG

CCAGTCACCG

CCGTCTGGTC

CCAAACATGG

TGCTTAGAGC

GCCACCTACA

CCCTGGGCTC

CAACTCCATA

CCCGAGTTGG

ATCTGGCAGC

ATGCCGGCCT

CTGCAGAGCT

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

GCTCTGGGGG

ACTTCGCTGT

TGGCCTCCAA

CAATCTCTAC

CTACACCATT

AAGTGAGGAA

AGCTGTGCCA

CCCTGAGCTC

GCGGCCTTTT

GTCCCACCTT

AGATGGAAGA

TCGCCTCTGC

TCCTGGAGGT

TGGGCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGC

AGGTAGTGGT

CAAAATCCGT

CCTGCAGTAC

TATCAACCCG

AGGCCCTGCC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

GGACACACTG

ACTGGGAATG

TTTCCAGCGC

GTCGTACCGC

CGGCTGGTCC TGGCACAGCG CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA GGTGGTTCTG GCGGAGGATC ACCCAGGACT GCTCCTTCCA GAGCTGTCTG ACTACCTGCT GTAGAGGGCG GTGGAGGCTC TCTCCTCCGT CTAAAGAATC AGCTCCCTGC CCCAGAGCTT GATGGCGCAG CGCTCCAGGA CTGGTGCTGC TCGGACACTC CAGGCCCTGC AGCTGGCAGG GGGCTCCTGC AGGCCCTGGA CAGCTGGACG TCGCCGACTT GCCCCTGCCC TGCAGCCCAC CGGGCAGGAG GGGTCCTGGT GTTCTACGCC ACCTTGCGCA

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CGGCGGCGGA

ACACAGCCCC

TCAAGATTAC

CCCGGGTGAA

TCATAAATCT

CCTGCTCAAG

GAAGCTGTGT

TCTGGGCATC

CTGCTTGAGC

AGGGATATCC

TGCCACCACC

CCAGGGTGCC

TGCTAGCCAT

GCCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1134 INFORMATION FOR SEQ ID NO:290: SEQUENCE CHARACTERISTICS: LENGTH: 1134 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:290: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG WO 98/17810 CGGCCCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGGGCGGTG, GGTCAGGAGG AGCGGAGGTG GCTCTGGGGG ATCTCCTCCG ACTTCGCTGT CCAGTCACCG TGGCCTCCAA.

CCGTCTGGTC CAATCTCTAC CCAAACATGG CTACACCATT TGCTTAGAGC AAGTGAGGAA GCCACCTACA AGCTGTGCCA CCCTGGGCTC CCCTGAGCTC CALACTCCATA GCGGCCTTTT CCCGAGTTGG GTCCCACCTT ATCTGGCAGC AGATGGAAGA ATGCCGGCCT TCGCCTCTGC CTGCAGAGCT TCCTGGAGGT

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGC

AGGTAGTGGT

CAA.AATCCGT

CCTGCAGTAC

TATCAACCCG

AGGCCCTGCC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

GGACACACTG

ACTGGGAATG

TTTCCAGC!GC

GTCGTACCGC

CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG

TCCGAGCAGC

GAGCTGCAGT

GGTGGTTCTG

ACCCAGGACT

GAGCTGTCTG

GTAGAGGGCG

TCTCCTCCGT

AGCTCCCTGC

GATGGCGCAG

CTGGTGCTGC!

CAGGCCCTGC

GGGCTCCTGC

CAGCTGGACG

GCCCCTGCCC!

CGGGCAGGAG

GTTCTACGCC

TGGTGGCGCT

GTCAGCCCGA

GCGGAGGATC

GCTCCTTCCA

ACTACCTGCT

GTGGAGGCTC

CTAAAGAATC

CCCAGAGCTT

CGCTCCAGGA

TCGGACACTC

AGCTGGCAGG

AGGCCCTGGA

TCGCCGACTT

TGCAGCCCAC

GGGTCCTGGT

ACCTTGCGCA

PCTIUS97/20037 GAACACGGAG 120 CTTCGTCCAG 180 GAAGCCCTGG 240 CTCCTCAACC 300 CGGCGGCGGA 360 ACACAGCCCC 420 TCAAGATTAC 480 CCCGGGTGAA 540 TCATAAATCT 600 CCTGCTCAAG 660 GAAGCTGTGT 720 TCTGGGCATC 780 CTGCTTGAGC 840 AGGGATATCC 900 TGCCACCACC 960 CCAGGGTGCC 1020 TGCTAGCCAT 1080 GCCC 1134 INFORMATION FOR SEQ ID NO:291: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 291:

GCGGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGCCGCCAC

CCTCTGACCC

ATCCGTGAGC

CAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

AGCTGTGCGG

CTGTCGCTGG,

TCACCA.AATG

CCCGCCTCCT

AGAACTTCTC

CGTGGAGCCC

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

CTCCGTCTAA.

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

GCGTCCACTC

CTTCCAACAC

CCTGCTTCAA

AGGCACCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGCGCCACCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC!

AGCCATCTGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

CACCGACCGC

CCTCC!GACTT

TCACCGTGGC

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

TGGACAACCG

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

ACCATTAGGC

GAGGAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:292: SEQUENCE CHARACTERISTICS: LENGTH: 1041 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:292: GCTGATGAGG AGCTGTGTGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC TTTCAC!CGTG TCAGCCAGGA CAACACAGCC CCATCTCCTC CTTCAAGATT ACCCAGTCAC TCCCCGGGTG GTGGTTCTGG TCCCTGCCCC AGAGCTTCCT GGCGCAGCGC TCCAGGAGAA GTGCTGCTCG GACACTCTCT GCCCTGCAGC TGGCAGGCTG CTCCTGCAGG CCCTGGAAGG CTGGACGTCG CCGACTTTGC CCTGCCCTGC AGCCCACCCA

TGGTCTGTGG

GTCCAAGATG

TGCCTTTC!AG

GCAGGAGACC

CCGGTGCCTG

TGGTCTAGAT

CGACTTCGCT

CGTGGCCTCC

CGGCGGCTCC

GCTCAAGTCT

GCTGTGTGCC

GGGCATCCCC

CTTGAGCCAA

GATATCCCCC

CACCACCATC

GGGTGCCATG

CGGCTGGTCC! TGGCACAGCG CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGT

CTCCTGACCT

GTCAAAATCC

AACCTGCAGT

AACATGGCTA

TTAGAGCAAG

ACTAACAAGC

TGGGCTCCC

CTCCATAGCG

GAGTTGGGTC

TGGCAGCAGA

CCGGCCTTCG

CGACCCAGGA

GTGAGCTGTC

ACGTAGAGGG

CACCATTGGG

TGAGAAAGAT

TGTGCCACCC

TGAGCTCCTG

GCCTTTTCCT

CCACCTTGGA

TGGAAGAACT

CCTCTGCTTT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

AGAGACGGTG

CTGCTCCTTC

TGACTACCTG

CGGTGGAGGC

CCCTGCCAGC

CCAGGGCGAT

CGAGGAGCTG

CCCCAGCCAG

CTACCAGGGG

CACACTGCAG

GGGAATGGCC

CCAGCGCCGG

WC 98/17810 4JK' P~C, GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC G INFORMATION FOR SEQ ID NO:293: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1152 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:293; IUS97/20037 1020 1041

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

GAACCGTCTG

TCTCCAAACA

GCTGTCAAAA

TCCAACCTGC

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

AGGGCGGTGG

CTCCGTCTAA

CCCTGCCCCA

GCGCAGCGCT

TGCTGCTCGG

CCCTGCAGCT

TCCTGCAGGC

TGGACGTCGC

CTGCCCTGCA

CAGGAGGGGT

TACGCCACCT

GTCCAATCTC

TGGCAACCCA

TCCGTGAGCT

AG

TGGGCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

AGGCTCCCCG

AGAATCTCAT

GAGCTTCCTG

CCAGGAGAAG

ACACTCTCTG

GGCAGGCTGC

CCTGGAAGGG

CGACTTTGCC

GCCCACCCAG

CCTGGTTGCT

TGCGCAGCCC

TACTATCAAC

GGACTGCTCT

GTCTGACTAC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGAACCGT

AAATCTCCAA

CTCAAGTCTT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATOT

GGTGCCATGC

AGCCATCTGC

TACGTAGAGG

CCGTCTCCTC

TTTCAACACA

CTGCTTCAAG

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

CTGGTCCAAT

ACATGGCTAC

TAGAGCAAGT

CCTACAAGCT

GGGCTCCCCT

TCCATAGCGG

AGTTGGGTCC

GGCAGCAGAT

CGGCCTTCGC

AGAGCTTCCT

GCGGTGGAGG

CGTCTAAAGA

GCCCCATCTC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CTCTACTATC

ACCATTGGGC

GAGAAAGATC

GTGCCACCCC

GAGCTCCTGC

CCTTTTCCTC

CACCTTGGAC

GGAAGAACTG

CTCTGCTTTC

GGAGGTGTCG

CTCCCCGGGT

ATCTCATAA.A

CTCCGACTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1152 ATTACCCAGT CACCGTGGCC INFORMATION FOR SEQ ID NO: 294: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 1047 base pairs TYPE: nucleic acid CC) STRAN~DEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

GCCACCCAGG

CGTGAGCTGT

GAGCCGAAGA

AGCTCCCTGC

GATGGCGCAG

CTGGTGCTGC

CAGGCCCTGC

GGGCTCCTGC

CAGCTGGACG

GCCCCTGCCC

CGGGCAGGAG

GTTCTACGCC

CCGCCATCCC

GTCCTGGCAC

TTGCTGGAGC

CCCAGCTGCC

CAGCTGGTGG

CAGTGTCAGC

ACTGCTCCTT

CTGACTACCT

GCCCGGACAC

CCCAGAGCTT

CGCTCCAGGA

TCGGACACTC

AGCTGGCAGG

AGGCCCTGGA

TCGCCGACTT

TGCAGCCCAC

GGGTCCTGGT

ACCTTGCGCA

CGGGTTCTAA

AGCGCTGGAT

GCGTGAACAC

TTCGCTTCGT

CGCTGAAGCC

CCGACTCCTC

TCAACACAGC

GCTTCAAGAT

CCATACTAGT

CCTGCTCAAG

GAAGCTGTGT

TCTGGGCATC

CTGCTTGAGC

AGGGATATCC

TGCCACCACC

CCAGGGTGCC

TGCTAGCCAT

GCCCTCTGCA

TCTGCAAGAT

GGAGCGGCTC

GGAGATACAC

CCAGACCAAC

CTGGATCACT

AACCCTG

CCCATCTCCT CCGACTTCGC TACCCAGTCA CCGTGGCCTC CCGCCATCTC CGACACCATT TCTTTAGAGC AAGTGAGAAA GCCACCTACA AGCTGTGCCA CCCTGGGCTC CCCTGAGCTC CAACTCCATA GCGGCCTTTT CCCGAGTTGG GCCCCACCTT ATCTGGCAGC AGATGGAAGA ATGCCGGCCT TCGCCTCTGC CTGCAGAGCT TCCTGGAGGT GAACCGAAAT CTCCGGATAC GAAGAGCTGT GCGGGGGCCT AAGACTGTCG CTGGGTCCAA TTTGTCACCA AATGTGCCTT ATCTCCCGCC TCCTGCAGGA CGCCAGAACT TCTCCCGGTG

TGTCAAAATC

CAACCTGCAG

AGGCCCTGCC

GATCCAGGGC

CCCCGAGGAG

CTGCCCCAGC

CCTCTACCAG

GGACACACTG

ACTGGGAATG

TTTCCAGCGC

GTCGTACCGC

TCATACCAGC

CTGGCGGCTG

GATGCAAGGC

TCAGCCCCCC

GACCTCCGAG

CCTGGAGCTG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 INFORMATION FOR SEQ ID NO:295: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1043 base pairs TYPE: nucleic acid STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:-295: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC WO 98/17810

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

CCGGGTACAC

GAGCAAGTGA

ACAAGCTGTG

CTCCCCTGAG

ATAGCGGCCT

TGGGTCCCAC

AGCAGATGGA

CCTTCGCCTC

GCTTCCTGGA

AATCTCCGGA

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

PCTIUS97/20037

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCA.AATGTGC

CATTGGGCCC

GAAAGATCCA

CCACCCCGAG

CTCCTGCCCC

TTTCCTCTAC

CTTGGACACA

AGAACTGGGA

TGCTTTCCAG

GGTGTCGTAC

TACTCATACC

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCCGAAG

TGCCAGCTCC

GGGCGATGGC

GAGCTGGTGC

AGCCAGGCCC

CAGGGGCTCC

CTGCAGCTGG

ATGGCCCCTG

CGCCGGGCAG

CGCGTTCTAC

AGCCCGCCAT

ACCAACATCT

ATCACTCGCC

CTG

TACCCAGTCA CCGTGGCCTC' CTGGTCCTGG CACAGCGCTG GGCTGGCAGG GGCGCGTGAA.

AGCCCGGACA CCCATACTAG, CTGCCCCAGA GCTTCCTGCT GCAGCGCTCC AGGAGAAGCT TGCTCGGACA CTCTCTGGGC TGCAGCTGGC AGGCTGCTTG TGCAGGCCCT GGAAGGGATA ACGTCGCCGA. CTTTGCCACC CCCTGCAGCC CACCCAGGGT GAGGGGTCCT GGTTGCTAGC GCCACCTTGC GCAGCCCTCT CCCCGG3GTAA GGCCTTTCAG CCCGCCTCCT GCAGGAGACC AGAACTTCTC CCGGTGCCTG

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

TCCGCCATCT

CAAGTCTTTA

GTGTGCCACT

ATCCCCTGGG

AGCCAACTCC

TCCCCCGAGT

ACCATCTGGC

GCCATGCCGG

CATCTGCAGA

GCAGAACCGA

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1043 INFORMATION FOR SEQ ID NO:296:, SEQUENCE CHARACTERISTICS: LENGTH: 1065 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 296:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

AACTGTGTGG

CTGTCGCTGG

TCACCAAATC

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTCCTC

TGTCTGACTA

AGGGCGGTGG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCA.A

AGGCTCCCCG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGGTGGTT

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGCGGCGG

TCCTGCTCAA.

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCA.AA

CTCCAACCTG

CTCCAACATG

GTCTTTAGAG

TGCCACTAAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1065 INFORMATION FOR SEQ ID NO:297: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID 510:297: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CAAGTGAGAA AGATCCAGGG CGATGGCGCA AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG AGCGGCCTTT TCCTCTACCA GGGGCTCCTG GGTCCCACCT TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT GGCCCCTGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA TTCCTGGAGG TGTCGTACCG CGTTCTACGC GGAGGCTCCC CGGGTGAACC GTCTGGTCCA AAAGAATCTC ATAAATCTCC AAACATGGCT CTGGTCCTGG CACAGCGCTG GATGGAGCGG GGCTTGCTGG AGCGCGTGAA CACGGAGATA CCCCCCAGCT GTCTTCGCTT CGTCCAGACC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGATCCGGAG GTGGCTCAGG GGGAGGTAGT CCCATCTCCT CCGACTTCGC TGTCAAAATC CCCCAGAGCT TCCTGCTCA.A GCGCTCCAGG AGAAGCTGTG CTCGGACACT CTCTGGGCAT CAGCTGGCAG GCTGCTTGAG CAGGCCCTGG AAGGGATATC GTCGCCGACT TTGCCACCAC CTGCAGCCCA CCCAGGGTGC GGGGTCCTGG TTGCTAGCCA CACCTTGCGC AGCCCTACGT ATCTCTACTA TCAACCCGTC GATGAAGAAC TGTGTGGTGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATCTGC AACATCTCCC GCCTCCTGCA ACTCGCCAGA ACTTCTCCCG GGCGGTGGGT CAGGAGGTGG GGTACCCAGG ACTCCTCCTT CGCGAGCTGT CTGACTACCT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGG.AG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 WO 98/17810 TACCCAGTCA CCGTGGCCTC CAACCTGCAG ZI F7' PCTIUS97/20037 1110 INFORMATION FOR SEQ ID NO:298: SEQUENCE CHARACTERISTICS: LENGTH: 1065 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGT.ACCG

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTA

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGGTGGTT

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTCTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG CTCAGCCCGA CTCCTCAACC GAGGTGGCTC AGGGGGAGGT CCTCCGACTT CGCTGTCA.AA.

TCACCGTGGC CTCCAACCTG CTGGCGGCGG CTCCAACATG TCCTGCTCAA GTCTTTAGAG AGAAGCTGTG TGCCACTAAC CTCTGGGCAT CCCCTGGGCT GCTGCTTGAG CCAACTCCAT ALAGGGATATC CCCCGAGTTG TTGCCACCAC CATCTGGCAG CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGAGC

AGCCG

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1065 INFORMATION FOR SEQ ID NO:299: SEQUENCE CHARACTERISTICS: LENGTH: 1110 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:299: GCTACACCAT TGGGCCCTGC CAAGTGAGAA AGATCCAGGG AAGCTGTGCC ACCCCGAGGA CCCCTGAGCT CCTGCCCCAG AGCGGCCTTT TCCTCTACCA GGTCCCACCT TGGACACACT CAGATGGAAG AACTGGGAAT TTCGCCTCTG CTTTCCAGCG TTCCTGGAGG TGTCGTACCG GGAGGCTCCc CGGGTGAACC AAAGAATCTC ATAAATCTCC CTGGTCCTGG CACAGCGCTG GGCTTGCTGG AGCGCGTGAA CCCCCCAGCT CTCTTCGCTT GAGCAGCTGG TGGCGCTGAA CTGCAGTCTC AGCCCGACTC GGATCCGGAG GTGGCTCAGG CCCATCTCCT CCGACTTCGC TACCCAGTCA CCGTGGCCTC

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCA

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACTCAGG

CGTGAGCTGT

TCCTGCTCAX GTCTTTAGAG AGAAGCTGTG TGCCACCTAC CTCTGGGCAT CCCCTGGGCT GCTGCTTGAG CCAACTCCAT AAGGGATATC CCCCGAGTTG TTGCCACCAC CATCTGGCAG CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGAGC AGCCCTACGT AGAGGGCGGT

TCAACCCGTC

TGTGTGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

AC TTCTC CCG

CAGGAGGTGG

ACTGTTCTTT

CTGACTACCT

TCCTCCGTCT

CCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

TCAACACAGC

GCTTCAAGAT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 INFORMATION FOR SEQ ID NO:300: SEQUENCE CHARACTERISTICS: LENGTH: 1002 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

ACTCCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGC!CTC CAACCTGCAG TCTGCGGGGG CCTCTGGtGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG WO 98/17810

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

ACACCATTGG

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

TCGCTGGGTC

CCAAATCTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CTCCCCGGGT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGTGGTTCTG

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCG.ACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

PCT/US97/20037 AGCGCGTGAA CACGGAGATA 240 GTCTTCGCTT CGTCCAGACC 300 TGGCGCTGAA GCCCTGGATC 360 AGCCCGACTC CTCAACCCTG 420 GCGGCGGCTC CAACATGGCT 480 TGCTCAAGTC TTTAGAGCAA 540 AGCTGTGTGC CACTAACAAG 600 TGGGCATCCC CTGGGCTCCC 660 GCTTGAGCCA ACTCCATAGC 720 GGATATCCCC CGAGTTGGGT 780 CCACCACCAT CTGGCAGCAG 840 AGGGTGCCAT GCCGGCCTTC 900 CTAGCCATCT GCAGAGCTTC 960 CG 1002 INFORMATION FOR SEQ ID NO:301: SEQUENCE CHARACTERISTICS: LENGTH: 1002 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

ACACCATTOG

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

ACTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CTCCCCGGGT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTCTC

GGTGGTTCTG

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

CTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GCGGCGGCTC

TGCTCAAGTC

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CG

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

CAACATGGCT

TTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1002 INFORMATION FOR SEQ ID NO:302: SEQUENCE CHARACTERISTICS: LENGTH: 978 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

CCGGGTGGTG

CTGCCCCAGA

GCAGCGCTCC

CTGCTCGGAC

CTGCAGCTGG

CTGCAGGCCC

GACGTCGCCG

GCCCTGCAGC

GGAGGGGTCC

ACTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAA.ATGTGC

GCCTCCTGCA

ACTTCTCCCG

GTTCTGGCGG

GCTTCCTGCT

AGGAGAAGCT

ACTCTCTGGG

CAGGCTGCTT

TGGAAGGGAT

ACTTTGCCAC

CCACCCAGGG

TGGTTGCTAG

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

CGGCTCCAAC

CAAGTCTTTA

GTGTGCCACT

CATCCCCTGG

GAGCCAACTC

ATCCCCCGAG

CACCATCTGG

TGCCATGCCG

CCATCTGCAG

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTACG

ATGGCTACAC

GAGCAAGTGA

AACAAGCTGT

GCTCCCCTGA

CATAGCGGCC

TTGGGTCCCA

CAGCAGATGG

GCCTTCGCCT

AGCTTCCTGG

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

TAGAGGGCGG

CATTGGGCCC

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

TGGAGGCTCC

TGCCAGCTCC

GAAAGATCCA GGGCGATGGC GCCACCCCGA GGAGCTGGTG GCTCCTGCCC CAGCCAGGCC 'rTTTCCTCTA CCAGGGGCTC CCTTGGACAC ACTGCAGCTG AAGAACTGGG AATGGCCCCT CTGCTTTCCA GCGCCGGGCA AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCG INFORMATION FOR SEQ ID NO:303: SEQUENCE CHARACTERISTICS: LENGTH: 1002 base pairs WO98/17810 9 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 303: PCTIUS97/20037 GCCACTCAGG ACTGTTCTTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATGTGC AACATCTCCC GCCTCCTGCA ACTCGCCAGA ACTTCTCCCG TACGTAGAGG GCGGTGGAGG ACACCATTGG GCCCTGCCAG GTGAGAAAGA TCCAGGGCGA CTGTGCCACC CCGAGGAGCT CTGAGCTCCT GCCCCAGCCA GGCCTTTTCC TCTACCAGGG CCCACCTTGG ACACACTGCA ATGGAAGAAC TGGGAATGGC GCCTCTGCTT TCCAGCGCCG CTGGAGGTGT CGTACCGCGT TCAACACAGC CCCATCTCCT GCTTCAAGAT TACCCAGTCA CCTCTGGCGG CTGGTCCTGG, CAAGATGCAA GGCTTGCTGG CTTTCAGCCC CCCCCCAGCT GGAGACCTCC GAGCAGCTGG GTGCCTGGAG CTGCAGTCTC CTCCCCGGGT GGTGGTTCTG CTCCCTGCCC CAGAGCTTCC! TGGCGCAGCG CTCCAGGAGA GGTGCTGCTC GGACACTCTC GGCCCTGCAG CTGGCAGGCT GCTCCTGCAG GCCCTGGAAG GCTGGACGTC GCCGACTTTG CCCTGCCCTG CAGCCCACCC GGCAGGAGGG GTCCTGGTTG TCTACGCCAC CTTGCGCAGC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA.

AGCCCGACTC

GCGGCGGCTC

TGCTCAAGTC

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

CG

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

CAACATGGCT

TTTAGAGCAA

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1002 INFORMATION FOR SEQ ID NO:304: SEQUENCE CHARACTERISTICS: LENGTH: 1001 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO0:304:

GCCACTCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

TACGTAGAGG

ACACCATTGG

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

GCCTCTGCTT

CTGGAGGTGT

ACTGTTCTTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

GCGGTGGAGG

GCCCTGCCAG

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TCCAGCGCCG

CGTACCGCGT

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GCGCCTGGAG

CTCCCCGGGT

CTCCCTGCCC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

GGCAGGAGGG

TCTACGCCAC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTCTC

GGTGGTTCTG,

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCACCC

GTCCTGGTTG

CTTGCGCAGC!

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA.

AGCCCGACTC

GCGGCGGCTC

TGCTCAAGTC

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

AGGGTGCCAT

CTAGCCATCT

C

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

C6TCCAGACC

GCCCTGGATC

CTCAACCCTG

CAACATGGCT

TTTAGAGCAA

CACTAACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

GCCGGCCTTC

GCAGAGCTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1001 INFORMATION FOR SEQ ID 14:305: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 1056 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO0:305:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCc

ATCCGTGAGC

CAGTACGTAG

GCTACTCAAG

CTGGTTGCTA

GCGCAGCCCT

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

GTGCTATGCC

GCCATCTGCA

CTGGCGGCTC

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

AGCTTTTGCT

GAGCTTCCTG

TGGCGGCTCT

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGGTGGTT

TCTGCTTTTC

GAGGTGTCGT

CAGAGCTTCC!

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGCGGCGG

AACGTCGTGC

ACCGCGTTCT

TGCTCAAGTC

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCCAACATG

AGGTGGTGTT

ACGCCACCTT

TTTAGAGCAA

WO 98/1 7810

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

4,90 PCTIUS97/20037 CTCCAGGAGA AGCTGTGTGC CACCTACAAG 780 GGACACTCTC TGGGCATCCC CTGGGCTCCC 840 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 900 GCCCTGGAAG GGATATCCCC CGAGTTGGGT 960 GCCGACTTTG OCACCACCAT CTGGCAGCAG 1020 CAGCCC 1056 INFORMATION FOR SEQ ID NO:306: SEQUENCE CHARACTERISTICS: LENGTH: 1101 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:

GCTACTCAAG

CTGGTTGCTA

GCGCAGCCCT

GTGAGAAAGA

CTGTGCCACC

CTGAGCTCCT

GGCCTTTTCC

CCCACCTTGG

ATGGAAGAAC

CCGGGTGAAC

CATAAATCTC

GCACAGCGCT

GAGCGCGTGA

TGTCTTCGCT

GTGGCGCTG.A

CAGCCCGACT

GGTGGCTCAG

TCCGACTTCG

ACCGTGGCCT

GTGCTATGCC

GCCATCTGCA

CTGGCGGCTC

TCCAGGGCGA

CCGAGGAGCT

GCCCCAGCCA

TCTACCAGGG

ACACACTGCA

TGGGAATGGC

CGTCTGGTCC

CAAACATGGC

GGATGGAGCG

ACACGGAGAT

TCGTCCAGAC

AGCCCTGGAT

CCTCAACCCT

GGGGAGGTAG

CTGTCAAAAT

CCAACCTGCA

AGCTTTTGCT

GAGCTTCCTG

TGGCGGCTCT

TGGCGCAGCG

GGTGCTGCTC

GGCCCTGCAG

GCTCCTGCAG

GCTGGACGTC

CCCTGCCCTG

AATCTCTACT

CGACGAGGAG

GCTCAAGACT

ACACTTTGTC

CAACATCTCC

CACTCGCCAG

GGGCGGTGGG

TGGTACCCAG

CCGTGAGCTG

G

TCTGCTTTTC

GAGGTGTCGT

CAGAGCTTCC

CTCCAGGAGA

GGACACTCTC

CTGGCAGGCT

GCCCTGGAAG

GCCGACTTTG

CAGCCCTACG

ATCAACCCGT

CTCTGCGGGG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTGCTCCT

TCTGACTACC

AACGTCGTGC

ACCGCGTTCT

TGCTCAAGTC

AGCTGTGTGC

TGGGCATCCC

GCTTGAGCCA

GGATATCCCC

CCACCACCAT

TAGAGGGCGG

CTCCTCCGTC

GCCTCTGGCG

CCAAGATGCA

CCTTTCAGCC

AGGAGACCTC

GGTGCCTGGA

GGTCAGGAGG

TCCAACACAG

TGCTTCAAGA

AGGTGGTGTT

ACGCCACCTT

TTTAGAGCA.A

CACCTACAAG

CTGGGCTCCC

ACTCCATAGC

CGAGTTGGGT

CTGGCAGCAG

TGGAGGCTCC

TAAAGAATCT

GCTGGTCCTG

AGGCTTGCTG

CCCCCCCAGC

CGAGCAGCTG

GCTGCAGTGT

TGGATCCGGA

CCCCATCTCC

TTACCCAGTC

120 180 240 300 360 420 480 540 600 660 720 840 900 960 1020 1080 1101 INFORMATION FOR SEQ ID NO:307: SEQUENCE CHARACTERISTICS: LENGTH: 1032 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

GCCGACGAGG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

GCTGTCAA.AA

TCCAACCTGC

AGCTGTGCGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCACCCA

TCCGTGAGCT

AG

TGGCCTCTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

GTCTGGTCCA

AAACATGGCC

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGACTGCTCC

GTCTGACTAC

CGGCTGGTCC TGGCACAGCG CAAGGCTTGC TGGAGCGCGT CCCCCCCCCA GCTGTCTTCG TCCGAGCAGC TGGTGGCGCT GAGCTGCAGT GTCAGCCCGA GGTGGATCCG GAGGTGGAAC TTCGCTGTCA AAATCCGTGA GCCTCCAACC TGCAGTACGT ATCTCTACTA TCAACCCGTC GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGC!TGGGTC CACTTTGTCA CCAAATGTGC AACATCTCCC GCCTCCTGCA ACTCGCCAGA ACTTCTCCCG GGCGGTGGGT CAGGAGGTGG TTCCAACACA GCCCCATCTC CTGCTTCAAG ATTACCCAGT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

CCAGGACTGC

GCTGTCTGAC

AGAGGGCGGT

TCCTCCGTCT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CTCCGACTTC

CACCGTGGCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1032 INFORMATION FOR SEQ ID N0:308: SEQUENCE CHARACTERISTICS: LENGTH: 1005 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/1 7810 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:308: PCT/US97/20037

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

AACCCGTCTC

TCCTTCCAAC

TACCTGCTTC

GGGGGCCTCT

GGGTCCAAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

CTCCGTCTAA

ACAGCCCCAT

AAAATTACCC

GGCGGCTGGT

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

AGAATCtCAT

CTCCTCCGAC

AGTCACCGTG

CCTGGCACAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG,

GGTGAACCGT

AAATCTCCAA

TTCGCTGTCA

GCCTCCAACC

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCAA

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGTCCAAT

ACATGGCTAC

AAATCCGTGA

TGCAGGACGA

AGCGGCTCAA

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCTACTATC

CCAGGACTGC

GCTGTCTGAC

GGAGCTCTGC

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1005 INFORMATION FOR SEQ ID NO:309: SEQUENCE CHARACTERISTICS: LENGTH: 1650 base pairs TYPE: nucleic acid STRANDEDNESs: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

AACTGTGTGG

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

AGGACTGCTC

TGTCTGACTA

AGGGCGGTGG

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

TGGTCTGTGG

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTTCCAACAC

CCTGCTTCAA

AGGCTCCCCG

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGGTGGTT

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CTGGCGGCGG

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

TGTGTGGTGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CAGGAGGTGG

ACTGCTCCTT

CTGACTACCT

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

CTCCAACATG

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1650 INFORMATION FOR SEQ ID NO:310; SEQUENCE CHARACTERISTICS: LENGTH: 1632 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

CAGCTCCCTG

CGATGGCGCA

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

CCCCAGAGCT

GCGCTCCAGG

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

WO 98/17810

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

GAACCGTCTG

TCTCCAAACA

GCTGTCAAA.A

TCCAACCTGC

TGGATGGAGC

AACACGGAGA

TTCGTCCAGA

AAGCCCTGGA

TCCTCAACCC

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

GTCCAATCTC

TGGCTACCCA

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

TACTATCAAC

GGACTGCTCC

4.9),

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

TACGTAGAGG

CCGTCTCCTC

TTCCAACACA

CTGCTTCAAG

GGCCTCTGGC

TCCAAGATGC

GCCTTTCAGC

CAGGAGACCT

CGOTGCCTGG

PCT

CCCAGGGTGC CATGCCGGCC TTGCTAGCCA TCTGCAGA.GC AGCCCTACGT AGAGGGCGGT TCAACCCGTC TCCTCCGTCT TGTGTGGTGG TCTGTGGCGG TCGCTGGGTC CAAGATGCAA CCAAATGTGC CTTTCAGCCC GCCTCCTGCA GGAGACCTCC ACTTCTCCCG GTGCCTGGAG CAGGAGGTGG GTCAGGAGGT ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAAGAT GCGGTGGAGG CTCCCCGGGT CGTCTAAAGA ATCTCATAAA GCCCCATCTC CTCCGACTTC ATTACCCAGT CACCGTGGCC GGCTGGTCCT GGCACAGCGC AAGGCTTGCT GGAGCGCGTG CCCCCCCCAG CTGTCTTCGC CCGAGCAGCT GGTGGCGCTG AGCTGCAGTG TCAGCAC~ 1US97120037 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1632 TCCGTGAGCT GTCTGACTAC AGGACGAGGA GCTCTGCGGG GGCTCAAGAC TGTCGCTGGG TACACTTTGT CACCAAATGT CCAACATCTC CCGCCTCCTG TCACTCGCCA GAACTTCTCC

TG

INFORMATION FOR SEQ ID NO:311:' SEQUENCE CHARACTERISTICS: LENGTH: 1695 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:

GCTACACCAT

CAAGTGAGAA

AAGCTGTGCC

CCCCTGAGCT

AGCGGCCTTT

GGTCCCACCT

CAGATGGAAG

TTCGCCTCTG

TTCCTGGAGG

GGAGGCTCCC

AAAGAATCTC

CTGGTCCTGG

GGCTTGCTGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

GGATCCGGAG

CCCATCTCCT

TACCCAGTCA

GAACCGTCTG

TCTCCAAACA

CGCTGGATGG

GTGAACACGG

CGCTTCGTCC

CTGAAGCCCT

GACTCCTCA-A

TCAGGGGGAG

TTCGCTGTCA

GCCTCCAACC

TGGGCCCTGC

AGATCCAGGG

ACCCCGAGGA

CCTGCCCCAG

TCCTCTACCA

TGGACACACT

AACTGGGAAT

CTTTCCAGCG

TGTCGTACCG

CGGGTGAACC

ATAAATCTCC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA.

AGCCCGACTC

GTGGCTCAGG

CCGACTTCGC

CCGTGGCCTC

GTCCAATCTC

TGGCTGATGA

AGCGGCTCAA

AGATACACTT

AGACCAACAT

GGATCACTCG

CCCTGGGCGG

GTAGTGGTAC

AAATCCGTGA

TGCAG

CAGCTCCCTG CCCCAGAGCT CGATGGCGCA GCGCTCCAGG

GCTGGTGCTG

CCAGGCCCTG

GGGGCTCCTG

GCAGCTGGAC

GGCCCCTGCC

CCGGGCAGGA

CGTTCTACGC

GTCTGGTCCA

AAACATGGCT

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

GGGAGGTAGT

TGTCAAAATC

CAACCTGCAG

TACTATCAAC

AGA.ACTGTGT

GACTGTCGCT

TGTCACCAAA

CTCCCGCCTC

CCAGAACTTC

TGGGTCAGGA

CCAGGACTGC

GCTGTCTGAC

CTCGGACACT

CAGCTGGCAG

CAGGCCCTGG

GTCGCCGACT

CTGCAGCCCA

GGGGTCCTGG

CACCTTGCGC

ATCTCTACTA

GATGAAGAAC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GGCGGTGGGT

GGTACCCAGG

CGTGAGCTGT

TACGTAGAGG

CCGTCTCCTC

GGTGGTCTGT

GGGTCCAAGA

TGTGCCTTTC

CTGCAGGAGA

TCCCGGTGCC

GGTGGGTCAG

TCCTTCCAAC

TACCTGCTTC

TCCTGCTCAA

AGAAGCTGTG

CTCTGGGCAT

GCTGCTTGAG

AAGGGATATC

TTGCCACCAC

CCCAGGGTGC

TTGCTAGCCA

AGCCCTACGT

TCAACCCGTC

TGTGTGGTGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

CAGGAGGTGG

ACTGCTCCTT

CTGACTACCT

GCGGTGGAGG

CGTCTAAAGA

GGCGGCTGGT

TGCAAGGCTT

AGCCCCCCCC

CCTCCGAGCA

TGGAGCTGCA

GAGGTGGATC

ACAGCCCCAT

GTCTTTAGAG

TGCCACCTAC

CCCCTGGGCT

CCAACTCCAT

CCCCGAGTTG

CATCTGGCAG

CATGCCGGCC

TCTGCAGAGC

AGAGGGCGGT

TCCTCCGTCT

TCTGTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG

GTCAGGAGGT

CCAACACAGC

GCTTCAAGAT

CTCCCCGGGT

ATCTCATAAA

CCTGGCACAG

GCTGGAGCGC

CAGCTGTCTT

GCTGGTGGCG

GTGTCAGCCC

CGGAGGTGGC

CTCCTCCGAC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1695 AAGATTACCC AGTCACCGTG INFORMATION FOR SEQ ID NO:312.: SEQUENCE CHARACTERISTICS'.

LENGTH: 1506 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 12: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT WO 98/17810 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC TGATGAAGAA GCACAGCGCT GGATGGAGCG GCTCAAGACT GAGCGCGTGA ACACGGAGAT ACACTTTGTC TGTCTTCGCT TCGTCCAGAC CAACATCTCC GTGGCGCTGA AGCCCTGGAT CACTCGCCAG CAGCCCGACT CCTCAACCCT GGGCGGTGGG GGTGGCTCAG GGGGAGGTAG TGGTACCCkG TCCGACTTCG CTGTCAAAAT CCGTGAGCTG ACCGTGGCCT CCAACCTGCA GTACGTAGAG GGTCCAATCT CTACTATCAA CCCGTCTCCT ATGGCTGATG AAGAACTGTG TGGTGGTCTG GAGCGGCTCA AGACTGTCGC TGGGTCCAIAG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGACCAACA TCTCCCGCCT CCTGCAGGAG TGGATCACTC GCCAGAACTT CTCCCGGTGC ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA AAAATCCGTG AGCTGTCTGA CTACCTGCTT

CTGCAG

0-3

GCTGTCAAGA

TGTCTGCCCT

TGGCAAGAAT

CAACAGTACG

ATCAACCCGT

CTGTGTGGTG

GTCGCTGGGT

ACCAAATGTG

CGCCTCCTGC

AACTTCTCCC

TCAGGAGGTG

GACTGCTCCT

TCTGACTACC

GGCGGTGGAG

CCGTCTAAAG

TGGCGGCTGG

ATGCAAGGCT

CAGCCCCCC

ACCtCCGAGC

CTGGAGCTGC

GGAGGTGGAT

CACAGCCCCA

CAAGATTACC

PCTIUS97120037 ACTTAGAAAA TGCATCAGGT 180 CTGCCACGGC CGCACCCTCT 240 TCCGGGAAAA ACTGACGTTC 300 TAGAGGGCGG TGGAGGCTCC 360 CTCCTCCGTC TAAAGAATCT 420 GTCTGTGGCG GCTGGTCCTG 480 CCAAGATGCA AGGCTTGCTG 540 CCTTTCAGCC CCCCCCCAGC 600 AGGAGACCTC CGAGCAGCTG 660 GGTGCCTGGA GCTGCAGTGT 720 GGTCAGGAGG TGGATCCGGA 780 TCCAACACAG CCCCATCTCC 840 TGCTTCAAGA TTACCCAGTC 900 GCTCCCCGGG TGAACCGTCT 960 AATCTCATAA ATCTCCAAAC 1020 TCCTGGCACA GCGCTGGATG 1080 TGCTGGAGCG CGTGAACACG 1140 CCAGCTGTCT TCGCTTCGTC 1200 AGCTGGTGGC GCTGAAGCCC 1260 AGTGTCAGCC CGACTCCTCA 1320 CCGGAGGTGG CTCAGGGGGA 1380 TCTCCTCCGA CTTCGCTGTC 1440 CAGTCACCGT GGCCTCCAAC 1500 1506 INFORMATION FOR SEQ ID NO:313: SEQUENCE CHARACTERISTICS: LENGTH: 1674 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG,

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

GCTGATGAAG

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

AGTGGTACCC

ATCCGTGAGC

CAGTACGTAG

AACCCGTCTC

CCTGCCAGCT

CAGGGCGATG

GAGGAGCTGG

CCCAGCCAGG

TACCAGGGGC

ACACTGCAGC

GGAATGGCCC

CAGCGCCGGG

TACCGCGTTC

AACTGTGTGG TGGTCTGTGG CTGTCGCTGG GTCCAAGATG TCACCAAATG TGCCTTTCAG, CCCGCCTCCT GCAGGAGACC AGAACTTCTC CCGGTGCCTG GGTCAGGAGG TGGGTCAGGA AGGACTGCTC CTTCCAACAC TGTCTGACTA CCTGCTTCA.A AGGGCGGTGG AGGCTCCCCG AACTGTGTGG TGGTCTGTGG CTGTCGCTGG GTCCAAGATG TCACCAAATG TGCCTTTCAG, CCCGCCTCCT GCAGGAGACC AGAACTTCTC CCGGTGCCTG GGTCAGGAGG TGGGTCAGGA AGGACTGCTC CTTCCAACAC TGTCTGACTA CCTGCTTCAA AGGGCGGTGG AGGCTCCCCG CTCCGTCTAA AGALATCTCAT CCCTGCCCCA GAGCTTCCTG GCGCAGCGCT CCAGGAGAAG, TGCTGCTCGG ACACTCTCTG CCCTGCAGCT GGCAGGCTGC TCCTGCAGGC CCTGGAAGGG TGGACGTCGC CGACTTTGCC CTGCCCTGCA GCCCACCCAG CAGGAGGGGT CCTGGTTGCT TACGCCACCT TGCGCAGCCC

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGGTGGTT

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

GGTGAACCGT

AAATCTCCAA

CTCAAGTGCT

CTGTGTGCCA

GGCATCCCCT

TTGAGCCAAC

ATATCCCCCG

ACCACCATCT

GGTGCCATGC

AGCCATCTGC

TGATAAGGAT

TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC GAGGTGGCTC AGGGGGAGGT CCTCCGACTT CGCTGTCAAA TCACCCTGGC CTCCAACCTG CTGGCGGCGG CTCCAACATG TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC GAGGTGGCTC AGGGGGAGGT CCTCCGACTT CGCTGTCAAA TCACCGTGGC CTCCAACCTG CTGGTCCAAT CTCTACTATC ACATGGCTAC ACCATTAGGC TAGAGCAAGT GAGGAAGATC CCTACAAGCT GTGCCACCCC GGGCTCCCCT GAGCTCCTGC TCCATAGCGG CCTTTTCCTC AGTTGGGTCC CACCTTGGAC GGCAGCAGAT GGAAGAACTG C!GGCCTTCGC CTCTGCTTTC AGAGCTTCCT GGAGGTGTCG C!CGAATTCGG CAGC 600 660 720 780 840 900 960 1020 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1674 INFORMATION FOR SEQ ID NO:314: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1470 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:314: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG WO 98/17810

CGGCTCAAGA

ATACACTTTG

ACCAACATCT

ATCACTCGCC

CTGGGCGGTG

TCCTTCCAAC

TACCTGCTTC

GGAGGCTCCC

AAAGAATCTC

CATCACTTAA

ATGGATATCC

GTCAAGCACT

CTGCCCTCTG

CAAGAATTCC

CAGTACGTAG

AACCCGTCTC

TGCGGGGGCC

GCTGGGTCCA

AAATGTGCCT

CTCCTGCAGG

TTCTCCCGGT

GGAGGTGGGT

CCCATCTCCT

TACCCAGTCA

CTGTCGCTGG

TCACCAAATG

CCCGCCTCCT

AGAACTTCTC

GGTCAGGAGG

ACAGCCCCAT

AAGATTACCC

CGGGTGAACC

ATAAATCTCC

AGAGACCACC

TGATGGAACG

TAGAAAATGC

CCACGGCCGC

GGGAAAAACT

AGGGCGGTGG

CTCCGTCTAA

TCTGGCGGCT

AGATGCAAGG

TTCAGCCCCC

AGACCTCCGA

GCCTGGAGCT

CAGGAGGTGG

CCGACTTCGC

CCGTGGCCTC

GTCCAAGATG

TGCCTTTCAG

GCAGGAGACC

CCGGTGCCTG

TGGGTCAGGA

CTCCTCCGAC

AGTCACCGTG

GTCTGGTCCA

AAACATGGCT

TAACCCTTTG

AAACCTTCGA

ATCAGGTATT

ACCCTCTCGA

GACGTTCTAT

AGGCTCCCCG

AGAATCTCAT

GGTCCTGGCA

CTTGCTGGAG

CCCCAGCTGT

GCAGCTGGTG

GCAGTGTCAG

ATCCGGAGGT

TGTCAAAATC

CAACCTGCAG

44

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

TTCGCTGTCA

GCCTCCAACC

ATCTCTACTA

AACTGCTCTA

CTGGACCCGA

ACTCCAAZACC

GAGGCAATrTC

CATCCAATCA

CTGGTTACcC

GGTGAACCGT

AAATCTCCAAI

CAGCGCTGGA

CGCGTGAACA

CTTCGC!TTCG

GCGCTGAAGC

CCCGACTCCT

GGCACCCAGG

CGTGAGCTGT

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGALAC

AAATCCGTGA

TGCAGTACGT

TCAACCCGTC

TAATGATCGA

ACAACCTCAA

TGCTCGCATT

TTCGTAATCT

TCATCAAGGC

TTGAGCAAGC

CTGGTCCAAT

ACATGGCCGA

TGGAGCGGCT

CGGAGATACA.

TCCAGACCAA

CCTGGATCAC

CAACCCTGGG

ACTGCTCCTT

CTGACTACCT

PCTIUS97/20037 GAACACGGAG 120 CTTCGTCCAG 180 GAAGCCCTGG 240 CTCCTCAACC 300 CCAGGACTGC 360 GCTGTCTGAC 420 AGAGGGCGGT 480 TCCTCCGTCT 540 TGAAATTATA 600 TTCTGAAGAC 660 CGTAAGGGCT 720 CCAACCATGT 780 AGGTGACTGG 840 GCAGGAACAA 900 CTCTACTATC 960 CGAGGAGCTC 1020 CAAGACTGTC 1080 CTTTGTCACC 1140 CATCTCCCGC 1200 TCGCCAGAAC 1260 CGGTGGGTCA 1320 CCAACACAGC 1380 GCTTCAAGAT 1440 1470 INFORMATION FOR SEQ ID NO:315: SEQUENCE CHARACTERISTICS: LENGTH: 1194 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:315: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA AGTGGTACCC AGGACTGCTC CTTCCAACAC ATCCGTGAGC TGTCTGACTA CCTGCTTCA.A CAGGAATTCA AGCTTGAGCC CAGAGGGCCC CCAGCACCTA ACCTCTTGGG TGGACCATCC GTACTCATGA TCTCCCTGAG CCCCATAGTC GACCCAGATG TCCAGATCAG CTGGTTTGTG CAAACCCATA GAGAGGATTA CAACAGTACT CACCAGGACT GGATGAGTGG CAAGGAGTTC GCGCCCATCG AGAGAACCAT CTCAAAACCC GTCTTGCCTC CACCAGAAGA AGAGATGACT ACAGACTTCA TGCCTGAAGA CATTTACGTG AACTACAAGA ACACTGAACC AGTCCTGGAC CTGAGAGTGG AAAAGAAGAA. CTGGGTGGAA GAGGGTCTGC ACAATCACCA CACGACTAAG

CGGCTGGTCC

CAAGGCTTGC

CCCCCCCCCA

TCCGAGCAGC

GAGCTGCAGT

GGTGGATCCG

AGCCCCATCT

GATTACCCAG

ACAATCAAGC

GTCTTCATCT

ACATGTGTGG

AACAACGTGG

CTCCGGGCGG

AAATGCAAGG

AAAGGGTCAG

AAGAAACAGG

GAGTGGACCA

TCTGATGGTT

AGAAATAGCT

AGCTTCTCCC

TGGCACAGCG

TGGAGCGCGT

GCTGTCTTCG

TGGTGGCGCT

GTCAGCCCGA

GAGGTGGCTC

CCTCCGACTT

TCACCGTGGC

CC!TGTCCTCC

TCCCTCCAAA

TGGTGGATGT

AAGTACACAC

TCAGTGCCCT

TCAACAACAA

TAAGAGCTCC

TCACTCTGAC

ACAACGGGAA

CTTACTTCAT

A.CTCCTGTTC

GGACTCCGGG

CTGGATGGAG

GAACACGGAG

CTTCGTCCAG

GAAGCCCTGG

CTCCTCAACC

AGGGGGAGGT

CGCTGTCAAA

CTCCAACCTG

ATGCAAATGC

GATCAAGGAT

GAGCGAGGAT

AGCTCAGACA

CCCCATCCAG

AGACCTCCCA

ACAGGTATAT

CTGCATGGTC

AACAGAGCTA

GTACAGCAAG

AGTGGTCCAC

TAAA

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1194 INFORMATION FOR SEQ ID NO:316: SEQUENCE CHARACTERISTICS: LENGTH: 1131 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:316;

GCCACCCAGG

CGTGAGCTGT

GACGAGGAGC

CTCAAGACTG

CACTTTGTCA

AACATCTCCC

ACTCGCCAGA

GAATTCAAGC

GCACCTAACC

ACTGCTCCTT

CTGACTACCT

TCTGCGGGGG

TCGCTGGGTC

CCAAATGTGC

GCCTCCTGCA

ACTTCTCCCG

TTGAGCCCAG

TCTTGGGTGG

TCAACACAGC

GCTTCAAGAT

CCTCTGGCGG

CAAGATGCAA

CTTTCAGCCC

GGAGACCTCC

GTGCCTGGAG,

AGGGCCCACA

ACCATCCGTC

CCCATCTCCT

TACCCAGTCA

CTGGTCCTGG

GGCTTGC!TGG

CCCCCCAGCT

GAGCAGCTGG

CTGCAGTGTC

ATCAAGCCCT

TTCATCTTCC

CCGACTTCGC

CCGTGGCCTC

CACAGCGCTG

AGCGCGTGAA

GTCTTCGCTT

TGGCGCTGAA

AGCCCGACTC

GTCCTCCATG

CTCCAAAGAT

TGTCAAAATC

CAACCTGCAG

GATGGAGCGG

CACGGAGATA

CGTCCAGACC

GCCCTGGATC

CTCAACCCTG

CAAATGCCCA

CAAGGATGTA

WO 98/17810 CTCATGATCT CCCTGAGCCC CATAGTCACA -CCAGATGTCC AGATCAGCTG GTTTGTGAAC ACCCATAGAG AGGATTACAA CAGTACTCTC CAGGACTGGA TGAGTGGCAA GGAGTTCAAA CCCATCGAGA GAACCATCTC AAAACCCAAA TTGCCTCCAC CAGAAGAAGA GATGACTAAG GACTTCATGC CTGAAGACAT TTACGTGGAG TACAAGAACA CTGAACCAGT CCTGGACTCT AGAGTGGAAA AGAAGAACTG GGTGGAAAGA GGTCTGCACA ATCACCACAC GACTAAGAGC 4'5 TGTGTGGTGG TGGATGTGAG AACGTGGAAG TACACACAGC CGGGCGGTCA GTGCCCTCCC TGCAAGGTCA ACAACAAAGA GGGTCAGTAA GAGCTCCACA AAACAGGTCA CTCTGACCTG TGGACCAACA ACGGGAAAAC GATGGTTCTT ACTTCATGTA AATAGCTACT CCTGTTCAGT TTCTCCCGGA CTCCGGGTAA PCT/US97/20037 CGAGGATGAC 600 TCAGACACAA 660 CATCCAGCAC 720 CCTCCCAGCG 780 GGTATATGTC 840 CATGGTCACA 900 AGAGCTAAAC 960 CAGCAAGCTG 1020 GGTCCACGAG 1080 A 1131 INFORMATION FOR SEQ ID NO:317: SEQUENCE CHARACTERISTICS: LENGTH: 45 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:317: ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGCACTCC GAGTC INFORMATION FOR SEQ ID NO:318: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:318: ATGCACGAAT TCCCTGACGC AGAGGGTGGA INFORMATION FOR SEQ ID NO:319: SEQUENCE CHARACTERISTICS: LENGTH: 33 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:319: TGACAAGCTT ACCTGACGCA GAGGGTGGAC CCT INFORMATION FOR SEQ ID NO:320: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:320:

AATTCGGCAA

INFORMATION FOR SEQ ID NO:321: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:321:

CATGTTGCCG

INFORMATION FOR SEQ ID NO:322: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 13 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:322: AATTCGGCGG CAA 13 INFORMATION FOR SEQ ID NO:323: SEQUENCE CHARACTERISTICS: LENGTH: 13 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:323: CATGTTGCCG CCG 13 INFORMATION FOR SEQ ID NO:324: SEQUENCE CHARACTERISTICS: LENGTH: 22 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:324: AATTCGGCGG CAACGGCGGC AA 22 INFORMATION FOR SEQ ID NO;325: SEQUENCE CHARACTERISTICS: LENGTH: 22 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:325: CATGTTGCCG CCGTTGCCGC CG 22 INFORMATION FOR SEQ ID NO:326: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:326: CGATCCATGG AGGTTCACCC TTTGCCT 27 INFORMATION FOR SEQ ID NO:327: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:327: GATCAAGCTT ATGGGCACTG GCTCAGTCT on WO 98/17810 4 PCT/US97/20037 INFORMATION FOR SEQ ID NO:328: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:328: CGATACATGT TGCCTACACC TGTCCTG 27 INFORMATION FOR SEQ ID NO:329: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:329: GATCAAGCTT AAGGGTGAAC CTCTGGGCA 29 INFORMATION FOR SEQ ID NO:330: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:330: CGATCCATGG TCCTGCTGCC TGCTGTG 27 INFORMATION FOR SEQ ID NO:331: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:331: GATCAAGCTT AAGGTGTAGG CAAAGGGTG 29 INFORMATION FOR SEQ ID NO:332: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:332: CGATCCATGG CTGTGGACTT TAGCTTGGGA INFORMATION FOR SEQ ID NO:333: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:333: GATCAAGCTT AAGGCAGCAG GACAGGTGT 29 WO 98/17810 4 g PCT/US97/20037 INFORMATION FOR SEQ ID N0:334: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:334: CGATCCATGG ACTTTAGCTT GGGAGAA 27 INFORMATION FOR SEQ ID N0:335: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:335: GATCAAGCTT ACACAGCAGG CAGCAGGAC 29 INFORMATION FOR SEQ ID N0:336: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:336; CGATCCATGG GAGAATGGAA AACCCAG 27 INFORMATION FOR SEQ ID N0:337: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:337: GATCAAGCTT ACAAGCTAAA GTCCACAGC 29 INFORMATION FOR SEQ ID N0:338: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:338: CGATCCATGG GACCCACTTG CCTCTCA 27 INFORMATION FOR SEQ ID NO:339: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:339: WO 98/17810 49 PCTIUS97/20037 GATCAAGCTT ACAGTTGTCC CCGTGCTGC 29 INFORMATION FOR SEQ ID NO:340: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:340: CAGTCCATGG GAACCCAGCT TCCTCCA 27 INFORMATION FOR SEQ ID NO:341: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:341: GATCAAGCTT AAAGGAGGCT CTGCAGGGC 29 INFORMATION FOR SEQ ID NO:342: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:342: CGATCCATGG GCAGGACCAC AGCTCAC 27 INFORMATION FOR SEQ ID NO:343: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:343: GATCAAGCTT ACTGTGGAGG AAGCTGGGTT INFORMATION FOR SEQ ID NO:344: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:344: CGATCCATGG CTCACAAGGA TCCCAATGCC INFORMATION FOR SEQ ID NO:345: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ IDNO:345: WO 98/17810 PCT/US97/20037 GATCAAGCTT ATGTGGTCCT GCCCTGTGG 29 INFORMATION FOR SEQ ID NO:346: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:346: CGATCCATGG ATCCCAATGC CATCTTCCTG INFORMATION FOR SEQ ID NO:347: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:347: GATCAAGCTT ACTTGTGAGC TGTGGTCCT 29 INFORMATION FOR SEQ ID NO:348: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:348: CGATCCATGG CCATCTTCCT GAGCTTCCAA INFORMATION FOR SEQ ID NO:349: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:349: GATCAAGCTT AATTGGGATC CTTGTGAGCT GT 32 INFORMATION FOR SEQ ID NO:350: SEQUENCE CHARACTERISTICS: LENGTH: 83 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:350: AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC 83 INFORMATION FOR SEQ ID NO:351: SEQUENCE CHARACTERISTICS: LENGTH: 83 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 5bf PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:351: CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG 83 INFORMATION FOR SEQ ID NO:352: SEQUENCE CHARACTERISTICS: LENGTH: 59 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:352: GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TATAATGAT 59 INFORMATION FOR SEQ ID NO:353: SEQUENCE CHARACTERISTICS: LENGTH: 56 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:353: CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG 56 INFORMATION FOR SEQ ID NO:354: SEQUENCE CHARACTERISTICS: LENGTH: 83 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:354: GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT 83 INFORMATION FOR SEQ ID NO:355: SEQUENCE CHARACTERISTICS: LENGTH: 80 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:355: CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG INFORMATION FOR SEQ ID NO:356: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:356: GATCGACCAT GGCTCTGGAC CCGAACAACC TC 32 INFORMATION FOR SEQ ID NO:357: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs WO 98/17810 50L PCT/US97/20037 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:357: CTCGATTACG TACAAAGGTG CAGGTGGT 28 INFORMATION FOR SEQ ID NO:358: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:358: GATCGACCAT GGCTAATGCA TCAGGTATTG AG 32 INFORMATION FOR SEQ ID NO:359: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:359: CTCGATTACG TATTCTAAGT TCTTGACA 28 INFORMATION FOR SEQ ID NO:360: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:360: GATCGACCAT GGCTGCACCC TCTCGACATC CA 32 INFORMATION FOR SEQ ID NO:361: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:361: CTCGATTACG TAGGCCGTGG CAGAGGGC 28 INFORMATION FOR SEQ ID NO:362: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:362: GATCGACCAT GGCTGCAGGT GACTGGCAAG AA 32 INFORMATION FOR SEQ ID NO:363: SEQUENCE CHARACTERISTICS: WO 98/17810 LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:363: CTCGATTACG TACTTGATGA TGATTGGA INFORMATION FOR SEQ ID N0:364: SEQUENCE CHARACTERISTICS: LENGTH: 54 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:364: GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG INFORMATION FOR SEQ ID NO:365: SEQUENCE CHARACTERISTICS: LENGTH: 54 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:365: CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG INFORMATION FOR SEQ ID NO:366: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:366: GGGCTGCGCA AGGTGGCG INFORMATION FOR SEQ ID NO:367: SEQUENCE CHARACTERISTICS: LENGTH: 21 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:367: ACACCATTGG GCCCTGCCAG C INFORMATION FOR SEQ ID NO:368: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:368: GATCGACCAT GGCTTACAAG CTGTGCCACC CC INFORMATION FOR SEQ ID NO:369: WO 98/17810 5,o PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:369: CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT 36 INFORMATION FOR SEQ ID NO:370: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:370: GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC 32 INFORMATION FOR SEQ ID NO:371: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:371: CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT 36 INFORMATION FOR SEQ ID NO:372: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:372: GATCGACCAT GGCTATGGCC CCTGCCCTGC AG 32 INFORMATION FOR SEQ ID NO:373: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:373: CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT 36 INFORMATION FOR SEQ ID NO:374: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:374: GATCGACCAT GGCTACCCAG GGTGCCATGC CG 32 INFORMATION FOR SEQ ID NO:375: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:375: CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA 36 INFORMATION FOR SEQ ID NO:376: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:376: GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG 32 INFORMATION FOR SEQ ID NO:377: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:377: CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC 36 INFORMATION FOR SEQ ID NO:378: SEQUENCE CHARACTERISTICS: LENGTH: 21 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:378: GTAGAGGGCG GTGGAGGCTC C 21 INFORMATION FOR SEQ ID NO:379: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:379: CCGGGGAGCC TCCACCGCCC TCTAC INFORMATION FOR SEQ ID NO:380: SEQUENCE CHARACTERISTICS: LENGTH: 53 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:380: TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG 53 WO 98/17810 .506 PCT/US97/20037 INFORMATION FOR SEQ ID NO:381: SEQUENCE CHARACTERISTICS: LENGTH: 53 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:381: CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA 53 INFORMATION FOR SEQ ID N0:382: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:382: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37 INFORMATION FOR SEQ ID NO:383: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:383: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37 INFORMATION FOR SEQ ID N0:384: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:384: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38 INFORMATION FOR SEQ ID NO:385: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:385: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC 38 INFORMATION FOR SEQ ID NO:386: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:386: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38 WO 98/17810 PCT/US97/20037 INFORMATION FOR SEQ ID NO:387: SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:387: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC 39 INFORMATION FOR SEQ ID NO:388: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:388: TCTGACAAGC TTACACGGTG ACTGGGTAAT CTTGAAGC 38 INFORMATION FOR SEQ ID NO:389: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:389: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37 INFORMATION FOR SEQ ID NO:390: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:390: GTCAAGAAGC TTACGGCTGA AAGGCACATT TG 32 INFORMATION FOR SEQ ID NO:391: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:391: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 36 INFORMATION FOR SEQ ID NO:392: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:392: WO 98/17810 <00 PCT/US97/20037 CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37 INFORMATION FOR SEQ ID NO:393: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:393: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57 INFORMATION FOR SEQ ID N0:394: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: GTTGCCATGG CNAAYCTGCA RGAYGARGAR INFORMATION FOR SEQ SEQUENCE CHARACTERISTIC LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQ ID NO:394: CTGTGYGGGG GCCTCTGGCG GCTGGTC ID NO:395: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:395: GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG INFORMATION FOR SEQ ID NO:396: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:396: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA INFORMATION FOR SEQ ID NO:397: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:397: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG INFORMATION FOR SEQ ID NO:398: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:398: ITO no/1l1 n P'TUln/ Ann3 GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGt TGGTCCTGGC ACAGCGC 57 INFORMATION FOR SEQ ID NO:399: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:399: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57 INFORMATION FOR SEQ ID NO:400: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:400: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 INFORMATION FOR SEQ ID NO:401: SEQUENCE CHARACTERISTICS: LENGTH: 42 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:401: GTTGCCATGG CWGATGAAGA ACTGTGTGGN GGNCTGTGGC GG 42 INFORMATION FOR SEQ ID NO:402: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:402: TATGCAAGCT TAGGCCACGG TGACTGGGTA INFORMATION FOR SEQ ID NO:403: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:403: TATGCAAGCT TAGGAGGCCA CGGTGACTGG INFORMATION FOR SEQ ID NO:404: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear LI I WO 98/17810 5"o0 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:404: TATGCAAGCT TAGTTGGAGG CCACGGTGAC INFORMATION FOR SEQ ID NO:405: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:405: TATGCAAGCT TACAGGTTGG AGGCCACGGT INFORMATION FOR SEQ ID NO:406: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:406: TATGCAAGCT TAGTCCAGGT TGGAGGCCAC INFORMATION FOR SEQ ID NO:407: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:407: TATGCAAGCT TACTCGTCCA GGTTGGAGGC INFORMATION FOR SEQ ID NO:408: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:408: TATGCAAGCT TACTCCTCGT CCAGGTTGGA INFORMATION FOR SEQ ID NO:409: SEQUENCE CHARACTERISTICS: LENGTH: 44 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:409: GACTAGCCAT GGCNGAYGAR GARCTGTGYG GTGGCCTCTG GCGG 44 INFORMATION FOR SEQ ID NO:410: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:410: GACTAGTACG TACTGCAGGT TGGAGGCCAC GG 32 INFORMATION FOR SEQ ID NO:411: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:411: GCAGGTTACG TATTGAAGCA GGTAGTCAGA CAGCTC 36 INFORMATION FOR SEQ ID NO:412: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:412: GCAGGTTACG TACACGGTGA CTGGGTAATC TTGAAG 36 INFORMATION FOR SEQ ID NO:413: SEQUENCE CHARACTERISTICS: LENGTH: 35 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:413: GCAGGTTACG TAAGTCTTGA GCCGCTCCAT CCAGC INFORMATION FOR SEQ ID NO:414: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:414: GCAGGTTACG TAGCCAGCGA CAGTCTTGAG CCGCTC 36 INFORMATION FOR SEQ ID NO:415: SEQUENCE CHARACTERISTICS: LENGTH: 49 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:415: GTCAAGCCAT GGCNCCRCCR AGCTGTCTRC GCTTCGTTCA GACCAACTC 49 INFORMATION FOR SEQ ID NO:416: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear v-.

WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:416: GCAGGTTACG TACGGCTGAA AGGCACATTT GGTGACAA 38 INFORMATION FOR SEQ ID NO:417: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:417: GCAGGTTACG TAAAGACAGC TGGGGGGGGG INFORMATION FOR SEQ ID NO:418: SEQUENCE CHARACTERISTICS: LENGTH: 34 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:418: GCAGGTTACG TACTGGACGA AGCGAAGACA GCTG 34 INFORMATION FOR SEQ ID NO:419: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:419: TATGCTACGT AGGCCACGGT GACTGGGTA 29 INFORMATION FOR SEQ ID NO:420: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:420: TATGCTACGT AGGAGGCCAC GGTGACTGG 29 INFORMATION FOR SEQ ID NO:421: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:421: TATGCTACGT AGTTGGAGGC CACGGTGAC 29 INFORMATION FOR SEQ ID NO:422: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single

WO

98/17810 543 PCT/US97/20 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:422: TATGCTACGT ACAGGTTGGA GGCCACGGT 29 INFORMATION FOR SEQ ID NO:423: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:423: TATGCTACGT AGTCCAGGTT GGAGGCCAC 29 INFORMATION FOR SEQ ID NO:424: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:424: TATGCTACGT ACTCGTCCAG GTTGGAGGC 29 INFORMATION FOR SEQ ID NO:425: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:425: TATGCTACGT ACTCCTCGTC CAGGTTGGA 29 INFORMATION FOR SEQ ID NO:426: SEQUENCE CHARACTERISTICS: LENGTH: 46 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:426: TCAGTTGGAT CCGGCGGCGG AAGCGGAGGT GGCTCTGGGG GAGGTA 46 INFORMATION FOR SEQ ID NO:427: SEQUENCE CHARACTERISTICS: LENGTH: 48 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:427: TCAGTTGGAT CCTCCGCCAG AACCACCGCC TGACCCACCT CCTGACCC 48 INFORMATION FOR SEQ ID NO:428: SEQUENCE CHARACTERISTICS: LENGTH: 60 base pairs TYPE: nucleic acid 37 WO 98/17810 PCT/US97/20037 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: GTCTGAGGCG CCACCGCACC GACCGCTGGA INFORMATION FOR SEQ SEQUENCE CHARACTERISTIC LENGTH: 46 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: GTCTGAGGCG CCACCGCACC GACCACCCAG INFORMATION FOR SEQ SEQUENCE CHARACTERISTIC LENGTH: 60 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQ ID NO:428: CAACCGCCTC TGACCCAGGA CTGCTCCTTC ID NO:429:

S:

SEQ ID NO:429: GACTGCTCCT TCCAAC ID NO:430: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:430: GTCTGAGGCG CCGAGTGGAC GCGGGCTCCA CGGTGGCGGC AGGGTTGAGG AGTCGGGCTG INFORMATION FOR SEQ ID NO:431: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: GTTGCCATGG CNTCNAAYCT GCARGAYGAR INFORMATION FOR SEQ SEQUENCE CHARACTERISTIC LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: GTTGCCATGG CNAAYCTGCA RGAYGARGAR INFORMATION FOR SEQ SEQUENCE CHARACTERISTIC LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQ ID NO:431: GARCTGTGCG GGGGCCTCTG GCGGCTG ID NO:432:

S:

SEQ ID NO:432: CTGTGYGGGG GCCTCTGGCG GCTGGTC ID NO:433: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:433: GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG INFORMATION FOR SEQ ID NO:434: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs WO 98/17810 PCT/US97/20037 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:434: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA 57 INFORMATION FOR SEQ ID NO:435: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:435: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 57 INFORMATION FOR SEQ ID NO:436: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:436: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC 57 INFORMATION FOR SEQ ID NO:437: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:437: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57 INFORMATION FOR SEQ ID NO:438: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:438: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 INFORMATION FOR SEQ ID NO:439: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:439: TATGCAAGCT TAGGCCACGG TGACTGGGTA INFORMATION FOR SEQ ID NO:440: SEQUENCE CHARACTERISTICS: WO 98/17810 PCT/US97/20037 LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:440: TATGCAAGCT TAGGAGGCCA CGGTGACTGG INFORMATION FOR SEQ ID NO:441: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:441: TATGCAAGCT TAGTTGGAGG CCACGGTGAC INFORMATION FOR SEQ ID NO:442: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:442: TATGCAAGCT TACAGGTTGG AGGCCACGGT INFORMATION FOR SEQ ID NO:443: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:443: TATGCAAGCT TACTGCAGGT TGGAGGCCAC INFORMATION FOR SEQ ID NO:444: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:444: TATGCAAGCT TAGTCCTGCA GGTTGGAGGC INFORMATION FOR SEQ ID N0:445: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:445: TATGCAAGCT TACTCGTCCT GCAGGTTGGA INFORMATION FOR SEQ ID NO:446: WO 98/17810 540 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:446: TATGCAAGCT TACTCCTCGT CCTGCAGGTT INFORMATION FOR SEQ ID N0:447: SEQUENCE CHARACTERISTICS: LENGTH: 47 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:447: GCTACGTCTA GATCTCCTGA CCTCGACCCA GGACTGCTCC TTCCAAC 47 INFORMATION FOR SEQ ID N0:448: SEQUENCE CHARACTERISTICS: LENGTH: 68 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:448: GCTAGTTCTA GACCATCCTG GCTGACACGG TGAAACACCG TCTCTACGGG CTGACACTGC AGCTCCAG 68 INFORMATION FOR SEQ ID NO:449: SEQUENCE CHARACTERISTICS: LENGTH: 56 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:449: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGCTCCTGC AGGTTGGAGG CCACGG 56 INFORMATION FOR SEQ ID NO:450; SEQUENCE CHARACTERISTICS: LENGTH: 45 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:450: GTCAGTACTA GTCCGCCATC TCCGACACCA TTAGGCCCTG CCAGC INFORMATION FOR SEQ ID NO:451: SEQUENCE CHARACTERISTICS: LENGTH: 49 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:451: GTCAGTTCCG GAGATTTCGG TTCTGCAGAG GGCTGCGCAA GGTGGCGTA 49 WO 98/17810 54? PCT/US97/20037 INFORMATION FOR SEQ ID NO:452: SEQUENCE CHARACTERISTICS: LENGTH: 64 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:452: GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT TCTAATCTGC AAGATGAAGA GCTG 64 INFORMATION FOR SEQ ID NO:453: SEQUENCE CHARACTERISTICS: LENGTH: 61 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:453: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGAAAGGCA CATTTGGTGA CAAAGTGTAT C 61 INFORMATION FOR SEQ ID NO:454: SEQUENCE CHARACTERISTICS: LENGTH: 48 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:454: GTCAGTACTA GTCCGCCATC TCCGGGTACA CCATTAGGCC CTGCCAGC 48 INFORMATION FOR SEQ ID NO:455: SEQUENCE CHARACTERISTICS: LENGTH: 63 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:455: GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT AAGGCCTTTC AGCCCCCCCC CAG 63 INFORMATION FOR SEQ ID NO:456: SEQUENCE CHARACTERISTICS: LENGTH: 33 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:456: GTCAGACCAT GGCCACTCAG GACTCCTCTT TTC 33 INFORMATION FOR SEQ ID NO:457: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:457: CACTTTGTCA CCAAATCTGC CTTTCAG 27 INFORMATION FOR SEQ ID NO:458: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:458: CTGAAAGGCA GATTTGGTGA CAAAGTG 27 INFORMATION FOR SEQ ID NO:459: SEQUENCE CHARACTERISTICS: LENGTH: 21 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:459: GCCCCCCCCC AGCTCTCTTC G 21 INFORMATION FOR SEQ ID NO:460: SEQUENCE CHARACTERISTICS: LENGTH: 21 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:460: CGAAGAGAGC TGGGGGGGGG C 21 INFORMATION FOR SEQ ID NO:461: SEQUENCE CHARACTERISTICS: LENGTH: 41 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:461: GTCAGTTACG TACAGGGTTG AAGGAGTCGG GCTGAGACTG C 41 INFORMATION FOR SEQ ID NO:462: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:462: GTCAGTCCAT GGCTACTCAA GGTGCTATGC INFORMATION FOR SEQ ID NO:463: SEQUENCE CHARACTERISTICS: LENGTH: 31 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:463: GTAGCATACG TAGGGCTGCA GGGCAGGGGC C INFORMATION FOR SEQ ID NO:464: SEQUENCE CHARACTERISTICS: LENGTH: 166 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Pro Pro Arg Leu Glu Ala Lys Glu Ser Leu Asn Glu Ala Trp Lys Arg Gly Leu Ala Leu Val Asn Ser Ser Ala Val Ser Gly 100 Ala Gin Lys Glu 115 Leu Arg Thr Ile 130 Ser Asn Phe Leu Arg Thr Gly Asp 165 DESCRIPTION: SEQ ID N0:464: Ile Cys Ala Glu Asn Ile Met Glu Leu Ser Gin Pro Leu Arg Ala Ile Thr Ala 135 Arg Gly 150 Arg INFORMATION FOR SEQ ID NO:465: SEQUENCE CHARACTERISTICS: LENGTH: 165 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Glu Gly Ile Cys Arg 1 5 Lys Leu Val Ala Asn Val Pro Gly Met Asp Val Val Gin Leu Ser Asn Ile Ser Glu Gly Asn Ile Val Asp Asp Asp Leu Lys Lys Ser 100 Glu Glu Phe Phe Arg 115 Phe Val Val Ala Ser 130 Ser Pro Glu Lys Asp 145 Pro Pro Val Ala Ala 165 DESCRIPTION: SEQ ID N0:465: Asn Arg Val Thr Asn Asn Val 10 Leu Pro Lys Asp Tyr Met Ile Val Leu Pro Ser His Cys Trp Asp Ser Leu Thr Asp Leu Leu 55 Leu Ser Asn Tyr Ser Ile Ile 70 75 Leu Val Glu Cys Val Lys Glu 90 Phe Lys Ser Pro Glu Pro Arg 105 Ile Phe Asn Arg Ser Ile Asp 120 Glu Thr Ser Asp Cys Val Val 135 140 Ser Arg Val Ser Val Thr Lys 150 155 Val Thr Lys Tyr Glu Met Phe Ser Leu Val Ser Lys Thr Pro Lys Asp Thr Leu Met Leu 160 INFORMATION FOR SEQ ID NO:466: WO 98/17810 SEQUENCE CHARACTERISTICS: LENGTH: 139 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None PCT/US97/20037 (xi) SEQUENCE Thr Gin Asp Cys Ser 1 5 Val Lys Ile Arg Glu Thr Val Ala Ser Asn Arg Leu Val Leu Ala Gly Ser Lys Met Gin Phe Val Thr Lys Cys Val Gin Thr Asn Ile 100 Val Ala Leu Lys Pro 115 Glu Leu Gin Cys Gin DESCRIPTION: SEQ ID Phe Gin His Ser Pro Leu Ser Asp Tyr Leu Leu Gin Asp Glu Glu Gin Arg Trp Met Glu 55 Gly Leu Leu Glu Arg 70 Ala Phe Gin Pro Pro Ser Arg Leu Leu Gin 105 Trp Ile Thr Arg Gin 120 Pro Asp Ser Ser Thr 135 NO: 466: Ile Ser Leu Gln Leu Cys Arg Leu Val Asn Pro Ser Glu Thr Asn Phe Leu INFORMATION FOR SEQ ID N0:467: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ser 1 Arg His Gly Gly Leu Val Pro Leu Val 145 (ii) MOLECULE (xi) SEQUENCE Pro Ala Pro Pro 5 Asp Ser His Val Pro Leu Pro Thr Glu Trp Lys Thr Ala Val Thr Leu Gly Pro Thr Cys Arg Leu Leu Leu 100 Pro Gin Gly Arg 115 Ser Phe Gin His 130 Gly Gly Ser Thr TYPE: None DESCRIPTION: SEQ ID NO:467: Ala Cys Asp Leu His Ser Pro Val Leu 40 Gin Met Glu 55 Leu Leu Glu 70 Leu Ser Ser Gly Ala Leu Thr Thr Ala 120 Leu Leu Arg 135 Leu Cys Val 150 Leu Arg Val Leu Ser Arg Leu Ser Gin Cys Leu Pro Ala Val Asp Glu Thr Lys Ala Gin Gly Val Met Ala Ala Leu Leu Gly Gin Leu Gin Ser Leu Leu Gly 105 His Lys Asp Pro Asn 125 Gly Lys Val Arg Phe 140 Arg Glu Phe 155 INFORMATION FOR SEQ ID N0:468: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:468: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val WO 98/17810 Leu Pro Trp Lys Val Thr Pro Thr Leu Leu 100 Gin Gly 115 Phe Gin Gly Ser Ala Pro Ser His 180 Leu Pro 195 Trp Lys Val Thr Pro Thr Leu Leu 260 Thr Ala 275 Leu Arg Cys Val 522 25 Leu Leu Pre Glu Glu Th] Glu Gly Va: Ser Leu Lei Leu Gin Sei 105 Ala His Ly! 120 Arg Gly Ly! Val Arg Ghl Asp Leu Ar( 17( Ser Arg Lei 185 Leu Leu Pr( 200 Glu Glu Thi Glu Gly Val Ser Leu Let Leu Gin Sei 265 Pro Asn Al 280 Arg Phe Let PCT/US97/20037 Phe Ser Asp Ile Arg Gly Ser Gly Thr Gin 110 Ala Ile Leu Met Asn Met Lys Leu 175 Pro Glu 190 Phe Ser Asp Ile Arg Gly Ser Gly 255 Thr Gin 270 Ser Phe Gly Gly INFORMATION FOR SEQ ID NO:469: SEQUENCE CHARACTERISTICS: LENGTH: 312 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ser Pro Ala Pro Pro 1 5 Arg Asp Ser His Val His Pro Leu Pro Thr Gly Glu Trp Lys Thr Gly Ala Val Thr Leu Leu Gly Pro Thr Cys Val Arg Leu Leu Leu 100 Pro Pro Gin Gly Arg 115 Leu Ser Phe Gin His 130 Val Gly Gly Ser Thr 145 Pro Ala Pro Pro Ala 165 Asp Ser His Val Leu 180 Pro Leu Pro Thr Pro 195 Glu Trp Lys Thr Gin TYPE: None DESCRIPTION: SEQ ID NO:469: Ala Cys Asp Leu Leu His Ser Arg Pro Val Leu Leu Gin Met Glu Glu Leu Leu Glu Gly 70 Leu Ser Ser Leu Gly Ala Leu Gin 105 Thr Thr Ala His 120 Leu Leu Arg Gly 135 Leu Cys Val Arg 150 Cys Asp Leu Arg His Ser Arg Leu 185 Val Leu Leu Pro 200 Met Glu Glu Thr Arg Val Leu Ser Pro Ala Thr Lys Val Met Leu Gly Ser Leu Lys Asp Lys Val Glu Phe 155 Val Leu 170 Ser Gin Ala Val Lys Ala WO 98/17810 210 Ala Val 225 Gly Pro 5Z3 Thr Leu Leu Thr Cys Leu 245 Leu Leu Gly 260 Gly Arg Thr 275 Gin His Leu Ser Thr Leu Met Ala 235 Gly Gin 250 Leu Leu Asp Pro Val Arg PCT/US97/20037 Arg Gly Gin Leu 240 Ser Gly Gin Val 255 Thr Gin Leu Pro 270 Ala Ile Phe Leu 285 Leu Met Leu Val INFORMATION FOR SEQ ID NO:470: SEQUENCE CHARACTERISTICS: LENGTH: 313 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Pro Ala Pro Pro Asp Ser His Vai Pro Leu Pro Thr Giu Trp Lys Thr Ala Val Thr Leu Gly Pro Thr Cys Arg Leu Leu Leu 100 Pro Gin Giy Arg 115 Ser Phe Gin His 130 Gly Gly Ser Thr Pro Ala Pro Pro 165 Asp Ser His Vai 180 Pro Leu Pro Thr 195 Glu Trp Lys Thr 210 Ala Vai Thr Leu Gly Pro Thr Cys 245 Arg Leu Leu Leu 260 Pro Gln Gly Arg 275 Ser Phe Gin.His 290 Gly Gly Ser Thr DESCRIPTION: SEQ ID NO:470: Asp Leu Ser Arg Leu Leu Glu Giu Glu Giy Ser Leu Leu Gln 105 Ala His 120 Arg Giy Vai Arg Asp Leu Ser Arg 185 Leu Leu 200 Glu Giu Glu Giy Ser Leu Leu Gin 265 Ala His 280 Arg Gly Val Arg Arg Vai 10 Leu Ser Pro Ala Thr Lys Val Met Leu Gly 90 Ser Leu Lys Asp Lys Val Glu Phe 155 Arg Val 170 Leu Ser Pro Ala Thr Lys Val Met 235 Leu Gly 250 Ser Leu Lys Asp Lys Val Leu Glu Ser I l'e Giy Gly Gin Ile Met Met Leu 175 GlU Ser Ile Gly Gly 255 Gin I le Met INFORMATION FOR SEQ ID NO.471: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 316 amino acids TYPE: amino acid CC) STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (xi) SEQUENCE 524 DESCRIPTION: SEQ Leu Arg Leu Glu C ly Leu Gin 105 His Gly Arg Ala Leu 185 Pro Gin Leu Leu C ly 265 Thr Leu Leu ID 140:471: Arg Val Leu Leu Ser Gln Pro Ala Val Thr Lys Ala Val Met Ala Leu Gly Gin Ser Leu Leu Lys Asp Pro Lys Val Arg 140 Giu Phe Gly 155 Cys Asp Leu 170 His Ser Arg Val Leu Leu Met Glu Glu 220 Leu Glu Gly 235 Ser Ser Leu 250 Ala Leu Gln Thr Ala His Leu Arg Gly 300 Cys Val Arg 315 NO: 472: PCTIUS97120037 INFORMATION FOR SEQ ID Wi SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (Xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ilie Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Tyr Lye 130 Ser Leu Gly Ile TYPE: None DESCRIPTION: SEQ ID Ile Asp Gu Ile Ile Asp Pro Asn Asn Leu 25 Asn Leu Arg Leu Pro 40 Leu Glu Asn Ala Ser 55 Cys Leu Pro Ser Ala Lye Ala Gly Asp Trp, Val Thr Leu Giu Gin 105 Gly Ser Pro Gly Gly 120 Leu Cys His Pro Giu 135 Pro Trp Ala Pro Leu 150 NO: 47 2: His His Leu Lye Asn Asp Glu Asp Asn Leu Glu Ser Gly Ile Glu Ala Thr Ala Ala Pro Gin Giu Phe Arg Ala Gin Glu Gin 110 Gly Ser Gly Gly 125 Giu Leu Val Leu 140 Ser Ser Cys Pro 155 Leu His Ser Gly Leu Gin Leu Ala Gly Cys Leu Ser Leu Phe 175 WO 98/17810 525 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly 180 185 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val 195 200 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met 210 215 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 225 230 235 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 245 250 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 260 265 Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 275 280 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 290 295 INFORMATION FOR SEQ ID NO:473: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 Asn 1 Pro Ile Arg Arg His Leu Val Thr Met 145 Ser Leu Tyr Pro Ile 225 Thr Gly Tyr Ser Gly 305 (ii) MOLECULE (xi) SEQUENCE Cys Ser Ile Met 5 Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Tyr Lys Leu Leu Gly Ile Pro 165 Gin Leu Ala Gly 180 Gin Gly Leu Leu 195 Thr Leu Asp Thr 210 Trp Gin Gin Met Gin Gly Ala Met 245 Gly Val Leu Val 260 Arg Val Leu Arg 275 Gin Ser Phe Leu 290 Asp Gly Ala Ala TYPE: None DESCRIPTION: SEQ ID NO:473: Ile Asp Glu Ile Ile Asp Pro Asn Asn Leu Asn Leu Arg Leu Pro Leu Glu Asn Ala Ser Cys Leu Pro Ser Ala Lys Ala Gly Asp Trp Val Thr Leu Glu Gin 105 Gly Ser Pro Gly Glu 120 Pro Pro Ser Lys Glu 135 Cys His Pro Glu Glu 150 Trp Ala Pro Leu Ser 170 Cys Leu Ser Gin Leu 185 Gin Ala Leu Glu Gly 200 Leu Gin Leu Asp Val 215 Glu Glu Leu Gly Met 230 Pro Ala Phe Ala Ser 250 Ala Ser His Leu Gin 265 His Leu Ala Gin Pro 280 Leu Lys Ser Leu Glu 295 Leu Gin Glu Lys Leu INFORMATION FOR SEQ ID NO:474: SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCTIUS97/20037 (ii) MOLECULE (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Pro Glu 130 Ala Asp Phe Ala Ala Pro Ala Leu 165 Ala Phe Gin Arg 180 Ser Phe Leu Glu 195 Ser Gly Gly Ser 210 Gin Val Arg Lys Cys Ala Thr Tyr 245 His Ser Leu Gly 260 Ala Leu Gin Leu 275 Leu Tyr Gin Gly 290 TYPE: None DESCRIPTION: SEQ ID Ile Asp Glu Ile Ile Asp Pro Asn Asn Leu Asn Leu Arg Leu Pro Leu Glu Asn Ala Ser 55 Cys Leu Pro Ser Ala Lys Ala Gly Asp Trp Val Thr Leu Glu Gin 105 Gly Ser Pro Gly Gly 120 Leu Gly Pro Thr Leu 135 Thr Thr Ile Trp Gin 150 Gin Pro Thr Gin Gly 170 Arg Ala Gly Gly Val 185 Val Ser Tyr Arg Val 200 Gly Gly Ser Gin Ser 215 Ile Gin Gly Asp Gly 230 Lys Leu Cys His Pro 250 Ile Pro Trp Ala Pro 265 Ala Gly Cys Leu Ser 280 Leu Leu Gin Ala Leu 295 N0:474: His His Asn Asp Asn Leu Gly lie Thr Ala Gin Glu Ala Gin Gly Ser Asp Thr 140 Gin Met 155 Ala Met Leu Val Leu Arg Phe Leu 220 Ala Ala 235 Glu Glu Leu Ser Gin Leu Glu Gly 300 INFORMATION FOR SEQ ID NO:475: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Pro Glu Leu Asp Phe Ala Thr DESCRIPTION: SEQ ID N0:475: Asp Glu Ile Ile His 10 Pro Asn Asn Leu Asn 25 Leu Arg Leu Pro Asn 40 Glu Asn Ala Ser Gly 55 Leu Pro Ser Ala Thr Ala Gly Asp Trp Gin 90 Thr Leu Glu Gin Ala 105 Ser Pro Gly Glu Pro 120 Pro Ser Lys Glu Ser 135 Pro Thr Leu Asp Thr 155 Ile Trp Gln Gin Met His Leu Lys Arg Pro Asp Glu Asp Val Ser Leu Glu Ser Phe Val Ile Glu Ala Ile Leu Ala Ala Pro Ser Arg Glu Phe Arg Glu Lys Gln Glu Gin Gin Tyr 110 Ser Gly Pro Ile Ser 125 His Lys Ser Pro Asn 140 Leu Gin Leu Asp Val 160 Glu Glu Leu Gly Met WO 98/17810 PCT/US97/20037 Gin Gly 185 Gly Val 200 Arg Val Gin Ser Asp Gly His Pro 265 Ala Pro 280 Leu Ser Ala Leu 170 Ala Met Leu Val Leu Arg Phe Leu 235 Ala Ala 250 Glu Glu Leu Ser Gin Leu Glu Gly 315 NO:476: 175 Phe Ala 190 His Leu Ala Gin Ser Leu Glu Lys 255 Leu Leu 270 Pro Ser Gly Leu INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Met 1 5 Pro Ala Pro Leu Leu Ile Leu Met Asp Arg Arg Ala Val Lys Asn Arg Asn Leu Gin Pro His Pro Ile Ile Ile Leu Thr Phe Tyr Leu 100 Val Glu Gly Gly Gly 115 Asn Met Ala Met Ala 130 Ala Phe Ala Ser Ala 145 Ser His Leu Gin Ser 165 Leu Ala Gin Pro Ser 180 Lys Ser Leu Glu Gin 195 Gin Glu Lys Leu Cys 210 Val Leu Leu Gly His 225 Cys Pro Ser Gin Ala 245 Ser Gly Leu Phe Leu 260 Ser Pro Glu Leu Gly 275 Asp Phe Ala Thr Thr DESCRIPTION: SEQ ID NO:476: Ile Asp Glu Ile Ile His His 10 Asp Pro Asn Asn Leu Asn Asp 25 Asn Leu Arg Leu Pro Asn Leu 40 Leu Glu Asn Ala Ser Gly Ile 55 Cys Leu Pro Ser Ala Thr Ala 70 Lys Ala Gly Asp Trp Gin Glu 90 Val Thr Leu Glu Gin Ala Gin 105 Gly Ser Pro Gly Gly Gly Ser 120 Pro Ala Leu Gin Pro Thr Gin 135 140 Phe Gin Arg Arg Ala Gly Gly 150 155 Phe Leu Glu Val Ser Tyr Arg 170 Gly Gly Ser Gly Gly Ser Gin 185 Val Arg Lys Ile Gin Gly Asp 200 Ala Thr Tyr Lys Leu Cys His 215 220 Ser Leu Gly Ile Pro Trp Ala 230 235 Leu Gin Leu Ala Gly Cys Leu 250 Tyr Gin Gly Leu Leu Gin Ala 265 Pro Thr Leu Asp Thr Leu Gin 280 Ile Trp Gin Gin Met Glu Glu 295 300 Leu Glu Glu Glu Ala Phe Glu Gly 125 Gly Val Val Ser Gly 205 Pro Pro Ser Leu Leu 285 Leu Lys Arg Asp Val Ser Phe Ala Ile Pro Ser Arg Glu Gin Gin 110 Gly Gly Ala Met Leu Val Leu Arg 175 Phe Leu 190 Ala Ala Glu Glu Leu Ser Gin Leu 255 Glu Gly 270 Asp Val Gly INFORMATION FOR SEQ ID NO:477: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid STRANDEDNESS: single WO 98/17810 PCT/US97/20037 TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Met Ala Pro Ala Ser Ala Phe 165 Leu Gin Ser Phe 180 Gin Pro Ser Gly 195 Leu Glu Gin Val 210 Lys Leu Cys Ala Leu Gly His Ser 245 Ser Gin Ala Leu 260 Leu Phe Leu Tyr 275 Glu Leu Gly Pro 290 Ala Thr Thr Ile DESCRIPTION: SEQ Ile Asp Glu Ile Asp Pro Asn Asn 25 Asn Leu Arg Leu 40 Leu Glu Asn Ala 55 Cys Leu Pro Ser Lys Ala Gly Asp Val Thr Leu Glu 105 Gly Ser Pro Gly 120 Pro Pro Ser Lys 135 Ala Leu Gin Pro 150 Gin Arg Arg Ala Leu Glu Val Ser 185 Gly Ser Gly Gly 200 Arg Lys Ile Gin 215 Thr Tyr Lys Leu 230 Leu Gly Ile Pro Gin Leu Ala Gly 265 Gin Gly Leu Leu 280 Thr Leu Asp Thr 295 Trp Gin Gin Met 310 ID NO:477: Ile His His Leu Asn Asp Pro Asn Leu Ser Gly Ile Ala Thr Ala Trp Gin Glu Gin Ala Gin Glu Pro Ser Glu Ser His 140 Thr Gin Gly 155 Gly Gly Val 170 Tyr Arg Val Ser Gin Ser Gly Asp Gly 220 Cys His Pro 235 Trp Ala Pro 250 Cys Leu Ser Gin Ala Leu Leu Gin Leu 300 Glu Glu Leu 315 NO:478: Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro 125 Lys Ser Ala Met Leu Val Leu Arg 190 Phe Leu 205 Ala Ala Glu Glu Leu Ser Gin Leu 270 Glu Gly 285 Asp Val Gly INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Thr Gin 130 TYPE: None DESCRIPTION: SEQ ID Ile Asp Glu Ile Ile 10 Asp Pro Asn Asn Leu 25 Asn Leu Arg Leu Pro 40 Leu Glu Asn Ala Ser 55 Cys Leu Pro Ser Ala Lys Ala Gly Asp Trp 90 Val Thr Leu Glu Gin 105 Gly Ser Pro Gly Gly 120 Gly Ala Met Pro Ala 135 NO:478: His His Asn Asp Asn Leu Gly Ile Thr Ala 75 Gin Glu Ala Gin Gly Ser Phe Ala 140 Leu Lys Arg Pro Glu Asp Val Ser Glu Ser Phe Val Glu Ala Ile Leu Ala Pro Ser Arg Phe Arg Glu Lys Glu Gln Gln Tyr 110 Gly Gly Gly Ser 125 Ser Ala Phe Gin WO 98/17810 Val Arg Leu Ala 200 Giu Ser Leu Gly Val 280 Met PCTIUS97/20037 Leu 160 Gly Arg Thr Leu Gin 240 Gin Thr Trp INFORMATION FOR SEQ ID NO:479: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gln Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Thr Gln Gly Ala Gly Gly Val 165 Ser Tyr Arg Val 180 Gly Ser Gin Ser 195 Gln Gly Asp Gly 210 Leu Cys His Pro Pro Trp Ala Pro 245 Gly Cys Leu Ser 260 Leu Gin Ala Leu 275 Thr Leu Gln Leu 290 Met Glu Glu Leu TYPE: None DESCRIPTION: SEQ ID NO:479: Asp Pro Leu Glu Leu Ala Thr Ser Pro 135 Met Val Arg Leu Ala 215 Giu Ser Leu Gly Val 295 Met Giu Asn Arg As n Pro Gly Leu Pro 120 Ser Pro Ala His Leu 200 Leu Leu Ser His I le 280 Ala Ala Ile Asn Leu Ala Ser Asp Giu 105 Gly Lys Ala Ser Leu 185 Lys Gin Val Cys Ser 265 Ser Asp Pro Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser Phe Ala 155 His Leu 170 Ala Gin Ser Leu Glu Lys Leu Leu 235 Pro Ser 250 Gly Leu Pro Glu Phe Ala Ala Leu 315 NO: 4 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: WO98/17810 53- LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None PCTIUS97/20037 Asn 1 Pro Ile Arg Arg His Leu Val Asn Ser 145 Leu Lys Gln Val Cys 225 Ser Ser Asp Pro (xi) SEQUENCE Cys Ser Ile Met 5 Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Ser Ala 130 His Leu Gin Ser Ala Gin Pro Ser 165 Ser Leu Glu Gin 180 Glu Lys Leu Cys 195 Leu Leu Gly His 210 Pro Ser Gin Ala Gly Leu Phe Leu 245 Pro Glu Leu Gly 260 Phe Ala Thr Thr 275 Ala Leu Gin Pro 290 Ile Asp Glu Ile Asp Pro Asn Asn 25 Asn Leu Arg Leu 40 Leu Glu Asn Ala 55 Cys Leu Pro Ser 70 Lys Ala Gly Asp Val Thr Leu Glu 105 Gly Ser Pro Gly 120 Phe Gin Arg Arg 135 Phe Leu Glu Val 150 Gly Gly Ser Gly Val Arg Lys Ile 185 Ala Thr Tyr Lys 200 Ser Leu Gly Ile 215 Leu Gin Leu Ala 230 Tyr Gin Gly Leu Pro Thr Leu Asp 265 Ile Trp Gin Gin 280 Thr Gin Gly Ala 295 Ile His His Leu Lys Arg 10 Leu Asn Asp Glu Asp Val Pro Asn Leu Glu Ser Phe Ser Gly Ile Glu Ala Ile Ala Thr Ala Ala Pro Ser Trp Gin Glu Phe Arg Glu 90 Gin Ala Gin Glu Gin Gin 110 Gly Gly Ser Gly Gly Gly 125 Ala Gly Gly Val Leu Val 140 Ser Tyr Arg Val Leu Arg 155 Gly Ser Gin Ser Phe Leu 170 175 Gin Gly Asp Gly Ala Ala 190 Leu Cys His Pro Glu Glu 205 Pro Trp Ala Pro Leu Ser 220 Gly Cys Leu Ser Gin Leu 235 Leu Gin Ala Leu Glu Gly 250 255 Thr Leu Gin Leu Asp Val 270 Met Glu Glu Leu Gly Met 285 Met Pro Ala Phe Ala 300 DESCRIPTION: SEQ ID NO:480: INFORMATION FOR SEQ ID NO:481: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser TYPE: None DESCRIPTION: SEQ ID Ile Asp Glu Ile Ile Asp Pro Asn Asn Leu Asn Leu Arg Leu Pro Leu Glu Asn Ala Ser 55 Cys Leu Pro Ser Ala Lys Ala Gly Asp Trp Val Thr Leu Glu Gin 105 Gly Ser Pro Gly Glu 120 Pro Pro Ser Lys Glu NO:481: His His Asn Asp Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin Pro Ser Ser His WO 98/17810 PCT/US97/20037 53,4 Arg Ala Val Ser Gly Gly 185 Ile Gin 200 Lys Leu Ile Pro Ala Gly Leu Leu 265 Asp Thr 280 Gin Met Ala Met Gly Gly 155 Tyr Arg 170 Ser Gin Gly Asp Cys His Trp Ala 235 Cys Leu 250 Gin Ala Leu Gin Glu Glu Pro Ala 315 N0:482: INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Tyr Lys 130 Ser Leu Gly Ile Leu Gin Leu Ala 165 Tyr Gin Gly Leu 180 Pro Thr Leu Asp 195 Ile Trp Gin Gin 210 Thr Gin Gly Ala Gly Gly Val Leu 245 Tyr Arg Val Leu 260 Ser Ser Leu Pro 275 Lys Ile Gin Gly 290 DESCRIPTION: SEQ ID NO:482: Glu Ile Asn Asn Arg Leu Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly 120 His Pro Ala Pro Leu Ser Ala Leu 185 Gin Leu 200 Glu Leu Ala Phe Ser His Leu Ala 265 Phe Leu 280 Ala Ala WO 98/17810 2 INFORMATION FOR SEQ ID NO:483: SEQUENCE CHARACTERISTICS: LENGTH: 320 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gln Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Tyr Lys Leu Leu Gly Ile Pro 165 Gin Leu Ala Gly 180 Gin Gly Leu Leu 195 Thr Leu Asp Thr 210 Trp Gin Gln Met Gin Gly Ala Met 245 Gly Val Leu Val 260 Arg Val Leu Arg 275 Ser Leu Pro Gln 290 Ile Gin Gly Asp DESCRIPTION: SEQ ID NO:483: Ile Asp Glu Ile Ile His His Leu Asp Pro Asn Asn Leu Asn Asp Glu Asn Leu Arg Leu Pro Asn Leu Glu 40 Leu Glu Asn Ala Ser Gly Ile Glu 55 Cys Leu Pro Ser Ala Thr Ala Ala Lys Ala Gly Asp Trp Gin Glu Phe Val Thr Leu Glu Gln Ala Gln Glu 105 Gly Ser Pro Gly Glu Pro Ser Gly 120 125 Pro Pro Ser Lys Glu Ser His Lys 135 140 Cys His Pro Glu Glu Leu Val Leu 150 155 Trp Ala Pro Leu Ser Ser Cys Pro 170 Cys Leu Ser Gin Leu His Ser Gly 185 Gin Ala Leu Glu Gly Ile Ser Pro 200 205 Leu Gln Leu Asp Val Ala Asp Phe 215 220 Glu Glu Leu Gly Met Ala Pro Ala 230 235 Pro Ala Phe Ala Ser Ala Phe Gln 250 Ala Ser His Leu Gin Ser Phe Leu 265 His Leu Ala Gln Pro Thr Pro Leu 280 285 Ser Phe Leu Leu Lys Ser Leu Glu 295 300 Gly Ala Ala Leu Gin Glu Lys Leu 310 315 INFORMATION FOR SEQ ID NO:484: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:484: Cys Ser Ile Met Ile Asp Glu Ile Ile His His Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile 55 Asn Leu Gln Pro Cys Leu. Pro Ser Ala Thr Ala Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu WO 98/17810 PCTIUS97/20037 533 Thr Leu Ser Pro 120 Gly Pro 135 Thr Ile Pro Thr Ala Gly Ser Tyr 200 Ala Ser 215 Arg Lys Thr Tyr Leu Gly Gin Leu 280 Gin Gly 295 Ala Gin Gly Ser Asp Thr 140 Gin Met 155 Ala Met Leu Val Leu Arg Pro Gin 220 Gly Asp 235 Cys His Trp Ala Cys Leu Gin Ala 300 Gin Gin 110 Gly Gly Gin Leu Glu Leu Ala Phe 175 Ser His 190 Leu Ala Phe Leu Ala Ala Glu Glu 255 Leu Ser 270 Gin Leu Glu Gly INFORMATION FOR SEQ ID NO:485: SEQUENCE CHARACTERISTICS: LENGTH: 320 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:485: Met Ile Leu Asp Arg Asn Asn Leu Pro Cys Ile Lys Leu Val Gly Gly Ser Pro Leu Gly 150 Thr Thr 165 Gin Pro Arg Ala Val Ser Pro Ala 230 Val Arg 245 Ala Thr Asp Glu Ile Pro Asn Asn Leu Arg Leu Glu Asn Ala Leu Pro Ser Ala Gly Asp Thr Leu Glu 105 Ser Pro Gly 120 Pro Ser Lys 135 Pro Thr Leu Ile Trp Gin Thr Gin Gly 185 Gly Gly Val 200 Tyr Arg Val 215 Ser Ser Leu Lys Ile Gin Tyr Lys Leu ,)rl; Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser Asp Thr 155 Gin Met 170 Ala Met Leu Val Leu Arg Pro Gin 235 Gly Asp 250 Cys His Leu Leu Gly 275 Ser Leu Gly Pro Trp Ala Pro Ser Ser Cys WO 98/17810 PCT/US97/20037 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 290 295 300 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 305 310 315 320 INFORMATION FOR SEQ ID NO:486: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Met Ala 130 Phe Ala Ser Ala His Leu Gin Ser 165 Ala Gin Pro Thr 180 Leu Leu Lys Ser 195 Ala Leu Gin Glu 210 Glu Leu Val Leu Ser Ser Cys Pro 245 Leu His Ser Gly 260 Gly Ile Ser Pro 275 Val Ala Asp Phe 290 DESCRIPTION: SEQ ID NO:486: Ile Asp Glu Ile Ile His Leu Asp Glu Leu Glu Ile Glu Ala Ala Glu Phe Gin Glu Ser Gly 125 Gin Gly 140 Gly Val Arg Val Ser Leu Ile Gin 205 Lys Leu 220 Ile Pro Ala Gly Leu Leu Asp Thr 285 Gin Met 300 Lys Arg Pro Asp Val Ser Ser Phe Val Ala Ile Leu Pro Ser Arg Arg Glu Lys Gin Gin Tyr 110 Gly Gly Ser Ala Met Pro Leu Val Ala 160 Leu Arg His 175 Pro Gin Ser 190 Gly Asp Gly Cys His Pro Trp Ala Pro 240 Cys Leu Ser 255 Gin Ala Leu 270 Leu Gin Leu Glu Glu Leu INFORMATION FOR SEQ ID NO:487: SEQUENCE CHARACTERISTICS: LENGTH: 320 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:487: Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 10 Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 40 Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu WO 98/17810 Arg Asn His Pro Leu Thr 1 Val Glu Thr Ile 130 Met Ala 1 145 Phe Ala His Leu Ala Gin Leu Leu I 210 Ala Leu 225 Glu Leu Ser Ser Leu His Gly Ile 290 Val Ala i 305 PCT/US97/20037 Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser Thr Gin 155 Gly Gly 170 Tyr Arg Ser Ser Lys Ile Tyr Lys 235 Gly Ile 250 Leu Ala Gly Leu Leu Asp Gin Gin 315 INFORMATION FOR SEQ ID NO:488: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Met Ala Thr Gin 130 Arg Ala Gly Gly Val Ser Tyr Arg 165 Pro Ala Ser Ser 180 Val Arg Lys Ile 195 Ala Thr Tyr Lys 210 Ser Leu Gly Ile Leu Gin Leu Ala DESCRIPTION: SEQ ID NO:488: Ile Asp Glu Ile Asp Pro Asn Asn 25 Asn Leu Arg Leu Leu Glu Asn Ala Cys Leu Pro Ser Lys Ala Gly Asp Val Thr Leu Glu 105 Gly Ser Pro Gly 120 Gly Ala Met Pro 135 Val Leu Val Ala 150 Val Leu Arg His Leu Pro Gin Ser 185 Gin Gly Asp Gly 200 Leu Cys His Pro 215 Pro Trp Ala Pro 230 Gly Cys Leu Ser Ile His 10 Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin 90 Gin Ala Gly Gly Ala Phe Ser His 155 Leu Ala 170 Phe Leu Ala Ala Glu Glu Leu Ser 235 Gin Leu Lys Arg Asp Val Ser Phe Ala Ile Pro Ser Arg Glu Gin Gin 110 Gly Gly Ala Phe Ser Phe Thr Pro 175 Ser Leu 190 Glu Lys Leu Leu Pro Ser Gly Leu WO 98/17810 53( PCT/US97/20037 245 Gly Leu Leu Gin Ala Leu 260 265 Leu Asp Thr Leu Gin Leu 280 Gin Gin Met Glu Glu Leu 295 250 255 Glu Gly Ile Ser Pro Glu Leu 270 Asp Val Ala Asp Phe Ala Thr 285 Gly Met Ala Pro Ala Leu Gin 300 INFORMATION FOR SEQ ID NO:489: SEQUENCE CHARACTERISTICS: LENGTH: 320 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Cys Ser Ile Met Ala Pro Leu Leu Leu Met Asp Arg Ala Val Lys Asn Asn Leu Gin Pro Pro Ile Ile Ile Thr Phe Tyr Leu 100 Glu Gly Gly Gly 115 Ile Asn Pro Ser 130 Ala Thr Gin Gly Ala Gly Gly Val 165 Ser Tyr Arg Val 180 Ala Ser Ser Leu 195 Arg Lys Ile Gin 210 Thr Tyr Lys Leu Leu Gly Ile Pro 245 Gin Leu Ala Gly 260 Gin Gly Leu Leu 275 Thr Leu Asp Thr 290 Trp Gin Gin Met DESCRIPTION: SEQ ID N0:489: Ile Ile Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Glu Gin 105 Gly Glu Lys Glu Ala Phe Ser His 170 Leu Ala 185 Phe Leu Ala Ala Glu Glu Leu Ser 250 Gin Leu 265 Glu Gly Asp Val Gly Met INFORMATION FOR SEQ ID NO:490: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:490: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 WO098/17810 Pro Ala Ile Leu Arg Ala Arg Asn His Pro Leu Thr Vai Glu Asn Met 130 Ser His 145 Leu Ala Phe Leu Ala Ala Glu Glu 210 Leu Ser 225 Gin Leu Giu Gly Asp Val Giy Met 290 Ala 305 Leu Asp Arg Asn Asn Leu Pro Cys 70 Ile Lys Leu Val Giy Giy Ala Phe Ser Phe 150 Thr Pro 165 Ser Leu Glu Lys Leu Leu Pro Ser 230 Gly Leu 245 Pro Giu Phe Ala Ala Leu Pro Asn Leu Arg Giu Asn Leu Pro Ala Gly Thr Leu Ser Pro 120 Gln Arg 135 Leu Glu Leu Gly Giu Gin Leu Cys 200 Gly His 215 Gin Ala Phe Leu Leu Gly Thr Thr 280 Gin Pro 295 PCTIUS97/20037 Ser Val Leu Arg Lys Tyr Ser Ala His 160 Ser Gly Pro Pro Ser 240 Leu Leu Leu Phe INFORMATION FOR SEQ ID NO:49i: SEQUENCE CHARACTERISTICS: LENGTH: 320 amino acids TYPE: amino acid* STRANDEDNESS: single TOPOLOGY: linear (ii) (xi) Cys Se: Ala Pr Leu Mel Ala Va Asn Lei Pro Ii Thr Ph Glu G1' 11 Ile As: 130 Ala Se: Leu G1: Gin Pr M COLECULE

SEQUENCE

Ile Met Leu Leu t Asp Arg 1. Lys Asn u Gin Pro e Ile Ile e Tyr Leu 100 y Giy Gly 5 n Pro Ser r Ala Phe n Ser Phe 165 o Thr Pro 180 TYPE: None DESCRIPTION: SEQ ID NO:49i: Ile Asp Glu Ile Ile 10 Leu Pro Ser Ala Trp 90 Gin Giu Glu Gly Tyr 170 Ser Leu Lys Arg Pro Giu Asp Val Ser Giu Ser Phe Val Glu Ala Ile Leu Ala Pro Ser Arg Phe Arg Glu Lys Glu Gin Gin Tyr 110 Gly Pro Ile Ser 125 Lys Ser Pro Asn Leu Val Ala Ser 160 Leu Arg His Leu 175 Pro Gln Ser Phe 190 Gly Asp Gly Ala 205 Leu Leu Lys 195 Ser Leu Glu Gin Arg Lys Ile Gln WO 98/17810 53 Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys 210 215 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 225 230 235 Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 245 250 Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 260 265 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 275 280 Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin 290 295 Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 305 310 315 INFORMATION FOR SEQ ID NO:492: SEQUENCE CHARACTERISTICS: LENGTH: 321 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Cys His Trp Ala Cys Leu Gin Ala 270 Leu Gin 285 Glu Glu Pro Ala PCT/US97/20037 Glu Leu 240 Gin Glu Asp Gly Ala 320 (ii) MOLECULE (xi) SEQUENCE Asp Pro Asn Asn Asn Leu Arg Leu Leu Glu Asn Ala Cys Leu Pro Ser Lys Ala Gly Asp Val Thr Leu Glu Ser Ile Met Ile 100 Pro Leu Tyr Val 115 Pro Ile Ser Thr 130 Ser Pro Asn Met Phe Gin Arg Arg 165 Phe Leu Glu Val 180 Gly Gly Ser Gly 195 Val Arg Lys Ile 210 Ala Thr Tyr Lys Ser Leu Gly Ile 245 Leu Gin Leu Ala 260 Tyr Gin Gly Leu 275 Pro Thr Leu Asp 290 Ile Trp Gin Gin TYPE: None DESCRIPTION: SEQ ID NO:492: Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin Ile His 105 Gly Gly Ser Pro Gly Ala Val Leu 170 Val Leu 185 Ser Phe INFORMATION FOR SEQ ID NO:493: SEQUENCE CHARACTERISTICS: LENGTH: 321 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 Asn Pro Gly Leu Met Leu Arg Asn Gly Lys 145 Ala Ser Ser Gin Cys 225 His Ala Leu Gly Thr 305 Pro (ii) MOLECULE (xi) SEQUENCE Ala Ser Gly Ile Ser Ala Thr Ala Asp Trp Gin Giu Glu Gln Ala Gln Ile Asp Glu Ile Asp Pro Asn Asn Asn Leu Arg Leu 100 Leu Glu Tyr Val 115 Pro Ile Ser Thr 130 Ser Pro Asn Met Phe Gin Arg Arg 165 Phe Leu Giu Val 180 Gly Gly Ser Gly 195 Val Arg Lys Ile 210 Ala Thr Tyr Lys Ser Leu Gly Ile 245 Leu Gin Leu Ala 260 Tyr Gin Gly Leu 275 Pro Thr Leu Asp 290 Ile Trp Gin Gin TYPE: None DESCRIPTION: SEQ ID NO:493: Giu Ala Phe Giu Ile 70 Leu Pro Giu Ile Al a 150 Ala Ser Giy Gin Lieu 230 Pro Gly Leu rhr Me t 310 Al a Pro Arg Gin 55 His Asn Asn.

Gly Asn 135 Thr Gly Tyr Ser Gly 215 Cys Trp Cys Gin Leu 295 Glu Ile Ser Giu 40 Gin His Asp Leu Gly 120 Pro Gin Gly Arg Gin 200 Asp His Ala Leu Ala 280 Gin Giu Leu Arg Asn 10 Arg His Pro 25 Lys Leu Thr Gly Gly Gly Leu Lys Arg 75 Giu Asp Val 90 Glu Ser Phe 105 Giy Gly Ser Ser Pro Pro Gly Ala Met 155 Val Leu Val 170 Vai Leu Arg 185 Ser Phe Leu Gly Ala Ala Pro Giu Giu 235 Pro Leu Ser 250 Ser Gin Leu 265 Leu Giu Gly Leu Asp Val Leu Gly Met 315 Leu Ilie Phe Ser Pro Ser Val Pro Ser 140 Pro Ala His Leu Leu 220 Leu Ser His Ile Ala 300 Ala Gin Ile Tyr Asn Pro Ile Arg Giy 125 Lys Ala Ser Leu Lys 205 Gin Vali Cys Ser Ser 285 Asp Pro Pro Cys Ile Lys Leu Vai Cys Ser Ala Pro Leu Met Ala Val 110 Giu Pro Giu Ser Phe Ala His Leu 175 Ala Gin 190 Ser Leu Giu Lys Leu Leu Pro Ser 255 Gly Leu 270 Pro Giu Phe Ala Ala Leu Leu Ala Thr Ile Leu Asp Lys Ser His Ser 160 Gin Pro Glu Leu Giy 240 Gin Phe Leu Thr Gin 320 INFORMATION FOR SEQ ID NO:494: SEQUENCE CHARACTERISTICS: LENGTH: 321 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Phe Glu Ile Leu Pro Ser Ala Giy (ii) MOLECULE (xi) SEQUENCE Pro Ser Arg His 5 Arg Giu Lys Leu Gin Gin Gly Gly His His Leu Lys Asn Asp Giu Asp Asn Leu Giu Ser Gly Ile Giu Ala 100 Thr Ala Tyr Val 115 Pro Ile Ser Thr TYPE: None DESCRIPTION: SEQ ID NO:494: Pro Ile Ile Ile Lys Leu Vai Cys Ser Ala Pro Leu Met Ala Val Asn Leu 105 Gly Gly Ser Pro WO 98/17810 Asn Met Arg Arg 165 Glu Val 180 Ser Gly Lys Ile Tyr Lys Gly Ile 245 Leu Ala 260 Gly Leu Leu Asp Gin Gin 540 140 iy Ala Met Pro 155 al Leu Val Ala 170 al Leu Arg His er Phe Leu Leu iy Ala Ala Leu 220 ro Glu Glu Leu 235 ro Leu Ser Ser 250 er Gin Leu His eu Glu Gly Ile eu Asp Val Ala 300 eu Gly Met Ala 315 WO 9817810PCT/US97/20037 INFORMATION FOR SEQ ID NO:495: Wi SEQUENCE CHARACTERISTICS: LENGTH: 321 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) Gly Asp Leu Glu Met Ile 3 5 Leu Asp so Arg Asr Asn Leu Pro Cys Ile Lys 115 Pro Ile 130 Ser Pro Phe Gin Phe Leu Gly Gly 195 Val Arg 210 Ala Thr Ser Leu Leu Gin Tyr Gin 275 Pro Thr 290 Ile Trp

SEQUENCE

Trp Gin IGin Ala Asp Giu Pro Asn Leu Arg Giu Asn Leu Pro 100 Tyr Vai Ser Thr Asn Met Arg Arg 165 Giu Vai 180 *Ser Giy Lys Ile *Tyr Lys Giy Ile 245 Leu Ala 260 Giy Leu *Leu Asp DESCRIPTION: SEQ ID NO:495: Tyr Leu Asn Cys Pro Ala Ile Leu Arg Ala Arg Asn His Pro 110 Giu Pro Giu Ser Phe Ala His Leu 175 Ala Gin 190 Ser Leu Giu Lys Leu Leu Pro Ser 255 Giy Leu 270 Pro Giu Phe Ala Gin Gin Met Giu Giu Leu Gly Met Pr Al e Gi Pro Ala Leu Gln WO 98/17810 305 Pro 544J PCT/US97/20037 320 INFORMATION FOR SEQ ID NO:496: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Leu Asp Pro Asn Asn 1 5 Arg Asn Leu Arg Leu Asn Leu Glu Asn Ala Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp Leu Val Thr Leu Glu Gly Gly Ser Gly Gly 100 Ile His His Leu Lys 115 Gly Gly Ser Pro Gly 130 Ser Pro Pro Ser Lys 145 Gly Ala Met Pro Ala 165 Val Leu Val Ala Ser 180 Val Leu Arg His Leu 195 Ser Phe Leu Leu Lys 210 Gly Ala Ala Leu Gln 225 Pro Glu Glu Leu Val 245 Pro Leu Ser Ser Cys 260 Ser Gln Leu His Ser 275 Leu Glu Gly Ile Ser 290 Leu Asp Val Ala Asp 305 Leu Gly Met Ala Pro 325 TYPE: None DESCRIPTION: SEQ ID NO:496: Leu Met Ala Val Asn Leu Pro Ile Thr Phe Gly Ser Asp Glu 110 Glu Gly Ile Asn Ala Thr Ala Gly 175 Ser Tyr 190 Gly Ser Gln Gly Leu Cys Pro Trp 255 Gly Cys 270 Leu Gin Thr Leu Met Glu INFORMATION FOR SEQ ID NO:497: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:497: Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu 1 5 10 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala 25 Gly.Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 40 WO 98/17810 :54 Leu Gly Leu Giu Glu Gly Ser 145 Gly Val Val Ser Gly 225 Pro Pro Ser Leu Leu 305 Leu Gin Ala Gly Ser Arg Pro Vai Ser 100 Phe Vai 115 Ser Pro Pro Ser Met Pro Val Ala 180 Arg His 195 Leu Leu Ala Leu Glu Leu Ser Ser 260 Leu His 275 Gly Ile Val Ala Met Ala Gly Ser Asp Giu 75 Pro Asn Leu Arg Giu Tyr Ile Ser 140 Pro Asn.

155 Gin Arg Leu Giu Gly Ser Arg Lys 220 Thr Tyr 235 Leu Gly Gin Leu Gin Gly Thr Leu 300 Trp, Gin 315 Gly Giy Ile His Leu Asn Pro Asn 110 Glu Giy Ile Asn Ala Thr Ala Giy 175 Ser Tyr 190 Gly Ser Gin Giy Leu Cys Pro Trp 255 Gly Cys 270 Leu Gin Thr Leu Met Giu PCT/US97/20037 Ser His Asp Leu Gly Pro Gin 160 Gly Arg Gin Asp His 240 Aia Leu Aia Gin Giu 320 INFORMATION FOR SEQ ID NO:498: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRAN~DEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Pro Ser Arg His i 5 Phe Arg Giu Lys Leu Giu Gin Gin Giy Gly Cys Ser Ile Met Ile Ala Pro Leu Leu Asp Leu Met Asp Arg Asn Ala Val Lys Asn Leu i00 Asn Leu Gin Pro Cys 115 Giy Giy Ser Pro Giy 130 Ser Pro Pro Ser Lys 145 Gly Ala Met Pro Ala 165 Val Leu Val Aia Ser 180 Val Leu Arg His Leu 195 TYPE: None DESCRIPTION: SEQ ID NO:498: Pro Ile Ile Ile Lys Ala Giy 10 Thr Phe Tyr Leu Val Thr Leu 25 Gly Ser Gly Gly Gly Ser Gly Asp Gu Ile Ile His His Leu 55 Pro Asn Asn Leu Asn Asp Giu 70 75 Leu Arg Leu Pro Asn Leu Giu 90 Giu Asn Ala Ser Gly Ile Giu 105 Leu Pro Ser Ala Thr Ala Tyr 120 Giu Pro Ser Gly Pro Ile Ser 135 140 Giu Ser His Lys Ser Pro Asn 150 155 Phe Ala Ser Aia Phe Gin Arg 170 His Leu Gin Ser Phe Leu Glu 185 Ala Gin Pro Ser Gly Gly Ser 200 Ser Leu Giu Gin Val Aro Lys Trp Gin Glu is Gin Aia Gin Gly Ser Asn Arg Pro Pro Val Ser Ile Phe Val Arg Ile Leu Arg 110 Giu Giy Gly Ile Asn Pro Ala Thr Gin 160 Ala Gly Gly 175 Ser Tyr Arg 190 Gly Ser Gin Gin Giy Asp Ser Phe 210 Leu Leu Lys 215 -220 WO 98/17810 54 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 225 230 PCTIUS97/20037 Thr Tyr Lys Leu Cys His 235 240 Gl Le G1 Gl 29 As Gl u Glu Leu Val Leu Leu Gly His Ser Leu 245 250 u Ser Ser Cys Pro Ser Gin Ala Leu Gin 260 265 .n Leu His Ser Gly Leu Phe Leu Tyr Gin 275 280 .u Gly Ile Ser Pro Glu Leu Gly Pro Thr '0 295 .p Val Ala Asp Phe Ala Thr Thr Ile Trp 310 315 y Met Ala Pro Ala Leu Gin Pro 325 INFORMATION FOR SEQ ID NO:499: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Gly Leu Gly Leu 300 Gin Pro Trp 255 Gly Cys 270 Leu Gin Thr Leu Met Glu Ala 1 Thr Ser His Asp Leu Ile Ala Gly Ser 145 Gly Val Val Ser Gly 225 Pro Pro Ser Leu Leu 305 Leu (ii) MOLECULE (xi) SEQUENCE Gly Asp Trp Gin 5 Leu Glu Gin Ala Gly Gly Gly Ser Leu Lys Arg Pro Glu Asp Val Ser Glu Ser Phe Val Glu Ala Ile Leu 100 Ala Pro Ser Arg 115 Gly Ser Pro Gly 130 Pro Pro Ser Lys Ala Met Pro Ala 165 Leu Val Ala Ser 180 Leu Arg His Leu 195 Phe Leu Leu Lys 210 Ala Ala Leu Gin Glu Glu Leu Val 245 Leu Ser Ser Cys 260 Gin Leu His Ser 275 Glu Gly Ile Ser 290 Asp Val Ala Asp Gly Met Ala Pro 325 TYPE: None DESCRIPTION: SEQ ID NO:499: Glu Phe Arg Glu Lys Leu Thr Phe 10 Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu 40 Pro Ala Pro Leu Leu Asp Pro Asn 55 Ile Leu Met Asp Arg Asn Leu Arg 70 75 Arg Ala Val Lys Asn Leu Glu Asn 90 Arg Asn Leu Gin Pro Cys Leu Pro 105 His Pro Ile Ile Ile Lys Tyr Val 120 125 Glu Pro Ser Gly Pro Ile Ser Thr 135 140 Glu Ser His Lys Ser Pro Asn Met 150 155 Phe Ala Ser Ala Phe Gin Arg Arg 170 His Leu Gin Ser Phe Leu Glu Val 185 Ala Gin Pro Ser Gly Gly Ser Gly 200 205 Ser Leu Glu Gin Val Arg Lys Ile 215 220 Glu Lys Leu Cys Ala Thr Tyr Lys 230 235 Leu Leu Gly His Ser Leu Gly Ile 250 Pro Ser Gin Ala Leu Gin Leu Ala 265 Gly Leu Phe Leu Tyr Gin Gly Leu 280 285 Pro Glu Leu Gly Pro Thr Leu Asp 295 300 Phe Ala Thr Thr Ile Trp Gin Gin 310 315 Ala Leu Gin Pro Leu Val Gly Gly Ile His Leu Asn Pro Asn Ser Gly Ala Thr Gly Gly Asn Pro Thr Gin 160 Gly Gly 175 Tyr Arg Ser Gin Gly Asp Cys His 240 Trp Ala 255 Cys Leu Gin Ala Leu Gin Glu Glu INFORMATION FOR SEQ ID NO:500: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Pro Pro Ala Pro Ser Ile Leu Met Val Arg Ala Val Leu Arg Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 130 Asn Met Ala Tyr His Ser Leu Gly 165 Ala Leu Gin Leu 180 Leu Tyr Gin Gly 195 Gly Pro Thr Leu 210 Thr Ile Trp Gin Pro Thr Gin Gly 245 Ala Gly Gly Val 260 Ser Tyr Arg Val 275 Met Ala Thr Pro 290 Leu Lys Ser Leu Leu Gin Glu Lys 325 544 TYPE: None DESCRIPTION: SEQ ID Ile Met Ile NO:500: Ile Ile Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Glu Gin Gly Glu Lys Glu 140 Glu Glu 155 Leu Ser Gin Leu Glu Gly Asp Val 220 Gly Met 235 Ala Ser Leu Gin Gin Pro Ser Leu 300 Ile Gin 315 His His Asn Asp Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin 110 Pro Ser 125 Ser His Leu Val Ser Cys His Ser 190 Ile Ser 205 Ala Asp Ala Pro Ala Phe Ser Phe 270 Gly Gly 285 Pro Gin Gly Asp INFORMATION FOR SEQ ID NO:501: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Asn Cys Ser Pro Pro Ala Pro Ser Ile Leu Met Val Arg Ala Val Leu Arg Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn DESCRIPTION: SEQ ID Ile Met Ile Asp Glu 10 Leu Leu Asp Pro Asn Asp Arg Asn Leu Arg 40 Lys Asn Leu Glu Asn 55 Gin Pro Cys Leu Pro Ile Ile Lys Ala Gly 90 Tyr Leu Val Thr Leu 105 Gly Gly Gly Ser Pro 120 Pro Ser Pro Pro Ser NO:501: Ile Ile His Asn Leu Asn Leu Pro Asn Ala Ser Gly Ser Ala Thr 75 Asp Trp Gin Glu Gin Ala Gly Glu Pro 125 Lys Glu Ser Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin Gly Pro Lys Ser WO 98/17810 130 Pro Asn Met Ala 145 Asp Val Ala Asp Gly Met Ala Pro 180 Ala Ser Ala Phe 195 Leu Gin Ser Phe 210 Gln Pro Gly Gly 225 Ser Leu Pro Gin Ile Gin Gly Asp 260 Lys Leu Cys His 275 Ile Pro Trp Ala 290 Ala Gly Cys Leu 305 Leu Leu Gin Ala Leu Gin Glu Glu 175 Pro Ala 190 Ala Ser His Leu Pro Ala Val Arg 255 Ala Thr 270 Ser Leu Leu Gin Tyr Gin PCT/US97/20037 Leu 160 Leu Phe His Ala Ser 240 Lys Tyr Gly Leu Gly 320 INFORMATION FOR SEQ ID NO:502: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Met 1 Arg Val Phe Ile Ser Glu Gin Ile Pro 145 Ala His Pro Val Ala 225 Ser Leu Tyr Pro Ile (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser 5 Pro Pro Ala Pro Ser Ile Leu Met Val Arg Ala Val Leu Arg Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 130 Asn Met Ala Ser Ser His Leu Gin 165 Leu Ala Gin Pro 180 Ala Ser Ser Leu 195 Arg Lys Ile Gin 210 Thr Tyr Lys Leu Leu Gly Ile Pro 245 Gin Leu Ala Gly 260 Gin Gly Leu Leu 275 Thr Leu Asp Thr 290 Trp Gin Gin Met TYPE: None DESCRIPTION: SEQ ID NO:502: Ile Met Ile Asp Glu Ile Ile 10 Leu Leu Asp Pro Asn Asn Leu 25 Asp Arg Asn Leu Arg Leu Pro Lys Asn Leu Glu Asn Ala Ser 55 Gin Pro Cys Leu Pro Ser Ala 70 Ile Ile Lys Ala Gly Asp Trp 90 Tyr Leu Val Thr Leu Glu Gin 105 Gly Gly Gly Ser Pro Gly Glu 120 Pro Ser Pro Pro Ser Lys Glu 135 140 Ala Phe Gin Arg Arg Ala Gly 150 155 Ser Phe Leu Glu Val Ser Tyr 170 Gly Gly Gly Ser Asp Met Ala 185 Pro Gin Ser Phe Leu Leu Lys 200 Gly Asp Gly Ala Ala Leu Gin 215 220 Cys His Pro Glu Glu Leu Val 230 235 Trp Ala Pro Leu Ser Ser Cys 250 Cys Leu Ser Gin Leu His Ser 265 Gin Ala Leu Glu Gly Ile Ser 280 Leu Gin Leu Asp Val Ala Asp 295 300 Glu Glu Leu Gly Met Ala Pro His Leu Asp Glu Leu Glu Ile Glu Ala Ala Glu Phe Gin Glu 110 Ser Gly His Lys Val Leu Val Leu 175 Pro Leu 190 Leu Glu Lys Leu Leu Gly Ser Gin 255 Leu Phe 270 Glu Leu Ala Thr Leu Gin WO 98/17810 4 305 310 315 Thr Gin Gly Ala Met Pro Ala Phe Ala 325 INFORMATION FOR SEQ ID NO:503: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:503: Ala Asn Pro Pro Ser Ile Val Arg Leu Arg Arg His Lys Leu Tyr Val 115 Ser Thr 130 Asn Met Ala Phe Ser His Leu Ala 195 Ala Ser 210 Arg Lys Thr Tyr Leu Gly Gin Leu 275 Gin Gly 290 Thr Leu Trp Gin Ser Ile Pro Leu Met Asp Val Lys Leu Gin Ile Ile Phe Tyr Gly Gly Asn Pro Met Ala 150 Ser Ala 165 Gin Ser Pro Gly Leu Pro Gin Gly 230 Leu Cys 245 Pro Trp Gly Cys Leu Gin Thr Leu 310 Met Glu 325 Ile Asn Leu Ala Ser 75 Asp Glu Gly Lys Pro 155 Ala Ser Met Leu Leu 235 Leu Ser His Ile Ala 315 PCT/US97/20037 320 Lys Asp Ser Ala Pro Arg Gin Pro Ser Met 160 Val Arg Gly Gin Cys 240 His Ala Leu Gly Thr 320 INFORMATION FOR SEQ ID NO:504: SEQUENCE CHARACTERISTICS: LENGTH: 329 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:504: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 40 WO 98/17810 Phe Val Arg Ile Leu Arg Ser Arg His Glu Lys Leu Gin Tyr Val 115 Ile Ser Thr 130 Pro Asn Met 145 Gin Arg Arg Leu Glu Val Gly Ser Asp 195 Ser Phe Leu 210 Gly Ala Ala 225 Pro Glu Glu Pro Leu Ser Ser Gin Leu 275 Leu Glu Gly 290 Leu Asp Val 305 Leu Gly Met 547 PCT/US97/20037 Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala 55 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 70 75 Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg 90 Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin 100 105 110 Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 120 125 Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 135 140 Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 150 155 160 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Gly Gly 180 185 190 Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin 200 205 Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 215 220 Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 230 235 240 Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Ser Cys Pro Ser Gin Ala Leu Gln Leu Ala Gly Cys Leu 260 265 270 His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 280 285 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 295 300 Ala Asp Phe Ala Thr Thr Ile TrD Gin Gin Met Glu Glu INFORMATION FOR SEQ ID NO:505: SEQUENCE CHARACTERISTICS: LENGTH: 319 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Met 1 Gin Gin Phe Ile Thr Arg Gin Ile Pro 145 Gin Leu Gly Arg (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser 5 Pro Pro Leu Pro Asp Ile Leu Met Asn Arg Ala Val Leu Lys Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 130 Asn Met Ala Thr Arg Arg Ala Gly 165 Glu Val Ser Tyr 180 Ser Gly Gly Ser 195 Lys Ile Gin Gly 210 TYPE: None DESCRIPTION: SEQ ID NO:505: Asn Met Ile Asp Glu Ile Ile 10 Leu Leu Asp Phe Asn Asn Leu 25 Asp Asn Asn Leu Arg Arg Pro Lys Ser Leu Gin Asn Ala Ser 55 Leu Pro Cys Leu Pro Leu Ala 70 His Ile Lys Asp Gly Asp Trp 90 Tyr Leu Lys Thr Leu Glu Asn 105 Gly Gly Gly Ser Pro Gly Glu 120 Pro Ser Pro Pro Ser Lys Glu 135 140 Gin Gly Ala Met Pro Ala Phe 150 155 Gly Val Leu Val Ala Ser His 170 Arg Val Leu Arg His Leu Ala 185 Gin Ser Phe Leu Leu Lys Ser 200 Asp Gly Ala Ala Leu Gin Glu 215 220 His Leu Gly Glu Leu Glu Ile Glu Ala Ala Glu Phe Gin Ala 110 Ser Gly His Lys Ser Ala Gin Ser 175 Pro Ser 190 Glu Gin Leu Cys WO 98/17810 54 PCTIUS97/20037 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 Leu Gin Gin Thr Trp 305 Met 1 Gin Gin Phe Ile Thr Arg Gin Ile Pro 145 Gin Leu Leu Glu Leu 225 Gly Gin Phe Leu Thr 305 Gin 230 y Ile Pro Trp Ala Pro Leu Ser 245 u Ala Gly Cys Leu Ser Gin Leu 260 265 y Leu Leu Gin Ala Leu Glu Gly 275 280 u Asp Thr Leu Gin Leu Asp Val 0 295 n Gin Met Glu Glu Leu Gly Met 310 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 322 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear 235 Ser Cys 250 His Ser Ile Ser Ala Asp Ala Pro 315 NO:506: Gin Ala 255 Phe Leu 270 Leu Gly Thr Thr Gin Pro (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser 5 Pro Pro Leu Pro Asp Ile Leu Met Asn Arg Ala Val Leu Lys Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 130 Asn Met Ala Thr Arg Arg Ala Gly 165 Glu Val Ser Tyr 180 Gly Pro Ala Ser 195 Gin Val Arg Lys 210 Cys Ala Thr Tyr His Ser Leu Gly 245 Ala Leu Gin Leu 260 Leu Tyr Gin Gly 275 Gly Pro Thr Leu 290 Thr Ile Trp Gin Pro TYPE: None DESCRIPTION: SEQ ID NO:506: Asn Met Ile Asp Asp Phe 25 Asn Leu 40 Leu Gin Cys Leu Arg Asp Lys Thr 105 Gly Ser 120 Pro Pro Ala Met Leu Val Leu Arg 185 Pro Gin 200 Gly Asp Cys His Trp Ala Cys Leu 265 Gin Ala 280 Leu Gin Glu Glu Glu 10 Asn Arg Asn Pro Gly 90 Leu Pro Ser Pro Ala 170 His Ser Gly Pro Pro 250 Ser Leu Leu Leu Thr Asn Asn Ala Thr Asn Ala Pro 125 Ser Ala Leu Gin Leu 205 Leu Leu Ser His Ile 285 Ala Ala His Leu Gly Glu Leu Glu Ile Glu Ala Ala Glu Phe Gin Ala 110 Ser Gly His Lys Ser Ala Gin Ser 175 Pro Thr 190 Lys Ser Gin Glu Val Leu Cys Pro 255 Ser Gly 270 Ser Pro Asp Phe Pro Ala INFORMATION FOR SEQ ID NO:507: SEQUENCE CHARACTERISTICS: LENGTH: 319 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (xi) SEQUENCE PCT/US97/20037 DESCRIPTION: SE DESCRIPTION: SE,Q ID Met Ala Asn Cys 1 Gin Pro Pro Leu Gin Asp Ile Leu Phe Asn Arg Ala Ile Leu Lys Asn Thr Arg His Pro Arg Lys Leu Thr 100 Gin Tyr Val Glu 115 Ile Ser Thr Ile 130 Pro Asn Met Ala 145 Gin Arg Arg Ala Leu Glu Val Ser 180 Gly Ser Gly Gly 195 Arg Lys Ile Gin 210 Thr Tyr Lys Leu 225 Leu Gly Ile Pro Gin Leu Ala Gly 260 Gin Gly Leu Leu 275 Thr Leu Asp Thr 290 Trp Gin Gin Met Ser 5 Pro Met Val Leu Ile Phe Gly Asn Thr Gly 165 Tyr Ser Gly Cys Trp 245 Cys Gin Leu Glu Asn Met Ile Asp Glu 10 Leu Leu Asp Phe Asn 25 Glu Asn Asn Leu Arg Lys Ser Leu Gin Asn 55 Leu Pro Cys Leu Pro 70 Ile Ile Arg Asp Gly 90 Tyr Leu Lys Thr Leu 105 Gly Gly Gly Ser Pro 120 Pro Ser Pro Pro Ser 135 Gin Gly Ala Met Pro 150 Gly Val Leu Val Ala 170 Arg Val Leu Arg His 185 Gin Ser Phe Leu Leu 200 Asp Gly Ala Ala Leu 215 His Pro Glu Glu Leu 230 Ala Pro Leu Ser Ser 250 Leu Ser Gin Leu His 265 Ala Leu Glu Gly Ile 280 Gin Leu Asp Val Ala 295 Glu Leu Gly Met Ala NO: 507: Ile Ile Asn Leu Arg Pro Ala Ser Leu Ala Asp Trp Glu Asn Gly Glu Lys Glu 140 Ala Phe 155 Ser His Leu Ala Lys Ser Gin Glu 220 Val Leu 235 Cys Pro Ser Gly Ser Pro Asp Phe 300 Pro Ala 315 508: His Leu Gly Glu Leu Glu Ile Glu Ala Ala Glu Phe Gin Ala 110 Ser Gly His Lys Ser Ala Gin Ser 175 Pro Ser 190 Glu Gin Leu Cys Gly His Gin Ala 255 Phe Leu 270 Leu Gly Thr Thr Gin Pro NO:5 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 322 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Asn Cys Ser Pro Pro Leu Pro Asp Ile Leu Met Asn Arg Ala Val Leu Lys Asn Leu Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 130 Asn Met Ala Thr Arg Arg Ala Gly DESCRIPTION: SEQ ID NO:508: Glu Ile Asn Asn Arg Arg Asn Ala Pro Leu Gly Asp Leu Glu Pro Gly Ser Lys Pro Ala 155 Ala Ser WO 98/17810 PCT/US97/20037 165 Tyr Arg Ser Ser Lys Ile Tyr Lys 230 Gly Ile 245 Leu Ala Gly Leu Leu Asp Gin Gin 310 Leu Phe Ala Glu 235 Leu Gin Glu Asp Gly 315 INFORMATION FOR SEQ ID NO:509: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gln His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Glu Val His Phe Ser Leu Gly 165 Asp Ile Leu Gly 180 Arg Gly Gin Leu 195 Ser Gly Gin Val 210 Thr Gln Leu Pro Ala Ile Phe Leu 245 Leu Met Leu Val 260 Asn Met Ala Ser 275 Lys Leu Leu Arg 290 Pro TYPE: None DESCRIPTION: SEQ ID NO:509: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Leu Pro Asn Asn Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gln Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Pro Leu Pro Thr Pro Val Leu 150 155 Glu Trp Lys Thr Gin Met Glu 170 Ala Val Thr Leu Leu Leu Glu 185 Gly Pro Thr Cys Leu Ser Ser 200 Arg Leu Leu Leu Gly Ala Leu 215 220 Pro Gin Gly Arg Thr Thr Ala 230 235 Ser Phe Gin His Leu Leu Arg 250 Gly Gly Ser Thr Leu Cys Val 265 Pro Ala Pro Pro Ala Cys Asp 280 Asp Ser His Val Leu His Ser 295 300 INFORMATION FOR SEQ ID NO:510: WO 98/17810 55- SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Leu Pro Thr Glu Trp Lys Thr 165 Ala Val Thr Leu 180 Gly Pro Thr Cys 195 Arg Leu Leu Leu 210 Pro Gln Gly Arg Ser Phe Gln His 245 Gly Gly Ser Thr 260 Pro Ala Pro Pro 275 Asp Ser His Val 290 Pro DESCRIPTION: SEQ ID NO:510: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Ala Val 155 Lys Ala Met Ala Gly Gin Leu Leu 220 Asp Pro 235 Val Arg Phe Gly Val Leu Ser Gin 300 Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Phe Ser Asp Ile 175 Arg Gly 190 Ser Gly Thr Gin Ala Ile Leu Met 255 Asn Met 270 Lys Leu Pro Glu Arg Val Phe Ile Ser Glu Gin Ile Pro Leu 160 Leu Gin Gin Leu Phe 240 Leu Ala Leu Val Arg Val Phe Ile Ser Glu Gln INFORMATION FOR SEQ ID NO:511: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala 75 His Pro Ile Ile-Ile Lys Ala Gly Asp Trp Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin 100 105 511: His Asn Asn Gly Thr Gin Ala WO 98/17810 Tyr Val PCTIUS97/20037 Gly Gly Gly Gly Ser 120 Asn Pro Ser Pro Pro 135 Leu Leu Pro Ala Val 150 Giu Glu Thr Lys Ala 165 Giu Gly Val Met Ala 180 Ser Leu Leu Gly Gin 200 Leu Gin Ser Leu Leu 215 Ala His Lys Asp Pro 230 Arg Gly Lys Val Arg 245 Val Arg Glu Phe Gly 260 Asp Leu Arg Val Leu 280 Ser Arg Leu Ser Gin Pro Ser Asp Gin Ala 185 Leu Gly Asn Phe Gly 265 Ser Cys Gly Glu Pro Gly Pro Ile INFORMATION FOR SEQ ID NO:512: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:512: Ser Ile Met Pro Leu Leu Met Asp Arg Val Lys Asn Leu Gin Pro Ile Ile Ile Phe Tyr Leu 100 Gly Gly Gly Asn Pro Ser Val Asp Phe 150 Ala Gin Asp 165 Ala Ala Arg 180 Gin Leu Ser Leu Gly Thr Pro Asn Aia 230 Arg Phe Leu 245 Gly Giy Asn 260 Leu Ser Lys Gin Cys Pro Ile Asp Asp Pro Asn Leu Leu Giu Cys Leu Lys Ala Val Thr Gly Ser 120 Pro Pro 135 Ser Leu Ile Leu Giy Gin Gly Gin 200 Gin Leu 215 Ile Phe Met Leu Met Aia Leu Leu 280 Giu Val 295 His Leu Asp Giu Leu Giu Ile Giu Ala Ala Giu Phe Gin Giu 110 Ser Gly 125 His Lys Thr Gin Leu Leu Cys Leu 190 Leu Giy 205 Arg Thr His Leu Thr Leu Pro Ala 270 Val Leu 285 Thr Pro WO 98/17810 Leu Pro 305 PCT/US97/20037 INFORMATION FOR SEQ ID NO:513: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:513: Ala Asn Cys Ser Ile Met Leu Leu Asp Arg Lys Asn Gin Pro Ile Ile Tyr Leu Gly Gly Pro Ser Ser Leu 150 Ile Leu 165 Gly Gin Gly Gin Gin Leu Ile Phe 230 Met Leu 245 Met Ala Leu Leu Glu Val His Leu Lys Asp Glu Asp Leu Glu Ser Ile Glu Ala Ala Ala Pro Glu Phe Arg Gin Glu Gin 110 Ser Gly Pro 125 His Lys Ser Met Glu Glu Leu Glu Gly 175 Ser Ser Leu 190 Ala Leu Gin 205 Thr Ala His Leu Arg Gly Cys Val Arg 255 Cys Asp Leu 270 His Ser Arg 285 Val Leu Leu INFORMATION FOR SEQ ID NO:514: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:514: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 10 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn 25 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 40 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr His Leu Lys Arg Asp Glu Asp Val Leu Glu Ser Phe Ile Glu Ala Ile Ala Ala Pro Ser WO 98/17810 5 PCT/US97/20037 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser 180 185 190 Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr 195 200 205 Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala 210 215 220 Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn 245 250 255 Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys 260 265 270 Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro 275 280 285 Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe 290 295 300 Ser Leu 305 INFORMATION FOR SEQ ID NO:515: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:515: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160 Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin 165 170 175 Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile 180 185 190 Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met 210 215 220 Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu 225 230 235 240 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu 245 250 255 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser WO 98/17810 PCT/US97/20037 260 265 270 Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile 275 280 285 Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly 290 295 300 Gin Leu 305 INFORMATION FOR SEQ ID NO:516: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:516: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg 195 200 205 Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu 210 215 220 Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 225 230 235 240 Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 245 250 255 Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 260 265 270 Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu 275 280 285 Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser 290 295 300 Leu Leu 305 INFORMATION FOR SEQ ID NO:517: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:517: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 WO 98/17810 Ser Ile Leu Met Asp Arg Val Arg Ala Val Lys Asn Leu Arg Asn Leu Gin Pro Arg His Pro Ile Ile Ile Lys Leu Thr Phe Tyr Leu 100 Tyr Val Glu Gly Gly Gly 115 Ser Thr Ile Asn Pro Ser 130 Asn Met Gly Arg Thr Thr 145 150 Ser Phe Gin His Leu Leu 165 Gly Gly Ser Thr Leu Cys 180 Pro Ala Pro Pro Ala Cys 195 Asp Ser His Val Leu His 210 Pro Leu Pro Thr Pro Val 225 230 Glu Trp Lys Thr Gin Met 245 Ala Val Thr Leu Leu Leu 260 Gly Pro Thr Cys Leu Ser 275 Arg Leu Leu Leu Gly Ala 290 Pro Gin 305 PCT/US97/20037 Asn Leu Cys Lys Val Gly Pro 135 Ala Arg Val Asp Ser 215 Leu Glu Glu Ser Leu 295 Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Ile Phe Met Leu 175 Met Ala 190 Leu Leu Glu Val Ser Leu Ile Leu 255 Gly Gin 270 Gly Gin Gin Leu Ser Leu Leu INFORMATION FOR SEQ ID NO:518: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:518: Asn Cy Pro Al Ile Lei Arg Al Arg Asr His Pr Leu Th Val Gl 11! Thr Il1 130 Met Al Leu Ar Cys Va: Cys As 19! His Se: 210 s Ser Ile a Pro Leu u Met Asp a Val Lys n Leu Gin o Ile Ile r Phe Tyr 100 u Gly Gly 5 e Asn Pro a His Lys g Gly Lys 165 1 Arg Glu 180 p Leu Arg 5 r Arg Leu Met Ile Asp Leu Asp Pro Arg Asn Leu Asn Leu Glu Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Asp Pro Asn 150 Val Arg Phe Phe Gly .Gly Val Leu Ser 200 Ser Gin Cys 215 Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Phe Gin Gly Ser 175 Ala Pro 190 Ser His Leu Pro WO 98/17810 55- Pro Val Leu Leu Pro Ala Val Asp Phe 225 230 Gin Met Glu Glu Thr Lys Ala Gin Asp 245 Leu Leu Glu Gly Val Met Ala Ala Arg 260 265 Leu Ser Ser Leu Leu Gly Gin Leu Ser 275 280 Gly Ala Leu Gin Ser Leu Leu Gly Thr 290 295 PCT/US97/20037 Ser Leu Gly Glu Trp Lys Thr 235 .240 Ile Leu Gly Ala Val Thr Leu 250 255 Gly Gin Leu Gly Pro Thr Cys 270 Gly Gin Val Arg Leu Leu Leu 285 Gin Leu Pro Pro Gin Gly Arg 300 INFORMATION FOR SEQ ID NO:519: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Gly Arg Leu Arg Leu 225 Glu Gly Leu Gin His 305 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Asp Pro Asn Lys Val Arg Phe 165 Glu Phe Gly Gly 180 Arg Val Leu Ser 195 Leu Ser Gin Cys 210 Pro Ala Val Asp Thr Lys Ala Gin 245 Val Met Ala Ala 260 Leu Gly Gin Leu 275 Ser Leu Leu Gly 290 Lys TYPE: None DESCRIPTION: SEQ ID NO:519: Met Ile Asp Leu Asp Pro Arg Asn Leu Asn Leu Glu Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Ala Ile Phe 150 Leu Met Leu Asn Met Ala Lys Leu Leu 200 Pro Glu Val 215 Phe Ser Leu 230 Asp Ile Leu Arg Gly Gin Ser Gly Gin 280 Thr Gin Leu 295 Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Leu Leu Leu Cys 175 Ala Cys 190 Leu His Pro Val Gin Met Leu Leu 255 Leu Ser 270 Gly Ala Thr Thr INFORMATION FOR SEQ ID NO:520: SEQUENCE CHARACTERISTICS: LENGTH: 306 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:520: WO 98/17810 PCT/US97/20037 Cys Ser Ala Pro Leu Met Ala Val Asn Leu Pro Ile Thr Phe 100 Glu Gly 115 Ile Asn Ala Ile Leu Met Asn Met 180 Lys Leu 195 Pro Glu Phe Ser Asp Ile Arg Gly 260 Ser Gly 275 Thr Gin Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Gly Lys Arg Glu 175 Leu Arg 190 Arg Leu Leu Pro Glu Thr Gly Val 255 Leu Leu 270 Gin Ser His Lys INFORMATION FOR SEQ ID NO:521: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro'Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Glu Val His 145 Asp Phe Ser Leu Gly 165 TYPE: None DESCRIPTION: SEQ ID NO:521: Ile Ile Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Glu Gin Gly Glu Lys Glu Pro Val 155 Gin Met 170 Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala WO 98/17810 PCT/US97/20037 180 Gin Leu Gin Val Leu Pro Phe Leu 245 Leu Val 260 Ser Pro Arg Asp 190 Leu Gly Ser Leu Lys Asp Lys Val 255 Glu Phe 270 Val Leu Ser Gin INFORMATION FOR SEQ ID NO:522: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:522: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His INFORMATION FOR SEQ ID NO:523: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single WO 98/17810 TOPOLOGY: 1: (i i) (xi) Asn Cys Pro Ala Ile Let Arg Ala Arg Asr His Pro Leu Thr Val Glu 115 Thr Ile 130 Met Val Gin Met Leu Leu Leu Ser 195 Gly Ala 210 Thr Thr Leu Lei.

Leu Cys Cys Asr 275 His Sei 290 MOLECULE TYPI SEQUENCE DES( Ser Ile Met Pro Leu Leu 1Met Asp Arg Val Lys Asn 1Leu Gin Pro Ile Ile Ile Phe Tyr Leu i00 1Gly Gly Giy Asn Pro Ser Leu Leu Pro Giu Giu Thr 165 Giu Giy Vai Ser Leu Leu Leu Gin Ser Aia His Lys 230 1Arg Gly Lys 245 Vai Arg Giu 260 Leu Arg Vai Arg Leu Ser 56c, inear E:None CRIPTION: SEQ ID NO:523: PCTIUS97/20037 Ile Asp Asp Pro Asn Leu Leu Giu Cys Leu Lys Aia Val Thr Giy Ser i2 0 Pro Pro 135 Ala Val Lys Ala Met Ala Giy Gin 200 Leu Leu 215 Asp Pro Vai Arg Phe Giy Leu Ser 280 Gin Cys 295 Ile His His Leu Lys Giu Asp Giu Ser Giu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Giu Trp Ala Val 175 Gly Pro 190 Arg Leu Pro Gin Ser Phe Gly Gly 255 Ala Pro 270 Ser His Leu Pro INFORMATION FOR SEQ ID NO:524: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (Xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Vai Giu Gly Gly 115 Thr Ile Asn Pro 130 TYPE: None DESCRIPTION: SEQ ID NO:524: Met Ile Asp Giu Ile Ilie Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Giu Gin Gly Giu Lys Giu His Asp Leu Ile Ala Giu Gin Ser 125 His WO 98/17810 Val Asp Phe 150 Ala Gin Asp 165 Ala Ala Arg 180 Gin Leu Ser Leu Gly Thr Pro Asn Ala 230 Arg Phe Leu 245 Gly Asn Met 260 Ser Lys Leu Cys Pro Glu SGly Gly L Leu 185 SVal Pro SLeu Val Pro 265 Asp Pro Glu'Trp Lys 155 Ala Val Thr 170 Gly Pro Thr Arg Leu Leu Pro Gin Gly 220 Ser Phe Gin 235 Gly Gly Ser 250 Ala Pro Pro Ser His Val Leu Pro Thr 300 PCT/US97/20037 305 INFORMATION FOR SEQ ID NO:525: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Lys Met Gly Leu Asp 225 Val Phe Leu Gin Val 305 (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Asp Phe Ser Ala Gin Asp Ile 165 Ala Ala Arg Gly 180 Gin Leu Ser Gly 195 Leu Gly Thr Gin 210 Pro Asn Ala Ile Arg Phe Leu Met 245 Gly Asn Met Ala 260 Ser Lys Leu Leu 275 Cys Pro Glu Val 290 DESCRIPTION: SEQ ID NO:525: Met Ile Asp Glu Ile Ile His His 10 Leu Asp Pro Asn Asn Leu Asn Asp 25 Arg Asn Leu Arg Leu Pro Asn Leu 40 Asn Leu Glu Asn Ala Ser Gly Ile 55 Pro Cys Leu Pro Ser Ala Thr Ala 70 Ile Lys Ala Gly Asp Trp Gin Glu 90 Leu Val Thr Leu Glu Gin Ala Gin 105 Gly Gly Ser Pro Gly Glu Pro Ser 120 125 Ser Pro Pro Ser Lys Glu Ser His 135 140 Leu Gly Glu Trp Lys Thr Gin Met 150 155 Leu Gly Ala Val Thr Leu Leu Leu 170 Gin Leu Gly Pro Thr Cys Leu Ser 185 Gin Val Arg Leu Leu Leu Gly Ala 200 205 Leu Pro Pro Gin Gly Arg Thr Thr 215 220 Phe Leu Ser Phe Gin His Leu Leu 230 235 Leu Val Gly Gly Ser Thr Leu Cys 250 Ser Pro Ala Pro Pro Ala Cys Asp 265 Arg Asp Ser His Val Leu His Ser 280 285 His Pro Leu Pro Thr Pro Val Leu Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Glu Glu Glu Gly 175 Ser Leu 190 Leu Gin Ala His Arg Gly Val Arg 255 Leu Arg 270 Arg Leu Leu Pro INFORMATION FOR SEQ ID N0:526: WO 98/17810 PCT/US97/20037 56Z SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Gly Glu Trp 145 Ile Leu Gly Ala Val 165 Gly Gin Leu Gly Pro 180 Gly Gin Val Arg Leu 195 Gin Leu Pro Pro Gin 210 Ile Phe Leu Ser Phe 225 Met Leu Val Gly Gly 245 Ala Ser Pro Ala Pro 260 Leu Arg Asp Ser His 275 Val His Pro Leu Pro 290 Leu 305 TYPE: None DESCRIPTION: SEQ ID NO:526: Met Ile Asp Leu Asp Pro Arg Asn Leu 40 Asn Leu Glu 55 Pro Cys Leu 70 Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Lys Thr Gin 150 Thr Leu Leu Thr Cys Leu Leu Leu Gly 200 Glv Ara Thr Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Glu Thr 155 Gly Val Leu Leu Gin Ser His Lys 220 Gly Lys 235 Arg Glu Arg Val Leu Ser Pro Ala 300 His Asp Leu Ile Ala Glu Gin Ser 125 His Lys Met Gly Leu 205 Asp Val Phe Leu Gin 285 Val Leu Arg Cys Val 250 Asp Leu 265 Ser Arg Leu Leu INFORMATION FOR SEQ ID NO:527: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:527: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 70 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin WO 98/17810 563 PCT/US97/20037 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160 Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin 165 170 175 Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile 180 185 190 Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala 210 215 220 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 225 230 235 240 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 245 250 255 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 260 265 270 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 275 280 285 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 290 295 300 Leu 305 INFORMATION FOR SEQ ID NO:528: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:528: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val 195 200 205 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 210 215 220 Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 225 230 235 240 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys 245 250 255 Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met 260 265 270 Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly 275 280 285 Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu WO 98/17810 290 Leu 305 PCT/US97/20037 INFORMATION FOR SEQ ID NO:529: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Ser Gly Ala Ser Leu 225 Trp Val Pro Leu Gln 305 Ala 1 Pro Ser Val (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gln His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Gly Arg Thr Phe Gin His Leu 165 Gly Ser Thr Leu 180 Pro Pro Ala Cys 195 His Val Leu His 210 Pro Thr Pro Val Lys Thr Gin Met 245 Thr Leu Leu Leu 260 Thr Cys Leu Ser 275 Leu Leu Gly Ala 290 TYPE: None DESCRIPTION: SEQ ID NO:529: Ile Asp Asn Leu 55 Cys Lys Val Gly Pro 135 Ala Arg Val Leu Arg 215 Leu Glu Gly Leu Gin 295 Ile 10 Asn Leu Ala Ser Asp 90 Glu Gly Lys Asp Val 170 Phe Leu Gin Val Ala 250 Ala Gin Leu Ile Leu Pro Ser Ala Trp Gin Glu Glu Pro 155 Arg Gly Ser Cys Asp 235 Gin Ala Leu Gly His Asn Asn Gly Thr Gin Ala Pro Ser 140 Asn Phe Asn Lys Pro 220 Phe Asp Arg Ser Thr 300 Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Ile Phe Met Leu 175 Ala Ser 190 Leu Arg Val His Leu Gly Leu Gly 255 Gin Leu 270 Gin Val Leu Pro INFORMATION FOR SEQ ID NO:530: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:530: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 5 10 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 WO 98/1 7810 Leu Arg Arg His Lys Leu Tyr Val Ser Thr 130 Asn Met 145 Leu Leu Leu Cys Cys Asp His Ser 210 Val Leu 225 Met Giu Leu Giu i Ser SerI Ala Leu 290 Thr 305 5,65 Cys Leu Pro Asn Leu Gin Pro 70 Ser Ala Thr Ala 75 Asp Trp Gin Giu 90 Giu Gin Ala Gin Gly Giu Pro Ser 125 L.ys Giu Ser His 140 Ile Phe Leu Ser 155 M4et Leu Val Gly 170 Ala Ser Pro Ala Ueu Arg Asp Ser 205 Val His Pro Leu 220 Leu Gly Giu Trp 235 Leu Giy Ala Val 250 Gin Leu Gly Pro Glm Val Arg Leu 285 .eu Pro Pro Gin 300 PCT/US97/20037 Ala Pro Ser Phe Arg Giu Glu Gin Gin 110 Gly Pro Ile Lys Ser Pro Phe Gin His 160 Gly Ser Thr 175 Pro Pro Ala 190 His Val Leu Pro Thr Pro Lys Thr Gin 240 Thr Leu Leu 255 Thr Cys Leu 270 Leu Leu Gly Gly Arg Thr INFORMATION FOR SEQ ID NO:53i: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRA JDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr i00 Val Giu Gly Gly 115 Thr Ile Asn Pro 130 Met Asp Pro Asn Lys Vai Arg Phe 165 Giu Phe Gly Asn 180 Val Leu Ser Lys 195 Ser Gin Cys Pro 210 Aia Vai Asp Phe Lys Ala Gin Asp 245 TYPE: None DESCRIPTION: SEQ ID NO:531: Met Ile Asp Giu Leu Asp Pro Asn 25 Arg Asm Leu Arg Asn Leu Giu Asn 55 Pro Cys Leu Pro 70 Ile Lys Ala Gly Leu Val Thr Leu i05 Giy Gly Ser Pro 120 Ser Pro Pro Ser 135 Ala Ile Phe Leu 150 Leu Met Leu Vai Met Ala Ser Pro 185 Leu Leu Arg Asp 200 Giu Val His Pro 215 Ser Leu Gly Giu 230 Ile Leu Gly Ala Ile Ile 10 Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp 90 Giu Gin Gly Giu Lys Giu Ser Phe 155 Gly Gly 170 Ala Pro Ser His Leu Pro Trp Lys 235 Val Thr 250 Leu Lys Glu Asp Giu Ser Glu Ala Ala Pro Phe Arg Giu Gin 110 Gly Pro Lys Ser Leu Leu Leu Cys 175 Cys Asp 190 His Ser Vai Leu Met Giu Leu Glu WO 98/17810 Val Met Ala Leu Gly Gin 275 Ser Leu Leu 290 Lys 305 :5(1(.PCTIUS97/20037 Ala Arg Gly Gin Leu Gly Pro'Thr Cys Leu Ser Ser Leu 260 265 270 Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin 280 285 Gly Thr Gin Leu Pro Pro Gin Gliy Arg Thr Thr Ala His 295 300 INFORMATION FOR SEQ ID NO:532: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE Ala Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Arg Gly Ser Cys Asp 225 Gin Ala Leu Gly Asn 305 (xi) Asn Cy~ Pro Ale Ile Lei Arg Alz Arg Asr His Prc Leu Thi Val Gil 115 Thr Ile 130 Met Ala Phe Leu Asn Met Lys Leu 195 Pro Glu 210 Phe Ser Asp Ile Arg Gly Ser Gly 275 Thr Gin 290

SEQUENCE

s Ser Ile 5 i Pro Leu Met Asp ~Val Lys iLeu Gin Ile Ile 85 Phe Tyr 100 Gly Gly Asn Pro Ile Phe Met Leu 165 Ala Ser 180 Leu Arg Val His Leu Gly Leu Gly 245 *Gin Leu 260 *Gin Val *Leu Pro TYPE: None DESCRIPTION: SEQ ID NO:532: Ile Asp Asn Leu 55 Cys Lys Val Gly Pro 135 Ser Gly Ala Ser Leu 215 Trp Val Pro Leu Gln 295 Asp Glu Pro Asn Leu Arg 40 Giu Asn Leu Pro Ala Gly Thr Leu 105 Ser Pro 120 Pro Ser Phe Gin Gly Ser Pro Pro 185 His Val 200 Pro Thr Lys Thr Thr Leu Thr Cys 265 Leu Leu 280 Gly Arg Ile Ile Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Giu Gin Gly Glu Lys Glu His Leu 155 Thr Leu 170 Ala Cys Leu His Pro Vai Gin Met 235 Leu Leu 250 Leu Ser Gly Ala Thr Thr His Asn Asn Gly Thr Gin Ala Pro Ser 140 Leu Cys Asp Ser Leu 220 Giu Glu Ser Leu Ala 300 His Asp Leu Ile Ala Giu Gln Ser 125 His Arg Val Leu Arg 205 Leu Giu Gly Leu Gin 285 His INFORMATION FOR SEQ ID NO:533: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:533: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ilie His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val WO 98/17810 5"67 Asp Arg Asn Lys Asn Leu Gin Pro Cys Ile Ile Lys Tyr Leu Val Gly Gly Gly Pro Ser Pro 135 His Pro Leu 150 Gly Glu Trp 165 Gly Ala Val Leu Gly Pro Val Arg Leu 215 Pro Pro Gin 230 Leu Ser Phe 245 Val Gly Gly Asn Met Ala Lys Leu Leu 295 Pro Arg Leu Asn Ala Pro Ser Gly Asp 90 Leu Glu 105 Pro Gly Ser Lys Thr Pro Thr Gin 170 Leu Leu 185 Cys Leu Leu Gly Arg Thr His Leu 250 Thr Leu 265 Pro Ala Asp Ser Pro Asn Ser Gly Ala Thr 75 Trp Gin Gin Ala Glu Pro Glu Ser 140 Val Leu 155 Met Glu Leu Glu Ser Ser Ala Leu 220 Thr Ala 235 Leu Arg Cys Val Pro Pro His Val 300 Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Pro Ala Thr Lys 175 Val Met 190 Leu Gly Ser Leu Lys Asp Lys Val 255 Glu Phe 270 Cys Asp His Ser PCT/US97/20037 Phe Ile Ser Glu Gin Ile Pro Val 160 Ala Ala Gin Leu Pro 240 Arg Gly Leu Arg INFORMATION FOR SEQ ID N0:534: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Leu Pro Thr Glu Trp Lys Thr 165 Ala Val Thr Leu 180 Gly Pro Thr Cys 195 Arg Leu Leu Leu TYPE: None DESCRIPTION: SEQ ID NO:534: Met Ile Asp Glu Ile 10 Asn Asn 25 Arg Leu Asn Ala Pro Ser Gly Asp 90 Leu Glu 105 Pro Gly Ser Lys Leu Pro Glu Thr 170 Gly Val 185 Leu Leu Gin Ser Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Phe Ser Asp Ile 175 Arg Gly 190 Ser Gly Thr Gin WO 98/17810 210 Pro Pro 225 Leu Ser Val Gly Asn Met Lys Leu 290 Pro Glu 1 305 PCT/US97/20037 SEg Ala His Arg Gly Val Arg 265 Pro Ala 280 Val Leu Asp 235 Val Phe Asp Ser Asn Ala Ile Phe 240 Phe Leu Met Leu 255 Gly Asn Gly Gly 270 Arg Val Leu Ser 285 Leu Ser Gin Cys INFORMATION FOR SEQ ID NO:535: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Val Leu Leu Gin Met Glu Glu 165 Leu Leu Glu Gly 180 Leu Ser Ser Leu 195 Gly Ala Leu Gin 210 Thr Thr Ala His Leu Leu Arg Gly 245 Leu Cys Val Arg 260 Ala Pro Pro Ala 275 Ser His Val Leu 290 Leu Pro Thr Pro TYPE: None DESCRIPTION: SEQ ID NO:535: Met Ile Asp Glu Ile Ile 10 Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp 90 Glu Gin Gly Glu Lys Glu Phe Ser 155 Asp Ile 170 Arg Gly Ser Gly Thr Gin Ala Ile 235 Leu Met 250 Asn Gly Val Leu Ser Gin Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Glu Trp Ala Val 175 Gly Pro 190 Arg Leu Pro Gin Ser Phe Gly Gly 255 Met Ala 270 Leu Leu Glu Val INFORMATION FOR SEQ ID NO:536: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single .TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (Xi) SEQUENCE PCTIUS97/20037 DESCRIPTION: SEQ ID NO:-536: Met Ile Asp Giu Ile Leu Lys Giu Asp Giu Ser Giu Aia Ala Pro Phe Arg Giu Gin 110 Giy Pro Lys Ser Gin Met Leu Leu 175 Leu Ser 190 Gly Ala Thr Thr Leu Leu Leu Cys 255 Ala Pro 270 Ser His Leu Pro INFORMATION FOR SEQ ID NO:537: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Giu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Asp Phe Ser 145 Lys Ala Gin ASP Ile 165 DESCRIPTION: SEQ ID NO:537: Giu Ile 10 Asn Asn 25 Arg Leu Asn Ala Pro Ser Gly Asp 90 Leu Giu 105 Pro Gly Ser Lys Trp Lys Val Thr 170 Ile Leu Pro Ser Ala 75 Trp Gin Giu Giu Thr 155 Leu Leu Lys Arg Giu Asp Val Giu Ser Phe Giu Ala Ile Ala Pro Ser Phe Arg Giu Giu Gin Gin 110 Gly Pro Ile Lys Ser Pro Giu Giu Thr 160 Giu Gly Val 175 WO 98/17810 Met Ala Ala Pro Thr Cys Leu Ser Gly Gin Leu Gly Gly Leu Asp 225 Val Phe Asp Ser Leu 305 180 185 Leu Ser Gly Gin Val Arg Leu 195 200 Gly Thr Gin Leu Pro Pro Gin 215 Asn Ala Ile Phe Leu Ser Phe 230 Phe Leu Met Leu Val Gly Gly 245 Gly Asn Gly Gly Asn Met Ala 260 265 Arg Val Leu Ser Lys Leu Leu 275 280 Leu Ser Gin Cys Pro Glu Val 295 Pro Ala Val Gly Thr 220 Leu Leu Ala Ser Leu 300 PCT/US97/20037 Ser Leu Leu 190 Leu Gln Ser Ala His Lys Arg Gly Lys 240 Val Arg Glu 255 Pro Ala Cys 270 Val Leu His Thr Pro Val INFORMATION FOR SEQ ID NO:538: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Ile Gly Gly Gin Ile 225 Met Gly Leu Gin Val 305 (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Gly Glu Trp Leu Gly Ala Val 165 Gin Leu Gly Pro 180 Gin Val Arg Leu 195 Leu Pro Pro Gin 210 Phe Leu Ser Phe Leu Val Gly Gly 245 Gly Asn Met Ala 260 Ser Lys Leu Leu 275 Cys Pro Glu Val 290 Asp Phe Ser Leu DESCRIPTION: SEQ ID NO:538: Met Ile Asp Glu Ile Ile His His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Glu Thr 155 Gly Val Leu Leu Gin Ser His Lys 220 Gly Lys 235 Arg Glu Ala Cys Leu His Pro Val 300 INFORMATION FOR SEQ ID NO:539: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid WO 98/17810

ST

4 PCT/US97/20037 STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:539: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro ASn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160 Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin 165 170 175 Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile 180 185 190 Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly 210 215 220 Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu 225 230 235 240 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser.Gln 245 250 255 Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 260 265 270 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 275 280 285 Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 290 295 300 Ala Arg Gly Gin Leu 305 INFORMATION FOR SEQ ID NO:540: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:540: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 .105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro WO 98/17810 PCT/US97/20037 Gin Leu 150 Ile Phe 165 Met Leu Gly Gly Leu Ser Gin Cys 230 Val Asp 245 Ala Gin Ala Ala Gin Leu Leu 140 Pro Gin Gly Arg Thr 155 Ser Phe Gin His Leu 170 Gly Gly Ser Thr Leu 185 Met Ala Ser Pro Ala 200 Leu Leu Arg Asp Ser 220 Glu Val His Pro Leu 235 Ser Leu Gly Glu Trp 250 Ile Leu Gly Ala Val 265 Gly Gin Leu Gly Pro 280 Gly Gin Val Arg Leu 300 His Lys 160 Gly Lys 175 Arg Glu Ala Cys Leu His Pro Val 240 Gin Met 255 Leu Leu Leu Ser Gly Ala INFORMATION FOR SEQ ID NO:541: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Ser Gly Met Leu Glu 225 Ser Ile Gly Gly Gin 305 (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Gly Arg Thr Phe Gin His Leu 165 Gly Ser Thr Leu 180 Ala Ser Pro Ala 195 Leu Arg Asp Ser 210 Val His Pro Leu Leu Gly Glu Trp 245 Leu Gly Ala Val 260 Gin Leu Gly Pro 275 Gin Val Arg Leu 290 Leu Pro Pro Gin DESCRIPTION: SEQ ID NO:541: Met Ile Asp Glu Ile Ile His 10 Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Leu Pro Asn 40 Asn Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr 70 75 Ile Lys Ala Gly Asp Trp Gin 90 Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Thr Ala His Lys Asp Pro Asn 150 155 Leu Arg Gly Lys Val Arg Phe 170 Cys Val Arg Glu Phe Gly Gly 185 Pro Pro Ala Cys Asp Leu Arg 200 His Val Leu His Ser Arg Leu 215 220 Pro Thr Pro Val Leu Leu Pro 230 235 Lys Thr Gin Met Glu Glu Thr 250 Thr Leu Leu Leu Glu Gly Val 265 Thr Cys Leu Ser Ser Leu Leu 280 Leu Leu Gly Ala Leu Gin Ser 295 300 Leu Lys Arg Glu Asp Val Glu Ser Phe Glu Ala Ile Ala Pro Ser Phe Arg Glu Glu Gin Gin 110 Gly Pro Ile Lys Ser Pro Ile Phe Leu 160 Met Leu Val 175 Gly Gly Asn 190 Leu Ser Lys Gin Cys Pro Val Asp Phe 240 Ala Gin Asp 255 Ala Ala Arg 270 Gin Leu Ser Leu Gly Thr WO 98/17810 7- INFORMATION FOR SEQ ID NO:542: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Leu Leu Ala Ser Leu 225 Trp Val Pro Leu Gin 305 Ala 1 Pro Ser Val Leu Arg (ii) MOLECULE (xi) SEQUENCE n Cys Ser Ile 5 o Ala Pro Leu e Leu Met Asp g Ala Val Lys g Asn Leu Gln s Pro Ile Ile u Thr Phe Tyr 100 1 Glu Gly Gly 115 r Ile Asn Pro 0 t Ala His Lys u Arg Gly Lys 165 s Val Arg Glu 180 3 Pro Ala Cys 195 s Val Leu His 3 3 Thr Pro Val s Thr Gin Met 245 r Leu Leu Leu 260 r Cys Leu Ser 275 i Leu Gly Ala Arg Thr Thr y Arg Thr Thr TYPE: None DESCRIPTION: SEQ ID NO:542: Met Ile Asp Leu Asp Pro Arg Asn Leu 40 Asn Leu Glu 55 Pro Cys Leu 70 Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Asp Pro Asn 150 Val Arg Phe Phe Gly Gly Asp Leu Arg 200 Ser Arg Leu 215 Leu Leu Pro 230 Glu Glu Thr Glu Gly Val Ser Leu Leu 280 Leu Gin Ser 295 Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Phe Leu 155 Leu Val Gly Asn Ser Lys Cys Pro 220 Asp Phe 235 Gin Asp Ala Arg Leu Ser Gly Thr 300 His Asp Leu Ile Ala Glu Gin Ser 125 His Ser Gly Met Leu 205 Glu Ser Ile Gly Gly 285 Gin His Asp Leu Ile Ala Glu Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Phe Gln Gly Ser 175 Ala Ser 190 Leu Arg Val His Leu Gly Leu Gly 255 Gin Leu 270 Gln Val Leu Pro INFORMATION FOR SEQ ID NO:543: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:543: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 5 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn 25 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 40 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 70 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin WO 98/17810 Lys Leu Tyr Val Ser Thr 130 Asn Met 145 Gly Lys Arg Glu Ala Cys Leu His 210 Pro Val 225 Gin Met Leu Leu Leu Ser Gly Ala 290 Thr Thr 305 Tyr Leu Val Gly Gly Gly Pro Ser Pro 135 Asn Ala Ile 150 Phe Leu Met 165 Gly Asn Gly Arg Val Leu Leu Ser Gin 215 Pro Ala Val 230 Thr Lys Ala 245 Val Met Ala Leu Gly Gin Ser Leu Leu 295 Lys Leu Glu Gin Ala 105 Pro Gly Glu Pro Ser Lys Glu Ser 140 Leu Ser Phe Gln 155 Val Gly Gly Ser 170 Asn Met Ala Ser 185 Lys Leu Leu Arg Pro Glu Val His 220 Phe Ser Leu Gly 235 Asp Ile Leu Gly 250 Arg Gly Gin Leu 265 Ser Gly Gin Val Thr Gin Leu Pro 300 PCT/US97/20037 Gin Ile Pro Arg 160 Val Pro Val Thr Thr 240 Leu Cys Leu Arg INFORMATION FOR SEQ ID NO:544: SEQUENCE CHARACTERISTICS: LENGTH: 309 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Arg Gly Leu Arg Leu 225 Glu Gly Leu (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ile Phe Phe Leu Met Leu 165 Gly Asn Gly Gly 180 Arg Val Leu Ser 195 Leu Ser Gin Cys 210 Pro Ala Val Asp Thr Lys Ala Gin 245 Val Met Ala Ala 260 Leu Gly Gin Leu 275 DESCRIPTION: SEQ ID NO:544: Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Gly Lys Arg Glu 175 Ala Cys 190 Leu His Pro Val Gin Met Leu Leu 255 Leu Ser 270 Gly Ala WO 98/17810 PCT/US97/20037 55 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 290 295 300 His Lys Asp Pro Asn 305 INFORMATION FOR SEQ ID NO:545: SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Asp Pro Asn Lys Val Arg Phe 165 Glu Phe Gly Gly 180 Arg Val Leu Ser 195 Leu Ser Gin Cys 210 Pro Ala Val Asp Thr Lys Ala Gin 245 Val Met Ala Ala 260 Leu Gly Gin Leu 275 Ser Leu Leu Gly 290 TYPE: None DESCRIPTION: SEQ ID NO:545: Ile Ile Asn Leu Leu Pro Ala Ser Ser Ala Asp Trp Glu Gin Gly Glu Lys Glu Ser Phe 155 Gly Gly 170 Pro Ala Asp Ser Pro Leu Glu Trp 235 Ala Val 250 Gly Pro Arg Leu Thr Thr INFORMATION FOR SEQ ID NO:546: SEQUENCE CHARACTERISTICS: LENGTH: 153 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:546: Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu 5 10 Asp Ser His Val Leu His Ser Arg Leu Ser Gin 25 Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 40 Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 55 Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ser 1 Arg His Gly Gly Ser Lys Leu Leu Cys Pro Glu Val Asp Phe Ser Leu Gin Asp Ile Leu Ala Arg Gly Gin WO 98/17810 Leu Gly Val Arg Pro Pro Leu Ser 130 Val Gly 145 Thr Cys Leu Leu 100 Gly Arg Gin His Ser Thr 70 Leu Ser Ser Leu Gly Ala Leu Gin 105 Thr Thr Ala His 120 Leu Leu Arg Gly 135 Leu Cys Val Arg 150 PCT/US97/20037 75 Leu Gly Gin Leu Ser Gly Gin 90 Ser Leu Leu Gly Thr Gin Leu 110 Lys Asp Pro Asn Ala Ile Phe 125 Lys Val Arg Phe Leu Met Leu 140 INFORMATION FOR SEQ ID NO:547: SEQUENCE CHARACTERISTICS: LENGTH: 149 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Pro Ala Pro Pro Asp Ser His Val Pro Leu Pro Thr Glu Trp Lys Thr Ala Val Thr Leu Gly Pro Thr Cys Arg Leu Leu Leu 100 Thr Thr Ala His 115 Leu Leu Arg Gly 130 Leu Cys Val Arg TYPE: None DESCRIPTION: SEQ ID NO:547: Ala Cys Asp Leu His Ser Pro Val Leu Gin Met Glu Leu Leu Glu Leu Ser Ser Gly Ala Leu Lys Asp Pro 120 Lys Val Arg 135 Leu Arg Arg Leu Leu Pro Glu Thr Gly Val Leu Leu Gln Ser 105 Asn Ala Phe Leu INFORMATION FOR SEQ ID NO:548: SEQUENCE CHARACTERISTICS: LENGTH: 153 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE TYPE: None DESCRIPTION: SEQ ID NO:548: Pro Ala Pro Pro Ala Cys Asp Leu Arg His Ser Arg Leu Val Leu Leu Pro Met Glu Glu Thr Leu Glu Gly Val Ser Ser Leu Leu Ala Leu Gin Ser 105 Thr Ala His Lys 120 Leu Arg Gly Lys 135 Cys Val Arg Val Ser Ala Lys Met Gly Leu Asp Val His Leu Thr Leu 150 WO 98/17810 "77 INFORMATION FOR SEQ ID NO:549: SEQUENCE CHARACTERISTICS: LENGTH: 135 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE TYPE: None Ala 1 Ala Val Trp Ala His Phe Leu Leu (xi) SEQUENCE Thr Gln Asp Cys 5 Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gln Thr Asn 100 Val Ala Leu Lys 115 Glu Leu Gln Cys 130 DESCRIPTION: SEQ ID Ser Phe Gin His Ser Glu Leu Ser Asp Tyr Asn Leu Gln Asp Glu Ala Gin Arg Trp Met 55 Gln Gly Leu Leu Glu 70 Cys Ala Phe Gin Pro Ile Ser Arg Leu Leu 105 Pro Trp Ile Thr Arg 120 Gln Pro 135 NO: 549: Pro Ile Leu Leu Glu Leu Glu Arg Arg Val Pro Pro Gln Glu Gln Asn INFORMATION FOR SEQ ID NO:550: SEQUENCE CHARACTERISTICS: LENGTH: 140 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Glu Leu Gln Cys 130 TYPE: None DESCRIPTION: SEQ ID NO:550: Ser Asp Asp Tyr Gly Gly Lys Thr Thr Glu Cys Leu Ser Glu 110 Ser Arg INFORMATION FOR SEQ ID NO:551: SEQUENCE CHARACTERISTICS: LENGTH: 122 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:551: Ala Thr Gln Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 WO 98/178 Ala Va Vai TI- Trp, Ar Ala Gl His Ph~ Ala Le Leu Gl 10 t8 LI Lys Ile Arg Glu Leu Ser Asp Tyr Leu 25 ~r Val Ala Ser Asn Leu Gin Asp Giu Giu 40 g Leu Val Leu Ala Gin Arg Trp Met Giu 55 .y Ser Lys Met Gin Gly Leu Leu Giu Arg 70 75 *e Val Thr Lys Cys Aia Phe Gin Giu Thr 90 *u Lys Pro Trp Ile Thr Arg Gin Asn Phe 105 *n Cys Gin Pro Asp Ser Ser Thr Leu 115 120 INFORMATION FOR SEQ ID NO:552: SEQUENCE CHARACTERISTICS: LENGTH: i35 amino acids TYPE: amino acid STRANDEDNESS: singie TOPOLOGY: linear Leu Leu Arg Val Ser Ser PCT1US97/20037 Pro Leu Val' I le Val Glu (ii) MOLECULE (Xi) SEQUENCE Thr Gin Asp Cys Vai Lys Ile Arg Thr Val Aia Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Glu Leu Gin Cys 130 TYPE: None DESCRIPTION: SEQ ID NO:552: Ser Phe Gin His Ser Pro Tie- Ser Asp is Asp Tyr Gly Gly Lys Thr Thr Giu Cys Leu Ser Giu 110 Ser Arg INFORMATION FOR SEQ ID NO:553: SEQUENCE CHARACTERISTICS: LENGTH: 140 amino acids TYPE:-amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Aia Ser Arg Leu Vai Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Giu Leu Gin Cys 130 DESCRIPTION: SEQ ID N0:553: Ser Phe Gin His Ser Pro Ile WO 98/17810 PCT/US97/20037 579 INFORMATION FOR SEQ ID NO:554: SEQUENCE CHARACTERISTICS: LENGTH: 135 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:554: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 25 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 40 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 55 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 70 75 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 90 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro 130 135 INFORMATION FOR SEQ ID NO:555: SEQUENCE CHARACTERISTICS: LENGTH: 140 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:555: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 25 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 40 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 55 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 70 75 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 90 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 INFORMATION FOR SEQ ID NO:556: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:556: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly WO 98/17810 PCT/US97/20037 Leu Phe Arg Ile Asp Gly Ser Asp 145 Ala 1 Arg Leu Phe Arg Ile Asp Gin Lys Val 145 Ala 1 Arg Leu Phe Arg Ile Asp iu Glu Arg Val Asn Thr Glu Ile .n Pro Pro Pro Ser Cys Leu Arg !u Leu Gin Glu Thr Ser Glu Gin 70 ir Arg Gin Asn Phe Ser Arg Cys !r Ser Thr Leu Ser Gly Gly Asn 100 105 .y Asn Gly Thr Gin Asp Cys Ser 115 120 ;p Phe Ala Val Lys Ile Arg Glu 0 135 'r Pro Val Thr Val Ala Ser Asn 150 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear His Phe Val Phe Val Gin Leu Val Ala Leu Glu Leu Gly Ser Gly Phe Gin His Leu Ser Asp 140 Leu Gin 155 NO:557: (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Asp Cys Ser Phe 115 Ile Arg Glu Leu 130 Ala Ser Asn Leu TYPE: None DESCRIPTION: SEQ ID NO:557: Arg Leu Gly Ser Phe Val Val Gin Val Ala Glu Leu Ser Gly Ser Ser Gin Asp 140 INFORMATION FOR SEQ ID NO:558: SEQUENCE CHARACTERISTICS: LENGTH: 145 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:558: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 5 10 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 25 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 70 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 90 Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin 100 105 Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Cys Ser 110 WO 98/17810 5, PCT/US97/20037 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 115 120 125 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 130 135 140 Gin 145 INFORMATION FOR SEQ ID NO:559: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ser Lys Met Gin Val Thr Lys Cys Gin Thr Asn Ile Ala Leu Lys Pro Leu Gin Cys Gin Gly Gly Asn Gly His Ser Pro Ile 100 Asp Tyr Leu Leu 115 Asp Glu Glu Leu 130 Trp Met Glu Arg TYPE: None DESCRIPTION: SEQ ID NO:559: Gly Leu Ala Phe Ser Arg Trp Ile Pro Asp Ser Gly Ser Ser Gin Asp Cys Gly 135 Leu Lys Arg Val Pro Pro Gin Glu Gin Asn Thr Leu Gly Thr Ala Val Val Thr Trp Arg Ala Gly 155 NO:560: INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Phe Val Val Glu Ser Ser Gin Cys Leu 145 (ii) MOLECULE (xi) SEQUENCE Ser Lys Met Gin 5 Val Thr Lys Cys Gin Thr Asn Ile Ala Leu Lys Pro Leu Gin Cys Gin Gly Gly Asn Gly Ser Asp Phe Ala 100 Asp Tyr Pro Val 115 Gly Gly Leu Trp 130 Lys Thr Val Ala TYPE: None DESCRIPTION: SEQ ID NO:560: Gly Leu Leu Ala Phe Gin Ser Arg Leu Trp Ile Thr Pro Asp Ser 70 Thr Gin Asp Val Lys Ile Thr Val Ala 120 Arg Leu Val 135 Gly 150 Arg Val Pro Pro Gin Glu Gin Asn Thr Leu Ser Phe Glu Leu Asn Leu Ala Gin INFORMATION FOR SEQ ID NO:561: SEQUENCE CHARACTERISTICS: LENGTH: 145 amino acids WO 98/17810 PCT/US97/20037 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Phe Val Val Glu Thr Val Thr Arg Gly 145 (ii) MOLECULE (xi) SEQUENCE Ser Lys Met Gin 5 Val Thr Lys Cys Gin Thr Asn Ile Ala Leu Lys Pro Leu Gin Cys Gin Gin Asp Cys Ser Lys Ile Arg Glu 100 Val Ala Ser Asn 115 Leu Val Leu Ala 130 TYPE: None DESCRIPTION: SEQ ID NO:561: Leu Leu Glu Arg Val Pro Pro Gin Glu Gin Asn Thr Leu Pro Ile Leu Leu Glu Leu Glu Arg INFORMATION FOR SEQ ID NO:562: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Pro Pro Ser Cys Gin Glu Thr Ser Gin Asn Phe Ser Thr Leu Ser Gly Gly Thr Gin Asp Ala Val Lys Ile Val Thr Val Ala 100 Trp Arg Leu Val 115 Ala Gly Ser Lys 130 His Phe Val Thr DESCRIPTION: SEQ ID Leu Arg Phe Val Gin Glu Gin Leu Val Ala Arg Cys Leu Glu Leu Gly Asn Gly Ser Gly 55 Cys Ser Phe Gin His Arg Glu Leu Ser Asp Ser Asn Leu Gin Asp 105 Leu Ala Gin Arg Trp 120 Met Gin Gly Leu Leu 135 Lys Cys Ala Phe Gin 150 NO:562: Thr Asn Leu Lys Gin Cys Gly Asn Ser Pro Tyr Leu Glu Glu Met Glu Glu Arg 140 Pro 155 563: NO: INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Pro Pro Ser Cys 1 5 Leu Gln Glu Thr Ser DESCRIPTION: SEQ ID NO:563: Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 10 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr WO 98/17810 59 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Ser Thr Leu Ser Gly Gly Asn Giy Ser Gly Gly Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp -70 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 85 Ser Asn Leu Gin Asp Giu Giu Leu Cys Gly Giy 100 105 Leu Aia Gin Arg Trp Met Giu Arg Leu Lys Thr 115 120 Met Gin Giy Leu Leu Giu Arg Vai Asn Thr Giu 130 135 Lys Cys Aia Phe Gin Pro 145 150 INFORMATION FOR SEQ ID NO:564: SEQUENCE CHARACTERISTICS: LENGTH: 145 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE Pro Pro Ser Cys Gin GlU Thr Ser Gin Asn Phe Ser Thr Leu Ser Gly Pro Ile Ser Ser Leu Leu Gin Asp Giu Leu Cys Gly 100 Giu Arg Leu Lys 115 Arg Val Asn Thr 130 DESCRIPTION: SEQ ID NO:564: Lau Arg Phe Val Gin Thr Asn Ile Ser Arg INFORMATION FOR SEQ ID NO:565: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:565: Asp Giu Giu Leu Cys Giy Gly Leu Trp Arg Leu Trp Met Giu Arg Leu Lys Thr Val Ala Gly Ser Leu Giu Arg Val Asn Thr Glu Ile His Phe Val Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Giu Thr Ser Giu Gin Leu Val Ala 70 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Lau Ser Ser Thr Leu Ser Gly Gly Ser Giy Ser Gly i00 105 WO 98/17810 S?4 PCT/US97/20037 Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 INFORMATION FOR SEQ ID N0:566: SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Arg Leu Phe Arg Ile Asp Gin Lys Val 145 (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Asp Cys Ser Phe 115 Ile Arg Glu Leu 130 Ala Ser Asn Leu TYPE: None DESCRIPTION: SEQ ID NO:566: Gly Leu Trp Arg Leu Gly Ser Phe Val Val Gin Val Ala Glu Leu Ser Gly Ser Ser Gin Asp 140 INFORMATION FOR SEQ ID NO:567: SEQUENCE CHARACTERISTICS: LENGTH: 145 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Thr Gin Asp Ala Val Lys Ile Val Thr Val Ala Trp Arg Leu Val Ala Gly Ser Lys His Phe Val Thr Phe Val Gin Thr 100 Leu Val Ala Leu 115 Leu Glu Leu Gin 130 TYPE: None DESCRIPTION: SEQ ID Cys Ser Phe Gin His 10 Arg Glu Leu Ser Asp 25 Ser Asn Leu Gin Asp Leu Ala Gin Arg Trp 55 Met Gin Gly Leu Leu Lys Cys Ala Phe Gin 90 Asn Ile Ser Arg Leu 105 Lys Pro Trp Ile Thr 120 Cys Gin Pro Asp Ser 135 NO:567: Ser Pro Tyr Leu Glu Glu Met Glu Glu Arg 75 Pro Pro Leu Gin Arg Gin Ser Thr 140 Ser Ser Asp Gin Asp Tyr Cys Gly Gly Leu Lys Thr Asn Thr Glu Ser Cys Leu Thr Ser Glu 110 Phe Ser Arg Gly Gly Gly INFORMATION FOR SEQ ID N0:568: SEQUENCE CHARACTERISTICS: LENGTH: 143 amino acids WO 98/17810 PCT/US97/20037 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:568: Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 1 5 10 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 25 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 40 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 55 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 70 75 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser 90 Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr 100 105 110 Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe 115 120 125 Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 INFORMATION FOR SEQ ID NO:569: SEQUENCE CHARACTERISTICS: LENGTH: 149 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:569: Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 1 5 10 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 25 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 40 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 55 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 70 75 lie His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 90 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 100 105 110 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 115 120 125 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 130 135 140 Ser Gly Gly Gly Ser 145 INFORMATION FOR SEQ ID NO:570: SEQUENCE CHARACTERISTICS: LENGTH: 144 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:570: Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 1 5 10 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 25 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu WO 98/17810 PCTIUS97/20037 Arg Leu Gly Ser Phe Val Val Gin Val Ala Glu Leu 135 5%6 Leu Al Met Gl: Lys Cy Asn II 105 Lys Pr Cys Gl: Arg Leu Phe Arg Ile Asp 140 Met Glu Glu Arg Pro Pro Leu Gln 110 Arg Gin Ser Thr INFORMATION FOR SEQ ID NO:571: SEQUENCE CHARACTERISTICS: LENGTH: 153 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Thr Gin Asp Ala Val Lys Ile Val Thr Val Ala Trp Arg Leu Val Ala Gly Ser Lys His Phe Val Thr Phe Val Gin Thr 100 Leu Val Ala Leu 115 Leu Glu Leu Gin 130 Gly Gly Gly Ser TYPE: None DESCRIPTION: SEQ ID NO:571: Gin His Ser Asp Gin Asp Arg Trp Leu Leu Phe Gin Arg Leu 105 Ile Thr Asp Ser Ser Ser Tyr Glu Met Glu Pro Leu Arg Ser INFORMATION FOR SEQ ID NO:572: SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Gly 1 Phe Leu Leu Gin Gly Ala Ser Trp (ii) MOLECULE (xi) SEQUENCE Ser Gly Gly Gly Gin His Ser Pro Ser Asp Tyr Leu Gin Asp Glu Glu Arg Trp Met Glu Leu Leu Glu Arg Phe Gin Pro Pro 100 Arg Leu Leu Gin 115 Ile Thr Arg Gin 130 TYPE: None DESCRIPTION: SEQ ID NO:572: Gly Thr Ala Val Val Thr Trp Arg Ala Gly His Phe Phe Val Leu Val Leu Glu 140 WO 98/17810 Pro Asp Ser Ser Thr Leu 145 150 PCT/US97/20037 INFORMATION FOR SEQ ID NO:573: SEQUENCE CHARACTERISTICS: LENGTH: 146 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gin His Ser Pro 115 Ser Asp Tyr Leu 130 Gin TYPE: None DESCRIPTION: SEQ ID NO:573: Trp Arg 10 Ala Gly His Phe Phe Val Leu Val Leu Glu 90 Gly Gly Phe Ala Pro Val Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Asp Cys 110 Ile Arg Ala Ser INFORMATION FOR SEQ ID NO:574: SEQUENCE CHARACTERISTICS: LENGTH: 147 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: N( (xi) SEQUENCE DESCRIP Asp Glu Glu Leu Cys Gly Trp Met Glu Arg Leu Lys Leu Glu Arg Val Asn Thr Gin Pro Pro Pro Ser Cys 55 Leu Leu Gin Glu Thr Ser Thr Arg Gin Asn Phe Ser Ser Ser Thr Leu Gly Gly 100 Phe Gin His Ser Pro Ile 115 Leu Ser Asp Tyr Leu Leu 130 135 Leu Gin one PION: SEQ ID NO:574: Gly Leu Trp Arg Leu Thr Val Ala Gly Ser Glu Ile His Phe Val Leu Arg Phe Val Gin Glu Gin Leu Val Ala Arg Cys Leu Glu Leu Gly Ser Gly Gly Gly 105 Ser Ser Asp Phe Ala 120 Gin Asp Tyr Pro Val INFORMATION FOR SEQ ID NO:575: SEQUENCE CHARACTERISTICS: LENGTH: 150 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 Ala 1 Arg Leu Phe Arg Ile Asp Gin Lys Val 145 (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Asp Cys Ser Phe 115 Ile Arg Glu Leu 130 Ala Ser Asn Leu TYPE: None DESCRIPTION: SEQ ID N0:575: Cys Gly Gly Leu Trp Arg Leu Val Leu Leu Lys Thr Val Ala Gly Ser Lys Met 25 Asn Thr Glu Ile His Phe Val Thr Lys 40 Ser Cys Leu Arg Phe Val Gin Thr Asn 55 Thr Ser Glu Gin Leu Val Ala Leu Lys 70 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gly Gly Gly Ser Gly Gly Gly Ser Gly 105 110 Gin His Ser Pro Ile Ser Ser Asp Phe 120 125 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 135 140 INFORMATION FOR SEQ ID NO:576: SEQUENCE CHARACTERISTICS: LENGTH: 153 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Thr Gin Asp 115 Ala Val Lys Ile 130 Val Thr Val Ala TYPE: None DESCRIPTION: SEQ ID N0:576: Leu Trp 10 Val Ala 25 Ile His Arg Phe Gin Leu Cys Leu 90 Ser Gly 105 Gin His Ser Asp Gin Arg Leu Gly Ser Phe Val Val Gln Val Ala Glu Leu Gly Gly Ser Pro Tyr Leu 140 Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Gly Gly 110 Ser Ser Gin Asp INFORMATION FOR SEQ ID NO:577: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:577: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 25 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 40 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser WO98/17810 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 70 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 90 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 100 105 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin 115 120 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 130 135 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 INFORMATION FOR SEQ ID NO:578: SEQUENCE CHARACTERISTICS: LENGTH: 161 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 Leu Lys Pro Gin Cys Gin Ser Gly Gly 110 Ser Pro Ile 125 Tyr Leu Leu Ala 1 Arg Leu Phe Arg Ile Asp Ser Gin Ser 145 Gin Ala 1 Pro Ser Val Leu Arg Lys Tyr (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Ser .115 His Ser Pro Ile 130 Asp Tyr Leu Leu TYPE: None DESCRIPTION: SEQ ID N0:578: Gly Thr Glu 40 Leu Glu Arg Gly Gly 120 Asp Tyr Leu Val Ser Lys Val Thr Gin Thr Ala Leu Leu Gin Gly Ser Gin Asp 125 Lys Ile 140 Val Ala INFORMATION FOR SEQ ID NO:579: SEQUENCE CHARACTERISTICS: LENGTH: 281 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile 5 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Ile Leu Met Asp Arg Asn Leu Arg Leu Pro 40 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala 70 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu 115 120 579: His His Asn Asp Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin Pro Ser 125 WO 98/17810 Ser Thr 130 Asn Met 145 Asp Phe Tyr Pro Ala Leu Thr Val 210 Glu Ile 225 Leu Arg Glu Gin Arg Cys Ile Asn Ala Thr Ala Val Val Thr 180 Trp Arg 195 Ala Gly His Phe Phe Val Leu Val 260 Leu Glu 275 Ser Pro 135 Asp Cys 150 Ile Arg Ala Ser Val Leu Lys Met 215 Thr Lys 230 Thr Asn Leu Lys Gin Cys -50 Ser L: Phe G Leu Si 1' Leu G: 185 Gin A: Gly Li Ala P] Ser A: 2! Trp I: 265 Pro PCT/US97/20037 Pro Ser, 160 Asp Gly Lys Thr Cys 240 Ser Ser INFORMATION FOR SEQ ID NO:580: SEQUENCE CHARACTERISTICS: LENGTH: 286 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Ala Thr Gln 145 Asp Phe Ala Val Lys 165 Tyr Pro Val Thr Val 180 Ala Leu Trp Arg Leu 195 Thr Val Ala Gly Ser 210 Glu Ile His Phe Val 225 Leu Arg Phe Val Gin 245 Glu Gin Leu Val Ala 260 Arg Cys Leu Glu Leu 275 TYPE: None DESCRIPTION: SEQ ID NO:580: Met Ile Asp Leu Asp Pro Arg Asn Leu Asn Leu Glu 55 Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Asp Cys Ser 150 Ile Arg Glu Ala Ser Asn Val Leu Ala 200 Lys Met Gin 215 Thr Lys Cys 230 Thr Asn Ile Leu Lys Pro Gln Cys Gin 280 His Asn Asn Gly Thr Gin Ala Pro Ser 140 Ser Tyr Glu Met Glu 220 Pro Leu Arg Ser Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gln 110 Gly Pro Lys Ser Ile Ser Leu Gin 175 Leu Cys 190 Arg Leu Val Asn Pro Ser Glu Thr 255 Asn Phe 270 Leu INFORMATION FOR SEQ ID NO:581: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 65U PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Ala Asp Glu 145 Ala Gin Arg Trp Met 165 Gin Gly Leu Leu Glu 180 Cys Ala Phe Gin Pro 195 Ile Ser Arg Leu Leu 210 Pro Trp Ile Thr Arg 225 Gin Pro Asp Ser Ser 245 Gly Thr Gin Asp Cys 260 Ala Val Lys Ile Arg 275 Val Thr Val Ala Ser 290 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Leu Asp Pro Arg Asn Leu Asn Leu Glu 55 Pro Cys Leu 70 Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Glu Leu Cys 150 Glu Arg Leu Arg Val Asn Pro Pro Ser 200 Gin Glu Thr 215 Gin Asn Phe 230 Thr Leu Ser Ser Phe Gin Glu Leu Ser 280 Asn Leu Gin 295 NO:581: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Leu Trp 155 Val Ala Ile His Arg Phe Gin Leu 220 Cys Leu 235 Asn Gly Pro Ile Leu Leu Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Leu Val Ser Lys 175 Val Thr 190 Gin Thr Ala Leu Leu Gin Gly Gly 255 Ser Asp.

270 Asp Tyr INFORMATION FOR SEQ ID NO:582: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Ala Asp Glu 145 Ala Gln Arg Trp Met TYPE: None DESCRIPTION: SEQ ID NO:582: Met Ile Asp Glu Ile Ile His 10 Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Leu Pro Asn Asn Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr 70 Ile Lys Ala Gly Asp Trp Gin 90 Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Glu Leu Cys Gly Gly Leu Trp 150 155 Glu Arg Leu Lys Thr Val Ala Leu Lys Glu Asp Glu Ser Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Leu Val Ser Lys WO98/17810 5u PCTIUS97/20037 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 INFORMATION FOR SEQ ID NO:583: SEQUENCE CHARACTERISTICS: LENGTH: 291 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:583: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 225 230 235 240 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 245 250 255 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 260 265 270 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 275 280 285 Val Ala Gly 290 INFORMATION FOR SEQ ID NO:584: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 5 Pro Pro Ala Pro Leu Ser Ile Leu Met Asp Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115' Ser Thr Ile Asn Pro 130 Asn Met Ala Ser Lys 145 Ile His Phe Val Thr 165 Arg Phe Val Gin Thr 180 Gin Leu Val Ala Leu 195 Cys Leu Glu Leu Gin 210 Asn Gly Ser Gly Gly 225 Pro Ile Ser Ser Asp 245 Leu Leu Gin Asp Tyr 260 Glu Leu Cys Gly Gly 275 Glu Arg Leu Lys Thr 290 PCT/US97/20037 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Leu Asn Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser 70 Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 Met Gin Gly Leu Leu 150 Lys Cys Ala Phe Gin 170 Asn Ile Ser Arg Leu 185 Lys Pro Trp Ile Thr 200 Cys Gin Pro Asp Ser 215 Asn Gly Thr Gin Asp 230 Phe Ala Val Lys Ile 250 Pro Val Thr Val Ala 265 Leu Trp Arg Leu Val 280 Val Ala Gly 295 NO:584: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Glu Arg 155 Pro Pro Leu Gin Arg Gin Ser Thr 220 Cys Ser 235 Arg Glu Ser Asn Leu Ala INFORMATION FOR SEQ ID N0:585: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Glu Gin Arg Trp Met 165 DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Leu Asn Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 Glu Leu Cys Gly Gly 150 Glu Arg Leu Lys Thr 170 NO:585: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Leu Trp 155 Val Ala WO 98/17810 Gin Gly PCTIUS97/20037 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr .Lys 180 185 190 a Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 195 200 !r Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 0 215 220 -p Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 230 235 *o Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 245 250 !r Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe 260 265 !r Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 275 280 n Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 0 295 300 INFORMATION FOR SEQ ID NO:586: SEQUENCE CHARACTERISTICS: LENGTH: 291 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Arg Ile Asp Gin Ser 225 Gin Arg Leu Phe (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Pro Pro Leu Leu Gin Glu 165 Thr Arg Gin Asn 180 Ser Ser Thr Leu 195 His Ser Pro Ile 210 Asp Tyr Leu Leu Asp Glu Glu Leu 245 Trp Met Glu Arg 260 Leu Glu Arg Val 275 Gin Pro 290 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Leu Asn Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser 70 Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 Ser Cys Leu Arg Phe 150 Thr Ser Glu Gin Leu 170 Phe Ser Arg Cys.Leu 185 Ser Gly Gly Asn Gly 200 Ser Ser Asp Phe Ala 215 Gin Asp Tyr Pro Val 230 Cys Gly Gly Leu Trp 250 Leu Lys Thr Val Ala 265 Asn Thr Glu Ile His 280 NO:586: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Val Gin 155 Val Ala Glu Leu Thr Gin Val Lys 220 Thr Val 235 Arg Leu Gly Ser Phe Val INFORMATION FOR SEQ ID N0:587: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (xi) SEQUENCE PCT/US97/20037 555.

DESCRIPTION:, SEQ ID NO:587: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Giu Ser 140 Val Gin Vai Ala Glu Leu Ser Gly Ser Ser 220 Gin Asp 235 Cys Gly Leu Lys Asn Thr INFORM4ATION FOR SEQ ID NO:588: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala Pro Ser Val Leu Arg Lys Tyr Ser Asn 145 Arg Ile (i i) (xi) Asn Cys Pro Ala Ile Let Arg Ala Arg Asr His Prc Leu Thi Val Gi.

Thr Ilf 130.

Met Ala Leu Let Thr Arc

M

SEQUENCE DESC Ser Ile Met Pro Leu Leu Met Asp Arg Val Lys Asm Leu Gin Pro Ile Ile Ile Phe Tyr Leu 100 1Gly Gly Gly Asn Pro Ser Pro Pro Ser 150 iGin Glu Thr 165 j Gin Asn Phe IOLECULE TYPE :None RIPTION: SEQ ID NO:588: Ile Asp Glu Ile Ile His Leu Lys Glu Asp Giu Ser Giu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser As Ile Lys Pro 175 Cys Gin WO 98/17810 PCT/US97/20037 Asp Gly Ser 225 Asp Gly Lys Thr .r Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly 195 200 ,y Asn Gly Thr Gin Asp Cys Ser Phe Gin His 0 215 220 ;p Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 230 235 *r Pro Val Thr Val Ala Ser Asn Leu Gin Asp 245 250 y Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 260 265 Ir Val Ala Gly Ser Lys Met Gin Gly Leu Leu 275. 280 u Ile His Phe Val Thr Lys Cys Ala Phe Gin 0 295 300 INFORMATION FOR SEQ ID NO:589: SEQUENCE CHARACTERISTICS: LENGTH: 281 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Thr Gin Phe Ala Val Lys 165 Pro Val Thr Val 180 Leu Trp Arg Leu 195 Val Ala Gly Ser 210 Ile His Phe Val Arg Phe Val Gin 245 Gin Leu Val Ala 260 Cys Leu Glu Leu 275 TYPE: None DESCRIPTION: SEQ ID NO:589: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Asp Cys Ser Phe Gin His Ser 150 155 Ile Arg Glu Leu Ser Asp Tyr 170 Ala Ser Asn Leu Gin Asp Glu 185 Val Leu Ala Gin Arg Trp Met 200 Lys Met Gin Gly Leu Leu Glu 215 220 Thr Lys Cys Ala Phe Gin Pro 230 235 Thr Asn Ile Ser Arg Leu Leu 250 Leu Lys Pro Trp Ile Thr Arg INFORMATION FOR SEQ ID NO:590: SEQUENCE CHARACTERISTICS: LENGTH: 286 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:590: WO 98/17810 PCT/US97/20037 Asp Pro Leu Glu Leu Ala Thr Ser 120 Pro Ser Glu Asn Ala 200 Gin Cys Ile Pro Gin 280 Glu Ile Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Phe Gin Leu Ser 170 Leu Gin 185 Gin Arg Gly Leu Ala Phe Ser Arg 250 Trp Ile 265 Pro Asp His Asn Asn Gly Thr Gin Ala Pro Ser 140 Ser Tyr Glu Met Glu 220 Pro Leu Arg Ser INFORMATION FOR SEQ ID NO:591: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Ala Gin Cys (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Glu Gin Arg Trp Met 165 Gly Leu Leu Glu 180 Ala Phe Gin Pro 195 DESCRIPTION: SEQ ID NO:591: Ile Ser 210 Arg Leu Leu Gin Thr Ser Glu Gln WO 98/178 Pro Tr 225 Gln Pr Gly Th Ala Va Val Th 29 10 P< CT/US97/20037 599 p Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 230 235 240 *o Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 ir Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 .1 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Ir Val Ala Ser Asn Leu Gin 0 295 INFORMATION FOR SEQ ID NO:592: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Glu Gin Arg Trp Met 165 Gly Leu Leu Glu 180 Ala Phe Gin Pro 195 Ser Arg Leu Leu 210 Trp Ile Thr Arg Pro Asp Ser Ser 245 Ser Gly Gly Asn 260 Ser Ser Asp Phe 275 Gin Asp Tyr Pro 290 DESCRIPTION: SEQ ID NO:592: Met Ile Asp Glu Ile Ile His 10 Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin 90 Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Glu Leu Cys Gly Gly Leu Trp 150 155 Glu Arg Leu Lys Thr Val Ala 170 Arg Val Asn Thr Glu Ile His 185 Pro Pro Ser Cys Leu Arg Phe 200 Gin Glu Thr Ser Glu Gin Leu 215 220 Gin Asn Phe Ser Arg Cys Leu 230 235 Thr Leu Ser Gly Gly Asn Gly 250 Gly Thr Gin Asp Cys Ser Phe 265 Ala Val Lys Ile Arg Glu Leu 280 Val Thr Val Ala Ser Asn Leu Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Leu Val Ser Lys 175 Val Thr 190 Gin Thr Ala Leu Leu Gin Gly Gly 255 His Ser 270 Asp Tyr INFORMATION FOR SEQ ID NO:593: SEQUENCE CHARACTERISTICS: LENGTH: 291 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:593: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met WO 98/17810 WO 9817810PCTIUS97/20037 559 Asn Gly Thr Gin Al a Pro Ser 140 Arg Pro Gin Gin Thr- 220 Pro Leu Glu Glu Leu Ala Giu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Asn Thr Ser Cys 175 Thr Ser 190 Phe Ser Ser Gly Ser Ser Gin Asp 255 Cys Gly 270 Leu Lys INFORMATION FOR SEQ ID NO:594: Wi SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:594: Asn Cy Pro Asi Ile Lei Arg Al Arg As~ His Pri Leu Th: Val Gl Thr Ii 130 Met Al His Ph Phe Va Leu Va 19 Leu Gi 210 sSer Ile n Pro Leu u Met Glu a Val Lys n Leu Gin o Ile Ile r Phe Tyr 100 u Giy Gly Asn Pro Ser Lys Val Thr 165 1 Gin Thr 180 1 Ala Leu 5 Li Leu Gin His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Giu Ala Gin Pro Ser 125 Ser His 140 Arg Val Pro Pro Gin Glu Gin Asn 205 Thr Leu 220 Leu Lys Arg Glu Asp Met Leu Ala Phe Glu Ala Ile Ala Pro Ser Phe Arg Giu Glu Gin Gin 110 Gly Pro Ile Lys Ser Pro Asn Thr Glu, 160 Ser Cys Leu 175 Thr Ser Giu 190 Phe Ser Arg Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gin His Ser WO 98/17810 225 Pro Ile Leu Leu Glu Leu Glu Arg 290 Ser Asp 245 Asp Tyr 260 Gly Gly Lys Thr 600oo Val Lys Thr Val 265 Arg Leu 280 Gly 235 Arg Ser Leu PCT/US97/20037 240 Glu Leu Ser Asp Tyr 255 Asn Leu Gin Asp Glu 270 Ala Gin Arg Trp Met 285 INFORMATION FOR SEQ ID NO:595: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:595: Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Ile Arg Gin Cys Asn 225 Ser Glu Asn Ala Asn Cy Pro Asr Ile Lei Arg Al Arg Asi His Pr Leu Th: Val G1i 11 Thr Il 130 Met Al His Ph Phe Va Leu Va 19 Leu GI 210 Gly Se Phe G1 Leu Se Leu G1 27 Gin Ar 290 s Ser Ile 5 n Pro Leu u Met Glu a Val Lys n Leu Gin o Ile Ile r Phe Tyr 100 u Gly Gly 5 e Asn Pro a Ser Lys e Val Thr 165 1 Gin Thr 180 1 Ala Leu 5 u Leu Gin r Gly Gly n His Ser 245 r Asp Tyr 260 n Asp Glu 5 g Trp Met Met Ile Asp Leu Asp Pro Arg Asn Leu His Leu Glu 55 Pro Cys Leu 70 Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Met Gin Gly 150 Lys Cys Ala Asn Ile Ser Lys Pro Trp 200 Cys Gin Pro 215 Asn Gly Ser 230 Pro Ile Ser Leu Leu Gin Glu Leu Cys 280 Glu Arg Leu 295 Glu Ile Ile His Asn Asn Leu Asn Arg Thr Pro Asn Asn Ala Ser Gly Pro Ser Ala Thr Gly Asp Trp Gin Leu Glu Gin Ala 105 Pro Gly Glu Pro Ser Lys Glu Ser 140 Leu Leu Glu Arg 155 Phe Gin Pro Pro 170 Arg Leu Leu Gin 185 Ile Thr Arg Gin Asp Ser Ser Thr 220 Gly Gly Asn Gly 235 Ser Asp Phe Ala 250 Asp Tyr Pro Val 265 Gly Gly Leu Trp Lys Thr Val Ala 300 INFORMATION FOR SEQ ID NO:596: SEQUENCE CHARACTERISTICS: LENGTH: 291 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:596: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 WO 98/17810 Asp Ile Leu Val Arg Ala Leu Arg Asn Arg His Pro Lys Leu Thr Tyr Val Glu 115 Ser Thr Ile 130 Asn Met Ala 145 Arg Leu Leu Ile Thr Arg Asp Ser Ser 195 Gin His Ser 210 Ser Asp Tyr 225 Gln Asp Glu Arg Trp Met Leu Leu Glu 275 Phe Gin Pro 290 Asn Leu Leu Glu Cys Leu Lys Ala Val Thr Gly Ser 120 Pro Pro 135 Cys Leu Ser Glu Ser Arg Gly Gly 200 Ser Asp 215 Asp Tyr Gly Gly Lys Thr Thr Glu 280 bo4 Arg Asn Pro Gly Leu 105 Pro Ser Arg Gin Cys 185 Asn Phe Pro Leu Val 265 Ile PCTIUS97/20037 INFORMATION FOR SEQ ID N0:597: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Pro Pro Leu Leu Gln Glu 165 Thr Arg Gin Asn 180 Ser Ser Thr Leu 195 Asp Cys Ser Phe 210 Ile Arg Glu Leu TYPE: None DESCRIPTION: SEQ ID NO:597: Met Ile Asp Leu Asp Pro Arg Asn Leu His Leu Glu Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Ser Cys Leu 150 Thr Ser Glu Phe Ser Arg Ser Gly Gly 200 Gin His Ser 215 Ser Asp Tyr 230 WO 98/17810 Val Ala Leu Val Ser Lys Val Thr 290 Asn Leu 245 Ala Gin 260 Gin Gly Cys Ala (o2PCT/US97/20037 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 265 270 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 280 285 Phe Gin Pro 295 Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Arg Ile Asp Gly Ser 225 Asp Gly Lys Thr INFORMATION FOR SEQ ID NO:598: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:598: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 5 10 Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 40 Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 70 75 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 90 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 150 155 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 165 170 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 180 185 Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly 195 200 205 Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser 210 215 220 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 230 235 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 245 250 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 260 265 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 275 280 285 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300 Lys Arg Asp Met Ala Phe Ala Ile Pro Ser Arg Glu Gin Gin Pro Ile Ser Pro Ile Ser 160 Pro Trp 175 Gin Pro Gly Ser Ile Ser Leu Gin 240 Leu Cys 255 Arg Leu Val Asn INFORMATION FOR SEQ ID NO:599: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:599: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe WO 98117810 WO 9817810PCTIUS97/20037 Asn Ala Pro Ser Gly Asp Leu Giu 105 Pro Gly Ser Lys Gly Gly Lys Thr 170 Thr Glu 185 Cys Leu Ser Glu Ser Arg Gly Gly 250 His Ser 265 Asp Tyr Gly Ile Thr Ala Gin Giu Ala Gin Pro Ser 125 Ser His 140 Trp Arg Ala Giy His Phe Phe Val 205 L~eu Vai 220 Leu Giu Gly Ser Ile Ser Leu Gin 285 INFORMATION FOR SEQ ID NO:600: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Ala Gin Cys Ile Pro 225 Gin (ii) MOLECULE (Xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Vai Giu Gly Gly 115 Thr Ile Asn Pro 130 Met Aia Asp Giu Gin Arg Trp Met 165 Giy Leu Leu Glu 180 Ala Phe Gln Pro 195 Ser Arg Leu Leu 210 Trp Ile Thr Arg TYPE: None DESCRIPTION: SEQ ID NO:600: Met Ile Asp Giu Ile Asn Thr Ala Ser Asp Glu Gly Lys Gly Thr 170 Glu Leu Glu Arg Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly WO 98/17810 245 Gly Ser 260 Asp Phe Tyr Pro (0o4 PCT/US97/20037 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 280 285 Val Thr Val Ala Ser Asn Leu Gin 295 300 INFORMATION FOR SEQ ID NO:601: SEQUENCE CHARACTERISTICS: LENGTH: 281 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Thr Gin Asp Cys 1 5 Ala Val Lys Ile Arg Val Thr Val Ala Ser Trp Arg Leu Val Leu Ala Gly Ser Lys Met His Phe Val Thr Lys Phe Val Gin Thr Asn 100 Leu Val Ala Leu Lys 115 Leu Glu Leu Gin Cys 130 Gly Glu Pro Ser Gly 145 Lys Glu Ser His Lys 165 Asp Glu Ile Ile His 180 Pro Asn Asn Leu Asn 195 Leu Arg Thr Pro Asn 210 Glu Asn Ala Ser Gly 225 Leu Pro Ser Ala Thr 245 Ala Gly Asp Trp Gin 260 Thr Leu Glu Gin Ala 275 CRIPTION: SEQ ID NO:601: Ser Phe Gin His Ser Glu Leu Ser Asp Tyr Asn Leu Gin Asp Glu 40 Ala Gin Arg Trp Met 55 Gin Gly Leu Leu Glu Cys Ala Phe Gin Pro Ile Ser Arg Leu Leu 105 Pro Trp Ile Thr Arg 120 Gin Pro Tyr Val Glu 135 Pro Ile Ser Thr Ile 150 Ser Pro Asn Met Ala 170 His Leu Lys Arg Pro 185 Ser Glu Asp Met Asp 200 Leu Leu Ala Phe Val 215 Ile Glu Ala Ile Leu 230 Ala Ala Pro Ser Arg 250 Glu Phe Arg Glu Lys 265 Gin Glu Gln Gin 280 Ile Ser Leu Gin Leu Cys Arg Leu Val Asn Pro Ser Glu Thr Asn Phe 125 Gly Gly 140 Pro Ser Cys Ser Asn Pro Leu Met 205 Ala Val 220 Asn Leu Pro Ile Thr Phe INFORMATION FOR SEQ ID NO:602: SEQUENCE CHARACTERISTICS: LENGTH: 286 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:602: Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 10 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 25 Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 40 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 55 WO 98/17810 PTU9/03 PCT/VS97/20037 Gin Giy Cys Ala Ile Ser Pro Trp Gin Pro 135 Gly Giu 150 Lys Glu Asp Glu Pro Asn Leu Arg 215 Glu Asn 230 Leu Pro Ala Gly Thr Leu Asn Ser Thr Phe 125 Tyr Ser Asn Lys Asp 205 Ala Ala Pro Arg Gin 285 INFORMATION FOR SEQ ID NO:603: SEQUENCE CHARACTERISTICS: LENGTH: 268 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:603: Al a Pro Asp Val Leu Pro Lys Tyr Ser Asn 145 Asp Tyr Gly Thr Giu 225 Leu Leu Ser Ile Pro Leu Met Glu Val Lys Leu Gin Ile Ile Phe Tyr 100 Gly Gly Asn Pro Thr Gin Vai Lys 165 Thr Val 180 Arg Leu Gly Ser Phe Vai Leu Lys 245 Gln Cys 260 Asp Pro Leu Glu Leu Ala Thr Ser 120 Pro Ser Giu Asn Ala 200 Gin Cys Ile Asp Giu Ile Asn Asn Arg Thr Asn Aia Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Phe Gln Leu Ser 170 Leu Gln 185 Gln Arg Gly Leu Aia Phe Thr Arg 250 Ser Ser 265 His His Asn Ser Asn Leu Gly Ile Thr Ala Gln Glu Ala Gln Pro Ser 125 Ser His 140 Ser Pro Tyr Leu Giu Glu Met Glu 205 Glu Arg 220 Glu Thr Asfl Phe *Leu INFORMATION FOR SEQ ID NO:604: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Ala Gin Cys Ile Pro 225 Gin Cys Arg Ser Ala 1 Pro Asp Val Leu Arg Lys Tyr (xi) Asn Cys Pro Asi Ile Le Arg Ale Arg Asr His Prc Leu Thr Val Glu 115 Thr Ile 130 Met Ale Gin Arc Gly Leu Ala Phe 195 Ser Arc 210 Trp Ile Pro Asp Ser Phe Glu Leu 275 Asn Leu 290

SEQUENCE

s Ser Ile 5 i Pro Leu i Met Glu i Val Lys I Leu Gin o Ile Ile SPhe Tyr 100 SGly Gly SAsn Pro SAsp Glu STrp Met 165 SLeu Glu 180 Gin Pro Leu Leu Thr Arg Ser Ser 245 Gln His 260 Ser Asp Gin DESCRIPTION: SEQ ID NO:604: Asp Pro Leu 40 Glu Leu Ala Thr Ser 120 Pro Cys Leu Asn Ser 200 Thr Phe Gly Ile Leu 280 Glu Ile Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Gly Gly Lys Thr 170 Thr Glu 185 Cys Leu Ser Glu Ser Arg Gly Gly 250 Ser Ser 265 Gin Asp His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin Pro Ser 125 Ser His 140 Trp Arg Ala Gly His Phe Phe Val 205 Leu Val 220 Leu Glu Gly Gly Phe Ala Pro Val 285 INFORMATION FOR SEQ ID NO:605: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:605: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 5 Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 70 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro WO 98/17810 (01 WO 9817810PCTIUS97/20037 125 His Arg Gly Phe Val 205 Val1 Glu Gly Phe Pro INFORMATION FOR SEQ ID NO:606: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Giu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Glu Gin Arg Trp Met 165 Gly Leu Leu Glu 180 Ala Phe Gin Pro 195 Ser Arg Leu Leu 210 Trp Ile Thr Arg Pro Asp Ser Ser 245 Thr Gin Asp Cys 260 Val Lys Ile Arg 275 Thr Val Ala Ser 290 TYPE: None DESCRIPTION: SEQ ID NO:606: Ile Asp Asn Leu 55 Cys Lys Val Gly Pro 135 Leu Arg Val Pro Giu 215 Asn Leu Phe Leu Leu 295 Ile 10 Asn Thr Ala Ser Asp 90 Giu Gly Lys Gly Thr 170 Giu Leu Giu Arg Gly 250 Ser Tyr Ile His His Leu Asn Ser Pro Asn Leu Ser Gly Ile Ala Thr Ala Trp Gin Giu Gin Ala Gin Glu Pro Ser 125 Giu Ser His 140 Leu Trp Arg 155 Val Ala GZly Ile His Phe Arg Phe Val 205 Gin Leu Val 220 Cys Leu Giu 235 Ser Gly Gly Pro Ile Ser Leu Leu Gin 285 Leu Lys Glu Asp Leu Ala Giu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Leu Val Ser Lys 175 Val Thr 190 Gin Thr Ala Leu Leu Gin Gly Ser 255 Ser Asp 270 Asp Tyr INFORMATION FOR SEQ ID NO:607: WO 98/17810 SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:607: PCT/US97/20037 Ile Met Leu Leu Glu Arg Lys His Gin Pro Ile Ile Tyr Leu Gly Gly Pro Ser Glu Glu 150 Met Glu 165 Glu Arg Pro Pro Leu Gin Arg Gin 230 Ser Thr 245 Thr Gin Val Lys Thr Val Ile Asp Glu Ile His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin Pro Ser 125 Ser His 140 Trp Arg Ala Gly His Phe Phe Val 205 Leu Val 220 Leu Glu Gly Gly His Ser Asp Tyr 285 INFORMATION FOR SEQ ID NO:608: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 DESCRIPTION: SEQ ID Met Ile Asp Glu Ile 10 Leu Asp Pro Asn Asn 25 Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp 90 Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 NO:608: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro WO 98/17810 Ser Thr 130 Asn Met 145 Ala Gin Gin Gly Cys Ala Ile Ser 210 Pro Trp 225 Gin Pro Gly Gly Ile Ser Leu Gin 290 PCTIUS97/20037 feo9 Ser Ll Gly Gi Lys Tt 1i- Thr Gi 185 Cys LE Ser Gi Ser Ai Gly GI Asp Cy 265 Ile Ai Ala Se His Lys Arg Leu Gly Ser Phe Val 190 Val Gin 205 Val Ala Glu Leu Gly Gly Gin His 270 Ser Asp 285 Gin INFORMATION FOR SEQ ID NO:609: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Glu Gin Arg Trp Met 165 Gly Leu Leu Glu 180 Ala Phe Gin Pro 195 Ser Arg Leu Leu 210 Trp Ile Thr Arg Pro Asp Ser Ser 245 Gly Ser Gly Gly 260 Phe Gin His Ser 275 Leu Ser Asp Tyr 290 Leu Gin DESCRIPTION: SEQ ID NO:609: Met Ile Asp Leu Asp Pro Arg Asn Leu 40 His Leu Glu Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Glu Leu Cys 150 Glu Arg Leu Arg Val Asn Pro Pro Ser 200 Gin Glu Thr 215 Gin Asn Phe 230 Thr Leu Gly Gly Ser Gly Pro Ile Ser 280 Leu Leu Gin 295 His Leu Lys Ser Glu Asp Leu Leu Ala Ile Glu Ala Ala Ala Pro Glu Phe Arg Gin Glu Gin 110 Ser Gly Pro 125 His Lys Ser Arg Leu Val Gly Ser Lys 175 Phe Val Thr 190 Val Gin Thr 205 Val Ala Leu Glu Leu Gin Gly Gly Ser 255 Thr Gin Asp 270 Val Lys Ile 285 Thr Val Ala INFORMATION FOR SEQ ID NO:610: WO 98/17810 6b40 SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gln His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ser Lys His Phe Val Thr 165 Phe Val Gin Thr 180 Leu Val Ala Leu 195 Leu Glu Leu Gin 210 Gly Gly Thr Gin Phe Ala Val Lys 245 Pro Val Thr Val 260 Leu Trp Arg Leu 275 Val Ala Gly 290 TYPE: None DESCRIPTION: SEQ ID NO:610: Glu Ile Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Leu Leu Phe Gin 170 Arg Leu 185 Ile Thr Asp Ser Phe Gln Leu Ser 250 Leu Gin 265 Gln Arg INFORMATION FOR SEQ ID NO:611: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:611: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn 25 Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn 40 Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro His Leu Ser Glu Leu Leu Ile Glu Ala Ala Glu Phe Gln Glu 110 Ser Gly WO 98/17810 PCT/US97/20037 Pro Ser Gly Leu Ala Phe Ser Arg 185 Trp Ile 200 Pro Asp Cys Ser Arg Glu Ser Asn 265 Leu Ala 280 His Val Pro Glu Asn 205 Leu Ser Tyr Glu Met 285 INFORMATION FOR SEQ ID NO:612: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ser Lys His Phe Val Thr 165 Phe Val Gin Thr 180 Leu Val Ala Leu 195 Leu Glu Leu Gin 210 Gly Gly Gly Ser Ile Ser Ser Asp 245 Leu Gin Asp Tyr ,260 Leu Cys Gly Gly 275 Arg Leu Lys Thr 290 TYPE: None DESCRIPTION: SEQ ID NO:612: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Met Gin Gly Leu Leu Glu Arg 150 155 Lys Cys Ala Phe Gin Pro Pro 170 Asn Ile Ser Arg Leu Leu Gin 185 Lys Pro Trp Ile Thr Arg Gin 200 Cys Gin Pro Asp Ser Ser Thr 215 220 Gly Gly Thr Gin Asp Cys Ser 230 235 Phe Ala Val Lys Ile Arg Glu 250 Pro Val Thr Val Ala Ser Asn 265 Leu Trp Arg Leu Val Leu Ala INFORMATION FOR SEQ ID NO:613: WO098/17810 SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (i i) (xi) Ala Asn Cys 1 Pro Pro Asn Asp Ile L~u Val Arg Ala Leu Arg Asn Arg His Pro Lys Leu Thr Tyr Val Glu 115 Ser Thr Ile 130 Asn Met Ala 145 Ile His Phe Arg Phe Val Gln Leu Val 195 Cys Leu Glu 210 Ser Gly Gly 225 Gin His Ser Ser Asp Tyr Gln Asp Giu 275 Arg Trp Met 290 40LECULE

SEQUENCE

Ser Ile Pro Leu Met Glu Val Lys Leu Gln Ile Ile Phe Tyr 100 Gly Gly Asn Pro Ser Lys Val Thr 165 Gln Thr 180 Ala Leu Leu Gln Gly Ser Pro Ile 245 Leu Leu 260 Glu Leu Glu Arg TYPE: None DESCRIPTION: SEQ ID NO:613: Met Ile Asp Glu His His Asn Ser Asn Leu Gly Ile Thr Ala Gln Glu Ala Gln Pro Ser 125 Ser His 140 Arg Val Pro Pro Gln Glu Gln Asn 205 Thr Leu 220 Gin Asp Lys Ile Val Ala Leu Val 285 Leu Lys 295 INFORMATION FOR SEQ ID NO:614: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gln His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile 10 Leu Asp Pro Asn Asn 25 Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp 90 Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 NO: 614:- Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gln Gin Ala Glu Pro Leu Lys Giu Asp Leu Ala Giu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro WO 98/17810 lpf, 6943 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GJlu Ser His Lys Ser Pro 130 135 140d TIUS97/20037 Ala Ser Phe Val Val Gin 180 Val Ala 195 Glu Leu Gly Gly Gin His Ser Asp 260 Gin Asp 275 Arg Trp Arg Val Pro Pro Gin Glu Gin Asn 205 Thr Leu 220 Gly Thr Ala Val Val Thr Trp Arg 285 Ala Gly 300 INFORMATION FOR SEQ ID NO:615: Wi SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRAINDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ilie

S

Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Giy Gly 115 Thr Ile Asn Pro 130 Met Ala Ser Lys His Phe Val Thr 165 Phe Val Gin Thr 180 Leu Val Ala Leu 195 Leu Giu Leu Gin 210 Gly Gly Gly Ser Gly Thr Gin Asp 245 Ala Val Lys Ilie 260 Val Thr Val Ala 275 Trp Arg Leu Val 290 Ala Gly TYPE: None DESCRIPTION: SEQ ID NO:615: Met Ile Asp Glu Ile Ile His INFORMATION FOR SEQ ID NO:616: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Pro Pro Leu Leu Gin Glu 165 Thr Arg Gin Asn 180 Ser Ser Thr Leu 195 Gin His Ser Pro 210 Ser Asp Tyr Leu Gin Asp Glu Glu 245 Arg Trp Met Glu 260 Leu Leu Glu Arg 275 Phe Gin Pro 290 DESCRIPTION: SEQ ID NO:616: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Thr Pro Asn 40 His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Ser Cys Leu Arg Phe Val Gln 150 155 Thr Ser Glu Gin Leu Val Ala 170 Phe Ser Arg Cys Leu Glu Leu 185 Gly Gly Gly Ser Gly Gly Thr 200 Ile Ser Ser Asp Phe Ala Val 215 220 Leu Gin Asp Tyr Pro Val Thr 230 235 Leu Cys Gly Gly Leu Trp Arg 250 Arg Leu Lys Thr Val Ala Gly 265 Val Asn Thr Glu Ile His Phe His Leu Ser Glu Leu Leu Ile Glu Ala Ala Glu Phe Gin Glu 110 Ser Gly 125 His Lys Thr Asn Leu Lys Gln Cys 190 Gin Asp 205 Lys Ile Val Ala Leu Val Ser Lys 270 Val Thr 285 INFORMATION FOR SEQ ID NO:617: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:617: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 40 Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 55 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser WO 98/17810 WO 9817810PCTfUS97/20037 (245 Ser Pro 135 Ser Cys 150 Thr Ser Phe Ser Gly Gly Pro Ile 215 Leu Leu 230 Glu Leu Glu Arg Arg Val Glu Val1 155 Val Glu GIly Phe Pro 235 Leu Val1 Ile His Lys Thr Asn Leu Lys Gin Cys 190 Thr Gin 205 Val Lys Thr Val Arg Leu Gly Ser 270 Phe Val 285 INFORMATION FOR SEQ ID NO:.618: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 618: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn INFORMATION FOR SEQ ID NO:619: WO 98/17810 WO 9817810PCT/US97/20037 SEQUENCE CHARACTERISTICS; LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Arg Ile Asp Ser Phe 225 Pro Leu Val Ile Ala 1 Pro Asp Val Leu Arg Lys Tyr (xi) Asn Cy Pro AsI Ile Le.

Arg Al~ Arg Asi His Prc Leu Thi Val Gb.

Thr Il 130 Met Al~ Leu Let.

Thr Arc Ser Sei 191 Gly Th2 210 Ala Val Val Thi Trp Arc Ala Gl) 275 His PhE 290 SEQUENCE DESCRIPT] s Ser Ile met Ile 2 5 i Pro Leu Leu Asp 1 i Met Glu Arg Asn I i Val Lys His LeuC i Leu Gln Pro Cys 1 Ile Ile Ile Lys 1 :Phe Tyr Leu Val 100 SGly Gly Gly Gly ?Asn Pro Ser Pro 1 135 i Pro Pro Ser Cys I 150 SGln Glu Thr Ser 165 j Gln Asn Phe Ser 2 180 Thr Leu Gly Gly C Gln Asp Cys Ser I 215 Lys Ile Arg Glu I 230 Val Ala Ser Asn I 245 Leu Val Leu Ala C 260 rSer Lys Met Gln C Val Thr Lys Cy s 295 ION: SEQ ID NO:619.

Glu Ile Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Arg Phe Gln Leu 170 Cys Leu 185 Ser Gly Gln His Ser Asp Gln Asp 250 Arg Trp 265 Leu Leu Phe Gln Ile His His INFORMATION FOR SEQ ID NO:620: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:620: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 5 Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr 70 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro 115 120 WO 98/17810 Ser Thr Ile 130 Asn Met Ala 145 Arg Leu Leu Ile Thr Arg Asp Ser Ser .195 Ser Gly Gly 210 Ser Asp Phe 225 Asp Tyr Pro Gly Gly Leu Lys Thr Val 275 Thr Glu Ile 290 PCTIUS97/20037 Pro Ser Pro Ser 150 Giu Thr 165 Asn Phe Leu Gly Thr Gin Val Lys 230 Thr Val 245 Arg Leu Gly Ser Phe Val Lys Phe Leu 170 Leu Gly Phe Leu Leu 250 Gin Gly Ala INFORMATION FOR SEQ ID NO: 621: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRAN~DEDNESS; single TOPOLOGY: linear (ii) MOLECULE TYPE: Nnn Ala Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Arg Ile Asp Ser Gin 225 Ser Gin Arg Leu Phe 305 (xi) Asn Cys Pro Asr Ile Let Arg Aiz Arg Asr His Prc Leu Thi Val Git Thr 11 130 Met Al~ Leu Let Thr Ar~ Ser Se2 19! Gly Gl~ 210 His Se3 Asp Ty Asp Gl~ Trp Mel 27' Leu Gl 290 Gin Pri SEQUENCE DESCRIP 3Ser Ile Met Ile Pro Leu Leu Asp aMet Glu Arg Asn Vai Lys His Leu 55 aLeu Gln Pro Cys 70 hie Ile Ilie Lys Phe Tyr Leu Val 100 aGly Gly Gly Gly Asn Pro Ser Pro 135 iPro Pro Ser Cys 150 aGin Giu Thr Ser 165 j Gin Asn Phe Ser 180 Thr Leu Gly Gly ~Gly Ser Gly Gly 215 Pro Ile Ser Ser 230 rLeu Leu Gln Asp 245 .i Glu Leu Cys Gly 260 tGiu Arg Leu Lys 5 ia Arg Val Asn Thr 295 0 PION: SEQ ID NO:621: Asp Giu Ile Ile His Pro Asn Asn Leu Asn Leu Arg Thr Pro Asn Giu Asn Ala Ser Gly Leu Pro Ser Aia Thr Ala Gly Asp Trp Gin Thr Leu Glu Gin Ala 105 Ser Pro Gly Giu Pro 120 Pro Ser Lys Giu Ser 140 Leu Arg Phe Val Gin 155 Giu Gin Leu Val Ala 170 Arg Cys Leu Glu Leu 185 Gly Ser Gly Gly Gly 200 Gly Ser Gly Thr Gin 220 Asp Phe Ala Val Lys 235 Tyr Pro Val Thr Val 250 Gly Leu Trp Arg Leu 265 Thr Val Ala Gly Ser 280 Giu Ile His Phe Val INFORMATION FOR SEQ ID NO:622: WO 98/17810 64 SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Tyr Leu Cys Gly Gly 165 Arg Leu Lys Thr 180 Val Asn Thr Glu 195 Pro Ser Cys Leu 210 Glu Thr Ser Glu Asn Phe Ser Arg 245 Leu Gly Gly Gly 260 Phe Gin His Ser 275 Leu Ser Asp Tyr TYPE: None DESCRIPTION: SEQ ID NO:622: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Pro Val Thr Val Ala Ser Asn 150 155 Leu Trp Arg Leu Val Leu Ala 170 Val Ala Gly Ser Lys Met Gin 185 Ile His Phe Val Thr Lys Cys 200 Arg Phe Val Gin Thr Asn Ile 215 220 Gin Leu Val Ala Leu Lys Pro 230 235 Cys Leu Glu Leu Gin Cys Gin 250 Ser Gly Gly Gly Ser Gly Gly 265 Pro Ile Ser Ser Asp Phe Ala 280 Leu Leu Gin INFORMATION FOR SEQ ID N0:623: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:623: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro WO 98/17810 6;43 WO 9817810PCTIUS97/20037 Ser Pro Asp Glu 160 Trp Met 175 Leu Glu Gin Pro Leu Leu Thr Arg 240 Ser Ser 255 Gly Gly Asp Phe INFORMATION FOR SEQ ID NO:624: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (Xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ala Ser Arg Leu Val Leu 165 Gly Ser Lys Met 180 Phe Val Thr Lys 195 Val Gln Thr Asn 210 Vai Ala Leu Lys Glu Leu Gin Cys 245 Gly Gly Ser Gly 260 Ser Ser Asp Phe 275 Gln Asp Tyr Pro 290 DESCRIPTION: SEQ ID NO:624: Met Ile Asp Giu Ile Ile His His Leu Asp Pro Asn Asn Leu Asn Ser Arg Asn Leu Arg Thr Pro Asn Leu 40 His Leu Glu Asn Ala Ser Giy Ile 55 Pro Cys Leu Pro Ser Ala Thr Aia Ile Lys Ala Gly Asp Trp, Gin Giu Leu Val Thr Leu Glu Gin Ala Gin 105 Gly Gly Ser Pro Gly Glu Pro Ser 120 125 Ser Pro Pro Ser Lys Glu Ser His 135 140 Asn Leu Gin Asp Glu Glu Leu Cys 150 155 Ala Gin Arg Trp Met Glu Arg Leu 170 Gln Gly Leu Leu Giu Arg Val Asn 185 Cys Ala Phe Gln Pro Pro Pro Ser 200 205 Ile Ser Arg Leu Leu Gin Giu Thr 215 220 Pro Trp Ile Thr Arg Gin Asn Phe 230 235 Gin Pro Asp Ser Ser Thr Leu Giy 250 Gly Thr Gln Asp Cys Ser Phe Gin 265 Ala Val Lys Ile Arg Glu Leu Ser INFORMATION FOR SEQ ID NO:625: WO 98/17810 WO 9817810PCT/tJS97/20037 SEQUENCE CHARACTERISTICS: CA) LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) (xi) Asn Cy Pro Asi Ile Let Arg Al~ Arg Asi His Pr Leu Th Val Gl.

Thr IlE 130 Met A Arg Let Gly Se] Phe Va 19~ Val G1i 210 Val Al~ Glu Let Gly GlI Gln Hi~ 27~ Ser Asi 290 I 40LECULE TYPE: None

SEQUENCE

s Ser Ile -i Pro Leu ai Met Glu a Val Lys i Leu Gln Ile Ile *Phe Tyr 100 ai Gly Gly *Asn Pro Ala Ser i Val Leu 165 rLys Met 180 IThr Lys 'i Thr Asn a Leu Lys i Gln Cys 245 ~Ser Gly 260 sSer Pro ?Tyr Leu DESCRIPTION: SEQ ID NO:625: INFORMATION FOR SEQ ID NO:626: Wi SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid CC) STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn C-ys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 DESCRIPTION: SEQ ID NO:626: Met Ile Asp Giu Ile Ile His Leu Asp Pro Asn Asn LeU Asn 25 Arg Asn Leu Arg Thr Pro Asn 40 His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gln Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 His Leu Ser Giu Leu Leu Ile Glu Ala Ala Giu Phe Gin Glu 110 Ser Gly 125 WO 98/17810 Ser Thr 130 Asn Met 145 Asn Thr Ser Cys Thr Ser Phe Ser 210 Gly Gly 225 Gin His Ser Asp Gin Asp Arg Trp 290 PCTIUS97/20037 6214 Glu Gly 155 Ala Ser Trp Pro Thr 235 Val Thr Arg INFORMATION FOR SEQ ID N0:627: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Val Ala Thr Glu Ile His 165 Cys Leu Arg Phe 180 Ser Glu Gin Leu 195 Ser Arg Cys Leu 210 Gly Gly Ser Gly Asp Cys Ser Phe 245 Ile Arg Glu Leu 260 Ala Ser Asn Leu 275 Val Leu Ala Gin 290 TYPE: None DESCRIPTION: SEQ ID NO:627: Met Ile Asp Glu Ile Ile His 10 Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin 90 Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Gly Ser Lys Met Gin Gly Leu 150 155 Phe Val Thr Lys Cys Ala Phe 170 Val Gin Thr Asn Ile Ser Arg 185 Val Ala Leu Lys Pro Trp Ile 200 Glu Leu Gin Cys Gin Pro Asp 215 220 Gly Gly Ser Gly Gly Gly Ser 230 235 Gin His Ser Pro Ile Ser Ser 250 Ser Asp Tyr Leu Leu Gin Asp 265 Gin Asp Glu Glu Leu Cys Gly 280 Arg Trp Met Glu Arq Leu Lvs Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Glu Arg Pro Pro 175 Leu Gin 190 Arg Gin Ser Thr Gly Gly Phe Ala 255 Pro Val 270 Leu Trp INFORMATION FOR SEQ ID N0:628: SEQUENCE CHARACTERISTICS: WO 98/17810 LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None PCT/US97/20037 (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Arg Phe Ser Glu Gin Leu 165 Ser Arg Cys Leu 180 Gly Gly Ser Gly 195 His Ser Pro Ile 210 Asp Tyr Leu Leu Asp Glu Glu Leu 245 Trp Met Glu Arg 260 Leu Glu Arg Val 275 Gin Pro Pro Pro 290 DESCRIPTION: SEQ ID NO:628: Met Ile Asp Leu Asp Pro Arg Asn Leu His Leu Glu Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Val Gin Thr 150 Val Ala Leu Glu Leu Gin Gly Gly Ser 200 Ser Ser Asp 215 Gin Asp Tyr 230 Cys Gly Gly Leu Lys Thr Asn Thr Glu 280 Ser Cys Leu 295 Glu Ile Ile Asn Asn Leu Arg Thr Pro Asn Ala Ser Pro Ser Ala Gly Asp Trp Leu Glu Gin 105 Pro Gly Glu Ser Lys Glu Asn Ile Ser 155 Lys Pro Trp 170 Cys Gin Pro 185 Gly Gly Thr Phe Ala Val Pro Val Thr 235 Leu Trp Arg 250 Val Ala Gly 265 Ile His Phe INFORMATION FOR SEQ ID NO:629: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys NO:629: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser WO 98/17810 130 Asn Met 145 Thr Ser Phe Ser Gly Gly Gin Asp 210 Lys Ile 225 Val Ala Leu Val Ser Lys Val Thr 290 PCT/US97/20037 Leu Leu Thr Arg Ser Ser 190 Gly Gly 205 Asp Phe Tyr Pro Gly Leu Thr Val 270 Glu Ile 285 Leu INFORMATION FOR SEQ ID NO:630: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg ASn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Thr Asn Val Ala Leu Lys 165 Glu Leu Gin Cys 180 Gly Gly Ser Gly 195 Ser Ser Asp Phe 210 Gin Asp Tyr Pro Cys Gly Gly Leu 245 Leu Lys Thr Val 260 Asn Thr Glu Ile 275 Ser Cys Leu Arg TYPE: None DESCRIPTION: SEQ ID NO:630: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Thr Pro Asn 40 His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Ser Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Ile Ser Arg Leu Leu Gin Glu 150 155 Pro Trp Ile Thr Arg Gin Asn 170 Gin Pro Asp Ser Ser Thr Leu 185 Gly Thr Gin Asp Cys Ser Phe 200 Ala Val Lys Ile Arg Glu Leu 215 220 Val Thr Val Ala Ser Asn Leu 230 235 Trp Arg Leu Val Leu Ala Gin 250 Ala Gly Ser Lys Met Gin Gly 265 His Phe Val Thr Lys Cys Ala 280 Phe Val Gin 295 His Leu Ser Glu Leu Leu Ile Glu Ala Ala Glu Phe Gin Glu 110 Ser Gly 125 His Lys Thr Ser Phe Ser Gly Gly 190 Gin His 205 Ser Asp Gin Asp Arg Trp Leu Leu 270 Phe Gln 285 S(2) INFORMATION FOR SEQ ID NO:631: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids WO 98/17810 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gln His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Thr Asn Val Ala Leu Lys 165 Glu Leu Gin Cys 180 Gly Gly Ser Gly 195 Gin His Ser Pro 210 Ser Asp Tyr Leu Gin Asp Glu Glu 245 Arg Trp Met Glu 260 Leu Leu Glu Arg 275 Phe Gln Pro Pro 290 TYPE: None DESCRIPTION: SEQ ID NO:631: Met Ile Asp Leu Asp Pro Arg Asn Leu 40 His Leu Glu 55 Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Ile Ser Arg 150 Pro Trp Ile Gin Pro Asp Gly Gly Ser 200 Ile Ser Ser 215 Leu Gin Asp 230 Leu Cys Gly Arg Leu Lys Val Asn Thr 280 Pro Ser Cys 295 Glu Ile Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Leu Leu Thr Arg 170 Ser Ser 185 Gly Gly Asp Phe Tyr Pro Gly Leu 250 Thr Val 265 Glu Ile Leu Arg Ile His His Leu Asn Ser Pro Asn Leu Ser Gly Ile Ala Thr Ala Trp Gin Glu Gin Ala Gin Glu Pro Ser 125 Glu Ser His 140 Gin Glu Thr 155 Gin Asn Phe Thr Leu Gly Gly Thr Gln 205 Ala Val Lys 220 Val Thr Val 235 Trp Arg Leu Ala Gly Ser His Phe Val 285 Phe Val Gin 300 INFORMATION FOR SEQ ID N0:632: SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Thr 40 His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 NO:632: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 WO 98/17810 Asn Me 145 Glu Le Glu Ar Arg Va Pro Pr 21 Gin Gl 225 Gin As: Thr Le Ser Pr Tyr Le PCT/US97/20037 Tyr Pro Val Thr Val 150 Gly Leu Trp Arg Leu 165 Thr Val Ala Gly Ser 185 Glu Ile His Phe Val 200 Leu Arg Phe Val Gin 215 Glu Gin Leu Val Ala 230 Arg Cys Leu Glu Leu 245 Gly Ser Gly Gly Thr 265 Ser Asp Phe Ala Val Ala Ser Asn Leu Gin 155 Val Leu Ala Gin Arg 170 Lys Met Gin Gly Leu 190 Thr Lys Cys Ala Phe 205 Thr Asn Ile Ser Arg 220 Leu Lys Pro Trp Ile 235 Gin Cys Gin Pro Asp 250 Gin Asp Cys Ser Phe 270 Lys Ile Arg Glu Leu INFORMATION FOR SEQ ID N0:633: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Glu Glu Arg Pro Gin 225 Gin Thr His Asp (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Tyr Leu Cys Gly Gly 165 Arg Leu Lys Thr 180 Val Asn Thr Glu 195 Pro Ser Cys Leu 210 Glu Thr Ser Glu Asn Phe Ser Arg 245 Leu Gly Gly Gly 260 Ser Pro Ile Ser 275 Tyr Leu Leu Gin 290 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser 70 Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 Pro Val Thr Val Ala 150 Leu Trp Arg Leu Val 170 Val Ala Gly Ser Lys 185 Ile His Phe Val Thr 200 Arg Phe Val Gln Thr 215 Gin Leu Val Ala Leu 230 Cys Leu Glu Leu Gin 250 Ser Gly Gly Gly Thr 265 Ser Asp Phe Ala Val 280 NO:633 Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Ser Asn 155 Leu Ala Met Gin Lys Cys Asn Ile 220 Lys Pro 235 Cys Gin Gin Asp Lys Ile INFORMATION FOR SEQ ID N0:634: SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid WO 98/17810 WO 9817810PCTUS97/2OO37 STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Tyr Leu Cys Gly Gly 165 Arg Leu Lys Thr 180 Val Asn Thr Glu 195 Pro Ser Cys Leu 210 Giu Thr Ser Glu Asn Phe Ser Arg 245 Leu Gly Gly Gly 260 Asp Cys Ser Phe 275 Ile Arg Giu Leu 290 TYPE: None DESCRIPTION: SEQ ID NO:634: INFORMATION FOR SEQ ID NO:635: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (i i) (xi) Asn Cys Pro Asr Ile Le.

Arg Ala Arg Asr His Pro Leu Thr Val Git 115 Thr IlE 130 Met AlE

MOLECULE

SEQUENCE

Ser Ile Pro Leu Met Giu Val Lys Leu Gin Ile Ile Phe Tyr 100 Gly Gly Asn Pro Val Ala TYPE: None DESCRIPTION: SEQ ID NO:635: Met Ile Asp Giu Ile Ile His WO 98/1 7810 145 Asn T1 Ser C Thr SE Phe SE 21 Gly GI 225 Gly GI Ser SE Gin As Cys Gi 29 Leu Ly 305 150 Phe Val.

Val Gin Val Ala Glu Leu 215 Gly Gly 230 Thr Gin Val Lys Thr Val Arg Leu 295 155 Ala Phe Ser Arg Trp Ile Pro Asp 220 Gly Ser 235 Phe Gin Leu Ser Leu Gin Gin Arg 300 PCTIUS97/20037 160 Pro Glu Asn Leu Ser 240 Ile Leu Leu Arg INFORMATION FOR SEQ, ID NO:636: SEQUENCE CHAR<ACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) Asn Cys Pro Asn Ile Leu Arg Ala Arg Asn His Pro Leu Thr Val Glu 115 Thr Ile 130 Met Ala Arg Leu Gly Ser Phe Val 195 Val Gin 210 Val Ala Glu Leu Gly Thr Ala Val 275 Val Thr 290 MOLECULE TYP) SEQUENCE DES( Ser Ile Met Pro Leu Leu Met Glu Arg Val Lys His Leu Gin Pro Ile Ile Ile *Phe Tyr Leu 100 *Gly Gly Gly Asn Pro Ser Ala Ser Asn 150 Val Leu Ala 165 Lys Met Gin 180 Thr Lys Cys *Thr Asn Ile Leu Lys Pro 230 Gin Cys Gin 245 Gin Asp Cys 260 Lys Ile Arg Val1 E:None CRIPTION: SEQ ID NO:636: His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Giu Ala Gin Pro Ser 125 Ser His 140 Leu Cys Arg Leu Val Asn Pro Ser 205 GlU Thr 220 Asn Phe Leu Gly Pro Ile Leu Leu 285 Leu Lys Arg GiU ASP Met Leu Ala Phe Giu Ala Ile Ala Pro Ser Phe Arg Giu Giu Gin Gin 110 Gly Pro Ile Lys Ser Pro Gly Gly Leu 160 Lys Thr Val 175 Thr Giu Ile 190 Cys Leu Arg Ser Glu Gin Ser Arg Cys 240 Gly Gly Ser 255 Ser Ser Asp 270 Gin Asp Tyr S(2) INFORMATION FOR SEQ ID NO:637: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids WO 98/17810 6(2g PCT/US97/20037 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ala Ser Arg Leu Val Leu 165 Gly Ser Lys Met 180 Phe Val Thr Lys 195 Val Gin Thr Asn 210 Val Ala Leu Lys Glu Leu Gin Cys 245 Gly Gly Thr Gin 260 Phe Ala Val Lys 275 Pro Val Thr Val DESCRIPTION: SEQ ID NO:637: INFORMATION FOR SEQ ID NO:638: SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:638: n Cys Ser Ile Met Ile Asp Glu Ile Ile His o Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn e Leu Met Glu Arg Asn Leu Arg Thr Pro Asn g Ala Val Lys His Leu Glu Asn Ala Ser Gly g Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr s Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin u Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala 100 105 1 Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro 115 120 r Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser 0 135 140 WO 98/17810 Asn Met 145 Trp Arg Ala Gly His Phe Phe Val 210 Leu Val 225 Leu Giu Gly Gly His Ser Asp Tyr 290 Leu Gin Gly Ala Ser 215 Trp Pro Gly Asp Tyr 295 Gin Arg Leu Phe 200 Arg Ile Asp Ser Phe 280 Pro Asp Giu Giu Leu Cys 155 Trp Met Glu Arg Leu 170 Leu Glu Arg Val Asn 185 Gin Pro Pro Pro Ser 205 Leu Leu Gin Giu Thr 220 Thr Arg Gin Asn Phe 235 Ser Ser Thr Leu Giy 250 Gly Thr Gin Asp Cys 265 Ala Val Lys Ile Arg 285 Val Thr Val PCTIUS97/20037 Giy Gly Lys Thr 175 Thr Giu 190 Cys Leu Ser Giu Ser Arg Giy Gly 255 Ser Phe 270 Giu Leu LeU Leu Gin Asp INFORMATION FOR SEQ ID NO:639: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) (xi) Ala Asn Cys 1 Pro Pro Asn Asp Ile Leu Val Arg Aia Leu Arg Asn Arg His Pro Lys Leu Thr Tyr Val Giu Ser Thr Ile 130 Asn Met Ala 145 Trp, Arg Leu Ala Gly Ser His Phe Val 195 Phe Val Gin 210 Leu Val Ala 225 Leu Glu Leu Gly Giy Gly Giy Thr Gin 275 Ala Val Lys 290 Val Thr Vai 305

MOLECULE

SEQUENCE

Ser Ile 5 Pro Leu 20 Met Giu Val Lys Leu Gin Ile Ile 85 Phe Tyr 100 Gly Gly Asn Pro Ala Ser Val Leu 165 Lys Met 180 Thr Lys Thr Asn Leu Lys Gin Cys 245 Ser Gly 260 Asp Cys Ile Arg TYPE: None DESCRIPTION: SEQ ID NO.639: Met Ile Asp Gu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Giu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr 70 Ile Lys Ala Giy Asp Trp Gin Leu Val Thr Leu Giu Gin Ala 105 Gly Giy Ser Pro Giy Glu Pro 120 Ser Pro Pro Ser Lys Giu Ser 135 140 Asn Leu Gin Asp Giu Giu Leu 150 155 Ala Gin Arg Trp Met Giu Arg 170 Gin Gly Leu Leu Giu Arg Val 185 Cys Ala Phe Gin Pro Pro Pro 200 Ile Ser Arg Leu Leu Gln Giu 215 220 Pro Trp Ile Thr Arg Gin Asn 230 235 Gin Pro Asp Ser Ser Thr Leu 250 Gly Giy Ser Gly Gly Gly Ser 265 Ser Phe Gin His Ser Pro Ilie 280 Giu Leu Ser Asp Tyr Leu Leu 295 300 INFORMATION FOR SEQ ID NO:640: SEQUENCE CHARACTERISTICS: WO 98/17810 PCT/US97/20037 LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Asn Ser Thr Phe Gly 225 Ile Leu Leu Arg (ii) (xi) Asn Cys Pro Asr Ile Let Arg Ala Arg Asr His Prc Leu Thr Val Gl 11 Thr Ile 130 Met Ale Thr GlI Cys Let Ser Gli 19! Ser Ar 210 Gly Gl Ser Se Gln As Cys Gl 27! Leu Ly 290

D*

SEQUENCE DESCRIPTION: SEQ Ser Ile Met Ile Asp Glu 5 SPro Leu Leu Asp Pro Asn 25 SMet Glu Arg Asn Leu Arg 40 SVal Lys His Leu Glu Asn 55 SLeu Gln Pro Cys Leu Pro 70 SIle Ile Ile'Lys Ala Gly r Phe Tyr Leu Val Thr Leu 100 105 u Gly Gly Gly Gly Ser Pro 5 120 e Asn Pro Ser Pro Pro Ser 135 a Val Ala Gly Ser Lys Met 150 i Ile His Phe Val Thr Lys 165 u Arg Phe Val Gin Thr Asn 180 185 i Gln Leu Val Ala Leu Lys 5 200 g Cys Leu Glu Leu Gln Cys 215 y Ser Gly Gly Thr Gin Asp 230 r Asp Phe Ala Val Lys Ile 245 p Tyr Pro Val Thr Val Ala 260 265 y Gly Leu Trp Arg Leu Val 5 280 s Thr SID NO:640: Ile Ile His Asn Leu Asn Thr Pro Asn Ala Ser Gly Ser Ala Thr Asp Trp Gln Glu Gin Ala Gly Glu Pro Lys Glu Ser 140 Gin Gly Leu 155 Cys Ala Phe 170 Ile Ser Arg Pro Trp Ile Gln Pro Asp 220 Cys Ser Phe 235 Arg Glu Leu 250 Ser Asn Leu Leu Ala Glr IOLECULE TYPE: None His Leu Ser Glu Leu Leu Ile Glu Ala Ala Glu Phe Gin Glu 110 Ser Gly 125 His Lys Leu Glu Gin Pro Leu Leu 190 Thr Arg 205 Ser Ser Gin His Ser Asp Gin Asp 270 Arg Trp 285 INFORMATION FOR SEQ ID NO:641: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro TYPE: None DESCRIPTION: SEQ ID NO:641: Met Ile Asp Glu Ile Ile His 10 Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin 90 Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser WO 98/17810 130 Asn Met 145 Asn Thr Ser Cys Thr Ser Phe Ser 210 Gly Gly 225 Pro Ile Leu Leu Glu Leu Glu Arg 290 PCT/US97/20037 Gin Gly 155 Cys Ala 170 Ile Ser Pro Trp Gin Pro Asp Cys 235 Ile Arg 250 Ala Ser Val Leu Leu Glu Gin Pro Leu Leu 190 Thr Arg 205 Ser Ser Phe Gin Leu Ser Leu Gin 270 Gin Arg 285 INFORMATION FOR SEQ ID NO:642: SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Val Ala Thr Glu Ile His 165 Cys Leu Arg Phe 180 Ser Glu Gin Leu 195 Ser Arg Cys Leu 210 Gly Gly Ser Gly Ser Phe Gin His 245 Glu Leu Ser Asp 260 Asn Leu Gln Asp 275 Ala Gin Arg Trp 290 DESCRIPTION: SEQ ID NO:642: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Gly Ser Lys Met Gln Gly Leu 150 155 Phe Val Thr Lys Cys Ala Phe 170 Val Gin Thr Asn Ile Ser Arg 185 Val Ala Leu Lys Pro Trp Ile 200 Glu Leu Gin Cys Gin Pro Asp 215 220 Gly Gly Ser Gly Gly Gly Ser 230 235 Ser Pro Ile Ser Ser Asp Phe 250 Tyr Leu Leu Gln Asp Tyr Pro 265 Glu Glu Leu Cys Gly Gly Leu 280 Met Glu Arg Leu Lys Thr INFORMATION FOR SEQ ID NO:643: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids WO 98/17810 TYPE: amino acid STRANDEDNESS: single TOPOLOGY- linear &,32/ SEQ ID NO:-643: WO 9817810PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Val Ala Thr Glu Ile His 165 Cys Leu Arg Phe 180 Ser Glu Gin Leu 195 Ser Arg Cys Leu 210' Gly Gly Ser Gly Gly Gly Ser Gly 245 Ser Asp Phe Ala 260 Asp Tyr Pro Val 275 Gly Gly Leu Trp 290 Lys Thr TYPE: None

DESCRIPTION:

ASP

Pro Leu Glu Leu Al a Thr Ser 120 Pro Lys Thr Thr Leu 200 Gln Ser Asp Ile Al a 280 Val1 Ile Leu Pro Ser Ala Trp Gln Glu Glu Gly Al a Ser Trp Pro G ly 235 Phe Leu Leu Gln INFORMATION FOR SEQ ID NO:644: Mi SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLEC ULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:644: Asn Cys Ser Ile Met Ile Asp Gu Ile Ile His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn 25 Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn 40 Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala 100 105 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro 120 His Leu Ser Giu Leu Leu Ile Giu Ala Ala Giu Phe Gin Glu 110 Ser Gly 125 WO 98/17810 Ser Thr 130 Asn Met 145 Thr Ser Phe Ser Gly Gly Ile Ser 210 Leu Gin 225 Leu Cys Arg Leu Val Asn Pro Ser 290 PCT/US97/20037 Pro Pro Ser 135 Gin Thr Asn INFORMATION FOR SEQ ID NO:645: SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Arg Phe Ser Glu Gln Leu 165 Ser Arg Cys Leu 180 Gly Gly Ser Gly 195 Ile Ser Ser Asp 210 Leu Gin Asp Tyr Leu Cys Gly Gly 245 Arg Leu Lys Thr 260 Val Asn Thr Glu 275 Pro Ser Cys Leu 290 DESCRIPTION: SEQ ID NO:645: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Asn His Leu Glu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Glu Pro 120 Ser Pro Pro Ser Lys Glu Ser 135 140 Val Gin ThrAsn Ile Ser Arg 150 155 Val Ala Leu Lys Pro Trp Ile 170 Glu Leu Gin Cys Gin Pro Asp 185 Gly Gly Thr Gin Asp Cys Ser 200 Phe Ala Val Lys Ile Arg Glu 215 220 Pro Val Thr Val Ala Ser Asn 230 235 Leu Trp Arg Leu Val Leu Ala 250 Val Ala Gly Ser Lys Met Gln 265 Ile His Phe Val Thr Lys Cys INFORMATION FOR SEQ ID NO:646: SEQUENCE CHARACTERISTICS: WO 98/17810 PCT/US97/20037 LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Arg Phe Ser Glu Gin Leu 165 Ser Arg Cys Leu 180 Gly Gly Ser Gly 195 Ser Phe Gin His 210 Glu Leu Ser Asp Asn Leu Gin Asp 245 Ala Gin Arg Trp 260 Gin Gly Leu Leu 275 Cys Ala Phe Gin 290 TYPE: None DESCRIPTION: SEQ ID N0:646: Met Ile Asp Glu Ile Ile His His Leu Asp Pro Asn Asn Arg Thr Asn Ala Pro Ser Gly Asp Leu Glu 105 Pro Gly Ser Lys Asn Ile Lys Pro 170 Cys Gin 185 Gly Gly Ser Ser Gin Asp Cys Gly 250 Leu Lys 265 Asn Thr Ser Cys INFORMATION FOR SEQ ID NO:647: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro DESCRIPTION: SEQ ID Met Ile Asp Glu Ile 10 Leu Asp Pro Asn Asn 25 Arg Asn Leu Arg Thr 40 His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp 90 Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys N0:647: Ile His Asn Asn Gly Thr Gin Ala Pro Ser His Leu Lys Ser Glu Asp Leu Leu Ala Ile Glu Ala Ala Ala Pro Glu Phe Arg Gin Glu Gin 110 Ser Gly Pro 125 His Lys Ser WO98/17810 PCTIUS97/20037 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 195 200 205 Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 210 215 220 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 225 230 235 240 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 245 250 255 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 260 265 270 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 275 280 285 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 290 295 300 Ser Cys Leu 305 INFORMATION FOR SEQ ID NO:648: SEQUENCE CHARACTERISTICS: LENGTH: 292 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:648: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 195 200 205 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 210 215 220 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 225 230 235 240 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 245 250 255 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 260 265 270 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 275 280 285 Arg Phe Val Gin 290 INFORMATION FOR SEQ ID NO:649: WO 98/17810 SEQUENCE CHARACTERISTICS: LENGTH: 293 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Asn Cys Ser Ile 1 Pro Pro Asn Pro Leu Asp Ile Leu Met Glu Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Ala Thr Asn 145 Leu Val Ala Leu Lys 165 Leu Glu Leu Gln Cys 180 Gly Gly Gly Thr Gln 195 Asp Phe Ala Val Lys 210 Tyr Pro Val Thr Val 225 Gly Leu Trp Arg Leu 245 Thr Val Ala Gly Ser 260 Glu Ile His Phe Val 275 Leu Arg Phe Val Gln 290 TYPE: None DESCRIPTION: SEQ ID NO:649: Asp Pro Leu Glu Leu Ala Thr Ser 120 Pro Arg Ile Asp Ser 200 Glu Asn Ala Gin Cys 280 lie Leu Pro Ser Ala Trp Gin Glu Glu Gin 155 Gin Thr His Asp Asp 235 Trp Leu Gin INFORMATION FOR SEQ ID NO:650: SEQUENCE CHARACTERISTICS: LENGTH: 299 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 DESCRIPTION: SEQ ID Met Ile Asp Glu Ile Leu Asp Pro Asn Asn Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp Leu Val Thr Leu Glu 105 Gly Ser Ser Pro Gly 120 NO: 650: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro WO 98/17810 Ser Thr 130 Asn Met 145 Leu Val Leu Glu Gly Gly His Ser 210 Asp Tyr 225 Asp Glu Trp Met Leu Glu Gin Pro 290 PCT/US9720037 Lys Glu Leu Gin 155 Arg Gin 170 Ser Thr Thr Gin Val Lys Thr Val 235 Arg Leu 250 Gly Ser Phe Val Val Gin INFORMATION FOR SEQ ID NO:651: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Asn Cys Ser Ile 1 Pro Pro Asn Pro Leu Asp Ile Leu Met Glu Val Arg Ala Val Lys Leu Arg Asn Leu Gin Arg His Pro Ile Ile Lys Leu Thr Phe Tyr 100 Tyr Val Glu Gly Gly 115 Ser Thr Ile Asn Pro 130 Asn Met Ala Thr Asn 145 Leu Val Ala Leu Lys 165 Leu Glu Leu Gin Cys 180 Gly Gly Gly Ser Gly 195 Gly Thr Gin Asp Cys 210 Ala Val Lys Ile Arg 225 Val Thr Val Ala Ser 245 Trp Arg Leu Val Leu 260 Ala Gly Ser Lys Met 275 His Phe Val Thr Lys 290 Phe Val Gin 305 DESCRIPTION: SEQ ID NO:651: INFORMATION FOR SEQ ID NO:652: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 749 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ser Thr Met Ser Arg Pro Ala Met Leu Ile Asn His Tyr Pro Met Val Pro Gin Ser Ser Val Ser Ala Ser Ile Ser Cys Leu 100 His Phe Asp Leu 115 Met Thr Glu Thr 130 Ala Thr Asn Tyr Leu Tyr Thr Leu 165 Ala Leu Val Cys 180 Val Leu Cys Asp 195 Val Val Lys Lys 210 Ile Arg Cys Cys Phe Thr Ile Asp 245 Phe Leu Lys Val 260 Val Asn His Gly 275 Glu Glu Gly Asn 290 Met Ile Arg Ile Thr Gly Tyr Tyr 325 Leu Val Thr Ile 340 Glu Asp Tyr Glu 355 Phe Lys Ala Tyr 370 Ser Phe Pro Cys Lys Phe Cys Asn 405 Glu Asn Asp Asp 420 Arg Lys Pro Gin 435 Phe Ser Asp Gly 450 Asp Lys Ser Pro Arg Lys Ala Asn 485 Leu Asn Met Ser 500 Tyr Asn Ser Leu 515 TYPE: None DESCRIPTION: SEQ ID NO:652: Val Leu Gin Asp Asp Ser Pro Glu Tyr Glu Gin Val Lys His 105 Gly Val Glu Tyr Phe Thr Tyr Phe 170 Ser Val 185 Glu Ser Val Leu Glu Leu Thr Pro 250 Leu Trp 265 Thr Trp Met Ser Phe Val Ser Ser 330 Gly Phe 345 Tyr Glu Arg Cys Gly Leu Gin Pro 410 Thr Lys 425 Glu Ala Pro Ser Glu Glu Phe Gly 490 Lys Gly 505 Cys Glu Leu Leu Ser Asp Ala Leu Ser Val Leu Val 155 Arg Pro Cys His Gly 235 Gin Ile Glu Thr Ser 315 Lys Ile Glu Thr Asp 395 Gly Met Ser Trp Ile 475 Gin Phe Thr WO 98/17810 Pro Gly 530 Leu Phe 545 Leu Cys Asp Pro Glu Asp Leu Thr 610 His Asn 625 Val Leu Ser Gly Thr Ser Leu Leu 690 Phe Gin 705 Glu Asp Gly Ile PCT/US97/20037 Asp Asn Thr Cys Asn Pro 570 Ser Trp 585 Leu Gly Lys Lys Leu Pro Val Ser 650 Tyr Gly 665 Leu Arg Pro Lys Leu Val Leu Leu 730 Ala Leu 745 Glu Phe Ile Ile Leu Gly INFORMATION FOR SEQ ID NO:653: SEQUENCE CHARACTERISTICS: LENGTH: 349 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Thr Gin Asp 210 Ala Val Lys Ile Val Thr Val Ala 245 Trp Arg Leu Val 260 Ala Gly Ser Lys 275 TYPE: None DESCRIPTION: SEQ ID NO:653: Ser Leu Pro Gin Ile Gin Gly Asp Lys Leu Cys His Ile Pro Trp Ala Ala Gly Cys Leu Leu Leu Gin Ala Asp Thr Leu Gin 105 Gin Met Glu Glu Ala Met Pro Ala 140 Leu Val Ala Ser 155 Leu Arg His Leu 170 Gly Glu Pro Ser 185 Lys Glu Ser His Gin His Ser Pro 220 Ser Asp Tyr Leu 235 Gin Asp Glu Glu 250 Arg Trp Met Glu 265 Leu Leu Glu Arg WO 98/1781 Ile Hi 29 Arg Ph 305 Gin Le Cys Le 10 640 s Phe Val Thr Lys Cys Ala Phe Gln Pro 0 295 e Val Gin Thr Asn Ile Ser Arg Leu Leu 310 315 u Val Ala Leu Lys Pro Trp Ile Thr Arg 325 330 u Glu Leu Gin Cys Gin Pro Asp Ser Ser 340 345 INFORMATION FOR SEQ ID N0:654: SEQUENCE CHARACTERISTICS: LENGTH: 314 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 Pro Pro Ser Cys Leu 300 Gin Glu Thr Ser Glu 320 Gin Asn Phe Ser Arg 335 Thr Leu (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Glu Leu Gin Cys 130 Gly Gly Ser Pro Ser Pro Pro Ser 165 Asp Cys Ser Phe 180 Ile Arg Glu Leu 195 Ala Ser Asn Leu 210 Val Leu Ala Gin Lys Met Gin Gly 245 Thr Lys Cys Ala 260 Thr Asn Ile Ser 275 Leu Lys Pro Trp 290 Gin Cys Gin Pro DESCRIPTION: SEQ ID NO:654: Pro Leu Glu Glu Arg Pro Gin Gin Thr Pro 155 Ser Ser Gin Cys Leu 235 Asn Ser Thr Phe Ser Ser Asp Gin Asp Tyr Cys Gly Gly Leu Lys Thr Asn Thr Glu Ser Cys Leu Thr Ser Glu 110 Phe Ser Arg 125 Tyr Val Glu Ser Thr Ile Asn Met Ala 175 Asp Phe Ala 190 Tyr Pro Val 205 Gly Leu Trp Thr Val Ala Glu Ile His 255 Leu Arg Phe 270 Glu Gin Leu 285 Arg Cys Leu INFORMATION FOR SEQ ID N0:655: SEQUENCE CHARACTERISTICS: LENGTH: 349 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:655: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro WO 98/17810 44 PCT/US97/20037 Val Thr Trp Arg Ala Gly His Phe Phe Val Leu Val Leu Glu 130 Gly Gly 145 Pro Ser Pro Leu Leu Glu Lys Leu 210 Leu Gly 225 Ser Gin Leu Phe Glu Leu Ala Thr 290 Leu Gin 305 Arg Arg Glu Val Ala Val Lys Thr Thr 100 Leu Gin Ser Pro Pro 180 Val Ala Ser Leu Tyr 260 Pro Ile Thr Gly Tyr 340 Glu Glu Arg Pro Gin Gin Thr Pro 155 Ser Ser Gly Pro Pro 235 Ser Leu Leu Leu Phe 315 His Ala Leu Arg Val Pro Glu Asn Leu 140 Ile Pro Phe Ala Glu 220 Leu Gin Glu Asp Gly 300 Ala Leu Gin Cys Gly Leu Lys Asn Thr Ser Cys Thr Ser 110 Phe Ser 125 Tyr Val Ser Thr Asn Met Leu Leu 190 Ala Leu 205 Glu Leu Ser Ser Leu His Gly Ile 270 Val Ala 285 Met Ala Ser Ala Gin Ser Pro Gly Thr Glu Leu Glu Arg Glu Ile Ala 175 Lys Gin Val Cys Ser 255 Ser Asp Pro Phe Phe 335 INFORMATION FOR SEQ ID NO:656: SEQUENCE CHARACTERISTICS: LENGTH: 523 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly TYPE: None DESCRIPTION: SEQ ID NO:656: Pro Ala Ser Ser Val Arg Ala Thr Ser Leu Leu Gin Tyr Gin Pro Thr Ile Trp Thr Gin 135 Gly Gly 150 Tyr Arg Gly Ser Lys Ile 25 Tyr Lys 40 Gly Ile Leu Ala Gly Leu Leu Asp 105 Gin Gin 120 Gly Ala Val Leu Val Leu Pro Gly Leu Pro Gin Gly Leu Cys Pro Trp Gly Cys Leu Gin Thr Leu Met Glu Met Pro Val Ala 155 Arg His 170 Glu Pro Ser Phe Gly Ala Pro Glu Pro Leu Ser Gin Leu Glu Leu Asp 110 Leu Gly 125 Phe Ala His Leu Ala Gin Gly Pro WO 98/17810 WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID NO:657: SEQUENCE CHARACTERISTICS: LENGTH:.460 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE ASn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Vai Giu Gly Giy 115 Thr Ile Asn Pro 130 Met Aia Thr Gin Phe Aia Val Lys TYPE: None DESCRIPTION: SEQ ID NO:657: Met Ile Asp Glu Ile Ile His Leu Asp Pro Asn Asn Leu Asn 25 Arg Asn Leu Arg Leu Pro Asn 40 Asn Leu Glu Asn Aia Ser Gly 55 Pro Cys Leu Pro Ser Ala Thr le Lys Ala Giy Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Gly Ser Pro Gly Giu Pro i2 0 Ser Pro Pro Ser Lys Giu Ser 135 140 Asp Cys Ser Phe Gin His Ser 155 Ile Arg Giu Leu Ser ASn Tvr His Leu Asp Giu Leu Glu Ile Giu Aia Ala Glu Phe Gin Giu 110 Ser Gly 125 His Lys Pro Ile Leu Leu WO 98/17810 PCT/US97/20037 Val Thr 180 Trp Arg 195 Ala Gly His Phe Phe Val Leu Val 260 Leu Glu 275 Gly Gly Pro Ser Gin Asp Lys Ile 340 Val Ala 355 Leu Val Ser Lys Val Thr Gin Thr 420 Ala Leu 435 Leu Gin 170 Leu Gin 185 Gin Arg Gly Leu Ala Phe Ser Arg 250 Trp Ile 265 Pro Asp Glu Pro Glu Ser His Ser 330 Asp Tyr 345 Asp Glu Trp Met Leu Glu Gin Pro.

410 Leu Leu 425 Thr Arg Ser Ser Glu Met Glu 220 Pro Leu Arg Ser Gly 300 Lys Ile Leu Leu Arg 380 Val Pro Glu Asn Leu 460 INFORMATION FOR SEQ ID NO:658: SEQUENCE CHARACTERISTICS: LENGTH: 523 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Ash 100 Val Ala Leu Lys 115 Glu Leu Gin Cys 130 Gly Gly Ser Pro Ser Pro Pro Ser 165 Leu Gly Pro Ala 180 Glu Gin Val Arg 195 Leu Cys Ala Thr TYPE: None DESCRIPTION: SEQ ID N0:658: Ser Phe Gin His Ser Pro Ile 10 Glu Leu Ser Asp Tyr Leu Leu 25 Asn Leu Gin Asp Glu Glu Leu 40 Ala Gin Arg Trp Met Glu Arg 55 Gin Gly Leu Leu Glu Arg Val Cys Ala Phe Gin Pro Pro Pro 90 Ile Ser Arg Leu Leu Gin Glu 105 Pro Trp Ile Thr Arg Gin Asn 120 Gin Pro Asp Ser Ser Thr Leu 135 140 Gly Glu Pro Ser Gly Pro Ile 150 155 Lys Glu Ser His Lys Ser Pro 170 Ser Ser Leu Pro Gin Ser Phe 185 Lys Ile Gin Gly Asp Gly Ala 200 Tyr Lys Leu Cys His Pro Glu Ser Asp Asp Tyr Gly Gly Lys Thr Thr Glu Cys Leu Ser Glu 110 Ser Arg Val Glu Thr Ile Met Ala 175 Leu Lys 190 Leu Gin Leu Val WO 98/17810 b6 4 PCTIUS97/20037 Leu Gly 230 Gin Leu 245 Gin Gly Thr Leu Trp Gin Gin Gly 310 Gly Val 325 Arg Val Ser Pro Pro Ser Ser Phe 390 Glu Leu 405 Asn Leu Ala Gin Gin Gly Cys Ala 470 Ile Ser 485 Pro Trp Gin Pro 215 Ile Pro Ala Gly Leu Leu Asp Thr 280 Gin Met 295 Ala Met Leu Val Leu Arg Gly Glu 360 Lys Glu 375 Gin His Ser Asp Gin Asp Arg Trp 440 Leu Leu 455 Phe Gin Arg Leu Ile Thr Asp Ser 520 Ser Ser Leu His Gly Ile 270 Val Ala 285 Met Ala Ser Ala Gin Ser Pro Tyr 350 Ile Ser 365 Pro Asn Ser Asp Asp Tyr Gly Gly 430 Lys Thr 445 Thr Glu Cys Leu Ser Glu Ser Arg 510 INFORMATION FOR SEQ ID NO:659: SEQUENCE CHARACTERISTICS: LENGTH: 334 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Glu Leu Gin Cys 130 Gly Gly Ser Pro Pro Leu Gly Pro 165 Leu Glu Gin Val 180 Lys Leu Cys Ala DESCRIPTION: SEQ ID N0:659: Ser Phe Gin His Ser Ser Gin Asp Cys Gly Leu Lys Asn Thr Ser Cys Thr Ser 110 Phe Ser 125 Tyr Val Ser Asn Phe Leu Ala Ala 190 Glu Glu WO 98/17810 &46 PCT/US97/20037 195 200 u Gly His Ser Leu Gly Ile Pro 0 215 r Gin Ala Leu Gin Leu Ala Gly 230 u Phe Leu Tyr Gin Gly Leu Leu 245 u Leu Gly Pro Thr Leu Asp Thr 260 265 a Thr Thr Ile Trp Gin Gin Met 275 280 u Gin Pro Thr Gin Gly Ala Met 0 295 g Arg Ala Gly Gly Val Leu Val 310 u Val Ser Tyr Arg Val Leu Arg 325 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Trp Ala Cys Leu 235 Gin Ala 250 Leu Gin Glu Glu Pro Ala Ala Ser 315 His Leu 330 NO:660: 205 Pro Leu 220 Ser Gin Leu Glu Leu Asp Leu Gly 285 Phe Ala 300 His Leu Ala Gin (ii) (xi) Asn Cy Pro As Ile Le Arg Al Arg Asr His Pr Leu Th: Val GI 11! Thr Il 130 Met Al Leu Cyi Arg Le Val Asr 19 Pro Se: 210 Glu Th: Asn Ph Leu Gl Phe Gl 27 Leu Se; 290 M [OLECULE TYPE: None

SEQUENCE

s Ser Ile n Pro Leu u Met Glu a Val Lys n Leu Gin o Ile Ile r Phe Tyr 100 u Gly Gly 5 e Asn Pro a Asp Tyr s Gly Gly 165 u Lys Thr 180 n Thr Glu 5 r Cys Leu r Ser Glu e Ser Arg 245 y Gly Gly 260 n His Ser 5 r Asp Tyr DESCRIPTION: SEQ ID NO:660: Met Ile Asp Glu His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Glu Ala Gin Pro Ser 125 Ser His 140 Asn Leu Ala Gin Gin Gly Cys Ala 205 Ile Ser 220 Pro Trp Gin Pro Gly Thr Ala Val 285 Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Gin Asp Arg Trp 175 Leu Leu 190 Phe Gin Arg Leu Ile Thr Asp Ser 255 Gin Asp 270 Lys Ile INFORMATION FOR SEQ ID NO:661: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Glu Glu Arg Pro Gin 225 Gin Thr Gly Ala Asn Cys Ser Ile Met Ile 5 Pro Asn Pro Leu Leu Asp Ile Leu Met Glu Arg Asn Arg Ala Val Lys His Leu 55 Arg Asn Leu Gin Pro Cys 70 His Pro Ile Ile Ile Lys Leu Thr Phe Tyr Leu Val 100 Val Glu Gly Gly Gly Gly 115 Thr Ile Asn Pro Ser Pro 130 135 Met Ala Asp Tyr Pro Val 150 Leu Cys Gly Gly Leu Trp 165 Arg Leu Lys Thr Val Ala 180 Val Asn Thr Glu Ile His 195 Pro Ser Cys Leu Arg Phe 210 215 Glu Thr Ser Glu Gln Leu 230 Asn Phe Ser Arg Cys Leu 245 Leu Gly Gly Gly Ser Gly 260 Thr Gin Asp Cys Ser Phe 275 Val Lys Ile Arg Glu Leu 290 295 Asp Pro Leu Glu Leu Ala Thr Ser 120 Pro Thr Arg Gly Phe 200 Val Val Glu Gly Gin 280 Ser Ile Asn Thr Ala Ser Asp Glu Gly Lys Ala Val 170 Lys Thr Thr Leu Gin 250 Ser Ser Tyr NO:661: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Ser Asn 155 Leu Ala Met Gin Lys Cys Asn Ile 220 Lys Pro 235 Cys Gin Gly Gly Pro Ile Leu Leu 300 INFORMATION FOR SEQ ID NO:662: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Ala Ser Arg Leu Val Leu 165 TYPE: None DESCRIPTION: SEQ ID N0:662: WO 98/17810 PCTIUS97/20037 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val 290 295 INFORMATION FOR SEQ ID NO:663: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:663: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser 260 265 270 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 275 280 285 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 300 INFORMATION FOR SEQ ID NO:664: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:664: PCT/US97/20037 Ala Asn 1 Pro Pro Asp Ile Val Arg Leu Arg Arg His Lys Leu Tyr Val Ser Thr 130 Asn Met 145 Asn Thr Ser Cys Thr Ser Phe Ser 210 Gly Gly 225 Gin His Ser Asp Gin Asp Arg Trp 290 Cys Ser Ile Asn Leu Ala Asn Pro Thr Glu 115 Ile Ala Glu Leu Glu 195 Arg Gly Ser Tyr Glu 275 Met Met Ile Asp Leu Asp Pro Arg Asn His Leu 55 Pro Cys 70 Ile Lys Leu Val Gly Gly Ser Pro 135 Gly Ser 150 Phe Val Val Gin Val Ala Glu Leu 215 Gly Gly 230 Ser Ser Gin Asp Cys Gly Leu Lys 295 Glu Ile Ile His His Asn Asn Leu Asn Ser Arg Thr Pro Asn Leu Asn Ala Ser Gly Ile Pro Ser Ala Thr Ala Gly Asp Trp Gin Glu Leu Glu Gin Ala Gin 105 Pro Gly Glu Pro Ser 125 Ser Lys Glu Ser His 140 Met Gin Gly Leu Leu 155 Lys Cys Ala Phe Gin 170 Asn Ile Ser Arg Leu 185 Lys Pro Trp Ile Thr 205 Cys Gin Pro Asp Ser 220 Gly Gly Thr Gin Asp 235 Phe Ala Val Lys Ile 250 Pro Val Thr Val Ala 265 Leu Trp Arg Leu Val 285 INFORMATION FOR SEQ ID NO:665: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Val Ala Thr Glu Ile His 165 Cys Leu Arg Phe TYPE: None DESCRIPTION; SEQ ID NO:665: Lys Arg Asp Met Ala Phe Ala Ile Pro Ser Arg Glu Gin Gin Pro Ile Ser Pro Arg Val 160 Pro Pro 175 Gin Glu WO 98/17810 (44 PCT/US97/20037 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 245 250 255 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 260 265 270 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 275 280 285 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 INFORMATION FOR SEQ ID NO:666: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:666: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 195 200 205 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 260 265 270 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gin Pro Pro Pro Ser Cys Leu 290 295 INFORMATION FOR SEQ ID NO:667: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 (xi) SEQUENCE DESCRIPTION: SEQ ID DESCRIPTION: SEQ ID Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Thr Phe Gly Gin Lys 225 Val Leu Ser Val Asn Pro Ile Arg Arg His Leu Val Thr 130 Met Ser Ser Gly Asp 210 Ile Ala Val Lys Thr 290 Cys Asn Leu Ala Asn Pro Thr Glu 115 Ile Ala Glu Arg Gly 195 Cys Arg Ser Leu Met 275 Lys Met Ile Leu Asp Arg Asn His Leu 55 Pro Cys 70 Ile Lys Leu Val Gly Gly Ser Pro 135 Val Gin 150 Val Ala Glu Leu Gly Gly Gin His 215 Ser Asp 230 Gin Asp Arg Trp Leu Leu Phe Gin 295 Asp Glu Ile Pro Asn Asn Leu Arg Thr Glu Asn Ala Leu Pro Ser Ala Gly Asp Thr Leu Glu 105 Ser Pro Gly 120 Pro Ser Lys Thr Asn Ile Leu Lys Pro 170 Gin Cys Gin 185 Ser Gly Gly 200 Ser Pro Ile Tyr Leu Leu Glu Glu Leu 250 Met Glu Arg 265 Glu Arg Val 280 Pro Pro Pro NO:667: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Ser Arg 155 Trp Ile Pro Asp Gly Ser Ser Ser 220 Gin Asp 235 Cys Gly Leu Lys Asn Thr Ser Cys 300 PCT/US97/20037 INFORMATION FOR SEQ ID NO:668: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Thr Asn Val Ala Leu Lys 165 Glu Leu Gin Cys 180 TYPE: None DESCRIPTION: SEQ ID NO:668: Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Ser Glu Ser Arg 175 Gly Gly 190 WO 98/17810 Gly GI Ile SE 21 Leu GJ 225 Leu Cj Arg Le Val As Pro Se 29 &54 Ly Gly Ser Gly Gly Thr Gin Asp Cys Ser 195 200 ~r Ser Asp Phe Ala Val Lys Ile Arg Giu 0 215 .n Asp Tyr Pro Val Thr Val Ala Ser Asn 230 235 's Gly Gly Leu Trp Arg Leu Val Leu Ala 245 250 ~u Lys Thr Val Ala Gly Ser Lys Met Gin 260 265 n Thr Giu Ile His Phe Val Thr Lys Cys 275 280 :r Cys Leu Arg Phe Val Gin '0 295 INFORMATION FOR SEQ ID NO:669: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Gin His 205 Ser Asp Gin Asp Arg Trp Leu Leu 270 Phe Gin 285 PCTUS97/20037 Pro Leu Glu 240 Giu.

Arg Pro (ii) MOLECULE Ala Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Leu Leu Gly Phe Leul 225 Leu Gin Gly Ala (xi) Asn Cys Pro Asr Ile Leu Arg Ala Arg Asn His Pro Leu Thr Val Giu 115 Thr Ile 130 Met Ala Val Ala Glu Leu Gly Gly 195 Gin His 210 Ser Asp Gin Asp Arg Trp Leu Leu 275 Phe Gin 290

SEQUENCE

Ser Ile 5 Pro Leu 20 IMet Giu *Val Lys Leu Gin Sle Ile 85 *Phe Tyr 100 Gly Gly Asn Pro Thr Asn Leu Lys 165 Gin Cys 180 Ser Gly Ser Pro Tyr Leu Giu Glu 245 Met Giu 260 Giu Arg Pro Pro TYPE: None DESCRIPTION: SEQ ID NO:669: Met Ile ASP Glu Leu Arg His Pro 70 Ile Leu Gly Ser Ile 150 Pro Gln Gly Ile Leu 230 Leu Arg Val Pro Asn Arg Asn Pro Gly Leu 105 Pro Ser Leu Thr Ser 185 Gly Asp Tyr Gly Thr 265 Glu Leu Ile Ile Asn Leu Thr Pro Ala Ser Ser Ala Asp Trp Giu Gin Gly Glu Lys Giu Leu Gin 155 Arg Gin 170 Ser Thr Gly Gly Phe Ala Pro Val 235 Leu Trp 250 Val Ala Ile His Arg Phe INFORMATION FOR SEQ ID NO:670: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii).MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:670: WO 98/17810 PCTIUS97/20037 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 145 150 155 160 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 165 170 175 Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 180 185 190 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 195 200 205 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 210 215 220 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 225 230 235 240 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly, Gly Ser Gly 245 250 255 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 260 265 270 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 275 280 285 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 290 295 300 Thr Val Ala 305 INFORMATION FOR SEQ ID NO:671: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:671: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 145 150 155 160 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 165 170 175 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe WO 98/17810 WO 9817810PCTIUS97/20037 Val Gin Ala 225 Leu Gly Gin Lys Val 305 Ala Phe Gin Ser Arg Leu 215 Trp Ile Thr 230 Pro Asp Ser 245 Gly Ser Gly Phe Gin His Leu Ser Asp 295 Cys Leu 205 Ser Giu 220 Ser Arg GJly Gly Gly Gly Ser Asp 285 Asp Tyr 300 INFORMATION FOR SEQ ID NO:672: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Val Lys Thr Thr Leu 225 Gin Ser Asp le Ala 305 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Asn Pro Leu Ile Leu Met Giu Arg Ala Vai Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Giy Gly 115 Thr Ile Asn Pro 130 Met Ala Leu Gin Leu Aia Gin Arg 165 Met Gin Giy Leu 180 Lys Cys Ala Phe 195 Asn Ile Ser Arg 210 Lys Pro Trp Ile Cys Gin Pro Asp 245 Gly Gly Gly Ser 260 Cys Ser Phe Gin 275 Arg Giu Leu Ser 290 Ser Asn TYPE: None DESCRIPTION: SEQ ID NO:672: Ile Asp Asn Leu 55 Cys Lys Val Gly Pro 135 Giu Met Giu Pro Leu 215 Arg Ser Gly Ser Tyr 295 Ile Ile Asn Leu Thr Pro Ala Ser Ser Ala Asp Trp 90 Giu Gin Gly Giu Lys Giu Cys Gly 155 Leu Lys 170 Asn Thr Ser Cys Thr Ser Phe Ser 235 Gly Gly 250 Gly Gly Ser Ser Gin Asp His His Asn Ser Asn Leu Gly Ile Thr Ala Gin Giu Ala Gin Pro Ser 125 Ser His 140 Gly Leu Thr Vai Giu Ile Leu Arg 205 Giu Gin 220 Arg Cys Gly Ser Gly Ser Asp Phe -285 Tyr Pro 300 Leu Lys Giu Asp Leu Ala Glu Ala Ala Pro Phe Arg Giu Gin 110 Gly Pro Lys Ser Trp Arg Ala Gly 175 His Phe 190 Phe Val Leu Val Leu Giu, Giy Gly 255 Gly Thr 270 Ala Val Val Thr INFORMATION FOR SEQ ID NO:673: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS:. single WO 98/17810 b54 PCT/US97/20037 TOPOLOGY: linear Ala 1 Pro Asp Val Leu Arg Lys Tyr Ser Asn 145 Leu Met Lys Asn Lys 225 Cys Gly Cys Arg Ser 305 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100' Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Gin Asp Ala Gin Arg Trp 165 Gin Gly Leu Leu 180 Cys Ala Phe Gin 195 Ile Ser Arg Leu 210 Pro Trp Ile Thr Gin Pro Asp Ser 245 Gly Gly Ser Gly 260 Ser Phe Gin His 275 Glu Leu .Ser Asp 290 Asn Leu TYPE: None DESCRIPTION: SEQ ID NO:673: Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Gly Leu 155 Thr Val Glu Ile Leu Arg Glu Gin 220 Arg Cys 235 Gly Ser Gly Ser Asp Phe Tyr Pro 300 His Leu Lys Ser Glu Asp Leu Leu Ala Ile Glu Ala Ala Ala Pro Glu Phe Arg Gin Glu Gin 110 Ser Gly Pro 125 His Lys Ser Trp Arg Leu Ala Gly Ser 175 His Phe Val 190 Phe Val Gin 205 Leu Val Ala Leu Glu Leu Gly Gly Gly 255 Gly Thr Gin 270 Ala Val Lys 285 Val Thr Val INFORMATION FOR SEQ ID N0:674: SEQUENCE CHARACTERISTICS: LENGTH: 305 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Arg Asn Val Lys His Leu Leu Gin Pro Cys Ile Ile Ile Lys Phe Tyr Leu Val 100 Gly Gly Gly Gly 115 Asn Pro Ser Pro 130 TYPE: None DESCRIPTION: SEQ ID Met Ile Asp Glu Ile 10 Leu Asp Pro Asn Asn 25 Leu Arg Thr Pro Asn Glu Asn Ala Ser Gly 55 Leu Pro Ser Ala Thr Ala Gly Asp Trp Gin 90 Thr Leu Glu Gin Ala 105 Ser Pro Gly Glu Pro 120 Pro Ser Lys Glu Ser 135 NO:674: Ile His Leu Asn Leu Leu Ile Glu Ala Ala Glu Phe Gin Glu Ser Gly His Lys 140 Leu Lys Glu Asp Phe Val Ile Leu Ser Arg Glu Lys Gin Tyr 110 Ile Ser Pro Asn WO 98/1 7810 Ala Giu 145 Trp Met Leu Giu Gin Pro Leu Leu 210 Thr Arg 225 Ser Ser Gly Gly His Ser 6~5 Gly Leu TrP Arg PCT/US97/20037 Val Ile Arg 200 Gin Cys Ser Ser Phe 280 Pro Leu 155 Ser Val Gin Ala Leu 235 Gly Gin Lys Val1 Val Leu Ala Gin Asp Tyr Leu Leu Gin Asp Tyr 290 295 INFORMATION FOR SEQ ID NO:675: SEQUENCE CHARACTERISTICS., LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Aia 1 Pro Asp Vai Leu Arg Lys Tyr Ser Asn 145 Arg Leu Phe Arg Ile 225 Asp Ser Gin Ser Gin 305 (ii) MOLECULE (xi) SEQUENCE Asn Cys Ser Ile 5 Pro Asn Pro Leu Ile Leu Met Giu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Giu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Giu Leu Trp Met Giu Arg 165 Leu Giu Arg Val 180 Gin Pro Pro Pro 195 Leu Leu Gin Giu 210 Thr Arg Gin Asn Ser Ser Thr Leu 245 Gly Gly Gly Ser 260 His Ser Pro Ile 275 Asp Tyr Leu Leu 290 Asp Giu TYPE: None DESCRIPTION: SEQ ID NO:675: Met Ile Leu Asp Arg Asn His Leu 55 Pro Cys 70 Ile Lys Leu Val Gly Giy Ser Pro 135 Cys Gly 150 Leu Lys Asn Thr Ser Cys Thr Ser 215 Phe Ser 230 Gly Gly Giy Gly Ser Ser Gin Asp 295 Ile Leu Pro Ser Al a Trp Gin Giu Giu Arg 155 Gly Phe Val Val1 Giu 235 Gly Thr Val Thr INFORMATION FOR SEQ ID NO:676: WO 98/17810 SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE n Cys Ser Ile o Asn Pro Leu e Leu Met Glu g Ala Val Lys g Asn Leu Gin s Pro Ile Ile u Thr Phe Tyr 100 1 Glu Gly Gly 115 r Ile Asn Pro 0 t Ala Leu Cys t Glu Arg Leu 165 u Arg Val Asn 180 o Pro Pro Ser 195 u Gin Glu Thr 0 g Gin Asn Phe r Thr Leu Gly 245 y Gly Ser Gly 260 r Pro Ile Ser 275 r Leu Leu Gin 0 u Glu DESCRIPTION: SEQ ID NO:676: INFORMATION FOR SEQ ID N0:677: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:677: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly 55 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala WO 98/17810 Tyr Val Giu 115 Ser Thr Ile 130 Asn Met Ala 145 Arg Leu Val Gly Ser Lys Phe Val Thr 195 Val Gin Thr 210 Val Ala Leu 225 Giu Leu Gin Gly Gly Ser Thr Gin Asp 275 Val Lys Ile 290 Thr Val Ala Gly Gly Gly Pro 135 Gin Arg .Leu Phe Arg 215 Ile Asp Ser Gin Ser 295 6V~ 105 Ser Pro 120 Pro Ser Asp Gi Trp Met Leu Glu 185 Gin Pro 1 200 Leu. Leu Thr Arg Ser Ser Gly Gly( 265 His Ser 1 280 Asp Tyr I Giu Giu Leu 155 Arg Val Pro Giu Asn 235 Leu Ser Ile Leu 110 Ser Gly 125 His Lys Gly Gly Lys Thr Thr Glu 190 Cys Leu 205 Ser Giu Ser Arg Gly Gly Gly Gly 270 Ser Asp 285 Asp Tyr PCTIUS97/20037 Pro Ile Ser Pro Leu Trp 160 Val Ala 175 Ile His Arg Phe Gin Leu Cys Leu 240 Ser Giy 255 Ser Gly Ser Ala Pro Val INFORMATION FOR SEQ ID NO:678: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRAN~DEDNESS; single TOPOLOGY: linear (iMOLECULE (Xi) SEQUENCE Ala Asn Cys Ser Ile Pro Pro Asp Ile Val Arg Leu Arg Arg His Lys Leu Tyr Val Ser Thr 130 Asn Met 145 Leu Ala Met Gin Lys Cys Asn Ile 210 Lys Pro 225 Cys Gin Gly Gly Cys Ser Arg Giu TYPE: None DESCRIPTION: SEQ ID NO:678: Met Ile Asp Gu Ile Ile His Leu Asp Pro Asn Asn Leu Asn Arg Asn Leu Arg Thr Pro Aso His Leu Giu Asn Ala Ser Gly 55 Pro Cys Leu Pro Ser Aia Thr 70 Ile Lys Ala Gly Asp Trp Gin Leu Val Thr Leu Glu Gin Ala 105 Gly Giy Ser Pro Giy Giu Pro 120 Ser Pro Pro Ser Lys Giu Ser 135 140 Glu Giu Leu Cys Gly Gly Leu 150 155 Met Giu Arg Leu Lys Thr Val 170 Giu Arg Val Asn Thr Giu Ile 185 Pro Pro Pro Ser Cys Leu Arg 200 Leu Arg Giu Thr Ser Glu Gin 215 220 Arg Gin Asn Phe Ser Arg Cys 230 235 Ser Thr Leu Gly Gly Giy Ser 250 Gly Gly Ser Gly Gly Gly Ser 265 Ser Pro Ile Ser Ser Asp Phe 280 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala WO98/17810 09 290 295 Ser Asn Leu 305 INFORMATION FOR SEQ ID NO:679: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None PCT/US97/20037 (xi) SEQUENCE Asn Cys Ser Ile Pro Asn Pro Leu Ile Leu Met Glu Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Leu Cys Met Glu Arg Leu 165 Glu Arg Val Asn 180 Pro Pro Pro Ser 195 Leu Gin Glu Thr 210 Arg Gin Asn Phe Ser Thr Leu Gly 245 Gly Gly Ser Gly 260 Ser Pro Ile Ser 275 Tyr Leu Leu Gin 290 Glu Glu DESCRIPTION: SEQ ID N0:679: Met Ile Asp Glu Ile 10 Leu Asp Pro Asn Asn 25 Arg Asn Leu Arg Thr His Leu Glu Asn Ala 55 Pro Cys Leu Pro Ser Ile Lys Ala Gly Asp 90 Leu Val Thr Leu Glu 105 Gly Gly Ser Pro Gly 120 Ser Pro Pro Ser Lys 135 Gly Gly Leu Trp Arg 150 Lys Thr Val Ala Gly 170 Thr Glu Ile His Phe 185 Cys Leu Arg Phe Val 200 Ser Glu Gin Leu Val 215 Ser Arg Cys Leu Glu 230 Gly Gly Ser Gly Gly 250 Gly Gly Ser Gly Thr 265 Ser Asp Phe Ala Val 280 Aso Tvr Pro Val Thr Ile His Leu Asn Pro Asn Ser Gly Ala Thr Trp Gin Gin Ala Glu Pro Glu Ser 140 Leu Val 155 Ser Lys Val Thr Gin Thr Ala Leu 220 Leu Gin 235 Gly Ser Gin Asp Lys Ile Val Ala 300 Leu Lys Glu Asp Leu Ala Glu Ala Ala Pro Phe Arg Glu Gin 110 Gly Pro Lys Ser Ala Gin Gln Gly 175 Cys Ala 190 Ile Ser Pro Trp Arg Pro Gly Gly 255 Ser Phe 270 Glu Leu Asn Leu INFORMATION FOR SEQ ID NO:680: SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:680: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 25 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 40 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser 55 WO 98/17810 Arg Leu Ile Thr Asp Ser Ser Gly Gin His 130 Ser Asp 145 Gly Gly Pro Ser Cys Ser Asn Pro 210 Leu Met 225 Ala Val Asn Leu Pro Ile Thr Phe 290 Gin L Cys L 9 Ser G 105 Ser G Phe A Pro V Ser G His L, 185 Ile H.

Leu Ak Pro Ak Ser G 21 Ala T] 265 Trp G'.

Gin A' Ala Leu Giy Gin Lys 140 Val1 Ile Pro Leu Giu 220 Leu Giu Ala Phe Giu 300 Lys Pro Cys Gin Giy Gly 110 Cys Ser Arg Giu Val Giu Thr Ile 175 Met Ala 190 Arg Pro Met Asp Phe Val Ile Leu 255 Ser Arg 270 Giu Lys Gin PCTIUS97/20037 Trp Pro Gly Phe Leu Gly 160 Asn Asn Pro Ile Arg 240 Arg His Leu INFORMATION FOR SEQ ID NO: 681: SEQUENCE CHARACTERISTICS: LENGTH: 296 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala Arg Leu Phe Arg Ile Asp Gin Lys Val 145 Glu Glu Giu Asn Arg 225 Asn Pro (xi) SEQUENCE Asp Giu Giu Leu Trp Met GuArg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Giu Thr Arg Gin Asn Ser Ser Thr Leu 100 Asp Cys Ser Phe 115 Ile Arg Giu Leu 130 Ala Ser Asn Leu Pro Ser Gly Pro 165 Ser His Lys Ser 180 Ile Ile His His 195 Asn Leu Asn Ser 210 Thr Pro Asn Leu Ala Ser Gly Ile 245 Ser Ala Thr Ala 260 DESCRIPTION: SEQ ID NO:681: Arg Leu Val Leu WO 98/17810 PCT/US97/20037 Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 275 280 285 Leu Glu Gin Ala Gin Glu Gin Gin 290 295 INFORMATION FOR SEQ ID NO:682: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Thr 115 Asp Phe Ala Val 130 Tyr Pro Val Thr Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Glu Arg Asn Leu Lys His Leu Glu 245 Gin Pro Cys Leu 260 Ile Ile Lys Ala 275 Tyr Leu Val Thr 290 TYPE: None DESCRIPTION: SEQ ID N0:682: Leu Trp 10 Val Ala Ile His Arg Phe Gin Leu Cys Leu 90 Ser Gly 105 Ser Phe Glu Leu Asn Leu Gly Pro 170 Lys Ser 185 His His Asn Ser Asn Leu Gly Ile 250 Thr Ala 265 Gin Glu Ala Gin Arg Leu Gly Ser Phe Val Val Gin Val Ala Glu Leu Gly Gly Gin His Ser Asp 140 Gin Tyr 155 Ile Ser Pro Asn Leu Lys Glu Asp 220 Leu Ala 235 Glu Ala Ala Pro Phe Arg Glu Gin 300 Ala Gin Gin Gly Cys Ala Ile Ser Pro Trp Gin Pro Gly Gly Ile Ser Leu Gin Gly Gly 160 Asn Pro 175 Asn Cys Pro Asn Ile Leu Arg Ala 240 Arg Asn 255 His Pro Leu Thr INFORMATION FOR SEQ ID N0:683: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:683: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 10 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 25 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp WO 98/17810 664 PCT/US97/20037 70 75 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 Asp Ser.Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 INFORMATION FOR SEQ ID NO:684: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:684: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 1 5 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 25 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 40 Phe Gin Pro Pro Pro Ser Cys Leu Arg Leu Val Gin Thr Asn Ile Ser 55 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 70 75 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro WO 98/17810 (ploL PCT/US97/20037 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 INFORMATION FOR SEQ ID NO:685: SEQUENCE CHARACTERISTICS: LENGTH: 307.amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Gly Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Ser 115 His Ser Pro Ile 130 Asp Tyr Leu Leu Tyr Val Glu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Val Arg 245 Ala Ile Leu Arg 260 Pro Ser Arg His 275 Arg Glu Lys Leu 290 Gin Gin TYPE: None DESCRIPTION: SEQ ID NO:685: Gly Leu Trp Arg Thr Val Glu Ile 40 Leu Arg Glu Gin Arg Cys Gly Ser 105 Gly Ser 120 Asp Phe Tyr Pro Gly Ser Pro Pro 185 Ile Met 200 Leu Leu Glu Arg Lys His Gin Pro 265 Ile Ile 280 Tyr Leu Ala Gly His Phe Phe Val Leu Val Leu Glu Gly Gly Gly Thr Ala Val Val Thr 155 Pro Gly 170 Ser Lys Ile Asp Asp Pro Asn Leu 235 Leu Glu 250 Cys Leu Lys Ala Val Thr Leu Val Ser Lys Val Thr Gin Thr Ala Leu Leu Gin Gly Ser Gin Asp 125 Lys Ile 140 Val Ala Glu Pro Glu Ser Glu Ile 205 Asn Asn 220 Arg Thr Asn Ala Pro Ser Gly Asp 285 Leu Glu 300 INFORMATION FOR SEQ ID NO:686: SEQUENCE CHARACTERISTICS: LENGTH: 302 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:686: Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 10 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu 25 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 40 WO 98/17810 3 PCTIUS97/20037 Pro Gin Gin Thr Giy Ala Gly 160 Asn Asn Pro Ile Arg 240 Arg His Leu INFORMATION FOR SEQ ID NO:687: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Ala Ser Asn Leu 1 5 Leu Val Leu Ala Gin Ser Lys Met Gin Gly Val Thr Lys Cys Ala Gin Thr Asn Ile Ser Ala Leu Lys Pro Trp Leu Gin Cys Gin Pro 100 Gly Ser Gly Giy Gly 115 His Ser Pro Ile Ser 130 Asp Tyr Leu Leu Gin 145 Gly Gly Ser Pro Gly 165 Ser Pro Pro Ser Lys 180 Ser Ile Met Ile Asp 195 Pro Leu Leu Asp Pro 210 Met Giu Arg Asn Leu 225 Val Lys His Leu Giu 245 TYPE: None DESCRIPTION: SEQ ID NO:687: Asp Giu Trp Met Leu Glu 40 Gln Pro Leu Leu Thr Arg Ser Ser Gly Gly 120 Asp Phe 135 Tyr Pro Pro Ser Ser His Ile Ile 200 Asn Leu 215 Thr Pro Ala Ser Gly Leu Thr Val Giu Ile Leu Arg Glu Gin Arg Cys Gly Ser 110 Cys Ser 125 Arg Glu Val Glu Thr Ile Met Ala 190 Arg Pro 205 Met Asp Phe Val Ile Leu WO 98/17810 Leu Gin Pro Cys Leu 260 Ile Ile Ile Lys Ala 275 Phe Tyr Leu Val Thr 290 604 PCT/US97/20037 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 265 270 Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 280 285 Leu Glu Gin Ala Gin Glu Gin Gin 295 300 INFORMATION FOR SEQ ID NO:688: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Val Ala Gly Ser Ile His Phe Val Arg Phe Val Gin Gin Leu Val Ala Cys Leu Glu Leu Ser Gly Gly Gly Ser Phe Gin His 100 Glu Leu Ser Asp 115 Asn Leu Gin Asp 130 Ala Gin Arg Trp Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Glu Arg Asn Leu Lys His Leu Glu 245 Gin Pro Cys Leu 260 Ile Ile Lys Ala 275 Tyr Leu Val Thr 290 TYPE: None DESCRIPTION: SEQ ID NO:688: Lys Met Gin Thr Lys Cys Thr Asn Ile Leu Lys Pro 55 Gin Cys Gln Ser Gly Gly Ser Pro Ile Tyr Leu Leu 120 Glu Glu Leu 135 Met Glu Arg 150 Glu Pro Ser Glu Ser His Glu Ile Ile 200 Asn Asn Leu 215 Arg Thr Pro 230 Asn Ala Ser Pro Ser Ala Gly Asp Trp 280 Leu Glu Gin 295 Glu Pro Leu Arg Ser Gly Phe Pro Leu 140 Tyr Ser Asn Lys Asp 220 Ala Ala Pro Arg Gin 300 INFORMATION FOR SEQ ID NO:689: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:689: Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 10 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 25 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 40 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu WO 98/17810 WO 98/ 7810PCTUS97/20037 Thr Leu Gly Thr Ala Val Val Thr Trp Arg Ala Gly 155 Pro Ilie 170 Ser Pro His Leu Ser Giu Leu Leu 235 Ile Giu 250 Ala Ala Giu Phe Gin Giu Giy Gly Asp Cys Ile Arg 110 Ala Ser 125 Vai Leu Val Giu Thr Ile Met Ala 190 Arg Pro 205 Met Asp Phe Val Ile Leu Ser Arg 270 Giu Lys 285 Gln Ser Giy Ser Phe Giu Leu Asn Leu Ala Gin Gly Gly 160 Asn Pro 175 Asn Cys Pro Asn Ile Leu Arg Ala 240 Arg Asn 255 His Pro Leu Thr INFORMATION FOR SEQ ID NO:690: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Pro Pro Ser Cys Gin Giu Thr Ser Gin Asn Phe Ser Thr Leu Giy Gly Gly Thr Gin Asp Ala Val Lys Ile Val Thr Vai Aia 100 Trp Arg Leu Val 115 Ala Giy Ser Lys 130 His Phe Vai Thr Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Giu Arg Asn Leu Lys His Leu Giu 245 Gin Pro Cys Leu TYPE: None DESCRIPTION: SEQ ID NO:690: Leu Arg Phe Val Gin Thr Asn WO 98/17810 PCT/US97/20037 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 INFORMATION FOR SEQ ID NO:691: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Asn Ile Ser Leu Lys Pro Trp Gin Cys Gin Pro Ser Gly Gly Gly Ser Pro Ile Ser Tyr Leu Leu Gin Glu Glu Leu Cys 100 Met Glu Arg Leu 115 Glu Arg Val Asn 130 Pro Pro Pro Ser Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Glu Arg Asn Leu Lys His Leu Glu 245 Gin Pro Cys Leu 260 Ile Ile Lys Ala 275 Tyr Leu Val Thr 290 DESCRIPTION: SEQ ID NO:691: Arg Leu Leu Gin Glu Thr Ser Ile Thr Arg Gin Asn Phe Ser Asp Ser Ser Thr Leu Gly Gly Ser Gly Gly Gly Thr Gin Asp 55 Ser Asp Phe Ala Val Lys Ile Asp Tyr Pro Val Thr Val Ala Gly Gly Leu Trp Arg Leu Val 105 Lys Thr Val Ala Gly Ser Lys 120 Thr Glu Ile His Phe Val Thr 135 140 Cys Leu Arg Phe Val Gin Tyr 150 155 Glu Pro Ser Gly Pro Ile Ser 170 Glu Ser His Lys Ser Pro Asn INFORMATION FOR SEQ ID N0:692: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:692: Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 10 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 25 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 40 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 55 WO 98/17810 Cys Ser Arg Giu Ser Asn Leu Ala Met Gin 130 Lys Cys 145 Gly Giy Ser Pro Ser Ile Pro Leu 210 Met Giu 225 Val Lys Leu Gin Ile Ile Phe Tyr 290 Ser Pro 70 Tyr Leu Giu Giu Met Giu Giu Arg 135 Pro Pro 150 Giu Pro Giu Ser Giu Ile Asn Asn 215 Arg Thr 230 Asn Ala Pro Ser Giy ASP Leu Giu 295 Ser Ser Gin Asp Cys Gly .105 Leu Lys Asn Thr Ser Cys Gly Pro 170 Lys Ser 185 His His Asn Ser Asn Leu Gly Ile 250 Thr Ala 265 Gin Glu Ala Gin Phe Ala Pro Val Leu Trp Val Ala 125 Ile His 140 Tyr Val Ser Thr Asn Met Lys Arg 205 Asp Met 220 Ala Phe Ala Ile Pro Ser Arg Glu 285 Gin Gln 300 PCT[US97/20037 Ile Ala Vai Lys Thr Gly 160 Pro Cys Asn Leu Aia 240 Asn Pro Thr INFORMATION FOR SEQ ID NO:693: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: singie TOPOLOGY: linear Al a 1 Val Lys Thr Thr Leu Gin Ser Asp Ile 145 Ala Ile Pro Leu Giu 225 Leu Giu (ii) MOLECULE (xi) SEQUENCE Ser Asn Leu Gin 5 Leu Aia Gin Arg Met Gin Gly Leu Lys Cys Ala Phe Asn Ile Ser Arg Lys Pro Trp Ile Cys Gin Pro Asp 100 Giy Gly Giy Ser 115 Cys Ser Phe Gin 130 Arg Glu Leu Ser Tyr Val Giu Giy 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Vai Aig 245 Aia Ile Leu Arg 260 TYPE: None DESCRIPTION: SEQ ID Asp GiU Giu Leu Cys 10 Trp Met Glu Arg Leu 25 Leu Giu Arg Val Asn 40 Gin Pro Pro Pro Ser 55 Leu Leu Gin Giu Thr 70 Thr Arg Gin Asn Phe 90 Ser Ser Thr Leu Giy 105 Giy Gly Gly Ser Gly 120 His Ser Pro Ile Ser 135 Asp Tyr Leu Leu Gin 150 Gly Gly Giy Ser Pro 170 Pro Ser Pro Pro Ser 185 Cys Ser Ile Met Ilie 200 Asn Pro Leu Leu Asp 215 Leu Met Giu Arg Asn 230 Aia Vai Lys His Leu 250 Asn Leu Gln Pro Cys .265 NO: 693: Gly Gly Leu Lys Thr Val Thr Giu Ile Cys Leu Arg Ser Giu Gin 75 Ser Arg Cys Giy Gly Ser Giy Giy Ser 125 Ser Asp Phe 140 Asp Tyr Pro 155 Gly Giu Pro Lys Glu Ser Asp Giu Ile 205 Pro Asn Asn 220 Leu Arg Thr 235 Giu Asn Aia Leu Pro Ser Arg Leu Gly Ser Phe Val Val Gin Vai Ala Giu Leu Giy Gly Thr Gin Val Lys Thr Val 160 Giy Pro 175 Lys Ser His His Asn Ser Asn Leu 240 Gly Ile 255 Thr Ala WO 98/17810 PCT/US97/20037 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 INFORMATION FOR SEQ ID NO:694: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Leu Met Lys Asn Lys Cys Gly Cys Arg 145 Ser Ile Pro Leu Glu 225 Leu Glu Ala Phe Glu 305 Ala 1 Ala Gin (ii) MOLECULE (xi) SEQUENCE Asn Leu Gin Asp 5 Ala Gin Arg Trp Gin Gly Leu Leu Cys Ala Phe Gin Ile Ser Arg Leu Pro Trp Ile Thr Gin Pro Asp Ser 100 Gly Gly Ser Gly 115 Ser Phe Gin His 130 Glu Leu Ser Asp Tyr Val Glu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Val Arg 245 Ala Ile Leu Arg 260 Pro Ser Arg His 275 Arg Glu Lys Leu 290 Gin Gin E: None :RIPTION: SEQ ID NO:694: Glu Glu Leu Cys Met Glu Arg Leu 25 Glu Arg Val Asn 40 Pro Pro Pro Ser 55 Leu Gin Glu Thr 70 Arg Gin Asn Phe Ser Thr Leu Gly 105 Gly Gly Ser Gly 120 Ser Pro Ile Ser 135 Tyr Leu Leu Gin 150 Gly Gly Gly Ser Pro Ser Pro Pro 185 Cys Ser Ile Met 200 Asn Pro Leu Leu 215 Leu Met Glu Arg 230 Ala Val Lys His Asn Leu Gin Pro 265 Pro Ile Ile Ile 280 Thr Phe Tyr Leu 295 Gly Gly 10 Lys Thr Thr Glu Cys Leu Ser Glu Ser Arg 90 Gly Gly Gly Gly Ser Asp Asp Tyr 155 Pro Gly 170 Ser Lys Ile Asp Asp Pro Asn Leu 235 Leu Glu 250 Cys Leu Lys Ala Val Thr Leu Trp Val Ala Ile His Arg Phe Gin Leu Cys Leu Ser Gly Ser Gly 125 Phe Ala 140 Pro Val Glu Pro Glu Ser Glu Ile 205 Asn Asn 220 Arg Thr Asn Ala Pro Ser Gly Asp 285 Leu Glu 300 Arg Leu Gly Ser Phe Val Val Gin Val Ala Glu Leu Gly Gly 110 Thr Gin Val Lys Thr Val Ser Gly 175 His Lys 190 Ile His Leu Asn Pro Asn Ser Gly 255 Ala Thr 270 Trp Gin Gin Ala INFORMATION FOR SEQ ID NO:695: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:695: Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 5 10 Gin Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 25 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys WO 98/17810 PCT/US97/20037 Pro Pro Gin Glu Gin Asn Thr Leu Gly Ser Pro Ile 135 Leu Leu 150 Gly Gly Pro Ser Cys Ser Asn Pro 215 Leu Met 230 Ala Val Asn Leu Pro Ile Thr Phe 295 Gin Thr Ala Leu Leu Gin Gly Ser 110 Gin Asp Lys Ile Val Ala Ser Gly 175 His Lys 190 Ile His Leu Asn Pro Asn Ser Gly 255 Ala Thr 270 Trp Gin Gin Ala INFORMATION FOR SEQ ID N0:696: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Gin Asp Glu Glu 1 Gin Arg Trp Met Glu Gly Leu Leu Glu Arg Ala Phe Gln Pro Pro Ser Arg Leu Leu Gin Trp Ile Thr Arg Gin Pro Asp Ser Ser Thr 100 Gly Ser Gly Gly Gly 115 Phe Gin His Ser Pro 130 Leu Ser Asp Tyr Leu 145 Leu Tyr Val Glu Gly 165 Ile Ser Thr Ile Asn 180 Pro Asn Met Ala Asn 195 Leu Lys Arg Pro Pro 210 Glu Asp Met Asp Ile DESCRIPTION: SEQ ID NO:696: Cys Leu Asn Ser Thr Phe Gly Gly Ser 135 Gin Gly Ser Ser Pro 215 Met Trp Ala His Phe Leu Leu Gly Gly Ala Val 155 Gly Lys Asp Pro Leu WO 98/17810 225 Leu Ala Phe Glu Ala Ile Ala Pro Ser 275 Phe Arg Glu 290 Glu Gin Gin 305 (01o 230 Val Arg Ala Val Lys His 245 Leu Arg Asn Leu Gin Pro 260 265 Arg His Pro Ile Ile Ile 280 Lys Leu Thr Phe Tyr Leu 295 235 Leu Glu 250 Cys Leu Lys Ala Val Thr Asn Ala Ser Gly 255 Pro Ser Ala Thr 270 Gly Asp Trp Gin 285 Leu Glu Gin Ala 300 PCT/US97/20037 240 Ile Ala Glu Gin INFORMATION FOR SEQ ID N0:697: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Glu Glu Leu Cys Met Glu Arg Leu Glu Arg Val Asn Pro Pro Pro Ser Leu Gln Glu Thr Arg Gln Asn Phe Ser Thr Leu Gly 100 Gly Gly Ser Gly 115 Ser Pro Ile Ser 130 Tyr Leu Leu Gin Tyr Val Glu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Val Arg 245 Ala Ile Leu Arg 260 Pro Ser Arg His 275 Arg Glu Lys Leu 290 Gin Gin TYPE: None DESCRIPTION: SEQ ID NO:697: Gly Leu Trp Leu Ser Val Gin Ala Leu Gly Gin Lys Val 155 Gly Lys Asp Pro Leu 235 Glu Leu Ala Thr Leu Ala Gin Met Gin Gly Lys Cys Ala Asn Ile Ser Lys Pro Trp Cys Gin Pro Gly Gly Gly 110 Cys Ser Phe 125 Arg Glu Leu Ser Asn Leu Pro Ser Gly 175 Ser His Lys 190 Ile Ile His 205 Asn Leu Asn Thr Pro Asn Ala Ser Gly 255 Ser Ala Thr 270 Asp Trp Gin 285 Glu Gin Ala INFORMATION FOR SEQ ID N0:698: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:698: WO 98/17810 Ala Lei

I

Glu Ar( Arg Va' Pro Pr( Gin Gix Gin Asi Thr Let Gly Se] Pro 1I( 13( Leu Let 145 Giu Tyi Ile Se] Pro Asr Leu Ly] 21( Giu Asj 225 Leu Alh Giu A12 Ala Prc Phe Arc 29( Giu Glr 305 Trp Ala His Phe Leu Leu Gly Gly Ala 135 Val G ly Ser Ser Pro 215 Met Val1 Leu Ile Phe 295 614 Leu Ser Val Gin Ala Leu Gly 105 Gin Lys Val Ser Pro 185 Met Leu Arg His Pro 265 Ile Leu PCTfUS97/20037 Val Lys Thr Thr Leu Gin Ser Asp Ile Ala Pro 170 Ser Ile Asp Asn Leu 250 Cys Lys Val INFORMATION FOR SEQ ID NO:699: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala Glu Arg Pro Gin Gln Thr Giy Pro Leu 145 Glu Ile (ii) MOLECULE (xi) SEQUENCE Leu Cys Gly Gly Arg Leu Lys Thr Val Asn Thr Giu Pro Ser Cys Leu Glu Thr Ser Giu Asn Phe Ser Arg Leu Gly Giy Gly 100 Ser Gly Giy Gly 115 Ile Ser Ser Asp 130 Leu Gln Asp Tyr Tyr Val Giu Gly 165 Ser Thr Ile Asn 180 TYPE: None DESCRIPTION: SEQ ID NO:699: Trp Ala His Phe Leu Leu Gly Gly Ala 135 Val Gly Ser Val Lys Thr Thr Leu Gin Ser Asp Ile Ala Pro 170 Ser WO 98/17810 Pro Asn Met 195 PCT1US97/20037 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile 200 205 Asn Asn 220 Arg Thr Asn Ala Pro Ser Gly Asp 285 Leu Glu 300 Ile His Leu Asn Pro Asn Ser Gly 255 Ala Thr 270 Trp Gin Gin Ala INFORMATION FOR SEQ ID NO:700: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Leu Cys Gly Gly Arg Leu Lys Thr Val Asn Thr Glu Pro Ser Cys Leu Glu Thr Ser Glu Asn Phe Ser Arg Leu Gly Gly Gly 100 Ser Gly Gly Gly 115 Ile Ser Ser Asp 130 Leu Gin Asp Tyr Tyr Val Glu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Val Arg 245 Ala Ile Leu Arg 260 Pro Ser Arg His 275 Arg Glu Lys Leu 290 Gin Gin TYPE: None DESCRIPTION: SEQ ID NO:700: Gin Arg Gly Leu Ala Phe Ser Arg Trp Ile Pro Asp Gly Ser 110 Phe Gin 125 Leu Ser Leu Gin Pro Ser Ser His 190 Ile Ile 205 Asn Leu Thr Pro Ala Ser Ser Ala 270 Asp Trp 285 Glu Gin INFORMATION FOR SEQ ID NO:701: SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 -3- (ii) MOLECULE (xi) SEQUENCE Ser Lys Met Gin Val Thr Lys Cys Gin Thr Asn Ile Ala Leu Lys Pro Leu Gin Cys Gin Gly Ser Gly Gly His Ser Pro Ile 100 Asp Tyr Leu Leu 115 Asp Glu Glu Leu 130 Trp Met Glu Arg Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Glu Arg Asn Leu Lys His Leu Glu 245 Gin Pro Cys Leu 260 Ile Ile Lys Ala 275 Tyr Leu Val Thr 290 TYPE: None DESCRIPTION: SEQ ID NO:701: Glu Arg Pro Pro Leu Gin Arg Gin Ser Thr Gly Gly Phe Ala 105 Pro Val Leu Trp Val Ala Gly Pro 170 Lys Ser 185 His His Asn Ser Asn Leu Gly Ile 250 Thr Ala 265 Gin Glu Ala Gin INFORMATION FOR SEQ ID NO:702: SEQUENCE CHARACTERISTICS: LENGTH: 315 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Gin Asp Asp Glu Arg Trp Met Glu Leu Leu Glu Arg Phe Gin Pro Pro Arg Leu Leu Gin Ile Thr Arg Gin Asp Ser Ser Thr 100 Ser Gly Gly Gly 115 Ser Gly Thr Gin 130 Phe Ala Val Lys Pro Val Thr Val TYPE: None DESCRIPTION: SEQ ID NO:702: Leu Cys Gly Arg Leu Lys Val Asn Thr Pro Ser Cys Glu Thr Ser Asn Phe Ser Leu Gly Gly Ser Gly Gly 120 Asp Cys Ser 135 Ile Arg Glu 150 Ala Ser Asn Leu 10 Val Ile Arg Gin Cys 90 Ser Ser Gin Ser Tyr Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Gly Gly Gly Gly Ser Ser Gin Asp 160 Gly Gly WO 98/17810 b4 PCT/US97/20037 Ser Thr Asn Met Lys Arg Asp Met 235 Ala Phe 250 Ala Ile Pro Ser Arg Glu Gin Gin 315 NO:703: INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 301 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Gin Gly Ala Ser Trp Pro Ala Ser Gin 145 Gly Ser Ser Pro Met 225 Val Leu Ile Phe (ii) MOLECULE (xi) SEQUENCE Gin Asp Glu Glu Arg Trp Met Glu Leu Leu Glu Arg Phe Gin Pro Pro Arg Leu Leu Gin Ile Thr Arg Gin Asp Ser Ser Thr 100 Thr Ala Pro Thr 115 Ser Asp Phe Ala 130 Asp Tyr Pro Val Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Ile Met Ile Asp 195 Leu Leu Asp Pro 210 Glu Arg Asn Leu Lys His Leu Glu 245 Gin Pro Cys Leu 260 Ile Ile Lys Ala 275 Tyr Leu Val Thr 290 TYPE: None DESCRIPTION: SEQ ID NO:703: INFORMATION FOR SEQ ID NO:704: SEQUENCE CHARACTERISTICS: LENGTH: 307 amino acids TYPE: amino acid STRANDEDNESS: single WO 98/17810 TOPOLOGY: linear of5 PCT/US97/20037 Ala 1 Gin Gly Ala Ser Trp Pro Ala Phe Leu 145 Leu Ile Pro Leu Glu 225 Leu Glu Ala Phe Glu 305 (ii) MOLECULE (xi) SEQUENCE Gin Asp Glu Glu 5 Arg Trp Met Glu Leu Leu Glu Arg Phe Gin Pro Pro Arg Leu Leu Gin Ile Thr Arg Gin Asp Ser Ser Thr 100 Thr Ala Pro Thr 115 Gin His Ser Pro 130 Ser Asp Tyr Leu Tyr Val Glu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Asn 195 Lys Arg Pro Pro 210 Asp Met Asp Ile Ala Phe Val Arg 245 Ala Ile Leu Arg 260 Pro Ser Arg His 275 Arg Glu Lys Leu 290 Gin Gin TYPE: None DESCRIPTION: SEQ ID Leu Cys Gly Gly Leu Arg Leu Lys Thr Val Val Asn Thr Glu Ile Pro Ser Cys Leu Arg 55 Glu Thr Ser Glu Gin 70 Asn Phe Ser Arg Cys Leu Pro Pro Pro Trp 105 Ala Gly Gin Pro Pro 120 Ile Ser Ser Asp Phe 135 Leu Gin Asp Tyr Pro 150 Gly Gly Gly Ser Pro 170 Pro Ser Pro Pro Ser 185 Cys Ser Ile Met Ile 200 Asn Pro Leu Leu Asp NO:704: Trp Arg Ala Gly His Phe Phe Val Leu Val Leu Glu Ser Pro Leu Thr Ala Val 140 Val Thr 155 Gly Glu Lys Glu Asp Glu Pro Asn 220 Leu Arg 235 Glu Asn Leu Pro Ala Gly Thr Leu 300 INFORMATION FOR SEQ ID NO:705: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID Thr Pro Leu Gly Pro Ala Ser Ser Leu Ser Leu Glu Gin Val Arg Lys Ile Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu 40 Leu Leu Gly His Ser Leu Gly Ile Pro 55 Pro Ser Gin Ala Leu Gin Leu Ala Gly Gly Leu Phe Leu Tyr Gin Gly Leu Leu Pro Glu Leu Gly Pro Thr Leu Asp Thr 100 105 Phe Ala Thr Thr Ile Trp Gin Gin Met 115 120 Ala Leu Gin Pro Thr Gin Gly Ala Met 130 135 NO: 705: Pro Gin Gly Asp Cys His Trp Ala Cys Leu Gin Ala Leu Gin Glu Glu Pro Ala 140 WO 98/17810 WO 9817810PCTIUS97/20037 Phe 145 Phe Val Thr Met Gin 225 Gly Ala Ser Trp Pro 305 Gly Phe Leu Leu Gin Arg Arg Ala Leu Giu Ile Ala 210 Arg Leu Phe Arg Ile 290 Asp Ser Gin Ser Gin 370 Vai Ser 165 Gly Giy 180 Pro Ser Glu Giu Met Giu Giu Arg 245 Pro Pro 260 Leu Gin Arg Gin Ser Thr Giy Giy 325 Ser Pro 340 Tyr Leu Giy Val Leu Val Arg Vai Leu Arg 170 Ser Pro Gly Giu 185 Pro Ser Lys Giu 200 Cys.Gly Giy Leu 215 Leu Lys Thr Val Asn Thr Giu Ile 250 Ser Cys Leu Arg 265 Thr Ser Giu Gin 280 Phe Ser Arg Cys 295 Giy Gly Gly Ser Gly Giy Giy Ser 330 Ser Ser Asp Phe 345 Gin Asp Tyr Pro 360 INFORMATION FOR SEQ ID NO:706: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Aia

I

Lys Gin Vali Cys Ser Ser Asp Pro Phe 145 Phe Val1 Thr Met Val 225 Lys Thr (xi) SEQUENCE Thr Pro Leu Gly 5 Ser Leu Giu Gin Giu Lys Leu Cys Leu Leu Giy His Pro Ser Gin Ala Gly Leu Phe Leu Pro Giu Leu Gly i00 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gln Arg Arg Aia Leu Giu Val Ser 165 Giu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Asn Leu Gin 210 Leu Aia Gin Arg Met Gin Giy Leu 245 Lys Cys Aia Phe 260 DESCRIPTION: SEQ ID NO:706: Ala Ser Arg Lys Thr Tyr 40 Leu Giy 55 Gin Leu Gin Giy Thr Leu Trp Gin 120 Gin Gly 135 Giy Vai Arg Val Ser Pro Pro Ser 200 Giu Giu 215 Met Glu Glu Arg Pro Pro Gin Ser Asp Gly His Pro Ala Pro Leu Ser Ala Leu Gin Leu Glu Leu 125 Ala Phe 140 Ser His Leu Ala Ser Gly His Lys 205 Gly Leu 220 Thr Val Giu Ile Leu Arg WO 98/17810 Ile Asn Leu Lys 290 Gin Cys 305 Ser Gly Asp Cys Ile Arg Ala Ser 370 Gin Glu 280 Gin Asn Thr Leu Gly Ser Pro Ile 345 Leu Leu 360 PCT/US97/20037 INFORMATION FOR SEQ ID NO:707: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Thr Pro Leu Gly 1 5 Lys Ser Leu Glu Gin Gin Glu Lys Leu Cys Val Leu Leu Gly His Cys Pro Ser Gin Ala Ser Gly Leu Phe Leu Ser Pro Glu Leu Gly 100 Asp Phe Ala Thr Thr 115 Pro Ala Leu Gin Pro 130 Phe Gin Arg Arg Ala 145 Phe Leu Glu Val Ser 165 Val Glu Gly Gly Gly 180 Thr Ile Asn Pro Ser 195 Met Ala Pro Pro Ser 210 Leu Leu Gin Glu Thr 225 Thr Arg Gin Asn Phe 245 Ser Ser Thr Leu Gly 260 Gly Gly Gly Ser Gly 275 His Ser Pro Ile Ser 290 Asp Tyr Leu Leu Gin 305 Asp Glu Glu Leu Cys 325 Trp Met Glu Arg Leu 340 Leu Glu Arg Val Asn 355 Gin Pro 370 DESCRIPTION: SEQ ID NO:707: Pro Ala Ser Ser Leu Pro Gin 10 Val Arg Lys Ile Gin Gly Asp 25 Ala Thr Tyr Lys Leu Cys His Ser Leu Gly Ile Pro Trp Ala 55 Leu Gin Leu Ala Gly Cys Leu 70 Tyr Gin Gly Leu Leu Gin Ala 90 Pro Thr Leu Asp Thr Leu Gin 105 Ile Trp Gin Gin Met Glu Glu 120 Thr Gin Gly Ala Met Pro Ala 135 140 Gly Gly Val Leu Val Ala Ser 150 155 Tyr Arg Val Leu Arg His Leu 170 Gly Ser Pro Gly Glu Pro Ser 185 Pro Pro Ser Lys Glu Ser His 200 Cys Leu Arg Phe Val Gin Thr 215 220 Ser Glu Gin Leu Val Ala Leu 230 235 Ser Arg Cys Leu Glu Leu Gin 250 Gly Gly Ser Gly Gly Gly Ser 265 Gly Gly Ser Gly Thr Gin Asp 280 Ser Asp Phe Ala Val Lys Ile 295 300 Asp Tyr Pro Val Thr Val Ala 310 315 Gly Gly Leu Trp Arg Leu Val 330 Lys Thr Val Ala Gly Ser Lys 345 Thr Glu Ile His Phe Val Thr 360 Phe Leu Ala Ala Glu Glu Leu Ser Gin Leu Glu Gly Asp Val 110 Gly Met Ala Ser Leu Gin Gin Pro 175 Pro Ile 190 Ser Pro Ile Ser Pro Trp Gin Pro 255 Gly Gly 270 Ser Phe Glu Leu Asn Leu Ala Gin 335 Gin Gly 350 Cys Ala INFORMATION FOR SEQ ID NO:708: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Thr Pro Leu Gly 1 5 Lys Ser Leu Glu Gln Gin Glu Lys Leu Cys Val Leu Leu Gly His Cys Pro Ser Gin Ala Ser Gly Leu Phe Leu Ser Pro Glu Leu Gly 100 Asp Phe Ala Thr Thr 115 Pro Ala Leu Gin Pro 130 Phe Gin Arg Arg Ala 145 Phe Leu Glu Val Ser 165 Val Glu Gly Gly Gly 180 Thr Ile Asn Pro Ser 195 Met Ala Leu Gin Asp 210 Leu Ala Gin Arg Trp 225 Met Gin Gly Leu Leu 245 Lys Cys Ala Phe Gin 260 Asn Ile Ser Arg Leu 275 Lys Pro Trp Ile Thr 290 Cys Gin Pro Asp Ser 305 Gly Gly Gly Ser Gly 325 Cys Ser Phe Gin His 340 Arg Glu Leu Ser Asp 355 Ser Asn 370 TYPE: None DESCRIPTION: SEQ ID NO:708: Ala Ser Arg Lys Thr Tyr 40 Leu Gly Gin Leu Gin Gly Thr Leu Trp Gin 120 Gin Gly 135 Gly Val Arg Val Ser Pro Pro Ser 200 Glu Leu 215 Glu Arg Arg Val Pro Pro Gin Glu 280 Gin Asn 295 Thr Leu Gly Ser Pro Ile Leu Leu 360 Ser Leu Ile Gin Lys Leu Ile Pro Ala Gly Leu Leu Asp Thr 105 Gin Met Ala Met Leu Val Leu Arg 170 Gly Glu 185 Lys Glu Cys Gly Leu Lys Asn Thr 250 Ser Cys 265 Thr Ser Phe Ser Gly Gly Gly Gly 330 Ser Ser 345 Gin Asp Ser Gly Pro Pro Ser Leu Leu Leu 125 Phe His Ala Gly Lys 205 Trp Ala His Phe Leu 285 Leu Gly Gly Ala Val 365 INFORMATION FOR SEQ ID NO:709: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:709: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 25 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu WO 98/17810 PCT/US97/20037 Val Leu Cys Pro Ser Gly Ser Pro Asp Phe Pro Ala 130 Phe Gin 145 Phe Leu Val Glu Thr Ile Met Ala 210 Ala Gin 225 Gin Gly Cys Ala Ile Ser Pro Trp 290 Gin Pro 305 Gly Gly Ser Phe Glu Leu Asn Leu 370 His Ser Ala Let Leu Tyr Gly Pro Thr Ile Pro Thr Ala Gly 150 Ser Tyr 165 Gly Gly Ser Pro Glu Glu Met Glu 230 Glu Arg 245 Pro Pro Leu Gin Arg Gln Ser Thr 310 Gly Gly 325 Ser Pro Tyr Leu Ile Pro Ala Gly Leu Leu Asp Thr 105 Gin Met Ala Met Leu Val Leu Arg 170 Gly Glu 185 Lys Glu Gly Gly Lys Thr Thr Glu 250 Cys Leu 265 Ser Glu Ser Arg Gly Gly Gly Gly 330 Ser Asp 345 Asp Tyr Pro Ser Leu Leu Leu 125 Phe His Ala Gly Lys 205 Arg Gly Phe Val Val 285 Glu Gly Thr Val Thr 365 INFORMATION FOR SEQ ID NO:710: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:710: Ala Thr Pro Leu Gly Pro Gln Val Cys Ala His Ser Ala Leu Leu Tyr Gly Pro Thr Ile Pro Thr Ala Gly 150 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr WO 98/17 810 WO 9817810PCT1US97/20037 b fo Val Glu Gly Gly 180 Pro Glu Giu Arg Pro 260 Gin Gin Thr Gly Pro 340 Leu Gly Gly Ser Pro INFORMATION FOR SEQ ID NO:711: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gln Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Giu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gln Pro 130 Gln Arg Arg Ala Leu Glu Val Ser 165 Giu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala GiU Leu Cys 210 Met Glu Arg Leu Giu Arg Val Asn 245 Pro Pro Pro Ser 260 Leu Gln Glu Thr 275 TYPE: None DESCRIPTION: SEQ ID NO:711: Ser Leu Ile Gln Lys Leu Ile Pro Ala Gly Leu Leu Asp Thr 105 Gin Met Ala Met Leu Val Leu Arg 170 Gly Glu 185 Lys Glu Trp Arg Ala Gly His Phe 250 Phe Val 265 Leu Val Leu Leu Leu Ser His Ile Ala Ala Ala Ser 160 Tyr Ser Asn Arg Leu 240 Phe Arg I le Thr Arg Gln Asn Phe Ser Arg Thr rg Gn An Ph SerArg Leu Glu Leu Gin Cys Gin Pro Asp WO 98/17810 290 Ser Ser Thr 305 Gly Gly Gly His Ser Pro Asp Tyr Leu 355 Asp Glu 370 295 300 Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 310 315 Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 325 330 335 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 340 345 350 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 360 365 PCT/US97/20037 Ser 320 Gin Ser Gin INFORMATION FOR SEQ ID NO:712: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gln Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Leu Cys Gly 210 Glu Arg Leu Lys Arg Val Asn Thr 245 Pro Pro Ser Cys 260 Gin Glu Thr Ser 275 Gln Asn Phe Ser 290 Thr Leu Gly Gly Gly Ser Gly Gly 325 Pro Ile Ser Ser 340 Leu Leu Gin Asp 355 Glu 370 TYPE: None DESCRIPTION: SEQ ID NO:712: INFORMATION FOR SEQ ID NO:713: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids WO 98/17810 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Asp Glu Glu 210 Arg Trp Met Glu Leu Leu Glu Arg 245 Phe Gin Pro Pro 260 Arg Leu Leu Gin 275 Ile Thr Arg Gin 290 Asp Ser Ser Thr Thr Ala Pro Thr 325 Ser Asp Phe Ala 340 AsD Tvr Pro Val DESCRIPTION: SEQ ID Pro Ala Ser Ser Leu Val Arg Lys Ile Gin Ala Thr Tyr Lys Leu Ser Leu Gly Ile Pro 55 Leu Gin Leu Ala Gly Tyr Gin Gly Leu Leu Pro Thr Leu Asp Thr 105 Ile Trp Gin Gin Met 120 Thr Gin Gly Ala Met 135 Gly Gly Val Leu Val 150 Tyr Arg Val Leu Arg 170 Gly Ser Pro Gly Glu 185 Pro Pro Ser Lys Glu 200 Leu Cys Gly Gly Leu 215 Arg Leu Lys Thr Val 230 Val Asn Thr Glu Ile 250 Pro Ser Cys Leu Arg 265 Glu Thr Ser Glu Gin 280 Asn Phe Ser Arg Cys 295 Leu Pro Pro Pro Trp 310 Thr Gin Asp Cys Ser 330 Val Lys Ile Arg Glu 345 Thr Val Ala Ser Asn NO:713: Pro Gln Gly Asp Cys His Trp Ala Cys Leu Gln Ala Leu Gin Glu Glu Pro Ala 140 Ala Ser 155 His Leu Pro Ser Ser His Trp Arg 220 Ala Gly 235 His Phe Phe Val Leu Val Leu Glu 300 Ser Pro 315 Phe Gin Leu Ser Leu Gin INFORMATION FOR SEQ ID NO:714: SEQUENCE CHARACTERISTICS: LENGTH: 378 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:714: Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin 10 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 25 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 40 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 55 Pro Ser Gin Ala Leu Gln Leu Ala Gly Cys Leu Ser Phe Leu Gly Ala Ala Pro Glu Glu Pro Leu Ser Ser Gin Leu WO 98/17810 Gin Thr Trp Gin 135 Gly Arg Ser Pro Cys 215 Leu Asn Ser Thr Phe 295 Gly Gly Cys Arg Ser 375 693 Leu Leu Asp Thr 105 Gin Met Ala Met Leu Val Leu Arg 170 Gly Gin 185 Lys Glu Gly Leu Thr Val Glu Ile 250 Leu Arg 265 Giu Gin Arg Cys Gly Ser Gly Ser 330 Phe Gin 345 Len Ser Leu Gin WO 9817810PCTIUS97/20037 INFORMATION FOR SEQ ID NO:715: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala Lys Gin Val Cys Ser Ser Asp Pro Phe 145 Phe Val Thr (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Giu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Len Phe LeU Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Len Gln Pro 130 Gln Arg Arg Ala Leu Gin Val Ser 165 Gin Gly Gly Gly 180 Ile Asn Pro Ser 195 DESCRIPTION: SEQ ID NO:715: Pro Ala Ser Ser Leu Gin Leu Pro Gly Leu Thr Met Met Val Arg 170 Gin Gin Ser Phe Gly Ala Pro Giu Pro Len Ser Gin Len Glu Leu Asp 110 Len Gly 125 Phe Ala His Leu Ala Gin Gly Pro 190 Lys Ser 205 WO 98/17810 Met Ala 210 Gin Arg 225 Gly Leu Ala Phe Ser Arg Trp Ile 290 Pro Asp 305 Ala Thr Phe Gin Leu Ser Leu Gin Glu Leu Glu Arg 230 Arg Val 245 Pro Pro Gin Glu Gin Asn Thr Leu 310 Thr Ala 325 Pro Ile Leu Leu Gly Gly Leu Lys Thr Val Thr Glu Ile 250 Cys Leu Arg 265 Ser Glu Gin 280 Ser Arg Cys Pro Pro Trp Gin Pro Pro 330 Ser Asp Phe 345 Asp Tyr Pro 360 Arg Leu 220 Gly Ser Phe Val Val Gin Val Ala 285 Glu Leu 300 Pro Arg Thr Gin Val Lys Thr Val 365 PCT/US97/20037 Ala Gln 240 Cys Ile Pro Gin Gly 320 Ser Glu Asn INFORMATION FOR SEQ ID NO:716: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE; None (xi) SEQUENCE Ala Asp Tyr Pro Val 1 5 Cys Gly Gly Leu Trp Leu Lys Thr Val Ala Asn Thr Glu Ile His Ser Cys Leu Arg Phe Thr Ser Glu Gin Leu Phe Ser Arg Cys Leu 100 Gly Gly Gly Ser Gly 115 Gin Asp Cys Ser Phe 130 Lys Ile Arg Glu Leu 145 DESCRIPTION: SEQ ID NO:716: Thr Val Ala Ser Asn Leu Gin Arg Leu Val Leu Ala Gin Arg Gly Ser Lys Met Gin Gly Leu Phe Val Thr Lys Cys Ala Phe 55 Val Gin Thr Asn Ile Ser Arg 70 Val Ala Leu Lys Pro Trp Ile Glu Leu Gin Cys Gin Pro Asp 105 Gly Gly Ser Gly Gly Gly Ser 120 Gln His Ser Pro Ile Ser Ser 135 140 Ser Asp Tyr Leu Leu Gin INFORMATION FOR SEQ ID NO:717: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:717: Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 10 Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 25 Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 40 Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 55 Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Gly Leu Trp Arg Thr Val Ala Gly Glu Ile His Phe Leu Arg Phe Val Glu Gin Leu Val WO 98/17810 70 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 90 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 115 120 125 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 INFORMATION FOR SEQ ID NO:718: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Val Ala Gly Ser Ile His Phe Val Arg Phe Val Gin Gln Leu Val Ala Cys Leu Glu Leu Ser Gly Gly Gly Ser Phe Gin His 100 Glu Leu Ser Asp 115 Asn Leu Gin Asp 130 Ala Gin Arg Trp TYPE: None DESCRIPTION: SEQ ID NO:718: Met Lys Asn Lys 55 Cys Gly Pro Leu Glu 135 Glu Leu Leu Glu Arg Val Asn Thr 10 Phe Gin Pro Pro Pro Ser Cys Arg Leu Leu Gin Glu Thr Ser Ile Thr Arg Gin Asn Phe Ser Asp Ser Ser Thr Leu Gly Gly Ser Gly Gly Gly Thr Gin Asp 90 Ser Asp Phe Ala Val Lys Ile 110 Asp Tyr Pro Val Thr Val Ala 125 Gly Gly Leu Trp Arg Leu Val 140 Lys Thr 155 NO:719: INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Phe Val Val Glu Gly Gin Ser Gin Arg 145 (ii) (xi) Ser Ly Val Th Gin Th Ala Le Leu Gl Gly Se His Se Asp Ty 11 Asp Gl 130 Trp Me

M

SEQUENCE

s Met Gln 5 r Lys Cys r Asn Ile u Lys Pro n Cys Gin r Gly Gly r Pro Ile 100 r Leu Leu 5 u Glu Leu t Glu Arg

[OLECULE

Gly Ala Ser Trp Pro 70 Gly Ser Gin Cys Leu 150 TYPE: None DESCRIPTION: SEQ ID NO:719: Leu Phe Arg Ile Asp Ser Ser Asp Gly 135 Lys Leu Gin Leu 40 Thr Ser Gly Asp Tyr 120 Gly Thr Glu Pro 25 Leu Arg Ser Gly Phe 105 Pro Leu Val Val Pro Glu Asn Leu 75 Thr Val Thr Arg Gly 155 Thr Glu Ile His Cys Leu Arg Phe Ser Glu Gin Leu Ser Arg Cys Leu Gly Gly Ser Gly Asp Cys Ser Phe Ile Arg Glu Leu 110 Ala Ser Asn Leu 125 Val Leu Ala Gin WO 98/17810 INFORMATION FOR SEQ ID NO:720: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (ii) MOLECULE (xi) SEQUENCE Pro Pro Ser Cys Gln Glu Thr Ser Gln Asn Phe Ser Thr Leu Gly Gly Gly Thr Gin Asp Ala Val Lys Ile Val Thr Val Ala 100 Trp Arg Leu Val 115 Ala Gly Ser Lys 130 His Phe Val Thr TYPE: None DESCRIPTION: SEQ ID NO:720: INFORMATION FOR SEQ ID NO:721: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Arg Phe Val Gln Gln Leu Val Ala Cys Leu Glu Leu Ser Gly Gly Gly Ser Phe Gin His Glu Leu Ser Asp Asn Leu Gin Asp 100 Ala Gin Arg Trp 115 Gin Gly Leu Leu 130 Cys Ala Phe Gin DESCRIPTION: SEQ ID NO:721: Thr Asn Ile Ser Arg Leu Ile Thr Asp Ser Ser Gly Ser Asp Asp Tyr Gly Gly Lys Thr Thr Glu Cys Leu 155 Gln Glu Gin Asn Thr Leu Gly Thr Ala Val Val Thr Trp Arg 110 Ala Gly 125 His Phe INFORMATION FOR SEQ ID NO:722: SEQUENCE CHARACTERISTICS: LENGTH: 155 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gln Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Asp Glu Glu 210 Arg Trp Met Glu Leu Leu Glu Arg 245 Phe Gin Pro Pro 260 Arg Leu Leu Gin 275 Ile Thr Arg Gin 290 Asp Ser Ser Thr Thr Ala Pro Thr 325 Ser Asp Phe Ala 340 Asp Tyr Pro Val 355 TYPE: None DESCRIPTION: SEQ ID NO:713: Pro Ala Ser Ser Leu Val Arg Lys Ile Gin 25 Ala Thr Tyr Lys Leu 40 Ser Leu Gly Ile Pro 55 Leu Gin Leu Ala Gly Tyr Gin Gly Leu Leu Pro Thr Leu Asp Thr 105 Ile Trp Gin Gin Met 120 Thr Gin Gly Ala Met 135 Gly Gly Val Leu Val 150 Tyr Arg Val Leu Arg 170 Gly Ser Pro Gly Glu 185 Pro Pro Ser Lys Glu 200 Leu Cys Gly Gly Leu 215 Arg Leu Lys Thr Val 230 Val Asn Thr Glu Ile 250 Pro Ser Cys Leu Arg 265 Glu Thr Ser Glu Gin 280 Asn Phe Ser Arg Cys 295 Leu Pro Pro Pro Trp 310 Thr Gin Asp Cys Ser 330 Val Lys Ile Arg Glu 345 Thr Val Ala Ser Asn Gin Ser Phe Asp Gly Ala His Pro Glu Ala Pro Leu Leu Ser Gin Ala Leu Glu Gin Leu Asp 110 Glu Leu Gly 125 Ala Phe Ala 140 Ser His Leu Leu Ala Gin Ser Gly Pro 190 His Lys Ser 205 Arg Leu Val 220 Gly Ser Lys Phe Val Thr Val Gin Thr 270 Val Ala Leu 285 Glu Leu Gin 300 Pro Arg Pro Gin His Ser Ser Asp Tyr 350 Gin INFORMATION FOR SEQ ID NO:714: SEQUENCE CHARACTERISTICS: LENGTH: 378 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:714: Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu 10 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala 25 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu 40 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser 55 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu WO 98/17810 6 PCT/US97/20037 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 INFORMATION FOR SEQ ID NO:724: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asp Glu Glu Leu 1 Arg Trp Met Glu Arg Leu Leu Glu Arg Val Phe Gin Pro Pro Pro Arg Leu Leu Gin Glu Ile Thr Arg Gin Asn Asp Ser Ser Thr Leu 100 Ser Gly Gly Gly Ser 115 Gin His Ser Pro Ile 130 Ser Asp Tyr Leu Leu 145 Gin Tyr Val Glu Gly 165 Ile Ser Thr Ile Asn 180 Pro Asn Met Ala Thr 195 Phe Leu Leu Lys Cys 210 Ala Ala Leu Gin Glu 225 Glu Glu Leu Val Leu 245 Leu Ser Ser Cys Pro 260 Gin Leu His Ser Gly 275 Glu Gly Ile Ser Pro 290 Asp Val Ala Asp Phe 305 Gly Met Ala Pro Ala 325 Ala Ser Ala Phe Gin 340 Leu Gin Ser Phe Leu 355 Gin Pro 370 TYPE: None DESCRIPTION: SEQ ID NO:724: Gly Lys Thr Cys Ser Ser Gly Gly Ser 135 Asp Gly Ser Leu Glu 215 Leu Gly Gin Phe Leu 295 Thr Gin Arg Val Gly Thr Glu Leu Glu Arg Gly Gly 120 Asp Tyr Gly Pro Gly 200 Gin Cys His Ala Leu 280 Gly Thr Pro Ala Ser 360 Leu Val Ile Arg Gin Cys Ser 105 Ser Phe Pro Ser Pro 185 Pro Val Ala Ser Leu 265 Tyr Pro Ile Thr Gly 345 Tyr Arg Gly Phe Val Val Glu Gly Thr Val Thr 155 Gly Lys Ser Lys Tyr 235 Gly Leu Gly Leu Gin 315 Gly Val Val INFORMATION FOR SEQ ID NO:725: SEQUENCE CHARACTERISTICS: LENGTH: 354 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 WO 9817810PCTIUS97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:725: Ala Asp 1 Arg Trp Leu Leu Phe Gin Arg Leu Ile Thr Asp Ser Thr Ala Gin His 130 Ser Asp 145 Tyr Vai Ser Asn Phe Leu Ala Ala 210 Giu Glu 225 Leu Ser Gin Leu Glu Gly Asp Val 290 Gly Met 305 Ala Ser Leu Gin Gin Pro Glu Met Glu Pro Leu Arg Ser Pro 115 Ser Tyr Giu Met Leu 195 Leu Leu Ser His Ile 275 Ala Ala Ala Ser Giu Leu 5 Glu Arg Arg Val Pro Pro Gin Giu Gin Asn Thr Leu 100 Thr Ala Pro Ile Leu Leu Gly Gly 165 Ala Thr 180 Lys Ser Gin Giu Val Leu Cys Pro 245 Ser Gly 260 Ser Pro Asp Phe Pro Ala Phe Gin 325 Phe Leu 340 Gly Lys Thr Cy5 55 Ser Ser Pro Gin Ser 135 Asp Gly Leu Glu Leu 215 Gly Gin Phe Leu Thr 295 Gin Arg Val Gly Thr Giu 40 Leu Glu Arg Pro Pro 120 Asp Tyr Ser Giy Gin 200 Cys His Ala Leu Gly 280 Thr Pro Ala Ser Leu Val 25 Ile Arg Gin Cys Trp 105 Pro Phe Pro Pro Pro 185 Val Ala Ser Leu Tyr 265 Pro Ile Thr Giy Tyr 345 Trp 10 Ala His Phe Leu Leu 90 Ser Leu Al a Val Gly 170 Al a Arg Thr Leu Gin 250 Gin Thr Trp, Gin Gly 330 Arg Arg Leu Gly Ser Phe Val Val Gin Val Ala 75 Giu Leu Pro Arg Thr Gin Val Lys 140 Thr Val 155 Gly Gly Ser Ser Lys Ile Tyr Lys 220 Gly Ile 235 Leu Ala Gly Leu Leu Asp Gin Gin 300 Gly Ala 315 Val Leu Val Leu Val Lys Thr Thr Leu Gin Pro Asp 125 Ile Ala Ser Leu Gin 205 Leu Pro Gly Leu Thr 285 Met Met Val Arg Leu Met Lys Asn Lys Cys Leu 110 Cys Arg Ser Gly Pro 190 Gly Cys Trp Cys Gin 270 Leu Glu Pro Ala His 350 Ala Gin Cys Ile Pro Gin Gly Ser Giu Asn Gly 175 Gin Asp His Ala Leu 255 Ala Gin Giu Al a Ser 335 Leu Gin Gly Ala Ser Trp Pro Ala Phe Leu Leu 160 Gly Ser Gly Pro Pro 240 Ser Leu Leu Leu Phe 320 His Ala INFORMATION FOR SEQ ID NO:726: SEQUENCE CHARACTERISTICS: LENGTH: 363 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: Asp Giu Giu Leu Cys Gly Gly Leu Trp Arg 10 Trp Met Giu Arg Leu Lys Thr Val Ala Gly 25 Leu Giu Arg Val Asn Thr Glu Ile His Phe 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 75 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 90 726 Leu Ser Val Gin Ala Leu Gly Gly Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 100 105 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Giy Ser Gly Gly Gly 110 Ser Gly Gly Gly WO 98/17810 Ser Phe 145 Pro Ser Gly Gin Cys 225 His Ala Leu Gly Thr 305 Pro Ala Ser .lib Gly Thr 130 Ala Vai Val Thr Pro Gly Pro Ala 195 Val Arg 210 Ala Thr Ser Leu Leu Gin Tyr Gin 275 Pro Thr 290 Ile Trp Thr Gin Gly Gly Tyr Arg 355 Gin Lys Vai Gly 180 Ser Lys Tyr Gly Leu 260 Gly Leu Gin Gly VJal 340 Val Asp Ile Ala 165 Gly Ser Ile Lys Ile 245 Ala Leu Asp Gin Ala 325 Leu Leu Cys Arg 150 Ser Ser Leu Gin Leu 230 Pro Gly Leu Thr Met 310 Met Val Arg Ser 135 Giu Asn Giy Pro Gly 215 Cys Trp Cys Gin Leu 295 Giu Pro Ala His 120 *Phe *Leu Leu Gly Gin 200 Asp His Ala Leu Ala 280 Gin Giu Ala Ser Leu Gln Ser Gln Gly 185 Ser Gly Pro Pro Ser 265 Leu Leu Leu Phe His 345 PCT/US97/20037 His Asp Tyr 170 Ser Phe Ala Giu Leu 250 Gln Giu Asp Giy Ala 330 Leu Gln Ser Tyr 155 Val Asn Leu Ala Giu 235 Ser Leu Gly Val Met 315 Ser Gin Pro Pro 140 Leu Giu Met Leu Leu 220 Leu Ser His Ile Ala 300 Ala Ala Ser Ile Ser Leu Gin Gly Gly Ala Thr 190 Lys Ser 205 Gin Giu Val Leu Cys Pro Ser Gly 270 Ser Pro 285 Asp Phe Pro Ala Phe Gln Phe Leu 350 Ser Asp Giy 175 Pro Leu Lys Leu Ser 255 Leu Glu Ala Leu Arg 335 Giu Asp Tyr 160 Gly Leu Glu Leu Gly 240 Gin Phe Leu Thr Gin 320 Arg Val INFORMATION FOR SEQ ID NO:727: SEQUENCE

CHARACTERISTICS:

LENGTH: 348 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Asp Giu Glu Leu 1 5 Arg Trp Met Giu Arg 20 Leu Leu Giu Arg Val 35 Phe Gln Pro Pro Pro Arg Leu Leu Gin Glu Ile Thr Arg Gin Asn 85 Asp Ser Ser Thr Leu 100 Thr Ala Pro Thr Thr 115 Ser Asp Phe Ala Val 130 Asp Tyr Pro Val Thr 145 Gly Ser Pro Gly Gly 165 Leu Gly Pro Ala Ser 180 Giu Gin Val Arg Lys 195 Leu Cys Ala Thr Tyr 210 Gly His Ser Leu Gly 225 Gin Ala Leu Gin Leu 245 Phe Leu Tyr Gin Giy TYPE: None

DESCRIPTION:

SEQ ID NO:727: Cys Leu Asn Ser Thr 70 Phe Pro Gin Lys Vai 150 Gly Ser Ile Lys Ile 230 Alia Gly Lys Thr Cys 55 Ser Ser Pro Asp Ile i3 5 Ala Ser Leu Gin Leu 215 Pro Gly Gly Thr Glu 40 Leu Glu Arg Pro Cys 120 Arg Ser Gly Pro Gly 200 Cys Trp Cys Leu Val 25 Ile Arg Gln Cys Trp 105 Ser Giu Asn Gly Gin 185 Asp His Al a Leu Trp Arg Le Ala Gly Se His Phe Va Phe Val Gl 60 Leu Val Al~ 75 Leu Giu Lei 90 Ser Pro Arc Phe Gin Hi Leu Ser Asj 140 Leu Tyr Val 155 Gly Ser Asr 170 Ser Phe Leu Gly Ala Ala Pro Giu Glu 220 Pro Leu Ser 235 Ser Gin Leu u Val Leu Ala Gin r 1 n1 Lys Thr Thr Leu Gin Pro Ser 125 Tyr Glu Met Leu Leu 205 Leu Ser His Met Lys Asn Lys Cys Leu 110 Pro Leu Gly Ala Lys 190 Gin Val Cys Gin Gly Cys Ala Ile Ser Pro Trp Gln Pro Gly Ala Ile Ser Leu Gin Gly Gly 160 Thr Pro 175 Ser 'Leu Glu Lys Leu Leu Pro Ser 240 Gly Leu Ser ueu Leu Gin Ala Leu Giu Gly Ile Ser Pro Glu WO 98/17810 PCT/US97/20037 260 265 y Pro Thr Leu Asp Thr Leu Gin Leu Asp 275 280 r Ile Trp Gin Gin Met Glu Glu Leu Gly 0 295 o Thr Gin Gly Ala Met Pro Ala Phe Ala 310 315 a Gly Gly Val Leu Val Ala Ser His Leu 325 330 r Tyr Arg Val Leu Arg His Leu Ala Gin 340 345 INFORMATION FOR SEQ ID NO:728: SEQUENCE CHARACTERISTICS: LENGTH: 359 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear 270 Val Ala Asp Phe 285 Met Ala Pro Ala 300 Ser Ala Phe Gin Gin Ser Phe Leu 335 Pro (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Asp Cys Ser Phe 115 Ile Arg Glu Leu 130 Ala Ser Asn Leu Pro Ser Gly Pro 165 Ser His Lys Ser 180 Leu Pro Gin Ser 195 Gin Gly Asp Gly 210 Leu Cys His Pro Pro Trp Ala Pro 245 Gly Cys Leu Ser 260 Leu Gin Ala Leu 275 Thr Leu Gin Leu 290 Met Glu Glu Leu Met Pro Ala Phe 325 Val Ala Ser His 340 Arg His Leu Ala 355 TYPE: None DESCRIPTION: SEQ ID NO:728: INFORMATION FOR SEQ ID NO:729: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single WO 98/17810 PCTIUS97/20037 TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE p Glu Glu Leu p Met Glu Arg u Glu Arg Val n Pro Pro Pro u Leu Gln Glu r Arg Gin Asn r Ser Thr Leu 100 y Gly Gly Thr 115 p Phe Ala Val 0 r Pro Val Thr y Ser Pro Gly 165 o Pro Ser Lys 180 y Pro Ala Ser 195 n Val Arg Lys 0 s Ala Thr Tyr s Ser Leu Gly 245 a Leu Gin Leu 260 u Tyr Gin Gly 275 y Pro Thr Leu 0 r Ile Trp Gin o Thr Gin Gly 325 a Gly Gly Val 340 r Tyr Arg Val 355 DESCRIPTION: SEQ ID NO:729: Gin Gly Ala Ser Trp Pro Gly Ser Gin Gly 160 Pro Pro Leu Lys Leu 240 Ser Leu Glu Ala Leu 320 Arg Glu Gin Gly Ala Ser Trp Pro INFORMATION FOR SEQ ID NO:730: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:730: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Glu Thr Ser Glu Gln Leu Val Ala 75 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu WO 98/17810 WO 9817810PCT/US97/20037 cay Gly Gly Ser Gly Thr Gin Asp 125 Ala Val Lys Ile 140 Val Thr Val Ala 155 Pro Gly Giu Pro 170 Ser Lys Giu Ser Ala Ser Ser Leu 205 Arg Lys Ile Gin 220 Thr Tyr Lys Leu 235 Leu Gly Ile Pro 250 Gin Leu Ala Gly Gin Giy Leu Leu 285 Thr Leu Asp Thr 300 Trp Gin Gin Met 315 Gin Gly Ala met 330 Gly Val Leu Vai Arg Val Val Arq Giy Gly Gly 110 Cys Ser Phe Arg Giu Leu Ser Asn Leu 160 Ser Gly Pro 175 His Lys Ser 190 Pro Gin Ser Gly Asp Giy Cys His Pro 240 Trp Ala Pro 255 Cys Leu Ser 270 Gin Ala Leu Leu Gin Leu Giu Giu Leu 320 Pro Ala Phe 335 Ala Ser His 350 His Leu Ala INFORMATION FOR SEQ ID NO:73i: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (i i) (xi) Pro Pro Gin Gi Gin Asr Thr Lei.

Gly Thi Ala Val Val Thi Trp, Arc Ala Gi) 130 His PhE Gly Se2 Pro Prc Gly Prc i 9 Gin Va 210

MOLECULE

SEQUENCE

Ser Cys TYPE: None DESCRIPTION: SEQ ID NO:731: Leu Arg Phe

I

Thr Ser Glu Phe Ser Arg Gly Gly Gly Gin Asp Cys Lys Ile Arg Val Ala Ser 100 Leu Val Leu Ser Lys Met Val Thr Lys 150 Pro Gly Glu 165 Ser Lys Giu 180 Ala Ser Ser Arg Lys Ile Val Gin 10 Val Ala 25 Giu Leu Gly Gly Gin His Ser Asp 90 Gin Asp 105 Arg Trp Leu Leu Phe Gin Gly Pro 170 Lys Ser 185 Gin Ser Ser Arg is Trp Ile Pro Asp Gly Ser Ser Ser Gln Asp Cys Gly 110 Leu Lys Asn Thr Giu Gly Ile Asn 175 Ala Thr 1-90 Lys Cys Gin Giu Glu Gly Asp Gly Ala WO 98/17810 Leu Cys Ala 225 Gly His Ser Gin Ala Leu Phe Leu Tyr 275 Leu Gly Pro 290 Thr Thr Ile 305 Gin Pro Thr Arg Ala Gly Vai Ser Tyr 355 Thr Tyr Lys 230 Leu Giy Ile 245 Gin Leu Ala 260 Gin Gly Leu Thr Leu Asp Trp Gin Gin 310 Gin Giy Ala 325 Gly Val Leu 340 Arg Val Ile CysI Trp, CysI 280 Leu Giu Pro I Ala His I 360 Glu Ser Leu Gly Val 300 Met Ser Gin Pro PCTIUS97/20037 Leu 240 o Ser y Leu o Giu e Ala a Leu 320 ,1 Arg -i Glu INFORMATION FOR SEQ ID NO:732: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala Val Lys Thr Thr Leu Gin Ser Asp Ile 145 Ala Ile Pro Phe Al a 225 Giu Leu Gin Giu Asp 305 Gly Ala (ii) MOLECULE (xi) SEQUENCE Ser Asn Leu Gin 5 Leu Ala Gin Arg Met Gin Giy Leu Lys Cys Ala Phe Asn Ile Ser Arg Lys Pro Trp Ile Cys Gin Pro Asp i00 Gly Gly Gly Ser 115 Cys Ser Phe Gin i3 0 Arg Glu Leu Ser Tyr Vai Giu Gly 165 Ser Thr Ile Asn 180 Asn Met Ala Thr 195 Leu Leu Lys Cys 210 Ala Leu Gln Glu Glu Leu Val Leu .245 Ser Ser Cys Pro 260 Leu His Ser Gly 275 Gly Ile Ser Pro 290 Val Ala ASP Phe Met Ala Pro Ala 325 Ser Ala Phe Gin 340 TYPE: None DESCRIPTION: SEQ ID NO:732: Asp Glu Giu Leu Trp Met GiU Arg 25 Leu GiU Arg Val 40 Gin Pro Pro Pro 55 Leu Leu Gin Glu 70 Thr Arg Gin Asn Ser Ser Thr Leu 105 Gly Gly Gly Ser 120 His Ser Pro Ile 135 Asp Tyr Leu Leu 150 Gly Gly Gly Ser Pro Ser His Pro 185 Pro Leu Gly Pro 200 Leu Glu Gin Val 215 Lys Leu Cys Ala 230 Leu Gly His Ser Ser Gin Aia Leu 265 Leu Phe Leu Tyr 280 Giu Leu Gly Pro 295 Ala Thr Thr Ile 310 Leu Gln Pro Thr Arg Arg Ala Giy Cys 10 Leu Asn Ser Thr Phe 90 Gly Gly Ser Gin Pro 170 Ser Ala Arg Thr Leu 250 Gin Gin Thr Trp Gin 330 Gly Gly Lys Thr Cys Ser 75 Ser Gly Gly Ser Asp 155 Gly Lys Ser Lys Tyr 235 Gly, Leu Gly Leu Gin 315 Gly Val Gly Leu Trp Thr Val Ala Giu Ile His Leu Arg Phe Giu Gin Leu Arg Cys Leu Gly Ser Gly 110 Gly Ser Gly 125 Asp Phe Ala 140 Tyr Pro Val Glu Pro Ser Glu Ser His 190 Ser Leu Pro 205 Ile Gin Gly 220 Lys Leu Cys Ile Pro Trp Ala Gly Cys 270 Leu Leu Gin 285 Asp Thr Leu 300 Gin Met Giu Ala Met Pro Leu Val Ala 350 Leu Arg His '365 Arg Gly Phe Val Vai Giu Gly Thr Val Thr Gly 175 Lys Gin Asp His Ala 255 Leu Ala Gin Glu Ala 335 Ser Leu Leu Gin Ser 355 Phe LeU Giu Val Ser Tyr Arg Val 360 WO 98/17810 Gin Pro 370 6295 PCT/US97/20037 INFORMA.TION FOR SEQ ID NO:733: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Al a 1 Leu Me t Lys Asn Lys Cys Gly Cys Arg 145 Ser Ile Pro Phe Ala 225 Giu Leu Gln Giu Asp 305 Gly Ala Leu Gln (ii) (xi) Asn Leu Ala Gln Gln Gly Cys Ala Ile Ser Pro Trp Gln Pro Gly Gly 115 Ser Phe 130 Glu Leu Tyr Val Ser Thr Asn Met 195 Leu Leu 210 Ala Leu Giu Leu Ser Ser Leu His 275 Gly Ile 290 Val Ala Met Ala Ser Ala Gin Ser 355 Pro 370 40LECULE

SEQUENCE

Gln Asp 5 Arg Trp Leu Leu Phe Gin Arg Leu Ile Thr 85 Asp Ser 100 Ser Gly Gin His Ser Asp Glu Gly 165 Ile Asn 180 Ala Thr Lys Cys Gin Giu Val Leu 245 Cys Pro 260 Ser Giy Ser Pro Asp Phe Pro Ala 325 Phe Gin 340 Phe Leu TYPE: None DESCRIPTION: SEQ ID) NO:733: Giu Met Glu Pro Leu 70 Arg Ser Gly Ser Tyr 150 Gly Pro Pro Leu Lys 230 Leu Ser Leu Giu Ala 310 Leu Arg Glu Giu Giu Arg Pro 55 Gin Gin Thr Gly Pro 135 Leu Gly Ser Leu Giu 215 Leu Gly Gin Phe Leu 295 Thr Gin Arg Val Leu Arg Val 40 Pro Glu Asn Leu Ser 120 Ile Leu Gly Pro Gly 200 Gin Cys His Ala Leu 280 Gly Thr Pro Ala Ser 360 Gly Leu Thr Val Giu Ile Leu Arg 60 Glu Gin 75 Arg Cys Gly Ser Gly Ser Asp Phe 140 Tyr Pro 155 Gly Glu Lys Glu Ser Ser Lys Ilie 220 Tyr Lys 235 Gly Ilie Leu Ala Gly Leu Leu Asp 300 Gin Gin 315 Gly Ala Val Leu Val Ile Trp Ala His Phe Leu Leu Gly Gly 125 Ala Val Pro Ser Leu 205 Gin Leu Pro Gly Leu 285 Thr Met Met Val Arg 365 Arg Leu Gly Ser Phe Val Val Gin Val Ala Giu Leu Gly Gly 110 Thr Gin Val LYS Thr Val Ser Gly 175 His Lys 190 Pro Gin Gly Asp Cys His Trp Ala 255 Cys Leu 270 Gin Ala Leu Gin Giu Giu Pro Ala 335 Ala Ser 350 His Leu Val Lys Thr Thr Leu Gin Ser Asp Ile Ala 160 Pro Ser Ser Gly Pro 240 Pro Ser Leu Leu Leu 320 Phe His Ala INFORMATION FOR SEQ ID NO:734: Ci) SEQUENCE CHAR ACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single CD) TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE D ESCRIPTION: SEQ ID NO:734: Ala Leu Gin Asp Giu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu WO 98/17810 1 Al a Gin Cys Ile Pro Gin Gly Ser Glu 145 Asn Ile Pro Phe Ala 225 Glut Leu Gin Giu Asp 305 Gly Ala Leu C Gin I Gin Gly Ala Ser Trp, Pro Gly Phe 130 Leu Tyr Ser Asn Leu 210 Al a Glu Ser Leu Gly 290 Jal 4e t 3er ;ln ~ro Arg Leu Phe Arg Ile Asp Ser Gin Ser Val Thr Met 195 Leu Leu Leu Ser His 275 Ile Ala Ala Ala Ser 355 Leu Leu Gin Leu Thr Ser 100 Gly His Asp Glu Ile 180 Ala Lys Gin Val Cys 260 Ser Ser Asp Pro The 340 Phe 5 Met Glu Giu Arg Pro Pro Leu Gin 70 Arg Gin 85 Ser Thr Gly Gly Ser Pro Tyr Leu 150 Gly Gly 165 Asn Pro Thr Pro Cys Leu Giu Lys 230 Leu Leu 245 Pro Ser Gly Leu Pro Glu Phe Ala 310 Ala Leu 325 Gin Arg Leu Giu Arc Val Pro 55 Giu Asn Leu Ser Ile 135 Leu Giy Ser Leu Giu 215 Leu Gly Gin Phe Leu 295 Thr Gln krg lal Leu *Asn 40 ISer *Thr *Phe Gly Gly 120 Ser Gln Gly Pro Giy 200 Gln Cys His Ala Leu 280 Gly Thr Pro Ala Ser 360 Lys 25 Thr Cys Ser Ser Gly 105 Gly Ser Asp Ser Pro 185 Pro Val Ala Ser Leu 265 Tyr Pro Ile Thr Gly 345 Tyr Thr Val Glu Ile Leu Arg Giu Gin 75 Arg Cys 90 Gly Ser Gly Ser Asp Phe Tyr Pro 155 Pro Gly 170 Ser Lys Ala Ser Arg Lys Thr Tyr 235 Leu Gly 250 Gin Leu Gin Gly Thr Leu Trp Gin 315 Gin Gly 330 Gly Val Arg Val PCT/US97/20037 Ala Gly Ser Lys Met His Phe Leu Leu Gly Gly Ala 140 Val Glu Glu Ser Ile 220 Lys Ile Ala Leu Asp 300 Gln Ala Leu Lieu Phe Val Val Gln Val Ala Glu Leu Gly Gly 110 Thr Gin 125 Val Lys Thr Val Pro Ser Ser His 190 Leu Pro 205 Gln Gly Leu Cys Pro Trp, Gly Cys 270 Leu Gli 285 Thr Leu Met Glu Met Pro Val Ala 350 Arg His 365 Thr Thr Leu Gln Ser Asp Ile Ala Gly 175 Lys Gin Asp His Ala 255 Leu Ala Gln Glu Ala 335 Ser Leu Lys Asn Lys Cys Gly Cys Arg Ser 160 Pro Ser Ser Gly Pro 240 Pro Ser Leu Leu Leu 320 Phe His Ala INFORMATION FOR SEQ ID NO:735: Wi SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRAN~DEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Leu Cys Gly Gly 5 Arg Leu Lys Thr Val Asn Thr Giu Pro Ser Cys Leu Giu Thr Ser Giu Asn Phe Ser Arg 85 Leu Gly Gly Gly 100 Ser Gly Gly Gly 115 Ile Ser Ser Asp TYPE: None DESCRIPTION: SEQ ID NO:735: Leu Trp Arg Leu Val Leu Ala Val Ala Gly Ser Lys Met Gin Ile His Phe Val Thr Lys Cys Arg Phe Val Gln Thr Asn Ile 55 Gln Leu Val Ala Leu Lys Pro Cys Leu Giu Leu Gin Cys Gln Ser Gly Gly Gly Ser Gly Gly 105 Ser Gly Thr Gin Asp Cys Ser 120 Phe Ala Val Lys Ile Arg Glu WO 98/17810 130 Leu Leu 145 Glu Tyr Ile Ser Pro Asn Phe Leu 210 Ala Ala 225 Glu Glu Leu Ser Gin Leu Glu Gly 290 Asp Val 305 Gly Met Ala Ser Leu Gin Gin Pro 370 PCT/US97/20037 Gin Asp Tyr Val Glu Gly 165 Thr Ile Asn 180 Met Ala Thr 195 Leu Lys Cys Leu Gin Glu Leu Val Leu 245 Ser Cys Pro 260 His Ser Gly 275 Ile Ser Pro Ala Asp Phe Ala Pro Ala 325 Ala Phe Gin 340 Ser Phe Leu 355 135 Val Thr Va Gly Gly Se Ser Pro Pi 18 Leu Gly Pr 200 Glu Gin Va 215 Leu Cys Al Gly His Se Gin Ala Le 26 Phe Leu Ty 280 Leu Gly Pr 295 Thr Thr Ii Gin Pro Th Arg Ala Gl 34 Val Ser Ty 360 140 Asn Leu Glu Pro Glu Ser Ser Leu 205 Ile Gin 220 Lys Leu Ile Pro Ala Gly Leu Leu 285 Asp Thr 300 Gin Met Ala Met Leu Val Leu Arg 365 Asp Glu 160 Gly Pro 175 Lys Ser Gin Ser Asp Gly His Pro 240 Ala Pro 255 Leu Ser Ala Leu Gin Leu Glu Leu 320 Ala Phe 335 Ser His Leu Ala INFORMATION FOR SEQ ID NO:736: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Phe Val Val Glu Gly Gin Ser Gin Arg 145 Gly Ser Leu Glu Leu 225 Gly Gin (ii) MOLECULE (xi) SEQUENCE Ser Lys Met Gin 5 Val Thr Lys Cys Gin Thr Asn Ile Ala Leu Lys Pro Leu Gin Cys Gin Gly Ser Gly Gly His Ser Pro Ile 100 Asp Tyr Leu Leu 115 Asp Glu Glu Leu 130 Trp Met Glu Arg Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Gly Pro Ala Ser 195 Gin Val Arg Lys 210 Cys Ala Thr Tyr His Ser Leu Gly 245 Ala Leu Gin Leu TYPE: None DESCRIPTION: SEQ ID N0:736: Gly Leu Leu Glu Arg Val Asn 10 Ala Phe Gin Pro Pro Pro Ser 25 Ser Arg Leu Leu Gin Glu Thr Trp Ile Thr Arg Gin Asn Phe 55 Pro Asp Ser Ser Thr Leu Gly 70 Gly Ser Gly Gly Gly Thr Gin 90 Ser Ser Asp Phe Ala Val Lys 105 Gin Asp Tyr Pro Val Thr Val 120 Cys Gly Gly Leu Trp Arg Leu 135 140 Leu Lys Thr Val Ala Gly Tyr 150 155 Glu Pro Ser Gly Pro Ile Ser 170 3lu Ser His Lys Ser Pro Asn 185 Ser Leu Pro Gin Ser Phe Leu 200 Ile Gin Gly Asp Gly Ala Ala 215 220 Lys Leu Cys His Pro Glu Glu 230 235 Ile Pro Trp Ala Pro Leu Ser 250 Ala Gly Cys Leu Ser Gin Leu Ile Arg Gin Cys Ser Ser Glu Asn Ala Gly Asn 175 Thr Cys Glu Leu Pro 255 Gly WO 98/17810 WPCT/US97/20037 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 INFORMATION FOR SEQ ID NO:737: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:737: Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 25 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 40 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 55 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 70 75 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 90 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 INFORMATION FOR SEQ ID NO:738: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids WO 98/17810 64w PCT/US97/20037 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Glu Arg Pro Gln Gin Thr Gly Pro Leu 145 Glu Ile Pro Phe Ala 225 Glu Leu Gin Glu Asp 305 Gly Ala Leu Gin Ala 1 Met Glu Pro (xi) SEQUENCE Leu Cys Gly Gly 5 Arg Leu Lys Thr Val Asn Thr Glu Pro Ser Cys Leu Glu' Thr Ser Glu Asn Phe Ser Arg Leu Gly Gly Gly 100 Ser Gly Gly Gly 115 Ile Ser Ser Asn 130 Leu Gin Asp Tyr Tyr Val Glu Gly 165 Phe Thr Ile Asn 180 Asn Met Ala Thr 195 Leu Leu Lys Cys 210 Ala Leu Gin Glu Glu Leu Val Leu 245 Ser Ser Cys Pro 260 Leu His Ser Gly 275 Gly Ile Ser Pro 290 Val Ala Asp Phe Met Ala Pro Ala 325 Ser Ala Phe Gin 340 Gin Ser Phe Leu 355 Pro 370 DESCRIPTION: SEQ ID NO:738: Trp Arg Leu Val Ala Gly Ser Lys His Phe Val Thr 40 Phe Val Gin Thr 55 Leu Val Ala Leu Leu Glu Leu Gin Gly Gly Gly Ser 105 Gly Thr Gin Asp 120 Ala Val Lys Ile 135 Val Thr Val Ala Gly Gly Ser Pro 170 Ser Pro Pro Ser 185 Leu Gly Pro Ala 200 Glu Gin Val Arg 215 Leu Cys Ala Thr Gly His Ser Leu 250 Gin Ala Leu Gin 265 Phe Leu Tyr Gin 280 Leu Gly Pro Thr 295 Thr Thr Ile Trp Gin Pro Thr Gin 330 Arg Ala Gly Gly 345 Val Ser Tyr Arg 360 Leu Ala Gin Met Gin Gly Lys Cys Ala Asn Ile Ser Lys Pro Trp Cys Arg Pro Gly Gly Gly Cys Ser Phe 125 Arg Glu Leu 140 Ser Asn Leu 155 Gly Glu Pro Lys Glu Ser Ser Ser Leu 205 Lys Ile Gin 220 Tyr Lys Leu 235 Gly Ile Pro Leu Ala Gly Gly Leu Leu 285 Leu Asp Thr 300 Gin Gin Met 315 Gly Ala Met Val Leu Val Val Leu Arg 365 INFORMATION FOR SEQ ID NO:739: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:739: Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 5 10 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 25 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin 40 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 55 WO 98/17810 ltv Gin Leu Val ]PCTIUS97/20037 Lys Pro Trp Ile Thr Leu Arg Ser Gly Ser Tyr 145 Giu Ile Pro Phe Ala 225 Glu Leu Gin Glu Asp 305 Gly Ala Leu Gln Gin Gin Thr Giy Pro 130 Leu Tyr Ser Asn Leu 210 Ala Glu Ser Leu Gly 290 Vai Met Ser Gin Pro 370 Giu Thr Ser Giu Ala Leu Asn Leu Ser 115 Ile Leu Val Thr Met 195 Leu Leu Leu Ser His 275 Ile Ala Ala Al a Ser 355 Phe Gly 100 Gly Ser Gin Glu Ile 180 Aia Lys Gin Val Cys 260 Ser Ser Asp Pro Phe 340 Phe Ser 85 Gly Gly Ser Asp Gly 165 Asn Thr Cys Giu ILeu 245 Pro Gly Pro Phe Ala 325 Gln Lieu Arg Gly Gly Asp Tyr 150 Gly Pro Pro Leu Lys 230 Leu Ser Leu Giu Ala 310 Leu Arg Glu Cys Ser Ser Phe 135 Pro Gly Ser Leu Giu 215 Leu Gly Gin Phe Leu 295 Thr Gin Arg Val Leu Gly Gly 120.

Ala Val Gly Pro Gly 200 Gln Cys His Ala Leu 280 Gly Thr Pro Ala Ser 360 Giu Gly 105 Thr Val Thr Ser Pro 185 Pro Val Ala Ser Leu 265 Tyr Pro Ile rhr

G

1 y 345 Tyr Leu 90 Gly Gin Lys Val Pro 170 Ser Ala Arg Thr Leu 250 Gin Gin Thr Trp Gi 330 Gly Arg Cys Gly Cys Arg 140 Ser Glu Glu Ser Ile 220 Lys Ile Ala Leu Asp 300 Gin Ala Leu Leu Gin Pro Gly Gly 110 Ser Phe 125 Glu Leu Asn Leu Pro Ser Ser His 190 Leu Pro 205 Gin Gly Leu Cys Pro Trp Gly Cys 270 Leu Gin 285 Thr Leu Met Glu Met Pro Val Ala 350 Arg His 365 Asp Ser Gin Ser Gin Gly 175 Lys Gin Asp His Al a 255 Leu Ala Gin GiU Ala 335 Ser Leu Ser Gly His Asp Asp 160 Pro Ser Ser Gly Pro 240 Pro Ser Leu Leu Leu 320 Phe His Ala INFORM4ATION FOR SEQ ID NO:740: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:740: Ala Trp Leu Gin Leu Thr Ser Gly His Asp 145 Asp Ile Giu G1i Met Gli Glu Arc Pro Prc Leu Gi1 Arg Gir Ser Thi Gly Glj 115 Ser Prc 130 Tyr Leu Tyr Val Ser Thr u Leu Cys 5 1 Arg Leu ;Val Asn Pro Ser IGiu Thr 1Asn Phe 85 Leu Gly 100 Ser Gly Ile Ser ILeu Gin *Giu Gly 165 Sle Asn 180 Gly Leu Trp Thr Val Ala 25 Glu Ile His 40 Leu Arg Phe 55 Glu Gin Leu Arg Cys Leu Gly Ser Gly 105 Gly Ser Gly 120 Asp Phe Ala 135 Tyr Pro Val Gly Gly Ser Ser Pro Pro 185 Leu Val Ser Lys Val Thr Gin Thr Ala Leu Leu Gin Gly Ser Gin Asp Lys Ile 140 Val Ala 155 Gly Glu Lys Giu Leu Met Lys Asn Lys Cys Gdy Cys 125 Arg Ser Pro Ser WO 98/17810 Pro Asn Met 195 Phe Leu Leu 210 Ala Ala Leu 225 Glu Glu Leu Leu Ser Ser Gin Leu His 275 Glu Gly Ile 290 Asp Val Ala 305 Gly Met Ala Ala Ser Ala Leu Gin Ser 355 Gin Pro 370 Ala Thr Pro Leu A1'4 Gly Pro Ala Ser Ser Leu Pro Cys Leu Glu Lys 230 Leu Leu 245 Pro Ser Gly Leu Pro Glu Phe Ala 310 Ala Leu 325 Gin Arg Leu Glu Giu Gin Val Arg LYS 215 Leu Cys Ala Thr Tyr 235 Gly His Ser Leu Gly 250 Gin Ala Leu Gin Leu 265 Phe Leu Tyr Gin Gly 280 Leu Gly Pro Thr Leu 295 Thr Thr Ile Trp, Gin 315 Gin Pro Thr Gin Gly 330 Arg Ala Gly Gly Val 345 Val Ser Tyr Arg Val 360 Ile 220 Lys Ile Ala Leu Asp 300 Gin Ala Leu Leu PCT/US97/20037 n Ser p Giy 5 Pro 240 a Pro U Ser Leu Leu *i Leu 320 3 Phe r His 1i Ala INFORMATION FOR SEQ ID NO:741: Wi SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) Ala Gin Asp 1 Gin Arg Trp, Gly Leu Leu Ala Phe Gin Ser Arg Leu Trp Ile Thr Pro Asp Ser Gly Ser Gly 115 Phe Gin His 130 Leu Ser Asp 145 Leu Tyr Val Ile Ser Thr Pro Asn Met 195 Phe Leu Leu 210 Ala Ala Leu 225 Glu Glu Leu Leu Ser Ser Gin Leu His 275 Glu Gly Ile 290 Asp Val Ala 305

SEQUENCE

Giu Glu 5 Met Giu Giu Arg Pro Pro Leu Gin Arg Gin 85 Ser Thr 100 Gly Gly Ser Pro Tyr Leu Giu Gly 165 Ile Asn 180 Ala Thr Lys Cys Gin Giu Val Leu 245 Cys Pro 260 Ser Gly Ser Pro Asp Phe TYPE: None DESCRIPTION: SEQ ID NO:741: Leu Arg Val Pro Giu 70 Asn Leu Ser Ile Leu 150 Gly Pro Pro Leu Lys 230 Leu Ser Leu Giu Ala 310 Gly Gly Lys Thr 25 Thr Giu 40 Cys Leu Ser Glu Ser Arg Gly Gly 105 Gly Gly 120 Ser Asp Asp Tyr Gly Ser Pro Pro 185 Gly Pro 200 Gin Vai Cys Ala His Ser Ala Leu 265 Leu Tyr 280 Gly Pro Thr Ile Leu 10 Val Ilie Arg Gin Cys 90 Ser Ser Phe Pro Pro 170 Ser Ala Arg Thr Leu 250 Gin Gin Thr Trp Trp Ala His Phe Leu 75 Leu Gly Gly Ala Val 155 Gly Lys Ser Lys Tyr 235 Gly Leu Giy Leu.

Gin 315 Arg Gly Phe Val Val Giu Gly Thr Val 140 Thr Giu Giu Ser Ile 220 Lys Ile Aia Leu Asp 300 Gin Leu Val Ser Lys Val Thr Gin Thr Ala Leu Leu Gin Gly Ser 110 Gin Asp 125 Lys Ile Val Ala Pro Ser Ser His 190 Leu Pro 205 Gin Gly Leu Cys Pro Trp, Gly Cys 270 Leu Gin 285 Thr Leu Met Giu Ala Gin Cys Ile Pro Gin Giy Ser Giu Asn 160 Pro Ser Ser Gly Pro 240 Pro Ser Leu Leu Leu 320 WO 98/17810 Gly Met Ala Ser Leu Gin Gin Pro 370 10Z PCT/US97/20037 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 360 365 INFORMATION FOR SEQ ID NO:742: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Ala Leu Gly His Asp Asp Trp Leu Gin 145 Gly Ser Leu Glu Leu 225 Gly Gin Phe Leu Thr 305 Gin Arg Val (ii) MOLECULE (xi) SEQUENCE Thr Asn Ile Ser 5 Leu Lys Pro Trp Gin Cys Gin Pro Ser Gly Gly Gly Ser Pro Ile Ser Tyr Leu Leu Gin Glu Glu Leu Cys 100 Met Glu Arg Leu 115 Glu Arg Val Asn 130 Pro Pro Pro Ser Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Gly Pro Ala Ser 195 Gin Val Arg Lys 210 Cys Ala Thr Tyr His Ser Leu Gly 245 Ala Leu Gin Leu 260 Leu Tyr Gin Gly 275 Gly Pro Thr Leu 290 Thr Ile Trp Gin Pro Thr Gin Gly 325 Ala Gly Gly Val 340 Ser Tyr Arg Val 355 TYPE: None DESCRIPTION: SEQ ID NO:742: Arg Ile Asp Ser Ser 70 Asp Gly Lys Thr Cys 150 Glu Glu Ser Ile Lys 230 Ile Ala Leu Asp Gin 310 Ala Leu Leu Leu Arg Ser 40 Gly Phe Pro Leu Val 120 Ile Arg Ser His Pro 200 Gly Cys Trp Cys Gin 280 Leu Glu Pro Ala His 360 Thr Ser Phe Ser Gly Gly Gin Asp Lys Ile Val Ala Leu Val Ser Lys Val Thr 140 Gin Tyr 155 Ile Ser Pro Asn Phe Leu Ala Ala 220 Glu Glu 235 Leu Ser Gin Leu Glu Gly Asp Val 300 Gly Met 315 Ala Ser Leu Gin Gin Pro Glu Arg Gly Cys Arg Ser Leu Met 125 Lys Val Thr Met Leu 205 Leu Leu Ser His Ile 285 Ala Ala Ala Ser Gin Leu Cys Leu Ser Gly Ser Phe Glu Leu Asn Leu Ala Gin 110 Gin Gly Cys Ala Glu Gly Ile Asn 175 Ala Thr 190 Lys Cys Gin Glu Val Leu Cys Pro 255 Ser Gly 270 Ser Pro Asp Phe Pro Ala Phe Gin 335 Phe Leu 350 INFORMATION FOR SEQ ID NO:743: SEQUENCE CHARACTERISTICS: LENGTH: 355 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO098/17810 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO!743: PCT/US97/20037 Ala Arg Leu Phe Arg Ile Asp Ser Gin Ser 145 Gin Gly Ser Gly Pro 225 Pro Ser Leu Leu Leu 305 Phe His Ala Glu Glu Leu Met Giu Arg Giu Arg Val Pro Pro Pro Leu Gin Giu Arg Gin Asn 85 Ser Thr Leu 100 Gly Gly Ser 115 Ser Pro Ile Tyr Leu Leu Val Giu Giy 165 Asn Met Ala 180 Leu Leu Lys 195 Ala Leu Gin Glu Leu Val Ser Ser Cys 245 Leu His Ser 260 Gly Ile Ser 275 Val Ala Asp Met Ala Pro Ser Ala Phe 325 Gin Ser Phe 340 Pro 355 G iy Lys Thr Cys 55 Ser Ser Gly Gly Ser 135 Asp Gly Pro Leu Lys 215 Leu Ser Leu Glu Ala 295 Leu Arg Glu Gly Leu Trp, Thr Glu 40 Leu Glu Arg Gly Gly 120 Asp Tyr Gly Leu Glu 200 Leu Gly Gin Phe Leu 280 Thr Gin Arg Val Val 25 Ile Arg Gin Cys Ser 105 Ser Phe Pro Ser Gly 185 Gin Cys His Ala Leu 265 Gly Thr Pro Aia Ser 345 Arg Leu Gly Ser Phe Val Val Gin Vai Ala 75 Giu Leu Gly Gly Thr Gin Vai Lys 140 Thr Val 155 Gly Gly Ala Ser Arg Lys Thr Tyr 220 Leu Gly 235 Gin Leu Gin Gly Thr Leu Trp Gin Val Lys Thr Thr Leu Gin Ser Asp 125 Ile Ala Gly Ser Ile 205 Lys Ile Ala Leu Asp 285 Gin Leu Met Lys Asn Lys Cys Gly 110 Cys Arg Ser Ser Leu 190 Gin Leu Pro Gly Leu 270 Thr Met Met Val Arg 350 Ala Gin Cys Ile Pro Gin Gly Ser Glu Asn Gly 175 Pro Gly Cys Trp Cys 255 Gin Leu Glu Pro Ala 335 Hius Gin Gly Ala Ser Trp Pro Gly Phe Leu Leu 160 Gly Gin Asp His Ala 240 Leu Ala Gin Glu Ala 320 Ser Leu Gly Ala Val Leu Val Leu INFORMATION FOR SEQ ID NO:744: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (Xi) SEQUENCE Gin Asp Giu Glu Arg Trp Met Glu Leu Leu Giu Arg Phe Gin Pro Pro Arg Leu Leu Gln Ile Thr Arg Gin Asp Ser Ser Thr 100 Ser Gly Gly Gly DESCRIPTION: SEQ ID Leu Cys Gly Gly Leu Arg Leu Lys Thr Val 25 Val Asn Thr Giu Ile 40 Pro Ser Cys Leu Arg 55 Giu Thr Ser Glu Gin Asn Phe Ser Arg Cys Leu Gly Gly Giy Ser 105 Ser Gly Gly Gly Ser NO: 744: Trp Arg Ala Gly His Phe Phe Val Leu Val Leu Giu Gly Gly Gly Thr WO 98/17810 PCT/US97/20037 115 Gin His 130 Ser Asp Tyr Val Ser Thr Asn Met 195 Leu Leu 210 Ala Leu Glu Leu Ser Ser Leu His 275 Gly Ile 290 Val Ala Met Ala Ser Ala Gin Ser 355 Pro 370 Ser Pro Tyr Leu Glu Gly 165 Ile Asn 180 Ala Thr Lys Cys Gin Glu Val Leu 245 Cys Pro 260 Ser Gly Ser Pro Asp Phe Pro Ala 325 Phe Gin 340 Phe Leu 120 Ser Ser 135 Gin Asp Gly Gly Ser Pro I Leu Gly 200 Glu Gin 1 215 Leu Cys 1 Gly His Gin Ala I Phe Leu 1 280 Leu Gly I 295 Thr Thr Gin Pro 1 Arg Ala C Val Ser 1 360 125 Lys Val Pro Ser Leu 205 Gin Leu Pro Gly Leu 285 Thr Met Met Val Arg 365 Arg Ser Gly 175 Lys Gln Asp His Ala 255 Leu Ala Gin Glu Ala 335 Ser Leu INFORMATION FOR SEQ ID N0:745: SEQUENCE CHARACTERISTICS: LENGTH: 366 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Leu Cys Gly Gly Arg Leu Lys Thr Val Asn Thr Glu Pro Ser Cys Leu Glu Thr Ser Glu Asn Phe Ser Arg Leu Gly Gly Gly 100 Ser Gly Thr Gin 115 Phe Ala Val Lys 130 Pro Val Thr Val Gly Gly Gly Ser 165 Pro Ser Pro Pro 180 Pro Leu Gly Pro 195 Leu Glu Gin Val 210 Lys Leu Cys Ala Leu Gly His Ser TYPE: None DESCRIPTION: SEQ ID Leu Trp Arg Leu Val Val Ala Gly Ser Lys Ile His Phe Val Thr 40 Arg Phe Val Gin Thr 55 Gin Leu Val Ala Leu Cys Leu Glu Leu Gin Ser Gly Gly Gly Ser 105 Asp Cys Ser Phe Gin 120 Ile Arg Glu Leu Ser 135 Ala Ser Asn Leu Gin 150 Pro Gly Glu Pro Ser 170 Ser Lys Glu Ser His 185 Ala Ser Ser Leu Pro 200 Arg Lys Ile Gin Gly 215 Thr Tyr Lys Leu Cys 230 Leu Gly Ile Pro Trp NO: 745: Leu Ala Gin Met Gin Gly Lys Tyr Ala Asn Ile Ser Lys Pro Trp Cys Arg Pro Gly Gly Gly His Ser Pro 125 Asp Tyr Leu 140 Asp Glu Glu 155 Gly Pro Ile Lys Ser Pro Gin Ser Phe 205 Asp Gly Ala 220 His Pro Glu 235 Ala Pro Leu WO 98/17810 Pro Ser Gin Gly Leu Phe 275 Pro Glu Leu 290 Phe Ala Thr 305 Ala Leu Gin Gin Arg Arg Leu Glu Val 355 PCT/US97/20037 245 Ala Leu 260 Leu Tyr 250 Gin Leu Ala Gly Cys 265 Gin Gly Leu Leu Gin Pro Thr Ile Trp 310 Thr Gin 325 Gly Gly Tyr Arg Asp Gin Ala Leu Leu 360 Leu Ser Ala Leu Gin Leu 300 Glu Leu 315 Ala Phe Ser His Leu Ala Gin Leu 270 Glu Gly 285 255 His Ser Ile Ser INFORMATION FOR SEQ ID NO:746: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE Ala 1 Phe Val Val Glu Gly Gin Ser Gin Arg 145 Gly Ser Leu Glu Leu 225 Gly Gin Phe Leu Thr 305 Gin Arg Val (xi) Ser Lys Val Thi Gin Thr Ala Let Leu Glr Gly Ser His Ser Asp Tyr 115 Asp Glu 130 Trp Met Gly Ser Pro Pro Gly Pro 195 Gin Val 210 Cys Ala His Ser Ala Leu Leu Tyr 275 Gly Pro 290 Thr Ile Pro Thr Ala Gly Ser Tyr 355

SEQUENCE

s Met Gin 5 r Lys Cys r Asn Ile I Lys Pro SCys Gin Gly Gly Pro Ile 100 Leu Leu Glu Leu Glu Arg Pro Gly 165 SSer Lys 180 Ala Ser Arg Lys Thr Tyr Leu Gly 245 Gin Leu 260 Gin Gly Thr Leu Trp Gin Gin Gly 325 Gly Val 340 Arg Val TYPE: None DESCRIPTION: SEQ ID Gly Leu Leu Glu Arg 10 Ala Phe Gin Pro Pro 25 Ser Arg Leu Leu Gin 40 Trp Ile Thr Arg Gin 55 Pro Asp Ser Ser Thr 70 Gly Ser Gly Gly Gly 90 Ser Ser Asp Phe Ala 105 Gin Asp Tyr Pro Val 120 Cys Gly Gly Leu Trp 135 Leu Lys Thr Val Ala 150 Glu Pro Ser Gly Pro 170 Glu Ser His Lys Ser 185 Ser Leu Pro Gin Ser 200 Ile Gin Gly Asp Gly 215 Lys Leu Cys His Pro 230 Ile Pro Trp Ala Pro 250 Ala Gly Cys Leu Ser 265 Leu Leu Gin Ala Leu 280 Asp Thr Leu Gin Leu 295 Gin Met Glu Glu Leu 310 Ala Met Pro Ala Phe 330 Leu Val Ala Ser His 345 Leu Arg His Leu Ala 360 NO:746: Val Asn Pro Ser Glu Thr Asn Phe Leu Gly 75 Thr Gin Val Lys Thr Val Arg Leu 140 Gly Tyr 155 Ile Ser Pro Asn Phe Leu Ala Ala 220 Glu Glu 235 Leu Ser Gin Leu Glu Gly Asp Val 300 Gly Met 315 Ala Ser Leu Gin Gin Pro Thr Cys Ser Phe Gly Asp Ile Ala 125 Val Val Thr Met Leu 205 Leu Leu Ser His Ile 285 Ala Ala Ala Ser Glu Ile Leu Arg Glu Gin Arg Cys Gly Ser Cys Ser Arg Glu 110 Ser Asn Leu Ala Glu Gly Ile Asn 175 Ala Thr 190 Lys Cys Gin Glu Val Leu Cys Pro 255 Ser Gly 270 Ser Pro Asp Phe Pro Ala Phe Gin 335 Phe Leu 350 His Phe Leu Leu Gly Phe Leu Leu Gin Gly 160 Pro Pro Leu Lys Leu 240 Ser Leu Glu Ala Leu 320 Arg Glu INFORMATION FOR SEQ ID NO:747: WO 98/17810 SEQUENCE CHARACTERISTICS: LENGTH: 378 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 Ala 1 Gin Gly Ala Ser Trp Pro Gly Gly Asp 145 Tyr Ser Pro Pro Val 225 Ala Ser Leu Tyr Pro 305 Ile Thr Gly (ii) MOLECULE (xi) SEQUENCE Gin Asp Glu Glu 5 Arg Trp Met Glu Leu Leu Glu Arg Phe Gin Pro Pro Arg Leu Leu Gin Ile Thr Arg Gin Asp Ser Ser Thr 100 Ser Gly Gly Gly 115 Ser Gly Thr Gin 130 Phe Ala Val Lys Pro Val Thr Val 165 Pro Gly Glu Pro 180 Ser Lys Glu Ser 195 Ala Ser Ser Leu 210 Arg Lys Ile Gin Thr Tyr Lys Leu 245 Leu Gly Ile Pro 260 Gin Leu Ala Gly 275 Gin Gly Leu Leu 290 Thr Leu Asp Thr Trp Gin Gin Met 325 Gin Gly Ala Met 340 Gly Val Leu Val 355 TYPE: None DESCRIPTION: SEQ ID NO:747: Leu Cys Gly Arg Leu Lys Val Asn Thr 40 Pro Ser Cys 55 Glu Thr Ser 70 Asn Phe Ser Leu Gly Gly Ser Gly Gly 120 Asp Cys Ser 135 Ile Arg Glu 150 Ala Ser Asn Ser Gly Pro His Lys Ser 200 Pro Gin Ser 215 Gly Asp Gly 230 Cys His Pro Trp Ala Pro Cys Leu Ser 280 Gin Ala Leu 295 Leu Gin Leu 310 Glu Glu Leu Pro Ala Phe Ala Ser His 360 His Leu Ala Arg Leu Val Gly Ser Lys Phe Val Thr Val Gin Thr Val Ala Leu Glu Leu Gin Gly Gly Ser 110 Gly Gly Ser 125 Ser Pro Ile 140 Tyr Leu Leu Glu Gly Gly Ile Asn Pro 190 Ala Thr Pro 205 Lys Cys Leu 220 Gin Glu Lys Val Leu Leu Cys Pro Ser 270 Ser Gly Leu 285 Ser Pro Glu 300 Asp Phe Ala Pro Ala Leu Phe Gin Arg 350 Phe Leu Glu 365 Leu Met Lys Asn Lys Cys Gly Gly Ser Gin Gly 175 Ser Leu Glu Leu Gly 255 Gin Phe Leu Thr Gin 335 Arg Val Tyr Arg Val 370 Leu Arg INFORMATION FOR SEQ ID NO:748: SEQUENCE CHARACTERISTICS: LENGTH: 364 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:748: Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 25 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 40 WO 98/17810 Ala Ser Trp Pro Ala Ser Gin 145 Gly Ser Leu Giu Leu 225 Gly Gin Phe Leu Thr 305 Gin Arg Val Phe Arg Ile Asp Thr Ser 130 Asp Gly Pro Gly Gin 210 Cys His Ala Leu Gly 290 Thr Pro Ala Ser Gin Leu Thr Ser Ala 115 Asp Tyr Ser Pro Pro 195 Val Ala Ser Leu Tyr 275 Pro Ile Thr Gly Tyr 355 Pro Leu Arg Ser 100 Pro Phe Pro Pro Ser 180 Ala Arg Thr Leu Gin 260 Gin Thr Trp Gin Gly 340 Arg Pro Gin Gin 85 Thr Thr Ala Val Gly 165 Lys Ser Lys Tyr Gly 245 Leu Gly Leu Gin Gly.

325 Val Val Ser 55 Thr Phe Pro Gin Lys 135 Val Pro Sex Leu Gin 215 Leu Pro Gly Leu Thr 295 Met Met Val1 Arg Cys Ser Ser Pro Asp 120 Ile Ala Ser His Pro 200 Gly Cys Trp Cys Gin 280 Leu Giu Pro Ala His 360 Leu *Glu *Arg Pro 105 Cys Arg Ser Gly Lys 185 Gin Asp His Ala Leu 265 Ala Gin Glu Ala Ser 345 Leu Arg Gin Cys 90 Trp, Ser Giu Asn Pro 170 Ser Ser Gly Pro Pro 250 Sex Leu Leu Leu Phe 330 His Ala Phe Leu 75 Leu Ser Phe Leu Leu 155 Ile Pro Phe Ala Giu 235 Leu Gin Giu Asp Gly 315 Ala Leu Gin Val Val Glu Pro Gin Sex 140 Tyr Ser Asn Leu Ala 220 Giu Sex Leu Gly Val 300 Met Ser Gin Pro Gin Ala Leu Arg His 125 Asp Val1 Thr Met Leu 205 Leu Leu Sex His Ile 285 Ala Ala Ala Ser Thr *Leu *Gin *Pro 110 Ser Tyr Giu Ile Ala 190 Lys Gin Val Cys Sex 270 Ser Asp Pro Phe Phe 350 PCTIUS97/20037 Asn Ile Lys Pro Cys Gin Leu Gly Pro Ile Leu Leu Giy Gly 160 Asn Pro 175 Thr Pro Cys Leu Glu Lys Leu Leu 240 Pro Sex 255 Gly Leu Pro Giu Phe Ala Ala Leu 320 Gin Arg 335 Leu Glu INFORMATION FOR SEQ ID NO:749: SEQUENCE CHARACTERISTICS.

LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None Ala 1 Gin Gly Aia Ser Trp Pro Ala Phe Leu 145 Leu Ile (xi) Gin Asp Arg Trp Leu Leu Phe Gin Arg Leu Ile Thr Asp Sex Thr Ala 115 Gin His 130 Sex Asp Tyr Val Sex Thr SEQUENCE DESCRIPTI Giu GiU Leu Cys C 5 Met Giu Arg Leu I 20 Glu Arg Val Asn qI 4 Pro Pro Pro Sex C 55 Leu Gin Glu Thr S 70 *Arg Gin Asn Phe S 85 *Sex Thr Leu Pro r 100 *Pro Thr Ala Giy 0

I

Sex Pro Ile Ser S 135 Tyr LeU Leu Gin A 150 Giu Giy Gly Gly G 165 Ile Asn Pro Sex P 180 ON: SEQ ID NO:749: Gly Leu Thr Val Giu Ile Leu Arg Glu Gin Arg Cys Pro Txp 105 Pro Pro Asp Phe Tyr Pro Sex Pro 170 Pro Sex 185 Arg Leu Gly Sex Phe Val Val Gin Vai Ala Giu Leu Pro Arg Thr Gin 125 Val Lys 140 Thr Val Giu Pro Giu Sex WO 98/17810 Pro A; Phe L( 2: Ala A: 225 Glu G: Leu St Gin L Glu G] Asp Ve 305 Gly Me sn Met Ala Thr Pro Leu 195 Lys Cys Gin Glu Val Leu 245 Cys Pro 260 Ser Gly Ser Pro Asp Phe Pro Ala 325 Phe Gin 340 Phe Leu Leu Glu 215 Lys Leu 230 Leu Gly Ser Gin Leu Phe Glu Leu 295 Ala Thr 310 Leu Gin Arg Arg Glu Val Gly 200 Gin Cys His Ala Leu 280 Gly Thr Pro Ala Ser 360 Pro Val Ala Ser Leu 265 Tyr Pro Ile Thr Gly 345 Tyr PCT/US97/20037 Ala Ser Ser Leu Pro Gin Ser 205 Arg Lys Ile Gin Gly Asp Gly 220 Thr Tyr Lys Leu Cys His Pro 235 240 Leu Gly Ile Pro Trp Ala Pro 250 255 Gin Leu Ala Gly Cys Leu Ser 270 Gin Gly Leu Leu Gin Ala Leu 285 Thr Leu Asp Thr Leu Gin Leu 300 Trp Gin Gin Met Glu Glu Leu 315 320 Gin Gly Ala Met Pro Ala Phe 330 335 Gly Val Leu Val Ala Ser His 350 Arg Val Leu Arg His Leu Ala 365 Ser Ala Gin Ser 355 Pro 370 INFORMATION FOR SEQ ID NO:750: SEQUENCE CHARACTERISTICS: LENGTH: 378 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Arg Leu Phe Arg Ile Asp Ser Ser Phe 145 Pro Ser Pro Pro Val 225 Ala Ser Leu Tyr Pro 305 (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Ser 115 Gly Thr Gin Asp 130 Ala Val Lys Ile Val Thr Val Ala 165 Pro Gly Glu Pro 180 Ser Lys Glu Ser 195 Ala Ser Ser Leu 210 Arg Lys Ile Gin Thr Tyr Lys Leu 245 Leu Gly Ile Pro 260 Gin Leu Ala Gly 275 Gin Gly Leu Leu 290 Thr Leu Asp Thr TYPE: None DESCRIPTION: SEQ ID NO:750: Cys Leu Asn Ser Thr 70 Phe Gly Gly Cys Arg 150 Ser Ser His Pro Gly 230 Cys Trp Cys Gin Leu 310 Arg Leu Gly Ser Phe Val Val Gin Val Ala 75 Glu Leu Gly Gly Gly Gly Ser Pro 140 Tyr Leu 155 Val Glu Thr Ile Met Ala Leu Lys 220 Leu Gin 235 Leu Val Ser Cys His Ser Ile Ser 300 Ala Asp 315 Leu Ala Gin Met Gin Gly Lys Cys Ala Asn Ile Ser Lys Pro Trp Cys Gin Pro Gly Gly Gly 110 Gly Gly Gly Ser Ser Asp Gin Asp Tyr 160 Gly Gly Gly 175 Pro Ser Pro 190 Pro Leu Gly Leu Glu Gin Lys Leu Cys 240 Leu Gly His 255 Ser Gin Ala 270 Leu Phe Leu Glu Leu Gly Ala Thr Thr 320 WO 98/17810 Ile Trp Thr Gin Gly Gly Tyr Arg 370 Gin Met 325 Ala Met 340 Leu Val Leu Arg f9 PCT/US97/20037 Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 330 335 Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 345 350 Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 360 365 His Leu Ala Gin Pro 375 INFORMATION FOR SEQ ID NO:751: SEQUENCE CHARACTERISTICS: LENGTH: 378 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE Ala 1 Arg Leu Phe Arg Ile Asp Ser Ser Phe 145 Pro Ser Pro Pro Val 225 Ala Ser Leu Tyr Pro 305 Ile Thr Gly Tyr (xi) Asp Glu Trp Met Leu Glu Gin Pro Leu Leu Thr Arg Ser Ser Gly Gly 115 Gly Thr 130 Ala Val Val Thr Pro Gly Ser Lys 195 Ala Ser 210 Arg Lys Thr Tyr Leu Gly Gin Leu 275 Gin Gly 290 Thr Leu Trp Gin Gin Gly Gly Val 355 Arg Val 370

SEQUENCE

Glu Leu 5 Glu Arg Arg Val Pro Pro SGin Glu Gin Asn Thr Leu 100 Gly Ser Gin Asp Lys Ile Val Ala 165 Glu Pro 180 Glu Ser Ser Leu Ile Gin Lys Leu 245 Ile Pro 260 Ala Gly Leu Leu Asp Thr Gln Met 325 Ala Met 340 Leu Val Leu Arg TYPE: None DESCRIPTION: SEQ ID NO:751: Cys Pro Asn Ser Thr 70 Phe Gly Gly Cys Arg 150 Ser Ser His Pro Gly 230 Cys Trp Cys Gin Leu 310 Glu Pro Ala His Gly Lys Thr Cys 55 Ser Ser Gly Gly Ser 135 Glu Asn Gly Lys Gin 215 Asp His Ala Leu Ala 295 Gin Glu Ala Ser Leu 375 Arg Leu Val Gly Ser Lys Phe Val Thr Val Gin Thr Val Ala Leu Glu Leu Gin Gly Gly Ser Gly Gly Ser 125 Ser Pro Ile 140 Tyr Leu Leu 155 Val Glu Gly Thr Ile Asn Met Ala Thr 205 Leu Lys Cys 220 Leu Gin Glu 235 Leu Val Leu Ser Cys Pro His Ser Gly 285 Ile Ser Pro 300 Ala Asp Phe 315 Ala Pro Ala Ala Phe Gin Ser Phe Leu 365 Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Gly Gly 110 Gly Gly Ser Ser Gin Asp Gly Gly 175 Pro Ser 190 Pro Leu Leu Glu Lys Leu Leu Gly 255 Ser Gin 270 Leu Phe Glu Leu Ala Thr Leu Gin 335 Arg Arg 350 Glu Val INFORMATION FOR SEQ ID NO:752: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Asp Glu Glu Leu 1 5 Arg Trp Met Glu Arg Leu Leu Glu Arg Val Phe Gin Pro Pro Pro Arg Leu Leu Gin Glu Ile Thr Arg Gin Asn Asp Ser Ser Thr Leu 100 Thr Ala Pro Thr Ala 115 Gin His Ser Pro Ile 130 Ser Asp Tyr Leu Leu 145 Gin Tyr Val Glu Gly 165 Ile Ser Thr Ile Asn 180 Pro Asn Met Ala Thr 195 Phe Leu Leu Lys Cys 210 Ala Ala Leu Gin Glu 225 Glu Glu Leu Val Leu 245 Leu Ser Ser Cys Pro 260 Gin Leu His Ser Gly 275 Glu Gly Ile Ser Pro 290 Asp Val Ala Asp Phe 305 Gly Met Ala Pro Ala 325 Ala Ser Ala Phe Gin 340 Leu Gin Ser Phe Leu 355 Gin Pro 370 TYPE: None DESCRIPTION: SE Cys Gly Gly Leu Q ID NO:752: Trp Arg Leu Ala Gly Ser His Phe Val Phe Val Gin Leu Val Ala Leu Glu Leu Ser Pro Arg Leu Thr Gin Ala Val Lys 140 Val Thr Val 155 Pro Gly Glu 170 Ser Lys Glu Ala Ser Ser Arg. Lys Ile 220 Thr Tyr Lys 235 Leu Gly Ile 250 Gin Leu Ala Gin Gly Leu Thr Leu Asp 300 Trp Gin Gln 315 Gin Gly Ala 330 Gly Val Leu Arg Val Leu INFORMATION FOR SEQ ID NO:753: SEQUENCE CHARACTERISTICS: LENGTH: 347 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:753: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu WO98/17810 PCT/US97/20037 90 Val Glu Thr Val Phe His Arg Val Ser Gin Asp Gly Leu Asp Leu Leu 100 105 110 Thr Ser Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 115 120 125 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 130 135 140 Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly 145 150 155 160 Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu 165 170 175 Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu 180 185 190 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 195 200 205 Cys Ala Thr Asn Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly 210 215 220 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 225 230 235 240 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 245 250 255 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 260 265 270 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 275 280 285 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 290 295 300 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 305 310 315 320 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 325 330 335 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345 INFORMATION FOR SEQ ID NO:754: SEQUENCE CHARACTERISTICS: LENGTH: 384 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:754: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 25 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 40 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 55 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 70 75 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 Asp Ser Ser Thr Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu 100 105 110 Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu 115 120 125 Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 130 135 140 Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 145 150 155 160 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys 165 170 175 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 180 185 190 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 195 200 205 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 210 215 220 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 225 230 235 240 Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin WO 98/17810

;AL

PCT/US97/20037 Met Met Val Arg 305 Glu Glu His Asp Met Ser Gin Pro 310 Ile Pro Ser Asp Pro Ala Ser 300 Gly Ser Asp Ile Ala 380 Gin Gly 270 Gly Val Arg Val Ser Pro Pro Ser 335 Ser Phe 350 Glu. Leu Asn Leu INFORMATION FOR SEQ ID N0:755: SEQUENCE CHARACTERISTICS: LENGTH: 349 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear Ala 1 Ala Val Thr Gin Asp His Ala Leu Ala 145 Gin Glu Ala Ser Leu 225 Pro Leu Val Ile Arg 305 Gin Cys (ii) MOLECULE (xi) SEQUENCE Thr Gin Asp Cys 5 Val Lys Ile Arg Thr Val Ala Ser Ser Pro Pro Ser Ser Phe Leu Leu Gly Ala Ala Leu Pro Glu Glu Leu 100 Pro Leu Ser Ser 115 Ser Gin Leu His 130 Leu Glu Gly Ile Leu Asp Val Ala 165 Leu Gly Met Ala 180 Phe Ala Ser Ala 195 His Leu Gin Ser 210 Ala Gin Pro Ser Pro Ser Pro Gly 245 Trp Arg Leu Val 260 Ala Gly Ser Lys 275 His Phe Val Thr 290 Phe Val Gin Thr Leu Val Ala Leu 325 Leu Glu Leu Gin 340 TYPE: None DESCRIPTION: SEQ ID NO:755: Ser Phe Gin His Ser Pro Ile Ser 10 Glu Leu Ser Asp Tyr Leu Leu Gin 25 Asn Leu Gin Glu Pro Lys Ser Pro 40 Pro Thr Pro Leu Gly Pro Ala Ser 55 Lys Ser Leu Glu Gin Val Arg Lys 70 Gin Glu Lys Leu Cys Ala Thr Tyr 90 Val Leu Leu Gly His Ser Leu Gly 105 Cys Pro Ser Gin Ala Leu Gin Leu 120 125 Ser Gly Leu Phe Leu Tyr Gin Gly 135 140 Ser Pro Glu Leu Gly Pro Thr Leu 150 155 Asp Phe Ala Thr Thr Ile Trp Gin 170 Pro Ala Leu Gin Pro Thr Gin Gly 185 Phe Gin Arg Arg Ala Gly Gly Val 200 205 Phe Leu Glu Val Ser Tyr Arg Val 215 220 Ala Glu Pro Lys Ser Pro Asp Thr 230 235 Ser Asn Leu Gin Asp Glu Glu Leu 250 Leu Ala Gin Arg Trp Met Glu Arg 265 Met Gin Gly Leu Leu Glu Arg Val 280 285 Lys Cys Ala Phe Gin Pro Pro Pro 295 300 Asn Ile Ser Arg Leu Leu Gin Glu 310 315 Lys Pro Trp Ile Thr Arg Gin Asn 330 Cys Gin Pro Asp Ser Ser Thr Leu Asp Tyr Thr Leu Gin Leu Pro Gly Leu Thr Met 175 Met Val Arg Thr Gly 255 Lys Thr Cys Ser Ser 335 INFORMATION FOR SEQ ID NO:756: WO 98/17810 S 1 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 347 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Ala Thr Gin Asp Cys 1 5 Ala Val Lys Ile Arg Val Thr Val Ala Ser Trp Arg Leu Val Leu Ala Gly Ser Lys Met His Phe Val Thr Lys Ser Pro Pro Ser Pro 100 Gin Ser Phe Leu Leu 115 Asp Gly Ala Ala Leu 130 Pro Glu Glu Leu Val 145 Pro Leu Ser Ser Cys 165 Ser Gin Leu His Ser 180 Leu Glu Gly Ile Ser 195 Leu Asp Val Ala Asp 210 Leu Gly Met Ala Pro 225 Phe Ala Ser Ala Phe 245 His Leu Gin Ser Phe 260 Ala Gin Pro Ser Ala 275 Pro Ser Pro Gly Lys 290 Val Gin Thr Asn Ile 305 Val Ala Leu Lys Pro 325 Glu Leu Gin Cys Gin 340 TYPE: None DESCRIPTION: SEQ ID NO:756: Ser Phe Gin His Glu Leu Ser Asp 25 Asn Leu Gin Asp 40 Ala Gin Arg Trp 55 Gin Gly Trp Gin 70 Cys Ala Phe Pro Gly Thr Pro Leu 105 Lys Ser Leu Glu 120 Gin Glu Lys Leu 135 Leu Leu Gly His 150 Pro Ser Gin Ala Gly Leu Phe Leu 185 Pro Glu Leu Gly 200 Phe Ala Thr Thr 215 Ala Leu Gin Pro 230 Gin Arg Arg Ala Leu Glu Val Ser 265 Glu Pro Lys Ser 280 Ala Phe Gin Pro 295 Ser Arg Leu Leu 310 Trp Ile Thr Arg Pro Asp Ser Ser 345 Pro Ile Ser Ser Asp Leu Leu Gin Asp Tyr Glu Leu Cys Gly Gly Glu Arg Leu Lys Thr Arg Val Asn Thr Glu Ser Pro Asp Thr His Pro Ala Ser Ser Leu 110 Val Arg Lys Ile Gin 125 Ala Tyr Lys Leu Cys 140 Leu Gly Ile Pro Trp 155 Gin Leu Ala Gly Cys 175 Gin Gly Leu Leu Gin 190 Thr Leu Asp Thr Leu 205 Trp Gin Gin Met Glu 220 Gin Gly Ala Met Pro 235 Gly Val Leu Val Ala 255 Arg Val Leu Arg His 270 Asp Thr His Thr Ser 285 Pro Ser Cys Leu Arg 300 Glu Thr Ser Glu Gin 315 Asn Phe Ser Arg Cys 335 Leu INFORMATION FOR SEQ ID NO:757: SEQUENCE CHARACTERISTICS: LENGTH: 355 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:757: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 10 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 25 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Ser 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro WO 98/17810 Ile Asp Ser Gin Ser 145 Gin Gly Ser Gly Pro 225 Pro Ser Leu Leu Leu 305 Phe His Ala Thr Arg Ser Ser Gly Gly 115 His Ser 130 Asp Tyr Tyr Val Ser Asn Phe Leu 195 Ala Ala 210 Glu Glu Leu Ser Gin Leu Glu Gly 275 Asp Val 290 Gly Met Ala Ser Leu Gin Gin Pro 355 Phe Ser Arg Gly Gly Gly Gly Gly Gly 120 Ser Ser Asp 135 Gin Asp Tyr 150 Gly Gly Gly Thr Pro Leu Ser Leu Glu 200 Glu Lys Leu 215 Leu Leu Gly 230 Pro Ser Gin Gly Leu Phe Pro Glu Leu 280 Phe Ala Thr 295 Ala Leu Gin 310 Gin Arg Arg Leu Glu Val Glu Leu Gin Gly Gly Ser Thr Gin Asp 125 Val Lys Ile 140 Thr Val Ala 155 Gly Gly Gly Ala Ser Ser Arg Lys Ile 205 Thr Asn Lys 220 Leu Gly Ile 235 Gin Leu Ala Gin Gly Leu Thr Leu Asp 285 Trp Gin Gin 300 Gin Gly Ala 315 Gly Val Leu Arg Val Leu PCT/US97/20037 Gin Pro Gly Gly Ser Phe Glu Leu Asn Leu 160 Gly Gly 175 Pro Gin Gly Asp Cys His Trp Ala 240 Cys Leu 255 Gin Ala Leu Gin Glu Glu Pro Ala 320 Ala Ser 335 His Leu INFORMATION FOR SEQ ID NO:758: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Asp Glu Glu 210 DESCRIPTION: SEQ ID Pro Ala Ser Ser Leu 10 Val Arg Lys Ile Gin Ala Thr Tyr Lys Leu Ser Leu Gly Ile Pro 55 Leu Gin Leu Ala Gly Tyr Gin Gly Leu Leu 90 Pro Thr Leu Asp Thr 105 Ile Trp Gin Gin Met 120 Thr Gin Gly Ala Met 135 Gly Gly Val Leu Val 150 Tyr Arg Val Leu Arg 170 Gly Ser Pro Gly Glu 185 Pro Pro Ser Lys Glu 200 Leu Cys Gly Gly Leu 215 NO:758: Pro Gin Gly Asp Cys His Trp Ala Cys Leu 75 Gin Ala Leu Gln Glu Glu Pro Ala 140 Ala Ser 155 His Leu Pro Ser Ser His Trp Arg 220 Leu Leu Ala Leu Glu Leu Ser Ser Leu His Gly Ile Val Ala Met Ala Ser Ala Gin Ser 160 Pro Tyr 175 Ile Ser Pro Asn Leu Ala WO 98/17810 Gin Arg Trp Met Glu Leu Lys Thr Val Ala Gly Ser Lys Met Leu Lys Thr Val Ala Gly Ser Lys Met PCT/US97/20037 INFORMATION FOR SEQ ID N0:759: SEQUENCE CHARACTERISTICS: LENGTH: 355 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Glu Leu Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Ser 115 His Ser Pro Ile 130 Asp Tyr Leu Leu Tyr Val Glu Gly 165 Ser Asn Met Ala 180 Phe Leu Leu Lys 195 Ala Ala Leu Gln 210 Glu Glu Leu Val Leu Ser Ser Cys 245 Gin Leu His Ser 260 Glu Gly Ile Ser 275 Asp Val Ala Asp 290 Gly Met Ala Pro Ala Ser Ala Phe 325 Leu Gln Ser Phe 340 TYPE: None DESCRIPTION: SEQ ID N0:759: WO98/17810 7/ Ala Gin Pro 355 INFORMATION FOR SEQ ID NO:760: SEQUENCE CHARACTERISTICS: LENGTH: 370 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Thr Pro Leu Gly 1 5 Lys Ser Leu Glu Gin Gln Glu Lys Leu Cys Val Leu Leu Gly His Cys Pro Ser Gln Ala Ser Gly Leu Phe Leu Ser Pro Glu Leu Gly 100 Asp Phe Ala Thr Thr 115 Pro Ala Leu Gln Pro 130 Phe Gin Arg Arg Ala 145 Phe Leu Glu Val Ser 165 Val Glu Gly Gly Gly 180 Thr Ile Asn Pro Ser 195 Met Ala Asp Glu Glu 210 Gin Arg Trp Met Glu 225 Gly Leu Leu Glu Arg 245 Ala Phe Gln Pro Pro 260 Ser Arg Leu Leu Gin 275 Trp Ile Thr Arg Gin 290 Pro Asp Ser Ser Thr 305 Gly Ser Gly Gly Gly 325 Phe Gin His Ser Pro 340 Leu Ser Asp Tyr Leu 355 Leu Gin 370 TYPE: None DESCRIPTION: SEQ ID NO:760: Pro Ala Ser Val Arg Lys Ala Thr Tyr 40 Ser Leu Gly 55 Leu Gin Leu 70 Tyr Gin Gly Pro Thr Leu Ile Trp Gin 120 Thr Gln Gly 135 Gly Gly Val 150 Tyr Arg Val Gly Ser Pro Pro Pro Ser 200 Leu Cys Gly 215 Arg Leu Lys 230 Val Asn Thr Pro Ser Ser Glu Thr Ser 280 Asn Phe Ser 295 Leu Gly Gly 310 Ser Gly Gly Ile Ser Ser Leu Gln Asp 360 Gin Ser Phe Leu Asp Gly Ala Ala His Pro Glu Glu Ala Pro Leu Ser Leu Ser Gin Leu Ala Leu Glu Gly Gin Leu Asp Val 110 Glu Leu Gly Met 125 Ala Phe Ala Ser 140 Ser His Leu Gin Leu Ala Gin Pro 175 Ser Gly Pro Ile 190 His Lys Ser Pro 205 Arg Leu Val Leu 220 Gly Ser Lys Met Phe Val Thr Lys 255 Val Gin Thr Asn 270 Val Ala Leu Lys 285 Glu Leu Gin Ser 300 Gly Gly Ser Gly Thr Gin Asp Cys 335 Val Lys Ile Arg 350 Thr Val Ala Ser 365 INFORMATION FOR SEQ ID NO:761: SEQUENCE CHARACTERISTICS: LENGTH: 334 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Ala Thr Gin Asp Ser DESCRIPTION: SEQ ID NO:761: Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe WO 98/17810 1 Ala Val Val Thr Trp Arg Ala Gly His Phe Phe Val Leu Val Leu Giu 130 Gly Gly 145 Thr Pro Ser Leu Glu Lys Leu Leu 210 Pro Ser 225 Gly Leu Pro Giu Phe Ala Ala Leu 290 Gin Arg 305 Leu Giu Lys Ile Val Ala Leu Val Ser Lys Val Thr Gin Thr 100 Ala Leu 115 Leu Gin Gly Ser Leu Gly Giu Gin 180 Leu Cys 195 Giy His Gin Ala Phe Leu Leu Gly 260 Thr Thr 275 Gin Pro Arg Ala Val Ser 5 Arg Giu Ser Asn Leu Ala Met Gin 70 Lys Ser Asn Ile Lys Pro Cys Gin Pro Gly 150 Pro Ala 165 Val Arg Ala Thr Ser Leu Lieu Gin 230 I'yr Gin 245 Pro Thr Ile Trp rhr Gin 3iy Gly 310 ryr Arg Leu Ser Asp 25 Leu Gin Asp 40 Gin Arg Trp 55 Gly Leu Leu Ala Phe Gin Ser Arg Leu 105 Trp Ile Thr 120 Pro Asp Ser 135 Gly Gly Ser Ser Ser Leu Lys Ile Gin 185 Asn Lys Leu 200 Gly Ile Pro 215 Leu Ala Gly Gly Leu Leu Leu Asp Thr 265 Gin Gin Met 280 Gly Ala Met 295 Val Leu Val Val Leu Arg 10 Tyr Leu Leu Gin Giu Giu Leu Cys Met Giu Arg Leu Glu Arg Val Asn Pro Pro Pro Ser Leu Gin Glu Thr Arg Gin Asn Phe 125 Ser Thr Leu Tyr 140 Gly Gly Gly Ser 155 Pro Gin Ser Phe 170 Gly Asp Gly Ala Cys His Pro Giu 205 Trp Ala Pro Leu 220 Cys Leu Ser Gin 235 Gin Ala Leu Glu 250 Leu Gin Leu Asp Giu Giu Leu Gly 285 Pro Ala Phe Ala 300 Ala Ser His Leu 315 His Leu Ala Gin 330 NO: 762: PCT/US97/20037 Asp Tyr Pro Gly Gly Leu Lys Thr Val INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS- LENGTH: 334 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE Thr Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser Arg Leu Val Leu Gly Ser Lys Met Phe Val Thr Lys Val Gin Thr Asn 100 Val Ala Leu Lys 115 Giu Leu Gin Ser 130 Giy Gly Ser Pro Pro Leu Gly Pro 165 Leu Giu Gin Val DESCRIPTION: SEQ ID Ser Phe Gin His Ser Glu Leu Ser Asp Tyr 25 Asn Leu Gin Asp Giu Ala Gin Arg Trp, Met 55 Gin Gly Leu Leu Glu Cys Ala Phe Gin Pro Ile Ser Arg Leu Leu 105 Pro Trp Ile Thr Arg 120 Gin Pro Asp Ser Ser 135 Gly Gly Gly Ser Gly 150 Ala Ser Ser Leu Pro 170 Arg Lys Ile Gin Gly NO:762: Pro Ile Leu Leu Glu Leu Glu Arg Arg Val Pro Pro Gin Giu Gin Asn Thr Leu 140 Gly Gly 155 Gln Ser Asp Gly WO 98/17810 PCT/US97/20037 180 185 190 Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 260 265 270 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 290 295 300 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330 INFORMATION FOR SEQ ID NO:763: SEQUENCE CHARACTERISTICS: LENGTH: 326 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:763: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 25 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 40 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 55 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 70 75 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 90 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly 130 135 140 Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 145 150 155 160 Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 165 170 175 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Asn Lys 180 185 190 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 195 200 205 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gln Leu Ala 210 215 220 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 225 230 235 240 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 245 250 255 Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin 260 265 270 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 275 280 285 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu 290 295 300 Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 305 310 315 320 Arg His Leu Ala Gin Pro 325 INFORMATION FOR SEQ ID NO:764: WO 98/17810 Z7/ SEQUENCE CHARACTERISTICS: LENGTH: 334 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (ii) MOLECULE (xi) SEQUENCE Ala Thr Gln Asp Cys 1 5 Ala Val Lys Ile Arg Val Thr Val Ala Ser Trp Arg Leu Val Leu Ala Gly Ser Lys Met His Phe Val Thr Lys Phe Val Gin Thr Asn 100 Leu Val Ala Leu Lys 115 Leu Glu Leu Gln Ser 130 Gly Gly Gly Ser Pro 145 Thr Pro Leu Gly Pro 165 Ser Leu Glu Gln Val 180 Glu Lys Leu Cys Ala 195 Leu Leu Gly His Ser 210 Pro Ser Gin Ala Leu 225 Gly Leu Phe Leu Tyr 245 Pro Glu Leu Gly Pro 260 Phe Ala Thr Thr Ile 275 Ala Leu Gin Pro Thr 290 Gin Arg Arg Ala Gly 305 Leu Glu Val Ser Tyr 325 TYPE: None

DESCRIPTION:

SEQ ID NO:764: lis Ser Pro Ile 10 Lsp Tyr Leu Leu 15 ksp Glu Glu Leu 'rp Met Glu Arg ,eu Glu Arg Val ;ln Pro Pro Pro 90 ,eu Leu Gin Glu .05 'hr Arg Gin Asn ;er Ser Thr Leu 140 ier Gly Gly Gly 155 eu Pro Gin Ser 170 :In Gly Asp Gly .85 ieu Cys His Pro 'ro Trp Ala Pro 220 ;ly Cys Leu Ser 235 ,eu Gln Ala Leu 250 'hr Leu Gin Leu 65 let Glu Glu Leu let Pro Ala Phe 300 'al Ala Ser His 315 .rg His Leu Ala 330 Ser Asp Asp Tyr Gly Gly Lys Thr Thr Glu Cys Leu Ser Glu 110 Ser Arg Val Glu Asn Met Leu Leu 175 Ala Leu 190 Glu Leu Ser Ser Leu His Gly Ile 255 Val Ala 270 Met Ala Ser Ala Gln Ser Pro INFORMATION FOR SEQ ID NO:765: SEQUENCE CHARACTERISTICS: LENGTH: 334 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:765: Ala Thr Gln Asp Cys Ser Phe Gin His Ser Pro Ile 1 5 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 55 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 70 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro WO 98/1 7810 Phe Val- Leu Va- Leu Gli 13( Giy Gi) 145 Thr Prc Ser Let GiU Ly~c Leu Let 21( Pro Sex 225 Gly Let Pro Git Phe Ala Ala Let 29C Gin Arc 305 Leu Git Arg Leu 105 Ile Thr 120 Asp Ser Giy Ser Ser Leu Ile Gin 185 Lys Leu 200 Ile Pro Ala Giy Leu Leu Asp Thr 265 Gin Met 280 Ala Met Leu Vai Leu Arg Leu Gin Arg Gin Ser Thr Gly Giy 155 Pro Gin 170 Gly Asp Cys His Trp Ala Cys Leu 235 Gin Ala 250 Leu Gln Giu Giu Pro Ala Ala Ser 315 His Leu 330 NO: 766: Giu Thr Ser 110 Asn Phe Ser 125 Leu Tyr Val 140 Gly Ser Asn Ser Phe Leu Gly Ala Ala 190 Pro Glu Glu 205 Pro Leu Ser 220 Ser Gin Leu Leu Giu Gly Leu Asp Val 270 Leu Gly Met 285 Phe Ala Ser 300 His Leu Gin Ala Gin Pro PCTIUS97/20037 Gin Arg Gly Ala 160 Lys Gin Val Cys Ser 240 Ser Asp Pro Phe Phe 320 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 352 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Giu Leu Trp Met Glu Arg Leu Giu Arg Val Gin Pro Pro Pro Leu Leu Gin Giu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Ser 115 His Ser Pro Ile 130 Asp Tyr Leu Leu Tyr Val Glu Gly 165 Ser Asn Met Ala 180 Gin Arg Arg Ala 195 Leu Giu Val Ser 210 Gly Ser Gly Gly Arg Lys Ile Gin 245 Thr Tyr Lys Leu 260 TYPE: None DESCRIPTION: SEQ ID NO:766: Arg Leu Gly Ser Phe Val Val Gin Val Ala Git Leu Gly Gly Thr Gin Val Lys 140 Thr Val 155 Gly Gly Pro Ala Ala Ser His Leu 220 Leu Lys 235 Leu Gin Leu Val WO 98/1781( !u Gly Ile Pro Trp Ala Pro Leu Ser Ser 275 280 n Leu Ala Gly Cys Leu Ser Gin Leu His '0 295 n Gly Leu Leu Gin Ala Leu Glu Gly Ile 310 315 ir Leu Asp Thr Leu Gin Leu Asp Val Ala 325 330 p Gin Gin Met Glu Glu Leu Gly Met Ala 340 345 INFORMATION FOR SEQ ID N0:767: SEQUENCE CHARACTERISTICS: LENGTH: 367 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear PCTIUS97/20037 Cys Pro Ser 285 Ser Gly Leu 300 Ser Pro Glu Asp Phe Ala Pro Ala Leu 350 (ii) MOLECULE (xi) SEQUENCE Ala 1 Ala Ser Gly Gin Leu Pro Gly Leu Thr 145 Met Gly Pro Glu Met 225 Glu Pro Leu Arg Ser 305 Gly Thr Gin Gly Gly Tyr Arg Ser Gin Gly Asp Cys His Trp Ala Cys Leu 115 Gin Ala 130 Leu Gin Glu Glu Gly Gly Ser Pro 195 Glu Leu 210 Glu Arg Arg Val Pro Pro Gin Glu 275 Gin Asn 290 Thr Leu Gly Ser Gly Ala 5 Val Leu Val Leu Ser Phe Gly Ala Pro Glu Pro Leu 100 Ser Gin Leu Glu Leu Asp Leu Gly 165 Ser Pro 180 Pro Ser Cys Gly Leu Lys Asn Thr 245 Ser Cys 260 Thr Ser Phe Ser Gly Gly Gly Gly 325 Ser Ser 340 Gin Asp TYPE: None DESCRIPTION: SEQ ID Met Pro Ala Phe Ala Val Ala Ser His Leu Arg His Leu Ala Gin 40 Leu Leu Lys Ser Leu 55 Ala Leu Gin Glu Lys 70 Glu Leu Val Leu Leu Ser Ser Cys Pro Ser 105 Leu His Ser Gly Leu 120 Gly Ile Ser Pro Glu 135 Val Ala Asp Phe Ala 150 Met Ala Pro Ala Leu 170 Gly Glu Pro Ser Gly 185 Lys Glu Ser His Lys 200 Gly Leu Trp Arg Leu 215 Thr Val Ala Gly Ser 230 Glu Ile His Phe Val 250 Leu Arg Phe Val Gin 265 Glu Gin Leu Val Ala 280 Arg Cys Leu Glu Leu 295 Gly Ser Gly Gly Gly 310 Gly Ser Gly Thr Gin 330 Asp Phe Ala Val Lys 345 Tyr Pro Val Thr Val 360 NO:767: Ser Ala Gin Ser Pro Ser Glu Gin Leu Cys Gly His Gin Ala Phe Leu Leu Gly 140 Thr Thr 155 Gin Pro Pro Ile Ser Pro Val Leu 220 Lys Met 235 Thr Lys Thr Asn Leu Lys Gin Cys 300 Ser Gly 315 Asp Cys Ile Arg Ala Ser Phe Phe Gly Val Ala Ser Leu Tyr 125 Pro Ile Tyr Ser Asn 205 Ala Gin Cys Ile Pro 285 Gin Gly Ser Glu Asn 365 Ser Pro Ile Tyr Leu Leu 355 INFORMATION FOR SEQ ID NO:768: SEQUENCE CHARACTERISTICS: S(A) LENGTH: 344 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 22 PCT/US97/20037 (ii) MOLECULE TYPE: None Ala 1 Arg Leu Phe Arg Ile Asp Ser Ser Asp 145 Gly Ser Glu Glu Arg 225 Pro Gin Gin Thr Gly 305 Ala Val Ala 1 Arg Leu Phe Arg Ile Asp Ser (xi) SEQUENCE Asp Glu Glu Leu 5 Trp Met Glu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Asn Ser Ser Thr Leu 100 Gly Gly Gly Thr 115 Asp Phe Ala Val 130 Tyr Pro Val Thr Gly Ser Pro Gly 165 Pro Pro Ser Lys 180 Leu Cys Gly Gly 195 Arg Leu Lys Thr 210 Val Asn Thr Glu Pro Ser Cys Leu 245 Glu Thr Ser Glu 260 Asn Phe Ser Arg 275 Leu Gly Gly Gly 290 Thr Gin Asp Cys Val Lys Ile Arg 325 Thr Val Ala Ser 340 DESCRIPTION: SEQ ID N0:768: Cys Gly Gly Leu Trp Arg Leu 10 Leu Lys Thr Val Ala Gly Ser 25 Asn Thr Glu Ile His Phe Val 40 Ser Cys Leu Arg Phe Val Gin 55 Thr Ser Glu Gin Leu Val Ala 70 Phe Ser Arg Cys Leu Glu Leu 90 Gly Gly Gly Ser Gly Gly Gly 105 Gin Asp Cys Ser Phe Gin His 120 Lys Ile Arg Glu Leu Ser Asp 135 140 Val Ala Ser Asn Leu Gin Tyr 150 155 Glu Pro Ser Gly Pro Ile Ser 170 Glu Ser His Lys Ser Pro Asn 185 Leu Trp Arg Leu Val Leu Ala 200 Val Ala Gly Ser Lys Met Gin 215 220 Ile His Phe Val Thr Lys Cys 230 235 Arg Phe Val Gin Thr Asn Ile 250 Gin Leu Val Ala Leu Lys Pro 265 Cys Leu Glu Leu Gin Cys Gin 280 Ser Gly Gly Gly Ser Gly Gly 295 300 Ser Phe Gin His Ser Pro Ile 310 315 Glu Leu Ser Asp Tyr Leu Leu Val Leu Ala Lys Met Gin Thr Lys Cys Thr Asn Ile Leu Lys Pro Gin Cys Gin Ser Gly Gly 110 Ser Pro Ile 125 Tyr Leu Leu Val Glu Gly Thr Ile Asn 175 Met Ala Asp 190 Gin Arg Trp 205 Gly Leu Leu Ala Phe Gin Ser Arg Leu 255 Trp Ile Thr 270 Pro Asp Ser 285 Gly Ser Gly Ser Ser Asp Gin Asp Tyr 335 Val Leu Ala Lys Met Gin Thr Lys Cys Thr Asn Ile Leu Lys Pro Gin Cys Gin Ser Gly Gly 110 Asp Cys Ser INFORMATION FOR SEQ ID NO:769: SEQUENCE CHARACTERISTICS: LENGTH: 335 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:769: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 5 10 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 25 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 70 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 90 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 100 105 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin WO 98/17810 Gin His 130 Ser Asp 145 Gin Tyr Ile Ser Pro Asn Ser Asp 210 Asn Tyr 225 Gly Giy Lys Thr Thr Giu Cys Leu 290 Ser Giu 305 Ser Arg Ala Vai Val Thr 155 Pro Giy 170 Ser Lys Phe Gin Leu Ser Leu Gin 235 Gin Arg 250 Giy Leu Ala Phe Ser Arg Trp Ile 315 Pro Asp 330 NO: 7 PCTIUS97/20037 Leu Leu 160 Pro Ser Ser Gin Cys 240 Leu Asn Ser Thr Phe 320 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 550 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Giu Giu Leu Trp Met GiU Arg Leu Giu Arg Val Gin Pro Pro Pro Leu Leu Gin Glu Thr Arg Gin Aso Ser Ser Thr Leu 100 Gly Giy Gly Ser 115 His Ser Pro Ile 130 Asp Tyr Leu Leu Tyr Val Glu Giy 165 Ser Asn Met Aia 180 Phe Leu Leu Lys 195 Aia Ala Leu Gin 210 Giu Glu Leu Val Leu Ser Ser Cys' 245 Gin Leu His Ser 260 Giu Gly Ile Ser 275 Asp Val Ala Asp TYPE: None DESCRIPTION: SEQ ID NO:770: WO 98/17810 ~24 Leu 305 Phe His Ala Gly Lys 385 Leu Ser Val Gin Ala 465 Leu Gly Gin Lys Val 545 295 Met Ala Pro Ala Leu 310 Ser Ala Phe Gin Arg 325 Gin Ser Phe Leu Giu 340 Pro Tyr Val Giu Gly 355 Ile Ser Thr Ile Asn 375 Pro Asn Met Ala Asp 390 Leu Ala Gin Arg Trp 405 Met Gin Gly Leu Leu 420 Lys Cys Ala Phe Gin 435 Asn Ile Ser Arg Leu 455 Lys Pro Trp Ile Thr 470 Cys Gin Pro Asp Ser 485 Gly Gly Giy Ser Gly 500 Cys Ser Phe Gin His 515 Arg Glu Leu Ser Asp 535 Gin Pro Thr 300 Gin Gly PCT/US97/20037 Al a Ala Met Pro Aia Ser 345 Giy Ser Giu Giu Arg 425 Pro Gin Gin Thr Gly 505 Pro Leu 315 Gly Gly Val 330 Tyr Arg Vai Gly Ser Pro Pro Pro Ser 380 Leu Cys Gly 395 Arg Leu Lys 410 Val Asn Thr Pro Ser Cys Giu Thr Ser 460 Asn Phe Ser 475 Leu Gly Giy 490 Ser Gly Gly Ile Ser Ser Leu Gin Asp 540 Leu Leu Gly 365 Lys Gly Thr Giu Leu 445 Giu Arg Gly Gly Asp 525 Tyr Aia Ser 335 His Leu Pro Ser Ser His Trp Arg 400 Ala Gly 415 His Phe Phe Vai Leu Val Leu Giu 480 Gly Giy 495 Gly Thr AlaVal Val Thr INFORMATION FOR SEQ ID NO:77i: SEQUENCE CHARACTERISTICS: LENGTH: 544 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Giu Lys Leu Cys Leu Leu Giy His Pro Ser Gin Ala Giy Leu Phe Leu Pro Giu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Aia Leu Giu Val Ser 165 Giu Giy Gly Giy 180 Ile Asn Pro Ser 195 Aia Asp Giu Giu 210 Arg Trp Met Giu Leu Leu Glu Arg TYPE: None DESCRIPTION: SEQ ID NO:771: Pro Ala Vai Arg Aia Thr Ser Leu 55 Leu Gin Tyr Gin Pro Thr Ile Trp Thr Gin 135 Gly Gly 150 Tyr Arg Gly Ser Pro Pro Leu Cys 215 Arg Leu 230 Val Asn Ser Ser Leu Pro Gin Ser Phe Leu Leu 10 Lys Ile Gin Gly Asp Gly Aia Ala Leu 25 Tyr Lys Leu Cys His Pro Glu Giu Leu 40 Giy Ile Pro Trp Ala Pro Leu Ser Ser Leu Aia Gly Cys Leu Ser Gin Leu His 75 Gly Leu Leu Gin Ala Leu Giu Gly Ile 90 Leu Asp Thr Leu Gin Leu Asp Val Ala 105 110 Gin Gin Met Giu Glu Leu Giy Met Aia 120 125 Gly Aia Met Pro Ala Phe Ala Ser Ala 140 Val Leu Val Aia Ser His Leu Gin Ser 155 160 Vai Leu Arg His Leu Aia Gin Pro Tyr 170 175 Pro Giy Giu Pro Ser Giy Pro Ile Ser 185 190 Ser Lys Giu Ser His Lys Ser Pro Asn 200 205 Giy Gly Leu Trp Arg Leu Vai Leu Ala 220 Lys Thr Val Ala Gly Ser Lys Met Gin 235 240 Thr Giu Ile His Phe Val Thr Lys Cys WO 98/17810 Ala Phe Gin Pro 260 Ser Arg Leu Leu 275 Trp Ile Thr Arg 290 Pro Asp Ser Ser 305 Gly Ser Gly Gly Phe Gin His Ser 340 Leu Ser Asp Tyr 355 Leu Gin Tyr Val 370 Pro Ile Ser Thr 385 Ser Pro Asn Met Ser Ser Asp Phe 420 Gin Asp Tyr Pro 435 Cys Gly Gly Leu 450 Leu Lys Thr Val 465 Asn Thr Glu Ile Ser Cys Leu Arg 500 Thr Ser Glu Gin 515 Phe Ser Arg Cys PCT/US97/20037 Pro Pro Ser Cys Leu Arg 265 Gin Glu Thr Ser Glu Gin 280 Gin Asn Phe Ser Arg Cys 295 Thr Leu Gly Gly Gly Ser 310 Gly Ser Gly Gly Gly Ser 325 330 Pro Ile Ser Ser Asp Phe 345 Leu Leu Gin Asp Tyr Pro 360 Glu Gly Gly Gly Gly Ser 375 Ile Asn Pro Ser Pro Pro 390 Ala Thr Gin Asp Cys Ser 405 410 Ala Val Lys Ile Arg Glu 425 Val Thr Val Ala Ser Asn 440 Trp Arg Leu Val Leu Ala 455 Ala Gly Ser Lys Met Gin 470 His Phe Val Thr Lys Cys 485 490 Phe Val Gin Thr Asn Ile 505 Leu Val Ala Leu Lys Pro 520 Leu Glu Leu Gin Cys Gin Val Gin Val Ala 285 Glu Leu 300 Gly Gly Thr Gin Val Lys Thr Val 365 Gly Glu 380 Lys Glu Gin His Ser Asp Gin Asp 445 Arg Trp 460 Leu Leu Phe Gin Arg Leu Ile Thr 525 Asp Ser 540 INFORMATION FOR SEQ ID N0:772: SEQUENCE CHARACTERISTICS: LENGTH: 565 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Thr Pro Leu Gly Ser Leu Glu Gin Glu Lys Leu Cys Leu Leu Gly His Pro Ser Gin Ala Gly Leu Phe Leu Pro Glu Leu Gly 100 Phe Ala Thr Thr 115 Ala Leu Gin Pro 130 Gin Arg Arg Ala Leu Glu Val Ser 165 Glu Gly Gly Gly 180 Ile Asn Pro Ser 195 Ala Asp Glu Glu TYPE: None DESCRIPTION: SEQ ID NO:772: Pro Ala Val Arg Ala Thr Ser Leu 55 Leu Gin Tyr Gin Pro Thr Ile Trp Thr Gin 135 Gly Gly 150 Tyr Arg Gly Ser Pro Pro Leu Cys Gin Ser Asp Gly His Pro Ala Pro Leu Ser Ala Leu Gin Leu Glu Leu 125 Ala Phe 140 Ser His Leu Ala Ser Gly His Lys 205 Arg Leu WO 98/17810 210 Gin Arg 225 Gly Leu Ala Phe Ser Arg Trp Ile 290 Pro Asp 305 Giy Ser Phe Gin Leu Ser Leu Gin 370 Pro Ile 385 Ser Pro Vai Leu Lys Met Thr Lys 450 Thr Asn 465 Leu Lys Gin Cys Ser Giy Asp Cys 530 Ile Arg 545 Ala Ser 42Z Trp Met Giu Arg 230 Leu Giu Arg Vai 245 Gin Pro Pro Pro .260 Leu Leu Gin Giu 275 Thr Arg Gin Asn Ser Ser Thr Leu 310 Giy Giy Gly Ser 325 His Ser Pro Ile 340 Asp Tyr Leu Leu 355 Tyr Vai Giu Giy Ser Thr Ile Asn 390 Asn Met Aia Asp 405 Aia Gin Arg Trp 420 Gin Giy Leu Leu 435 Cys Aia Phe Gin Ile Ser Arg Leu 470 Pro Trp Ile Thr 485 Gin Pro Asp Ser 500 Giy Giy Ser Gly *515 Ser Phe Gin His Giu Leu Ser Asp 550 Asn Leu Gin 565 Leu Lys Thr Asn Thr GiU Ser Cys Leu 265 Thr Ser Giu 280 Phe Ser Arg 295 Giy Gly Gly Giy Gly Giy Ser Ser.Asp 345 Gin Asp Tyr 360 Gly Gly Gly 375 Pro Ser Pro Giu Giu Leu Met Giu Arg 425 Giu Arg Vai 440 Pro Pro Pro 455 Leu Gin Giu Arg Gin Asn Ser Thr Leu 505 Giy Gly Ser 520 Ser Pro Ile 535 Tyr Leu Leu 220 Aia Gly Ser Lys 235 His Phe Vai Thr Phe Vai Gin Thr 270 Leu Val Ala Leu 285 Leu Giu Leu Gin 300 Giy Giy Gly Ser 315 Giy Thr Gin Asp Ala Val Lys Ile 350 Val Thr Val Aia 365 Pro Gly Giu Pro 380 Ser Lys Glu Ser 395 Gly Gly Leu Trp Lys Thr Val Ala 430 Thr Glu Ile His 445 Cys Leu Arg Phe 460 Ser Giu Gin Leu 475 Ser Arg Cys Leu Giy Gly Ser Giy 510 Gly Gly Ser Gly 525 Ser Asp Phe Aia 540 Asp Tyr Pro Val 555 Met Lys 255 Asn Lys Cys Gly Cys 335 Arg Ser Ser His Arg 415 Gly Phe Vai Vai Giu 495.

Giy Thr VTal Thr PCTUS97ZOO37 Gin 240 Cys Ile Pro Gin Gly 320 Ser Giu Asn Gly Lys 400 Leu Ser Val Gin Ala 480 Leu Gly Gin Lys Val 560 INFORMATION FOR SEQ ID NO:773: SEQUENCE CHARACTERISTICS: LENGTH: 502 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (Xi) SEQUENCE Asn Cys Ser Ile Pro Ala Pro Leu Ile Leu Met Asp Arg Ala Val Lys Arg Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Vai Giu Gly Gly 115 Thr Ile Asn Pro 130 Met Ala Asp Giu TYPE: None DESCRIPTION: SEQ ID NO:.773: Met Ile Asp Leu Asp Pro Arg Asn Leu 40 Asn Leu Glu 55 Pro Cys Leu Ile Lys Ala Leu Val Thr Gly Gly Ser 120 Ser Pro Pro 135 Giu Leu Cys His His Asn Asp Asn Leu Gly Ile Thr Aia Gin Glu Ala Gin Pro Ser 125 Ser His 140 Trp Arg WO 98/17810 145 Ala Gin Gin Gly Cys Ala Ile Ser 210 Pro Trp 225 Gin Pro Giy Gly Ser Phe Giu Leu 290 Asn Leu 305 Giy Pro Lys Ser Leu Vai Ser Lys 370 Val Thr 385 Gin Thr Ala Leu Leu Gin Gly Ser 450 Gin Asp 465 Lys Ile Val Ala PCTIUS97/20037 Arg Leu Phe 195 Arg Ile Asp Ser Gin 275 Ser Gin Ile Pro Leu 355 Met Lys Asn Lys Cys 435 Giy Cys Arg Ser Trp Leu 180 Gin Leu Thr Ser Giy 260 His Asp Tyr Ser Asn 340 Ala Gin Cys Ile Pro 420 Gin Giy Ser Giu ASn 500 150 Giu Arg Pro Gin Gin 230 Thr Gly Pro Leu Giu 310 Ile Ala Arg Leu Phe 390 Arg Ile Asp Ser Gin 470 Ser Gin Leu Asn Ser 200 Thr Phe Gly Giy Ser 280 Gin Gly Pro Giu Met 360 Giu Pro Leu Arg Ser 440 Gly Ser Tyr Thr 170 Giu Leu Giu Arg Gly 250 Giy Asp Tyr Gly Pro 330 Leu Arg Val Pro Giu 410 Asn Leu Ser Ile Leu 490 155 Val Ala Ile His Arg Phe Gli Leu 220 Cys Leu 235 Ser Gly Ser Giy Phe Ala Pro Val 300 Ser Pro 315 Pro Ser Cys Giy Leu Lys Asn Thr 380 Ser Cys 395 Thr Ser Phe Ser Giy Gly Gly Gly 460 Ser Ser 475 Gin Asp Giy Phe Val 205 Val Glu Gly Thr Val 285 Thr Gly Lys Giy Thr 365 Giu Leu Giu Arg Gly 445 Giy Asp Tyr Lys 175 Thr Thr Leu Gin Ser 255 Asp Ile Aia Pro Ser 335 Trp Aia His Phe Leu 415 Leu Giy Gly Al a Val 495 INFORMATION FOR SEQ ID NO:774; SEQUENCE CHARACTERISTICS: LENGTH: 562 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE Asp Glu Giu Leu 5 Trp Met Giu Arg Leu Glu Arg Val Gin Pro Pro Pro Leu Leu Gin Giu Thr Arg Gin Asn Ser Ser Thr Leu 100 Giy Giy Giy Ser 115 His Ser Pro Ile 130 TYPE: None DESCRIPTION: SEQ ID NO:774: Giy Leu Trp 10 Thr Val Ala 25 Giu Ile His 40 Leu Arg Phe Giu Gin Leu Arg Cys Leu 90 Giy Ser Gly 105 Giy Ser Gly 120 Asp Phe Ala Arg Leu Giy Ser Phe Val Vai Gin Val Ala Giu Leu Gly Giy Thr Gin Vai Lys 140 Thr Val Leu Ala Met Gin Lys Cys Asn Ile Lys Pro Cys Gin Gly Gly 110 Cys Ser Arg Giu Ser Asn Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val WO 98/17810 145 Gin Tyr Val Glu Gly Ser Asn Met 180 Val Leu Ala Gin 195 Lys Met Gin Gly 210 Thr Lys Cys Ala 225 Thr Asn Ile Ser Leu Lys Pro Trp 260 Gin Cys Gin Pro 275 Ser Gly Gly Gly 290 Asp Cys Ser Phe 305 Ile Arg Glu Leu Ala Ser Asn Leu 340 Pro Ser Gly Pro 355 Ser His Lys Ser 370 Leu Pro Gin Ser 385 Gin Gly Asp Gly Leu Cys His Pro 420 Pro Trp Ala Pro 435 Gly Cys Leu Ser 450 Leu Gin Ala Leu 465 Thr Leu Gin Leu Met Glu Glu Leu 500 Met Pro Ala Phe 515 Val Ala Ser His 530 Arg His Leu Ala 545 Gly Ser PCT/US97/20037 150 Gly Gly Gly Asp Glu Glu Trp Met Glu 200 Leu Glu Arg 215 Gin Pro Pro 230 Leu Leu Gin Thr Arg Gin Ser Ser Thr 280 Gly Gly Gly 295 His Ser Pro 310 Asp Tyr Leu Tyr Val Glu Ser Thr Ile 360 Asn Met Ala 375 Leu Leu Lys 390 Ala Leu Gin Glu Leu Val Ser Ser Cys 440 Leu His Ser 455 Gly Ile Ser 470 Val Ala Asp Met Ala Pro Ser Ala Phe 520 Gin Ser Phe 535 Pro Ser Thr 550 Ser Leu 185 Arg Val Pro Glu Asn 265 Leu Ser Ile Leu Gly 345 Asn Thr Cys Glu Leu 425 Pro Gly Pro Phe Ala 505 Gin Leu Pro 155 Gly Gly Gly Ser Gly Gly Leu Trp 190 Lys Thr Val Ala 205 Thr Glu Ile His 220 Cys Leu Arg Phe 235 Ser Glu Gin Leu Ser Arg Cys Leu 270 Gly Gly Ser Gly 285 Gly Gly Ser Gly 300 Ser Asp Phe Ala 315 Asp Tyr Pro Val Gly Gly Ser Pro 350 Ser Pro Pro Ser 365 Leu Gly Pro Ala 380 Glu Gin Val Arg 395 Leu Cys Ala Thr Gly His Ser Leu 430 Gin Ala Leu Gin 445 Phe Leu Tyr Gin 460 Leu Gly Pro Thr 475 Thr Thr Ile Trp Gin Pro Thr Gin 510 Arg Ala Gly Gly 525 Val Ser Tyr Arg 540 Thr Pro Gly Ser 555 160 Gly Gly 175 Arg Leu Gly Ser Phe Val Val Gin 240 Val Ala 255 Glu Leu Gly Gly Thr Gin Val Lys 320 Thr Val 335 Gly Glu Lys Glu Ser Ser Lys Ile 400 Tyr Lys 415 31y Ile Leu Ala 31y Leu Leu Asp 480 31n Gin 495 1ly Ala Val Leu Val Leu l3u Phe 560 INFORMATION FOR SEQ ID N0:775: SEQUENCE CHARACTERISTICS: LENGTH: 490 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:775: Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 55 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu WO 98/17810 WO 9817810PCT/US97/20037 Asp Ser Ser Gly Ser Asp 130 Asp Tyr 145 Giy Giy Ser Pro Ser Ile Pro Leu 210 Met Giu 225 Val Lys Leu Gin Ile Ile Phe Tyr 290 Gly Gly 305 Asn Pro Asp Giu Trp Met Leu Glu 370 Gin Pro 385 Leu Leu Thr Arg Ser Ser Giy Gly 450 Asp Phe 465 Ser Gly 115 Phe Pro Ser Pro Met 195 Leu Arg His Pro Ile 275 Leu Gly Ser Giu Giu 355 Arg Pro Gin Gin Thr 435 Giy Ala Thr Leu Giy 100 Giy Thr Gin Ala Vai Lys Val Thr Vai i50 Pro Gly Giu 165 Ser Lys GIlu 180 Ile Asp Giu Asp Pro Asn Asn Leu Arg 230 Leu Giu Asn 245 Cys Leu Pro 260 Lys Ala Gly Vai Thr Leu Giy Ser Pro 310 Pro Pro Ser 325 Leu Cys Giy 340 Arg Leu Lys Val Asn Thr Pro Ser Cys 390 Giu Thr Ser 405 Asn Phe Ser 420 Leu Giy Gly Thr Gin Asp Val Lys Ile 470 Thr Vai Ala Giy Giy Asp Cys 120 Ile Arg 135 Aia Ser Pro Ser Ser His Ile Ile 200 Asn Leu 215 Thr Pro Aia Ser Ser Aia Asp Trp 280 Giu Gin 295 Giy Giu Lys Giu Giy Leu Thr Vai 360 Giu Ile 375 Leu Arg Glu Gin Arg Cys Giy Ser 440 Cys Ser 455 Arg Giu Ser Asn 90 I Gly Gij Phe Gir Leu Ser Leu Gir 155 Pro Ile 170 Ser Prc His Leu Ser Glu Leu Leu 235 Ile Gil 250 Aia Aia Giu Phe Gin Gil Ser Gly 315 His Lys 330 Arg Leu Giy Ser Phe Val Vai Gin 395 Vai Ala 410 Giu Leu Giy Gly Gin His Ser Asp 475 Gin 490 Gly His Asp 140 Tyr Ser Asn Lys Asp 220 Ala Ala *Pro Arg *Gin 300 *Pro Ser Val Lys Thr 380 Thr Leu Gin Ser Ser 460 Tyr Ser Ser 125 Tyr Val Thr Met Arg 205 Met Phe Ile Ser Giu 285 Gin Ilie Pro Leu Met 365 Lys Asn.

Lys Cys Gly 445 Pro Leu Val LysI Thr Thr Leu Gin Ser Giy Giy Ile Ser Leu Gin Gly Gly 160 Asn Pro 175 Asn Cys Pro Asn Ile Leu Arg Ala 240 Arg Asn 255 His Pro Leu Thr Vai Giu Thr Ile 320 Met Ala 335 Gin Arg Giy Leu Ala Phe Ser Arg 400 Trp Ile 415 Pro Asp Gly Ser Ser Ser Gin Asp 480 Ala Gin Gin Giy Cys Aia Ile Ser Pro Trp Gin Pro Gly Gly Tyr Pro Vai INFORMATION FOR SEQ ID NO:7 Ci) SEQUENCE CHARACTERISTICS: LENGTH: 398 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID Asp Giu Giu Leu Cys Giy Gly Leu Trp 10 Trp Met Giu Arg Leu Lys Thr Val Ala 25 Leu Giu Arg Val Asn Thr Giu Ile His 40 Gin Pro Pro Pro Ser Cys Leu Arg Phe 55 Leu Leu Gin Giu Thr Ser Giu Gin Leu Thr Arg Gin Asn Phe Ser Arg Cys Leu 90 Ser Ser Thr Leu Gly Giy Gly Ser Giy 176: NO:776: Arg Leu Gly Ser Phe Val Val Gin Val Ala 75 Giu Leu Gly Gly WO 98/17810 WO 98/ 7810PCT/US97/20037 Ser Gin Ser 145 Gin Pro Ile Ile Gin 225 Gin Leu Lys Lys Pro 305 Thr Lys Giy Val1 Asn 385 Ser Gly Ile Ser Leu Gin 150 Leu Giu 165 Pro Ala Lys Ile Val Val Phe Vai 230 Giu Asp 245 His Gin Lys Asp Ser Val Met Thr 310 Pro Giu 325 Asn Tyr Met Tyr Ser Tyr Thr Lys 390 Gly Ala Val Pro 170 Leu Leu Ser Giu Thr 250 Ser Pro Gin Vai Val 330 Giu Arg Vai Arg Gin Asp 125 Lys Ile 140 Val Aia Ile Lys Giy Pro Ile Ser 205 Asp Asp 220 His Thr Arg Aia Lys Giu Giu Arg 285 Tyr Val 300 Leu Thr Trp Thr Val Leu Glu Lys 365 His Giu 380 Pro Giy INFORM~ATION FOR SEQ ID NO:777: SEQUENCE CHARACTERISTICS: LENGTH: 377 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE (xi) SEQUENCE TYPE: None DESCRIPTION: SEQ ID NO:777:- Thr Gin ASP Cys Ser Phe Arg Giu Leu Ser Asn Leu Leu Aia Gin Met Gin Gly Lys Cys Ala Asn Ile Ser Lys Pro Trp Cys Gin Pro 135 Pro Thr Ile 150 Leu Giy Gly 165 Leu Met Ile Ser Giu Asp Giu Vai His WO 98/17810 1734 PCT/US97/20037 Asp Tyr 225 Gin Asp Asp Leu Val Arg Thr Lys 290 Glu Asp 305 Tyr Lys Tyr Ser Tyr Ser Lys Ser 370 Pro Ile Val Asn Pro Lys 270 Glu Glu 285 Asp Phe Thr Glu Ser Tyr Glu Arg 350 His His 365 INFORMATION FOR SEQ ID NO:778: SEQUENCE CHARACTERISTICS: LENGTH: 4 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: Gly Gly Ser SEQ ID N0:778: INFORMATION FOR SEQ ID N0:779: SEQUENCE CHARACTERISTICS: LENGTH: 8 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:779: Gly Gly Gly Ser Gly Gly Gly Ser 1 INFORMATION FOR SEQ ID NO:780: SEQUENCE CHARACTERISTICS: LENGTH: 12 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:780: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 1 5 INFORMATION FOR SEQ ID NO:781: SEQUENCE CHARACTERISTICS: LENGTH: 7 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 12, (xi) SEQUENCE DESCRIPTION: SEQ ID NO:781: Ser Gly Gly Ser Gly Gly Ser 1 INFORMATION FOR SEQ ID N0:782: SEQUENCE CHARACTERISTICS: LENGTH: 5 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:782: Glu Phe Gly Asn Met 1 INFORMATION FOR SEQ ID NO:783: SEQUENCE CHARACTERISTICS: LENGTH: 6 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:783: Glu Phe Gly Gly Asn Met 1 INFORMATION FOR SEQ ID NO:784: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:784: Glu Phe Gly Gly Asn Gly Gly Asn Met 1 INFORMATION FOR SEQ ID NO:785: SEQUENCE CHARACTERISTICS: LENGTH: 7 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:785: Gly Gly Ser Asp Met Ala Gly 1 INFORMATION FOR SEQ IDNO:786: SEQUENCE CHARACTERISTICS: LENGTH: 5 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:786: PCT/US97/20037 WO 98/17810 33j PCT/US97/20037 Ser Gly Gly Asn Gly 1 INFORMATION FOR SEQ ID NO:787: SEQUENCE CHARACTERISTICS: LENGTH: 10 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:787: Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 1 5 INFORMATION FOR SEQ ID N0:788: SEQUENCE CHARACTERISTICS: LENGTH: 15 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:788: Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 1 5 10 INFORMATION FOR SEQ ID NO:789: SEQUENCE CHARACTERISTICS: LENGTH: 10 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:789: Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 1 5 INFORMATION FOR SEQ ID NO:790: SEQUENCE CHARACTERISTICS: LENGTH: 15 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:790: Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 1 5 10 INFORMATION FOR SEQ ID NO:791: SEQUENCE CHARACTERISTICS: LENGTH: 6 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:791: Gly Gly Gly Ser Gly Gly 1 r~ wu /511/u 7134 PCI INFORMATION FOR SEQ ID NO:792: SEQUENCE CHARACTERISTICS: LENGTH: 7 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:792: Gly Gly Gly Ser Gly Gly Gly 1 INFORMATION FOR SEQ ID NO:793: SEQUENCE CHARACTERISTICS: LENGTH: 10 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:793: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 INFORMATION FOR SEQ ID NO:794: SEQUENCE CHARACTERISTICS: S(A) LENGTH: 13 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:794: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 1 5 INFORMATION FOR SEQ ID NO:795: SEQUENCE CHARACTERISTICS: LENGTH: 15 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID N0:795: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 1 5 10 INFORMATION FOR SEQ ID NO:796: SEQUENCE CHARACTERISTICS: LENGTH: 21 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:796: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 1 5 10 Gly Gly Gly Ser Gly /US97/20037 WO 98/17810 PCTIUS97/20037 -735 INFORMATION FOR SEQ ID N0:797: SEQUENCE CHARACTERISTICS: LENGTH: 21 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:797: Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr Ala 1 5 10 Gly Gln Pro Pro Leu INFORMATION FOR SEQ ID N0:798: SEQUENCE CHARACTERISTICS: LENGTH: 15 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:798: Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr 1 5 10 INFORMATION FOR SEQ ID NO:799: SEQUENCE CHARACTERISTICS: LENGTH: 16 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:799: Val Glu Thr Val Phe His Arg Val Ser Gin Asp Gly Leu Leu Thr Ser 1 5 10 INFORMATION FOR SEQ ID NO:800: SEQUENCE CHARACTERISTICS: LENGTH: 36 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:800: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly 1 5 10 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser 25 Gly Gly Gly Ser INFORMATION FOR SEQ ID NO:801: SEQUENCE CHARACTERISTICS: LENGTH: 24 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None WO 98/17810 73 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:801: Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro 1 5 10 Ser Lys Glu Ser His Lys Ser Pro INFORMATION FOR SEQ ID NO:802: SEQUENCE CHARACTERISTICS: LENGTH: 28 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:802: Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 1 5 10 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro INFORMATION FOR SEQ ID NO:803: SEQUENCE CHARACTERISTICS: LENGTH: 112 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:803: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 INFORMATION FOR SEQ ID NO:804: SEQUENCE CHARACTERISTICS: LENGTH: 112 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:804: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 WO 98/17810 PCT/US97/20037 INFORMATION FOR SEQ ID NO:805: SEQUENCE CHARACTERISTICS: LENGTH: 112 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:805: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Val 1 5 10 Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met 25 Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe 40 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 55 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 70 75 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu 90 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gin 100 105 110 INFORMATION FOR SEQ ID NO:806: SEQUENCE CHARACTERISTICS: LENGTH: 111 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO:806: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 40 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 55 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 70 75 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys 90 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 100 105 110 INFORMATION FOR SEQ ID NO:807: SEQUENCE CHARACTERISTICS: LENGTH: 33 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:807: CTGACCATGG CNACCCAGGA CTGCTCCTTC CAA 33 INFORMATION FOR SEQ ID NO:808: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 M PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:808: ACTGAAGCTT AGGGCTGACA CTGCAGCTCC AG 32 INFORMATION FOR SEQ ID NO:809: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:809: ACTGAAGCTT ACAGGGTTGA GGAGTCGGGC TG 32 INFORMATION FOR SEQ ID NO:810: SEQUENCE CHARACTERISTICS: LENGTH: 46 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:810: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46 INFORMATION FOR SEQ ID NO:811: SEQUENCE CHARACTERISTICS: LENGTH: 46 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:811: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46 INFORMATION FOR SEQ ID NO:812: SEQUENCE CHARACTERISTICS: LENGTH: 22 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:812: TGTCCAAACT CATCAATGTA TC 22 INFORMATION FOR SEQ ID NO:813: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:813: CATGGCCATG GCCGACGAGG AGCTCTGCGG GGGCCTCT 38 INFORMATION FOR SEQ ID NO:814: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:814: GCTAGAAGCT TACTGCAGGT TGGAGGCCAC GGTGAC 36 INFORMATION FOR SEQ ID NO:815: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:815: CATGGCCATG GCCTCCAAGA TGCAAGGCTT GCTGGAGC 38 INFORMATION FOR SEQ ID NO:816: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:816: GCTAGAAGCT TACCCAGCGA CAGTCTTGAG CCGCTC 36 INFORMATION FOR SEQ ID NO:817: SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:817: CATGGCCATG GCCCCCCCCA GCTGTCTTCG CTTCGT 36 INFORMATION FOR SEQ ID NO:818: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:818: GCTAGAAGCT TAGGGCTGAA AGGCACATTT GGTGACA 37 INFORMATION FOR SEQ ID NO:819: SEQUENCE CHARACTERISTICS: LENGTH: 42 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:819: CCCTGTCTGG CGGCAACGGC ACCCAGGACT GCTCCTTCCA AC 42 INFORMATION FOR SEQ ID NO:820: SEQUENCE CHARACTERISTICS: LENGTH: 48 base. pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/17810 PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:820: GCGGTAACGG CAGTGGAGGT AATGGCACCC AGGACTGCTC CTTCCAAC 48 INFORMATION FOR SEQ ID NO:821: SEQUENCE CHARACTERISTICS: LENGTH: 57 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:821: ACGGCAGTGG TGGCAATGGG AGCGGCGGAA ATGGAACCCA GGACTGCTCC TTCCAAC 57 INFORMATION FOR SEQ ID N0:822: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:822: GTGCCGTTGC CGCCAGACAG GGTTGAGGAG TCGGGCTG 38 INFORMATION FOR SEQ ID N0:823: SEQUENCE CHARACTERISTICS: LENGTH: 48 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:823: ATTACCTCCA CTGCCGTTAC CGCCTGACAG GGTTGAGGAG TCGGGCTG 48 INFORMATION FOR SEQ ID NO:824: SEQUENCE CHARACTERISTICS: LENGTH: 54 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:824: GCTCCCATTG CCACCACTGC CGTTACCTCC AGACAGGGTT GAGGAGTCGG GCTG 54 INFORMATION FOR SEQ ID NO:825: SEQUENCE CHARACTERISTICS: LENGTH: 60 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:825: GATGAGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCACC INFORMATION FOR SEQ ID N0:826: SEQUENCE CHARACTERISTICS: LENGTH: 45 base pairs TYPE: nucleic acid STRANDEDNESS: single WO 98/17810 74 PCT/US97/20037 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:826: GATGACGGAT CCGTTACCTC CAGACAGGGT TGAGGAGTCG GGCTG INFORMATION FOR SEQ ID NO:827: SEQUENCE CHARACTERISTICS: LENGTH: 46 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:827: GATGACGGAT CCGGAGGTAA TGGCACCCAG GACTGCTCCT TCCAAC 46 INFORMATION FOR SEQ ID NO:828: SEQUENCE CHARACTERISTICS: LENGTH: 29 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:828: GACTGCCATG GCCGACGAGG AGCTCTGCG 29 INFORMATION FOR SEQ ID N0:829: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:829: GACTCAAGCT TACTGCAGGT TGGAGGCC 28 INFORMATION FOR SEQ ID NO:830: SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:830: GACTCGGGAT CCGGAGGTTC TGGCACCCAG GACTGCTCC 39 INFORMATION FOR SEQ ID NO:831: SEQUENCE CHARACTERISTICS: LENGTH: 41 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:831: GACTGGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC C 41 INFORMATION FOR SEQ ID N0:832: SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid WO 98/17810 4L PCT/US97/20037 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:832: GACTTGGGAT CCACTACCTC CAGACAGGGT TGAGGAGTC 39 INFORMATION FOR SEQ ID NO:833: SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:833: ACTGACGGAT CCACCGCCCA GGGTTGAGGA GTCGGGCTG 39 INFORMATION FOR SEQ ID N0:834: SEQUENCE CHARACTERISTICS: LENGTH: 51 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:834: ACTGACGGAT CCACCTCCTG ACCCACCGCC CAGGGTTGAG GAGTCGGGCT G 51 INFORMATION FOR SEQ ID NO:835: SEQUENCE CHARACTERISTICS: LENGTH: 63 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:835: ACTGACGGAT CCACCTCCTG ACCCACCTCC TGACCCACCG CCCAGGGTTG AGGAGTCGGG CTG 63 INFORMATION FOR SEQ ID N0:836: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:836: ACGTAAAGCT TACAGGGTTG AGGAGTCG 28 INFORMATION FOR SEQ ID NO:837: SEQUENCE CHARACTERISTICS: LENGTH: 40 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:837: GTCAGTGGAT CCGGAGGTAC CCAGGACTGC TCCTTCCAAC INFORMATION FOR SEQ ID NO:838: SEQUENCE CHARACTERISTICS: 9 n/to/ 1l1n T nt'T fl TOIn J* AA n i-

TTV/

l 0io ao lL I I U IILUU: LENGTH: 43 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:838: GTCAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AAC 43 INFORMATION FOR SEQ ID NO:839: SEQUENCE CHARACTERISTICS: LENGTH: 60 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:839: TCAGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC INFORMATION FOR SEQ ID NO:840: SEQUENCE CHARACTERISTICS: LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:840: TAGTCCATGG CCACCCAGGA CTGCTCC 27 INFORMATION FOR SEQ ID NO:841: SEQUENCE CHARACTERISTICS: LENGTH: 31 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:841: GCATTACGTA GGGCTGACAC TGCAGCTCCA G 31 INFORMATION FOR SEQ ID N0:842: SEQUENCE CHARACTERISTICS: LENGTH: 31 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:842: GCATTACGTA CAGGGTTGAG GAGTCGGGCT G 31 INFORMATION FOR SEQ ID NO:843: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:843: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37 INFORMATION FOR SEQ ID NO:844: 3I WO 98/17810 -74/ PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:844: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC 39 INFORMATION FOR SEQ ID NO:845: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:845: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37 INFORMATION FOR SEQ ID NO:846: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:846: TCTGACAAGC TTACACGGTG ACTGGGTAAC TTGAAGC 37 INFORMATION FOR SEQ ID NO:847: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:847: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38 INFORMATION FOR SEQ ID NO:848: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:848: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37 INFORMATION FOR SEQ ID NO:849: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:849: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC 38 INFORMATION FOR SEQ ID NO:850: WO 98/17810 PCT/US97/20037 SEQUENCE CHARACTERISTICS: LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:850: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 36 INFORMATION FOR SEQ ID NO:851: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:851: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38 INFORMATION FOR SEQ ID NO:852: SEQUENCE CHARACTERISTICS: LENGTH: 37 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:852: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37 INFORMATION FOR SEQ ID NO:853: SEQUENCE CHARACTERISTICS: LENGTH: 33 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:853: GATCACATGT CTACAAATCA AGATCTGCCT GTG 33 INFORMATION FOR SEQ ID NO:854: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:854: GATCGAATTC GTTGTCTTGG ATGAAAGGGA INFORMATION FOR SEQ ID NO:855: SEQUENCE CHARACTERISTICS: LENGTH: 32 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:855: ACTTGAATTC ATCATCCTGG GCCTGTTCGG GC 32 WO 98/17810 INFORMATION FOR SEQ ID N0:856: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear PCT/US97/20037 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:856: ACTCAAGCTT AGAAGCTCCC CAGCGCCTCC INFORMATION FOR SEQ ID N0:857: SEQUENCE CHARACTERISTICS: LENGTH: 64 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:857: GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC

ATGG

INFORMATION FOR SEQ ID NO: 858: SEQUENCE CHARACTERISTICS: LENGTH: 174 amino acids TYPE: amino acid STRANDEDNESS: unknown TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Modified-site LOCATION:1 OTHER INFORMATION:/note= "Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:2 OTHER INFORMATION:/note= "Xaa at position 2 is Pro or Leu;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:3 OTHER INFORMATION:/note= "Xaa at position 3 is Leu, Arg, Tyr or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:13 OTHER INFORMATION:/note= "Xaa at position 13 is Phe, Ser, His, Thr or Pro;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:16 OTHER INFORMATION:/note= "Xaa at position 16 is Lys, Pro, Ser, thr or His;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:17 OTHER INFORMATION:/note= "Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg;" (ix) FEATURE: NAME/KEY: Modified-site WO 98/17810 WO 9817810PCTIUS97/20037 LOCATION:18 OTHER INFORNATION:/note= "Xaa at Thr, Pro, His, Ile or Cys;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:22 OTHER INFORMATION:-/note= "Xaa at Tyr, Ser, Thr or Ala;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:24 OTHER INFORMATION:/note= "Xaa at Pro, Tyr or Leu;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:27 OTHER INFORMATION:/note= 1Xaa at or Gly;' (ix) FEATURE: NAME/KEY: modified-site OTHER INFORMATION:/note= "Xaa at Ile, Leu or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:34 OTHER INFORMATION:/note= 'Xaa at or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:36 OTHER INFORMATION:/note= "Xaa at or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:42 OTHER INFORMATION.-/note= "Xaa at or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:43 OTHER INFORMATION:/note= "Xaa at Thr, Gly, Val, Lys, Trp, Ala, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:44 OTHER INFORMATION;/note= 'Xaa at Gly, Arg, Asp, Val, Ala, His, (ix) FEATURE: NAME/KEY: modified-site LOCATION:46 OTHER INFORMATION:/note= "Xaa at Arg, Phe, Arg, Ile or Ala;" (ix) FEATURE: NAME/KEY: modified-site LOCATION:47 OTHER INFORMATION:/note= "Xaa at or Thr;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:49 CD) OTHER INFORMATION:/note= "Xaa at Phe, Arg or Ser;" position 18 is Leu, position 22 is Arg, position 24 is Ile, Position 27 is Asp, position 30 is Ala, position 34 is Lys position 36 is Cys position 42 is Cys position 43 is His, Arg, Cys, or Leu; 1 position 44 is Pro, Trp, Gin, or Thr;" position 46 is Giu, position 47 is Leu position 49 is Leu, (ix) FEATURE: WO 98/17810 PCT/US97/20037 NAME/KEY: Modified-site OTHER INFORMATION:/note= "'Xaa at position 50 is Leu, Ile, His, Pro or Tyr;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:54 OTHER INFORMATION:/note= "Xaa at position 54 is Leu or His;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:64 OTHER INFORMATION:/note= -Xaa at position 64 is Cys or Ser;11 (ix) FEATURE, NAME/KEY: Modified-site LOCATION:67 OTHER INFORMATION:/note= 'Xaa at position 67 is Gin, Lys, Leu or Cys;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 70 is Gin, Pro, Leu, Arg or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:74 OTHER INFORMATION:/note= "Xaa at position 74 is Cys or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:104 OTHER INFORMATION:/note= "Xaa at position 104 is Asp, Gly or Val;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:iOS OTHER INFORMATION:/note= "Xaa Aia, Vai, Arg, Trp, Gin or at position Giy; i08 is Leu, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:liS OTHER INFORMATION:/note= His, Leu or Aia;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:120 OTHER INFORMATION:/note= Gly, Arg, Lys or His" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i223 OTHER INFORMATION:/note= Arg, Phe or Thr" "Xaa at position 115 is Thr, "Xaa at position i20 is Gin, "Xaa at position i23 is Giu, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:144 OTHER INFORMATION:/note= "Xaa His, Arg, Pro, Leu, Gin or at position Giu; i44 is Phe, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i46 OTHER INFORMATION:/note= or Gin;" "Xaa at positioni46 is Arg WO 981 7810 (ix) FEATURE: NME/KEY: Modified-site LOCATION:147 OTHER INFORMATION:/note= "Xaa or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:156 OTHER INFORMATION: /note= "Xaa Gly or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:159 OTHER INFORMATION:/note= "Xaa Arg, Thr, Tyr, Val or Gay;"1 (ix) FEATURE: NAME/KEY: Modified-site LOCATION:162 OTHER INFORMATION:/note= "Xaa Leu, Gly or Trp;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:163 OTHER INFORMATION:/note= "Xaa Gly, Arg or Ala;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:169 OTHER INFORMATION:/note= "Xaa Ser, Leu, Arg or Cys;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:170 OTHER INFORMATION:/note= "Xaa Arg or Ser;" PCTfUS97/20037 ap position 147 is Arg at position 156 is His, at position 159 is Ser, at position 162 is Glu, at position 163 is Val, at position 169 is Arg, at position 170 is His, (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 858: Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Xaa Glu Xaa Pro Gly Pro Phe Ala Gin 145 Leu Leu Xaa Xaa Ser Leu Gly Val 110 Met Ser Gin Pro WO 98/17810 PCT/US97/20037 INFORMATION FOR SEQ ID NO: 859: SEQUENCE CHARACTERISTICS: LENGTH: 133 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Modified-site LOCATION:17 OTHER INFORMATION:/note= "Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:18 OTHER INFORMATION:/note= "Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:19 OTHER INFORMATION:/note= "Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 20 is Ile, Cys, Gin, Glu, Arg, Pro, or Ala;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:21 OTHER INFORMATION:/note= "Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:22 OTHER INFORMATION:/note= "Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:23 OTHER INFORMATION:/note= "Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:24 OTHER INFORMATION:/note= "Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, Leu;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:26 OTHER INFORMATION:/note= "Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, Trp;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:27 OTHER INFORMATION:/note= "Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;" WO98/17810_/5- (ix) FEATURE: NAME/KEY: Modified-site LOCATION:28 OTHER INFORMATION: /note= "Xaa at position Arg, Leu, Gin, Gly, Pro, Val or Trp; PCTIUS97/20037 28 is Lys, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:29 OTHER INFORMATION:/note= "Xaa at Asn, Leu, Pro, Arg, or Val;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at His, Thr, Gly, Asp, Gin, Ser, position 29 is Gin, Position 30 is Pro, Leu, or L. (ix) FEATURE: NAME/KEY: Modified-site LOCATION:31 OTHER INFORMATION: /note= "Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:32 OTHER INFORMATION: /note= 'Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Giu;'1 (ix) FEATURE: NAME/KEY: Modified-site LOCATION:33 OTHER INFORMATION:/note= "Xaa at Leu, Gin, Ala, Thr, or Giu;1" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:34 OTHER INFORMATION:/note= 'Xaa at Val, Gly, Ser, LYS, Giu, Gin, Met;" position 33 is Pro, position 34 is Leu, Thr, Arg, Ala, Phe, Ile or (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position Ala, Gly, Asn, Pro, Gin, or Val;" 35 is Leu, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:36 OTHER INFORMATION:/note= "Xaa Leu, or Vai;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:37 OTHER INFORMATION:/note= "Xaa Ser, Pro, Trp, or Ile;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:38 OTHER INFORMATION:/note= "Xaa or Ala;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa Trp, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:41 at position 36 is Asp, at position 37 is Phe, at position 38 is Asn, at position 40 is Leu, WO 98/17810 PCTIUS97/20037 OTHER INFORMATION: -/note= "Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or pro;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:42 OTHER INFORMATION:/note= "'Xaa at Asp, Ser, Cys, Asn, Lys, Thr, position 42 is -Gly, Leu, Val, Giu, Phe, Tyr, Ile, Met Ser; or Ala; (ix) FEATURE: NAME/KEY: Modified-site LOCATION:43 OTHER INFORMATION:/note= "Xaa at Asn, Tyr, Leu, Phe, Asp, Ala, position 43 is Glu, Cys, Gin, Arg, Thr, Gly, or (ix) FEATURE: NAME/KEY: Modified-site (B3) LOCATION:44 OTHER INFORMATION:/note= "Xaa at Ser, Leu, Arg, Lys, Thr, Met, Pro;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at Pro, Phe, Val, Met, Leu, Thr, Ala, Ile, Giu or His;" position 44 is Asp, Trp, Glu, Asn, Gin, Ala or position 45 is Gin, Lys, Trp, Asp, Asn, Arg, Ser, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:46 OTHER INFORMATION:/note= "Xaa at position 46 is Phe, Ser, Thr, Cys, Giu, Asn, Gin, Lys, His, Asp, Ala, Tyr, Ile, or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:47 OTHER INFORMATION;/note= "Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:48 OTHER INFORMATION:/note=, "Xaa at Ser, Cys, Arg, Ile, His, Phe, Asn;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:49 OTHER INFORMATION:/note= "Xaa at Arg, Ala, Gly, Pro, Asn, His, (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "'Xaa at Leu, Thr, Asp, Tyr, Lys, Asn, position 48 is Leu, Giu, Lys, Thr, Ala, Met, Val position 49 is Met, or Asp;" position 50 is Giu, Ser, Ala, Ile, Val, His, Phe, or Gin;" (ix) FEATURE: NAME/KEY: modified-site OTHER INFORMATION:/note= "xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or his;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:52 WO098/17810 -73PCT/US97/20037 OTHER INFORMATION: /note= "Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;" (ix) FEATURE; NAME/KEY: modified-site LOCATION:53 OTHER INFORMATION: /note= "Xaa at position 53 is Leu, Thr, Ala, Gly, Gin, Pro, Lys, 'Ser, or 1 (ix) FEATURE: NAME/KEY: Modified-site LOCATION:54 OTHER INFORMATION:/note= "Xaa at Asp, Ile, Ser, Val, Thr, Gin, (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at Thr, Val, Ser, Leu, or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:56 OTHER INFORMATION:/note= "Xaa at Gly, Cys, Ser, Gin, Giu, Arg, or Lys;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:57 OTHER INFORMATION:/note= "Xaa at or Giy;" position 54 is Arg, Asn, LYS, His, Ala or Len;" position 55 is Arg, position 56 is Pro, His, Thr, Ala, Tyr, Phe, Len, position 57 is Asn (ix) FEATURE: NAME/KEY: Modified-site LOCATION:58 OTHER INFORMATION:/note= "Xaa at position Ser, Asp, Arg, Gin, Val, or Cys;' 58 is Leu, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:59 OTHER INFORMATION-/note= 'Xaa at Tyr, His, Leu, Pro, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= 'Xaa at Ser, Pro, Tyr, Asn, or Thr;" position 59 is Gin, position 60 is Ala, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:6l OTHER INFORMATION:/note= "Xaa at position 61 is Phe, Asn, Gin, Pro, Lys, Arg, or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:62 OTHER INFORMATION:/note= I-Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:63 OTHER INFORMATION:/note= "Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:64 OTHER INFORMATION:/note= 'Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;" WO 98/17810 (ix) PCT/US97/20037

FEATURE:

NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:66 OTHER INFORMATION:/note= "Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:67 OTHER INFORMATION:/note= "Xaa at Ala, Phe, Val, Gly, Asn, Ile, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:68 OTHER INFORMATION:/note= "Xaa at Val, Trp, Ser, Ile, Phe, Thr, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:69 OTHER INFORMATION:/note= "Xaa at Ala, Pro, Thr, Glu, Arg, Trp, (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at Leu, Val, Trp, pro, or Ala;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:71 OTHER INFORMATION:/note= "Xaa at Met, Leu, Pro, Arg, Glu, Thr, postion 67 is Ser, Pro, or His;" position 68 is Leu, or His;" position 69 is Gin, Gly, or position 70 is Asn, position 71 is Ala, Gin, Trp, or Asn;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:72 OTHER INFORMATION:/note= "Xaa at position Glu, Met, Ala, His, Asn, Arg, or Asp;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:73 OTHER INFORMATION:/note= "Xaa at position Glu, Asp, Leu, Ser, Gly, Thr, or Arg;" 72 is Ser, 73 is Ala, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:74 OTHER INFORMATION:/note= "Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:76 OTHER INFORMATION:/note= "Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or (ix) FEATURE: NAME/KEY; Modified-site LOCATION:77 OTHER INFORMATION:/note= "Xaa at Ser, Arg, Thr, or Leu;" position 77 is Ile, WO 98/1781075 (ix) FEATURE: NAME/KEY: Modified-site.

LOCATION:78 OTHER INFORMATION. /note= "Xaa at position Ala, Ser, Glu, Phe, Gly, or Arg;"- (ix) FEATURE: NAME/KEY: Modified-site LOCATION:79 OTHER INFORMATION: /note= 'Xaa at position Thr, Asn, Met, Arg, Ile, Gly, or Asp;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION: /note= 'Xaa position at Trp, Val, Gly, Thr, Leu, Glu, or Arg; 1 PCTIUS97/20037 78 is Leu, 79 is Lys, 80 is Asn, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:81 OTHER INFORMATION: /note= "Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:82 OTHER INFORMATION: /note= "Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:83 OTHER INFORMATION:/note= "Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:84 OTHER INFORMATION:/note=z "Xaa at position 84 is Cys, Giu, Gly, Arg, Met, or Val;" (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at position 85 is Leu, Asn, Val, or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:86 OTHER INFORMATION:/note= "Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:87 OTHER INFORMATION:/note= "Xaa at position 87 is Leu, Ser, Trp, or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:88 OTHER INFORMATION:/note= "Xaa at position 88 is Aia, Lys, Arg, Val, or Trp;" (ix) FEATURE: NAME/KEY: modified-site LOCATION:89 OTHER INFORMATION:/note= "Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Giu, His, Asn, or S.

(ix) FEATURE: NAME/KEY: Modified-site WO 98/17810 OTHER INFORMATION:/note= "Xaa at Pro, Ser, Thr, Gly, Asp, Ile, PCTIUS97/20037 position 90 is Ala, or ,Met; 1 (ix) FEATURE: NAME/KEY: Modified-site LOCATION:91 OTHER INFORMATION: /note= 'Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:92 OTHER INFORMATION:/note= "Xaa at Phe, Arg, Ser, Lys, His, Ala, position 92 is Pro, Gly, Ile or Leu;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:93 OTHER INFORMATION: /note= "Xaa at position 93 is Thr, ASP, Ser, Asn, Pro, Ala, Leu, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:94 OTHER INFORMATION:/note= "Xaa at posi Ile, Ser, Glu, Leu, Val, Gin, Lys, (ix) FEATURE: NAME/KEY: Modified-site OTHER INFORMATION:/note= "Xaa at posi Gin, Pro, Arg, Val, Leu, Gly, Thr, Phe, Ile, or Tyr;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:96 OTHER INFORMATION:/note= "Xaa at posi Lys, Tyr, Gly, Ile, or Thr;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:97 OTHER INFORMATION:/note= 'Xaa at pos: Val, Lys, Ala, or Asn;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:98 OTHER INFORMATION:/note= "Xaa at pos: Ile, Asn, Leu, Asp, Ala, Thr, Giu, Lys, Arg, Tyr, or Pro;" (ix) FEATURE: NAME/KEY: modified-site LOCATION:99 OTHER INFORMATION:/note= "Xaa at pos: Leu, Arg, Asp, Val, Pro, Gin, Giy.

(ix) FEATURE: NAME/KEY: Modified-site LOCATION:iOQ OTHER INFORMATION:/note= "Xaa at pos: Tyr, Leu, His, Arg, Ile, Ser, Gin (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i0i OTHER INFORMATION:/note= "Xaa at pos: Pro, Met, Lys, His, Thr, Val, Tyr Ile, Leu, or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:102 OTHER INFORMATION:/note= "Xaa at pos Leu, Giu, Lys, Ser, Tyr, or Pro;" Ltion 94 is Arg, His, Ala, or Pro;" Ltion 95 is His, Asn, Lys, Ser, Ala, Trp, Ltion 96 is Pro, Ltion 97 is Ile, Ltion 98 is His, Gin, Ser, Phe, Met, Val, ition 99 is Ile, ISer, Phe, or His;" ition 100 is Lys, I or ition is Asp, IGiu, Asn, Ser, Ala, Giy, ition i02 is Giy, WO 98117810 WO 9817810PCTIUS97/20037 75-1 (ix) FEATURE: NAME/KEY: modified-site LOCATION:103 OTHER INFORMATION: /note= "Xaa at position 103 is Asp, or Ser;"1 (ix) FEATURE: NAME/KEY: Modified-site LOCATION:104 OTHER INFORMATION: /note= "Xaa at Val, Cys, Tyr, Thr, Met, Pro, Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:105 OTHER INFORMATION: /note= "Xaa at Pro, Ala, Phe, Ser, Trp, Gin, His;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i06 CD) OTHER INFORMATION: /note= "Xaa at Ser, Ala, Lys, Thr, Ile, Gly, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:108 CD) OTHER INFORMATION: /note= "Xaa at Lys, Asp, Leu, Thr, Ile, Gin, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i09 OTHER INFORMATION: /note= 'Xaa at Thr,' Pro, Giu, Tyr, Leu, Ser, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:ilQ OTHER INFORMATION: /note= "Xaa at Ala, Asn, Thr, Leu, Arg, Gin, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:111 OTHER INFORMATION: /note= "Xaa at Ile, Arg, Asp, or Met;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:112 OTHER INFORMATION:/note= "Xaa at Val, Gin, Tyr, Giu, His, Ser, (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i13 OTHER INFORMATION:/note= "Xaa at Ser, Cys, His, Gly, Trp, Tyr, Asn;" position 104 is Trp, Leu, Gin, Lys, Aia, Phe, or po sition 105 is Asn, Tyr, Leu, Lys, Ile, Asp, or position 106 is Giu, or Pro;" position 108 is Arg, His, Ser, Ala or Pro;' position 109 is Arg, or Gly; 1 position 110 is Lys, His, Glu, Ser, or Trp;" position 111 is Leu, position 112 is Thr, or Phe; position 113 is Phe, Asp, Lys, Leu, Ile, Val or (ix) FEATURE: NAME/KEY: modified-site LOCATION:1i4 OTHER INFORMATION: /note= "Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;" (ix) FEATURE: NAME/KEY: Modified-site D) OTHER INFORMATION:/note=~ "-Xaa at Asn, Val, Pro, Arg, Ala, His, (ix) FEATURE: position 115 is Leu, Thr, Trp, or Met;" WO 98/17810 _75i NAME/KEY: Modified-site LOCATION:1l6 OTHER INFORMATION: /note= "Xaa at position Leu, Pro, Thr, Met, Asp, Val, Glu, Arg Ala, Tyr, Phe, Gin, or Ile;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:i17 OTHER INFORMATION:/note= 'Xaa at position Ser, Asn, Ile, Trp, Lys, or Pro;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:1i8 OTHER INFORMATION:/note= "Xaa at position Ser, Pro, Ala, Giu, Cys, Asp, or Tyr;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:119 OTHER INFORMATION:/note= "Xaa at position Ser, Lys, Pro, ieu, Thr, Tyr, or Arg;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:120 OTHER INFORMATION:/note= "Xaa at position Ala, Pro, Leu, His, Val, or Gin;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:12i OTHER INFORMATION:/note= "Xaa at position Ser, Ile, Asn, Pro, Lys, Asp, or Gly;" (ix) FEATURE: NAME/KEY: Modified-site LOCATION;i22 OTHER INFORMATION:/note= "Xaa at position Ser, Met, Trp, Arg, Phe, Pro, His, Ile.

(ix) FEATURE: NAME/KEY: Modified-site LOCATION:i23 OTHER INFORMATION:/note= "Xaa at position Met, Giu, His, Ser, Pro, Tyr, or Leu;'" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 859: PCT/US97/20037 116 is Lys, Trp, Ser, Asn, His, i17 is Thr, i18 is Leu, 119 is Giu, 120 is Asn, 121 is Ala, 122 is Gin, Tyr, or Cys;" i23 is Ala, Ala 1a Xaa Xaa Xaa Xaa Xaa Xaa Ser Lys Thr Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa~a Xaa Phe Xaa Xaa Xaa Gin w o9/17 ITr PrT/I JS97/20037 755.

INFORMATION FOR SEQ ID NO: 860: SEQUENCE CHARACTERISTICS: LENGTH: 153 amino acids TYPE: amino acid STRANDEDNESS: unknown TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Modified-site LOCATION:112 OTHER INFORMATION:/note= "position 112 is deleted or Leu, Ala,VA1, Ile, Pro, Phe, Trp or Met" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:113 OTHER INFORMATION:/note= "positoin 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp or Met" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:114 OTHER INFORMATION:/note= "position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp or Met" (ix) FEATURE: NAME/KEY: Modified-site LOCATION:115 OTHER INFORMATION:/note= "positon 115 is deleted or Gin, Gly, Ser, Thr, Tyr, or Asn" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 860: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 25 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 40 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 55 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 70 75 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 90 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Xaa 100 105 110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 INFORMATION FOR SEQ ID NO: 861: SEQUENCE CHARACTERISTICS: LENGTH: 1 amino acids TYPE: amino acid WO 98/17810 760 PCTIUS97/20037 STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Protein LOCATION:1 OTHER INFORMATION:/note= "where x=(glyglyglyser)n and where n is an integer" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 861: Xaa 1 INFORMATION FOR SEQ ID NO: 862: SEQUENCE CHARACTERISTICS: LENGTH: 1 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Peptide LOCATION:1 OTHER INFORMATION:/note= "where x=(glyglyglyglyser)n and where n is an integer" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 862: Xaa 1 INFORMATION FOR SEQ ID NO: 863: SEQUENCE CHARACTERISTICS: LENGTH: 1 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Protein LOCATION:1 OTHER INFORMATION:/note= "where x= (glyglyglyglyglyser)n and where n is an integer" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 863: Xaa 1 INFORMATION FOR SEQ ID NO: 864: SEQUENCE CHARACTERISTICS: LENGTH: 1 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Protein WO 98/17810 PCT/US97/20037 LOCATION:1 OTHER INFORMATION:/note= "where x= (gly n ser)n and where n is an integer" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 864: Xaa 1 INFORMATION FOR SEQ ID NO: 865: SEQUENCE CHARACTERISTICS: LENGTH: 1 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: NAME/KEY: Protein LOCATION:1 OTHER INFORMATION:/note= "where x=(alaglyser)n and where n is an integer" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 865: Xaa

Claims (26)

1. A hematopoietic protein comprising; an amino acid sequence of the formula: Ra-LI-1k 2 1 R 2 -LI- R 1 R 1 -R 2 or R 2 -R 1 wherein R 1 and R 2 are independently selected from the group consisting of; A human EPO receptor agonist polypeptide, comprising; a modified EPO amino acid sequence of the Formula: AlaProProArgLeulleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys GluAla~luAsnhleThrThrGlycysAlaGluHiscysSerLeuAsnGluAsnI leThr Val ProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValolyGlnGln~la ValGluValTrpOlnGlyLeuAlaLeuLeuSerGluAlaVa1LeuArgGlyGln~laLeu 70 LeuValAsnSerSerGlnProTrpGluProLeulnLeu-i sValAspLysAlaVal Ser 100 GlyLeuArgSerLeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlalleSer 110 120 ProProAspAlaAlaSerAlaAlaProLeuArgThrI leThrAlaAspThrPheArgLys 130 140 LeuPheArgValTyrSerAsnPheLeuArgGlyLys LeuLys LeuTyrThrG lyG luAla 150 160 CysArgThrGlyAspArg SEQ ID NO:464 166 wherein 1-6 amino acids from the N-terminus and/or from the C-terminus are optionally deleted from said EPO receptor agonist polypeptide; wherein the N-terminus Is joined to the C-terminus directly or through a linker (L 2 capable of joining the WO 98/17810 WO 9817810PCTIUS97/20037 N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23-24 47-48 109-110

24-25 48-49 110-111

25-26 49-50 111-112

26-27 50-51 112-113

27-28 51-52 113-114

28-29 52-53 114-115

29-30 53-54 115-116

30-31 54-55 116-117

31-32 55-56 117-118

32-33 56-57 118-119

33-34 57-58 119-120

34-35 77-78 120-121

35-36 78-79 121-122

36-37

79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44-45 88-89 130-131 45-46 108-109

131-132 46-47 respectively; (II) A human stem cell factor receptor agonist polypeptide, comprising; a modified stem cell factor amino acid sequence of the Formula: GluGlyIleCysArgAsnArgValThrAsnsnValLysAspValThrLysLeuValAla AsnLeuProLysAspTyrMetI 1eThrLeuLysTyrVa 1Pr oG lymetAspVa 1Leu Pro 30 SerHi scysTrpl 1leSerGluMe tValValG 1nLeuS erAspSerLeuThrAspLeubeu WO 98/17810 WO 9817810PCTTTSQ7/2nAV7 ?;4 AspLysPheSerAsnhleSerGluGlyLeuSerAsnTyrSerlel leAspLysLeuVal AsnI ieValAspAspLeuValGluCysValLysGluAsnSerSerLysAspLeuLysLys 100 Se~ey~rrGur~ge~e~rr~ul~eh~gl~es 110 120 ArgSerl leAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVal 130 140 Se~rh~ue~ol~ss~r~ga~ra~ry~oh~te 150 160 ProProValAlaAla SEQ ID NO:465 165 wherein 1-23 amino acids are optionally deleted from the C-terminus of said stem cell factor receptor agonist polypeptide; and wherein the N-terminus is joined to the C'-terminus directly or through a linker (L 2 capable of joining the N-terminus to~ the C-terminus and having *new C- and N- termini at amino acids; 23-24 39-40 96-97 24-25 40-41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 WO 98/17810 W5PCT/US97/20037 37-38 94-95 110-111 38-39 95-96 respectively; (III) A human flt-3 receptor agonist polypeptide, comprising.; a modified flt-3 ligand amino acid sequence of the Formula: ThrGlnAspcysSerPheclnHisSerProlleSerSerAspPheAlaValLys IleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProVa1ThrVa1AlaSerAsnLeuGl1sp GluGluLeucysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetcluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIl1eHis 2090 100 IleSerArgLeuLeuGlnc1umhrSerGluGlnLeuValAlaLeuLysProTrp~ leThr 110 120 ArgGlnAsnPheserArgcysLeucluLeuclnCysGlnProAspSer~erThr~eu 130 SEQ ID NO:466 wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt3 receptor agonist, polypeptide; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98' 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 WO 98/17810 38-39 39-40 40-41 41-42 PCT[US97/20037 90-91 91-92 92-93 101-102 102 -103 respectively; (IV) A polypeptide comprising; a modified human G- CSF amino acid sequence of the formula: Xaa Leu Ala Xaa Ala Xaa Leu Xaa Gin Gin Giy Ser Xaa Leu Xaa Giu Pro Leu Gin Thr 120 Gin Gly 150 Gly Tyr Xaa Xaa Leu Xaa Leu Ser Ala Leu Met Ala Val1 Arg Pro Xaa Giu Val Ser Leu Glu Xaa Xaa Pro Val Leu Ala Glu Xaa Xaa Xaa His Gly Asp Xaa Ala Ala Xaa Ser Gin Leu Xaa Pro Ser Ile 110 Val Gly 140 Phe Ser 170 Xaa Leu Xaa Ala His Xaa Leu Pro Asp Ala Ser Leu Ala Pro Lys Thr Ser Al a Phe Glu Phe Pro Ala Gin Gin Gin Xaa Tyr Xaa Leu Leu Leu Ala Ala Xaa Xaa Pro Xaa Gly Xaa Gly Leu Xaa Xaa Ile Pro Trp Leu Ala Gly Gin Gly Leu Pro Thr Leu Thr Ile Trp Gin Pro Thr Xaa Xaa Ala Leu Xaa Xaa ID NO:858 wherein Xaa Xaa Xaa Xaa Xaa Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; at position 2 is Pro or Leu; at position 3 is Leu, Arg, Tyr or Ser; at position 13 is Phe, Ser, His, Thr or Pro; at position 16 is Lys, Pro, Ser, Thr or His; at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or WO 98/17810 PCTIUS97/20037 Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile, Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30 is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa at position 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr; Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa at position at position at position at position at position at position at position at position at position at position at position Gly; at position at position at position at position Glu; at position at position at position at position at position at position at position at position 46 47 49 50 54 64 67 70 74 104 108 115 120 123 144 146 147 156 159 162 163 169 170 is is is is is is is is is is is is is is is t Glu, Arg, Phe, Arg, Ile or Ala; Leu or Thr; Leu, Phe, Arg or Ser; Leu, Ile, His, Pro or Tyr; Leu or His; Cys or Ser; Gin, Lys, Leu or Cys; Gin, Pro, Leu, Arg or Ser; Cys or Ser; Asp, Gly or Val; Leu, Ala, Val, Arg, Trp, Gin or Thr, Gin, Glu, Phe, His, Leu or Ala; Gly, Arg, Lys or His Arg, Phe or Thr His, Arg, Pro, Leu, Gin or Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa is Arg or Gin; is Arg or Gin; is His, Gly or Ser; is Ser, Arg, Thr, Tyr, Val or Gly; is Glu, Leu, Gly or Trp; is Val, Gly, Arg or Ala; is Arg, Ser, Leu, Arg or Cys; is His, Arg or Ser; wherein 1-11 amino acids from the N-terminus and/or amino acids from the C-terminus are optionally deleted from said modified human G-CSF amino acid sequence; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 38-39 39-40 40-41 41-42 62-63 63-64 64-65 65-66 123-124 124-125 125-126 126-127 WO 98/17810 42-43 43-44 45-46 48-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-59 59-60 60-61 61-62 PCTIUS97/20037 66-67 67-68 68-69 69-70 70-7 1 71-72 91-92 92-93 93-94 94-95 95-96 96-97 97-98 98-99 99 -10 0 128-129 128- 12 9 129-13 0 130 -13 1 131-132

132-133

133-134

134-13 135 -13 6

136-137

137-138 138 -13 9 13 9-140

140-141

141- 142 or .142-143 respectively; A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn cys Xaa. Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa. Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa. Xaa xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 0 105 WO 98/17810 PCT/US97/20037 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120 Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala Ile Phe SEQ ID NO:859 wherein Xaa at position 17 Xaa at position 18 is Asn, Xaa at position 19 is Met, Xaa at position 20 is Ile, Xaa at position 21 is Asp, Thr, Ser or Val; Xaa at position 22 is Glu, Leu, Val or Gly; is Ser, Lys, Gly, Asp, Met, Gin, or Arg; His, Phe, Cys, Phe, Leu, Ile, Gin, Lys, Ile, Arg, Glu, Arg, Phe, Gly, Arg, Ala, Arg, Ala, Pro, Gly, or Gin; or Cys; or Ala; Glu, Gin, Asn, Trp, Pro, Val, Ala, Ser, Ala, His, Asp, Asn, Gin, Xaa at position Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 'Leu, Ser, at position at position at position at position at position at position at position Lys; at position at position at position at position Arg, Ala, at position at position at position at position at position at position at position is Ile, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Gly, Trp, Lys, Phe, Gly, His, Thr, Gly, Arg, Asn, His, Val, Gly, Phe, Arg, Leu, Leu, Thr, Gly, Arg, Gin, Gly, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ala, Gin, Ala, Ser, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Arg, Asn, Thr, Lys, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gin, Ser, Leu, or Leu, or Gin; Gly, Ala, or Glu; or Glu; Glu, Gin, Thr, 31 is Pro, Asp, 32 is Leu, Val, 33 is Pro, Leu, 34 is Leu, Val, Phe, Ile or Met; 35 is Leu, Ala, 36 is Asp, Leu, 37 is Phe, Ser, 38 is Asn, or Al 40 is Leu, Trp, 41 is Asn, Cys, 42 is Gly, Asp, Gly, Asn, Pro, Gin, or Val; or Val; Pro, Trp, a; or Arg; Arg, Leu, Ser, Cys, or Ile; His, Met, or Pro; Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; WO 98/17810 PCT/US97/20037 Xaa at position Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Xaa at position Xaa at position Ala, Ile, Xaa at position Xaa at position Xaa at position Met; Xaa at position Lys, His, Xaa at position Xaa at position Thr, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position His; Xaa at position 43 is Glu, Asn, Tyr, Thr, Gly or Ser; 44 is Asp, Ser, Leu, Gin, Ala or Pro; 45 is Gin, Pro, Phe, Asn, Arg, Ser, Ala, Leu, Phe, Asp, Ala, Cys, Arg, Lys, Thr, Met, Trp, Val, Met, Ile, Glu o 46 is Asp, Phe, Ser, Thr, Cys, Ala, Tyr, Ile, Val or Gly; 47 is Ile, Gly, Val, Ser, Arg, 48 is Leu, Ser, Cys, Arg, Ile, Ala, Met, Val or Asn; 49 is Met, Arg, Ala, Gly, Pro, 50 is Glu, Leu, Thr, Asp, Tyr, Val, His, Phe, Met or Gin; 51 is Asn, Arg, Met, Pro, Ser, 52 is Asn, His, Arg, Leu, Gly, 53 is Leu, Thr, Ala, Gly, Glu, Leu, r His; Glu, Pro, His, Asn, Lys, Thr, Ser, Pro, Thr, Lys, Asn, Gin, or His; Phe, Glu, His, Asn, or Asp; Ser, or His; or Thr; Lys, Ser, 54 is Arg, Asp, Ala or Leu; Ile, Ser, Val, Thr, Gin, Asn, 55 is Arg, Thr, Val, Ser, 56 is Pro, Gly, Cys, Ser, Tyr, Phe, Leu, Val or Lys; 57 is Asn or Gly; 58 is Leu, Ser, Asp, Arg, 59 is Glu Tyr, His, Leu, P 60 is Ala, Ser, Pro, Tyr, 61 is Phe, Asn, Glu, Pro, 62 is Asn, His, Val, Arg, 63 is Arg, Tyr, Trp, Lys, 64 is Ala, Asn, Pro, Ser, 65 is Val, Thr, Pro, His, 66 is Lys, Ile, Arg, Val, 67 is Ser, Ala, Phe, Val, Leu, Gin, or Gly; Glu, Arg, His, Gin, Val, or Cys; ro, or Arg; Asn, or Thr; Lys, Arg, or Ser; Pro, Thr, Asp, or Ser, His, Pro, or or Lys; Leu, Phe, or Ser; Asn, Glu, or Ser; Gly, Asn, Ile, Pr Ile; Val; o, or 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; WO 98/17810 PCT/US97/20037 -77/ Xaa at position 69 Leu; is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Xaa at position 74 Xaa at position 75 Gin, or Leu; Xaa at position 76 Asp; Xaa at position 77 Xaa at position 78 Xaa at position 79 Xaa at position 80 Xaa at position 81 Xaa at position 82 His, Thr, Se: Xaa at position 83 Xaa at position 84 Xaa at position 85 Xaa at position 86 Xaa at position 87 Xaa at position 88 Xaa at position 89 Ser; Xaa at position 90 Xaa at position 91 Xaa at position 92 or Leu; Xaa at position 93 Xaa at position 94 Ala, or Pro; Xaa at position 95 Lys, Ser, Al Asn, Ala, Ser, Ala, Ile Glu, Leu, Val, Met, Leu, Glu, Met, Glu, Asp, ,Met, Thr Lys, Gly, Trp, Pro, Ala, Leu, ,Pro Asp, Pro, Arg, or Ala; Glu, Thr, Gin, His, Asn, Arg, or A Ser, Gly, Thr, or A ,Arg, Gly, Ala; Pro, Trp, Arg, Ser, sp; rg; is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or is Ile, is Leu, is Lys, is Asn, is Leu, is Leu, r, Ala, is Pro, is Cys, is Leu, is Pro, is Leu, is Ala, is Thr, Ser, Ala, Thr, Trp, Gin, Gin, Tyr, Ala, Glu, Asn, Cys, Ser, Lys, Asp, Pro, Pro, Phe, Asp, Ile, Arg, Thr, or Ser, Glu, Ph Asn, Met, Ar Val, Gly, Th Gly, Ala, Tr Lys, Trp, Ar Phe, Ile, Met Thr, Trp, Ar Gly, Arg, Me Val, or Gin; Arg, Ala, or Trp, or Gly; Arg, Val, or Cys, Leu, Va Leu; e, Gly, or g, Ile, Gl r, Leu, Gl p, Arg, Va g, Asp, Gl or Val; g, or Met; t, or Val; Arg; y, or Asp; u, or Arg; 1, or Lys; u, Asn, Lys; Trp; 1, Glu, His, Asn, or Ala, Ala, Pro, Thr, Arg, Ser, Ser, Arg, Ser, Ser, Thr, Thr, Ser, Asn, Glu, Gly, Phe, Lys, Pro, Leu, Asp, Leu, His, Ala, Val, Ile, Asp, Ala, Leu, Gin, or Met; or His; Gly, Ile or Arg; Lys, His, is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, a, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; WO 98/17810 PCT/US97/20037 Xaa at position 97 i Xaa at position 98 i Glu, Gin, Ser, Xaa at position 99 i Gly, Ser, Phe, Xaa at position 100 Pro; Xaa at position 101 Tyr, Glu, Asn, Xaa at position 102 Xaa at position 103 Xaa at position 104 Gin, Lys, Ala, Xaa at position 105 Leu, Lys, Ile, Xaa at position 106 Xaa at position 108 Ala or Pro; Xaa at position 109 Xaa at position 110 Ser, or Trp; Xaa at position 111 Xaa at position 112 Xaa at position 113 s Ile, Val, Lys, Ala, or Asn; s His, Ile, Asn, Leu, Asp, Ala, Thr, Phe, Met, Val, Lys, Arg, Tyr or Pro; ,s Ile, Leu, Arg, Asp, Val, Pro, Gin, or His; is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin, or is Asp, Pro, Met, Lys, His, Thr, Val, Ser, Ala, Gly, Ile, Leu, or Gin; is Gly, is Asp, is Trp, Phe, or is Asn, Asp, or is Glu, is Arg, Leu, Glu, or Ser; Val, Cys, Gly; Pro, Ala, His; Ser, Ala, Lys, Asp, Lys, Ser, Tyr, or Pro; Tyr, Thr, Met, Pro, Leu, Phe, Ser, Trp, Gin, Tyr, Arg, Lys, Leu, Thr, Phe, Thr, Ala, Ile, Val, Ser, Asn; Cys, Asn, Pro, Asn, Arg, Gin, Cys, His, Val, Lys, Leu, Glu, Thr, Asp, Tyr, His, Ser, Pro, Thr, Thr, Tyr, Leu, Ile, Ile, Leu, Arg, Gly, Gin, Ser, Gin, Ser, Tyr, or Pro; His, Ser, or Gly; His, Glu, or Phe; Asp, or Met; Glu, His, Gly, Trp, Lys, Leu, Xaa at position Xaa at position Trp, or Me Xaa at position Arg, Trp, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Ile, Tyr, I ii e, Val or 4 is Tyr, 5 is Leu, Trp, Arg, Arg, Ala, 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Ser, Asn, His, Ala, Tyr, Phe, Gin, or Ile; 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, or Cys; or Leu; His, Thr, WO 98/17810 PCT/US97/20037 Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids; 26-27 49-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-31 53-54 87-88 31-32 54-55 88-89 32-33 64-65 89-90 33-34 65-66 90-91 34-35 66-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38-39 70-71 99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83 102-103 or 103-104 respectively; (VI) A polypeptide comprising; a modified human c- mpl ligand amino acid sequence of the formula: SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer 1 5 10 HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro 20 25 30 ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu 45 50 W4 )98/17810 PCTIUS97/20037 ThrLysAlaGlnAspI leLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 65 70 AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuiLeuGlyGlnLeuSerGly 80 85 90 GlnValArgLeuLeuLeuclyAlaLeuclnSerLeuLeuGlyThrGlnXaaXaaXaa 100 105 110 XaaGlyArgThrThrA1aHi sLysAspProAsnAla11 ePheLeuSerPheG1n~ijs 115 120 125 130 LeuLeuArgGlyLysVa lArgPheLeuMetLeuValG lyG lySerThrLeuCys Va 1 135 140 145 150 Arg SEQ ID NO:860 153 wherein; Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is del eted or Gin, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining N-terminus to the C-terminus and having new C- and N- termini at amino acids; 26-27 51-52 108-109 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55 111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-115 34-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80 118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-122 the WO 98/17810 -7775 WO 9817810PCTIUS97/20037 43-44 44-45 4 6-47 47-48 48-49 50-51 83-84 84-85 85-86 86-87 87-88 88-89 122 -123 123 -124 124-125 125-126 12 6-127 or 127-128 respectively; (VII) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala Pro Met Thr Gin Thr Thr'Ser Leu Lys Thr Ser Trp Val cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 Gin 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Gin Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 Thr Thr Leu Ser Leu Ala Ile Phe SEQ ID NO:859 130 WO 98/17810 PCT/US97/20037 wherein Xaa at position 17 Xaa at position 18 is Asn, Xaa at position 19 is Met, Xaa at position 20 is Ile, Xaa at position 21 is Asp, Thr, Ser or Val; Xaa at position 22 is Glu, Leu, Val or Gly; is Ser, Lys, Gly, Asp, Met, Gin, or Arg; His, Phe, Cys, Phe, Leu, Ile, Gin, Lys, Ile, Arg, Glu, Arg, Gly, Arg, Ala, Arg, Ala, Pro, Gly, or Gin; or Cys; or Ala; Glu, Gin, Asn, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Xaa at position Leu, Ser, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Lys; Xaa at position Xaa at position Xaa at position Xaa at position Arg, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Val, Glu, Xaa at position Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, is Ile, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Val, Ala, Gly, Trp, Lys, Phe, Gly, His, Thr, Gly, Arg, Asn, His, Val, Gly, Phe, Arg, Leu, Leu, Thr, Gly, Arg, Gin, Gly, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ala, Gin, Ala, Ser, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Arg, Asn, Thr, Lys, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gin, Ser, Leu, or Leu, or Gin; Gly, Ala, or Glu; or Glu; Glu, Gin, Thr, is Pro, Asp, is Leu, Val, is Pro, Leu, is Leu, Val, Phe, Ile or Met; 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; 36 is Asp, Leu, or Val; 37 is Phe, Ser, Pro, Trp, or Ile; 38 is Asn, or Ala; 40 is Leu, Trp, or Arg; 41 is Asn, Cys, Arg, Leu, His, Met, 42 is Gly, Asp, Ser, Cys, Asn, Lys, or Pro; Thr, Leu, Phe, Tyr, Ile, Met or Ala; 43 is Glu, Asn, Tyr, Leu, Phe, Thr, Gly or Ser; 44 is Asp, Ser, Leu, Arg, Lys, Gin, Ala or Pro; Asp, Ala, Cys, Thr, Met, Trp, 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Asn, Arg, Ser, Ala, Ile, Glu or His; WO 98/17810 PCT/US97/20037 Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Xaa at position Xaa at position Ala, Ile, Xaa at position Xaa at position Xaa at position Met; Xaa at position Lys, His, Xaa at position Xaa at position Thr, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position His; Xaa at position Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Tyr, Ile, Val or Gly; 47 is Ile, Gly, Val, Ser, Arg, 48 is Leu, Ser, Cys, Arg, Ile, Ala, Met, Val or Asn; 49 is Met, Arg, Ala, Gly, Pro, 50 is Glu, Leu, Thr, Asp, Tyr, Val, His, Phe, Met or Gin; 51 is Asn, Arg, Met, Pro, Ser, 52 is Asn, His, Arg, Leu, Gly, 53 is Leu, Thr, Ala, Gly, Glu, 54 is Arg, Asp, Ile, Ser, Val, Ala or Leu; 55 is Arg, Thr, Val, Ser, Leu, 56 is Pro, Gly, Cys, Ser, Gin, Tyr, Phe, Leu, Val or Lys; 57 is Asn or Gly; 58 is Leu, Ser, Asp, Arg, Gin, 59 is Glu Tyr, His, Leu, Pro, 60 is Ala, Ser, Pro, Tyr, Asn, 61 is Phe, Asn, Glu, Pro, Lys, 62 is Asn, His, Val, Arg, Pro, 63 is Arg, Tyr, Trp, Lys, Ser, 64 is Ala, Asn, Pro, Ser, or L 65 is Val, Thr, Pro, His, Leu, 66 is Lys, Ile, Arg, Val, Asn, 67 is Ser, Ala, Phe, Val, Gly, Glu, Asn, Gin, Pro, His, Asn, Lys, Thr, Ser, Pro, or His; Phe, Glu, His, Asn, or Asp; Ser, or His; or Thr; Lys, Ser, or Thr, Gin, Asn, or Gly; Glu, Arg, His, Val, or or Arg; Cys; or Thr; Arg, or Ser; Thr, Asp, or His, Pro, or ys; Phe, or Ser; Glu, or Ser; Asn, Ile, Pr Ile; Val; o, or 68 69 Leu; Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Leu, Gin, Asn, Ala, Ser, Ala, Val, Ala, Leu, Met, Glu, Glu, Trp, Pro, Val, Leu, Met, Asp, Ser, Thr, Trp, Pro, Ala, Leu, Ile, Glu, Phe, Thr, or His; Arg, Trp, Gly, or Pro, or Ala; Arg, Glu, Thr, Gin, His, Asn, Arg, or Asp; Ser, Gly, Thr, or Arg; WO 98/17810 PCT/US97/20037 Xaa at position 74 is Xaa at position 75 is Gin, or Leu; Xaa at position 76 is Asp; Xaa at position 77 is Xaa at position 78 is Xaa at position 79 is Xaa at position 80 is Xaa at position 81 is Xaa at position 82 is His, Thr, Ser, Xaa at position 83 is Xaa at position 84 is Xaa at position 85 is Xaa at position 86 is Xaa at position 87 is Xaa at position 88 is Xaa at position 89 is Ser; Xaa at position 90 is Xaa at position 91 is Xaa at position 92 is or Leu; Xaa at position 93 is Xaa at position 94 is Ala, or Pro; Xaa at position 95 is Lys, Ser, Ala, Xaa at position 96 is Xaa at position 97 is Xaa at position 98 is Glu, Gin, Ser, Xaa at position 99 is Gly, Ser, Phe, Xaa at position 100 i Pro; Ile, Glu, Met, Lys, Thr, Gly, Pro, Asp, Arg, Gly, Pro, Trp, Ala; Arg, Ser, Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Ile, Ser, Leu, Ala, Lys, Thr, Asn, Trp, Leu, Gin, Leu, Gin, Ala, Tyr, Pro, Ala, Cys, Glu, Leu, Asn, Pro, Cys, Leu, Ser, Ala, Lys, Thr, Asp, Arg, Thr, or Ser, Glu, Ph Asn, Met, Ar Val, Gly, Th Gly, Ala, Tr Lys, Trp, Ar Phe, Ile, Met Thr, Trp, Ar Gly, Arg, Me Val, or Gin; Arg, Ala, or Trp, or Gly; Arg, Val, or Cys, Leu, Va Leu; e, Gly, g, Ile, r, Leu, P, Arg, g, Asp, or Val; or Arg; Gly, or Asp; Glu, or Arg; Val, or Lys; Glu, Asn, g, or Met; t, or Val; Lys; Trp; 1, Glu, His, Asn, or Ala, Ala, Pro, Thr, Arg, Pro, Pro, Phe, Asp, Ile, Ser, Ser, Arg, Ser, Ser, Thr, Thr, Ser, Asn, Glu, Gly, Phe, Lys, Pro, Leu, Asp, Leu, His, Ala, Val, Ile, Asp, Ala, Leu, Gin, or Met; or His; Gly, Ile or Arg; Lys, His, His, Gin, rrp, Phe, Pro, Lys, Ile, Val His, Ile Phe, Met, Pro, Arg, Val, Leu, Gly, Ile, or Tyr; Tyr, Gly, Ile, or Thr; ,Lys, Ala, or Asn; Asn, Leu, Asp, Ala, Thr, Val, Lys, Arg, Tyr or Pro; Thr, Asn, Ile, Leu, Arg, Asp, Val, Pro, Gin, or His; s Lys, Tyr, Leu,.His, Arg, Ile, Ser, Gin, or WO 98/17810 PCT/US97/20037 Xaa at position 101 Tyr, Glu, Asn, Xaa at position 102 Xaa at position 103 Xaa at position 104 Gin, Lys, Ala, Xaa at position 105 Leu, Lys, Ile, Xaa at position 106 Xaa at position 108 Ala or Pro; Xaa at position 109 Xaa at position 110 Ser, or Trp; Xaa at position 111 Xaa at position 112 Xaa at position 113 Lys, Leu, Ile, is Asp, Pro, Met, Lys, His, Thr, Val, Ser, Ala, Gly, Ile, Leu, or Gin; is Gly, is Asp, is Trp, Phe, or is Asn, Asp, or is Glu, is Arg, Leu, Glu, or Ser; Val, Cys, Gly; Pro, Ala, His; Ser, Ala, Lys, Asp, Lys, Ser, Tyr, or Pro; Tyr, Thr, Met, Pro, Leu, Phe, Ser, Trp, Gin, Tyr, Arg, Lys, is Leu, is Thr, is Phe, Val or Thr, Ala, Ile, Val, Ser, Asn; Cys, Asn, Pro, Asn, Arg, Gin, Cys, His, Val, Lys, Leu, Glu, Thr, Asp, Tyr, His, Ser, Pro, Thr, Thr, Tyr, Leu, Leu, Arg, or Met; Glu, His, Gly, Trp, Ile, Ile, Gly, or Pro; Gin, His, Ser, Ser, or Gly; Gin, His, Glu, Ser, or Phe; Tyr, Asp, or Leu; His, Thr, Xaa at position 114 is Tyr, Xaa at position 115 is Leu, Trp, or Met; Trp, Arg, Arg, Ala, Xaa at position Arg, Trp, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Ile, Tyr, Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or 117 is Thr, Ser, Asn, lie, Trp, Lys, 118 is Leu, Ser, Pro, Ala, Glu, Cys, 119 is Glu, Ser, Lys, Pro, Leu, Thr, 120 is Asn, Ala, Pro, Leu, His, Val, 121 is Ala, Ser, Ile, Asn, Pro, Lys, 122 is Gin, Ser, Met, Trp, Arg, Phe, or Cys; 123 is Ala, Met, Glu, His, Ser, Pro, Val, Glu, Ile; or Pro; Asp, or Tyr; Tyr, or Arg; or Gin; Asp, or Gly; Pro, His, Tyr, or Leu; wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from C-2994/PCT 780 2 the corresponding amino acids of native (1- 1 31 human interleukin- 3 and (VIII) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; and wherein L 1 is a linker capable of linking R 1 to R 2 said hematopoietic protein can optionally be immediately preceded by (methionine-1), (alanine-1) or (methionine- 2 alanine-); with the proviso that at least RI or R 2 is selected from the polypeptide of formula or (III). 2. A hematopoietic protein comprising; an amino acid sequence of the formula: Ri-L 1 -R 2 R 2 -L 1 -RI, Ri-R 2 or R 2 -R1 wherein R, and R 2 are independently selected from the group consisting of; A human EPO receptor agonist polypeptide, comprising; a modified EPO amino acid sequence of the Formula: AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys GluAlaGluAsnIlehrThrGlyCysAlaGluHisCysSerLeuAsnGluAsnIleThr ValProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValGlyGlnGlnAla ValGluValTrp GlnyLeuAlaLeuLeuSerGluAlaValLeuArgGlyGnAlaLeu 0 0 WO 98/17810 WO 9817810PCTIUS97/20037 LeuVal1AsnSerSerGlnProTrpGl1uProLeuGlnLeuHi sValAspLysAlaVal1 Ser 100 Gl~ur~re~rh~ue~g~ae~yl~ny~ul~ee 110 120 ProProAspAlaAlaSerAlaAlaProLeuArgThrIleThrAlaAspThrPheArg~ys 130 140 LeuPheArgVa lTyrSerAsnPheLeuArgGlyLys LeuLys LeuTyrThrGlyG luAla 150 160 CysArgThrGlyAspArg SEQ ID NO:464 166 wherein 1-6 amino acids from the N-terminus and/or from the C-terminus are optionally deleted from said EPO receptor agonist polypeptide; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus arnd having new C- and N- termini at amino acids; 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27-28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 118-119 33-34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 WO 98/17810 IA/ PCT1US97/20037 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44-45 88-89 130-131 45-46 108-109 131-132 46-47 respectively; (II) A human stem cell factor receptor agonist polypeptide, comprising; a modified stem cell factor amino acid sequence of the Formula: GluGlyIleCysArgAsnArgValThrAsnAsnValLysA AsnLeuProLysAspTyrMetIleThrLeuLysTyrValProGlyMetAspValLeuPro SerHiscysTrplleSerGuMetValValGlnLeuSerAspSerLeuThrAspLeuLeu 50 AspLysPheSerAsnhleSerGluGlyLeuSerAsnTyrSerllelleAspLysLeuVal AsnhleValAspAspLeuValGlucysValLysGluAsnserserLysAspLeuLysLys 100 SerPheLysSerProGluProArgLeuPheThrProG1uGluPhePheArg lePheAsn 110 120 ArgSerlleAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVa1 130 140 SerSerThrLeuSerProGluLysAspSerArgValSerValThrLysProPheMetLeu 150 160 ProProValAlaAla SEQ ID NO:465 165 wherein 1-23 amino acids are optionally deleted from the C-terminus of said stem cell factor receptor agonist polypeptide; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the WO 98/17810 PCT/US97/20037 N-terminus to the C-terminus and having new C- and N- termini at amino acids; 23-24 39-40 96-97 24-25 40-41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 respectively; (III) A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence of the Formula: ThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlavalLyslleArg Gl~ue~py~ue~ns~r~oa~ra~ae~ne~ns GluGluLeucysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArgLeu LysThrValAlaolySerLysMetGlnGlyLeuLeuGlurgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 90 100 Il~rr~ue~n~uh~rl ne~a~ae~sr~pleThr WO 98/17810 WO 9817810PCT/US97/20037 110 120 ArgGlnAsnPhe~erArgCysLeuGluLeuolncysGnProAspSerSerThr~eu 130 SEQ ID NO:466 wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt3 receptor agonist polypeptide; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 28-29 42-43 93-94 29-30 64-65 94-95 .30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40-41 92-93 respectively; 41-42 (IV) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 40 Xaa Xaa Xaa Xaa xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 55 i 'I i WO 98/17810 PCT/US97/20037 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 0 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa 110 Gin 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 120 Xaa Xaa Xaa Gin Thr Thr Leu Ser Ala Ile Phe SEQ ID NO:859 Gly, Asp, Met, Gin, or Arg; wherein Xaa at position 17 Xaa at position 18 is Asn, Xaa at position 19 is Met, Xaa at position 20 is Ile, Xaa at position 21 is Asp, Thr, Ser or Val; Xaa at position 22 is Glu, Leu, Val or Gly; is Ser, Lys His, Leu, I: Phe, Ile, A: Cys, Gin, GI Phe, Lys, Al le, Phe, rg, Ju, Lg, Gly, Arg, Ala, Arg, Ala, Pro, Gly, or Gin; or Cys; or Ala; Glu, Gin, Asn, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Xaa at position 23 Leu, Ser, or Xaa at position 24 Xaa at position 25 Xaa at position 26 Xaa at position 27 Xaa at position 28 Xaa at position 29 Xaa at position 30 Lys; Xaa at position 31 Xaa at position 32 Xaa at position 33 is Ile, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Val, Ala, Gly, Trp, Lys, Phe, Gly, His, Thr, Gly, Arg, Asn, His, Asp, Val, Leu, Val, Gly, Phe, Arg, Leu, Leu, Thr, Gly, Arg, Gin, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ala, Gin, Ala, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Arg, Asn, Thr, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gin, Ser, Leu, or Leu, or Gin; Gly, Ala, or Glu; or Glu; Pro, Leu, Pro, WO 98/17810 PCT/US97/20037 Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Val, Glu, Xaa at position Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Xaa at position Xaa at position Ala, Ile, Xaa at position Xaa at position Xaa at position Met; Xaa at position Lys, His, Xaa at position Xaa at position Thr, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Phe, 35 is 36 is 37 is 38 is 40 is 41 is 42 is Phe, 43 is Thr, 44 is Gin, 45 is Asn, 46 is Ala, 47 is 48 is Ala, 49 is 50 is Val, 51 is 52 is 53 is Ile or Met; Leu, Ala, Gly, Asn, Pro, Gin, Asp, Leu, or Val; Phe, Ser, Pro, Trp, or Ile; Asn, or Ala; Leu, Trp, or Arg; Asn, Cys, Arg, Leu, His, Met, Gly, Asp, Ser, Cys, Asn, Lys, Tyr, Ile, Met or Ala; Glu, Asn, Tyr, Leu, Phe, Asp, Gly or Ser; Asp, Ser, Leu, Arg, Lys, Thr, Ala or Pro; Gin, Pro, Phe, Val, Met, Leu, Arg, Ser, Ala, Ile, Glu or His; Asp, Phe, Ser, Thr, Cys, Glu, Tyr, Ile, Val or Gly; Ile, Gly, Val, Ser, Arg, Pro, Leu, Ser, Cys, Arg, Ile, His, Met, Val or Asn; Met, Arg, Ala, Gly, Pro, Asn, SGlu, Leu, Thr, Asp, Tyr, Lys, His, Phe, Met or Gin; Asn, Arg, Met, Pro, Ser, Thr, Asn, His, Arg, Leu, Gly, Ser, Leu, Thr, Ala, Gly, Glu, Pro, or Val; or Pro; Thr, Leu, Ala, Cys, Met, Trp, Thr, Lys, Asn, Gin, or His; Phe, Glu, His, Asn, or Asp; Ser, or His; or Thr; Lys, Ser, or 54 is Arg, Asp, Ile, Ser, Val, Ala or Leu; 55 isArg, Thr, Val, Ser, Leu, 56 is Pro, Gly, Cys, Ser, Gin, Tyr, Phe, Leu, Val or Lys; 57 is Asn or Gly; 58 is Leu, Ser, Asp, Arg, GOn, Thr, Gin, Asn, or Gly; Glu, Arg, His, Val, or Cys; is Glu Tyr, His, Leu, Pro, or Arg; is Ala, Ser, Pro, Tyr, Asn, or Thr; WO 98/17810 PCT/US97/20037 Xaa at position 61 Xaa at position 62 Xaa at position 63 Xaa at position 64 Xaa at position 65 Xaa at position 66 Xaa at position 67 His; Xaa at position 68 Xaa at position 69 Leu; Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Xaa at position 74 Xaa at position 75 Gin, or Leu; Xaa at position 76 Asp; Xaa at position 77 Xaa at position 78 Xaa at position 79 Xaa at position 80 Xaa at position 81 Xaa at position 82 His, Thr, Sei Xaa at position 83 Xaa at position 84 Xaa at position 85 Xaa at position 86 Xaa at position 87 Xaa at position 88 Xaa at position 89 Phe, Asn, Arg, Ala, Val, Lys, Ser, Leu, Gin, Asn, Ala, Ser, Ala, Ile, Glu, Asn, His, Tyr, Asn, Thr, Ile, Ala, Val, Ala, Leu, Met, Glu, Glu, Met, Lys, Glu, Val, Trp, Pro, Pro, Arg, Phe, Trp, Pro, Val, Leu, Met, Asp, Thr, Gly, Pro, Arg, Lys, Ser, His, Val, Val, Ser, Thr, Trp, Pro, Ala, Leu, Pro, Asp, Lys, Arg, Pro, Thr, Ser, His, or Lys; Leu, Phe, Asn, Glu, Gly, Asn, or Ser; Asp, or Pro, or Ile; Val; or Ser; or Ser; Ile, Pro, or Ile, Glu, Pro, Arg, His, Ser, Arg, Pro, Phe, Arg, Thr, Trp, or Ala; Glu, Thr, or His; Gly, or Gin, or Asp; or Arg; Ser, Asn, Gly, Gly, Trp, Arg, Thr, Ala; Arg, is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or is Ile, is Leu, is Lys, is Asn, is Leu, is Leu, r, Ala, is Pro, is Cys, is Leu, is Pro, is Leu, is Ala, is Thr, Ser, Ala, Thr, Trp, Gin, Gin, Tyr, Ala, Glu, Asn, Cys, Ser, Lys, Asp, Arg, Ser, Asn, Val, Gly, Lys, Phe, Thr, Gly, Val, Arg, Trp, Arg, Cys, Thr, or Leu; Glu, Phe, Gly, or Arg; Met, Arg, Ile, Gly, or Asp; Gly, Thr, Leu, Glu, or Arg; Ala, Trp, Arg, Val, or Lys; Trp, Arg, Asp, Glu, Asn, Ile, Met or Val; Trp, Arg, or Met; Arg, Met, or Val; or Gin; Ala, or Lys; or Gly; Val, or Trp; Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; WO 98/17810 PCT/US97/20037 Xaa at position 91 is Ala, Xaa at position 92 is Pro, or Leu; Xaa at position 93 is Thr, Xaa at position 94 is Arg, Ala, or Pro; Xaa at position 95 is His, Lys, Ser, Ala, Trp, P1 Xaa at position 96 is Pro, Xaa at position 97 is Ile, Xaa at position 98 is His, Glu, Gin, Ser, Phe, M Xaa at position 99 is Ile, Gly, Ser, Phe, or His Xaa at position 100 is Lys, Pro; Xaa at position 101 is Asp, Tyr, Glu, Asn, Ser, A Xaa at position 102 is Gly, Xaa at position 103 is Asp, Xaa at position 104 is Trp, Gin, Lys, Ala, Phe, o Xaa at position 105 is Asn, Leu, Lys, Ile, Asp, o Xaa at position 106 is Glu, Xaa at position 108 is Arg, Ala or Pro; Xaa at position 109 is Arg, Xaa at position 110 is Lys, Ser, or Trp; Xaa at position 111 is Leu, Xaa at position 112 is Thr, Xaa at position 113 is Phe, Lys, Leu, Ile, Val oi Pro, Phe, Asp, Ile, 31n, he, Lys, Val, Ile, Ser, Arg, Ser, Ser, Thr, Ser, Asn, Glu, Phe, Lys, Pro, Leu, Leu, His, Ala, Val, Asp, Ala, Leu, Gin, or His; Gly, Ile or Arg; Lys, His, Pro, Arg, Val, Leu, Gly, Thr, Asn, Ile, or Tyr; Tyr, Gly, Ile, or Thr; Lys, Ala, or Asn; Asn, Leu, Asp, Ala, Thr, q et, Val, Lys, Arg, Tyr or Pro; Leu, Arg, Asp, Val, Pro, Gin, Tyr, Leu, His, Arg, Ile, Ser, Gin, or Pro, Met, Lys, His, Thr, Val, la, Gly, Ile, Leu, or Gin; Leu, Glu, or Ser; Val, Cys, r Gly; Pro, Ala, ir His; Lys, Ser, Tyr, or Pro; Tyr, Thr, Met, Pro, Leu, Phe, Ser, Trp, Gin, Tyr, Ser, Lys, r Thr, Ala, Ile, Val, Ser, Asn; Cys, Asn, Ala, Asp, Pro, Asn, Arg, Gin, Cys, His, Val, Lys, Leu, Glu, Thr, Asp, Tyr, His, Ser, Pro, Thr, Ile, Thr, Ile, Tyr, Leu, Leu, Arg, or Met; Glu, His, Gly, Trp, Gly, or Pro; Gin, His, Ser, Ser, or Gly; Gin, His, Glu, Ser, or Phe; Tyr, Asp, or Leu; His, Thr, Xaa at position 114 is Tyr, Xaa at position 115 is Leu, Trp, or Met; Trp, Arg, Arg, Ala, WO 98/17810 PCT/US97/20037 Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; wherein L i is a linker capable of linking R, to and wherein said hematopoietic protein can optionally be immediately preceded by (methionine-'), (alanine or (methionine 2 alanine with the proviso that at least R or R 2 is selected from the polypeptide of formula or (III). 3. The hematopoietic protein as recited in claim 2 wherein the polypeptide of (IV) is selected from the from the group consisting of; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys WO 98/17810 PCT/US97/20037 7 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ile Leu Met' Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin SEQ ID NO:803; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gln SEQ ID NO:804; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin SEQ ID NO:805; and Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu. Gin Ala Gin Glu Gin Gin SEQ ID NO:806. WO 98/17810 WO 9817810PCTIUS97/20037 4. A hematopoietic protein comprising; an amino acid sequence of the formula: R 1 -L 1 -R 2 1 R 2 L.-R 1 R 1 -R 2 or R -R 1 wherein R 1 is a polypeptide, comprising; a modified flt-3 ligand amino acid sequence of the Formula: ThrGlnAspCys~erPheGlnHisSerProlleSerSerAspPheAlaValLyslleArg GluLeu~erAspTyrLeuLeu~lnAspTyrProValThrValAlaSerAsnLeuGliAsp 30 GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGly~erLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 100 Ii e~erArgLeuLeuGlnGluThrSerGluG lnLeuValAlaLeuLysProTrpl leThr 110 120 Arg~lnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer~erThrLeu 130 SEQ ID N\O:466 wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40-41 92-93 respectively; 41-42 WO 98/17810 WO 9817810PCTIUS97/20037 wherein R 2 is a polypeptide comprising; a modified human IL-3 amino acid sequence of the formula: Ala Pro Met Thr 1 cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin 5 Xaa Xaa XaA Xaa Thr Thr Ser Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Xaa Xaa Xaa 100 Xaa 115 Thr Ser Trp Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Gin Thr Thr Leu Ser Ala Ile Phe SEQ ID NO:859 wherein Xaa at xaa atj Xaa at Xaa at Xaa at position position 18 is A~ position 19 is M~ position.20 is I: position 21 is A~ 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg; le, His, Phe, Cys, Phe, Leu, Ile, Phe, Arg, or Gin; Ile, Arg, Giy, Ala, or cys; Gin, Giu, Arg, Pro, or Aia; Lys, Arg, Ala, Giy, Glu, Gin, Asn, WO 98/17810 PCT/US97/20037 ;7^3 Thr, Ser or Val; Xaa at position 22 is Glu, Leu, Val or Gly; Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Lys; Xaa at position Xaa at position Xaa at position Xaa at position Arg, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Val, Glu, Xaa at position Gin, Arg, Xaa at position Glu, Asn, Xaa at position Trp, Asp, Xaa at position Lys, His, Xaa at position Xaa at position Lys, Thr, Arg; is Ile, is Thr, is His, is Leu, is Lys, is Gin, is Pro, Gly, His, Thr, Gly, Arg, Asn, His, Val, Gly, Phe, Arg, Leu, Leu, Thr, Arg, Gin, Gly, Thr, Gin, Pro, Gly, Ala, Gin, Ala, Ser, Ser, Arg, Arg, Ser, Gly, Arg, Asp, Arg, Asn, Thr, Lys, Phe, or Leu; Pro, or Ala; Ala, or Trp; or Ala; Pro, Val or Trp; or Val; Gln, Ser, Leu, or Leu, or Gin; Gly, Ala, or Glu; or Glu; Glu, Gin, Thr, 31 is Pro, Asp, Gly, 32 is Leu, Val, Arg, 33 is Pro, Leu, Gin, 34 is Leu, Val, Gly, Phe, Ile or Met; 35 is Leu, Ala, Gly, 36 is Asp, Leu, or V 37 is Phe, Ser, Pro, 38 is Asn, or Ala; 40 is Leu, Trp, or A 41 is Asn, Cys, Arg, 42 is Gly, Asp, Ser, Phe, Tyr, Ile, Met o Asn, Pro, Gin, or Val; al; Trp, or Ile; rg; Leu, His, Me Cys, Asn, Ly r Ala; t, s, or Pro; Thr, Leu, 43 is Glu, Asn, Tyr, Leu, Phe, Thr, Gly or Ser; 44 is Asp, Ser, Leu, Arg, Lys, Gin, Ala or Pro; Asp, Ala, Cys, Thr, Met, Trp, 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Asn, Arg, Ser, Ala, Ile, Glu or His; 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Ala, Tyr, Ile, Val or Gly; 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Ala, Met, Val or Asn; WO 98/17810 PCT/US97/20037 Xaa at position Xaa at position Ala, Ile, Xaa at position Xaa at position Xaa at position Met; Xaa at position Lys, His, Xaa at position Xaa at position Thr, Ala, Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position His; Xaa at position Xaa at position 49 is Met, Arg, Ala, Gly, Pro, 50 is Glu, Leu, Thr, Asp, Tyr, Val, His, Phe, Met or Gin; 51 is Asn, Arg, Met, Pro, Ser, 52 is Asn, His, Arg, Leu, Gly, 53 is Leu, Thr, Ala, Gly, Glu, Asn, Lys, Thr, Ser, Pro, His, Asn, or Asp; Ser, or His; or Thr; Lys, Ser, or 54 is Arg, Asp, Ala or Leu; Ile, Ser, Val, Thr, Gin, Asn, 55 is Arg, 56 is Pro, Tyr, Phe, 57 is Asn 58 is Leu, 59 is Glu 60 is Ala, 61 is Phe, 62 is Asn, 63 is Arg, 64 is Ala, 65 is Val, 66 is Lys, 67 is Ser, Thr, Val, Ser, Leu, Gly, Cys, Ser, Gin, Leu, Val or Lys; or Gly; Ser, Asp, Arg, Gin, or Gly; Glu, Arg, His, Val, or Cys; Tyr, His, Leu, Pro, or Arg; Leu; Xaa at position 70 Xaa at position 71 Trp, or Asn; Xaa at position 72 Xaa at position 73 Xaa at position 74 Xaa at position 75 Gin, or Leu; Xaa at position 76 Asp; Leu, Gin, Asn, Ala, Ser, Ala, Ile, Glu, Ser, Asn, His, Tyr, Asn, Thr, Ile, Ala, Val, Ala, Leu, Met, Glu, Glu, Met, Lys, Pro, Glu, Val, Trp, Pro, Pro, Arg, Phe, Trp, Pro, Val, Leu, Met, Asp, Thr, Gly, Tyr, Pro, Arg, Lys, Ser, His, Val, Val, Ser, Thr, Trp, Pro, Ala, Leu, Pro, Asp, Asn, or Thr; Lys, Arg, or Ser; Pro, Thr, Asp, or Ser, His, Pro, or or Lys; Leu, Phe, or Ser; Asn, Glu, or Ser; Gly, Asn, Ile, Pr Ile, Glu, Pro, Arg, His, Ser, Arg, Pro, Phe, Thr, Arg, Trp, or His; Gly, or Ile; Val; o, or or Ala; Glu, Thr, Gin, Asn, Arg, or Asp; Gly, Thr, or Arg; Gly, Ala; Trp, Arg, Ser, is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or WO 98/17810 PCT/US97/20037 Xaa at position 77 is Xaa at position 78 is Xaa at position 79 is Xaa at position 80 is Xaa at position 81 is Xaa at position 82 is His, Thr, Ser, I Xaa at position 83 is Xaa at position 84 is Xaa at position 85 is Xaa at position 86 is Xaa at position 87 is Xaa at position 88 is Xaa at position 89 is Ser; Xaa at position 90 is Xaa at position 91 is Xaa at position 92 is or Leu; Xaa at position 93 is Xaa at position 94 is Ala, or Pro; Xaa at position 95 is Lys, Ser, Ala, Xaa at position 96 is Xaa at position 97 is Xaa at position 98 is Glu, Gin, Ser, Xaa at position 99 is Gly, Ser, Phe, Xaa at position 100 i Pro; Xaa at position 101 i; Tyr, Glu, Asn, Xaa at position 102 i, Xaa at position 103 i Xaa at position 104 i Ile, Leu, Lys, Asn, Leu, Leu, Ala, Pro, Cys, Leu, Pro, Leu, Ala, Thr, Ala, Ala, Pro, Thr, Arg, His, rrp, Pro, Ile, Ser, Ala, Thr, Trp, Gin, Gin, Tyr, Ala, Glu, Asn, Cys, Ser, Lys, Asp, Pro, Pro, Phe, Asp, Ile, Gin, Phe, Lys, Val, Arg, Thr, or Ser, Glu, Ph Asn, Met, Ar Val, Gly, Th Gly, Ala, Tr Lys, Trp, Ar! Phe, Ile, Met Thr, Trp, Ar Gly, Arg, Me Val, or Gin; Arg, Ala, or Trp, or Gly; Arg, Val, or Cys, Leu, Va Leu; e, Gly, or g, Ile, G1 r, Leu, G1 p, Arg, Va g, Asp, G1 or Val; g, or Met; t, or Val; Arg; y, or Asp; u, or Arg; 1, or Lys; u, Asn, Lys; Trp; 1, Glu, His, Asn, or Ser, Ser, Arg, Ser, Ser, Pro, Ile, Tyr, 'Lys, Thr, Thr, Ser, Asn, Glu, Gly, Phe, Lys, Pro, Leu, Asp, Leu, His, Ala, Val, Ile, Asp, Ala, Leu, Gin, or Met; or His; Gly, Ile or Arg; Lys, His, Arg, Val, or Tyr; Gly, Ile, Leu, Gly, Thr, Asn, or Thr; Ala, or Asn; Leu, Asp, Ala, Thr, His, Ile, Asn, Phe, Met, Val, Lys, Arg, Tyr or Pro; Ile, Leu, Arg, Asp, Val, Pro, Gin, or His; s Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin, or s Asp, Pro, Met, Lys, His, Thr, Val, Ser, Ala, Gly, Ile, Leu, or Gin; s Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; s Asp, or Ser; s Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, WO 98/17810 PCT/US97/20037 Gin, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids optionally deleted from the C-terminus of said modified human interleukin-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein L is a linker capable of linking R, to R,; and WO 98/17810 WO 9817810PCTUS97ZOO37 said hematopoietic protein can optionally be immediately preceded by (methionine&') (alanine& 1 or (methionin- 2 alanin&'1). The hematopoeitic protein of claim 4 wherein R 2 is selected from the group consisting of; Ala Asn Arg Pro Asp Val Giu Ser Ile Giu Thr Ala Trp Gin Giu Gin Ala Gin Ile Pro Leu Arg Leu Ser Arg Giu Ile Pro Leu Arg Leu Ser Arg Giu Met Leu Met Ala Arg Arg Glu Ile Leu Glu Val1 Asn His Lys Asp Asp Arg Lys Leu Pro Leu Giu Ile Ile Pro Asn Asn Asn Leu Arg Asn Leu Giu Gin Pro cys Ilie Ile Ile Thr Phe Tyr His His Leu Asn Leu Pro Asn Aia Leu Pro Lys Ala Leu Val Leu Ala Asn Ser Ser Gly Thr Gin Gin SEQ ID NO:803; Aia Arg Asp Leu Ile Thr Trp Giu Met Leu Met Ala Arg Arg QlU Gin Ala Asn Cys Ser Ile Met Vai Pro Pro Aia Pro Leu Asp Met Asp Ile Leu Met Leu Ala Phe Vai Arg Ala Ile Giu Ala Ile Leu Arg Thr Ala Ala Pro Ser Arg Trp Gin Giu Phe Arg Giu Giu Gin Ala Gin Giu Gin Asn cys Ser Ile Met Ile Ile Leu Giu Val1 Asn His Lys Gin Ile Leu Glu Vai Asn His Lys Gin Asp Gu Ilie Ile Pro Asn Asn Asn Leu Arg His Leu Giu Gin Pro Cys Ilie Ilie Ile Thr Phe Tyr ID NO:804; Leu Ser Asn Ser Ser Gly Thr Asp Asp Arg Lys Leu Pro Leu SEQ Glu Giu Ser Asn Asn Gin Ile Thr His Asn Pro Ala Pro Ala Val Leu Ser Asn Ser Ser Giy Thr ID NO:805; and Ile Ile His His Leu Lys Arg WO 98/17810 PCTIUS97/20037 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Giu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Vai Lys Asn Leu Giu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Giu Phe Arg Giu Lys Leu Thr Phe Tyr Leu Val Thr Leu Giu Gin Ala Gin Giu Gin Gin SEQ ID NO:806. 6. A hematopoietic protein comprising; an amino acid sequence of the formula: RI-L 1 -R 2 1 R 2 -L 1 -R 1 R 1 -R 2 orR 2 -R 1 wherein R 1 is a polypeptide comprising; a modified flt-3 ligand amino acid sequence of the Formula: ThrGinAspCysSerPheGnHisSerProle~erSerAspPheAlaVaiLyslieArg GiubeuSerAspTyrLeuLeuGlnAspTyrProVaiThrValAlaSerAsnLeuGinAsp GiuGiuLeuCysGiyGiyLeuTrpArgLeuValLeuAiaGlnArgTrpMetGiuArgLeu 50 LysThrVaiAiaGiySerLysMetGinGiyLeuLeuGluArgValAsnThrGlul leHis PheValThrLyscysAiaPheGinProProProSerCysLeuArgPheVaiGinThrAsn 100 Ii eSerArgLeuLeuGinGiuThrSerGiuGinLeuVaiAiaLeuLys ProTrplieThr 110 120 ArgGlnAsnPheSerArgCysLeuGiuLeuGlnCysGinProAsrSerSerThrLeu 130 SEQ ID NO:466 wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 28-29 42-43 93-94 WO 98/17810 PCT/US97/20037 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40-41 .92-93 respectively; 41-42 wherein R 2 is a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; wherein L, is a linker capable of linking R, to R'; and said heznatopoietic protein can optionally be immediately preceded by (methionine& 1 (alanine&') or (methionine 2 alanine-'). 7. A hematopoietic protein comprising; an amino acid sequence of the formula: R 1 -L 1 -R 2 R -Li-R 1 l R 1 -R 2 or R 2 -R 1 wherein R 1 is a polypeptide comprising; a modified flt-3 ligand amino acid sequence of the Formula: ThrGlnAspcysSerPheGlnHisSerProl leSerSerAspPheAlaValLys IleArg 10 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeucysGlyGlyLeuTrpArgLeuvalLeuAlallArgTrpMetGluArgLeu LysThrValAlaGlyserLysmetolnolyLeuLeuoluArgValAsnThrclul leHis WO 08/17810 PrT/1TSQ71-7nflA7 PheVaiThrLysCysAlaPheGlnProProProSercysLeuArgPheValGlnThrAsn 100 IleSerArgLeuLeuGlnGiuThrSerGluGlnLeuValAlaLeuLysProTrplleThr 110 120 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsrSerSerThrLeu 130 SEQ ID NO:466 wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40-41 92-93 respectively; 4 1-42 wherein R 2 is a polypeptide, comprising; a modified human G-CSF amino acid sequence of the formula: 1 Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 100 WI 0911 /-70 in Pw'CTU 'n37 'V V O1W MIOI /V /U U II Leu Gin Ala Leu Glu Gly Ile Ser ProGlu Leu Gly Pro Thr Leu 110 Xaa Thr Leu Gin Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp 120 130 Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr 140 Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala 0UJ 150 Gly Gly Val Leu Val Ala Ser Tyr Arg Val Leu Xaa 160 Ser Xaa Leu Gin Xaa Phe Leu Xaa Xaa 170 Xaa Leu Ala Gin Pro SEQ ID NO:858 wherein Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Arg; Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; 2 is Pro or Leu; 3 is Leu, Arg, Tyr or Ser; 13 is Phe, Ser, His, Thr or Pro; 16 is Lys, Pro, Ser, Thr or His; 17 is Cys, Ser, Gly, Ala, Ile, Tyr or 18 is Leu, Thr, Pro, His, Ile or Cys; 22 is Arg, Tyr, Ser, Thr or Ala; 24 is Ile, Pro, Tyr or Leu; 27 is Asp, or Gly; 30 is Ala, Ile, Leu or Gly; 34 is Lys or Ser; 36 is Cys or Ser; 42 is Cys or Ser; 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr; Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Xaa at position Gly; Xaa at position Xaa at position Xaa at position Xaa at position Glu; Xaa at position 46 47 49 50 54 64 67 70 74 104 108 115 120 123 144 is Glu, Arg, Phe, Arg, Ile or Ala; is Leu or Thr; is Leu, Phe, Arg or Ser; is Leu, Ile, His, Pro or Tyr; is Leu or His; is Cys or Ser; is Gin, Lys, Leu or Cys; is Gin, Pro, Leu, Arg or Ser; is Cys or Ser; is Asp, Gly or Val; is Leu, Ala, Val, Arg, Trp, Gin or is Thr, His, Leu or Ala; is Gin, Gly, Arg, Lys or His is Glu, Arg, Phe or Thr is Phe, His, Arg, Pro, Leu, Gin or 146 is Arg or Gin; 'v 1 Q2111 0 in 'Dq/TT 0n7' T 'K .OZ/ R Lh uJI Xaa at position 147 is Arg or Gin; Xaa at position 156 is His, Gly or Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa at position 170 is His, Arg or Ser; wherein 1-11 amino acids from the N-terminus and/or amino acids from the C-terminus are optionally deleted from said modified human G-CSF amino acid sequence; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L 2 capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids; 38-39 39-40 40-41 41-42 42-43 43-44 45-46 48-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-59 59-60 60-61 61-62 62-63 63-64 64-65 65-66 66-67 67-68 68-69 69-70 70-71 71-72 91-92 92-93 93-94 94-95 95-96 96-97 97-98 98-99 99-100 123-124 124-125 125-126 126-127 128-129 128-129 129-130 130-131 131-132 132-133 133-134 134-135 135-136 136-137 137-138 138-139 139-140 140-141 141-142 or 142-143 respectively; wherein L is a linker capable of linking R to R 2 and said hematopoietic protein can optionally be immediately preceded by (methionine- 1 (alanine or (methionine 2 alanine WO 98/17810 WO 9817810PCTIUS97/20037 8. The hematopoietic protein as recited in claim 1, 2, 3, 4, 5, 6 or 7 wherein said linker (L 2 is selected from the group consisting of; Ser; Asn; Gly; Thr; GlySer; AlaAla; GlySerGly; G lyG lyGly; GlyAsnGly; GlyAlaGly; GlyThrGly; AlaSerAla; AlaAlaAla; GlyGlyGlySer SEQ ID NO:778; GlyGlyGlySerGlyGlyGlySer SEQ ID NO:779; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 780; SerGlyGlySerGlyGlySer SEQ ID NO:781; GluPheGlyAsnMet SEQ ID NO:782; GluPheGlyGlyAsriMet SEQ ID NO:783; GluPheGlyGlyAsnGlyGlyAsnvet SEQ ID NO:784; GlyGlySerAspMetAlaGly SEQ ID NO:785; SerGlyGlyAsnGly SEQ ID NO:786; SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:787; S erGlyGlyAsnGlySerGlyGlyAsnG lySerGlyGlyAsnGly SEQ ID NO:788; SerGlyGlySerGlySerGlyclySerGly SEQ ID NO:789; SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:790; GlyGlyGlySerGlyGly SEQ ID NO:791; GlyGlyGlySerGlyGlyGly SEQ ID NO:792; GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:793; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:794; GlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGly WO 98/17810 WO 9817810PCTIUS97/20037 SEQ ID NO:795; GlyGlyGlySerGlyGlydlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGly SEQ ID NO:796; ProProProTrpSerProArgProLeuGlyAlaThrAl aProThrAl aGly GlnProProLeu SEQ ID NO:797; ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO:798; and VaiG luThrVal PheHi sArgVal1SerGlnAspGlyLeuLeuThrSer SEQ ID NO:799. 9. The hematopoietic protein as recited in claim 1 wherein said protein is selected from the group consisting of; AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspG luAspVal Ser IieLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAl aValLysAsnLeuGluAsnAla~erGly I leGluAlalleLeuArgAsnLeuGlnProcysLeuProserAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlncluPheArgcluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluclyolyclyclySer ProGlyGluProSerGlyProlleSerThrl eAsnProSerProPro~erLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlhArgTrpMetGluArgLeuLysThrValAlaGlyserLysMetGlnolyLeuLeu GluArgValAsnThrGlulleHisPheValThrLysCysAlaPheclnProProProser CysbeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThr~erGluGlnLeu ValAl aLeuLys ProTrpl eThrArgGlnAsnPheSerArgcysLeuGluLeuGlnCys GlnProAspSerSerThrLeu~erGlyGlyAsnGlySerGlyGlyAsnolyThrolnAsp CysSerPheGlnHisSerProl le~erSerAspPheAlaValLyslleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlagerAsnLeuGln SEQ ID NO: 581; AlaAsncysSerlleMetlleAspGlulleleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSeroly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProserAlaThrAlaAlaProSer ArgHisProllellelleLysAlaGlyAspTrpolncluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlrlAlaGlnGluGlnGlnTyrValGluGlyclyGlyGlySer ProGlyGluProSerGlyProI le~erThrl leAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysmhrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGl1uI 1leHi s PheVa1ThrLysCysAlaPheGlnPro Pro ProSer cysLeuArgPheValGlnThrAsnhleserArgLeuLeuGlnGluThrSeroluGlnLeu ValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuoluLeuclncys GlnProAsp~erSerThrLeu~erGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsP Cys erPheG 1nHis erProIIeS erSerAspPheAlaVa 1Lys l eArgoluLeuSer AspT'yrLeuLeuGlnAspTyrProValThrValAlaSerAslLeuGln SEQ ID NO:582; WO 98/17810 PCTIUS97/20037 AiaAsnCysSerIleMetIl1eAspGluI 1 eIleHi sHi sbeuLysArgProProAlaPro LeuLeuAspProAsrlAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSeroly 11 eGluAlaI leLeuArgAsnLeuGlnProCysLeuPro SerAlaThrAl aAla ProSer ArgHis ProIleI leI leLytAlaG lyAspTrpDGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyolyGlyGlySer ProGlyGluProSerGlyProI leSerThrl leAsnProSerProProSerLysGluSer His Lys SerProAsri~.e tAl aSerLysMe tG lnG yLeuLeuG 1uArgVa lAsnThr 1 u I leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValoln ThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCyslnProAspSerSerphr LeuSerGlyGlyAsnGlyThrGlnAspCys SerPheGinHis SerProl leSerSerAsp PheAlaValLyslleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlniAspGluG luLeuCysGlyG lyLeuTrpArgLeuValLeuAl aGln ArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: :583; AlaAsnCysSerlleMetlleAspclullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspoluAspValSer IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuoluAsnAlaSeroly I leGluAlalleLeuArgAsnLeuolnProCysLeuProserAlaThrAlaAlaProser ArgHisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluolyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaSerLysMetclnGlyLeubeuGluArgValAsnThrGlu I leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValcln ThrAsnhleSerArgLeuLeuGlnGluThrseroluolnLeuValAlaLeuLysProTrp I leThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerserThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGinHi sSer Prol leSerSerAspPheAlaValLyslleArgGluLeuserAspTyrLeuLeuclnAsp TyrProValThrValAlaSerAsnLeuolnAspGluoluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO :584; AlaAsnCysSerlleMetlleAspolullelleHisHisLeuLysArgProProAlaPro LeubeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuoluAsn~laSeroly I leGluAlal leLeuArgAsnLeuGlnproCysLeuProSerAiaThrAlaAlaProSer ArgHisProl lellel leLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnoluGlnGlnTyrValGluGlyGlyolyolySer ProGlyGluProSer~lyProl leSerThrl leAsnProSerProProSerLysGluSer HisLys SerProAsnLMetAlaAspGluGluLeuCysGlyGly~euTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnmhrAsnleSerArgLeuLeuGlnGluThrseroluGlnLeu ValAlaLeuLys ProTrpl eThrArgGlnAsnPheSerArgCysLeuGiuLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGln-{s SerProl eSerSerAspPheAlaValLys I ieArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaserAsnLeu Gin SEQ ID NO:585; WO 98/17810 PCTIUS97/20037 AlaAsnCysSerIleMetIleAspGluIleI leHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerl leLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHi sProl lel lel leLysAlaGlyAspTrpGlnGluPheArgGlubysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaProProSerCysLeuArgPheValGlnThrAsnhleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlabeuLysProTrplleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProl leSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysolyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrVa lAlaGlySerLysMe tGlnGlyLeuLeuG luArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO :586; AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly I leGluAlal leLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgfisProllellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValG luGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSer ProProSerLysGiuSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnl leSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpl leThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnrProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerPro IleSerSer AspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGlulleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 587; AlaAsnCysSerIleMetIleAspGluIleIleHis-isLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSer IlebeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsriAlaSerGly I leGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHis Prol lellelleLysAlaclyAspTrpGlncluPheArgGlutysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProI leSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsniMetAlaProProSerCysLeuArgPheValGlnThrAsnl leSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrplleThrArgGli AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspserSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGyThrGlnJ~spCYSSerPheGlnHis SerProl leSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGll AspTyr ProValThrValAlaSerAsnLeuGlnAspG 1uGluLeuCysGlyGlyLeuTrp ArgLeuVal1LeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGlulleHjsPheValThrLysCysAlaPheGln Pro SEQ ID NO:588; WO 98/17810 WO 9817810PCT[US97/20037 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaG lnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI IeHis PheVal ThrLysCysAl aPheGl nPro Pro Pro SerCysLeuArgPheVa 1G lnThrAsnI 11eS erArgLeu LeuGlnGluThrSerGluGlnLuValA.aLeuLys ProTrp IleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerPro I leSerSerAspPheAlaValLys I leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVaI ThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProG inSerPheLeuLeuLysSer LeuGluGlnValArgLysIleGlnGlyAspGlyAla-AlaLeuGlnGluLysLeuCysAlaThrTyr Lys LeuCysHis sProGluGluLeuVa lLeuLeuGlyH is SerLeuG lyl 1eProTrpAl aProLeu SerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI leSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMe tAla ProAlaLeuGlnProThrGlnGlyAlaMetProA2.aPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVal SerTyrArgValLeuArgHisLeu AlaGinPro SEQ ID NO:743; AlaThrGlnAspCysSerPheGlnHisSerProI leSerSerAspPheAlaVa lLysl 11eArgGlu LeuSerAspTyrLeuLeuGlniAspTyrProValThrValAlaSerAs'nLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHis PheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlncluThrSer GluGinLeuValAlaLeuLys ProTrpl leThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsniMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPhebeuLeuLys SerLeuGluGlnValArgLys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr TyrLysLeuCysHi sProGluGluLeuValLeuLeuG lyHis SerLeuGlyI leProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeu 3 0 PheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyI 1 eSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrl 11eTrpGlnGlniMetGluGluLeuGlyMet AlaProAlaLeuGlnProThrGlnGlyAla~etProAlaPheAlaSerAlaPheGliArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVal SerTyrArgValLeuArgHis LeuAlaGlnPro SEQ ID NO:659; AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVal ArgLys I leGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlyI leProTrpAlaProLeuSerSerCys Pro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlyl leSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuASp ValAlaAspPheAlaThrThrI leTrpGlnGlniMetGluGluLeuGlyMetAlaProAlaLeuGln ProThrGlnGlyAlaMe tProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluVal.SerTyrAxgVa lLeuArgHisLeuAlaGlnProTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro I leSerThrl leAsnPro SerPro Pro SerLysGluSerHi sLys SerProAsnMe tAl aAspGluG luLeuCysGlyGlyLeuTrpArg LeuValLeuAlaclnArgTrpMetGluArgLeuLysThrVa lAlaG lySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluI 1 eHis PheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnl leSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpl leThrArgolnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLyslleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 705; AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluA-rgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnrhrGlul leHi sPheVal c -2994/PCT 803 Th~syAahGnror r~rylur PheVP 10 lnTh -ASflI eS~r~krcLeu C ysLeuGluLeuGflnCysG~fPrcAspSerSerThrLeuGlyG~~yGlySer ly lyGlyserGly Gly~lySerGlyO1yGlySerGlyGlyGlySerGlyThrGLn~spCyseZ elni~rr ThrValAlaSerAsflLeu~.,1TyrValGluGlyGlyGlyGlySer GlySerAsMetAlaThrProLeuGlYProAlaSerSerLeuProGlnSueuyse LeuGluGflValArgLys IleGlnGlYASpGlyAlaAlaLeuGlnO1uLysLeuCysAlaThrTyr LysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlyl leProTrpAlaproLCu SerSerCysProSerGlflAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPh LeuTyrG lnGlyLeuLeuGllaLeuG luGlyll1eSer ProGluLCuGlyProThrLeuAsP)Thr LeuGlnLeuAspVa]lAlaAspPheAlaThrThrIleTrpGlnGlrie~ul~ul~tl AlaGlnPro SEQ ID NO:743. 19. The hematopoietic protein of claim 1, 2 or 6, wherein said colony stimulating factor is selected from the group consisting of GM-CSF, G-CSF, G-CSF Ser 1 7 C- raol ligand (TPO), M-CSF, erythropoietin (EPO) IL-i, IL- 4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-lO, IL- 11, IL-l2, IL-13, IL-15, LIE, flt3/flk2 ligand, human growth hormone, B-cell growth factor, B-cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF). 11. The hematopoietic: protein of claim 10 wherein said colony stimulating factor is selected from the group consisting of G-CSF, G-CSF Ser1 7 G-CSF Ala' 7 and c-mpl ligand (TPO). 12. A nucleic acid molecule encoding said hematopoietic protein of claim 1. 13. A nucleic acid molecule encoding said hematopoietic protein of claim 2. 14. A nucleic acid molecule encoding said hematopoietic protein of claim 3. S~AEET c-2994/PCT 8C9 A nucleic acid molecule encodinlg said hematopoietic protein of claim 4.

167- A nucleic acid molecule encoding said hernatoPoietic protein of claim 17. A nucleic acid molecule encoding said hematopoietic protein of claim 6. 18. A nucleic acid molecule encoding said hematoPOietic protein of claim 7. 19. A nucleic acid molecule encoding said hematopoietic protein of claim 8. A nucleic acid molecule encoding said hematopoietic protein of claim 9. 21. A nucleic acid molecule encoding said hematopoietic protein of claim 22. A nucleic acid molecule encoding said hematopo2.etic protein of claim 11. 23.- The nucleic acid molecule according to claim 12 selected from group consisting of; GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAGGC ACCTGCACCTTTGCTGGACCCGACCCTCTGACGAGACTTT 3 0 TccTGATGGAccGAAAcCTTCGAcTTCcAACCTGGAGAGCTGAG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTTGA TCTCCA-ACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGATCA TATCTGGTTACCCTTGAGCAGCGCAGGACACAGTACGTAGAGGG TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCLCCG CTCCTCCGTCTAAGAATCTCATAAATCTCCA-kCATGGCCGACGGA cTcTGcGGGGGccTcTGGcGGcTGGTccTGGcAcAGcGcTGGATGAC GCTCAGACTGTCGCTGGGTcCCAGATGCA.GGCTTGCTGGAGCGGG ACAGGAGATACACTTTGTCACCAATGTGCCTTTCAGCCCCCCCAG 0 GTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGCT 3i CGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCGCACGT AMENDED SH-EET c -2994/PCT 310 AACGGCAGTGGAGGTAATGGCACCCAGGACGCTCTTCCACi'GC CATCTCCTCCGACTTCGCTGTCAA-TCCGTGAGCTGTCTGACTACG TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:12 1; GCTAa.CTGCTCTAT'AATGATCGATGAATTATACATCACTTAGGC ACCTGCACCTTTGCTGGACCCGAC-CCTCA-TGACGAAGACGCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAG GCTGTCAAGAACTTAGAA-TGCATCAGGTATTGAGGCAATTCTTCGTA TCTCCA.ACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCA TCATCATCAAGGCAGGTGACTGGCA-GATTCCGGGAACTGACGTT TATCTGGTTACCCTTGAGCAGCGCAGGAACkCAGTACGTAGAGGGG TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACG CTCCTCCGTCTAAAGAATCTCATAATCTCCAACATGGCCGACGAGA CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAC GCTCAAGACTGTCGCTGGGTCCAAGATGCAGGCTTGCTGGAGCGCGTG ACACGGAGATACACTTTGTCACC-ATGTGCCTTTCAGCCCCCCCCCG TGTCTTCCGCTTCGTCCAGACCkCATCTCCcGCCTCCTGCAGGAGCT CGAGCAGCTGGGGCGCTGAGCCCTGGATCACTCGCCAGAACTTCTC GGTGCCTGGAGCTGCAGTGTCGCCCGACTCCTC-CCCTGTCGAG ?ACGGATCCGGTGGCAATGGGAGCGGCGG~A. -TGGAACCCAGGACTGT CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGGG TGTCTGACTACCTGCTTCAAGATTAkCCCAGTCACCGTGGC CTCCALACCTG CAG SEQ ID NO:122; GCTAACTGCTCTAT.ATGATCGATGAAATTATACATCAC TTAJAGAGACC ACTCCTTCGACGAAACCzAGCAGCTTT TCCTGATGGACCGAACCTTCGACTTCCkACCTGGAGAGCTTCGTA.G 3 0 GCTGTCAkAGAACTTAGAAATGCATCAGGTATTGAGGC-TTCTGA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACTCk TCTACkGCGTATGAAATCGGA-ATAGT TATCTGGTTACCCTTGAGCAGCGCAGGACACAGTACGTAGAGC- TGGAGGCTCCCCGGGTGACCGTCTGGTCCATCTCTACTATCAACG 3 5 CTCCTCCGTCTkAAGALATCTCATAATCTCCAXCATGGCCTCCA-GT CAAGGCTTGCTGGAGCGCGTGACACGGAGATACACTTTGTCACCAAT TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAAC CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGCCCTG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCG CTCCTCA.ACCCTGTCTGGCGGCALACGGCACGCAGGACTGCTCCTTCCPA ACAGCCCCATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTGA TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAC CTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO:12 3 GCTAACTGCTCTATATGATCGATGATTATACATCACTTAAAAGC ACCTGCACCTTTGCTGGACCCGCACCTCAATGACGA-GACGTCA TCCTGATGGACCGAAACCTTCGACTTCCACCTGGAGAGCTTGAG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCATTCTTGA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACACA TCATCATCAAGGCAGGTGACTGGCGTTCCGGGAACTAGC TATCTGGTTACCCTTGAGCLGCGCAGGACACAGTACGTAGAGGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCATCTCTACTATCACG 55 ~AMENDED SHEET Cf2994/PCT TGcCTTTCAGCCCcCCCCCCAGCTGTCTTCCTCGTCCAGACkATT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA-GCT ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA CG CTCCTCA.CCCTGTCTGGAGGTAACGGATCCGGAGGTATGGCACCCAGG ACTGCTCCTTCCAkACACAGCCCCATCTCCTCCCACTTCGTCkAAC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACGGCT cAAccTrGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCGTTG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ 1D NO: 124; GCTAACTGCTCTATAATGATCGATGAATTATACATCATL-GGC ACCTGCACCTTTGCTGGACCCGAC-CCTCATGACGAGCTCA TCCTGATGGACCGAAACCTTCGACTTCCACCTGGAGCTTAG GCTGTCAAGAACTTAGAATGCATCAGGTATTGAGGCATTTGA TCTCCAACCATGTCTGCCCTCTCCCACGGCCGCACCCTCTCAACA TCATCATCAAGGCAGGTGACTGGCGTTCCGGGAAATGCGT TATCTGGTTACCCTTGAGCAGCGCAGG.CACAGTACGTGGGG TGGAGGCTCCCCGGGTG-CCGTCTGGTCCAATCTCTACTACACG CTCCTCCGTCTAAAGAATCTCATAATCTCC AACATGGCTCAGG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC-CAAT TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGCAAAC CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGACCG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCCCG CTCCTCkCCCTGTCTGGAGGTAACGGATCCGGTGGCAGGGGC GAAATGGAACCCAOGGACTGCTCCTTCCAACACAGCCCCATCCTCA TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTAGTCC AGTCACCGTGGCCTCCACCTGCAGGACGAGGAGCTCTGGGCTT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC.'AAT-CC GGG SEQ ID NO:2125; GCTAkACTGCTCTAT-TGATCGATGATTATACATCAzCTk',GGC ACCTGCACCTTTGCTGGACCCGAC-CCTCA.TGACGAGCTTT TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGACTGAG GCTGTCAAGACTTAGAATGCATCAGGTATTGAGGCAATTTGA TCTCCALACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGAACA TCTAC-GCGTATGAGATCGAAATAGT TATCTGGTTACCCTTGAGCAGCGCAGG.CACAGTACGTGGGG TGGAGGCTCCCCGGGTGACCGTCTGGTCCA-TCTCTACTATCACG CTCCTCCGTCTAAGATCTCATAATCTCCAACATGGCCCCCCG TGTCTTCGCTTCGTCCAGACCA-CATCTCCCGC CTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAGCCCTGGATCACTCGCCAGA-'CTTC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCGCG kLACGGCACCCAGGACTGCTCCTTCCPLCACAGCCCCATCTCTGAT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATAC TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC.GACGGTG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGCACGGAGATAATT TCACCAAATGTGCCTTTCAGCCC SEQ ID NO:126; S0 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAGGC ACCTGCACCTTTGCTGGACCCGCCCTCATGACGPLGACTTT TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTGAG GCTGTCAAGACTTAGAATGCATCAGGTATTGAGGCATTCTG II TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCTCL AMENDED SHEET C- 2994/ PCT TCATCATCAAGGCAGGTGACTGGCGA-TTCCGGk A-zC -AGTTC TATCTGGTTACCCT-IAGCAAGCGCAGGACACAGTACGTAGGGG TGGAGGCTCCCCGGGTGACCGTCTGGTCC-TCTCTACTATkACG CTCCTCICGTCTAAG.TCTCATAATCTCCAACATGGCCCCAG TGTCTPTCGCTTCG TCCAGACCA-CATCTCCCGCCTCCTGCAGGGCT CGAGCAGCTGGTGGCGCTGGCCCTGGATCACTCGCCAG-CTTC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCGCG AACGGCAGTGGAGGTAkATGGCACCCAGGACTGCTCCTTCCACAGC CATCTCCTCCGACTTCGCTGTCAATCCGTGAGCTGTCTGACATG TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGCT TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGGC CAAGACTGTCGCTGGGTCCAAGATGCA.GGCTTGCTGGAG C(TAA CGGAGATACACTTTGTCACCkATGTGCCTTTCAGCCC SEQ ID NO: 127; GCTAACTGCTCTATA'ATGATCGATGAAATTATACATCACTA-GAC ACCTGCACCTTTGCTGGACCCGCACCTCATGACG.GCTTT TCCTGATGCGACCGAAACCTTCGACTTCC-ACCTGGAGAGCTGAG GCTGTCAAGAACTTAGIATGCATCAGGTATTGAGGCAATTCGAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGATCA TATCTGGTTACCCTTGAGCGCGCAGGLCA-CAGTACTGGGG TGGAGGCTCCCCGGGTGACCGTCTGGTCCAATCTCTACACBCCG CTCCTCCGTCTAAGkTCTCATkATCTCCAACATGGCCCAC TGTCTTCGCTTCGTCCGACCCAkTCTCCCGCCTCCTGCAGGGCT CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGACTCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCGCGA AACGGCAGTGGTGGTAATGGGAGCGGCGGAATGGAACAGCGT CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAATCGGG TGTCTCGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCCACT CAGGACGAGGAGCTCTGCGGGGGC-CTCTGGCGGCTGGTCCTGAGC CTGGATCGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCGCTC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCATGTCTT CCC SEQ ID NO:128; GCTGATGALAGA-ACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGAGCTGTGGG CC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCTACCGGTC.CTGC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTGC.,ACAACCCCT CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGACCCCAACTTCG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGTGTAGGTGTAG GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGCGTCTCAAACC ATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGATCGTCA TTCC.GC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCGGGTGTTGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCAACTCGT-ATT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCkGAACTGGCCTC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCGGACCTGCCCT AGCTCCTGCCCCAOGCCAGGCCCTGCAGCTGGCAGGCTGCTTrACATCTGGCTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTGTCACTGCC CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGAACGGAGC CCTGCCCTGCAGCCCACCCAGGGTGCCATCCCGGCCTTCGCCTCTGCTTCACCGGAG GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGACCTCAGCCT GCGCAGCCG SEQ ID NO:282; GGCCACTCAGGACTGCTCTTTTC~kCACAGCCCCATCTCCTCCGATCCGCAACGG GCTGTCTGACTACCTGCTTCAAGATTATACTGCCTC CAACTCTGCGAAGGAC A"142ENDED SHEET Ct2994/PCT 813 GTCCAAGATGCAAGGCTTGCTGGAGCGCGTG.AACGCAGACA-T TACAA GGCT TCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCCCCTCGA, A:7 CGAGCAGCTGGGGCGCTGAGCCCTGGATCACTCGCCAGAATCCCGGCTGGTC GTGTiCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGTCCGTGGTCG CGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCTCCAGTCTCCA GTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCG. CGAAGTTT6A CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TTGCACCGGTC CCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTGCCLTCAGGCT TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGLGGGATATC CG TGGCCATGA CACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGACATA-GCGGT GGCCCCTGCCCTGCAGCCCACCCAkGGGTGCCATGCCGGCCTTC CT GTTCAGCGC AGGAGGGGTCCTGG-TTGCTAGCCATCTGCAGAGCTTCCT'GGAGTCTAGGTTCCA CCTTGCGCAGCCG SEQ ID NO:198; GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCTCCkGCTAACAT AGAAAGATCC.AGGGCGATGGCGCAGCGCTCCAGGAGLGCTG TCACACACGGCC CCC'GAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGCCCGATCGCC AGCCAGGCCCTGCAGCTGGCAGGCGCTTGAGCCACTCCAGCCTTCTTCAGG CTCCTGCAGGCCCTGGA:AGGG~,TATCCCGAGTTGGGTCCCACTGCCCG.,CGA GTCGCCGACTTTGCCACCACCTCTGGCACAGATGGAGATGATGCCTCCG CCCACCCAGGGTGCCTGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGAGGGTCGT GCTAGCCATCTGCA")GAGCTTCCTGGAGGTGTCGTACCGCGTCAG ACTCCGCTC GTAGAGGGCGGTGGAGGCTCCCCGGGTOACCGTCTGGTCPACCATTACCTTC CCGTCTAAAGATCTCATAA-ATCTCCAAACATGGCTGATGAAACGGGTGTTTGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAGACTGTCCGGCAGTCkGCT CTGGAGCGCGTGAAkCACGGAGATACACTTTGTCACCAATTGC ACCCCCGTT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGGCTCACGTGGCC. AAGCCCTGGATCACTCGCCAGAAkCTTCTCCCGGTGCCTGGTCGGCGCGkTCC ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGACGAGGCCGGGGTG CTGTCTGACTACCTGCTTCAGATTACCCAkGTCACCGTGGCCTCATGG SEQ NO: 244; GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGAACCGAGACGT 3 5 AAGACTG rCGCTGGGTCCAGATGCAAGGCTTGCTGGAGCGCGTGAACACGAAAATTT ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTGCAACAACCCCT CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGACTGCGATCCCG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTAGGTGTCGG GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGATCCTCACkACC ATCTCCTCCGACTTCGCTGTCAAALATCCGTGAGCTGTCTGACTCGTCAATCC.GC ACCGTGGCCTCCALACCTGCAGTACGTAGAGGGCGGTGGAGGCTC GGGTGT TGGC GGCTCCAACATGGCTACACCATTGGCCCTGCCAGCTCCGCCCGGTCTCCkGC TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCGAACTGGCCTC A.AGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGACCTGCCCT AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCATCTGGCTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTGTCACTGCC CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCATGAACGG.TGC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTCAGCGCGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTGACGTTCCACT GCGCAGCCG SEQ ID NO:28 2 24. A method of producing a hematopojetic protein uj U comprising: growing under suitable nutrienlt conditions, ~;EiNiED SHEET C'2994/PCT 814 a host cell transformed or t;ansfccted with. a replicable vector comprising a nucleic acid molecule of claim 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 in a manner allowing expression of said hematopoietic.protein and recovering said hematopoietic protein. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1, 2, 3, 4, 6, 7, 9, or 10; and a pharmaceutically acceptable carrier. 26. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering an effective amount of the hematopoietic protein as recited in claim 1, 2, 3, 4, 5, 6, 7, 9 or to said patient. 27. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of; culturing said hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; and harvesting said cultured cells. 28. A method for selective ex vivo expansion of hematopoietic cells, comprising the'steps of; separating hematopoietic cells from other cells; culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; and harvesting said cultured cells. 29. A method for treatment of a patient having a JUAV hematopoietic disorder, comprising the steps of; removing hematopoietic cells from said patient; C'02994/PCT 815 culturing said hematopoi-tic cells in a cultu Le medium comprising; the hematopoietic protein of claim 1; harvesting said cultured cells; and transplanting said cultured cells into said patient. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of; removing hematopoietic cells from said patient; separating hematopoietic cells from other cells; culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; harvesting said cultured cells; and transplanting said cultured cells into said patient. 31. A method of human gene therapy, comprising the steps of; removing hematopoietic cells from a patient; separating said hematopoietic cells from other cells; culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; introducing DNA into said cultured cells; harvesting said transduced cells; and transplanting said transduced cells into said patient. 32. The method according to claim 27, 28, 29, or 31 wherein said hematopoietic cells are CD34+ cells. 0 C-2994/PCT 816 33. The method according tc claim 27, 28, 29, 30' or 31 wherein said hematopoietic cells'are peripheral blood cells. 34. A method for the production of dendritic cells comprising the steps of; a) separating hematopoietic progenitor cells or CD34+ cells from other cells; and b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising the hematopoietic protein of claim 1, 2, 3 or 4. 35. The method of claim 34, further comprising the step of; c) pulsing said culturing hematopoietic progenitor cells or CD34+ cells with an antigen. 36. The method of claim 34, wherein said growth medium, further comprises; one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 37. The method of claim 35, wherein said growth medium, further comprises; one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 0 38. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step -0 C-2994/PCT 817 of; administering the hematoooietic protein of claim 1,2 2, 3, or 4, to said human. 39. The method of claim 38, further comprising; administrating one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 1 0 40. The method of claim 38, further comprising the step of; administering an antigen to said patient. 41. The method of claim 39, further comprising the step of; administering an antigen to said patient. 42. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; a) mobilizing dendritic cell progenitors or mature dendritic cells by administering the hematopoietic protein of claim 1 to said human; b) removing said dendritic cell precursors or mature dendritic cells by a blood draw or pheresis; c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human. 43. The method of claim 42, further comprising; administering in step one or more factor selected \A 35 from the group consisting of; GM-CSF, IL-4, TNF-a, stem O cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, C'2994/PCT 818 an IL-3 variant fusion protein, and a mulc(ifunctional receptor agonist. 44. The method of claim 42, .further comprising the step of; culturing said dendritic cell precursors or mature dendritic cells from step in a growth medium, comprising; the hematopoietic protein of claim 1, 2, 3 or 4. 45. The method of claim 43, further comprising the step of; culturing said dendritic cell precursors or mature dendritic cells from step in a growth medium, comprising; the hematopoietic protein of claim 1, 2, 3 or 4.

1546. The method of claim 44, wherein said growth medium, further comprises one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 47. The method of claim 45, wherein said growth medium, further comprises one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-c, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 48. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; a) removing hematopoietic progenitor cells or CD34+ cells from said human by a blood draw or pheresis; V 5 b) culturing said hematopoietic progenitor u cells or CD34+ cells in a growth medium, comprising the C'2994/PCT 819 hematopoietic protein of claim 1 to pcoduce dendritic cell precursors or mature dendritic cells; c) returning said dendritic cell precursors or mature dendritic cells to said human. 49. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; a) removing hematopoietic progenitor cells or CD34+ cells from said patient by a blood draw or pheresis; b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising; the hematopoietic protein of claim 1 to produce dendritic cell precursors or mature dendritic cells; c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human. 50. The method of claim 48, further comprising the step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing. 51. The method of claim 49, further comprising the step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing. 52. The method of claim 50, wherein said culture medium further comprises; one or more factor selected A ^5 from the group consisting of: GM-CSF, IL-4, TNF-a, stem Scell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, AMENDED SHEET C-2994/PCT 820 an IL-3 variant fusion protein, anana multi-,functionaL,': receptor agonist. 53. The method of claim 50, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. 54. The method of claim 50, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. The method of claim 51, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-a, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist. AMENDED SHEET